"Variant and risk allele",P-value,"P-value annotation",RAF,OR,Beta,CI,"Mapped gene","Reported trait",Trait(s),"Study accession",Location
rs76830467-<b>?</b>,"3 x 10-7",,NR,'-,'-,'-,NOS1,"Baseline cortisol levels in response to low dose short synacthen test in corticosteroid treated asthma","childhood onset asthma, cortisol measurement, response to corticosteroid, response to synacthen",GCST005925,12:117321510
rs201541519-<b>?</b>,"3 x 10-7",,NR,'-,'-,'-,"IGHA1, ELK2AP","Baseline cortisol levels in response to low dose short synacthen test in corticosteroid treated asthma","childhood onset asthma, cortisol measurement, response to corticosteroid, response to synacthen",GCST005925,14:105694756
rs117420762-<b>?</b>,"3 x 10-7",,NR,'-,'-,'-,SLC2A10,"Baseline cortisol levels in response to low dose short synacthen test in corticosteroid treated asthma","childhood onset asthma, cortisol measurement, response to corticosteroid, response to synacthen",GCST005925,20:46719767
rs140179402-<b>?</b>,"2 x 10-8",,NR,'-,'-,'-,BCL2L13,"Baseline cortisol levels in response to low dose short synacthen test in corticosteroid treated asthma","childhood onset asthma, cortisol measurement, response to corticosteroid, response to synacthen",GCST005925,22:17685512
rs111863753-<b>?</b>,"8 x 10-7",,NR,'-,'-,'-,GBA3,"Peak cortisol response to low dose short synacthen test in corticosteroid treated asthma","childhood onset asthma, cortisol measurement, response to corticosteroid, response to synacthen",GCST005926,4:22794376
rs149647891-<b>?</b>,"6 x 10-7",,NR,'-,'-,'-,PDE7B,"Peak cortisol response to low dose short synacthen test in corticosteroid treated asthma","childhood onset asthma, cortisol measurement, response to corticosteroid, response to synacthen",GCST005926,6:136006932
rs5875060-<b>?</b>,"8 x 10-8",,NR,'-,'-,'-,SCGN,"Peak cortisol response to low dose short synacthen test in corticosteroid treated asthma","childhood onset asthma, cortisol measurement, response to corticosteroid, response to synacthen",GCST005926,6:25701740
rs142161979-<b>?</b>,"9 x 10-9",,NR,'-,'-,'-,ANKS1B,"Peak cortisol response to low dose short synacthen test in corticosteroid treated asthma","childhood onset asthma, cortisol measurement, response to corticosteroid, response to synacthen",GCST005926,12:99392036
rs137939366-<b>?</b>,"3 x 10-7",,NR,'-,'-,'-,ELSPBP1,"Peak cortisol response to low dose short synacthen test in corticosteroid treated asthma","childhood onset asthma, cortisol measurement, response to corticosteroid, response to synacthen",GCST005926,19:48019433
rs142320277-<b>?</b>,"5 x 10-8",,NR,'-,'-,'-,LRP1B,"Peak cortisol response to low dose short synacthen test in corticosteroid treated asthma","childhood onset asthma, cortisol measurement, response to corticosteroid, response to synacthen",GCST005926,2:140665410
rs61893841-<b>?</b>,"9 x 10-7",,'-,3.659,'-,[2.129-6.288],MMP20,"Adverse response to antithyroid drugs in Graves disease","Graves disease, response to anti-thyroid drug",GCST006278,11:102591595
rs144542704-<b>?</b>,"4 x 10-8",,'-,5.549,'-,[2.835-10.86],RGS9,"Adverse response to antithyroid drugs in Graves disease","Graves disease, response to anti-thyroid drug",GCST006278,17:65208429
rs2424955-<b>C</b>,"1 x 10-7",,0.143,44.03,'-,[NR],BPIFB4,"Non-steroidal anti-inflammatory drug-induced enteropathy","response to non-steroidal anti-inflammatory, small intestine enteropathy",GCST007258,20:33105621
rs11583606-<b>T</b>,"2 x 10-7",,NR,7,'-,[3.37-14.5],TGFBR3,"Metamizole-induced agranulocytosis or neutropenia","neutropenia, response to metamizole, Drug-induced agranulocytosis",GCST011105,1:91883690
rs146378328-<b>G</b>,"3 x 10-7",,NR,8.31,'-,[3.69-18.7],EPHX4,"Metamizole-induced agranulocytosis or neutropenia","neutropenia, response to metamizole, Drug-induced agranulocytosis",GCST011105,1:92062490
rs143843248-<b>T</b>,"1 x 10-6",,NR,7.3,'-,[3.29-16.20],PTPRO,"Metamizole-induced agranulocytosis or neutropenia","neutropenia, response to metamizole, Drug-induced agranulocytosis",GCST011105,12:15480878
rs73163933-<b>A</b>,"1 x 10-6",,NR,5.36,'-,[2.73-10.5],STARD13,"Metamizole-induced agranulocytosis or neutropenia","neutropenia, response to metamizole, Drug-induced agranulocytosis",GCST011105,13:33393883
rs4427239-<b>A</b>,"6 x 10-7",,NR,5.47,'-,[2.81-10.65],SVEP1,"Metamizole-induced agranulocytosis","response to metamizole, Drug-induced agranulocytosis",GCST011106,9:110508321
rs55898176-<b>T</b>,"1 x 10-7",,NR,4.01,'-,[2.41-6.68],'-,"Metamizole-induced agranulocytosis","response to metamizole, Drug-induced agranulocytosis",GCST011106,9:26715296
rs145222507-<b>?</b>,"2 x 10-8",,'-,'-,"0.14 unit increase",[0.1-0.18],LINC00426,"Rapid response to perioperative phenylephrine (change in mean arterial pressure)","blood pressure change measurement, response to phenylephrine",GCST011771,13:30375983
rs111908123-<b>?</b>,"6 x 10-8",(EA),'-,'-,"0.49 unit increase",[0.31-0.67],SCMH1,"Rapid response to perioperative phenylephrine (change in mean arterial pressure)","blood pressure change measurement, response to phenylephrine",GCST011771,1:41054086
rs146535276-<b>?</b>,"1 x 10-8","(African American)",'-,'-,"1.27 unit decrease",[0.84-1.7],'-,"Rapid response to perioperative phenylephrine (change in diastolic blood pressure)","response to phenylephrine, diastolic blood pressure change measurement",GCST011770,8:16701952
rs143947120-<b>?</b>,"2 x 10-8","(African American)",'-,'-,"1.24 unit increase",[0.81-1.67],DUXAP11,"Rapid response to perioperative phenylephrine (change in diastolic blood pressure)","response to phenylephrine, diastolic blood pressure change measurement",GCST011770,16:59650558
rs145337816-<b>?</b>,"2 x 10-8",,'-,'-,"0.92 unit increase",[0.61-1.23],LINC02147,"Rapid response to perioperative phenylephrine (change in systolic blood pressure)","response to phenylephrine, systolic blood pressure change measurement",GCST011772,5:117875523
rs188427942-<b>?</b>,"5 x 10-8",(EA),'-,'-,"1.1 unit decrease",[0.71-1.49],CSNK1G3,"Rapid response to perioperative phenylephrine (change in systolic blood pressure)","response to phenylephrine, systolic blood pressure change measurement",GCST011772,5:123564719
rs147664194-<b>?</b>,"5 x 10-8",(EA),'-,'-,"1.17 unit decrease",[0.74-1.6],'-,"Rapid response to perioperative phenylephrine (change in systolic blood pressure)","response to phenylephrine, systolic blood pressure change measurement",GCST011772,5:123783350
rs6657443-<b>?</b>,"8 x 10-9",(Hispanic),'-,'-,"0.39 unit decrease",[0.25-0.53],LINC01774,"Rapid response to perioperative phenylephrine (change in systolic blood pressure)","response to phenylephrine, systolic blood pressure change measurement",GCST011772,1:209015920
kgp1734375-<b>?</b>,"2 x 10-6",,NR,3.4,'-,[2.1-5.7],'-,"Severe prolonged lymphopenia in dimethyl fumarate-treated relapsing-remitting multiple sclerosis","lymphopenia (disease), response to dimethyl fumarate, relapsing-remitting multiple sclerosis",GCST009546,"Mapping not available"
kgp4224365-<b>?</b>,"5 x 10-6",,NR,2.9,'-,[1.8-4.6],'-,"Severe prolonged lymphopenia in dimethyl fumarate-treated relapsing-remitting multiple sclerosis","lymphopenia (disease), response to dimethyl fumarate, relapsing-remitting multiple sclerosis",GCST009546,"Mapping not available"
kgp6724547-<b>?</b>,"6 x 10-6",,NR,3.8,'-,[2.1-6.8],'-,"Severe prolonged lymphopenia in dimethyl fumarate-treated relapsing-remitting multiple sclerosis","lymphopenia (disease), response to dimethyl fumarate, relapsing-remitting multiple sclerosis",GCST009546,"Mapping not available"
rs12249496-<b>?</b>,"1 x 10-6",,NR,2.2,'-,[1.6-3.0],"MLLT10, LINC02667","Moderate or severe prolonged lymphopenia in dimethyl fumarate-treated relapsing-remitting multiple sclerosis","lymphopenia (disease), response to dimethyl fumarate, relapsing-remitting multiple sclerosis",GCST009545,10:128875540
rs17417060-<b>?</b>,"1 x 10-6",,NR,2.1,'-,[1.6-2.9],"TMEM72, TMEM72-AS1","Moderate or severe prolonged lymphopenia in dimethyl fumarate-treated relapsing-remitting multiple sclerosis","lymphopenia (disease), response to dimethyl fumarate, relapsing-remitting multiple sclerosis",GCST009545,10:44917329
kgp3442760-<b>?</b>,"1 x 10-6",,NR,1.9,'-,[1.5-2.5],'-,"Moderate or severe prolonged lymphopenia in dimethyl fumarate-treated relapsing-remitting multiple sclerosis","lymphopenia (disease), response to dimethyl fumarate, relapsing-remitting multiple sclerosis",GCST009545,"Mapping not available"
kgp5383559-<b>?</b>,"3 x 10-6",,NR,2,'-,[1.5-2.8],'-,"Moderate or severe prolonged lymphopenia in dimethyl fumarate-treated relapsing-remitting multiple sclerosis","lymphopenia (disease), response to dimethyl fumarate, relapsing-remitting multiple sclerosis",GCST009545,"Mapping not available"
kgp4348860-<b>?</b>,"4 x 10-6",,NR,2.4,'-,[1.7-3.6],'-,"Moderate or severe prolonged lymphopenia in dimethyl fumarate-treated relapsing-remitting multiple sclerosis","lymphopenia (disease), response to dimethyl fumarate, relapsing-remitting multiple sclerosis",GCST009545,"Mapping not available"
kgp2538268-<b>?</b>,"6 x 10-6",,NR,1.8,'-,[1.4-2.3],'-,"Moderate or severe prolonged lymphopenia in dimethyl fumarate-treated relapsing-remitting multiple sclerosis","lymphopenia (disease), response to dimethyl fumarate, relapsing-remitting multiple sclerosis",GCST009545,"Mapping not available"
rs117491755-<b>?</b>,"2 x 10-9",,0.037,4.37,'-,2.702-7.06,ASTN2,"Drug-induced liver injury (isoniazid-containing anti-tuberculosis drugs)","response to anti-tuberculosis drug, drug-induced liver injury",GCST011752,9:116881377
rs12777823-<b>A</b>,"3 x 10-11",(AA),0.249,'-,"0.134 unit decrease",'-,"CTBP2P2, HELLS","Warfarin maintenance dose (adjusted for clinical factors)","response to anticoagulant",GCST008374,10:94645745
rs12772169-<b>A</b>,"8 x 10-10",(AA),0.41,'-,"0.102 unit decrease",'-,"CTBP2P2, HELLS","Warfarin maintenance dose (adjusted for clinical factors)","response to anticoagulant",GCST008374,10:94645572
exm1235612-<b>A</b>,"5 x 10-10",(AA),0.028,'-,"0.938 unit increase",'-,'-,"Warfarin maintenance dose (adjusted for clinical factors)","response to anticoagulant",GCST008374,"Mapping not available"
rs150862851-<b>G</b>,"2 x 10-6",,0.012,7.435,'-,[3.255-16.98],ALG10B,"Bisphosphonate-associated atypical femoral fracture","atypical femoral fracture, response to bisphosphonate",GCST008097,12:38399632
rs143302148-<b>T</b>,"2 x 10-6",,0.011,7.507,'-,[3.286-17.15],CPNE8,"Bisphosphonate-associated atypical femoral fracture","atypical femoral fracture, response to bisphosphonate",GCST008097,12:38706211
rs147502517-<b>T</b>,"4 x 10-7",,0.012,7.191,'-,[3.354-15.42],PAH,"Bisphosphonate-associated atypical femoral fracture","atypical femoral fracture, response to bisphosphonate",GCST008097,12:102871642
rs72698961-<b>G</b>,"6 x 10-7",,0.027,5.128,'-,[2.701-9.734],"TUNAR, TCL1A","Bisphosphonate-associated atypical femoral fracture","atypical femoral fracture, response to bisphosphonate",GCST008097,14:95812326
rs62026663-<b>C</b>,"2 x 10-6",,0.096,3.221,'-,[1.987-5.221],SHF,"Bisphosphonate-associated atypical femoral fracture","atypical femoral fracture, response to bisphosphonate",GCST008097,15:45193633
rs142484525-<b>T</b>,"3 x 10-6",,0.011,6.364,'-,[2.944-13.76],'-,"Bisphosphonate-associated atypical femoral fracture","atypical femoral fracture, response to bisphosphonate",GCST008097,15:94969491
rs145787127-<b>A</b>,"3 x 10-8",,0.016,7.366,'-,[3.633-14.93],NTN1,"Bisphosphonate-associated atypical femoral fracture","atypical femoral fracture, response to bisphosphonate",GCST008097,17:9239097
chr17:77861401-<b>T</b>,"9 x 10-7",,0.01,7.375,'-,[3.328-16.34],'-,"Bisphosphonate-associated atypical femoral fracture","atypical femoral fracture, response to bisphosphonate",GCST008097,"Mapping not available"
rs140824800-<b>A</b>,"1 x 10-6",,0.011,7.289,'-,[3.265-16.28],'-,"Bisphosphonate-associated atypical femoral fracture","atypical femoral fracture, response to bisphosphonate",GCST008097,20:12560459
rs149264569-<b>G</b>,"2 x 10-6",,0.019,6.037,'-,[2.878-12.66],"KCNG1, RPSAP1","Bisphosphonate-associated atypical femoral fracture","atypical femoral fracture, response to bisphosphonate",GCST008097,20:51098570
rs76232775-<b>A</b>,"2 x 10-6",,0.03,4.44,'-,[2.408-8.186],MTG2,"Bisphosphonate-associated atypical femoral fracture","atypical femoral fracture, response to bisphosphonate",GCST008097,20:62193854
rs149305693-<b>C</b>,"2 x 10-6",,0.012,8.11,'-,[3.435-19.15],"DCAF8L2, MAGEB10","Bisphosphonate-associated atypical femoral fracture","atypical femoral fracture, response to bisphosphonate",GCST008097,X:27790330
rs7188484-<b>T</b>,"9 x 10-7",,0.196,3.576,'-,[2.153-5.94],GALNS,"Atypical femoral fracture in phosphonate treatment","atypical femoral fracture, response to bisphosphonate",GCST008098,16:88852199
rs61753147-<b>A</b>,"5 x 10-6",,0.035,5.265,'-,[2.58-10.74],PIK3R5,"Atypical femoral fracture in phosphonate treatment","atypical femoral fracture, response to bisphosphonate",GCST008098,17:8905708
rs4765913-<b>A</b>,"2 x 10-6",,0.188,3.114,'-,[1.942-4.995],CACNA1C,"Atypical femoral fracture in phosphonate treatment","atypical femoral fracture, response to bisphosphonate",GCST008098,12:2310730
rs116941264-<b>A</b>,"7 x 10-6",,0.011,10.78,'-,[3.833-30.33],'-,"Atypical femoral fracture in phosphonate treatment","atypical femoral fracture, response to bisphosphonate",GCST008098,18:77748415
rs1913592-<b>C</b>,"1 x 10-6",,0.279,3.346,'-,[2.06-5.435],IGSF21,"Atypical femoral fracture in phosphonate treatment","atypical femoral fracture, response to bisphosphonate",GCST008098,1:18224343
rs11465606-<b>A</b>,"7 x 10-6",,0.022,6.86,'-,[2.958-15.91],IL18R1,"Atypical femoral fracture in phosphonate treatment","atypical femoral fracture, response to bisphosphonate",GCST008098,2:102371840
rs6768500-<b>C</b>,"1 x 10-6",,0.023,7.634,'-,[3.379-17.25],CNTN4,"Atypical femoral fracture in phosphonate treatment","atypical femoral fracture, response to bisphosphonate",GCST008098,3:2651574
rs2717296-<b>C</b>,"9 x 10-6",,0.426,2.864,'-,[1.802-4.552],"LINC02031, ATP11B","Atypical femoral fracture in phosphonate treatment","atypical femoral fracture, response to bisphosphonate",GCST008098,3:182739192
rs71526045-<b>A</b>,"5 x 10-6",,0.045,5.237,'-,[2.575-10.65],RNA5SP228,"Atypical femoral fracture in phosphonate treatment","atypical femoral fracture, response to bisphosphonate",GCST008098,7:24079333
rs2727797-<b>T</b>,"7 x 10-6",,0.44,3.142,'-,[1.909-5.169],AOAH,"Atypical femoral fracture in phosphonate treatment","atypical femoral fracture, response to bisphosphonate",GCST008098,7:36589155
rs17063092-<b>C</b>,"5 x 10-6",,0.238,2.958,'-,[1.86-4.703],CSMD1,"Atypical femoral fracture in phosphonate treatment","atypical femoral fracture, response to bisphosphonate",GCST008098,8:3247310
rs36009580-<b>G</b>,"8 x 10-6",,0.194,2.965,'-,[1.839-4.78],"PSAP, CHST3","Atypical femoral fracture in phosphonate treatment","atypical femoral fracture, response to bisphosphonate",GCST008098,10:71868028
rs7082862-<b>G</b>,"7 x 10-6",,0.071,3.851,'-,[2.139-6.93],"INPP5A, LINC01165","Atypical femoral fracture in phosphonate treatment","atypical femoral fracture, response to bisphosphonate",GCST008098,10:132528459
rs113093597-<b>A</b>,"1 x 10-7",,0.017,6.144,'-,[3.137-12.03],RNU6-755P,"Bisphosphonate-associated atypical femoral fracture","atypical femoral fracture, response to bisphosphonate",GCST008097,1:165048606
rs56272862-<b>G</b>,"8 x 10-7",,0.045,3.995,'-,[2.307-6.917],SPAST,"Bisphosphonate-associated atypical femoral fracture","atypical femoral fracture, response to bisphosphonate",GCST008097,2:32154594
chr2:102820009-<b>G</b>,"1 x 10-6",,0.024,5.092,'-,[2.652-9.779],'-,"Bisphosphonate-associated atypical femoral fracture","atypical femoral fracture, response to bisphosphonate",GCST008097,"Mapping not available"
rs11465606-<b>A</b>,"7 x 10-9",,0.024,6.149,'-,[3.324-11.37],IL18R1,"Bisphosphonate-associated atypical femoral fracture","atypical femoral fracture, response to bisphosphonate",GCST008097,2:102371840
rs145475960-<b>A</b>,"1 x 10-6",,0.02,5.499,'-,[2.778-10.89],SLC9A4,"Bisphosphonate-associated atypical femoral fracture","atypical femoral fracture, response to bisphosphonate",GCST008097,2:102513902
rs78797265-<b>T</b>,"6 x 10-7",,0.012,6.925,'-,[3.232-14.84],ITPRID2,"Bisphosphonate-associated atypical femoral fracture","atypical femoral fracture, response to bisphosphonate",GCST008097,2:181871540
rs76646538-<b>C</b>,"4 x 10-7",,0.04,3.933,'-,[2.317-6.676],CNTN4,"Bisphosphonate-associated atypical femoral fracture","atypical femoral fracture, response to bisphosphonate",GCST008097,3:2653043
rs73111385-<b>G</b>,"6 x 10-8",,0.031,5.042,'-,[2.811-9.045],SNTN,"Bisphosphonate-associated atypical femoral fracture","atypical femoral fracture, response to bisphosphonate",GCST008097,3:63659734
rs191328328-<b>C</b>,"2 x 10-7",,0.009,8.951,'-,[3.917-20.46],"LINC02269, HAND2-AS1","Bisphosphonate-associated atypical femoral fracture","atypical femoral fracture, response to bisphosphonate",GCST008097,4:173690559
rs7729897-<b>G</b>,"4 x 10-10",,0.01,10.27,'-,[4.949-21.31],"RNU7-156P, MIR5197","Bisphosphonate-associated atypical femoral fracture","atypical femoral fracture, response to bisphosphonate",GCST008097,5:143591297
rs1773013-<b>A</b>,"9 x 10-7",,0.092,3.277,'-,[2.041-5.261],"LINC02521, GMDS-DT","Bisphosphonate-associated atypical femoral fracture","atypical femoral fracture, response to bisphosphonate",GCST008097,6:2560478
rs9386997-<b>A</b>,"2 x 10-6",,0.011,7.389,'-,[3.237-16.87],SLC16A10,"Bisphosphonate-associated atypical femoral fracture","atypical femoral fracture, response to bisphosphonate",GCST008097,6:111092835
rs73010912-<b>A</b>,"2 x 10-6",,0.015,6.174,'-,[2.903-13.13],SCAF8,"Bisphosphonate-associated atypical femoral fracture","atypical femoral fracture, response to bisphosphonate",GCST008097,6:154746176
rs142711375-<b>G</b>,"2 x 10-6",,0.014,6.503,'-,[3.028-13.97],HMGN1P19,"Bisphosphonate-associated atypical femoral fracture","atypical femoral fracture, response to bisphosphonate",GCST008097,7:46562811
chr8:2410672-<b>T</b>,"7 x 10-7",,0.013,7.257,'-,[3.318-15.88],'-,"Bisphosphonate-associated atypical femoral fracture","atypical femoral fracture, response to bisphosphonate",GCST008097,"Mapping not available"
rs74463341-<b>C</b>,"1 x 10-6",,0.014,7.027,'-,[3.219-15.34],"RNU6-1151P, RNU6-526P","Bisphosphonate-associated atypical femoral fracture","atypical femoral fracture, response to bisphosphonate",GCST008097,8:9370824
rs74382792-<b>G</b>,"1 x 10-6",,0.014,6.941,'-,[3.181-15.15],CLVS1,"Bisphosphonate-associated atypical femoral fracture","atypical femoral fracture, response to bisphosphonate",GCST008097,8:61444141
rs150057407-<b>G</b>,"2 x 10-6",,0.024,4.92,'-,[2.563-9.445],RFX3,"Bisphosphonate-associated atypical femoral fracture","atypical femoral fracture, response to bisphosphonate",GCST008097,9:3276207
rs187960516-<b>A</b>,"2 x 10-6",,0.01,7.132,'-,[3.164-16.07],"CLTA, GNE","Bisphosphonate-associated atypical femoral fracture","atypical femoral fracture, response to bisphosphonate",GCST008097,9:36238457
rs148123055-<b>G</b>,"2 x 10-6",,0.014,6.626,'-,[3.044-14.42],TDRD7,"Bisphosphonate-associated atypical femoral fracture","atypical femoral fracture, response to bisphosphonate",GCST008097,9:97414334
rs12336042-<b>A</b>,"3 x 10-7",,0.015,6.731,'-,[3.252-13.93],TMEM38B,"Bisphosphonate-associated atypical femoral fracture","atypical femoral fracture, response to bisphosphonate",GCST008097,9:105775919
rs112889159-<b>T</b>,"7 x 10-7",,0.01,8.161,'-,[3.564-18.69],LARP4B,"Bisphosphonate-associated atypical femoral fracture","atypical femoral fracture, response to bisphosphonate",GCST008097,10:853363
rs116973965-<b>A</b>,"8 x 10-7",,0.011,8.121,'-,[3.542-18.62],"RNA5SP357, TUBB8P4","Bisphosphonate-associated atypical femoral fracture","atypical femoral fracture, response to bisphosphonate",GCST008097,12:34200007
rs146647050-<b>T</b>,"2 x 10-6",,0.019,5.931,'-,[2.871-12.25],'-,"Bisphosphonate-associated atypical femoral fracture","atypical femoral fracture, response to bisphosphonate",GCST008097,12:37797327
rs144094653-<b>A</b>,"4 x 10-8",,0.014,7.675,'-,[3.704-15.91],"TUBB8P5, RNA5SP359","Bisphosphonate-associated atypical femoral fracture","atypical femoral fracture, response to bisphosphonate",GCST008097,12:38199817
rs4776851-<b>A</b>,"6 x 10-6",,0.031,6.06,'-,[2.776-13.23],LINC02206,"Atypical femoral fracture in phosphonate treatment","atypical femoral fracture, response to bisphosphonate",GCST008098,15:66888582
rs1495741-<b>A</b>,"7 x 10-11",(recessive),0.59,6.01,'-,[3.42-10.57],NAT2,"Liver injury in anti-tuberculosis drug treatment","Tuberculosis, response to anti-tuberculosis drug, drug-induced liver injury",GCST007897,8:18415371
rs2756263-<b>G</b>,"7 x 10-6",(dominant),0.40,4.47,'-,[2.19-9.11],PRND,"Liver injury in anti-tuberculosis drug treatment","Tuberculosis, response to anti-tuberculosis drug, drug-induced liver injury",GCST007897,20:4725110
rs247617-<b>?</b>,"2 x 10-9",,NR,'-,"0.332 unit increase",[0.22-0.44],"CETP, HERPUD1","Response to fenofibrate (HDL cholesterol levels)","high density lipoprotein cholesterol measurement, response to fenofibrate",GCST007300,16:56956804
rs11725502-<b>T</b>,"5 x 10-15",,0.0983607,'-,'-,'-,UGT2B10,"Plasma norclozapine levels in treatment-resistant schizophrenia","treatment refractory schizophrenia, response to clozapine",GCST007686,4:68815224
rs2011425-<b>G</b>,"8 x 10-9",,0.0864838,'-,'-,'-,"UGT1A9, UGT1A7, UGT1A4, UGT1A5, UGT1A10, UGT1A6, UGT1A8","Plasma norclozapine levels in treatment-resistant schizophrenia","treatment refractory schizophrenia, response to clozapine",GCST007686,2:233718962
rs10023464-<b>T</b>,"9 x 10-66",,0.101,'-,'-,'-,UGT2B10,"Plasma clozapine-norclozapine ratio in treatment-resistant schizophrenia","treatment refractory schizophrenia, response to clozapine",GCST007684,4:68794020
rs12767583-<b>T</b>,"5 x 10-14",,0.143,'-,'-,'-,CYP2C19,"Plasma clozapine-norclozapine ratio in treatment-resistant schizophrenia","treatment refractory schizophrenia, response to clozapine",GCST007684,10:94787706
rs7668556-<b>A</b>,"4 x 10-13",,0.466,'-,'-,'-,"UGT2B7, UGT2B11","Plasma clozapine-norclozapine ratio in treatment-resistant schizophrenia","treatment refractory schizophrenia, response to clozapine",GCST007684,4:69164555
rs2472297-<b>T</b>,"4 x 10-10",,0.280027,'-,'-,'-,"CYP1A2, CYP1A1","Plasma clozapine levels in treatment-resistant schizophrenia","treatment refractory schizophrenia, response to clozapine",GCST007685,15:74735539
rs2629529-<b>C</b>,"6 x 10-6",(AA),0.06,'-,'-,'-,"NPM1P31, ABRAXAS2","Asthma control x inhaled corticosteroid treatment interaction (2df)","asthma symptoms measurement, response to corticosteroid",GCST008230,10:124845846
rs591118-<b>A</b>,"4 x 10-9",,NR,5.89,'-,[2.97-11.68],PDGFD,"Corticosteroid-induced adrenal suppression (peak cortisol < 350 nmol/L)","adrenal suppression measurement, response to corticosteroid",GCST005927,11:104095993
rs2449598-<b>A</b>,"2 x 10-10",,0.4808,'-,"0.4897 unit decrease",[0.34-0.64],DLG2,"Estrogen level change in anastrozole-treated breast cancer","estrogen measurement, estrogen-receptor positive breast cancer, response to aromatase inhibitor",GCST011407,11:83983729
rs1437153-<b>G</b>,"3 x 10-9",,0.0618,'-,"0.4028 unit decrease",[0.27-0.53],'-,"Estrogen level change in anastrozole-treated breast cancer","estrogen measurement, estrogen-receptor positive breast cancer, response to aromatase inhibitor",GCST011407,16:64410685
rs6981827-<b>?</b>,"2 x 10-8",(estradiol),NR,'-,'-,'-,CSMD1,"Estrogen level change in anastrozole-treated breast cancer","estrogen measurement, estrogen-receptor positive breast cancer, response to aromatase inhibitor",GCST011407,8:3217516
rs6981827-<b>?</b>,"2 x 10-8",(estrone),NR,'-,'-,'-,CSMD1,"Estrogen level change in anastrozole-treated breast cancer","estrogen measurement, estrogen-receptor positive breast cancer, response to aromatase inhibitor",GCST011407,8:3217516
rs6981827-<b>C</b>,"2 x 10-8","(estrone and estradiol)",0.0502,'-,"0.5978 unit decrease",[0.39-0.8],CSMD1,"Estrogen level change in anastrozole-treated breast cancer","estrogen measurement, estrogen-receptor positive breast cancer, response to aromatase inhibitor",GCST011407,8:3217516
rs9945654-<b>G</b>,"4 x 10-6",,0.0124,'-,"2.0652 unit decrease",[1.2-2.93],NETO1-DT,"Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,18:72975302
rs9945951-<b>A</b>,"4 x 10-6",,0.0126,'-,"2.0573 unit decrease",[1.19-2.93],NETO1-DT,"Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,18:72975319
rs4342892-<b>A</b>,"5 x 10-6",,0.2555,'-,"0.272 unit increase",[0.16-0.39],ST6GALNAC3,"Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,1:76398018
rs28845026-<b>T</b>,"5 x 10-8",,0.1987,'-,"0.3673 unit increase",[0.24-0.5],"ECEL1P3, ALPP","Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,2:232355544
rs12518356-<b>G</b>,"4 x 10-6",,0.3123,'-,"0.2618 unit increase",[0.15-0.37],RPSAP37,"Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,5:126041980
rs6460664-<b>C</b>,"2 x 10-6",,0.3768,'-,"0.2535 unit increase",[0.15-0.36],GALNT17,"Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,7:71535629
rs4489302-<b>C</b>,"3 x 10-6",,0.0143,'-,"1.3599 unit decrease",[0.8-1.92],MATN2,"Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,8:97892687
rs77628230-<b>T</b>,"5 x 10-7",,0.0278,'-,"0.7739 unit decrease",[0.48-1.07],SVIL,"Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,10:29653623
rs77034926-<b>A</b>,"2 x 10-6",,0.1805,'-,"0.3403 unit decrease",[0.2-0.48],LINC02452,"Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,12:96161387
rs8038589-<b>T</b>,"3 x 10-6",,0.0206,'-,"0.9179 unit decrease",[0.54-1.3],RPL7P5,"Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,15:99507178
rs11648166-<b>G</b>,"2 x 10-8",,0.1178,'-,"0.4401 unit increase",[0.29-0.59],"CNOT1, SLC38A7","Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,16:58662802
rs62112924-<b>A</b>,"2 x 10-6",,0.033,'-,"1.188 unit decrease",[0.7-1.67],LINC00683,"Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,18:76553300
rs76164207-<b>A</b>,"4 x 10-6",,0.1655,'-,"0.4204 unit decrease",[0.24-0.6],MUC16,"Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,19:8857556
rs6106324-<b>C</b>,"5 x 10-6",,0.381,'-,"0.2473 unit decrease",[0.14-0.35],'-,"Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,20:20984347
rs883013-<b>T</b>,"6 x 10-8",,0.1854,'-,"0.3644 unit increase",[0.23-0.5],ECEL1P3,"Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,2:232350693
rs4996188-<b>A</b>,"7 x 10-8",,0.1851,'-,"0.3631 unit increase",[0.23-0.49],ECEL1P3,"Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,2:232350750
rs6715083-<b>T</b>,"8 x 10-8",,0.1824,'-,"0.3649 unit increase",[0.23-0.5],"ECEL1P3, ALPP","Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,2:232353782
rs3784911-<b>T</b>,"4 x 10-8",,0.1191,'-,"0.4353 unit increase",[0.28-0.59],SLC38A7,"Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,16:58669712
rs60979655-<b>T</b>,"5 x 10-8",,0.1129,'-,"0.4378 unit increase",[0.28-0.59],"CNOT1, SLC38A7","Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,16:58661235
rs16960359-<b>A</b>,"5 x 10-8",,0.1189,'-,"0.4324 unit increase",[0.28-0.59],SLC38A7,"Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,16:58670592
rs76733922-<b>C</b>,"6 x 10-8",,0.1213,'-,"0.4257 unit increase",[0.27-0.58],SLC38A7,"Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,16:58668637
rs12149056-<b>A</b>,"7 x 10-8",,0.1162,'-,"0.4341 unit increase",[0.28-0.59],"CNOT1, SLC38A7","Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,16:58657060
rs2205986-<b>?</b>,"2 x 10-8",,'-,8.3,'-,[3.6-19.2],SYT14,"Drug-induced liver injury in interferon-beta-treated multiple sclerosis","multiple sclerosis, response to interferon beta, drug-induced liver injury",GCST006270,1:209942767
rs72734413-<b>?</b>,"7 x 10-6",,NR,'-,'-,'-,PLPPR5,"Response to long-term oxygen therapy in chronic obstructive pulmonary disease","response to supplemental oxygen, chronic obstructive pulmonary disease",GCST007558,1:99096066
rs398926-<b>?</b>,"2 x 10-6",,NR,'-,'-,'-,"CRYBA2, MIR375","Response to long-term oxygen therapy in chronic obstructive pulmonary disease","response to supplemental oxygen, chronic obstructive pulmonary disease",GCST007558,2:218998867
rs6825556-<b>?</b>,"8 x 10-6",,NR,'-,'-,'-,GABRB1,"Response to long-term oxygen therapy in chronic obstructive pulmonary disease","response to supplemental oxygen, chronic obstructive pulmonary disease",GCST007558,4:47393836
rs149605813-<b>?</b>,"4 x 10-6",,NR,'-,'-,'-,"MT2P1, TMPRSS11E","Response to long-term oxygen therapy in chronic obstructive pulmonary disease","response to supplemental oxygen, chronic obstructive pulmonary disease",GCST007558,4:68436223
rs16875861-<b>?</b>,"6 x 10-6",,NR,'-,'-,'-,LHFPL2,"Response to long-term oxygen therapy in chronic obstructive pulmonary disease","response to supplemental oxygen, chronic obstructive pulmonary disease",GCST007558,5:78746500
rs55924278-<b>?</b>,"7 x 10-6",,NR,'-,'-,'-,FSTL4,"Response to long-term oxygen therapy in chronic obstructive pulmonary disease","response to supplemental oxygen, chronic obstructive pulmonary disease",GCST007558,5:133265019
rs77506377-<b>?</b>,"2 x 10-6",,NR,'-,'-,'-,ZNF883,"Response to long-term oxygen therapy in chronic obstructive pulmonary disease","response to supplemental oxygen, chronic obstructive pulmonary disease",GCST007558,9:113010268
rs7870128-<b>?</b>,"1 x 10-6",,NR,'-,'-,'-,RPL35AP22,"Response to long-term oxygen therapy in chronic obstructive pulmonary disease","response to supplemental oxygen, chronic obstructive pulmonary disease",GCST007558,9:117673499
rs12261071-<b>?</b>,"7 x 10-6",,NR,'-,'-,'-,LRMDA,"Response to long-term oxygen therapy in chronic obstructive pulmonary disease","response to supplemental oxygen, chronic obstructive pulmonary disease",GCST007558,10:75845966
rs7928395-<b>?</b>,"6 x 10-7",,NR,'-,'-,'-,LINC02759,"Response to long-term oxygen therapy in chronic obstructive pulmonary disease","response to supplemental oxygen, chronic obstructive pulmonary disease",GCST007558,11:38559490
rs57705361-<b>?</b>,"5 x 10-6",,NR,'-,'-,'-,SERPINA12,"Response to long-term oxygen therapy in chronic obstructive pulmonary disease","response to supplemental oxygen, chronic obstructive pulmonary disease",GCST007558,14:94501304
rs4510073-<b>?</b>,"3 x 10-6",,NR,'-,'-,'-,ASIC2,"Response to long-term oxygen therapy in chronic obstructive pulmonary disease","response to supplemental oxygen, chronic obstructive pulmonary disease",GCST007558,17:33128407
rs11667764-<b>?</b>,"6 x 10-6",,NR,'-,'-,'-,HOOK2,"Response to long-term oxygen therapy in chronic obstructive pulmonary disease","response to supplemental oxygen, chronic obstructive pulmonary disease",GCST007558,19:12778410
rs12168060-<b>?</b>,"7 x 10-6",,NR,'-,'-,'-,FAM230I,"Response to long-term oxygen therapy in chronic obstructive pulmonary disease","response to supplemental oxygen, chronic obstructive pulmonary disease",GCST007558,22:23465394
rs4331189-<b>?</b>,"3 x 10-7",,'-,'-,'-,'-,C12orf45,"Beta blocker survival benefit in heart failure with reduced ejection fraction (time to all cause mortality x beta blocker interaction)","Reduced ejection fraction, heart failure, response to beta blocker, mortality",GCST010923,12:104992867
rs4075503-<b>?</b>,"9 x 10-7",,'-,'-,'-,'-,"KRT18P20, SLC41A2","Beta blocker survival benefit in heart failure with reduced ejection fraction (time to all cause mortality x beta blocker interaction)","Reduced ejection fraction, heart failure, response to beta blocker, mortality",GCST010923,12:104959466
rs16870234-<b>?</b>,"1 x 10-6",,'-,'-,'-,'-,LSINCT5,"Beta blocker survival benefit in heart failure with reduced ejection fraction (time to all cause mortality x beta blocker interaction)","Reduced ejection fraction, heart failure, response to beta blocker, mortality",GCST010923,5:2655665
rs75087282-<b>?</b>,"2 x 10-6",,'-,'-,'-,'-,NUDT12,"Beta blocker survival benefit in heart failure with reduced ejection fraction (time to all cause mortality x beta blocker interaction)","Reduced ejection fraction, heart failure, response to beta blocker, mortality",GCST010923,5:103642776
rs28548659-<b>?</b>,"3 x 10-6",,'-,'-,'-,'-,BTBD11,"Beta blocker survival benefit in heart failure with reduced ejection fraction (time to all cause mortality x beta blocker interaction)","Reduced ejection fraction, heart failure, response to beta blocker, mortality",GCST010923,12:107654295
rs782760-<b>?</b>,"4 x 10-6",,'-,'-,'-,'-,'-,"Beta blocker survival benefit in heart failure with reduced ejection fraction (time to all cause mortality x beta blocker interaction)","Reduced ejection fraction, heart failure, response to beta blocker, mortality",GCST010923,4:11262289
rs367841-<b>?</b>,"5 x 10-6",,'-,'-,'-,'-,CMTM6,"Beta blocker survival benefit in heart failure with reduced ejection fraction (time to all cause mortality x beta blocker interaction)","Reduced ejection fraction, heart failure, response to beta blocker, mortality",GCST010923,3:32484661
rs6013374-<b>?</b>,"5 x 10-6",,'-,'-,'-,'-,ZFP64,"Beta blocker survival benefit in heart failure with reduced ejection fraction (time to all cause mortality x beta blocker interaction)","Reduced ejection fraction, heart failure, response to beta blocker, mortality",GCST010923,20:52069476
rs189508091-<b>?</b>,"6 x 10-6",,'-,'-,'-,'-,ZNF547,"Beta blocker survival benefit in heart failure with reduced ejection fraction (time to all cause mortality x beta blocker interaction)","Reduced ejection fraction, heart failure, response to beta blocker, mortality",GCST010923,19:57376380
rs299453-<b>?</b>,"7 x 10-6",,'-,'-,'-,'-,TMTC1,"Beta blocker survival benefit in heart failure with reduced ejection fraction (time to all cause mortality x beta blocker interaction)","Reduced ejection fraction, heart failure, response to beta blocker, mortality",GCST010923,12:29535269
rs9737956-<b>?</b>,"8 x 10-6",,'-,'-,'-,'-,SLC41A2,"Beta blocker survival benefit in heart failure with reduced ejection fraction (time to all cause mortality x beta blocker interaction)","Reduced ejection fraction, heart failure, response to beta blocker, mortality",GCST010923,12:104806310
rs6773175-<b>?</b>,"9 x 10-6",,'-,'-,'-,'-,NAALADL2,"Beta blocker survival benefit in heart failure with reduced ejection fraction (time to all cause mortality x beta blocker interaction)","Reduced ejection fraction, heart failure, response to beta blocker, mortality",GCST010923,3:175704057
rs591118-<b>A</b>,"4 x 10-10",,NR,4.05,'-,[2.00-8.21],PDGFD,"Corticosteroid-induced adrenal suppression (peak cortisol < 500 nmol/L)","adrenal suppression measurement, response to corticosteroid",GCST005924,11:104095993
rs3755963-<b>C</b>,"9 x 10-7",,NR,'-,"0.1412 unit decrease",[0.085-0.197],GAK,"Meningococcal C IgG concentrations post childhood immunization","anti-meningococcal C IgG measurement, response to vaccine",GCST008498,4:900467
rs10517505-<b>T</b>,"3 x 10-6",,NR,'-,"0.2949 unit decrease",[0.17-0.42],'-,"Meningococcal C functional antibody titers post childhood immunization","anti-meningococcal C serum bactericidal antibody measurement, response to vaccine",GCST008499,4:60480254
rs17770331-<b>A</b>,"7 x 10-7",,NR,'-,"0.1421 unit increase",[0.086-0.198],"SIRPG-AS1, SIRPG","Meningococcal C functional antibody titers post childhood immunization","anti-meningococcal C serum bactericidal antibody measurement, response to vaccine",GCST008499,20:1634662
rs4813191-<b>C</b>,"8 x 10-6",,NR,'-,"0.1206 unit increase",[0.068-0.173],"SIRPG, SIRPG-AS1","Meningococcal C functional antibody titers post childhood immunization","anti-meningococcal C serum bactericidal antibody measurement, response to vaccine",GCST008499,20:1645833
rs3818168-<b>T</b>,"6 x 10-7",,NR,'-,"0.1452 unit increase",[0.088-0.202],SIRPB3P,"Meningococcal C functional antibody titers post childhood immunization","anti-meningococcal C serum bactericidal antibody measurement, response to vaccine",GCST008499,20:1671323
rs6135736-<b>A</b>,"6 x 10-8",,NR,'-,"0.158 unit increase",[0.1-0.22],SIRPB3P,"Meningococcal C functional antibody titers post childhood immunization","anti-meningococcal C serum bactericidal antibody measurement, response to vaccine",GCST008499,20:1706804
rs4814511-<b>C</b>,"4 x 10-7",,NR,'-,"0.1427 unit increase",[0.088-0.198],"SIRPB3P, CKAP2LP1","Meningococcal C functional antibody titers post childhood immunization","anti-meningococcal C serum bactericidal antibody measurement, response to vaccine",GCST008499,20:1729626
rs2523650-<b>?</b>,"1 x 10-9",,NR,'-,"0.1117 unit increase",[0.076-0.147],MICB-DT,"Tetanus toxoid IgG concentrations post childhood immunization","anti-tetanus toxoid IgG measurement, response to vaccine",GCST008500,6:31481245
rs5747408-<b>?</b>,"9 x 10-6",,'-,'-,"0.113 unit increase",'-,MICAL3,"Response to hepatitis B vaccine","response to vaccine",GCST005606,22:17914354
rs3132969-<b>?</b>,"2 x 10-6",,'-,'-,"0.147 unit decrease",'-,TSBP1-AS1,"Response to hepatitis B vaccine","response to vaccine",GCST005606,6:32261461
rs17588573-<b>?</b>,"6 x 10-6",,'-,'-,"0.208 unit increase",'-,LINC01179,"Response to hepatitis B vaccine","response to vaccine",GCST005606,4:165673036
rs10947096-<b>?</b>,"2 x 10-6",,'-,'-,"0.197 unit increase",'-,"HCG20, LINC00243","Response to hepatitis B vaccine","response to vaccine",GCST005606,6:30798118
rs12527394-<b>?</b>,"5 x 10-8",,'-,'-,"0.174 unit decrease",'-,"C6orf15, RNU6-1133P","Response to hepatitis B vaccine","response to vaccine",GCST005606,6:31087241
rs3130473-<b>?</b>,"8 x 10-6",,'-,'-,"0.128 unit decrease",'-,"HCG27, HLA-C","Response to hepatitis B vaccine","response to vaccine",GCST005606,6:31231431
rs4248166-<b>?</b>,"1 x 10-12",,'-,'-,"0.124 unit decrease",'-,"BTNL2, TSBP1-AS1","Response to hepatitis B vaccine","response to vaccine",GCST005606,6:32398644
rs6923338-<b>?</b>,"8 x 10-6",,'-,'-,"0.116 unit decrease",'-,TMEM14A,"Response to hepatitis B vaccine","response to vaccine",GCST005606,6:52684524
rs4355011-<b>?</b>,"7 x 10-6",,'-,'-,"0.122 unit increase",'-,CDH2,"Response to hepatitis B vaccine","response to vaccine",GCST005606,18:27877334
rs2395179-<b>?</b>,"5 x 10-14",,'-,'-,"0.221 unit decrease",'-,"TSBP1-AS1, HLA-DRA","Response to hepatitis B vaccine","response to vaccine",GCST005606,6:32439525
rs34039593-<b>?</b>,"6 x 10-12",,'-,'-,"0.2 unit increase",'-,"HLA-DQA1, HLA-DRB1","Response to hepatitis B vaccine","response to vaccine",GCST005606,6:32602534
rs7745040-<b>?</b>,"2 x 10-10",,'-,'-,"0.162 unit decrease",'-,"HLA-DQB1, MTCO3P1","Response to hepatitis B vaccine","response to vaccine",GCST005606,6:32696555
rs1015166-<b>?</b>,"1 x 10-8",,'-,'-,"0.16 unit decrease",'-,TAP2,"Response to hepatitis B vaccine","response to vaccine",GCST005606,6:32830954
rs9277549-<b>?</b>,"6 x 10-11",,'-,'-,"0.175 unit decrease",'-,HLA-DPB1,"Response to hepatitis B vaccine","response to vaccine",GCST005606,6:33087642
rs3819686-<b>?</b>,"7 x 10-6",,'-,'-,"0.15 unit decrease",'-,"CDSN, PSORS1C1","Response to hepatitis B vaccine","response to vaccine",GCST005606,6:31118047
rs9268202-<b>?</b>,"8 x 10-8",,'-,'-,"0.168 unit decrease",'-,"TSBP1-AS1, TSBP1","Response to hepatitis B vaccine","response to vaccine",GCST005606,6:32311563
rs9268831-<b>?</b>,"1 x 10-13",,'-,'-,"0.192 unit decrease",'-,HLA-DRB9,"Response to hepatitis B vaccine","response to vaccine",GCST005606,6:32459971
rs9273062-<b>?</b>,"2 x 10-10",,'-,'-,"0.165 unit increase",'-,HLA-DQA1,"Response to hepatitis B vaccine","response to vaccine",GCST005606,6:32644384
rs9277176-<b>?</b>,"1 x 10-7",,'-,'-,"0.219 unit decrease",'-,"HLA-DOA, HLA-DPA1","Response to hepatitis B vaccine","response to vaccine",GCST005606,6:33055373
rs9277464-<b>?</b>,"7 x 10-11",,'-,'-,"0.175 unit decrease",'-,HLA-DPB1,"Response to hepatitis B vaccine","response to vaccine",GCST005606,6:33085575
rs9277356-<b>A</b>,"7 x 10-31",(Adults),0.4716,1.474164,'-,[1.38-1.574],HLA-DPB1,"Response to hepatitis B vaccine","Anti-hepatitis B virus surface antigen IgG measurement, response to vaccine",GCST008435,6:33080917
rs3821977-<b>A</b>,"2 x 10-6",,0.8304,'-,"1.126 unit increase",[0.66-1.59],G3BP2,"Response to (pegylated) interferon in HBeAg-negative hepatitis B","response to interferon, chronic hepatitis B virus infection",GCST009172,4:75703167
rs6928374-<b>A</b>,"3 x 10-6",,0.5523,'-,"0.8138 unit decrease",[0.47-1.16],SLC16A10,"Response to (pegylated) interferon in HBeAg-negative hepatitis B","response to interferon, chronic hepatitis B virus infection",GCST009172,6:8204180
rs9419644-<b>G</b>,"3 x 10-6",,0.08867,'-,"1.302 unit increase",[0.76-1.85],LINC01164,"Response to (pegylated) interferon in HBeAg-negative hepatitis B","response to interferon, chronic hepatitis B virus infection",GCST009172,10:131720732
rs11043479-<b>G</b>,"2 x 10-6",,0.3278,'-,"0.8571 unit increase",[0.51-1.21],"TIMM17BP1, LINC02378","Response to (pegylated) interferon in HBeAg-negative hepatitis B","response to interferon, chronic hepatitis B virus infection",GCST009172,12:17476022
rs371991-<b>G</b>,"3 x 10-6",,0.5519,'-,"0.7406 unit decrease",[0.43-1.05],PRELID2,"Response to (pegylated) interferon in HBeAG-positive hepatitis B","response to interferon, chronic hepatitis B virus infection",GCST009173,5:145833218
rs9399955-<b>T</b>,"4 x 10-6",,0.08606,'-,"1.422 unit increase",[0.82-2.03],RN7SKP211,"Response to (pegylated) interferon in HBeAG-positive hepatitis B","response to interferon, chronic hepatitis B virus infection",GCST009173,6:105877510
rs78900671-<b>C</b>,"6 x 10-7",,0.03649,'-,"1.434 unit increase",[0.87-2],COL22A1,"Response to (pegylated) interferon in chronic hepatitis B","response to interferon, chronic hepatitis B virus infection",GCST009174,8:138653967
rs61886277-<b>T</b>,"1 x 10-6",,0.2252,'-,"0.6342 unit increase",[0.38-0.89],PLCE1,"Response to (pegylated) interferon in chronic hepatitis B","response to interferon, chronic hepatitis B virus infection",GCST009174,10:94012060
rs2824122-<b>A</b>,"3 x 10-6",,0.3259,'-,"0.5717 unit decrease",[0.33-0.81],'-,"Response to (pegylated) interferon in chronic hepatitis B","response to interferon, chronic hepatitis B virus infection",GCST009174,21:16913154
rs6916777-<b>A</b>,"1 x 10-6",,NR,'-,"14.03 unit increase",[8.47-19.59],RNF217-AS1,"Response to antidepressants (symptom improvement)","depressive symptom measurement, response to antidepressant",GCST011528,6:124930228
rs12597726-<b>A</b>,"9 x 10-6",,NR,'-,"14.25 unit decrease",[8.06-20.44],PIEZO1,"Response to antidepressants (symptom improvement)","depressive symptom measurement, response to antidepressant",GCST011528,16:88753893
rs6696969-<b>C</b>,"4 x 10-6",,NR,'-,"15.19 unit decrease",[8.89-21.49],'-,"Response to antidepressants (symptom improvement)","depressive symptom measurement, response to antidepressant",GCST011528,1:79874736
rs10204266-<b>T</b>,"4 x 10-6",,NR,'-,"22.49 unit decrease",[13.12-31.86],"DNAJC27, ADCY3","Response to antidepressants (symptom improvement)","depressive symptom measurement, response to antidepressant",GCST011528,2:24923820
rs74865692-<b>T</b>,"2 x 10-6",,NR,'-,"23.67 unit decrease",[14.02-33.33],ERBB4,"Response to antidepressants (symptom improvement)","depressive symptom measurement, response to antidepressant",GCST011528,2:212297304
rs9905054-<b>G</b>,"4 x 10-6",,NR,'-,"21.58 unit decrease",[12.58-30.58],"CACNG4, RNA5SP446","Response to antidepressants (symptom improvement)","depressive symptom measurement, response to antidepressant",GCST011528,17:66937666
rs77547060-<b>C</b>,"2 x 10-6",,NR,'-,"25.59 unit decrease",[15.25-35.93],SLC12A5,"Response to antidepressants (symptom improvement)","depressive symptom measurement, response to antidepressant",GCST011528,20:46033306
rs6916777-<b>A</b>,"4 x 10-6",,NR,2.58,'-,[1.73-3.85],RNF217-AS1,"Remission after antidepressant treatment in major depression","remission, response to antidepressant",GCST011531,6:124930228
rs2962466-<b>G</b>,"2 x 10-6",,NR,0.37,'-,[0.24-0.56],'-,"Remission after antidepressant treatment in major depression","remission, response to antidepressant",GCST011531,16:62774103
rs12597726-<b>A</b>,"1 x 10-6",,NR,0.33,'-,[0.21-0.51],PIEZO1,"Remission after antidepressant treatment in major depression","remission, response to antidepressant",GCST011531,16:88753893
rs188352979-<b>?</b>,"3 x 10-7",,'-,2.87,'-,[2.47-3.28],"HMX3, ACADSB","Antidepressant treatment resistance (> 2 drugs prescribed)","response to antidepressant",GCST007355,10:123090884
rs145842949-<b>?</b>,"4 x 10-7",,'-,2.42,'-,[2.08-2.77],MON1B,"Antidepressant treatment resistance (> 2 drugs prescribed)","response to antidepressant",GCST007355,16:77110846
rs111968111-<b>?</b>,"4 x 10-7",,'-,3,'-,[2.58-3.42],"SLC26A8, SRPK1","Antidepressant treatment resistance (> 2 drugs prescribed)","response to antidepressant",GCST007355,6:35930341
rs138583130-<b>?</b>,"5 x 10-7",,'-,2.5,'-,[2.13-2.87],"CNTN1, MUC19","Antidepressant treatment resistance (> 2 drugs prescribed)","response to antidepressant",GCST007355,12:40629678
rs116902282-<b>?</b>,"2 x 10-7",,'-,'-,"0.49 unit increase",[0.34-0.64],"RPL5P26, LINC02651","Antidepressant treatment resistance (number of drugs prescribed)","response to antidepressant",GCST007356,10:69714608
rs188352979-<b>?</b>,"4 x 10-7",,'-,'-,"0.33 unit increase",[0.2-0.46],"HMX3, ACADSB","Antidepressant treatment resistance (number of drugs prescribed)","response to antidepressant",GCST007356,10:123090884
rs182041872-<b>?</b>,"5 x 10-7",,'-,'-,"0.3 unit increase",[0.18-0.42],"ACADSB, HMX3","Antidepressant treatment resistance (number of drugs prescribed)","response to antidepressant",GCST007356,10:123093218
rs4400118-<b>?</b>,"5 x 10-7",,'-,'-,"0.29 unit increase",[0.18-0.4],KCNN2,"Antidepressant treatment resistance (number of drugs prescribed)","response to antidepressant",GCST007356,5:114275928
rs7851998-<b>G</b>,"3 x 10-6",(Hispanic/Latino),0.809,1.92,'-,[1.45-2.50],LHX2,"Asthma exacerbations in inhaled corticosteroid treatment","asthma exacerbation measurement, response to corticosteroid",GCST007100,9:124066235
rs2125362-<b>A</b>,"2 x 10-7",(Hispanic/Latino),0.684,1.84,'-,[1.46-2.30],ME3,"Asthma exacerbations in inhaled corticosteroid treatment","asthma exacerbation measurement, response to corticosteroid",GCST007100,11:86456094
rs35514893-<b>C</b>,"7 x 10-6","(African American)",0.918,3.45,'-,[2.00-5.88],ARPC3P5,"Asthma exacerbations in inhaled corticosteroid treatment","asthma exacerbation measurement, response to corticosteroid",GCST007100,6:15909294
rs11121611-<b>T</b>,"2 x 10-6",(Hispanic/Latino+AfricanAmerican),0.799,1.82,'-,[1.43-2.33],ACOT7,"Asthma exacerbations in inhaled corticosteroid treatment","asthma exacerbation measurement, response to corticosteroid",GCST007100,1:6307159
rs35514893-<b>C</b>,"3 x 10-6",(Hispanic/Latino+AfricanAmerican),0.98,2.78,'-,[1.82-4.35],ARPC3P5,"Asthma exacerbations in inhaled corticosteroid treatment","asthma exacerbation measurement, response to corticosteroid",GCST007100,6:15909294
rs4897302-<b>T</b>,"2 x 10-6",(Hispanic/Latino+AfricanAmerican),0.505,1.58,'-,[1.31-1.91],TRDN,"Asthma exacerbations in inhaled corticosteroid treatment","asthma exacerbation measurement, response to corticosteroid",GCST007100,6:123565086
rs61585310-<b>T</b>,"3 x 10-6",(Hispanic/Latino+AfricanAmerican),0.204,1.64,'-,[1.33-2.04],LHFPL3,"Asthma exacerbations in inhaled corticosteroid treatment","asthma exacerbation measurement, response to corticosteroid",GCST007100,7:104366062
rs7851998-<b>G</b>,"4 x 10-6",(Hispanic/Latino+AfricanAmerican),0.809,1.79,'-,[1.39-2.27],LHX2,"Asthma exacerbations in inhaled corticosteroid treatment","asthma exacerbation measurement, response to corticosteroid",GCST007100,9:124066235
rs2125362-<b>A</b>,"4 x 10-6",(Hispanic/Latino+AfricanAmerican),0.684,1.31,'-,[0.68-2.56],ME3,"Asthma exacerbations in inhaled corticosteroid treatment","asthma exacerbation measurement, response to corticosteroid",GCST007100,11:86456094
rs450789-<b>A</b>,"3 x 10-6",(Hispanic/Latino+AfricanAmerican),0.666,1.56,'-,[1.30-1.89],"TOMM22P3, KL","Asthma exacerbations in inhaled corticosteroid treatment","asthma exacerbation measurement, response to corticosteroid",GCST007100,13:33004095
rs12959468-<b>G</b>,"3 x 10-6",(Hispanic/Latino+AfricanAmerican),0.961,2.56,'-,[1.72-3.85],BNIP3P3,"Asthma exacerbations in inhaled corticosteroid treatment","asthma exacerbation measurement, response to corticosteroid",GCST007100,18:15182382
rs2278992-<b>T</b>,"4 x 10-6",(Hispanic/Latino+AfricanAmerican),0.824,1.69,'-,[1.35-2.13],KCNN1,"Asthma exacerbations in inhaled corticosteroid treatment","asthma exacerbation measurement, response to corticosteroid",GCST007100,19:17984960
rs6001366-<b>C</b>,"3 x 10-6",(Hispanic/Latino+AfricanAmerican),0.921,2.13,'-,[1.54-2.86],"APOBEC3C, APOBEC3B-AS1","Asthma exacerbations in inhaled corticosteroid treatment","asthma exacerbation measurement, response to corticosteroid",GCST007100,22:39003936
rs5995653-<b>G</b>,"5 x 10-6",(Hispanic/Latino+AfricanAmerican),0.715,1.52,'-,[1.27-1.79],"APOBEC3C, APOBEC3B-AS1","Asthma exacerbations in inhaled corticosteroid treatment","asthma exacerbation measurement, response to corticosteroid",GCST007100,22:39008244
rs540731596-<b>?</b>,"1 x 10-6",(Hispanic/Latino+AfricanAmerican),NR,2.44,'-,[1.69-3.45],'-,"Asthma exacerbations in inhaled corticosteroid treatment","asthma exacerbation measurement, response to corticosteroid",GCST007100,18:15097278
rs5995653-<b>G</b>,"3 x 10-7",,0.715,1.43,'-,[1.23-1.64],"APOBEC3C, APOBEC3B-AS1","Asthma exacerbations in inhaled corticosteroid treatment","asthma exacerbation measurement, response to corticosteroid",GCST007100,22:39008244
rs12026039-<b>G</b>,"4 x 10-6",,NR,3.5248504,'-,[2.99-4.06],'-,"Tinnitus in cisplatin-treated testicular cancer","Tinnitus, testicular carcinoma, response to cisplatin",GCST007796,1:104028469
rs73231578-<b>T</b>,"4 x 10-6",,NR,2.9383,'-,[2.48-3.4],ADRA1A,"Tinnitus in cisplatin-treated testicular cancer","Tinnitus, testicular carcinoma, response to cisplatin",GCST007796,8:26823683
rs10842948-<b>T</b>,"5 x 10-6",,NR,2.483855,'-,[2.09-2.88],PPFIBP1,"Tinnitus in cisplatin-treated testicular cancer","Tinnitus, testicular carcinoma, response to cisplatin",GCST007796,12:27596109
rs7532231-<b>A</b>,"1 x 10-6",,NR,2.2114108,'-,[1.89-2.53],FTLP17,"Tinnitus in cisplatin-treated testicular cancer","Tinnitus, testicular carcinoma, response to cisplatin",GCST007796,1:104193445
rs6552561-<b>A</b>,"9 x 10-6",,NR,1.8521,'-,[1.58-2.12],TENM3,"Tinnitus in cisplatin-treated testicular cancer","Tinnitus, testicular carcinoma, response to cisplatin",GCST007796,4:182372363
rs498518-<b>A</b>,"9 x 10-6",,NR,1.8635,'-,[1.59-2.14],"LINC01132, LINC00184","Tinnitus in cisplatin-treated testicular cancer","Tinnitus, testicular carcinoma, response to cisplatin",GCST007796,1:234694843
rs117764890-<b>C</b>,"6 x 10-6",,NR,3.4188,'-,[2.89-3.95],LINC02664,"Tinnitus in cisplatin-treated testicular cancer","Tinnitus, testicular carcinoma, response to cisplatin",GCST007796,10:31176968
rs7606353-<b>G</b>,"2 x 10-6",,NR,4.2043,'-,[3.61-4.8],"COPS9, OR5S1P","Tinnitus in cisplatin-treated testicular cancer","Tinnitus, testicular carcinoma, response to cisplatin",GCST007796,2:240124959
rs6671895-<b>T</b>,"1 x 10-6",,NR,4.3219,'-,[3.73-4.91],MIR3659HG,"Tinnitus in cisplatin-treated testicular cancer","Tinnitus, testicular carcinoma, response to cisplatin",GCST007796,1:38089354
rs141382055-<b>A</b>,"3 x 10-6",,NR,5.7029,'-,[4.97-6.43],PIP4K2A,"Tinnitus in cisplatin-treated testicular cancer","Tinnitus, testicular carcinoma, response to cisplatin",GCST007796,10:22570882
rs3825243-<b>A</b>,"4 x 10-8",,NR,'-,'-,'-,"YEATS4, LYZ","Response to SSRI in MDD or conscientiouness","conscientiousness measurement, unipolar depression, response to selective serotonin reuptake inhibitor",GCST005836,12:69357059
rs2979204-<b>T</b>,"8 x 10-11",,NR,'-,'-,'-,PRAG1,"Remission after SSRI treatment in MDD or neuroticism","unipolar depression, neuroticism measurement, response to selective serotonin reuptake inhibitor",GCST005835,8:8441347
rs11990063-<b>T</b>,"9 x 10-9",,NR,'-,'-,'-,MSRA,"Remission after SSRI treatment in MDD or neuroticism","unipolar depression, neuroticism measurement, response to selective serotonin reuptake inhibitor",GCST005835,8:10307685
rs35792458-<b>C</b>,"1 x 10-12",,NR,'-,'-,'-,XKR6,"Remission after SSRI treatment in MDD or neuroticism","unipolar depression, neuroticism measurement, response to selective serotonin reuptake inhibitor",GCST005835,8:10964921
rs12555870-<b>G</b>,"1 x 10-8",,NR,'-,'-,'-,'-,"Remission after SSRI treatment in MDD or neuroticism","unipolar depression, neuroticism measurement, response to selective serotonin reuptake inhibitor",GCST005835,9:23347726
rs4761545-<b>G</b>,"8 x 10-10",,NR,'-,'-,'-,RN7SKP263,"Remission after SSRI treatment in MDD or neuroticism","unipolar depression, neuroticism measurement, response to selective serotonin reuptake inhibitor",GCST005835,12:94032692
rs144733372-<b>G</b>,"3 x 10-11",,NR,'-,'-,'-,PLEKHM1,"Remission after SSRI treatment in MDD or neuroticism","unipolar depression, neuroticism measurement, response to selective serotonin reuptake inhibitor",GCST005835,17:45486856
rs11082011-<b>C</b>,"4 x 10-8",,NR,'-,'-,'-,CELF4,"Remission after SSRI treatment in MDD or neuroticism","unipolar depression, neuroticism measurement, response to selective serotonin reuptake inhibitor",GCST005835,18:37565159
rs55679149-<b>T</b>,"8 x 10-7",,NR,'-,'-,'-,"GBP1, PTGES3P1","Remission after SSRI treatment in MDD or openness","unipolar depression, response to selective serotonin reuptake inhibitor, openness measurement",GCST005833,1:89068655
rs11728985-<b>T</b>,"4 x 10-7",,NR,'-,'-,'-,C4orf33,"Remission after SSRI treatment in MDD or openness","unipolar depression, response to selective serotonin reuptake inhibitor, openness measurement",GCST005833,4:129115280
rs11155372-<b>T</b>,"1 x 10-7",,NR,'-,'-,'-,UTRN,"Remission after SSRI treatment in MDD or openness","unipolar depression, response to selective serotonin reuptake inhibitor, openness measurement",GCST005833,6:144698602
rs7828021-<b>C</b>,"4 x 10-7",,NR,'-,'-,'-,PSAT1P1,"Remission after SSRI treatment in MDD or openness","unipolar depression, response to selective serotonin reuptake inhibitor, openness measurement",GCST005833,8:49727454
rs1411216-<b>A</b>,"5 x 10-7",,NR,'-,'-,'-,IZUMO3,"Remission after SSRI treatment in MDD or openness","unipolar depression, response to selective serotonin reuptake inhibitor, openness measurement",GCST005833,9:24520196
rs7189979-<b>C</b>,"3 x 10-7",,NR,'-,'-,'-,SNX29,"Remission after SSRI treatment in MDD or openness","unipolar depression, response to selective serotonin reuptake inhibitor, openness measurement",GCST005833,16:12536330
rs7555693-<b>A</b>,"1 x 10-6",,NR,'-,'-,'-,'-,"Response to SSRI in MDD or openness","unipolar depression, response to selective serotonin reuptake inhibitor, openness measurement",GCST005834,1:106295917
rs9321987-<b>A</b>,"5 x 10-7",,NR,'-,'-,'-,UTRN,"Response to SSRI in MDD or openness","unipolar depression, response to selective serotonin reuptake inhibitor, openness measurement",GCST005834,6:144709148
rs352759-<b>T</b>,"6 x 10-7",,NR,'-,'-,'-,TUSC3,"Response to SSRI in MDD or openness","unipolar depression, response to selective serotonin reuptake inhibitor, openness measurement",GCST005834,8:15742205
rs7828021-<b>C</b>,"7 x 10-8",,NR,'-,'-,'-,PSAT1P1,"Response to SSRI in MDD or openness","unipolar depression, response to selective serotonin reuptake inhibitor, openness measurement",GCST005834,8:49727454
rs11591827-<b>A</b>,"9 x 10-7",,NR,'-,'-,'-,RPA2P2,"Response to SSRI in MDD or openness","unipolar depression, response to selective serotonin reuptake inhibitor, openness measurement",GCST005834,10:81128126
rs7189979-<b>C</b>,"2 x 10-7",,NR,'-,'-,'-,SNX29,"Response to SSRI in MDD or openness","unipolar depression, response to selective serotonin reuptake inhibitor, openness measurement",GCST005834,16:12536330
rs4693974-<b>A</b>,"1 x 10-6",,0.427,'-,"0.042 unit increase",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88889244
rs3857043-<b>T</b>,"2 x 10-6",,0.416,'-,"0.042 unit increase",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88961439
rs1398942-<b>A</b>,"4 x 10-6",,0.607,'-,"0.042 unit increase",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:89009241
rs6537275-<b>A</b>,"4 x 10-6",,0.618,'-,"0.042 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144321510
rs35305377-<b>A</b>,"5 x 10-6",,0.574,'-,"0.042 unit increase",NR,"STAG3L5P, STAG3L5P-PVRIG2P-PILRB","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,7:100341332
rs11733975-<b>T</b>,"2 x 10-6",,0.617,'-,"0.043 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144465321
rs9995482-<b>A</b>,"3 x 10-6",,0.639,'-,"0.043 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144337602
rs4256190-<b>A</b>,"3 x 10-6",,0.62,'-,"0.043 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144315274
rs3825807-<b>A</b>,"4 x 10-6",,0.599,'-,"0.043 unit increase",NR,ADAMTS7,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78796769
rs11638321-<b>T</b>,"5 x 10-6",,0.601,'-,"0.043 unit increase",NR,ADAMTS7,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78799841
rs6852928-<b>T</b>,"3 x 10-7",,0.534,'-,"0.044 unit increase",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:89005042
rs1795720-<b>T</b>,"3 x 10-7",,0.533,'-,"0.044 unit increase",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:89008103
rs6823536-<b>T</b>,"3 x 10-7",,0.533,'-,"0.044 unit increase",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:89007381
rs2178586-<b>T</b>,"4 x 10-7",,0.535,'-,"0.044 unit increase",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:89004169
rs10021465-<b>A</b>,"1 x 10-6",,0.552,'-,"0.044 unit increase",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88829210
rs4834988-<b>A</b>,"1 x 10-6",,0.612,'-,"0.044 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144557625
rs4321584-<b>A</b>,"2 x 10-6",,0.646,'-,"0.044 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144319000
rs13118748-<b>A</b>,"2 x 10-6",,0.614,'-,"0.044 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144337974
rs7177699-<b>T</b>,"2 x 10-6",,0.411,'-,"0.044 unit increase",NR,ADAMTS7,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78797392
rs6854014-<b>A</b>,"3 x 10-6",,0.621,'-,"0.044 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144315085
rs7699291-<b>A</b>,"3 x 10-6",,0.704,'-,"0.044 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144385659
rs7515360-<b>A</b>,"3 x 10-6",,0.29,'-,"0.044 unit increase",NR,"TGFB2, LINC02869","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:218453278
rs6827753-<b>C</b>,"3 x 10-6",,0.702,'-,"0.044 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144393636
rs6657698-<b>A</b>,"4 x 10-6",,0.409,'-,"0.044 unit increase",NR,"LINC02869, TGFB2","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:218449933
rs6836151-<b>A</b>,"4 x 10-6",,0.684,'-,"0.044 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144394633
rs141627167-<b>A</b>,"4 x 10-6",,0.684,'-,"0.044 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144392695
rs7002002-<b>A</b>,"5 x 10-6",,0.375,'-,"0.044 unit increase",NR,PLEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,8:143923759
rs7016416-<b>T</b>,"5 x 10-6",,0.375,'-,"0.044 unit increase",NR,PLEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,8:143923488
rs1140522-<b>T</b>,"5 x 10-6",,0.375,'-,"0.044 unit increase",NR,PLEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,8:143924001
rs1797070-<b>A</b>,"5 x 10-6",,0.291,'-,"0.044 unit increase",NR,"LINC02869, TGFB2","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:218456859
rs6984820-<b>T</b>,"5 x 10-6",,0.627,'-,"0.044 unit increase",NR,PLEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,8:143919156
rs2904259-<b>T</b>,"2 x 10-7",,0.465,'-,"0.045 unit increase",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88964563
rs6830970-<b>A</b>,"4 x 10-7",,0.377,'-,"0.045 unit increase",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88855930
rs7663578-<b>A</b>,"7 x 10-7",,0.586,'-,"0.045 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144547639
rs6537297-<b>T</b>,"8 x 10-7",,0.617,'-,"0.045 unit increase",NR,"HHIP-AS1, KRT18P51","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144580877
rs4376087-<b>T</b>,"1 x 10-6",,0.687,'-,"0.045 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144400203
rs7378179-<b>A</b>,"1 x 10-6",,0.698,'-,"0.045 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144363056
rs7663740-<b>T</b>,"1 x 10-6",,0.604,'-,"0.045 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144547693
rs7693416-<b>T</b>,"1 x 10-6",,0.695,'-,"0.045 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144384205
rs4420930-<b>T</b>,"1 x 10-6",,0.696,'-,"0.045 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144400085
rs12640763-<b>T</b>,"1 x 10-6",,0.638,'-,"0.045 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144314504
rs10029738-<b>A</b>,"2 x 10-6",,0.694,'-,"0.045 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144376267
rs10029931-<b>T</b>,"2 x 10-6",,0.694,'-,"0.045 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144376466
rs7681655-<b>A</b>,"2 x 10-6",,0.694,'-,"0.045 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144377677
rs7676032-<b>C</b>,"2 x 10-6",,0.694,'-,"0.045 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144399916
rs4318599-<b>T</b>,"2 x 10-6",,0.694,'-,"0.045 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144380971
rs4370082-<b>T</b>,"2 x 10-6",,0.694,'-,"0.045 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144379477
rs7665807-<b>A</b>,"2 x 10-6",,0.694,'-,"0.045 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144380230
rs4373117-<b>A</b>,"2 x 10-6",,0.688,'-,"0.045 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144399368
rs3923388-<b>A</b>,"3 x 10-6",,0.378,'-,"0.045 unit increase",NR,"EPPK1, PLEC","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,8:143912510
rs6558407-<b>T</b>,"4 x 10-6",,0.377,'-,"0.045 unit increase",NR,PLEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,8:143921326
rs11777402-<b>A</b>,"4 x 10-6",,0.377,'-,"0.045 unit increase",NR,PLEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,8:143921568
rs11786903-<b>A</b>,"4 x 10-6",,0.377,'-,"0.045 unit increase",NR,PLEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,8:143922430
rs55646585-<b>T</b>,"4 x 10-6",,0.371,'-,"0.045 unit increase",NR,PLEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,8:143925453
rs6845536-<b>T</b>,"2 x 10-7",,0.407,'-,"0.046 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144531631
rs4886580-<b>T</b>,"2 x 10-7",,0.597,'-,"0.046 unit increase",NR,CHRNB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78677043
rs1489761-<b>A</b>,"3 x 10-7",,0.6,'-,"0.046 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144534339
rs7674469-<b>A</b>,"5 x 10-7",,0.605,'-,"0.046 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144536849
rs4846479-<b>T</b>,"1 x 10-6",,0.714,'-,"0.046 unit increase",NR,TGFB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:218425068
rs3743078-<b>C</b>,"3 x 10-6",,0.354,'-,"0.046 unit increase",NR,CHRNA3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78602417
rs142653380-<b>A</b>,"3 x 10-6",,0.737,'-,"0.046 unit increase",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88874493
rs28459962-<b>T</b>,"4 x 10-6",,0.741,'-,"0.046 unit increase",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88865131
rs28455964-<b>T</b>,"1 x 10-7",,0.621,'-,"0.047 unit increase",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88849758
rs7661046-<b>T</b>,"3 x 10-7",,0.663,'-,"0.047 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144339343
rs1489765-<b>T</b>,"4 x 10-7",,0.61,'-,"0.047 unit increase",NR,"HHIP-AS1, KRT18P51","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144595226
rs6843820-<b>C</b>,"6 x 10-7",,0.581,'-,"0.047 unit increase",NR,"KRT18P51, MANBA","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144531552
rs34225855-<b>C</b>,"6 x 10-7",,0.625,'-,"0.047 unit increase",NR,"ADAMTS7, CHRNB4","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78729794
rs11639181-<b>A</b>,"7 x 10-7",,0.409,'-,"0.047 unit increase",NR,"CHRNB4, ADAMTS7","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78731674
rs13106167-<b>T</b>,"7 x 10-7",,0.437,'-,"0.047 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144308558
rs11639049-<b>A</b>,"7 x 10-7",,0.625,'-,"0.047 unit increase",NR,"ADAMTS7, CHRNB4","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78731388
rs1825083-<b>T</b>,"7 x 10-7",,0.625,'-,"0.047 unit increase",NR,"ADAMTS7, CHRNB4","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78731125
rs6658473-<b>T</b>,"8 x 10-7",,0.286,'-,"0.047 unit increase",NR,TGFB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:218427077
rs1890995-<b>A</b>,"9 x 10-7",,0.286,'-,"0.047 unit increase",NR,TGFB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:218431336
rs10482792-<b>A</b>,"9 x 10-7",,0.286,'-,"0.047 unit increase",NR,TGFB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:218432119
rs1065837-<b>A</b>,"1 x 10-6",,0.379,'-,"0.047 unit increase",NR,PLEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,8:143916167
rs6990361-<b>T</b>,"1 x 10-6",,0.377,'-,"0.047 unit increase",NR,"PLEC, EPPK1","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,8:143913053
rs3923387-<b>T</b>,"1 x 10-6",,0.378,'-,"0.047 unit increase",NR,"PLEC, EPPK1","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,8:143912625
rs7658614-<b>A</b>,"1 x 10-7",,0.595,'-,"0.048 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144524542
rs4465995-<b>T</b>,"2 x 10-7",,0.684,'-,"0.048 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144370054
rs35583595-<b>C</b>,"4 x 10-7",,0.619,'-,"0.048 unit increase",NR,"ADAMTS7, CHRNB4","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78727810
rs62308745-<b>T</b>,"6 x 10-7",,0.7,'-,"0.048 unit increase",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88880152
rs11631955-<b>A</b>,"7 x 10-7",,0.593,'-,"0.048 unit increase",NR,ADAMTS7,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78793573
rs12324870-<b>T</b>,"7 x 10-7",,0.317,'-,"0.048 unit increase",NR,CHRNB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78703459
rs1505766-<b>T</b>,"9 x 10-7",,0.276,'-,"0.048 unit increase",NR,STX18,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144387147
rs1394998-<b>T</b>,"9 x 10-7",,0.725,'-,"0.048 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144381003
rs8027972-<b>T</b>,"1 x 10-6",,0.645,'-,"0.048 unit increase",NR,"ADAMTS7, CHRNB4","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78730273
rs10033824-<b>T</b>,"2 x 10-6",,0.746,'-,"0.048 unit increase",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88887588
rs4887057-<b>A</b>,"4 x 10-8",,0.421,'-,"0.049 unit increase",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78468576
rs4835639-<b>T</b>,"6 x 10-8",,0.603,'-,"0.049 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144530761
rs6840871-<b>T</b>,"1 x 10-7",,0.315,'-,"0.049 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144342862
rs987246-<b>T</b>,"1 x 10-7",,0.685,'-,"0.049 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144349715
rs62308746-<b>T</b>,"3 x 10-7",,0.702,'-,"0.049 unit increase",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88884818
rs7668636-<b>T</b>,"3 x 10-7",,0.7,'-,"0.049 unit increase",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88898156
rs4693976-<b>T</b>,"3 x 10-7",,0.422,'-,"0.049 unit increase",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88918689
rs8038543-<b>A</b>,"3 x 10-7",,0.618,'-,"0.049 unit increase",NR,CHRNB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78725343
rs28529050-<b>A</b>,"3 x 10-7",,0.7,'-,"0.049 unit increase",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88899639
rs12499537-<b>T</b>,"3 x 10-7",,0.3,'-,"0.049 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144426946
rs76919723-<b>T</b>,"5 x 10-7",,0.623,'-,"0.049 unit increase",NR,CHRNB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78724939
rs2869554-<b>T</b>,"7 x 10-7",,0.632,'-,"0.049 unit increase",NR,"CHRNB4, ADAMTS7","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78728695
rs615098-<b>T</b>,"2 x 10-6",,0.772,'-,"0.049 unit increase",NR,"MMP3, MMP12","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:102849947
rs117068593-<b>T</b>,"3 x 10-6",,0.169,'-,"0.06 unit increase",NR,RIN3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,14:92651884
rs931794-<b>A</b>,"2 x 10-11",,0.407,'-,"0.061 unit increase",NR,HYKK,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78533838
rs17019354-<b>T</b>,"3 x 10-9",,0.278,'-,"0.061 unit increase",NR,TET2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144445825
rs13105210-<b>T</b>,"3 x 10-9",,0.281,'-,"0.061 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144341775
rs12441354-<b>A</b>,"7 x 10-9",,0.219,'-,"0.061 unit increase",NR,HYKK,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78528674
rs28681284-<b>T</b>,"2 x 10-7",,0.185,'-,"0.061 unit increase",NR,CHRNA3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78616223
rs34174370-<b>T</b>,"3 x 10-7",,0.167,'-,"0.061 unit increase",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128130901
rs11714619-<b>A</b>,"5 x 10-7",,0.157,'-,"0.061 unit increase",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128131233
rs73192978-<b>A</b>,"5 x 10-7",,0.156,'-,"0.061 unit increase",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128149432
rs73192979-<b>T</b>,"5 x 10-7",,0.156,'-,"0.061 unit increase",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128149478
rs11709066-<b>A</b>,"6 x 10-7",,0.157,'-,"0.061 unit increase",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128156069
rs35347185-<b>T</b>,"6 x 10-7",,0.157,'-,"0.061 unit increase",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128135684
rs13095660-<b>T</b>,"6 x 10-7",,0.156,'-,"0.061 unit increase",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128129313
rs6788497-<b>T</b>,"6 x 10-7",,0.156,'-,"0.061 unit increase",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128129545
rs3875149-<b>A</b>,"6 x 10-7",,0.386,'-,"0.061 unit increase",NR,"CYP2A7, CYP2A6","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,19:40854091
rs73197383-<b>T</b>,"6 x 10-7",,0.155,'-,"0.061 unit increase",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128311631
rs56287882-<b>A</b>,"6 x 10-7",,0.156,'-,"0.061 unit increase",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128311500
rs13059975-<b>T</b>,"7 x 10-7",,0.156,'-,"0.061 unit increase",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128130841
rs61044849-<b>T</b>,"7 x 10-7",,0.155,'-,"0.061 unit increase",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128346623
rs11118102-<b>A</b>,"1 x 10-6",,0.134,'-,"0.061 unit increase",NR,TGFB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:218398662
rs189256434-<b>A</b>,"2 x 10-6",,0.726,'-,"0.061 unit increase",NR,CYP2F2P,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,19:40818449
rs4416442-<b>T</b>,"1 x 10-12",,0.548,'-,"0.062 unit increase",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88945562
rs2938670-<b>T</b>,"2 x 10-12",,0.608,'-,"0.062 unit increase",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78448346
rs2656052-<b>A</b>,"2 x 10-12",,0.608,'-,"0.062 unit increase",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78448590
rs10519203-<b>A</b>,"6 x 10-12",,0.637,'-,"0.062 unit increase",NR,HYKK,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78521704
rs525119-<b>T</b>,"7 x 10-7",,0.884,'-,"0.018 unit decrease",NR,WTAPP1,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,11:102831415
rs563096-<b>A</b>,"7 x 10-7",,0.884,'-,"0.018 unit decrease",NR,"MMP3, WTAPP1","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,11:102836635
rs646760-<b>A</b>,"7 x 10-7",,0.884,'-,"0.018 unit decrease",NR,WTAPP1,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,11:102832547
rs553542-<b>T</b>,"7 x 10-7",,0.884,'-,"0.018 unit decrease",NR,WTAPP1,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,11:102830645
rs611705-<b>T</b>,"9 x 10-7",,0.884,'-,"0.018 unit decrease",NR,WTAPP1,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,11:102823737
rs470292-<b>A</b>,"1 x 10-6",,0.884,'-,"0.018 unit decrease",NR,WTAPP1,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,11:102814664
rs470928-<b>A</b>,"1 x 10-6",,0.884,'-,"0.018 unit decrease",NR,WTAPP1,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,11:102814649
rs28381684-<b>A</b>,"4 x 10-6",,0.89,'-,"0.018 unit decrease",NR,MMP12,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,11:102866461
rs737693-<b>A</b>,"4 x 10-6",,0.89,'-,"0.018 unit decrease",NR,"MMP12, MMP3","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,11:102855411
rs72983513-<b>T</b>,"4 x 10-6",,0.891,'-,"0.018 unit decrease",NR,"MMP12, MMP3","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,11:102858254
rs17368582-<b>T</b>,"4 x 10-6",,0.891,'-,"0.018 unit decrease",NR,MMP12,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,11:102867344
rs190065944-<b>A</b>,"1 x 10-6",,0.304,'-,"0.017 unit decrease",NR,CHRNA5,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78567268
rs17368814-<b>A</b>,"5 x 10-6",,0.534,'-,"0.017 unit decrease",NR,"MMP12, BOLA3P1","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,11:102877965
rs146862558-<b>A</b>,"2 x 10-6",,0.72,'-,"0.016 unit decrease",NR,CFH,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:196714701
rs56077333-<b>A</b>,"1 x 10-7",,0.379,'-,"0.014 unit decrease",NR,CHRNA3,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78606661
rs147144681-<b>T</b>,"2 x 10-7",,0.373,'-,"0.014 unit decrease",NR,CHRNA3,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78608566
rs147499554-<b>T</b>,"4 x 10-7",,0.36,'-,"0.014 unit decrease",NR,CHRNA3,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78608308
rs7820838-<b>T</b>,"7 x 10-7",,0.242,'-,"0.014 unit decrease",NR,NRG1,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,8:32548461
rs34684276-<b>A</b>,"2 x 10-6",,0.345,'-,"0.014 unit decrease",NR,HYKK,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78520813
rs1051730-<b>A</b>,"2 x 10-7",,0.6,'-,"0.013 unit decrease",NR,'-,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,"Mapping not available"
rs114205691-<b>T</b>,"3 x 10-7",,0.4,'-,"0.013 unit decrease",NR,CHRNA3,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78608771
rs2869548-<b>A</b>,"3 x 10-7",,0.421,'-,"0.013 unit decrease",NR,CHRNB4,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78630296
rs6817238-<b>T</b>,"2 x 10-6",,0.664,'-,"0.013 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144542381
rs138641402-<b>A</b>,"2 x 10-6",,0.652,'-,"0.013 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144524627
rs2466104-<b>C</b>,"5 x 10-6",,0.216,'-,"0.013 unit decrease",NR,NRG1,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,8:32553194
rs3885907-<b>G</b>,"1 x 10-6",(Dominant),0.18,2.66,'-,[1.71-4.13],ALOX5AP,"Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU)","response to epirubicin, response to cyclophosphamide, chemotherapy-induced alopecia, response to 5' fluorouracil",GCST002176,13:30740318
rs4474258-<b>A</b>,"5 x 10-6",(Recessive),0.43,1.89,'-,[1.29-2.75],SLC44A3-AS1,"Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU)","response to epirubicin, response to cyclophosphamide, chemotherapy-induced alopecia, response to 5' fluorouracil",GCST002176,1:94615889
rs7089227-<b>G</b>,"7 x 10-6",(Dominant),0.41,1.99,'-,[1.37-2.90],PRPF18,"Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU)","response to epirubicin, response to cyclophosphamide, chemotherapy-induced alopecia, response to 5' fluorouracil",GCST002176,10:13625731
rs527430-<b>G</b>,"4 x 10-7","(Citalopram+Buspirone, General side effects)",0.39,'-,'-,'-,"RPL21P24, FOXD2","Response to anti-depressant treatment in major depressive disorder","antidepressant-induced side effect, response to citalopram, response to buspirone, response to antidepressant",GCST001308,1:47453149
rs17766217-<b>A</b>,"3 x 10-7","(Citalopram+Buspirone, General side effects)",0.01,'-,'-,'-,CASC8,"Response to anti-depressant treatment in major depressive disorder","antidepressant-induced side effect, response to citalopram, response to buspirone, response to antidepressant",GCST001308,8:127492252
rs16861531-<b>G</b>,"7 x 10-7","(Citalopram+Buspirone, Dizziness)",0.03,'-,'-,'-,LINC00276,"Response to anti-depressant treatment in major depressive disorder","response to citalopram, antidepressant-induced dizziness, response to buspirone, response to antidepressant",GCST001308,2:14257928
rs6795349-<b>G</b>,"2 x 10-6","(Citalopram+Buspirone, Dizziness)",0.03,'-,'-,'-,CHL1-AS2,"Response to anti-depressant treatment in major depressive disorder","response to citalopram, antidepressant-induced dizziness, response to buspirone, response to antidepressant",GCST001308,3:130794
rs491376-<b>C</b>,"2 x 10-6","(Citalopram+Buspirone, Dizziness)",0.01,'-,'-,'-,U6,"Response to anti-depressant treatment in major depressive disorder","response to citalopram, antidepressant-induced dizziness, response to buspirone, response to antidepressant",GCST001308,4:13115138
rs573332-<b>G</b>,"1 x 10-6","(Citalopram+Buspirone, Dizziness)",0.11,'-,'-,'-,U6,"Response to anti-depressant treatment in major depressive disorder","response to citalopram, antidepressant-induced dizziness, response to buspirone, response to antidepressant",GCST001308,4:13120911
rs2163287-<b>A</b>,"3 x 10-6","(Citalopram+Buspirone, Dizziness)",0.02,'-,'-,'-,ZDHHC14,"Response to anti-depressant treatment in major depressive disorder","response to citalopram, antidepressant-induced dizziness, response to buspirone, response to antidepressant",GCST001308,6:157620251
rs7015622-<b>C</b>,"1 x 10-6","(Citalopram+Buspirone, Dizziness)",0.01,'-,'-,'-,'-,"Response to anti-depressant treatment in major depressive disorder","response to citalopram, antidepressant-induced dizziness, response to buspirone, response to antidepressant",GCST001308,8:82991579
rs10988449-<b>T</b>,"3 x 10-6","(Citalopram+Buspirone, Dizziness)",0.17,'-,'-,'-,"LINC00963, NTMT1","Response to anti-depressant treatment in major depressive disorder","response to citalopram, antidepressant-induced dizziness, response to buspirone, response to antidepressant",GCST001308,9:129608081
rs8039808-<b>A</b>,"5 x 10-7","(Citalopram+Buspirone, Dizziness)",0.06,'-,'-,'-,DTWD1,"Response to anti-depressant treatment in major depressive disorder","response to citalopram, antidepressant-induced dizziness, response to buspirone, response to antidepressant",GCST001308,15:49647649
rs2034588-<b>G</b>,"2 x 10-6","(Citalopram+Buspirone, Dizziness)",0.02,'-,'-,'-,LINC02152,"Response to anti-depressant treatment in major depressive disorder","response to citalopram, antidepressant-induced dizziness, response to buspirone, response to antidepressant",GCST001308,16:8279325
rs12157904-<b>G</b>,"2 x 10-6","(Citalopram+Buspirone, Dizziness)",0.07,'-,'-,'-,"GGA1, LGALS2","Response to anti-depressant treatment in major depressive disorder","response to citalopram, antidepressant-induced dizziness, response to buspirone, response to antidepressant",GCST001308,22:37586005
rs16990008-<b>C</b>,"2 x 10-6","(Citalopram+Buspirone, Dizziness)",0.02,'-,'-,'-,DMD,"Response to anti-depressant treatment in major depressive disorder","response to citalopram, antidepressant-induced dizziness, response to buspirone, response to antidepressant",GCST001308,X:31997259
rs672203-<b>A</b>,"2 x 10-6",(Dominant),0.52,5.33,'-,[2.59-11.0],CTH,"Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU)","response to cyclophosphamide, chemotherapy-induced alopecia, response to 5' fluorouracil, response to doxorubicin",GCST002178,1:70421416
rs6475600-<b>C</b>,"2 x 10-6",(Allelic),0.63,7.78,'-,3.25-18.6],"RN7SL592P, SMARCA2","Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU)","response to cyclophosphamide, chemotherapy-induced alopecia, response to 5' fluorouracil, response to doxorubicin",GCST002178,9:2203938
rs6845621-<b>C</b>,"2 x 10-6",(Allelic),0.20,5.53,'-,[2.61-11.7],'-,"Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU)","response to cyclophosphamide, chemotherapy-induced alopecia, response to 5' fluorouracil, response to doxorubicin",GCST002178,4:18864546
rs10818894-<b>G</b>,"2 x 10-6",(Dominant),0.70,10.4,'-,[3.56-30.1],"DENND1A, LHX2","Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU)","response to cyclophosphamide, chemotherapy-induced alopecia, response to 5' fluorouracil, response to doxorubicin",GCST002178,9:123933491
rs10112481-<b>A</b>,"4 x 10-6",(Allelic),0.22,5.12,'-,[2.46-10.6],"CSMD1, CYP7B1","Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU)","response to cyclophosphamide, chemotherapy-induced alopecia, response to 5' fluorouracil, response to doxorubicin",GCST002178,8:5017650
rs637644-<b>G</b>,"7 x 10-6",(Allelic),0.80,32.5,'-,[4.08-259],'-,"Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU)","response to cyclophosphamide, chemotherapy-induced alopecia, response to 5' fluorouracil, response to doxorubicin",GCST002178,18:65231430
rs11644424-<b>T</b>,"8 x 10-6",(Dominant),0.44,3.32,'-,[1.71-6.44],CDH13,"Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU)","response to cyclophosphamide, chemotherapy-induced alopecia, response to 5' fluorouracil, response to doxorubicin",GCST002178,16:83292454
rs594206-<b>A</b>,"6 x 10-7",(Dominant),0.78,36.3,'-,[4.58-287],BCL9,"Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU)","response to cyclophosphamide, chemotherapy-induced alopecia, response to 5' fluorouracil, response to doxorubicin",GCST002178,1:147548685
rs10517287-<b>T</b>,"2 x 10-7","(Citalopram+Bupropion, Vision/hearing-related side effects)",0.11,'-,'-,'-,'-,"Response to anti-depressant treatment in major depressive disorder","antidepressant-induced visual impairment, response to bupropion, response to citalopram, response to antidepressant",GCST001308,4:33623080
rs17647114-<b>T</b>,"4 x 10-7","(Citalopram+Bupropion, Vision/hearing-related side effects)",0.03,'-,'-,'-,AGBL1,"Response to anti-depressant treatment in major depressive disorder","antidepressant-induced visual impairment, response to bupropion, response to citalopram, response to antidepressant",GCST001308,15:86893514
rs11124945-<b>G</b>,"5 x 10-8",,0.19,7.61,'-,[3.39-17.09],PLEKHH2,"Diabetes in response to antihypertensive drug treatment (treatment strategy interaction)","response to antihypertensive drug, diabetes mellitus, hypertension, response to beta blocker, response to calcium channel blocker",GCST003797,2:43650017
rs113296370-<b>C</b>,"2 x 10-7",(European),0.19,8.83,'-,[8.01-9.65],"Y_RNA, PLEKHH2","Diabetes in response to antihypertensive drug treatment (treatment strategy interaction)","response to antihypertensive drug, diabetes mellitus, hypertension, response to beta blocker, response to calcium channel blocker",GCST003797,2:43636315
rs4833103-<b>?</b>,"1 x 10-7",(European),0.50,5.26,'-,[4.63-5.89],TLR1,"Diabetes in response to antihypertensive drug treatment (treatment strategy interaction)","response to antihypertensive drug, diabetes mellitus, hypertension, response to beta blocker, response to calcium channel blocker",GCST003797,4:38813881
rs10785877-<b>T</b>,"7 x 10-7","(Allelic model)",0.66,2.58,'-,[1.766-3.769],"RNU6ATAC, LINC02247","Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin)","response to carboplatin, response to paclitaxel, response to antineoplastic agent",GCST002006,9:134233655
rs6429703-<b>T</b>,"8 x 10-6","(Allelic model)",0.078,2.942,'-,[1.802-4.804],KAZN,"Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin)","response to carboplatin, response to paclitaxel, response to antineoplastic agent",GCST002006,1:15013464
rs12310399-<b>A</b>,"2 x 10-7","(Recessive model)",0.567,1.852,'-,[1.329-2.58],FGD6,"Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin)","response to carboplatin, response to paclitaxel, response to antineoplastic agent",GCST002006,12:95096472
rs995834-<b>C</b>,"1 x 10-6","(Dominant model)",0.425,1.871,'-,[1.364-2.566],'-,"Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin)","response to carboplatin, response to paclitaxel, response to antineoplastic agent",GCST002006,19:28375689
rs922107-<b>G</b>,"3 x 10-6","(Recessive model)",0.211,1.788,'-,[1.25-2.558],LRRC8B,"Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin)","response to carboplatin, response to paclitaxel, response to antineoplastic agent",GCST002006,1:89557237
rs1425132-<b>T</b>,"5 x 10-6","(Recessive model)",0.666,1.43,'-,[1.013-2.017],"NECAP1P1, ELMO1","Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin)","response to carboplatin, response to paclitaxel, response to antineoplastic agent",GCST002006,7:37522765
rs1476029-<b>A</b>,"8 x 10-6","(Allelic model)",0.015,6.426,'-,[2.429-17.00],"RBFOX2, APOL3","Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin)","response to carboplatin, response to paclitaxel, response to antineoplastic agent",GCST002006,22:36121884
rs8093763-<b>A</b>,"3 x 10-8",,0.25,'-,"0.18 unit increase",[0.12-0.24],"PMAIP1, GLUD1P4","Response to bleomycin (chromatid breaks)","response to bleomycin, chromatid break measurement, response to antibiotic",GCST000882,18:59836146
rs4662834-<b>A</b>,"5 x 10-6",,0.41,'-,"0.08 unit decrease",[0.04-0.11],'-,"Response to bleomycin (chromatid breaks)","response to bleomycin, chromatid break measurement, response to antibiotic",GCST000882,2:128721268
rs708547-<b>A</b>,"9 x 10-7",,0.24,'-,"0.18 unit decrease",[0.11-0.24],REST,"Response to bleomycin (chromatid breaks)","response to bleomycin, chromatid break measurement, response to antibiotic",GCST000882,4:56955143
rs7532024-<b>C</b>,"4 x 10-6",,0.55,3.3112586,'-,[NR],CAMTA1,"Levodopa wearing off effect (time symptoms uncontrolled) in Parkinson's disease (response to zonisamide)","motor function measurement, response to zonisamide, response to levodopa",GCST010322,1:7119419
rs16854023-<b>T</b>,"4 x 10-8",,0.47,7.518797,'-,[NR],"RNA5SP74, LRRN2","Levodopa wearing off effect (time symptoms uncontrolled) in Parkinson's disease (response to zonisamide)","motor function measurement, response to zonisamide, response to levodopa",GCST010322,1:204582702
rs4418897-<b>A</b>,"5 x 10-6",,0.73,6.622517,'-,[NR],"GCNAP1, CD69","Levodopa wearing off effect (time symptoms uncontrolled) in Parkinson's disease (response to zonisamide)","motor function measurement, response to zonisamide, response to levodopa",GCST010322,12:9815217
rs1998049-<b>T</b>,"6 x 10-6",,0.04,5.834,'-,[NR],VSTM2L,"Levodopa wearing off effect (time symptoms uncontrolled) in Parkinson's disease (response to zonisamide)","motor function measurement, response to zonisamide, response to levodopa",GCST010322,20:37933480
rs17050901-<b>G</b>,"6 x 10-6",,0.16,8.17,'-,'-,'-,"Levodopa wearing off effect (motor symptom score change) in Parkinson's disease (response to zonisamide)","motor function measurement, response to zonisamide, response to levodopa",GCST010323,4:130211377
rs13432159-<b>G</b>,"9 x 10-8","(Sertraline, General side effects)",0.08,'-,'-,'-,LINC01812,"Response to anti-depressant treatment in major depressive disorder","response to sertraline, antidepressant-induced side effect, response to antidepressant",GCST001308,2:67746755
rs6724422-<b>T</b>,"4 x 10-7","(Sertraline, General side effects)",0.06,'-,'-,'-,LINC01812,"Response to anti-depressant treatment in major depressive disorder","response to sertraline, antidepressant-induced side effect, response to antidepressant",GCST001308,2:67749656
rs2936519-<b>A</b>,"2 x 10-7",,NR,1.8867927,'-,[1.49-2.33],"XKR5, AGPAT5","Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab)","progression free survival, metastatic colorectal cancer, response to cetuximab, response to CAPOX-B",GCST003058,8:6781719
rs2073016-<b>T</b>,"4 x 10-6",,NR,1.62,'-,[1.31-2],OARD1,"Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab)","progression free survival, metastatic colorectal cancer, response to cetuximab, response to CAPOX-B",GCST003058,6:41053183
rs4377367-<b>C</b>,"6 x 10-6",,NR,1.5873016,'-,[1.32-1.92],ARHGEF4,"Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab)","progression free survival, metastatic colorectal cancer, response to cetuximab, response to CAPOX-B",GCST003058,2:130967332
rs885036-<b>A</b>,"2 x 10-8",,'-,2.13,'-,[1.64-2.78],MGAT4A,"Progression free survival in metastatic colorectal cancer (chemotherapy interaction)","progression free survival, metastatic colorectal cancer, response to cetuximab, response to CAPOX-B",GCST003057,2:98688331
rs6685273-<b>T</b>,"4 x 10-7",,0.068,'-,'-,'-,VPS13D,"Cytokine and corticosteroid-stimulated IL-6 production","interleukin-6 measurement, response to corticosteroid, response to cytokine",GCST002858,1:12313691
rs4862562-<b>C</b>,"9 x 10-10",,0.076,'-,'-,'-,SORBS2,"Cytokine and corticosteroid-stimulated IL-6 production","interleukin-6 measurement, response to corticosteroid, response to cytokine",GCST002858,4:185681056
rs17318866-<b>G</b>,"1 x 10-6","(Allelic model)",0.79,7.559,'-,[2.689-21.263],"PXDC1, FAM50B","Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin)","response to camptothecin, response to antineoplastic agent",GCST001993,6:3836964
rs303386-<b>A</b>,"4 x 10-6","(Dominant model)",0.429,2.238,'-,[1.448-3.46],'-,"Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin)","response to camptothecin, response to antineoplastic agent",GCST001993,1:99123823
rs17027130-<b>C</b>,"3 x 10-6","(Allelic model)",0.387,2.865,'-,[1.844-4.452],HNRNPA1P57,"Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin)","response to camptothecin, response to antineoplastic agent",GCST001993,2:41046491
rs6039763-<b>A</b>,"2 x 10-6","(Dominant model)",0.09,5.966,'-,[2.502-14.23],SNAP25-AS1,"Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide)","response to etoposide, response to antineoplastic agent",GCST002000,20:10202869
rs12987465-<b>A</b>,"7 x 10-6","(Recessive model)",0.359,2.597,'-,[1.424-4.737],'-,"Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide)","response to etoposide, response to antineoplastic agent",GCST002000,2:49487883
rs3095008-<b>T</b>,"9 x 10-6","(Dominant model)",0.846,'-,'-,'-,MACC1,"Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide)","response to etoposide, response to antineoplastic agent",GCST002000,7:20216082
rs2506991-<b>G</b>,"2 x 10-6","(Recessive model)",0.269,3.948,'-,[2.101-7.418],"ATP6V0E1P4, LINC01738","Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide)","response to etoposide, response to antineoplastic agent",GCST002000,1:47632734
rs55756123-<b>?</b>,"9 x 10-8",,NR,'-,"6.11 unit decrease",[3.89-8.32],LDB2,"Change in LVEF in response to paclitaxel and trastuzumab in HER2+ breast cancer","response to trastuzumab, left ventricular diastolic function measurement, response to paclitaxel",GCST004790,4:16501144
rs10117876-<b>?</b>,"6 x 10-7",,NR,'-,"7.79 unit decrease",[4.76-10.82],BRINP1,"Change in LVEF in response to paclitaxel and trastuzumab in HER2+ breast cancer","response to trastuzumab, left ventricular diastolic function measurement, response to paclitaxel",GCST004790,9:119096829
rs4305714-<b>?</b>,"1 x 10-6",,NR,'-,"1.87 unit decrease",[1.12-2.63],APOM,"Change in LVEF in response to paclitaxel and trastuzumab in HER2+ breast cancer","response to trastuzumab, left ventricular diastolic function measurement, response to paclitaxel",GCST004790,6:22957508
rs707557-<b>?</b>,"6 x 10-6",,NR,'-,"1.46 unit increase",[0.83-2.08],RAB22A,"Change in LVEF in response to paclitaxel and trastuzumab in HER2+ breast cancer","response to trastuzumab, left ventricular diastolic function measurement, response to paclitaxel",GCST004790,20:58367256
rs77679196-<b>?</b>,"8 x 10-6",,NR,'-,"7 unit decrease",[3.96-10.05],TRPC6,"Change in LVEF in response to paclitaxel and trastuzumab in HER2+ breast cancer","response to trastuzumab, left ventricular diastolic function measurement, response to paclitaxel",GCST004790,11:101582777
rs7698718-<b>?</b>,"8 x 10-6",,NR,'-,"1.78 unit increase",[1.01-2.56],LINC01060,"Change in LVEF in response to paclitaxel and trastuzumab in HER2+ breast cancer","response to trastuzumab, left ventricular diastolic function measurement, response to paclitaxel",GCST004790,4:188634793
rs1035147-<b>T</b>,"4 x 10-6","(Allelic model)",0.877,7.294,'-,[2.587-20.559],'-,"Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors)","response to topoisomerase inhibitor, response to antineoplastic agent",GCST001994,7:12055340
rs10074959-<b>T</b>,"1 x 10-6","(Recessive model)",0.237,1.524,'-,[1.048-2.217],RNU6-334P,"Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors)","response to topoisomerase inhibitor, response to antineoplastic agent",GCST001994,5:104872312
rs303386-<b>A</b>,"4 x 10-6",(Dominant),0.444,1.766,'-,[1.256-2.483],'-,"Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors)","response to topoisomerase inhibitor, response to antineoplastic agent",GCST001994,1:99123823
rs480409-<b>G</b>,"9 x 10-6","(Recessive model)",0.348,1.842,'-,[1.307-2.596],GRM7,"Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors)","response to topoisomerase inhibitor, response to antineoplastic agent",GCST001994,3:6968394
rs1632744-<b>T</b>,"5 x 10-6","(Recessive model)",0.258,1.387,'-,[0.959-2.007],RNU6-334P,"Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors)","response to topoisomerase inhibitor, response to antineoplastic agent",GCST001994,5:104863359
rs7494275-<b>C</b>,"9 x 10-6","(Recessive model)",0.406,1.732,'-,[1.232-2.433],"KTN1, RPL13AP3","Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors)","response to topoisomerase inhibitor, response to antineoplastic agent",GCST001994,14:55765082
rs894734-<b>G</b>,"4 x 10-6","(Dominant model)",0.776,1.619,'-,[1.279-2.05],HOXC13-AS,"Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs)","response to antineoplastic agent, response to antimetabolite",GCST002005,12:53925943
rs2055011-<b>C</b>,"9 x 10-6","(Recessive model)",0.143,1.347,'-,[1.075-1.686],CHODL,"Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs)","response to antineoplastic agent, response to antimetabolite",GCST002005,21:18109036
rs12582168-<b>C</b>,"9 x 10-6","(Dominant model)",0.256,1.454,'-,[1.21-1.748],NCOR2,"Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs)","response to antineoplastic agent, response to antimetabolite",GCST002005,12:124409638
rs7228133-<b>C</b>,"2 x 10-6","(Recessive model)",0.686,1.255,'-,[1.034-1.522],ELOCP27,"Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs)","response to antineoplastic agent, response to antimetabolite",GCST002005,18:4539085
rs9580312-<b>G</b>,"8 x 10-6","(Dominant model)",0.409,1.33,'-,[1.12-1.581],LINC00540,"Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs)","response to antineoplastic agent, response to antimetabolite",GCST002005,13:22179954
rs8127977-<b>A</b>,"2 x 10-6","(Dominant model)",0.722,1.587,'-,[1.282-1.966],LINC00158,"Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs)","response to antineoplastic agent, response to antimetabolite",GCST002005,21:25454202
rs2964475-<b>C</b>,"4 x 10-6","(Allelic model)",0.415,2.248,'-,[1.592-3.174],"ICE1, MTCO1P31","Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin)","response to epirubicin, response to antineoplastic agent",GCST001996,5:5407701
rs4149639-<b>C</b>,"3 x 10-7","(Allelic model)",0.042,4.443,'-,[2.571-7.677],TNFRSF1A,"Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin)","response to epirubicin, response to antineoplastic agent",GCST001996,12:6332835
rs1923834-<b>G</b>,"5 x 10-6","(Dominant model)",0.77,3.236,'-,[1.823-5.744],"POLR1D, GSX1","Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin)","response to epirubicin, response to antineoplastic agent",GCST001996,13:27786350
rs908366-<b>A</b>,"7 x 10-6","(Allelic model)",0.328,2.199,'-,[1.564-3.092],"LHPP, NKX1-2","Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin)","response to epirubicin, response to antineoplastic agent",GCST001996,10:124456270
rs1553091-<b>G</b>,"7 x 10-6","(Recessive model)",0.358,1.48,'-,[1.053-2.08],LINC01991,"Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin)","response to epirubicin, response to antineoplastic agent",GCST001996,3:187999098
rs111365677-<b>?</b>,"1 x 10-7",,'-,17.54386,'-,[4.33-71.43],LINC01708,"Response to citalopram or escitalopram in depression","unipolar depression, response to escitalopram, response to citalopram, mood disorder",GCST003802,1:99463578
rs188843168-<b>?</b>,"4 x 10-7",,'-,449.83,'-,[5.402-Inf],ATP5MK,"Response to citalopram or escitalopram in depression","unipolar depression, response to escitalopram, response to citalopram, mood disorder",GCST003802,10:103390184
rs6063349-<b>?</b>,"7 x 10-7",,'-,1.183432,'-,[1.11-1.27],CSE1L,"Non-response to citalopram or escitalopram and depression","unipolar depression, response to escitalopram, response to citalopram, mood disorder",GCST003810,20:49065345
rs142641502-<b>?</b>,"8 x 10-7",,'-,4.565,'-,[2.155-9.671],CSTF3,"Non-response to citalopram or escitalopram and depression","unipolar depression, response to escitalopram, response to citalopram, mood disorder",GCST003810,11:33109861
rs201569130-<b>?</b>,"9 x 10-7",,'-,3.009,'-,[1.785-5.073],FOXF2,"Non-response to citalopram or escitalopram and depression","unipolar depression, response to escitalopram, response to citalopram, mood disorder",GCST003810,6:1402916
rs1548076-<b>?</b>,"1 x 10-6",,'-,2.4937656,'-,[1.63-3.82],DRAIC,"Non-response to citalopram or escitalopram and depression","unipolar depression, response to escitalopram, response to citalopram, mood disorder",GCST003810,15:69934284
rs182377406-<b>?</b>,"1 x 10-6",,'-,5.773,'-,[3.250-10.254],"CORO1B, GPR152","Non-response to citalopram or escitalopram and depression","unipolar depression, response to escitalopram, response to citalopram, mood disorder",GCST003810,11:67449378
rs143934587-<b>?</b>,"7 x 10-7",,'-,6.711409,'-,[3.61-12.5],SLC24A3,"Response to citalopram or escitalopram and depression","unipolar depression, response to escitalopram, response to citalopram, mood disorder",GCST003811,20:19165806
rs74860738-<b>?</b>,"3 x 10-7",,'-,1.2870014,'-,[1.17-1.41],"LINC02720, ARL6IP1P3","Response to citalopram or escitalopram and depression","unipolar depression, response to escitalopram, response to citalopram, mood disorder",GCST003811,11:80671683
rs189864513-<b>?</b>,"8 x 10-7",,'-,12.345678,'-,[5.65-27.03],LINC01618,"Response to citalopram or escitalopram and depression","unipolar depression, response to escitalopram, response to citalopram, mood disorder",GCST003811,4:52767390
rs11924809-<b>?</b>,"1 x 10-6",,'-,1.215,'-,[1.122-1.316],DGKG,"Response to citalopram or escitalopram and depression","unipolar depression, response to escitalopram, response to citalopram, mood disorder",GCST003811,3:186353656
rs117375960-<b>?</b>,"2 x 10-6",,'-,142.85713,'-,[2.9-∞],NT5C2,"Response to citalopram or escitalopram and depression","unipolar depression, response to escitalopram, response to citalopram, mood disorder",GCST003811,10:103161907
rs142484554-<b>?</b>,"3 x 10-7",,'-,1.459854,'-,[1.26-1.69],SPSB4,"Response to citalopram or escitalopram in depression","unipolar depression, response to escitalopram, response to citalopram, mood disorder",GCST003802,3:141059454
rs6546604-<b>?</b>,"5 x 10-7",,'-,1.2787724,'-,[1.16-1.41],"TGFA, BRD7P6","Response to citalopram or escitalopram in depression","unipolar depression, response to escitalopram, response to citalopram, mood disorder",GCST003802,2:70415675
rs34177316-<b>?</b>,"6 x 10-7",,'-,1.355,'-,[1.203-1.528],APBB2,"Response to citalopram or escitalopram in depression","unipolar depression, response to escitalopram, response to citalopram, mood disorder",GCST003802,4:40985283
rs201921722-<b>?</b>,"7 x 10-7",,'-,1.2642225,'-,[1.15-1.39],"ZNF202, SCN3B","Response to citalopram or escitalopram in depression","unipolar depression, response to escitalopram, response to citalopram, mood disorder",GCST003802,11:123680000
rs80278479-<b>?</b>,"8 x 10-7",,'-,14.492754,'-,[3.88-55.56],TFAP2D,"Response to citalopram or escitalopram in depression","unipolar depression, response to escitalopram, response to citalopram, mood disorder",GCST003802,6:50758466
rs2512987-<b>T</b>,"7 x 10-6","(Allelic model)",0.417,2.985,'-,[1.855-4.803],"PRSS23, ME3","Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin)","response to antineoplastic agent, response to doxorubicin",GCST002009,11:86703240
rs11857176-<b>A</b>,"8 x 10-7","(Recessive model)",0.515,1.8,'-,[1.127-2.874],"CSPG4P13, LINGO1","Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin)","response to antineoplastic agent, response to doxorubicin",GCST002009,15:77872364
rs4380275-<b>G</b>,"5 x 10-6","(Recessive model)",0.152,3.604,'-,[2.041-6.365],LINC01115,"Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin)","response to antineoplastic agent, response to doxorubicin",GCST002009,2:773278
rs2742417-<b>T</b>,"5 x 10-7","(Bupropion, Sexual side effects)",0.49,'-,'-,'-,SACM1L,"Response to anti-depressant treatment in major depressive disorder","antidepressant-induced sexual dysfunction, response to bupropion, response to antidepressant",GCST001308,3:45689959
rs7136572-<b>G</b>,"3 x 10-7","(Bupropion, Sexual side effects)",0.04,'-,'-,'-,PGAM1P5,"Response to anti-depressant treatment in major depressive disorder","antidepressant-induced sexual dysfunction, response to bupropion, response to antidepressant",GCST001308,12:95566012
rs10857636-<b>T</b>,"2 x 10-7","(Bupropion, General side effects)",0.06,'-,'-,'-,WDFY4,"Response to anti-depressant treatment in major depressive disorder","response to bupropion, antidepressant-induced side effect, response to antidepressant",GCST001308,10:48777065
rs17150687-<b>C</b>,"3 x 10-6","(Bupropion, Sexual side effects)",0.02,'-,'-,'-,MAGI2,"Response to anti-depressant treatment in major depressive disorder","antidepressant-induced sexual dysfunction, response to bupropion, response to antidepressant",GCST001308,7:78413974
rs11949289-<b>T</b>,"2 x 10-7","(Venlafaxine, Dizziness)",0.42,'-,'-,'-,LINC02103,"Response to anti-depressant treatment in major depressive disorder","response to venlafaxine, antidepressant-induced dizziness, response to antidepressant",GCST001308,5:28340066
rs6740660-<b>G</b>,"4 x 10-6","(Allelic model)",0.894,3.386,'-,[1.87-6.131],"SERPINE2, USP21P1","Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil)","response to 5' fluorouracil, response to antineoplastic agent",GCST001997,2:224078968
rs1567482-<b>G</b>,"6 x 10-6","(Allelic model)",0.875,2.846,'-,[1.716-4.719],ARAP2,"Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil)","response to 5' fluorouracil, response to antineoplastic agent",GCST001997,4:36025125
rs10488226-<b>A</b>,"3 x 10-6","(Dominant model)",0.107,2.026,'-,[1.50-2.737],"SCIN, ARL4A","Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil)","response to 5' fluorouracil, response to antineoplastic agent",GCST001997,7:12673445
rs6706693-<b>A</b>,"9 x 10-6","(Recessive model)",0.219,1.743,'-,[1.362-2.232],"BIN1, NABP1","Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil)","response to 5' fluorouracil, response to antineoplastic agent",GCST001997,2:191600872
rs1367448-<b>C</b>,"5 x 10-6","(Dominant model)",0.526,1.554,'-,[1.212-1.993],"GNG12-AS1, WLS","Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs)","response to antineoplastic agent, response to anthracycline-based chemotherapy",GCST002008,1:68168241
rs4149639-<b>C</b>,"7 x 10-6","(Allelic model)",0.047,2.763,'-,[1.781-4.287],TNFRSF1A,"Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs)","response to antineoplastic agent, response to anthracycline-based chemotherapy",GCST002008,12:6332835
rs12615435-<b>T</b>,"4 x 10-6","(Allelic model)",0.773,2.214,'-,[1.555-3.154],FTCDNL1,"Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs)","response to antineoplastic agent, response to anthracycline-based chemotherapy",GCST002008,2:199773786
rs1654260-<b>A</b>,"8 x 10-6","(Allelic model)",0.488,1.749,'-,[1.365-2.24],"ZNF486, BNIP3P17","Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs)","response to antineoplastic agent, response to anthracycline-based chemotherapy",GCST002008,19:20218302
rs2505059-<b>G</b>,"5 x 10-6","(Allelic model)",0.398,1.765,'-,[1.383-2.252],MIR2113,"Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs)","response to antineoplastic agent, response to anthracycline-based chemotherapy",GCST002008,6:98048076
rs10040979-<b>G</b>,"5 x 10-7","(Recessive model)",0.618,1.452,'-,[1.12-1.883],EBF1,"Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs)","response to antineoplastic agent, response to anthracycline-based chemotherapy",GCST002008,5:158997383
rs17022006-<b>G</b>,"3 x 10-8",,NR,'-,"7.16 unit decrease",[4.63-9.69],CNTN4,"Response to aripiprazole in schizophrenia","schizophrenia, response to aripiprazole, response to antipsychotic drug",GCST006285,3:2897050
rs68057166-<b>G</b>,"4 x 10-7",,NR,'-,"6.15 unit decrease",[3.76-8.54],TENM2,"Response to aripiprazole in schizophrenia","schizophrenia, response to aripiprazole, response to antipsychotic drug",GCST006285,5:167805815
rs12660691-<b>A</b>,"4 x 10-6","(Allelic model)",0.819,3.199,'-,[1.899-5.391],ARHGAP18,"Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel)","response to docetaxel, response to antineoplastic agent",GCST001995,6:129687300
rs1756650-<b>G</b>,"2 x 10-6","(Recessive model)",0.162,1.386,'-,[0.954-2.014],LINC02296,"Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel)","response to docetaxel, response to antineoplastic agent",GCST001995,14:87274681
rs837841-<b>T</b>,"8 x 10-6","(Recessive model)",0.662,1.279,'-,[0.930-1.759],LINC01854,"Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel)","response to docetaxel, response to antineoplastic agent",GCST001995,2:129276439
rs4727963-<b>C</b>,"1 x 10-6","(Dominant model)",0.618,2.094,'-,[1.505-2.914],SLC13A1,"Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel)","response to docetaxel, response to antineoplastic agent",GCST001995,7:123119926
rs4553720-<b>T</b>,"7 x 10-6","(Recessive model)",0.281,1.547,'-,[1.131-2.116],LINC01924,"Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel)","response to docetaxel, response to antineoplastic agent",GCST001995,18:64503491
rs488248-<b>T</b>,"3 x 10-6","(Allelic model)",0.795,2.896,'-,[1.802-4.665],'-,"Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel)","response to docetaxel, response to antineoplastic agent",GCST001995,13:105944370
rs3747851-<b>T</b>,"6 x 10-7","(Allelic model)",0.176,2.377,'-,[1.693-3.339],DAB2IP,"Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel)","response to docetaxel, response to antineoplastic agent",GCST001995,9:121758981
rs35123024-<b>C</b>,"4 x 10-6",,0.15,2.57,'-,'-,"OR5H14, OR5H1","Uncontrolled blood pressure in combination therapy (beta blocker and thiazide diuretic)","blood pressure, response to thiazide, response to beta blocker",GCST005039,3:98140850
rs261316-<b>T</b>,"9 x 10-8",,0.60,2.16,'-,'-,ALDH1A2,"Uncontrolled blood pressure in combination therapy (beta blocker and thiazide diuretic)","blood pressure, response to thiazide, response to beta blocker",GCST005039,15:58341621
rs7562028-<b>G</b>,"8 x 10-6",,0.07,'-,"6.05 unit decrease",'-,LINC01102,"Systolic blood pressure in combination therapy (beta blocker and thiazide diuretic)","systolic blood pressure, response to thiazide, response to beta blocker",GCST005040,2:104434714
rs148514273-<b>A</b>,"3 x 10-7",,0.03,'-,"7.85 unit decrease",'-,SETD7,"Diastolic blood pressure in combination therapy (beta blocker and thiazide diuretic)","diastolic blood pressure, response to thiazide, response to beta blocker",GCST005041,4:139543924
rs142521164-<b>T</b>,"5 x 10-6",,0.40,'-,"2.01 unit increase",'-,'-,"Diastolic blood pressure in combination therapy (beta blocker and thiazide diuretic)","diastolic blood pressure, response to thiazide, response to beta blocker",GCST005041,3:164343182
rs192336334-<b>T</b>,"9 x 10-6",,0.05,'-,"5.35 unit increase",'-,'-,"Diastolic blood pressure in combination therapy (beta blocker and thiazide diuretic)","diastolic blood pressure, response to thiazide, response to beta blocker",GCST005041,14:39921969
rs2519974-<b>T</b>,"4 x 10-6","(Dominant model)",0.381,1.647,'-,[1.264-2.146],HS3ST2,"Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide)","response to cyclophosphamide, response to antineoplastic agent",GCST002002,16:22877865
rs10922438-<b>T</b>,"6 x 10-6","(Allelic model)",0.106,2.301,'-,[1.608-3.293],ATP6V1G3,"Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide)","response to cyclophosphamide, response to antineoplastic agent",GCST002002,1:198500032
rs3745571-<b>T</b>,"8 x 10-6","(Dominant model)",0.67,1.73,'-,[1.276-2.345],DENND1C,"Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide)","response to cyclophosphamide, response to antineoplastic agent",GCST002002,19:6475602
rs9961113-<b>C</b>,"1 x 10-6","(Allelic model)",0.403,2.473,'-,[1.706-3.584],"LINC01029, RNA5SP461","Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine)","response to gemcitabine, response to antineoplastic agent",GCST002003,18:77893443
rs9609078-<b>T</b>,"4 x 10-6","(Allelic model)",0.009,10.89,'-,[3.528-33.61],OSBP2,"Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine)","response to gemcitabine, response to antineoplastic agent",GCST002003,22:30757289
rs2547917-<b>A</b>,"3 x 10-6","(Recessive model)",0.212,1.997,'-,[1.345-2.965],PDE4D,"Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine)","response to gemcitabine, response to antineoplastic agent",GCST002003,5:59417854
rs12900463-<b>C</b>,"4 x 10-6","(Recessive model)",0.115,2.154,'-,[1.342-3.457],ALPK3,"Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine)","response to gemcitabine, response to antineoplastic agent",GCST002003,15:84872155
rs6863418-<b>A</b>,"7 x 10-6","(Dominant model)",0.055,3.623,'-,[2.042-6.429],NSG2,"Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine)","response to gemcitabine, response to antineoplastic agent",GCST002003,5:174198151
rs4591358-<b>C</b>,"7 x 10-6","(Allelic model)",0.215,1.578,'-,[1.297-1.92],RNU6-169P,"Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)","response to antineoplastic agent, response to antimicrotubule agent",GCST002001,2:195501166
rs12882718-<b>T</b>,"6 x 10-6","(Dominant model)",0.643,1.555,'-,[1.283-1.884],LINC02309,"Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)","response to antineoplastic agent, response to antimicrotubule agent",GCST002001,14:86435710
rs6961860-<b>G</b>,"5 x 10-6","(Recessive model)",0.495,1.283,'-,[1.078-1.527],AHR,"Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)","response to antineoplastic agent, response to antimicrotubule agent",GCST002001,7:17045697
rs11651483-<b>C</b>,"3 x 10-7","(Recessive model)",0.665,1.357,'-,[1.12-1.643],ARHGAP44,"Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)","response to antineoplastic agent, response to antimicrotubule agent",GCST002001,17:12874085
rs4771859-<b>G</b>,"1 x 10-6","(Recessive model)",0.709,1.328,'-,[1.088-1.623],GPC5,"Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)","response to antineoplastic agent, response to antimicrotubule agent",GCST002001,13:92436398
rs12145418-<b>T</b>,"2 x 10-6","(Recessive model)",0.274,1.331,'-,[1.104-1.604],ESRRG,"Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)","response to antineoplastic agent, response to antimicrotubule agent",GCST002001,1:216542978
rs12935229-<b>A</b>,"4 x 10-6","(Recessive model)",0.182,1.495,'-,[1.214-1.84],ADAMTS18,"Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)","response to antineoplastic agent, response to antimicrotubule agent",GCST002001,16:77294998
rs1043763-<b>T</b>,"7 x 10-6","(Dominant model)",0.574,1.496,'-,[1.248-1.795],MLXIP,"Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)","response to antineoplastic agent, response to antimicrotubule agent",GCST002001,12:122146362
rs8022296-<b>G</b>,"7 x 10-6","(Recessive model)",0.608,1.269,'-,[1.058-1.521],LINC02325,"Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)","response to antineoplastic agent, response to antimicrotubule agent",GCST002001,14:97521520
rs9386485-<b>T</b>,"3 x 10-6","(Allelic model)",0.492,1.524,'-,[1.279-1.817],RN7SKP211,"Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)","response to antineoplastic agent, response to antimicrotubule agent",GCST002001,6:105881180
rs4235898-<b>A</b>,"1 x 10-6","(Allelic model)",0.74,1.718,'-,[1.377-2.142],LINC02540,"Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)","response to antineoplastic agent, response to antimicrotubule agent",GCST002001,6:76556471
rs6817170-<b>G</b>,"9 x 10-6","(Allelic model)",0.286,1.517,'-,[1.264-1.822],"TMEM131L, MND1","Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)","response to antineoplastic agent, response to antimicrotubule agent",GCST002001,4:153453832
rs2291477-<b>C</b>,"3 x 10-8","(Hispanic or Latino)",0.884,'-,"9.31 unit increase",[6.04-12.58],TGFBR3,"QT interval (tricyclic/tetracyclic antidepressant use interaction)","response to tetracyclic antidepressant, QT interval, response to tricyclic antidepressant",GCST004010,1:91712778
rs6737205-<b>A</b>,"8 x 10-9",(EA),0.94,'-,"56.3 unit increase",[37.29-75.31],BABAM2,"RR interval (tricyclic/tetracyclic antidepressant use interaction)","RR interval, response to tetracyclic antidepressant, response to tricyclic antidepressant",GCST004011,2:28106446
rs9830388-<b>A</b>,"2 x 10-8",(EA),0.51,'-,"25.2 unit increase",[16.38-34.02],UBE2E2,"RR interval (tricyclic/tetracyclic antidepressant use interaction)","RR interval, response to tetracyclic antidepressant, response to tricyclic antidepressant",GCST004011,3:23518056
rs11867129-<b>T</b>,"3 x 10-7",(EA),0.09,'-,"35.7 unit increase",[22.18-49.22],ABCA3,"RR interval (tricyclic/tetracyclic antidepressant use interaction)","RR interval, response to tetracyclic antidepressant, response to tricyclic antidepressant",GCST004011,16:2315287
rs3845905-<b>G</b>,"4 x 10-6","(Allelic model)",0.85,1.894,'-,[1.433-2.503],LRIG1,"Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs)","response to platinum based chemotherapy, response to antineoplastic agent",GCST001998,3:66475539
rs4886670-<b>A</b>,"1 x 10-6","(Allelic model)",0.227,1.605,'-,[1.330-1.937],"Metazoa_SRP, RPL36AP45","Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs)","response to platinum based chemotherapy, response to antineoplastic agent",GCST001998,15:75157333
rs33428-<b>G</b>,"3 x 10-6","(Dominant model)",0.403,1.375,'-,[1.160-1.629],ZNF536,"Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs)","response to platinum based chemotherapy, response to antineoplastic agent",GCST001998,19:30446936
rs12589282-<b>G</b>,"4 x 10-6","(Recessive model)",0.437,1.48,'-,[1.25-1.752],"TRDC, TRDV3","Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs)","response to platinum based chemotherapy, response to antineoplastic agent",GCST001998,14:22468664
rs1895302-<b>C</b>,"7 x 10-6","(Dominant model)",0.478,1.34,'-,[1.132-1.587],"FOXI1, KRT18P41","Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs)","response to platinum based chemotherapy, response to antineoplastic agent",GCST001998,5:170115596
rs16825455-<b>T</b>,"9 x 10-6","(Dominant model)",0.605,1.425,'-,[1.193-1.702],ALPL,"Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs)","response to platinum based chemotherapy, response to antineoplastic agent",GCST001998,1:21511262
rs7989332-<b>G</b>,"5 x 10-6","(Allelic model)",0.738,2.056,'-,[1.507-2.806],CRYL1,"Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin)","response to carboplatin, response to antineoplastic agent",GCST002004,13:20476436
rs11071200-<b>T</b>,"9 x 10-7","(Dominant model)",0.008,8.241,'-,[2.888-23.520],PRTG,"Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin)","response to carboplatin, response to antineoplastic agent",GCST002004,15:55657884
rs3845905-<b>G</b>,"6 x 10-6","(Allelic model)",0.828,2.433,'-,[1.645-3.598],LRIG1,"Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin)","response to carboplatin, response to antineoplastic agent",GCST002004,3:66475539
rs12446319-<b>A</b>,"9 x 10-6","(Allelic model)",0.143,2.026,'-,[1.48-2.774],PLCG2,"Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin)","response to carboplatin, response to antineoplastic agent",GCST002004,16:81741193
rs1623879-<b>G</b>,"4 x 10-6","(Recessive model)",0.321,1.669,'-,[1.297-2.148],FLNB,"Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin)","response to carboplatin, response to antineoplastic agent",GCST002004,3:58041470
rs936229-<b>G</b>,"4 x 10-6","(Dominant model)",0.595,1.685,'-,[1.302-2.18],ULK3,"Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin)","response to carboplatin, response to antineoplastic agent",GCST002004,15:74839978
rs1714746-<b>G</b>,"7 x 10-6","(Recessive model)",0.435,1.61,'-,[1.261-2.056],CSMD1,"Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin)","response to carboplatin, response to antineoplastic agent",GCST002004,8:4247625
rs1277203-<b>A</b>,"9 x 10-6","(Recessive model)",0.626,1.615,'-,[1.243-2.098],AKNAD1,"Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin)","response to carboplatin, response to antineoplastic agent",GCST002004,1:108850215
rs3822735-<b>G</b>,"2 x 10-6","(Dominant model)",0.752,2.062,'-,[1.500-2.834],SPEF2,"Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin)","response to carboplatin, response to antineoplastic agent",GCST002004,5:35799892
rs12025262-<b>?</b>,"7 x 10-7",,NR,'-,'-,'-,ZNF731P,"Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50)","response to platinum based chemotherapy, ovarian carcinoma, cytotoxicity measurement, response to paclitaxel",GCST003443,1:247193430
rs10674174-<b>?</b>,"8 x 10-7",,NR,'-,'-,'-,PCDH20,"Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50)","response to platinum based chemotherapy, ovarian carcinoma, cytotoxicity measurement, response to paclitaxel",GCST003443,13:61317943
rs7572644-<b>?</b>,"6 x 10-6",,NR,'-,'-,'-,BABAM2,"Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50)","response to platinum based chemotherapy, ovarian carcinoma, cytotoxicity measurement, response to paclitaxel",GCST003443,2:28097166
rs201023017-<b>?</b>,"6 x 10-7",,NR,'-,'-,'-,SLC9A9,"Response to carboplatin and paclitaxel in ovarian cancer (MTT IC50)","response to platinum based chemotherapy, ovarian carcinoma, cytotoxicity measurement, response to paclitaxel",GCST003444,3:143384827
rs66696671-<b>?</b>,"7 x 10-7",,NR,'-,'-,'-,"RAD1P1, TIAL1","Response to carboplatin and paclitaxel in ovarian cancer (MTT IC50)","response to platinum based chemotherapy, ovarian carcinoma, cytotoxicity measurement, response to paclitaxel",GCST003444,10:119607441
rs187234497-<b>G</b>,"5 x 10-6",,0.012,3.978,'-,[2.198-7.199],PSEN2,"Angioedema in response to angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker","response to angiotensin-converting enzyme inhibitor, response to angiotensin receptor blocker, angioedema",GCST010247,1:165085776
rs113325073-<b>A</b>,"6 x 10-7",,0.013,3.969,'-,[2.307-6.828],DCLK1,"Angioedema in response to angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker","response to angiotensin-converting enzyme inhibitor, response to angiotensin receptor blocker, angioedema",GCST010247,13:35943293
rs2350090-<b>A</b>,"2 x 10-6",,0.013,3.818,'-,[2.191-6.651],KCNQ5,"Angioedema in response to angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker","response to angiotensin-converting enzyme inhibitor, response to angiotensin receptor blocker, angioedema",GCST010247,6:72867964
rs193153064-<b>T</b>,"1 x 10-6",,0.013,3.842,'-,[2.221-6.645],'-,"Angioedema in response to angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker","response to angiotensin-converting enzyme inhibitor, response to angiotensin receptor blocker, angioedema",GCST010247,18:72418127
rs181415750-<b>G</b>,"1 x 10-6",,0.013,3.788,'-,[2.203-6.512],KDM2A,"Angioedema in response to angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker","response to angiotensin-converting enzyme inhibitor, response to angiotensin receptor blocker, angioedema",GCST010247,11:67212032
rs114930791-<b>T</b>,"2 x 10-6",,0.015,3.734,'-,[2.178-6.401],AMY1C,"Angioedema in response to angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker","response to angiotensin-converting enzyme inhibitor, response to angiotensin receptor blocker, angioedema",GCST010247,1:103825222
rs138831395-<b>A</b>,"5 x 10-6",,0.014,3.576,'-,[2.07-6.178],RPL5P19,"Angioedema in response to angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker","response to angiotensin-converting enzyme inhibitor, response to angiotensin receptor blocker, angioedema",GCST010247,6:91967412
rs55636532-<b>C</b>,"2 x 10-6",,0.019,3.495,'-,[2.077-5.883],FGF12,"Angioedema in response to angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker","response to angiotensin-converting enzyme inhibitor, response to angiotensin receptor blocker, angioedema",GCST010247,3:192194678
rs7569878-<b>T</b>,"8 x 10-6",,0.017,3.234,'-,[1.93-5.419],"CRIM1-DT, RPL21P36","Angioedema in response to angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker","response to angiotensin-converting enzyme inhibitor, response to angiotensin receptor blocker, angioedema",GCST010247,2:36331996
rs79445594-<b>C</b>,"1 x 10-6",,0.024,3.113,'-,[1.962-4.938],'-,"Angioedema in response to angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker","response to angiotensin-converting enzyme inhibitor, response to angiotensin receptor blocker, angioedema",GCST010247,7:12050026
rs78655262-<b>G</b>,"5 x 10-6",,0.025,2.899,'-,[1.835-4.578],VWDE,"Angioedema in response to angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker","response to angiotensin-converting enzyme inhibitor, response to angiotensin receptor blocker, angioedema",GCST010247,7:12372714
rs114514212-<b>A</b>,"1 x 10-6",,0.035,2.634,'-,[1.776-3.908],PDE4D,"Angioedema in response to angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker","response to angiotensin-converting enzyme inhibitor, response to angiotensin receptor blocker, angioedema",GCST010247,5:60103418
rs2253201-<b>G</b>,"4 x 10-8",,0.063,2.474,'-,[1.79-3.419],KCNMA1,"Angioedema in response to angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker","response to angiotensin-converting enzyme inhibitor, response to angiotensin receptor blocker, angioedema",GCST010247,10:77596639
rs866539-<b>C</b>,"7 x 10-8",,0.068,2.399,'-,[1.744-3.299],KCNMA1,"Angioedema in response to angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker","response to angiotensin-converting enzyme inhibitor, response to angiotensin receptor blocker, angioedema",GCST010247,10:77490046
rs77440358-<b>T</b>,"5 x 10-7",,0.073,2.267,'-,[1.648-3.118],"LINC02441, LINC02369","Angioedema in response to angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker","response to angiotensin-converting enzyme inhibitor, response to angiotensin receptor blocker, angioedema",GCST010247,12:128074297
rs6913724-<b>A</b>,"2 x 10-7",,0.432,1.804,'-,[1.446-2.252],POM121L2,"Angioedema in response to angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker","response to angiotensin-converting enzyme inhibitor, response to angiotensin receptor blocker, angioedema",GCST010247,6:27287064
rs10963602-<b>C</b>,"4 x 10-6",,0.204,1.758,'-,[1.383-2.234],ADAMTSL1,"Angioedema in response to angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker","response to angiotensin-converting enzyme inhibitor, response to angiotensin receptor blocker, angioedema",GCST010247,9:18419152
rs11070816-<b>T</b>,"2 x 10-7",,0.425,1.778,'-,[1.43-2.212],TRPM1,"Angioedema in response to angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker","response to angiotensin-converting enzyme inhibitor, response to angiotensin receptor blocker, angioedema",GCST010247,15:31114132
rs1711774-<b>G</b>,"8 x 10-6",,0.597,1.724138,'-,[1.36-2.19],"ZDHHC20P4, RNU7-88P","Angioedema in response to angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker","response to angiotensin-converting enzyme inhibitor, response to angiotensin receptor blocker, angioedema",GCST010247,13:59515109
rs11944965-<b>T</b>,"2 x 10-6","(Dominant model)",0.678,1.986,'-,[1.475-2.676],HMGN1P11,"Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin)","response to cisplatin, response to antineoplastic agent",GCST002007,4:62558371
rs4627050-<b>G</b>,"4 x 10-6","(Allelic model)",0.649,1.932,'-,[1.452-2.572],"MRGPRX8P, PTPN5","Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin)","response to cisplatin, response to antineoplastic agent",GCST002007,11:18800490
rs10253216-<b>T</b>,"2 x 10-7","(Dominant model)",0.468,1.478,'-,[1.155-1.891],AGR2,"Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin)","response to cisplatin, response to antineoplastic agent",GCST002007,7:16822225
rs2406342-<b>T</b>,"2 x 10-6","(Dominant model)",0.475,1.697,'-,[1.323-2.177],"ZNF236-DT, CCND3P2","Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin)","response to cisplatin, response to antineoplastic agent",GCST002007,18:76776324
rs6077251-<b>T</b>,"3 x 10-6","(Allelic model)",0.153,2.065,'-,[1.537-2.773],'-,"Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin)","response to cisplatin, response to antineoplastic agent",GCST002007,20:7771719
rs11774576-<b>A</b>,"3 x 10-6","(Dominant model)",0.581,1.699,'-,[1.307-2.208],SCARA5,"Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin)","response to cisplatin, response to antineoplastic agent",GCST002007,8:27882900
rs12142335-<b>A</b>,"8 x 10-6","(Dominant model)",0.004,9.713,'-,[3.175-29.71],VAV3,"Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin)","response to cisplatin, response to antineoplastic agent",GCST002007,1:107760300
rs9386485-<b>T</b>,"1 x 10-6","(Allelic model)",0.477,1.821,'-,[1.429-2.32],RN7SKP211,"Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel)","response to paclitaxel, response to antineoplastic agent",GCST001999,6:105881180
rs3138083-<b>A</b>,"4 x 10-6","(Allelic model)",0.117,2.136,'-,[1.551-2.942],"SIT1, CD72","Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel)","response to paclitaxel, response to antineoplastic agent",GCST001999,9:35648953
rs4886670-<b>A</b>,"7 x 10-6","(Allelic model)",0.229,1.835,'-,[1.412-2.383],"Metazoa_SRP, RPL36AP45","Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel)","response to paclitaxel, response to antineoplastic agent",GCST001999,15:75157333
rs792975-<b>T</b>,"8 x 10-6","(Allelic model)",0.519,1.746,'-,[1.366-2.232],ERGIC1,"Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel)","response to paclitaxel, response to antineoplastic agent",GCST001999,5:172844004
rs922106-<b>T</b>,"9 x 10-7","(Recessive model)",0.202,1.679,'-,[1.277-2.207],LRRC8B,"Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel)","response to paclitaxel, response to antineoplastic agent",GCST001999,1:89559960
rs2444896-<b>T</b>,"2 x 10-6","(Dominant model)",0.603,1.754,'-,[1.355-2.269],MATN2,"Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel)","response to paclitaxel, response to antineoplastic agent",GCST001999,8:98009781
rs3786094-<b>C</b>,"6 x 10-6","(Recessive model)",0.422,1.531,'-,[1.206-1.944],GAS7,"Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel)","response to paclitaxel, response to antineoplastic agent",GCST001999,17:9971888
rs4666360-<b>C</b>,"3 x 10-6","(Dominant model)",0.114,2.136,'-,[1.546-2.95],"LAPTM4A-DT, RPS16P2","Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel)","response to paclitaxel, response to antineoplastic agent",GCST001999,2:20135948
rs4842407-<b>C</b>,"3 x 10-7",,0.44,5.4,'-,[2.8-10.3],SYT1,"Liver injury in combined anti-retroviral and anti-tuberculosis drug-treated HIV with tuberculosis","response to rifampicin, Tuberculosis, response to efavirenz, HIV infection, drug-induced liver injury",GCST004262,12:78807293
rs11012476-<b>A</b>,"1 x 10-6",,0.03,14.3,'-,[5.3-39.9],NEBL,"Liver injury in combined anti-retroviral and anti-tuberculosis drug-treated HIV with tuberculosis","response to rifampicin, Tuberculosis, response to efavirenz, HIV infection, drug-induced liver injury",GCST004262,10:21003994
rs251891-<b>A</b>,"4 x 10-6",,0.11,5.2,'-,[2.9-9.5],"TMED7, H3P24","Liver injury in combined anti-retroviral and anti-tuberculosis drug-treated HIV with tuberculosis","response to rifampicin, Tuberculosis, response to efavirenz, HIV infection, drug-induced liver injury",GCST004262,5:115714665
rs72894781-<b>?</b>,"7 x 10-6",,'-,3.43,'-,[2.01-5.87],TEAD3,"Severe carbamazepine- or oxcarbazepine-induced hyponatremia in epilepsy","carbamazepine-induced hyponatremia, response to oxcarbazepine, oxcarbazepine-induced hyponatremia, epilepsy, response to carbamazepine",GCST007810,6:35494090
rs9833158-<b>?</b>,"1 x 10-6",,'-,1.56,'-,[1.32-1.89],"CDYLP1, PLCL2","Carbamazepine- or oxcarbazepine-induced hyponatremia in epilepsy","carbamazepine-induced hyponatremia, response to oxcarbazepine, oxcarbazepine-induced hyponatremia, epilepsy, response to carbamazepine",GCST007809,3:16742882
rs4895178-<b>?</b>,"1 x 10-6",,'-,1.55,'-,[1.30-1.85],RPL23AP44,"Carbamazepine- or oxcarbazepine-induced hyponatremia in epilepsy","carbamazepine-induced hyponatremia, response to oxcarbazepine, oxcarbazepine-induced hyponatremia, epilepsy, response to carbamazepine",GCST007809,5:121518937
rs148646711-<b>?</b>,"2 x 10-6",,'-,1.96,'-,[1.48-2.59],"FLJ31104, ANKRD55","Carbamazepine- or oxcarbazepine-induced hyponatremia in epilepsy","carbamazepine-induced hyponatremia, response to oxcarbazepine, oxcarbazepine-induced hyponatremia, epilepsy, response to carbamazepine",GCST007809,5:56067696
rs1394074-<b>?</b>,"1 x 10-6",,'-,7.75,'-,[3.41-17.61],OLFML3,"Severe carbamazepine- or oxcarbazepine-induced hyponatremia in epilepsy","carbamazepine-induced hyponatremia, response to oxcarbazepine, oxcarbazepine-induced hyponatremia, epilepsy, response to carbamazepine",GCST007810,1:114005041
rs7300380-<b>?</b>,"2 x 10-6",,'-,3.07,'-,[1.93-4.87],"ITPR2, SSPN","Severe carbamazepine- or oxcarbazepine-induced hyponatremia in epilepsy","carbamazepine-induced hyponatremia, response to oxcarbazepine, oxcarbazepine-induced hyponatremia, epilepsy, response to carbamazepine",GCST007810,12:26322620
rs112513025-<b>?</b>,"1 x 10-9",,NR,'-,'-,'-,"DDX27, STAU1","Change in quality of life in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease","chronic obstructive pulmonary disease, response to corticosteroid, response to salmeterol, respiratory symptom change measurement",GCST008292,20:49191622
rs2869693-<b>?</b>,"1 x 10-6",,NR,'-,'-,'-,CSE1L,"Response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease","respiratory symptom measurement, chronic obstructive pulmonary disease, response to corticosteroid, response to salmeterol",GCST008294,20:49051608
rs10899426-<b>?</b>,"2 x 10-7",,NR,2.74,'-,'-,"KCTD14, INTS4","Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel","progression free survival, ovarian carcinoma, response to cisplatin, response to paclitaxel",GCST004897,11:78008566
rs6256-<b>?</b>,"1 x 10-6",,NR,1.93,'-,'-,PTH,"Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel","progression free survival, ovarian carcinoma, response to cisplatin, response to paclitaxel",GCST004897,11:13492506
rs10832063-<b>?</b>,"5 x 10-6",,NR,1.8,'-,'-,"PTH, HMGN2P36","Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel","progression free survival, ovarian carcinoma, response to cisplatin, response to paclitaxel",GCST004897,11:13553087
rs10500780-<b>?</b>,"5 x 10-6",,NR,1.79,'-,'-,BTBD10,"Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel","progression free survival, ovarian carcinoma, response to cisplatin, response to paclitaxel",GCST004897,11:13401400
rs1564271-<b>?</b>,"9 x 10-6",,NR,1.62,'-,'-,PDSS1,"Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin","overall survival, ovarian carcinoma, response to cisplatin, response to paclitaxel",GCST004896,10:26722183
rs10899426-<b>?</b>,"9 x 10-6",,NR,2.29,'-,'-,"KCTD14, INTS4","Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin","overall survival, ovarian carcinoma, response to cisplatin, response to paclitaxel",GCST004896,11:78008566
rs4618572-<b>?</b>,"9 x 10-6",,NR,1.86,'-,'-,"FOXF2, RN7SL352P","Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin","overall survival, ovarian carcinoma, response to cisplatin, response to paclitaxel",GCST004896,6:1492427
rs295315-<b>?</b>,"8 x 10-7",,NR,1.82,'-,'-,"RASA2, LINC02618","Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin","overall survival, ovarian carcinoma, response to cisplatin, response to paclitaxel",GCST004896,3:141643383
rs17693104-<b>?</b>,"8 x 10-7",,NR,1.65,'-,'-,SH2D4B,"Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin","overall survival, ovarian carcinoma, response to cisplatin, response to paclitaxel",GCST004896,10:80608465
rs868767-<b>?</b>,"2 x 10-6",,NR,2.12,'-,'-,"LINC02618, RASA2","Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin","overall survival, ovarian carcinoma, response to cisplatin, response to paclitaxel",GCST004896,3:141658488
rs2050203-<b>?</b>,"4 x 10-6",,NR,1.78,'-,'-,"GAPDHP53, SYNDIG1","Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin","overall survival, ovarian carcinoma, response to cisplatin, response to paclitaxel",GCST004896,20:24451198
rs11621975-<b>?</b>,"5 x 10-6",,NR,2.31,'-,'-,"DIO3, LINC02320","Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin","overall survival, ovarian carcinoma, response to cisplatin, response to paclitaxel",GCST004896,14:101629499
rs17548007-<b>?</b>,"5 x 10-6",,NR,1.86,'-,'-,ASCL1,"Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin","overall survival, ovarian carcinoma, response to cisplatin, response to paclitaxel",GCST004896,12:102981636
rs202280-<b>?</b>,"6 x 10-6",,NR,2,'-,'-,FABP5,"Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin","overall survival, ovarian carcinoma, response to cisplatin, response to paclitaxel",GCST004896,8:81290982
rs3738441-<b>?</b>,"9 x 10-7",(AA),NR,'-,"0.039 unit increase",'-,TGFBR3,"HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","HDL cholesterol change measurement, response to simvastatin, type II diabetes mellitus, response to fenofibrate",GCST004763,1:91758510
rs2028196-<b>?</b>,"9 x 10-7",,NR,'-,"0.013 unit decrease",'-,"LINC01381, POMC","HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","HDL cholesterol change measurement, response to simvastatin, type II diabetes mellitus, response to fenofibrate",GCST004763,2:25175973
rs1597595-<b>?</b>,"7 x 10-7",(AA),NR,'-,"0.025 unit increase",'-,'-,"HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","HDL cholesterol change measurement, response to simvastatin, type II diabetes mellitus, response to fenofibrate",GCST004763,2:147192553
rs7709909-<b>?</b>,"1 x 10-8",(AA),NR,'-,"0.045 unit decrease",'-,MSH3,"HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","HDL cholesterol change measurement, response to simvastatin, type II diabetes mellitus, response to fenofibrate",GCST004763,5:80705351
rs7214842-<b>?</b>,"1 x 10-6",(AA),NR,'-,"0.024 unit increase",'-,STX8,"HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","HDL cholesterol change measurement, response to simvastatin, type II diabetes mellitus, response to fenofibrate",GCST004763,17:9445693
rs71313049-<b>?</b>,"7 x 10-7",(AA),NR,'-,"0.043 unit decrease",'-,CELSR1,"HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","HDL cholesterol change measurement, response to simvastatin, type II diabetes mellitus, response to fenofibrate",GCST004763,22:46458337
rs9285630-<b>?</b>,"8 x 10-7",(EA),NR,'-,"0.022 unit decrease",'-,SNX7,"LDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","LDL cholesterol change measurement, response to simvastatin, type II diabetes mellitus, response to fenofibrate",GCST004764,1:98677991
rs1653969-<b>?</b>,"9 x 10-7",(AA),NR,'-,"0.037 unit increase",'-,FOXP1,"LDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","LDL cholesterol change measurement, response to simvastatin, type II diabetes mellitus, response to fenofibrate",GCST004764,3:71282213
rs112284299-<b>?</b>,"7 x 10-7",(AA),NR,'-,"0.107 unit increase",'-,PEX5L,"LDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","LDL cholesterol change measurement, response to simvastatin, type II diabetes mellitus, response to fenofibrate",GCST004764,3:179850308
rs72804453-<b>?</b>,"4 x 10-7",(AA),NR,'-,"0.111 unit increase",'-,BICC1,"LDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","LDL cholesterol change measurement, response to simvastatin, type II diabetes mellitus, response to fenofibrate",GCST004764,10:58827232
rs2607653-<b>?</b>,"4 x 10-7",,NR,'-,"0.038 unit increase",'-,FGF14,"LDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","LDL cholesterol change measurement, response to simvastatin, type II diabetes mellitus, response to fenofibrate",GCST004764,13:102066314
rs73354145-<b>?</b>,"2 x 10-7",,NR,'-,"0.032 unit increase",'-,MRPL12,"LDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","LDL cholesterol change measurement, response to simvastatin, type II diabetes mellitus, response to fenofibrate",GCST004764,17:81706393
rs150268548-<b>?</b>,"9 x 10-8",(EA),NR,'-,"0.028 unit decrease",'-,"GATAD2A, MAU2","LDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","LDL cholesterol change measurement, response to simvastatin, type II diabetes mellitus, response to fenofibrate",GCST004764,19:19383674
rs2631781-<b>?</b>,"1 x 10-6",(AA),NR,'-,"0.051 unit increase",'-,ST6GALNAC3,"Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","response to simvastatin, type II diabetes mellitus, total cholesterol change measurement, response to fenofibrate",GCST004765,1:76128101
rs181126208-<b>?</b>,"7 x 10-8",(AA),NR,'-,"0.066 unit increase",'-,EDARADD,"Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","response to simvastatin, type II diabetes mellitus, total cholesterol change measurement, response to fenofibrate",GCST004765,1:236495210
rs75639901-<b>?</b>,"5 x 10-7",(AA),NR,'-,"0.039 unit increase",'-,SCGN,"Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","response to simvastatin, type II diabetes mellitus, total cholesterol change measurement, response to fenofibrate",GCST004765,6:25667803
rs9472719-<b>?</b>,"9 x 10-7",,NR,'-,"0.008 unit increase",'-,"ENPP5, ACTG1P9","Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","response to simvastatin, type II diabetes mellitus, total cholesterol change measurement, response to fenofibrate",GCST004765,6:46183649
rs7810240-<b>?</b>,"2 x 10-7",,NR,'-,"0.015 unit decrease",'-,ZNF775,"Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","response to simvastatin, type II diabetes mellitus, total cholesterol change measurement, response to fenofibrate",GCST004765,7:150387372
rs34030778-<b>?</b>,"4 x 10-8",(AA),NR,'-,"0.124 unit increase",'-,"CLN8, KBTBD11-OT1","Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","response to simvastatin, type II diabetes mellitus, total cholesterol change measurement, response to fenofibrate",GCST004765,8:1771328
rs114007472-<b>?</b>,"8 x 10-7",(AA),NR,'-,"0.071 unit increase",'-,RN7SKP135,"Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","response to simvastatin, type II diabetes mellitus, total cholesterol change measurement, response to fenofibrate",GCST004765,8:63563681
rs4988198-<b>?</b>,"9 x 10-7",(AA),NR,'-,"0.058 unit increase",'-,MCM6,"Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","response to simvastatin, type II diabetes mellitus, total cholesterol change measurement, response to fenofibrate",GCST004765,2:135861240
rs141864436-<b>?</b>,"1 x 10-7",(AA),NR,'-,"0.062 unit increase",'-,NRXN1,"Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","response to simvastatin, type II diabetes mellitus, total cholesterol change measurement, response to fenofibrate",GCST004765,2:50971652
rs145010525-<b>?</b>,"8 x 10-7",(AA),NR,'-,"0.058 unit increase",'-,DARS1,"Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","response to simvastatin, type II diabetes mellitus, total cholesterol change measurement, response to fenofibrate",GCST004765,2:135975206
rs115990514-<b>?</b>,"5 x 10-7",(AA),NR,'-,"0.065 unit increase",'-,KCNH8,"Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","response to simvastatin, type II diabetes mellitus, total cholesterol change measurement, response to fenofibrate",GCST004765,3:19055898
rs115092681-<b>?</b>,"1 x 10-6",(AA),NR,'-,"0.061 unit increase",'-,NLGN1,"Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","response to simvastatin, type II diabetes mellitus, total cholesterol change measurement, response to fenofibrate",GCST004765,3:174201323
rs112284299-<b>?</b>,"1 x 10-7",(AA),NR,'-,"0.065 unit increase",'-,PEX5L,"Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","response to simvastatin, type II diabetes mellitus, total cholesterol change measurement, response to fenofibrate",GCST004765,3:179850308
rs10034465-<b>?</b>,"1 x 10-7",(AA),NR,'-,"0.053 unit increase",'-,LINC02484,"Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","response to simvastatin, type II diabetes mellitus, total cholesterol change measurement, response to fenofibrate",GCST004765,4:34193882
rs6847878-<b>?</b>,"1 x 10-6",(AA),NR,'-,"0.062 unit increase",'-,"RASGEF1B, RNU5A-2P","Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","response to simvastatin, type II diabetes mellitus, total cholesterol change measurement, response to fenofibrate",GCST004765,4:81419698
rs80333777-<b>?</b>,"5 x 10-7",,NR,'-,"0.02 unit increase",'-,FBXL7,"Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","response to simvastatin, type II diabetes mellitus, total cholesterol change measurement, response to fenofibrate",GCST004765,5:15524361
rs75298135-<b>?</b>,"4 x 10-7",(AA),NR,'-,"0.065 unit increase",'-,'-,"Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","response to simvastatin, type II diabetes mellitus, total cholesterol change measurement, response to fenofibrate",GCST004765,5:28184372
rs113816795-<b>?</b>,"2 x 10-7",(AA),NR,'-,"0.072 unit increase",'-,HSPB3,"Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","response to simvastatin, type II diabetes mellitus, total cholesterol change measurement, response to fenofibrate",GCST004765,5:99159794
rs146807753-<b>?</b>,"7 x 10-7",(AA),NR,'-,"0.06 unit increase",'-,"TDGF1P4, FAM50B","Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","response to simvastatin, type II diabetes mellitus, total cholesterol change measurement, response to fenofibrate",GCST004765,6:3904005
rs72804453-<b>?</b>,"8 x 10-11",(AA),NR,'-,"0.078 unit increase",'-,BICC1,"Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","response to simvastatin, type II diabetes mellitus, total cholesterol change measurement, response to fenofibrate",GCST004765,10:58827232
rs116616455-<b>?</b>,"7 x 10-7",(AA),NR,'-,"0.047 unit increase",'-,"LINC02403, RN7SKP65","Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","response to simvastatin, type II diabetes mellitus, total cholesterol change measurement, response to fenofibrate",GCST004765,12:58041829
rs112209655-<b>?</b>,"2 x 10-7",(AA),NR,'-,"0.066 unit increase",'-,"TSPAN19, SLC6A15","Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","response to simvastatin, type II diabetes mellitus, total cholesterol change measurement, response to fenofibrate",GCST004765,12:84947358
rs143838781-<b>?</b>,"4 x 10-7",(AA),NR,'-,"0.061 unit increase",'-,RBM19,"Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","response to simvastatin, type II diabetes mellitus, total cholesterol change measurement, response to fenofibrate",GCST004765,12:113940539
rs138270994-<b>?</b>,"6 x 10-7",(AA),NR,'-,"0.045 unit increase",'-,"DDX39AP1, SNORD36","Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","response to simvastatin, type II diabetes mellitus, total cholesterol change measurement, response to fenofibrate",GCST004765,13:22791997
rs2607653-<b>?</b>,"1 x 10-7",,NR,'-,"0.023 unit increase",'-,FGF14,"Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","response to simvastatin, type II diabetes mellitus, total cholesterol change measurement, response to fenofibrate",GCST004765,13:102066314
rs76043556-<b>?</b>,"7 x 10-7",(AA),NR,'-,"0.058 unit increase",'-,"GOLGA8J, SYNGR2P1","Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","response to simvastatin, type II diabetes mellitus, total cholesterol change measurement, response to fenofibrate",GCST004765,15:30060226
rs117168171-<b>?</b>,"2 x 10-7",(AA),NR,'-,"0.066 unit increase",'-,"OR4F28P, OR4F13P","Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","response to simvastatin, type II diabetes mellitus, total cholesterol change measurement, response to fenofibrate",GCST004765,15:101854599
rs250567-<b>?</b>,"1 x 10-7",(AA),NR,'-,"0.072 unit increase",'-,"SCNN1B, COG7","Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","response to simvastatin, type II diabetes mellitus, total cholesterol change measurement, response to fenofibrate",GCST004765,16:23383078
rs80147136-<b>?</b>,"2 x 10-8",(AA),NR,'-,"0.071 unit increase",'-,"NETO2, DNAJA2-DT","Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","response to simvastatin, type II diabetes mellitus, total cholesterol change measurement, response to fenofibrate",GCST004765,16:47050042
rs73354145-<b>?</b>,"3 x 10-7",,NR,'-,"0.018 unit increase",'-,MRPL12,"Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","response to simvastatin, type II diabetes mellitus, total cholesterol change measurement, response to fenofibrate",GCST004765,17:81706393
rs57504626-<b>?</b>,"6 x 10-7",(EA),NR,'-,"0.014 unit decrease",'-,PBX4,"Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","response to simvastatin, type II diabetes mellitus, total cholesterol change measurement, response to fenofibrate",GCST004765,19:19609590
rs2823310-<b>?</b>,"3 x 10-7",(AA),NR,'-,"0.043 unit increase",'-,CYCSP42,"Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","response to simvastatin, type II diabetes mellitus, total cholesterol change measurement, response to fenofibrate",GCST004765,21:15497529
rs62210650-<b>?</b>,"7 x 10-7",(AA),NR,'-,"0.064 unit increase",'-,"NIPA2P3, SREK1IP1P1","Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","response to simvastatin, type II diabetes mellitus, total cholesterol change measurement, response to fenofibrate",GCST004765,21:19649854
rs58847779-<b>?</b>,"7 x 10-7",(AA),NR,'-,"0.039 unit increase",'-,TRIOBP,"Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","response to simvastatin, type II diabetes mellitus, total cholesterol change measurement, response to fenofibrate",GCST004765,22:37736644
rs6693796-<b>?</b>,"6 x 10-8",,NR,'-,"0.019 unit increase",'-,PRRX1,"Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes","response to simvastatin, type II diabetes mellitus, total cholesterol change measurement, response to fenofibrate",GCST004765,1:170674137
rs79128089-<b>?</b>,"3 x 10-8",(AA),NR,'-,"0.108 unit increase",'-,BCL9,"Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes","triglyceride change measurement, response to simvastatin, type II diabetes mellitus, response to fenofibrate",GCST004766,1:147605222
rs2185774-<b>?</b>,"3 x 10-7",(AA),NR,'-,"0.159 unit increase",'-,"PRSS38, WNT9A","Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes","triglyceride change measurement, response to simvastatin, type II diabetes mellitus, response to fenofibrate",GCST004766,1:227908878
rs73934724-<b>?</b>,"4 x 10-7",(AA),NR,'-,"0.174 unit increase",'-,ASB3,"Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes","triglyceride change measurement, response to simvastatin, type II diabetes mellitus, response to fenofibrate",GCST004766,2:53557787
rs200803778-<b>?</b>,"7 x 10-7",(AA),NR,'-,"0.152 unit increase",'-,LINC02010,"Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes","triglyceride change measurement, response to simvastatin, type II diabetes mellitus, response to fenofibrate",GCST004766,3:146921799
rs138945390-<b>?</b>,"2 x 10-7",(AA),NR,'-,"0.167 unit increase",'-,ENPP7P10,"Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes","triglyceride change measurement, response to simvastatin, type II diabetes mellitus, response to fenofibrate",GCST004766,4:9112775
rs137945355-<b>?</b>,"3 x 10-7",(AA),NR,'-,"0.127 unit increase",'-,CCDC149,"Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes","triglyceride change measurement, response to simvastatin, type II diabetes mellitus, response to fenofibrate",GCST004766,4:24942593
rs7657890-<b>?</b>,"5 x 10-7",,NR,'-,"0.019 unit decrease",'-,'-,"Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes","triglyceride change measurement, response to simvastatin, type II diabetes mellitus, response to fenofibrate",GCST004766,4:156252512
rs116116673-<b>?</b>,"3 x 10-7",(AA),NR,'-,"0.147 unit increase",'-,'-,"Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes","triglyceride change measurement, response to simvastatin, type II diabetes mellitus, response to fenofibrate",GCST004766,5:143951835
rs148347825-<b>?</b>,"2 x 10-8",(AA),NR,'-,"0.166 unit increase",'-,LRFN2,"Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes","triglyceride change measurement, response to simvastatin, type II diabetes mellitus, response to fenofibrate",GCST004766,6:40416077
rs114176593-<b>?</b>,"5 x 10-8",(AA),NR,'-,"0.153 unit increase",'-,LINC01010,"Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes","triglyceride change measurement, response to simvastatin, type II diabetes mellitus, response to fenofibrate",GCST004766,6:134370090
rs1017568-<b>?</b>,"3 x 10-7",(AA),NR,'-,"0.265 unit increase",'-,GLIS3,"Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes","triglyceride change measurement, response to simvastatin, type II diabetes mellitus, response to fenofibrate",GCST004766,9:3948365
rs7357773-<b>?</b>,"4 x 10-7",(AA),NR,'-,"0.114 unit increase",'-,LINGO2,"Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes","triglyceride change measurement, response to simvastatin, type II diabetes mellitus, response to fenofibrate",GCST004766,9:28227169
rs77972797-<b>?</b>,"8 x 10-7",(AA),NR,'-,"0.111 unit increase",'-,RHOBTB1,"Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes","triglyceride change measurement, response to simvastatin, type II diabetes mellitus, response to fenofibrate",GCST004766,10:60978985
rs75229567-<b>?</b>,"9 x 10-7",,NR,'-,"0.041 unit increase",'-,BEST3,"Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes","triglyceride change measurement, response to simvastatin, type II diabetes mellitus, response to fenofibrate",GCST004766,12:69694564
rs201486960-<b>?</b>,"2 x 10-7",(AA),NR,'-,"0.124 unit increase",'-,'-,"Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes","triglyceride change measurement, response to simvastatin, type II diabetes mellitus, response to fenofibrate",GCST004766,12:84532353
rs116517707-<b>?</b>,"1 x 10-7",(AA),NR,'-,"0.147 unit increase",'-,"MIR4472-2, LINC02457","Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes","triglyceride change measurement, response to simvastatin, type II diabetes mellitus, response to fenofibrate",GCST004766,12:116481563
rs11619726-<b>?</b>,"6 x 10-8",(AA),NR,'-,"0.173 unit increase",'-,SERTM1,"Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes","triglyceride change measurement, response to simvastatin, type II diabetes mellitus, response to fenofibrate",GCST004766,13:36601856
rs61960346-<b>?</b>,"5 x 10-8",(AA),NR,'-,"0.162 unit increase",'-,MTND4P1,"Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes","triglyceride change measurement, response to simvastatin, type II diabetes mellitus, response to fenofibrate",GCST004766,13:84421272
rs11636249-<b>?</b>,"5 x 10-7",(AA),NR,'-,"0.153 unit increase",'-,LINC02694,"Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes","triglyceride change measurement, response to simvastatin, type II diabetes mellitus, response to fenofibrate",GCST004766,15:38887084
rs73607972-<b>?</b>,"2 x 10-7",(EA),NR,'-,"0.026 unit decrease",'-,RPGRIP1L,"Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes","triglyceride change measurement, response to simvastatin, type II diabetes mellitus, response to fenofibrate",GCST004766,16:53634741
rs76069656-<b>?</b>,"5 x 10-7",(AA),NR,'-,"0.103 unit increase",'-,"SLC7A5, KLHDC4","Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes","triglyceride change measurement, response to simvastatin, type II diabetes mellitus, response to fenofibrate",GCST004766,16:87822832
rs41308713-<b>?</b>,"2 x 10-7",(AA),NR,'-,"0.114 unit increase",'-,SNHG17,"Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes","triglyceride change measurement, response to simvastatin, type II diabetes mellitus, response to fenofibrate",GCST004766,20:38421365
rs2823310-<b>?</b>,"7 x 10-8",(AA),NR,'-,"0.109 unit increase",'-,CYCSP42,"Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes","triglyceride change measurement, response to simvastatin, type II diabetes mellitus, response to fenofibrate",GCST004766,21:15497529
rs111886096-<b>?</b>,"3 x 10-7",,NR,'-,"0.022 unit decrease",'-,"RPGRIP1L, AKTIP","Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes","triglyceride change measurement, response to simvastatin, type II diabetes mellitus, response to fenofibrate",GCST004766,16:53564398
rs62056376-<b>?</b>,"5 x 10-7",(AA),NR,'-,"0.244 unit increase",'-,"CCL8, CCL13","Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes","triglyceride change measurement, response to simvastatin, type II diabetes mellitus, response to fenofibrate",GCST004766,17:34342002
rs115025532-<b>?</b>,"8 x 10-7",(AA),NR,'-,"0.103 unit increase",'-,TTLL8,"Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes","triglyceride change measurement, response to simvastatin, type II diabetes mellitus, response to fenofibrate",GCST004766,22:50032791
rs477692-<b>?</b>,"1 x 10-8",,NR,'-,'-,'-,MGMT,"Response to temozolomide","response to temozolomide",GCST001730,10:129627758
rs11666341-<b>A</b>,"1 x 10-9",,0.45,'-,'-,'-,"ZNF616, ZNF841","Bronchodilator response in asthma (inhaled corticosteroid treatment interaction)","response to bronchodilator, response to corticosteroid, asthma",GCST002291,19:52098146
rs12460587-<b>G</b>,"2 x 10-9",,0.33,'-,'-,'-,"ZNF432, ZNF841","Bronchodilator response in asthma (inhaled corticosteroid treatment interaction)","response to bronchodilator, response to corticosteroid, asthma",GCST002291,19:52083666
rs2288884-<b>T</b>,"5 x 10-8",,0.34,'-,'-,'-,ZNF614,"Bronchodilator response in asthma (inhaled corticosteroid treatment interaction)","response to bronchodilator, response to corticosteroid, asthma",GCST002291,19:52029018
rs6469488-<b>G</b>,"7 x 10-6",,0.07,'-,'-,'-,Y_RNA,"Bronchodilator response in asthma (inhaled corticosteroid treatment interaction)","response to bronchodilator, response to corticosteroid, asthma",GCST002291,8:113873203
rs10411428-<b>T</b>,"1 x 10-9",,0.41,'-,'-,'-,"ZNF616, ZNF841","Bronchodilator response in asthma (inhaled corticosteroid treatment interaction)","response to bronchodilator, response to corticosteroid, asthma",GCST002291,19:52104512
rs6778436-<b>A</b>,"5 x 10-6",,0.007,'-,'-,'-,ST6GAL1,"Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)","response to methylphenidate",GCST000903,3:186966576
rs17228156-<b>C</b>,"8 x 10-6",,0.094,'-,'-,'-,"RASGRF2, CKMT2-AS1","Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)","response to methylphenidate",GCST000903,5:81207084
rs12099085-<b>A</b>,"5 x 10-6",,0.007,'-,'-,'-,MARK2,"Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)","response to methylphenidate",GCST000903,11:63899472
rs544434-<b>C</b>,"6 x 10-6",,0.014,'-,'-,'-,FGF14,"Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)","response to methylphenidate",GCST000903,13:102196915
rs6493206-<b>T</b>,"4 x 10-6",,0.011,'-,'-,'-,MTND5P40,"Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)","response to methylphenidate",GCST000903,15:46277268
rs1432364-<b>T</b>,"4 x 10-6",,0.422,'-,'-,'-,LSAMP,"Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)","response to methylphenidate",GCST000903,3:116726477
rs2241437-<b>C</b>,"3 x 10-6",,0.016,'-,'-,'-,PTCD3,"Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)","response to methylphenidate",GCST000903,2:86133450
rs2516513-<b>T</b>,"3 x 10-8",,0.41,'-,'-,'-,"MICB-DT, HCP5","Recurrence of Clostridium difficile infection x bezlotuxumab treatment interaction (2df test)","clostridium difficile infection, response to bezlotoxumab",GCST010380,6:31479811
rs795484-<b>A</b>,"3 x 10-7",(EA),0.34,'-,"16.1 unit increase",[10.0-21.1],TAOK3,"Morphine dose requirement in tonsillectomy and adenoidectomy surgery","response to morphine",GCST002472,12:118152057
rs12777823-<b>?</b>,"2 x 10-13",(Amish),0.17,'-,'-,'-,"CTBP2P2, HELLS","Response to clopidogrel therapy","response to platelet aggregation inhibitor",GCST000467,10:94645745
rs1127354-<b>A</b>,"4 x 10-44",,NR,'-,'-,'-,ITPA,"Ribavirin-induced anemia","anemia (phenotype), response to ribavirin",GCST000729,20:3213196
c14.20107162.b37p0-<b>?</b>,"6 x 10-6",,NR,'-,"0.73 unit increase",'-,'-,"Triptolide cytotoxicity","response to triptolide, cytotoxicity measurement",GCST003008,"Mapping not available"
rs111315781-<b>?</b>,"6 x 10-7",,NR,'-,"0.61 unit decrease",'-,PPIL3,"Triptolide cytotoxicity","response to triptolide, cytotoxicity measurement",GCST003008,2:200874001
rs12723025-<b>?</b>,"9 x 10-6",,NR,'-,"0.56 unit increase",'-,TP53BP2,"Triptolide cytotoxicity","response to triptolide, cytotoxicity measurement",GCST003008,1:223789817
rs13059218-<b>?</b>,"5 x 10-7",,NR,'-,"0.62 unit increase",'-,'-,"Triptolide cytotoxicity","response to triptolide, cytotoxicity measurement",GCST003008,3:26869004
rs2016325-<b>?</b>,"8 x 10-6",,NR,'-,"0.56 unit increase",'-,"GTF2IP23, GTF2IRD1P1","Triptolide cytotoxicity","response to triptolide, cytotoxicity measurement",GCST003008,7:66858513
rs28447044-<b>?</b>,"5 x 10-6",,NR,'-,"0.57 unit increase",'-,'-,"Triptolide cytotoxicity","response to triptolide, cytotoxicity measurement",GCST003008,4:64037888
rs2950160-<b>?</b>,"6 x 10-6",,NR,'-,"0.57 unit decrease",'-,CSMD1,"Triptolide cytotoxicity","response to triptolide, cytotoxicity measurement",GCST003008,8:4562666
rs3125719-<b>?</b>,"7 x 10-6",,NR,'-,"0.56 unit decrease",'-,MTUS2,"Triptolide cytotoxicity","response to triptolide, cytotoxicity measurement",GCST003008,13:29416829
rs34044649-<b>?</b>,"6 x 10-6",,NR,'-,"0.57 unit decrease",'-,SHH,"Triptolide cytotoxicity","response to triptolide, cytotoxicity measurement",GCST003008,7:155862999
rs61457372-<b>?</b>,"9 x 10-6",,NR,'-,"0.56 unit increase",'-,LINC00511,"Triptolide cytotoxicity","response to triptolide, cytotoxicity measurement",GCST003008,17:72363633
rs6759004-<b>?</b>,"3 x 10-7",,NR,'-,"0.63 unit decrease",'-,"IMPDH1P10, CFLAR","Triptolide cytotoxicity","response to triptolide, cytotoxicity measurement",GCST003008,2:201139953
rs73439953-<b>?</b>,"8 x 10-7",,NR,'-,"0.61 unit decrease",'-,ZNF532,"Triptolide cytotoxicity","response to triptolide, cytotoxicity measurement",GCST003008,18:58935470
rs75518195-<b>?</b>,"3 x 10-6",,NR,'-,"0.58 unit increase",'-,TECRL,"Triptolide cytotoxicity","response to triptolide, cytotoxicity measurement",GCST003008,4:64201686
rs915650-<b>?</b>,"3 x 10-6",,NR,'-,"0.59 unit decrease",'-,ADGRA2,"Triptolide cytotoxicity","response to triptolide, cytotoxicity measurement",GCST003008,8:37800008
rs2133450-<b>?</b>,"4 x 10-8",,NR,'-,'-,'-,GRM7,"Early response to risperidone in schizophrenia","response to risperidone",GCST003432,3:7294765
rs1433265-<b>?</b>,"3 x 10-8",,0.29,2.77,'-,[1.9-4.0],'-,"Heparin-induced thrombocytopenia","response to heparin, Thrombocytopenia",GCST006144,"Mapping not available"
rs905227-<b>?</b>,"9 x 10-6",,0.56,2,'-,[1.43-2.50],ZNF84,"Heparin-induced thrombocytopenia","response to heparin, Thrombocytopenia",GCST006144,12:133052317
rs16902947-<b>A</b>,"1 x 10-7",,0.01,'-,"19.48 unit increase",[12.54-26.42],RANBP3L,"Serum tamsulosin hydrochloride concentration","response to tamsulosin",GCST001744,5:36308995
rs7779057-<b>C</b>,"2 x 10-7",,0.02,'-,"17.16 unit increase",[10.93-23.39],"PIK3CG, PRKAR2B","Serum tamsulosin hydrochloride concentration","response to tamsulosin",GCST001744,7:106954440
rs35681285-<b>T</b>,"4 x 10-7",,0.02,'-,"16.75 unit increase",[10.50-23.00],CRPPA,"Serum tamsulosin hydrochloride concentration","response to tamsulosin",GCST001744,7:16287021
rs2122469-<b>C</b>,"7 x 10-7",,0.02,'-,"18.57 unit increase",[11.49-25.65],'-,"Serum tamsulosin hydrochloride concentration","response to tamsulosin",GCST001744,8:20768810
rs2069661-<b>A</b>,"2 x 10-7",,0.01725,'-,"13.85 unit increase",[8.65-19.04],"F2RL2, IQGAP2","Phenylephrine infusion rate during anesthesia","response to phenylephrine",GCST008755,5:76620790
rs77080086-<b>T</b>,"4 x 10-7",,0.02468,'-,"11.07 unit increase",[6.81-15.33],PDE4B,"Phenylephrine infusion rate during anesthesia","response to phenylephrine",GCST008755,1:66261567
rs11572377-<b>C</b>,"6 x 10-7",,0.01689,'-,"13 unit increase",[7.89-18.11],"RNA5SP45, EDN2","Phenylephrine infusion rate during anesthesia","response to phenylephrine",GCST008755,1:41478124
rs145738725-<b>A</b>,"2 x 10-6",,0.01304,'-,"14.46 unit increase",[8.49-20.42],"LINC02250, ATP10A","Phenylephrine infusion rate during anesthesia","response to phenylephrine",GCST008755,15:25581314
rs77948500-<b>C</b>,"2 x 10-6",,0.01074,'-,"15.85 unit decrease",[22.39-9.31],'-,"Phenylephrine infusion rate during anesthesia","response to phenylephrine",GCST008755,12:59905207
rs148501690-<b>A</b>,"2 x 10-6",,0.01437,'-,"13.88 unit decrease",[19.61-8.15],NDUFA5P9,"Phenylephrine infusion rate during anesthesia","response to phenylephrine",GCST008755,6:86302642
rs4234482-<b>C</b>,"2 x 10-6",,0.2661,'-,"3.64 unit decrease",[5.15-2.14],CLSTN2,"Phenylephrine infusion rate during anesthesia","response to phenylephrine",GCST008755,3:140125403
rs74400620-<b>A</b>,"3 x 10-6",,0.01364,'-,"13.98 unit increase",[8.13-19.8],FAM3C,"Phenylephrine infusion rate during anesthesia","response to phenylephrine",GCST008755,7:121362648
rs2071336-<b>A</b>,"5 x 10-6",,0.03253,'-,"8.82 unit increase",[5.04-12.59],"TNFRSF17, NPIPB2","Phenylephrine infusion rate during anesthesia","response to phenylephrine",GCST008755,16:11967817
rs76054107-<b>T</b>,"6 x 10-6",,0.02113,'-,"10.76 unit increase",[6.09-15.42],CCNB3P1,"Phenylephrine infusion rate during anesthesia","response to phenylephrine",GCST008755,5:26671242
rs16835559-<b>A</b>,"9 x 10-6",,0.01467,'-,"12.47 unit increase",[6.96-17.98],NEK11,"Phenylephrine infusion rate during anesthesia","response to phenylephrine",GCST008755,3:131030758
rs114070671-<b>?</b>,"1 x 10-7",(AA),0.08,'-,'-,'-,APBB2,"Opioid sensitivity","response to opiate",GCST002235,4:41054699
rs60349741-<b>?</b>,"5 x 10-7",(AA),0.06,'-,'-,'-,KCNC1,"Opioid sensitivity","response to opiate",GCST002235,11:17774564
rs62103177-<b>?</b>,"4 x 10-10",(AA),0.06,'-,'-,'-,KCNG2,"Opioid sensitivity","response to opiate",GCST002235,18:79864479
rs6852435-<b>?</b>,"6 x 10-6",,0.27,'-,'-,'-,"CEP44, MIR4276","Response to acetaminophen (hepatotoxicity)","response to acetaminophen",GCST000924,4:174379628
rs2880961-<b>?</b>,"2 x 10-7",,0.34,'-,'-,'-,CSNKA2IP,"Response to acetaminophen (hepatotoxicity)","response to acetaminophen",GCST000924,3:88475025
rs5936441-<b>?</b>,"5 x 10-6",,0.36,'-,'-,'-,HAX1P1,"Response to acetaminophen (hepatotoxicity)","response to acetaminophen",GCST000924,X:148242736
rs3795578-<b>?</b>,"7 x 10-6",,0.40,'-,'-,'-,ETNK2,"Response to acetaminophen (hepatotoxicity)","response to acetaminophen",GCST000924,1:204143856
rs1532815-<b>?</b>,"6 x 10-7",,0.34,'-,'-,'-,"LMX1A, LMX1A-AS2","Response to acetaminophen (hepatotoxicity)","response to acetaminophen",GCST000924,1:165210852
rs6685273-<b>T</b>,"4 x 10-7",,0.068,'-,'-,'-,VPS13D,"Cytokine-stimulated IL-6 production","interleukin-6 measurement, response to cytokine",GCST002859,1:12313691
rs4862562-<b>C</b>,"3 x 10-8",,0.076,'-,'-,'-,SORBS2,"Cytokine-stimulated IL-6 production","interleukin-6 measurement, response to cytokine",GCST002859,4:185681056
rs137931178-<b>?</b>,"7 x 10-6",,NR,79,'-,[11.72-533.7],"TSBP1-AS1, TSBP1","Drug-induced liver injury","response to flupirtine, drug-induced liver injury",GCST003426,6:32361373
rs2523864-<b>T</b>,"5 x 10-9",,0.412,'-,'-,'-,"MUC22, HCG22","Change in intraocular pressure in response to steroid treatment (triamcinolone acetonide)","response to triamcinolone acetonide, intraocular pressure change measurement",GCST002837,6:31050769
rs1967309-<b>G</b>,"2 x 10-8",,0.55,1.54,'-,[1.32-1.79],ADCY9,"Response to Dalcetrapib treatment in acute coronary syndrome","response to dalcetrapib, acute coronary syndrome, cardiovascular event measurement",GCST002747,16:4015582
rs199670311-<b>A</b>,"3 x 10-8","(dominant model)",NR,'-,"0.1329 unit increase",'-,PGAP6,"Opioid requirements during laparoscopic-assisted colectomy","response to opioid, analgesia requirement measurement",GCST005364,16:377758
rs4839603-<b>C</b>,"4 x 10-6","(additive model)",NR,'-,"0.03503 unit decrease",'-,SLC9A9,"Opioid requirements during laparoscopic-assisted colectomy","response to opioid, analgesia requirement measurement",GCST005364,3:143592418
rs17054392-<b>C</b>,"3 x 10-6",,NR,'-,'-,'-,PALLD,"Response to iloperidone treatment (QT prolongation)","response to iloperidone",GCST000201,4:168609107
rs3924426-<b>T</b>,"2 x 10-6",,NR,'-,'-,'-,SLCO3A1,"Response to iloperidone treatment (QT prolongation)","response to iloperidone",GCST000201,15:91902643
rs7142881-<b>A</b>,"2 x 10-6",,NR,'-,'-,'-,NUBPL,"Response to iloperidone treatment (QT prolongation)","response to iloperidone",GCST000201,14:31624342
rs993648-<b>T</b>,"3 x 10-6",,NR,'-,'-,'-,CERKL,"Response to iloperidone treatment (QT prolongation)","response to iloperidone",GCST000201,2:181591267
rs4799915-<b>T</b>,"3 x 10-6",,NR,'-,'-,'-,CELF4,"Response to iloperidone treatment (QT prolongation)","response to iloperidone",GCST000201,18:37348676
rs4933824-<b>T</b>,"2 x 10-6",,NR,'-,'-,'-,NRG3,"Response to iloperidone treatment (QT prolongation)","response to iloperidone",GCST000201,10:82059369
rs1641025-<b>T</b>,"2 x 10-8",,0.27,'-,"0.36 unit increase",[NR],ABAT,"Response to opioid analgesics in cancer (pain decrease)","cancer, response to opioid",GCST007106,16:8777531
rs12494691-<b>A</b>,"4 x 10-8",,0.2,'-,"0.01 unit increase",[NR],DAZL,"Response to opioid analgesics in cancer (pain decrease)","cancer, response to opioid",GCST007106,3:16658827
rs2244613-<b>?</b>,"5 x 10-7","(Trough concentrations)",0.82,1.16,'-,[1.10-1.22],CES1,"Response to dabigatran etexilate treatment","response to dabigatran etexilate",GCST001895,16:55810697
rs8192935-<b>?</b>,"1 x 10-6","(Peak concentrations)",0.67,1.12,'-,[1.08-1.18],CES1,"Response to dabigatran etexilate treatment","response to dabigatran etexilate",GCST001895,16:55827882
rs9831928-<b>?</b>,"3 x 10-6",,NR,4.7619047,'-,[2.17-11.11],SGO1-AS1,"Atorvastatin-induced myopathy","response to atorvastatin, myopathy",GCST008554,3:21224048
rs4256319-<b>?</b>,"3 x 10-6",,NR,50,'-,[8.33-∞],ADCY2,"Atorvastatin-induced myopathy","response to atorvastatin, myopathy",GCST008554,5:7538189
rs6925743-<b>?</b>,"9 x 10-7",,NR,5.263158,'-,[2.17-12.5],PPP1R14C,"Atorvastatin-induced myopathy","response to atorvastatin, myopathy",GCST008554,6:150170920
rs11780883-<b>?</b>,"1 x 10-6",,NR,4.5454545,'-,[2.27-9.09],'-,"Atorvastatin-induced myopathy","response to atorvastatin, myopathy",GCST008554,8:83834281
rs10871700-<b>?</b>,"1 x 10-6",,NR,3.333333,'-,[2-5.88],'-,"Atorvastatin-induced myopathy","response to atorvastatin, myopathy",GCST008554,18:72302261
rs28420503-<b>?</b>,"4 x 10-6",,NR,4.79,'-,[2.17-10.56],"PCGF7P, ZNF92P2","Atorvastatin-induced myopathy","response to atorvastatin, myopathy",GCST008554,19:22133911
rs34312380-<b>?</b>,"3 x 10-6",,NR,4.7619047,'-,[2.17-11.11],ZNF676,"Atorvastatin-induced myopathy","response to atorvastatin, myopathy",GCST008554,19:22207269
rs33428-<b>?</b>,"1 x 10-6",,NR,3.846154,'-,[2.22-6.67],ZNF536,"Atorvastatin-induced myopathy","response to atorvastatin, myopathy",GCST008554,19:30446936
rs150707400-<b>?</b>,"5 x 10-6",,NR,64.6,'-,[8.20-508.8],GARRE1,"Atorvastatin-induced myopathy","response to atorvastatin, myopathy",GCST008554,19:34352219
rs652888-<b>?</b>,"2 x 10-11",,NR,4.73,'-,[3.00-7.44],"EHMT2-AS1, EHMT2","Anti-thyroid drug induced agranulocytosis","response to anti-thyroid drug, Drug-induced agranulocytosis",GCST003527,6:31883457
rs199564443-<b>?</b>,"7 x 10-11","(adjusted for rs652888)",NR,17.42,'-,[7.38-41.12],"FOXF2, FOXF2-DT","Anti-thyroid drug induced agranulocytosis","response to anti-thyroid drug, Drug-induced agranulocytosis",GCST003527,6:1388744
rs1071816-<b>?</b>,"2 x 10-9","(adjusted for rs652888, rs199564443)",NR,5.27,'-,[3.06-9.10],HLA-B,"Anti-thyroid drug induced agranulocytosis","response to anti-thyroid drug, Drug-induced agranulocytosis",GCST003527,6:31356759
rs111618861-<b>?</b>,"3 x 10-8","(adjusted for rs652888, rs199564443, rs1071816)",NR,13.75,'-,[5.46-34.64],"PLAG1, MOS","Anti-thyroid drug induced agranulocytosis","response to anti-thyroid drug, Drug-induced agranulocytosis",GCST003527,8:56131824
HLA-B*27:05-<b>?</b>,"7 x 10-8",,NR,5.44,'-,[2.94-10.06],'-,"Anti-thyroid drug induced agranulocytosis","response to anti-thyroid drug, Drug-induced agranulocytosis",GCST003527,"Mapping not available"
HLA-B*08:01-<b>?</b>,"2 x 10-6","(adjusted for HLA-B*27:058)",NR,3.88,'-,[2.21-6.81],'-,"Anti-thyroid drug induced agranulocytosis","response to anti-thyroid drug, Drug-induced agranulocytosis",GCST003527,"Mapping not available"
rs7912580-<b>A</b>,"1 x 10-6","(Total PANSS scores)",0.057,'-,'-,'-,"RTKN2, ARID5B","Response to haloperidol in psychosis","psychosis, response to haloperidol",GCST002465,10:62156213
rs2412459-<b>C</b>,"9 x 10-6","(Total PANSS scores)",0.218,'-,'-,'-,EIF2AK4,"Response to haloperidol in psychosis","psychosis, response to haloperidol",GCST002465,15:40003758
rs12509991-<b>?</b>,"3 x 10-7",,'-,'-,'-,'-,"H3P15, LINC02379","Response to Homoharringtonine (cytotoxicity)","response to homoharringtonine, cytotoxicity measurement",GCST002749,4:126075715
rs9355211-<b>?</b>,"7 x 10-7",,'-,'-,'-,'-,"SMOC2, DACT2","Response to Homoharringtonine (cytotoxicity)","response to homoharringtonine, cytotoxicity measurement",GCST002749,6:168415772
rs279875-<b>?</b>,"7 x 10-7",,'-,'-,'-,'-,"RNU6-1073P, DMRT3","Response to Homoharringtonine (cytotoxicity)","response to homoharringtonine, cytotoxicity measurement",GCST002749,9:998869
rs1263806-<b>?</b>,"9 x 10-7",,'-,'-,'-,'-,"SALL2, METTL3","Response to Homoharringtonine (cytotoxicity)","response to homoharringtonine, cytotoxicity measurement",GCST002749,14:21514802
rs7461360-<b>?</b>,"2 x 10-6",,'-,'-,'-,'-,"CPA6, NDUFS5P6","Response to Homoharringtonine (cytotoxicity)","response to homoharringtonine, cytotoxicity measurement",GCST002749,8:67765915
rs7106204-<b>?</b>,"3 x 10-6",,'-,'-,'-,'-,LINC02686,"Response to Homoharringtonine (cytotoxicity)","response to homoharringtonine, cytotoxicity measurement",GCST002749,11:24214550
rs67383251-<b>?</b>,"6 x 10-6",,'-,'-,'-,'-,LINC02247,"Response to Homoharringtonine (cytotoxicity)","response to homoharringtonine, cytotoxicity measurement",GCST002749,9:134279920
rs4769475-<b>?</b>,"6 x 10-6",,'-,'-,'-,'-,RNF6,"Response to Homoharringtonine (cytotoxicity)","response to homoharringtonine, cytotoxicity measurement",GCST002749,13:26157576
c9.93990003.b37p0-<b>?</b>,"7 x 10-6",,'-,'-,'-,'-,'-,"Response to Homoharringtonine (cytotoxicity)","response to homoharringtonine, cytotoxicity measurement",GCST002749,"Mapping not available"
rs12514883-<b>?</b>,"7 x 10-6",,'-,'-,'-,'-,LINC02223,"Response to Homoharringtonine (cytotoxicity)","response to homoharringtonine, cytotoxicity measurement",GCST002749,5:17790982
rs7701292-<b>?</b>,"2 x 10-8",,'-,1.79,'-,[1.59-1.99],'-,"Survival in endocrine treated breast cancer (estrogen-receptor positive)","event free survival time, estrogen-receptor positive breast cancer, response to endocrine therapy",GCST005900,5:105742977
rs7395555-<b>C</b>,"2 x 10-7","(Effect of Ziprasidone on CGI-S)",0.145,'-,'-,'-,'-,"Response to antipsychotic treatment","response to ziprasidone",GCST001773,11:80347435
rs1405687-<b>?</b>,"5 x 10-8","(ziprasidone-hip circumference)",0.088,'-,'-,'-,PPP3CA,"Response to antipsychotic treatment","response to ziprasidone",GCST000618,4:101010669
rs17390445-<b>?</b>,"1 x 10-7",(ziprasidone),NR,'-,17,[NR],'-,"Response to antipsychotic treatment","response to ziprasidone",GCST000473,4:34892233
rs1512651-<b>?</b>,"6 x 10-6",,NR,'-,'-,'-,SPATA2P1,"Warfarin maintenance dose","response to anticoagulant",GCST000792,13:56198562
rs2108622-<b>T</b>,"3 x 10-8",,NR,'-,'-,'-,CYP4F2,"Warfarin maintenance dose","response to anticoagulant",GCST000792,19:15879621
rs10270308-<b>?</b>,"6 x 10-6",,NR,'-,'-,'-,CDHR3,"Warfarin maintenance dose","response to anticoagulant",GCST000792,7:106030821
rs9923231-<b>?</b>,"9 x 10-31",,NR,'-,'-,'-,"BCKDK, VKORC1","Warfarin maintenance dose","response to anticoagulant",GCST000792,16:31096368
rs10509680-<b>?</b>,"4 x 10-7",,NR,'-,'-,'-,CYP2C9,"Warfarin maintenance dose","response to anticoagulant",GCST000792,10:94974582
rs12772169-<b>?</b>,"8 x 10-12",,NR,'-,'-,'-,"CTBP2P2, HELLS","Acenocoumarol maintenance dosage","response to anticoagulant",GCST000436,10:94645572
rs12767583-<b>?</b>,"3 x 10-7",,NR,'-,'-,'-,CYP2C19,"Acenocoumarol maintenance dosage","response to anticoagulant",GCST000436,10:94787706
rs2108622-<b>?</b>,"3 x 10-10",,NR,'-,'-,'-,CYP4F2,"Acenocoumarol maintenance dosage","response to anticoagulant",GCST000436,19:15879621
rs10935268-<b>?</b>,"8 x 10-7",,NR,'-,'-,'-,"NPM1P17, SOX14","Acenocoumarol maintenance dosage","response to anticoagulant",GCST000436,3:137728643
rs78132896-<b>C</b>,"2 x 10-11",,NR,8.27,'-,[4.18-16.38],EPHA7,"Warfarin-associated bleeding","response to anticoagulant",GCST007137,6:93420339
"rs10066908-<b>A</b>, rs4702795-<b>G</b>, rs13156459-<b>C</b>, rs9313082-<b>C</b>, rs13187757-<b>C</b>, rs10069475-<b>A</b>, rs13186039-<b>T</b>, rs12516470-<b>C</b>, rs1433265-<b>C</b>","5 x 10-6",,0.196,2.41,'-,[1.64-3.55],"No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes","Heparin-induced thrombocytopenia","response to heparin, Thrombocytopenia",GCST006144,5:4478434
rs2789047-<b>A</b>,"1 x 10-7",,0.28,'-,"0.053 unit decrease",[0.033-0.073],COX6A1P3,"Peak creatinine levels in vancomycin therapy","creatinine measurement, response to vancomycin",GCST002948,6:120868656
rs7828135-<b>?</b>,"5 x 10-8","(Maximum ALT, Conditioned on HLA- DRB1*07:01)",NR,'-,'-,'-,TPD52,"Lapatinib-induced hepatotoxicity","response to lapatinib, drug-induced liver injury",GCST002918,8:80146584
HLA-<b>DRB1*07:01</b>,"8 x 10-11",(case/control),NR,'-,'-,'-,'-,"Lapatinib-induced hepatotoxicity","response to lapatinib, drug-induced liver injury",GCST002918,"Mapping not available"
HLA-<b>DRB1*07:01</b>,"2 x 10-18","(Maximum ALT)",NR,'-,'-,'-,'-,"Lapatinib-induced hepatotoxicity","response to lapatinib, drug-induced liver injury",GCST002918,"Mapping not available"
rs2952768-<b>C</b>,"8 x 10-7",,NR,'-,"0.2932 unit increase",'-,"METTL21A, RPS29P9","Opioid sensitivity","response to opiate",GCST001751,2:207629510
rs2832270-<b>?</b>,"8 x 10-6",,NR,'-,"0.28 unit increase",[NR],"LINC00189, BACH1","Response to mTOR inhibitor (everolimus)","response to mTOR inhibitor",GCST002157,21:29222211
rs218869-<b>?</b>,"4 x 10-6",,NR,'-,"0.29 unit increase",[NR],"NKX2-6, STC1","Response to mTOR inhibitor (everolimus)","response to mTOR inhibitor",GCST002157,8:23778768
rs7694207-<b>?</b>,"4 x 10-6",,NR,'-,"0.28 unit increase",[NR],COX7A2P2,"Response to mTOR inhibitor (everolimus)","response to mTOR inhibitor",GCST002157,4:96959258
rs10987149-<b>?</b>,"5 x 10-6",,NR,'-,"0.28 unit increase",[NR],RALGPS1,"Response to mTOR inhibitor (everolimus)","response to mTOR inhibitor",GCST002157,9:126095572
rs12932018-<b>?</b>,"6 x 10-6",,NR,'-,"0.25 unit increase",[NR],USP10,"Response to mTOR inhibitor (everolimus)","response to mTOR inhibitor",GCST002157,16:84762997
rs2702449-<b>?</b>,"7 x 10-6",,NR,'-,"0.28 unit increase",[NR],RNA5SP173,"Response to mTOR inhibitor (everolimus)","response to mTOR inhibitor",GCST002157,4:178480279
rs16887552-<b>?</b>,"8 x 10-6",,NR,'-,"0.24 unit decrease",[NR],'-,"Response to mTOR inhibitor (everolimus)","response to mTOR inhibitor",GCST002157,4:12772370
rs1460196-<b>?</b>,"9 x 10-6",,NR,'-,"0.27 unit increase",[NR],DCC,"Response to mTOR inhibitor (everolimus)","response to mTOR inhibitor",GCST002157,18:52689042
rs2063142-<b>?</b>,"4 x 10-6",,NR,'-,"0.29 unit decrease",[NR],"RGS5, RGS4","Response to mTOR inhibitor (rapamycin)","response to mTOR inhibitor",GCST002156,1:163083499
rs1873283-<b>?</b>,"6 x 10-6",,NR,'-,"0.28 unit decrease",[NR],APBA2,"Response to mTOR inhibitor (rapamycin)","response to mTOR inhibitor",GCST002156,15:29046299
rs12636856-<b>?</b>,"7 x 10-6",,NR,'-,"0.28 unit decrease",[NR],KAT2B,"Response to mTOR inhibitor (rapamycin)","response to mTOR inhibitor",GCST002156,3:20095467
rs1334346-<b>?</b>,"8 x 10-6",,NR,'-,"0.28 unit decrease",[NR],RIMS1,"Response to mTOR inhibitor (rapamycin)","response to mTOR inhibitor",GCST002156,6:72483449
rs17664713-<b>?</b>,"5 x 10-6",,NR,'-,"0.28 unit decrease",[NR],'-,"Response to mTOR inhibitor (rapamycin)","response to mTOR inhibitor",GCST002156,15:94775357
rs10486003-<b>?</b>,"5 x 10-7",,NR,3.13,'-,[1.92-5.26],RN7SKP104,"Response to platinum-based agents","response to platinum based chemotherapy",GCST001291,7:97600466
rs2338-<b>?</b>,"5 x 10-6",,NR,2.27,'-,[1.58-3.26],'-,"Response to platinum-based agents","response to platinum based chemotherapy",GCST001291,"Mapping not available"
rs1464500-<b>?</b>,"1 x 10-7",(perphenazine-HDL),0.232,'-,'-,'-,"SOX5-AS1, SOX5","Response to antipsychotic treatment","response to perphenazine",GCST000618,12:24236726
rs153091-<b>?</b>,"2 x 10-6",(perphenazine-triglycerides),0.227,'-,'-,'-,SHISA9,"Response to antipsychotic treatment","response to perphenazine",GCST000618,16:13160099
rs11735070-<b>?</b>,"1 x 10-6",(perphenazine-triglycerides),0.338,'-,'-,'-,DAPP1,"Response to antipsychotic treatment","response to perphenazine",GCST000618,4:99792608
rs17410015-<b>?</b>,"2 x 10-6",(perphenazine-triglycerides),0.063,'-,'-,'-,DPH5,"Response to antipsychotic treatment","response to perphenazine",GCST000618,1:101086370
rs6735179-<b>?</b>,"1 x 10-7",(perphenazine-triglycerides),0.346,'-,'-,'-,"PXDN, MYT1L","Response to antipsychotic treatment","response to perphenazine",GCST000618,2:1773378
rs10202231-<b>?</b>,"7 x 10-7",(perphenazine-triglycerides),0.457,'-,'-,'-,MIR4432HG,"Response to antipsychotic treatment","response to perphenazine",GCST000618,2:60273009
rs17651157-<b>?</b>,"1 x 10-7",(perphenazine-triglycerides),0.068,'-,'-,'-,FHOD3,"Response to antipsychotic treatment","response to perphenazine",GCST000618,18:36527489
rs11163585-<b>?</b>,"9 x 10-7",(perphenazine-HDL),0.24,'-,'-,'-,LINC01362,"Response to antipsychotic treatment","response to perphenazine",GCST000618,1:82846152
rs1187614-<b>?</b>,"2 x 10-7","(perphenazine-total cholesterol)",0.313,'-,'-,'-,CLMN,"Response to antipsychotic treatment","response to perphenazine",GCST000618,14:95205534
rs6741819-<b>?</b>,"2 x 10-7",(perphenazine-triglycerides),0.305,'-,'-,'-,RNF144A,"Response to antipsychotic treatment","response to perphenazine",GCST000618,2:7007842
rs4838255-<b>?</b>,"3 x 10-7",(perphenazine-triglycerides),0.139,'-,'-,'-,ASTN2,"Response to antipsychotic treatment","response to perphenazine",GCST000618,9:117164147
rs4685959-<b>?</b>,"1 x 10-6",,'-,'-,"1.1 unit decrease",[NR],'-,"Duloxetine response in major depressive disorder (% change in symptom score)","unipolar depression, response to duloxetine",GCST004738,3:5645577
rs13147572-<b>?</b>,"8 x 10-6",,'-,'-,"0.44 unit decrease",[NR],SORBS2,"Duloxetine response in major depressive disorder (% change in symptom score)","unipolar depression, response to duloxetine",GCST004738,4:18291521
rs16957893-<b>C</b>,"2 x 10-8",,0.08,5.61,'-,3.08-10.21,"HCN4, REC114","Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe ocular complications","Stevens-Johnson syndrome, toxic epidermal necrolysis, response to cold medicine",GCST004072,15:73437142
rs9888871-<b>C</b>,"2 x 10-7",,0.092,2.24,'-,1.66-3.02,"RPL34P29, ZNF423","Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe ocular complications","Stevens-Johnson syndrome, toxic epidermal necrolysis, response to cold medicine",GCST004072,16:49916730
rs6500265-<b>T</b>,"1 x 10-7",,0.14,2.07,'-,1.58-2.71,"ZNF423, RPL34P29","Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe ocular complications","Stevens-Johnson syndrome, toxic epidermal necrolysis, response to cold medicine",GCST004072,16:49912759
rs6688363-<b>T</b>,"2 x 10-7","(Effect of Olanzapine on CGI-S)",0.166,'-,'-,'-,"ATP1A2, IGSF8","Response to antipsychotic treatment","response to olanzapine",GCST001773,1:160108064
rs10170310-<b>G</b>,"1 x 10-7","(Effect of Olanzapine on PGI)",0.213,'-,'-,'-,SPOPL,"Response to antipsychotic treatment","response to olanzapine",GCST001773,2:138521352
rs977396-<b>?</b>,"3 x 10-7","(olanzapine-total cholesterol)",0.089,'-,'-,'-,ZFPM2,"Response to antipsychotic treatment","response to olanzapine",GCST000618,8:104980468
rs1967256-<b>?</b>,"3 x 10-8","(olanzapine-hemoglobin A1c",0.148,'-,'-,'-,ADGRV1,"Response to antipsychotic treatment","response to olanzapine",GCST000618,5:91003406
rs4783227-<b>?</b>,"4 x 10-7","(olanzapine-total cholesterol)",0.424,'-,'-,'-,CDH13,"Response to antipsychotic treatment","response to olanzapine",GCST000618,16:82560778
rs1040994-<b>?</b>,"2 x 10-6",(olanzapine),NR,'-,9,[NR],"HIVEP1, EDN1","Response to antipsychotic treatment","response to olanzapine",GCST000473,6:12196980
rs10888501-<b>?</b>,"1 x 10-6",(olanzapine),NR,'-,9,[NR],"LCE3E, CRCT1","Response to antipsychotic treatment","response to olanzapine",GCST000473,1:152565478
rs7635839-<b>?</b>,"3 x 10-6",(olanzapine),NR,'-,9,[NR],'-,"Response to antipsychotic treatment","response to olanzapine",GCST000473,3:191949988
rs7968606-<b>?</b>,"3 x 10-7",(olanzapine),NR,'-,10,[NR],ANKS1B,"Response to antipsychotic treatment","response to olanzapine",GCST000473,12:99423064
rs17382202-<b>T</b>,"4 x 10-8","(Effect of Quetiapine on PGI)",0.153,'-,'-,'-,PDE4D,"Response to antipsychotic treatment","response to quetiapine",GCST001773,5:59684120
rs518590-<b>?</b>,"2 x 10-7",(quetiapine-HDL),0.21,'-,'-,'-,"FGF9, RN7SL766P","Response to antipsychotic treatment","response to quetiapine",GCST000618,13:21730960
rs4959235-<b>?</b>,"2 x 10-7",(Quetiapine),NR,'-,'-,'-,SLC22A23,"Antipsychotic drug-induced QTc interval prolongation","response to quetiapine",GCST000822,6:3359103
rs10946737-<b>A</b>,"4 x 10-6",,NR,3.4,'-,[2.2-5.3],RIPOR2,"Liver injury in anti-tuberculosis drug treatment","response to rifampicin, Tuberculosis, drug-induced liver injury",GCST003792,6:24967012
rs320035-<b>G</b>,"5 x 10-6",,NR,2.3,'-,[1.6-3.3],AGBL4,"Liver injury in anti-tuberculosis drug treatment","response to rifampicin, Tuberculosis, drug-induced liver injury",GCST003792,1:48623525
rs1800625-<b>G</b>,"8 x 10-9","(Time to ALT>3 x upper limit of normal event)",NR,1.8,'-,[1.5-2.1],"AGER, PBX2","Response to Pazopanib in cancer (hepatotoxicity)","cancer, response to pazopanib, serum alanine aminotransferase measurement",GCST003232,6:32184665
rs8050896-<b>T</b>,"4 x 10-8","(Effect of Risperidone on CGI-S)",0.161,'-,'-,'-,'-,"Response to antipsychotic treatment","response to risperidone",GCST001773,16:66124833
rs2980976-<b>A</b>,"3 x 10-7","(Effect of Risperidone on CGI-S)",0.168,'-,'-,'-,"RPL17P44, TNFRSF11A","Response to antipsychotic treatment","response to risperidone",GCST001773,18:62412879
rs2636697-<b>G</b>,"4 x 10-7","(Effect of Risperidone on CGI-S)",0.038,'-,'-,'-,PPA2,"Response to antipsychotic treatment","response to risperidone",GCST001773,4:105376356
rs711355-<b>T</b>,"2 x 10-7","(Effect of Risperidone on PGI)",0.33,'-,'-,'-,TJP1,"Response to antipsychotic treatment","response to risperidone",GCST001773,15:29901265
rs2885135-<b>?</b>,"9 x 10-6",,'-,'-,'-,'-,"BRWD1P1, PDPN","Response to cytadine analogues (cytosine arabinoside)","response to cytosine arabinoside",GCST002345,1:13580032
rs10495285-<b>?</b>,"4 x 10-7",,'-,'-,'-,'-,"URB2, HMGB1P26","Response to cytadine analogues (cytosine arabinoside)","response to cytosine arabinoside",GCST002345,1:229669248
rs2653165-<b>?</b>,"9 x 10-6",,'-,'-,'-,'-,PLD5,"Response to cytadine analogues (cytosine arabinoside)","response to cytosine arabinoside",GCST002345,1:242202980
rs10208516-<b>?</b>,"7 x 10-6",,'-,'-,'-,'-,CHMP4AP1,"Response to cytadine analogues (cytosine arabinoside)","response to cytosine arabinoside",GCST002345,2:81347634
rs2583612-<b>?</b>,"7 x 10-6",,'-,'-,'-,'-,PDE5A,"Response to cytadine analogues (cytosine arabinoside)","response to cytosine arabinoside",GCST002345,4:119691563
rs9363058-<b>?</b>,"8 x 10-6",,'-,'-,'-,'-,EPHA7,"Response to cytadine analogues (cytosine arabinoside)","response to cytosine arabinoside",GCST002345,6:93298817
rs1450679-<b>?</b>,"5 x 10-7",,'-,'-,'-,'-,TOPORSLP,"Response to cytadine analogues (cytosine arabinoside)","response to cytosine arabinoside",GCST002345,9:104264531
rs2857891-<b>?</b>,"2 x 10-6",,'-,'-,'-,'-,ZNF215,"Response to cytadine analogues (cytosine arabinoside)","response to cytosine arabinoside",GCST002345,11:6941726
rs4936323-<b>?</b>,"4 x 10-6",,'-,'-,'-,'-,CADM1,"Response to cytadine analogues (cytosine arabinoside)","response to cytosine arabinoside",GCST002345,11:115220399
rs888468-<b>?</b>,"5 x 10-6",,'-,'-,'-,'-,"FGF6, FGF23","Response to cytadine analogues (cytosine arabinoside)","response to cytosine arabinoside",GCST002345,12:4424213
rs970084-<b>?</b>,"5 x 10-6",,'-,'-,'-,'-,RAD21L1,"Response to cytadine analogues (cytosine arabinoside)","response to cytosine arabinoside",GCST002345,20:1240527
rs6011674-<b>?</b>,"2 x 10-6",,'-,'-,'-,'-,"BIRC7, YTHDF1","Response to cytadine analogues (cytosine arabinoside)","response to cytosine arabinoside",GCST002345,20:63223100
rs2139424-<b>?</b>,"7 x 10-6",,'-,'-,'-,'-,"SLC6A5, NELL1","Response to cytadine analogues (cytosine arabinoside)","response to cytosine arabinoside",GCST002345,11:20662494
rs9512755-<b>?</b>,"4 x 10-6",,'-,'-,'-,'-,LNX2,"Response to cytadine analogues (cytosine arabinoside)","response to cytosine arabinoside",GCST002345,13:27584092
rs7170930-<b>?</b>,"5 x 10-6",,'-,'-,'-,'-,DIS3L-AS1,"Response to cytadine analogues (cytosine arabinoside)","response to cytosine arabinoside",GCST002345,15:66288515
rs6128386-<b>?</b>,"1 x 10-6",,'-,'-,'-,'-,APCDD1L-DT,"Response to cytadine analogues (cytosine arabinoside)","response to cytosine arabinoside",GCST002345,20:58618493
rs11700100-<b>?</b>,"8 x 10-6",,NR,'-,'-,'-,CTCFL,"Response to cytadine analogues (cytosine arabinoside)","response to cytosine arabinoside",GCST002345,20:57504993
rs7588926-<b>?</b>,"9 x 10-6",,'-,'-,'-,'-,"ABHD1, CGREF1","Response to cytadine analogues (cytosine arabinoside)","response to cytosine arabinoside",GCST002345,2:27120026
rs11710229-<b>?</b>,"6 x 10-6",,'-,'-,'-,'-,WNT5A,"Response to cytadine analogues (cytosine arabinoside)","response to cytosine arabinoside",GCST002345,3:55463925
rs4078252-<b>?</b>,"2 x 10-7",,'-,'-,'-,'-,MCC,"Response to cytadine analogues (cytosine arabinoside)","response to cytosine arabinoside",GCST002345,5:113119770
rs2172820-<b>?</b>,"2 x 10-6",,'-,'-,'-,'-,TUSC3,"Response to cytadine analogues (cytosine arabinoside)","response to cytosine arabinoside",GCST002345,8:15468159
rs4553261-<b>?</b>,"9 x 10-6",,'-,'-,'-,'-,"FAM241B, MTND1P20","Response to cytadine analogues (cytosine arabinoside)","response to cytosine arabinoside",GCST002345,10:69616033
rs1568679-<b>?</b>,"1 x 10-8","(risperidone-hip circumference)",0.103,'-,'-,'-,MEIS2,"Response to antipsychotic treatment","response to risperidone",GCST000618,15:37057601
rs6092078-<b>?</b>,"3 x 10-6","(risperidone-hip circumference)",0.115,'-,'-,'-,'-,"Response to antipsychotic treatment","response to risperidone",GCST000618,20:55184590
rs7105881-<b>?</b>,"3 x 10-7","(risperidone-hip circumference)",0.367,'-,'-,'-,LINC02763,"Response to antipsychotic treatment","response to risperidone",GCST000618,11:112585498
rs13335336-<b>?</b>,"7 x 10-7","(risperidone-hemoglobin A1c)",0.078,'-,'-,'-,ATF7IP2,"Response to antipsychotic treatment","response to risperidone",GCST000618,16:10465406
rs8092443-<b>?</b>,"1 x 10-6","(risperidone-hemoglobin A1c)",0.225,'-,'-,'-,"RN7SL795P, RPS2P6","Response to antipsychotic treatment","response to risperidone",GCST000618,18:70475178
rs11663206-<b>?</b>,"2 x 10-6","(risperidone-hemoglobin A1c)",0.289,'-,'-,'-,"RPS2P6, RN7SL795P","Response to antipsychotic treatment","response to risperidone",GCST000618,18:70486384
rs17100498-<b>?</b>,"5 x 10-7","(risperidone-hemoglobin A1c)",0.126,'-,'-,'-,"RNU7-156P, MIR5197","Response to antipsychotic treatment","response to risperidone",GCST000618,5:143624040
rs1117324-<b>?</b>,"3 x 10-7","(risperidone-hip circumference)",0.156,'-,'-,'-,LINC01822,"Response to antipsychotic treatment","response to risperidone",GCST000618,2:21617221
rs888219-<b>?</b>,"2 x 10-7",(risperidone),NR,'-,11,[NR],'-,"Response to antipsychotic treatment","response to risperidone",GCST000473,9:126166744
rs17727261-<b>?</b>,"5 x 10-7",(risperidone),NR,'-,10,[NR],CNTNAP5,"Response to antipsychotic treatment","response to risperidone",GCST000473,2:124524333
rs17815774-<b>?</b>,"3 x 10-6",(risperidone),NR,'-,9,[NR],TRPM1,"Response to antipsychotic treatment","response to risperidone",GCST000473,15:31042159
rs12526186-<b>?</b>,"3 x 10-6",(risperidone),NR,'-,9,[NR],HCG20,"Response to antipsychotic treatment","response to risperidone",GCST000473,6:30768374
rs10458561-<b>?</b>,"4 x 10-7",(Risperidone),NR,'-,'-,'-,"CTH, CHORDC1P5","Antipsychotic drug-induced QTc interval prolongation","response to risperidone",GCST000822,1:70455490
rs6468544-<b>?</b>,"8 x 10-7",(Risperidone),NR,'-,'-,'-,"TSPYL5, SNORD3H","Antipsychotic drug-induced QTc interval prolongation","response to risperidone",GCST000822,8:97317537
rs7262634-<b>?</b>,"1 x 10-6",,NR,25,'-,[NR],"ZMYND8, EYA2","Response to protease inhibitor treatment in hepatitis c (bilirubin toxicity)","hepatitis C virus infection, response to protease inhibitor, bilirubin measurement",GCST002347,20:47205635
kgp6774393-<b>?</b>,"6 x 10-6",,NR,4.35,'-,[NR],'-,"Response to protease inhibitor treatment in hepatitis c (bilirubin toxicity)","hepatitis C virus infection, response to protease inhibitor, bilirubin measurement",GCST002347,"Mapping not available"
kgp9755615-<b>?</b>,"8 x 10-6",,NR,3.23,'-,[NR],'-,"Response to protease inhibitor treatment in hepatitis c (bilirubin toxicity)","hepatitis C virus infection, response to protease inhibitor, bilirubin measurement",GCST002347,"Mapping not available"
rs2978048-<b>?</b>,"1 x 10-6",,NR,'-,"0.25 unit increase",[NR],"ST3GAL1-DT, Metazoa_SRP","Response to protease inhibitor treatment in hepatitis c (peak serum total bilirubin levels)","hepatitis C virus infection, response to protease inhibitor, bilirubin measurement",GCST002349,8:133603893
kgp3085785-<b>?</b>,"1 x 10-6",,NR,'-,"0.36 unit increase",[NR],'-,"Response to protease inhibitor treatment in hepatitis c (peak serum total bilirubin levels)","hepatitis C virus infection, response to protease inhibitor, bilirubin measurement",GCST002349,"Mapping not available"
kgp11613116-<b>?</b>,"2 x 10-6",,NR,'-,"0.37 unit increase",[NR],'-,"Response to protease inhibitor treatment in hepatitis c (peak serum total bilirubin levels)","hepatitis C virus infection, response to protease inhibitor, bilirubin measurement",GCST002349,"Mapping not available"
rs7224000-<b>?</b>,"3 x 10-6",,NR,'-,"0.12 unit increase",[NR],PITPNC1,"Response to protease inhibitor treatment in hepatitis c (peak serum total bilirubin levels)","hepatitis C virus infection, response to protease inhibitor, bilirubin measurement",GCST002349,17:67414818
rs4676380-<b>?</b>,"2 x 10-6",,NR,'-,'-,NR,"AQP12A, KIF1A","Response to metformin (IC50)","cytotoxicity measurement, response to metformin",GCST003791,2:240703856
rs12995491-<b>?</b>,"2 x 10-6",,NR,'-,'-,NR,THNSL2,"Response to metformin (IC50)","cytotoxicity measurement, response to metformin",GCST003791,2:88227895
rs1298472-<b>?</b>,"3 x 10-6",,NR,'-,'-,NR,SH3TC1,"Response to metformin (IC50)","cytotoxicity measurement, response to metformin",GCST003791,4:8201114
rs827625-<b>?</b>,"3 x 10-6",,NR,'-,'-,NR,LINC02676,"Response to metformin (IC50)","cytotoxicity measurement, response to metformin",GCST003791,10:8956555
rs4611433-<b>?</b>,"4 x 10-6",,NR,'-,'-,NR,"CRAT37, SV2B","Response to metformin (IC50)","cytotoxicity measurement, response to metformin",GCST003791,15:91400953
rs10899021-<b>?</b>,"6 x 10-6",,NR,'-,'-,NR,POLD3,"Response to metformin (IC50)","cytotoxicity measurement, response to metformin",GCST003791,11:74627009
rs10220253-<b>?</b>,"6 x 10-6",,NR,'-,'-,NR,SNRPFP3,"Response to metformin (IC50)","cytotoxicity measurement, response to metformin",GCST003791,13:69109042
rs7653022-<b>?</b>,"7 x 10-6",,NR,'-,'-,NR,GOLIM4,"Response to metformin (IC50)","cytotoxicity measurement, response to metformin",GCST003791,3:168057803
rs4889609-<b>?</b>,"9 x 10-6",,NR,'-,'-,NR,"STX1B, STX4","Response to metformin (IC50)","cytotoxicity measurement, response to metformin",GCST003791,16:31015106
rs4414922-<b>?</b>,"9 x 10-6",,NR,'-,'-,NR,'-,"Response to metformin (IC50)","cytotoxicity measurement, response to metformin",GCST003791,4:91768108
rs2950163-<b>?</b>,"2 x 10-7",,NR,'-,'-,'-,SILC1,"Response to metformin (IC50)","cytotoxicity measurement, response to metformin",GCST003791,2:6041529
rs5917288-<b>?</b>,"2 x 10-6",,NR,'-,'-,NR,LINC01281,"Response to metformin (IC50)","cytotoxicity measurement, response to metformin",GCST003791,X:39270838
rs56378326-<b>?</b>,"7 x 10-7",,NR,Infinity,'-,NR,PKIB,"Response to direct-acting antiviral treatment in hepatitis C virus genotype 3","hepatitis C virus infection, response to antiviral drug",GCST008520,6:122670278
rs76810409-<b>?</b>,"1 x 10-6",,NR,Infinity,'-,NR,'-,"Response to direct-acting antiviral treatment in hepatitis C virus genotype 3","hepatitis C virus infection, response to antiviral drug",GCST008520,7:109456395
rs59888390-<b>?</b>,"5 x 10-7",,NR,3.846154,'-,NR,RPL23AP56,"Response to direct-acting antiviral treatment in hepatitis C virus genotype 3","hepatitis C virus infection, response to antiviral drug",GCST008520,8:134989069
rs35384524-<b>?</b>,"5 x 10-7",,NR,3.5714285,'-,NR,NCAM2,"Response to direct-acting antiviral treatment in hepatitis C virus genotype 3","hepatitis C virus infection, response to antiviral drug",GCST008520,21:21017373
rs7670514-<b>?</b>,"2 x 10-6",,NR,2.4,'-,NR,"HSBP1P2, ELOVL6","Response to direct-acting antiviral treatment in hepatitis C virus genotype 3","hepatitis C virus infection, response to antiviral drug",GCST008520,4:110212212
rs10011468-<b>?</b>,"2 x 10-6",,NR,2.43,'-,NR,"APELA, SMIM31","Response to direct-acting antiviral treatment in hepatitis C virus genotype 3","hepatitis C virus infection, response to antiviral drug",GCST008520,4:164845587
rs62042908-<b>?</b>,"1 x 10-6",,NR,2.56,'-,NR,'-,"Response to direct-acting antiviral treatment in hepatitis C virus genotype 3","hepatitis C virus infection, response to antiviral drug",GCST008520,15:93306014
rs12323963-<b>?</b>,"2 x 10-6",,NR,2.75,'-,NR,SHC4,"Response to direct-acting antiviral treatment in hepatitis C virus genotype 3","hepatitis C virus infection, response to antiviral drug",GCST008520,15:48938914
rs57030374-<b>?</b>,"2 x 10-6",,NR,3.72,'-,NR,'-,"Response to direct-acting antiviral treatment in hepatitis C virus genotype 3","hepatitis C virus infection, response to antiviral drug",GCST008520,6:91130685
rs116399066-<b>?</b>,"1 x 10-6",,NR,6.39,'-,NR,"RNVU1-23, RNVU1-18","Response to direct-acting antiviral treatment in hepatitis C virus genotype 3","hepatitis C virus infection, response to antiviral drug",GCST008520,1:143723149
rs9380237-<b>?</b>,"8 x 10-6",,NR,3.5714285,'-,[1.96-6.25],LINC02571,"Leukoderma in response to rhododendrol","Vitiligo, response to rhododendrol",GCST010676,6:31296615
rs12089229-<b>?</b>,"8 x 10-6",,NR,3.448276,'-,[1.92-6.25],LINC02814,"Leukoderma in response to rhododendrol","Vitiligo, response to rhododendrol",GCST010676,1:229094028
rs2706660-<b>?</b>,"6 x 10-6",,NR,3.030303,'-,[1.82-5.26],MICAL2,"Leukoderma in response to rhododendrol","Vitiligo, response to rhododendrol",GCST010676,11:12252982
rs8019978-<b>?</b>,"9 x 10-6",,NR,2.9411764,'-,[1.79-5],"LGALS3, MAPK1IP1L","Leukoderma in response to rhododendrol","Vitiligo, response to rhododendrol",GCST010676,14:55090566
rs13035343-<b>?</b>,"5 x 10-6",,NR,6.3,'-,[2.7-15],"FTOP1, CHORDC1P1","Leukoderma in response to rhododendrol","Vitiligo, response to rhododendrol",GCST010676,2:42822916
rs3793055-<b>?</b>,"2 x 10-6",,NR,3.7,'-,[2.1-6.5],COL19A1,"Leukoderma in response to rhododendrol","Vitiligo, response to rhododendrol",GCST010676,6:70107036
rs10786910-<b>?</b>,"6 x 10-6",,NR,3.1,'-,[1.8-5.1],LINC02624,"Leukoderma in response to rhododendrol","Vitiligo, response to rhododendrol",GCST010676,10:106125117
rs3783370-<b>?</b>,"2 x 10-6",,NR,3.8,'-,[2.1-6.8],PPP2R5C,"Leukoderma in response to rhododendrol","Vitiligo, response to rhododendrol",GCST010676,14:101919120
rs1364301-<b>?</b>,"1 x 10-7",,NR,4.6,'-,[2.4-8.6],CDH13,"Leukoderma in response to rhododendrol","Vitiligo, response to rhododendrol",GCST010676,16:83350163
rs6509418-<b>?</b>,"9 x 10-6",,NR,5.7,'-,[2.5-13],PPFIA3,"Leukoderma in response to rhododendrol","Vitiligo, response to rhododendrol",GCST010676,19:49147062
rs4958351-<b>A</b>,"4 x 10-7",,0.27,1.75,'-,[1.41-2.17],GRIA1,"Asparaginase hypersensitivity in acute lymphoblastic leukemia","asparaginase hypersensitivity",GCST000715,5:153790814
rs6475448-<b>A</b>,"2 x 10-9",,NR,'-,"129 mL increase",[NR],MLLT3,"Response to montelukast in asthma (change in FEV1)","FEV change measurement, response to montelukast, asthma",GCST002979,9:20497144
rs7794356-<b>A</b>,"9 x 10-7",,NR,'-,"110 mL increase",[NR],GALNT17,"Response to montelukast in asthma (change in FEV1)","FEV change measurement, response to montelukast, asthma",GCST002979,7:71273743
rs4861477-<b>C</b>,"8 x 10-6",,0.15,'-,'-,'-,'-,"Response to tamoxifen in oestrogen receptor positive/HER2 negative breast cancer","response to tamoxifen, HER2 status, estrogen-receptor positive breast cancer",GCST006615,4:181490427
rs17198973-<b>C</b>,"6 x 10-6",,0.35,'-,'-,'-,'-,"Response to tamoxifen in oestrogen receptor positive/HER2 negative breast cancer","response to tamoxifen, HER2 status, estrogen-receptor positive breast cancer",GCST006615,4:181486725
rs9316695-<b>A</b>,"6 x 10-6",,0.12,4.46,'-,[2.30-8.47],LINC00458,"Trastuzumab-induced cardiotoxicity in cancer","cancer, response to trastuzumab, cardiotoxicity",GCST009381,13:54041638
rs9272105-<b>A</b>,"4 x 10-10",,0.44,'-,"0.26 unit increase",[NR],HLA-DQA1,"Response to interferon beta therapy","response to interferon beta",GCST001043,6:32632222
rs4961252-<b>G</b>,"3 x 10-8",,0.40,'-,"0.23 unit increase",[NR],"DENND3, PTK2","Response to interferon beta therapy","response to interferon beta",GCST001043,8:141094845
rs2011738-<b>G</b>,"6 x 10-6",(EA),NR,'-,"1.34 unit increase",[0.71-1.97],IQSEC3,"Response to angiotensin II receptor blocker therapy","response to candesartan, hypertension",GCST001520,12:110822
rs12762955-<b>C</b>,"8 x 10-6",(EA),NR,'-,"1.17 unit decrease",[0.62-1.72],IDI2-AS1,"Response to angiotensin II receptor blocker therapy","response to candesartan, hypertension",GCST001520,10:1032842
rs13107740-<b>G</b>,"5 x 10-6",(AA),NR,'-,"1.51 unit decrease",[0.78-2.24],EMCN,"Response to angiotensin II receptor blocker therapy","response to candesartan, hypertension",GCST001520,4:100885375
rs790123-<b>T</b>,"6 x 10-6",(AA),NR,'-,"1.07 unit increase",[0.58-1.56],"EIF4BP8, PARP14","Response to angiotensin II receptor blocker therapy","response to candesartan, hypertension",GCST001520,3:122670146
rs13075436-<b>C</b>,"6 x 10-6",(AA),NR,'-,"1.3 unit decrease",[0.71-1.89],"PRR20G, RNU6-1047P","Response to angiotensin II receptor blocker therapy","response to candesartan, hypertension",GCST001520,3:127242305
rs3913363-<b>T</b>,"4 x 10-7",(AA),NR,'-,"1.3 unit increase",[0.75-1.85],TMEM212,"Response to angiotensin II receptor blocker therapy","response to candesartan, hypertension",GCST001520,3:171936113
rs4663476-<b>G</b>,"8 x 10-6",(AA),NR,'-,"1.23 unit decrease",[0.66-1.80],LINC01173,"Response to angiotensin II receptor blocker therapy","response to candesartan, hypertension",GCST001520,2:234692420
rs2074409-<b>T</b>,"2 x 10-6",(EA),NR,'-,"1.2 unit increase",[0.67-1.73],SYNRG,"Response to angiotensin II receptor blocker therapy","response to candesartan, hypertension",GCST001520,17:37538240
rs11020821-<b>C</b>,"9 x 10-7",(EA),NR,'-,"1.4 unit increase",[0.79-2.01],"C11orf97, PIWIL4","Response to angiotensin II receptor blocker therapy","response to candesartan, hypertension",GCST001520,11:94538497
rs11753937-<b>T</b>,"6 x 10-6",(EA),NR,'-,"1.12 unit increase",[0.61-1.63],EYA4,"Response to angiotensin II receptor blocker therapy","response to candesartan, hypertension",GCST001520,6:133342451
rs2166775-<b>G</b>,"3 x 10-6",(EA),NR,'-,"0.99 unit increase",[0.54-1.44],SLC9A9,"Response to angiotensin II receptor blocker therapy","response to candesartan, hypertension",GCST001520,3:143785691
rs659580-<b>T</b>,"1 x 10-6",(EA),NR,'-,"1.28 unit increase",[0.71-1.85],PRRX1,"Response to angiotensin II receptor blocker therapy","response to candesartan, hypertension",GCST001520,1:170664755
rs16838131-<b>A</b>,"2 x 10-6",(AA),NR,'-,"2.26 unit decrease",[1.01-3.51],"C4orf50, JAKMIP1","Response to angiotensin II receptor blocker therapy","response to candesartan, hypertension",GCST001520,4:6056770
rs4265793-<b>T</b>,"6 x 10-6",(AA),NR,'-,"1.22 unit decrease",[0.65-1.79],TMC7,"Response to angiotensin II receptor blocker therapy","response to candesartan, hypertension",GCST001520,16:19017227
rs2992257-<b>T</b>,"3 x 10-7",(AA),NR,'-,"8.63 unit increase",[-2.13040-19.39040],APBB1IP,"Response to angiotensin II receptor blocker therapy","response to candesartan, hypertension",GCST001520,10:26445658
rs6871087-<b>G</b>,"1 x 10-6",(AA),NR,'-,"1.4 unit increase",[0.79-2.01],'-,"Response to angiotensin II receptor blocker therapy","response to candesartan, hypertension",GCST001520,5:30899410
rs37439-<b>A</b>,"9 x 10-6",(AA),NR,'-,"1 unit decrease",[0.53-1.47],DNAJC21,"Response to angiotensin II receptor blocker therapy","response to candesartan, hypertension",GCST001520,5:34951045
rs4719147-<b>T</b>,"2 x 10-6",(AA),NR,'-,"1.13 unit increase",[0.64-1.62],GALNT17,"Response to angiotensin II receptor blocker therapy","response to candesartan, hypertension",GCST001520,7:71551174
rs4491175-<b>T</b>,"8 x 10-6",(AA),NR,'-,"1.1 unit increase",[0.59-1.61],LINC02748,"Response to angiotensin II receptor blocker therapy","response to candesartan, hypertension",GCST001520,11:91223046
rs7772131-<b>?</b>,"3 x 10-6",(AA),NR,'-,"6.73 unit decrease",[0.89-12.57],LINC00243,"Response to angiotensin II receptor blocker therapy","response to candesartan, hypertension",GCST001520,6:30827394
rs11020821-<b>C</b>,"4 x 10-6",(EA),NR,'-,'-,'-,"C11orf97, PIWIL4","Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy)","response to candesartan, hypertension",GCST001518,11:94538497
rs7587205-<b>T</b>,"4 x 10-6",(AA),NR,'-,'-,'-,MAP4K3-DT,"Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy)","response to candesartan, hypertension",GCST001518,2:39616057
rs7168353-<b>C</b>,"1 x 10-6",(AA),NR,'-,'-,'-,RGMA,"Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy)","response to candesartan, hypertension",GCST001518,15:93095172
rs790116-<b>G</b>,"2 x 10-7",(AA),NR,'-,'-,'-,EIF4BP8,"Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy)","response to candesartan, hypertension",GCST001518,3:122662076
rs3758785-<b>G</b>,"2 x 10-6",(EA),NR,'-,'-,'-,GPR83,"Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy)","response to candesartan, hypertension",GCST001518,11:94398973
rs977145-<b>A</b>,"7 x 10-6",,NR,'-,'-,'-,"NEGR1, ZRANB2-AS2","Venlafaxine response in generalised anxiety disorder (HAMA-A score reduction after 24 weeks)","response to venlafaxine, generalized anxiety disorder",GCST004271,1:71463606
rs7853333-<b>A</b>,"4 x 10-6",,NR,'-,'-,'-,"DCAF12, RN7SKP114","Venlafaxine response in generalised anxiety disorder (HAMA-A score reduction after 24 weeks)","response to venlafaxine, generalized anxiety disorder",GCST004271,9:34065661
rs76778048-<b>A</b>,"8 x 10-6",(CGI),0.25,10.2,'-,'-,LINC02549,"Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 12 weeks)","response to venlafaxine, generalized anxiety disorder",GCST004270,6:68220040
rs3819595-<b>A</b>,"4 x 10-6",(HAM-A),0.35,6.45,'-,'-,PCP4,"Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 12 weeks)","response to venlafaxine, generalized anxiety disorder",GCST004270,21:39910773
rs2070419-<b>A</b>,"5 x 10-6",(CGI),0.47,6.09,'-,'-,"TIAM1, FBXW11P1","Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 12 weeks)","response to venlafaxine, generalized anxiety disorder",GCST004270,21:31560711
rs3020264-<b>A</b>,"3 x 10-6",(HAM-A),0.48,4.7,'-,'-,"MCPH1-AS1, MCPH1","Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks)","response to venlafaxine, generalized anxiety disorder",GCST004273,8:6631056
rs10914746-<b>G</b>,"9 x 10-6",(CGI),0.43,4.63,'-,'-,CSMD2,"Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks)","response to venlafaxine, generalized anxiety disorder",GCST004273,1:33574244
rs7984972-<b>A</b>,"8 x 10-6",(CGI),0.57,4.17,'-,'-,'-,"Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks)","response to venlafaxine, generalized anxiety disorder",GCST004273,13:31433871
rs13129231-<b>A</b>,"6 x 10-6",(CGI),0.90,5.88,'-,'-,CAMK2D,"Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks)","response to venlafaxine, generalized anxiety disorder",GCST004274,4:113431725
rs2236295-<b>A</b>,"5 x 10-6",(CGI),0.52,4.14,'-,'-,ADO,"Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks)","response to venlafaxine, generalized anxiety disorder",GCST004274,10:62805132
rs7152947-<b>A</b>,"3 x 10-6",(HAM-A),0.89,5.88,'-,'-,ANGEL1,"Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks)","response to venlafaxine, generalized anxiety disorder",GCST004274,14:76825750
rs8020289-<b>G</b>,"9 x 10-6",(HAM-A),0.88,5.26,'-,'-,LRRC74A,"Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks)","response to venlafaxine, generalized anxiety disorder",GCST004274,14:76827177
rs2307441-<b>G</b>,"3 x 10-6",(HAM-A),0.22,14.38,'-,'-,POLG,"Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 24 weeks)","response to venlafaxine, generalized anxiety disorder",GCST004275,15:89318595
rs6712232-<b>G</b>,"5 x 10-6",(CGI),0.22,14.28,'-,'-,RPS20P10,"Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 24 weeks)","response to venlafaxine, generalized anxiety disorder",GCST004275,2:71903902
rs3013580-<b>G</b>,"2 x 10-6",(CGI),0.59,6.23,'-,'-,LINC00364,"Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 24 weeks)","response to venlafaxine, generalized anxiety disorder",GCST004275,13:67329484
rs75965524-<b>G</b>,"4 x 10-6",(CGI),0.22,14.47,'-,'-,AGAP1,"Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 24 weeks)","response to venlafaxine, generalized anxiety disorder",GCST004275,2:235921494
rs6918679-<b>A</b>,"8 x 10-7",(CGI),0.28,11.97,'-,'-,'-,"Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 24 weeks)","response to venlafaxine, generalized anxiety disorder",GCST004275,6:74822861
rs185386680-<b>?</b>,"4 x 10-29",,NR,24.7,'-,9.2-66.3,"HLA-C, HCG27","Antithyroid drug-induced agranulocytosis","response to thioamide, Drug-induced agranulocytosis",GCST003580,6:31207153
rs1858826-<b>G</b>,"1 x 10-7",,0.1,3.448276,'-,[2.17-5.56],GNGT1,"Taxane-induced peripheral neuropathy in breast cancer","peripheral neuropathy, breast carcinoma, response to taxane",GCST005804,7:93719703
rs910920-<b>A</b>,"5 x 10-6",,0.31,1.754386,'-,[1.37-2.22],"MRM3, NXN","Taxane-induced peripheral neuropathy in breast cancer","peripheral neuropathy, breast carcinoma, response to taxane",GCST005804,17:797882
rs1857798-<b>C</b>,"8 x 10-6",,0.38,2.2727273,'-,[1.52-3.45],MARCHF1,"Taxane-induced peripheral neuropathy in breast cancer","peripheral neuropathy, breast carcinoma, response to taxane",GCST005804,4:164448974
rs78239784-<b>G</b>,"5 x 10-11",(EA),0.01,7,'-,[3.2-16],CFHR4,"Phenytoin-induced maculopapular exanthema","maculopapular eruption, response to phenytoin",GCST005200,1:196899970
rs8113308-<b>G</b>,"6 x 10-7",,0.152,1.69,'-,[1.37-2.07],ZNF613,"Survival in endocrine treated breast cancer (estrogen-receptor positive)","survival time, estrogen-receptor positive breast cancer, breast carcinoma, response to endocrine therapy",GCST002901,19:51942133
rs17070488-<b>G</b>,"2 x 10-6",,0.433,'-,'-,'-,PRICKLE2,"prednisolone sensitivity in B-cell precursor acute lymphoblastic leukaemia","B-cell acute lymphoblastic leukemia, response to prednisolone",GCST011997,3:64354851
rs904419-<b>A</b>,"4 x 10-8",,0.395,'-,'-,'-,FRMD4B,"prednisolone sensitivity in B-cell precursor acute lymphoblastic leukaemia","B-cell acute lymphoblastic leukemia, response to prednisolone",GCST011997,3:69508620
rs8017036-<b>A</b>,"9 x 10-6",,0.349,'-,'-,'-,'-,"prednisolone sensitivity in B-cell precursor acute lymphoblastic leukaemia","B-cell acute lymphoblastic leukemia, response to prednisolone",GCST011997,14:98550429
rs2306888-<b>C</b>,"1 x 10-6",,0.186,'-,'-,'-,TGFBR3,"dexamethasone sensitivity in B-cell precursor acute lymphoblastic leukaemia","B-cell acute lymphoblastic leukemia, response to dexamethasone",GCST011996,1:91734825
rs904419-<b>A</b>,"3 x 10-6",,0.395,'-,'-,'-,FRMD4B,"dexamethasone sensitivity in B-cell precursor acute lymphoblastic leukaemia","B-cell acute lymphoblastic leukemia, response to dexamethasone",GCST011996,3:69508620
rs11133333-<b>T</b>,"5 x 10-6",,0.325,'-,'-,'-,LINC02260,"dexamethasone sensitivity in B-cell precursor acute lymphoblastic leukaemia","B-cell acute lymphoblastic leukemia, response to dexamethasone",GCST011996,4:54514304
rs17636071-<b>G</b>,"2 x 10-6",(MMSE),0.09,'-,"4.74 unit decrease",[NR],'-,"Response to cholinesterase inhibitors in Alzheimer's disease","response to cholinesterase inhibitor, Alzheimer's disease",GCST001835,"Mapping not available"
rs2270875-<b>G</b>,"9 x 10-6",(MMSE),0.16,'-,"2.84 unit decrease",[NR],EFR3A,"Response to cholinesterase inhibitors in Alzheimer's disease","response to cholinesterase inhibitor, Alzheimer's disease",GCST001835,8:131987689
rs17798800-<b>?</b>,"7 x 10-6","(cases vs. controls)",0.71,2.63,'-,[1.72-4],LINC02343,"Response to cholinesterase inhibitors in Alzheimer's disease","response to cholinesterase inhibitor, Alzheimer's disease",GCST001835,13:34376390
rs4149080-<b>C</b>,"6 x 10-21",,0.18,'-,"12 mL/min/m2 decrease",[NR],SLCO1B1,"Methotrexate clearance (acute lymphoblastic leukemia)","response to methotrexate",GCST001770,12:21224625
rs9266634-<b>?</b>,"3 x 10-8",,NR,5.37,'-,[2.97-9.69],"ZDHHC20P2, FGFR3P1","Sulfasalazine-induced agranulocytosis","response to sulfasalazine, Drug-induced agranulocytosis",GCST004781,6:31379201
rs202233001-<b>?</b>,"4 x 10-8",,NR,6.76,'-,[3.41-13.38],"SLC25A6P1, RPL41P1","Sulfasalazine-induced agranulocytosis","response to sulfasalazine, Drug-induced agranulocytosis",GCST004781,20:21754716
rs111876221-<b>?</b>,"3 x 10-8","(conditioned on rs9266634)",NR,12.65,'-,[5.15-31.1],SERINC5,"Sulfasalazine-induced agranulocytosis","response to sulfasalazine, Drug-induced agranulocytosis",GCST004781,5:80239381
rs113887891-<b>?</b>,"5 x 10-8","(conditioned on rs9266634 and rs111876221)",NR,9.52,'-,[4.24-21.37],LINC01762,"Sulfasalazine-induced agranulocytosis","response to sulfasalazine, Drug-induced agranulocytosis",GCST004781,1:116464248
rs12082628-<b>?</b>,"3 x 10-8","(conditioned on rs9266634, rs111876221 and rs113887891)",NR,14.99,'-,[5.75-39.04],CHRM3,"Sulfasalazine-induced agranulocytosis","response to sulfasalazine, Drug-induced agranulocytosis",GCST004781,1:239634406
rs9266634-<b>?</b>,"3 x 10-8",,NR,5.37,'-,[2.97-9.69],"ZDHHC20P2, FGFR3P1","Sulfasalazine-induced agranulocytosis","response to sulfasalazine, Drug-induced agranulocytosis",GCST004781,6:31379201
rs202233001-<b>?</b>,"4 x 10-8",,NR,6.76,'-,[3.41-13.38],"SLC25A6P1, RPL41P1","Sulfasalazine-induced agranulocytosis","response to sulfasalazine, Drug-induced agranulocytosis",GCST004781,20:21754716
rs9675270-<b>?</b>,"1 x 10-7",,NR,4.64,'-,[2.64-8.18],RTN4RL1,"Sulfasalazine-induced agranulocytosis","response to sulfasalazine, Drug-induced agranulocytosis",GCST004781,17:1964741
rs74512480-<b>?</b>,"2 x 10-7",,NR,7.11,'-,[3.40-14.88],LINC01357,"Sulfasalazine-induced agranulocytosis","response to sulfasalazine, Drug-induced agranulocytosis",GCST004781,1:112873635
rs9372971-<b>?</b>,"2 x 10-7",,NR,7.02,'-,[3.37-14.64],Y_RNA,"Sulfasalazine-induced agranulocytosis","response to sulfasalazine, Drug-induced agranulocytosis",GCST004781,6:130643292
rs76801208-<b>?</b>,"2 x 10-7",,NR,7.31,'-,[3.44-15.53],GNAS,"Sulfasalazine-induced agranulocytosis","response to sulfasalazine, Drug-induced agranulocytosis",GCST004781,20:58898673
rs117767021-<b>?</b>,"3 x 10-7",,NR,10.78,'-,[4.35-26.68],"LINC02843, MIR4289","Sulfasalazine-induced agranulocytosis","response to sulfasalazine, Drug-induced agranulocytosis",GCST004781,9:88685871
rs74997117-<b>?</b>,"3 x 10-7",,NR,5.32,'-,[2.81-10.06],"PAXIP1-DT, HTR5A-AS1","Sulfasalazine-induced agranulocytosis","response to sulfasalazine, Drug-induced agranulocytosis",GCST004781,7:155060018
chr12:55328807-<b>?</b>,"3 x 10-7",,NR,10.92,'-,[4.37-27.29],'-,"Sulfasalazine-induced agranulocytosis","response to sulfasalazine, Drug-induced agranulocytosis",GCST004781,"Mapping not available"
rs200629715-<b>?</b>,"3 x 10-7",,NR,5.34,'-,[2.81-10.15],"IFT88, CRYL1","Sulfasalazine-induced agranulocytosis","response to sulfasalazine, Drug-induced agranulocytosis",GCST004781,13:20561201
rs572589-<b>?</b>,"3 x 10-7",,NR,4.13,'-,[2.40-7.13],"GRHL2, RN7SL563P","Sulfasalazine-induced agranulocytosis","response to sulfasalazine, Drug-induced agranulocytosis",GCST004781,8:101473534
rs113887891-<b>?</b>,"3 x 10-7",,NR,6.95,'-,[3.30-14.64],LINC01762,"Sulfasalazine-induced agranulocytosis","response to sulfasalazine, Drug-induced agranulocytosis",GCST004781,1:116464248
rs114431066-<b>?</b>,"3 x 10-7",,NR,8.64,'-,[3.77-19.79],DLG1-AS1,"Sulfasalazine-induced agranulocytosis","response to sulfasalazine, Drug-induced agranulocytosis",GCST004781,3:197381461
rs73165468-<b>?</b>,"4 x 10-7",,NR,4.88,'-,[2.65-8.97],IFT88,"Sulfasalazine-induced agranulocytosis","response to sulfasalazine, Drug-induced agranulocytosis",GCST004781,13:20680227
rs150938367-<b>?</b>,"4 x 10-7",,NR,9.72,'-,[4.04-23.39],GSE1,"Sulfasalazine-induced agranulocytosis","response to sulfasalazine, Drug-induced agranulocytosis",GCST004781,16:85605787
rs118137040-<b>?</b>,"4 x 10-7",,NR,6.57,'-,[3.17-13.64],TSPOAP1,"Sulfasalazine-induced agranulocytosis","response to sulfasalazine, Drug-induced agranulocytosis",GCST004781,17:58321731
rs143510029-<b>?</b>,"5 x 10-7",,NR,9.11,'-,[3.86-21.50],TTC6,"Sulfasalazine-induced agranulocytosis","response to sulfasalazine, Drug-induced agranulocytosis",GCST004781,14:37865546
rs149020156-<b>?</b>,"6 x 10-7",,NR,7.41,'-,[3.38-16.25],"LINC02756, TUBB4BP4","Sulfasalazine-induced agranulocytosis","response to sulfasalazine, Drug-induced agranulocytosis",GCST004781,11:91940355
rs11352430-<b>?</b>,"6 x 10-7",,NR,3.63,'-,[2.19-6.02],MROH6,"Sulfasalazine-induced agranulocytosis","response to sulfasalazine, Drug-induced agranulocytosis",GCST004781,8:143571358
rs144251347-<b>?</b>,"7 x 10-7",,NR,5.1,'-,[2.69-9.70],TMEM245,"Sulfasalazine-induced agranulocytosis","response to sulfasalazine, Drug-induced agranulocytosis",GCST004781,9:109119117
rs622871-<b>?</b>,"7 x 10-7",,NR,3.29,'-,[2.06-5.27],C2,"Sulfasalazine-induced agranulocytosis","response to sulfasalazine, Drug-induced agranulocytosis",GCST004781,6:31910718
rs142915233-<b>?</b>,"7 x 10-7",,NR,9.86,'-,[3.99-24.34],OSBPL3,"Sulfasalazine-induced agranulocytosis","response to sulfasalazine, Drug-induced agranulocytosis",GCST004781,7:24803381
rs74461346-<b>?</b>,"7 x 10-7",,NR,5.22,'-,[2.72-10.02],"LINC01603, SULF1","Sulfasalazine-induced agranulocytosis","response to sulfasalazine, Drug-induced agranulocytosis",GCST004781,8:69449390
chr12:1662065-<b>?</b>,"7 x 10-7",,NR,4.57,'-,[2.51-8.33],'-,"Sulfasalazine-induced agranulocytosis","response to sulfasalazine, Drug-induced agranulocytosis",GCST004781,"Mapping not available"
rs111876221-<b>?</b>,"7 x 10-7",,NR,8.71,'-,[3.70-20.52],SERINC5,"Sulfasalazine-induced agranulocytosis","response to sulfasalazine, Drug-induced agranulocytosis",GCST004781,5:80239381
rs143354638-<b>?</b>,"7 x 10-7",,NR,10,'-,[4.02-24.88],CD8B2,"Sulfasalazine-induced agranulocytosis","response to sulfasalazine, Drug-induced agranulocytosis",GCST004781,2:106508384
rs16919354-<b>?</b>,"8 x 10-7",,NR,6.58,'-,[3.11-13.89],MAPK6P1,"Sulfasalazine-induced agranulocytosis","response to sulfasalazine, Drug-induced agranulocytosis",GCST004781,8:53554028
rs4262906-<b>C</b>,"7 x 10-7",(Allelic),0.31,4.36,'-,[2.41-7.89],MIR548AP,"Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel)","chemotherapy-induced alopecia, response to docetaxel",GCST002180,15:85919621
rs4234284-<b>T</b>,"3 x 10-6",(Dominant),0.23,3.01,'-,[1.62-5.6],"Y_RNA, RNU6-1047P","Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel)","chemotherapy-induced alopecia, response to docetaxel",GCST002180,3:127231283
rs6117615-<b>C</b>,"7 x 10-6",(Dominant),0.24,3.89,'-,[2.1-7.18],"SLC52A3, FAM110A","Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel)","chemotherapy-induced alopecia, response to docetaxel",GCST002180,20:778672
rs10443215-<b>C</b>,"9 x 10-6",(Allelic),0.04,9.39,'-,[2.77-31.8],'-,"Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel)","chemotherapy-induced alopecia, response to docetaxel",GCST002180,1:55647101
rs10176318-<b>?</b>,"1 x 10-7","(dCCB versus ACE, AA)",NR,'-,"0.172 unit increase",[0.11-0.24],TEX41,"Left ventricular mass x antihypertensive treatment interaction","response to antihypertensive drug, left ventricular mass",GCST009835,2:145235033
rs9314972-<b>?</b>,"5 x 10-7","(dCCB versus TD, AA)",NR,'-,"0.135 unit decrease",[0.082-0.188],UBL3,"Left ventricular mass x antihypertensive treatment interaction","response to antihypertensive drug, left ventricular mass",GCST009835,13:29753832
rs326641-<b>?</b>,"1 x 10-7","(dCCB versus TD, AA)",NR,'-,"0.208 unit increase",[0.13-0.28],BICD1,"Left ventricular mass x antihypertensive treatment interaction","response to antihypertensive drug, left ventricular mass",GCST009835,12:32246935
rs7262682-<b>?</b>,"5 x 10-8","(dCCB versus ACE, AA)",NR,'-,"0.141 unit increase",[0.09-0.192],PGAM3P,"Relative wall thickness x antihypertensive treatment interaction","response to antihypertensive drug, heart relative wall thickness",GCST009836,20:11546281
rs2217884-<b>?</b>,"1 x 10-7","(dCCB versus ACE, AA)",NR,'-,"0.09 unit increase",[0.057-0.123],THRB,"Relative wall thickness x antihypertensive treatment interaction","response to antihypertensive drug, heart relative wall thickness",GCST009836,3:24425711
rs10805321-<b>?</b>,"9 x 10-6",,NR,'-,"0.3944 unit increase",[NR],LINC01182,"Response to antipsychotic therapy (extrapyramidal side effects)","response to antipsychotic drug",GCST001271,4:13912749
rs12476047-<b>C</b>,"3 x 10-6",,NR,3.21,'-,[1.97-5.25],'-,"Response to antipsychotic treatment","response to antipsychotic drug",GCST000462,2:163461366
rs4662945-<b>?</b>,"3 x 10-6",,'-,'-,'-,'-,PPIAP65,"Response to cytidine analogues (gemcitabine)","response to gemcitabine",GCST002343,2:129458470
rs3775182-<b>?</b>,"3 x 10-6",,'-,'-,'-,'-,MAPK10,"Response to cytidine analogues (gemcitabine)","response to gemcitabine",GCST002343,4:86058430
rs7719624-<b>?</b>,"4 x 10-6",,'-,'-,'-,'-,TGFBI,"Response to cytidine analogues (gemcitabine)","response to gemcitabine",GCST002343,5:136041877
rs13269021-<b>?</b>,"1 x 10-6",,'-,'-,'-,'-,"MCPH1, ANGPT2","Response to cytidine analogues (gemcitabine)","response to gemcitabine",GCST002343,8:6539242
rs4272382-<b>?</b>,"2 x 10-6",,'-,'-,'-,'-,RN7SL178P,"Response to cytidine analogues (gemcitabine)","response to gemcitabine",GCST002343,8:8575978
rs2274870-<b>?</b>,"4 x 10-6",,'-,'-,'-,'-,NIPSNAP3A,"Response to cytidine analogues (gemcitabine)","response to gemcitabine",GCST002343,9:104752933
rs2275540-<b>?</b>,"4 x 10-6",,'-,'-,'-,'-,DOCK1,"Response to cytidine analogues (gemcitabine)","response to gemcitabine",GCST002343,10:126999453
rs790006-<b>?</b>,"8 x 10-6",,'-,'-,'-,'-,C12orf66,"Response to cytidine analogues (gemcitabine)","response to gemcitabine",GCST002343,12:64212659
rs10513968-<b>?</b>,"1 x 10-6",,'-,'-,'-,'-,DOK6,"Response to cytidine analogues (gemcitabine)","response to gemcitabine",GCST002343,18:69615905
rs1598848-<b>?</b>,"7 x 10-7",,'-,'-,'-,'-,"LINC01673, NCSTNP1","Response to cytidine analogues (gemcitabine)","response to gemcitabine",GCST002343,21:27573957
rs17382119-<b>?</b>,"3 x 10-6",(AUC),NR,'-,'-,'-,LEKR1,"Clozapine-induced cytotoxicity","cytotoxicity measurement, response to clozapine",GCST002777,3:156891313
rs1149933-<b>?</b>,"3 x 10-6",(AUC),NR,'-,'-,'-,'-,"Clozapine-induced cytotoxicity","cytotoxicity measurement, response to clozapine",GCST002777,10:9151938
rs17662217-<b>?</b>,"3 x 10-6",(AUC),NR,'-,'-,'-,C17orf102,"Clozapine-induced cytotoxicity","cytotoxicity measurement, response to clozapine",GCST002777,17:34535171
rs11642282-<b>?</b>,"7 x 10-6",(AUC),NR,'-,'-,'-,WWOX,"Clozapine-induced cytotoxicity","cytotoxicity measurement, response to clozapine",GCST002777,16:79024360
rs11818084-<b>?</b>,"8 x 10-6",(AUC),NR,'-,'-,'-,OAT,"Clozapine-induced cytotoxicity","cytotoxicity measurement, response to clozapine",GCST002777,10:124298329
rs1387221-<b>?</b>,"8 x 10-6",(AUC),NR,'-,'-,'-,NSMAF,"Clozapine-induced cytotoxicity","cytotoxicity measurement, response to clozapine",GCST002777,8:58688998
rs12460584-<b>?</b>,"9 x 10-6",(AUC),NR,'-,'-,'-,SHANK1,"Clozapine-induced cytotoxicity","cytotoxicity measurement, response to clozapine",GCST002777,19:50682824
rs7732104-<b>?</b>,"9 x 10-6",(AUC),NR,'-,'-,'-,C7,"Clozapine-induced cytotoxicity","cytotoxicity measurement, response to clozapine",GCST002777,5:40983334
rs7968270-<b>?</b>,"9 x 10-6",(AUC),NR,'-,'-,'-,TMCC3,"Clozapine-induced cytotoxicity","cytotoxicity measurement, response to clozapine",GCST002777,12:94702062
rs6438504-<b>?</b>,"9 x 10-6",(AUC),NR,'-,'-,'-,B4GALT4,"Clozapine-induced cytotoxicity","cytotoxicity measurement, response to clozapine",GCST002777,3:119217152
rs17492380-<b>?</b>,"9 x 10-6",(AUC),NR,'-,'-,'-,"LINC02151, LINC02702","Clozapine-induced cytotoxicity","cytotoxicity measurement, response to clozapine",GCST002777,11:116568134
rs1293970-<b>?</b>,"2 x 10-6",(Vehicle),NR,'-,'-,'-,"HMCN1, PRG4","Clozapine-induced cytotoxicity","cytotoxicity measurement, response to clozapine",GCST002777,1:186289097
rs1293970-<b>?</b>,"3 x 10-6",(10x),NR,'-,'-,'-,"HMCN1, PRG4","Clozapine-induced cytotoxicity","cytotoxicity measurement, response to clozapine",GCST002777,1:186289097
rs1293970-<b>?</b>,"7 x 10-7",(20x),NR,'-,'-,'-,"HMCN1, PRG4","Clozapine-induced cytotoxicity","cytotoxicity measurement, response to clozapine",GCST002777,1:186289097
rs2709505-<b>?</b>,"1 x 10-8",(30x),NR,'-,'-,'-,MDFIC,"Clozapine-induced cytotoxicity","cytotoxicity measurement, response to clozapine",GCST002777,7:114956786
rs10457252-<b>?</b>,"2 x 10-8",(30x),NR,'-,'-,'-,'-,"Clozapine-induced cytotoxicity","cytotoxicity measurement, response to clozapine",GCST002777,6:112823582
rs6552496-<b>C</b>,"8 x 10-6",,NR,2,'-,[1.46-2.76],'-,"Bortezomib-induced peripheral neuropathy in multiple myeloma","peripheral neuropathy, multiple myeloma, response to bortezomib",GCST003964,4:181371930
rs12521798-<b>A</b>,"4 x 10-6",,NR,2.76,'-,[1.73-4.38],"CMYA5, LINC01455","Bortezomib-induced peripheral neuropathy in multiple myeloma","peripheral neuropathy, multiple myeloma, response to bortezomib",GCST003964,5:79890115
rs8060632-<b>A</b>,"2 x 10-6",,NR,2.31,'-,[1.61-3.32],CDH13,"Bortezomib-induced peripheral neuropathy in multiple myeloma","peripheral neuropathy, multiple myeloma, response to bortezomib",GCST003964,16:83591958
rs17748074-<b>A</b>,"9 x 10-6",,NR,1.96,'-,[1.45-2.65],DCC,"Bortezomib-induced peripheral neuropathy in multiple myeloma","peripheral neuropathy, multiple myeloma, response to bortezomib",GCST003964,18:52420925
rs13064411-<b>G</b>,"8 x 10-8",(EA),0.153,'-,"0.142 unit increase",[NR],CFAP44,"Response to simvastatin treatment (PCSK9 protein level change)","response to simvastatin, PCSK9 protein measurement",GCST002642,3:113327793
rs16914931-<b>A</b>,"1 x 10-6",(EA),0.121,'-,"0.198 unit increase",[NR],GABBR2,"Response to simvastatin treatment (PCSK9 protein level change)","response to simvastatin, PCSK9 protein measurement",GCST002642,9:98330034
rs4710191-<b>G</b>,"4 x 10-6",(EA),0.433,'-,"0.0854 unit decrease",[NR],TCP10L2,"Response to simvastatin treatment (PCSK9 protein level change)","response to simvastatin, PCSK9 protein measurement",GCST002642,6:167159054
rs17336353-<b>G</b>,"5 x 10-6",(EA),0.19,'-,"0.151 unit increase",[NR],PDLIM5,"Response to simvastatin treatment (PCSK9 protein level change)","response to simvastatin, PCSK9 protein measurement",GCST002642,4:94595365
rs7814749-<b>A</b>,"5 x 10-6",(EA),0.371,'-,"0.0913 unit decrease",[NR],CNGB3,"Response to simvastatin treatment (PCSK9 protein level change)","response to simvastatin, PCSK9 protein measurement",GCST002642,8:86709121
rs6903961-<b>A</b>,"9 x 10-6",(EA),0.167,'-,"0.111 unit decrease",[NR],FILNC1,"Response to simvastatin treatment (PCSK9 protein level change)","response to simvastatin, PCSK9 protein measurement",GCST002642,6:139832274
rs4149056-<b>C</b>,"2 x 10-9",,0.13,4.5,'-,[2.60-7.70],SLCO1B1,"Response to statin therapy","response to statin",GCST000213,12:21178615
rs1858231-<b>C</b>,"2 x 10-6",(Allelic),0.22,2.71,'-,[1.79-4.12],'-,"Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule)","chemotherapy-induced alopecia, response to antimicrotubule agent",GCST002177,"Mapping not available"
rs1870323-<b>T</b>,"2 x 10-6",(Allelic),0.64,2.92,'-,[1.87-4.57],ME3,"Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule)","chemotherapy-induced alopecia, response to antimicrotubule agent",GCST002177,11:86477110
rs4262906-<b>C</b>,"3 x 10-6",(Allelic),0.35,2.5,'-,[1.71-3.67],MIR548AP,"Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule)","chemotherapy-induced alopecia, response to antimicrotubule agent",GCST002177,15:85919621
rs2471042-<b>T</b>,"5 x 10-6",(Dominant),0.21,2.51,'-,[1.64-3.81],ADAMTS19,"Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule)","chemotherapy-induced alopecia, response to antimicrotubule agent",GCST002177,5:86881956
rs11255615-<b>G</b>,"5 x 10-6",(Allelic),0.38,2.4,'-,[1.65-3.53],LINC00708,"Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule)","chemotherapy-induced alopecia, response to antimicrotubule agent",GCST002177,10:8282926
rs1493354-<b>T</b>,"9 x 10-6",(Dominant),0.22,2.37,'-,[1.56-3.6],'-,"Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule)","chemotherapy-induced alopecia, response to antimicrotubule agent",GCST002177,5:86878330
rs2032224-<b>A</b>,"9 x 10-6",(Recessive),0.62,2.16,'-,[1.42-3.27],"SERPINB5, SERPINB12","Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule)","chemotherapy-induced alopecia, response to antimicrotubule agent",GCST002177,18:63509033
rs7428377-<b>?</b>,"3 x 10-6",,0.09,2.47,'-,[1.61-3.78],U3,"Capecitabine-induced hand-foot syndrome in breast or colorectal cancer","cancer, Hand-foot syndrome, response to fluoropyrimidines",GCST011420,3:30257774
rs2420903-<b>?</b>,"9 x 10-6",,0.41,0.52,'-,[0.39-0.69],RPL19P16,"Capecitabine-induced hand-foot syndrome in breast or colorectal cancer","cancer, Hand-foot syndrome, response to fluoropyrimidines",GCST011420,10:121042993
rs6093063-<b>?</b>,"1 x 10-7",,0.17,2.16,'-,[1.62–2.88],LINC01718,"Capecitabine-induced hand-foot syndrome in breast or colorectal cancer","cancer, Hand-foot syndrome, response to fluoropyrimidines",GCST011420,20:61148101
rs6129058-<b>?</b>,"1 x 10-8",,0.19,2.4,'-,[1.78-3.25],"LINC01718, CDH4","Capecitabine-induced hand-foot syndrome in breast or colorectal cancer","cancer, Hand-foot syndrome, response to fluoropyrimidines",GCST011420,20:61157266
rs62103056-<b>A</b>,"4 x 10-8",,0.25,2.98,'-,[1.99-4.46],'-,"Tafenoquine efficacy in P. vivax malaria (recurrence by 6 months)","Plasmodium vivax malaria, disease recurrence, response to tafenoquine",GCST010503,18:43844132
rs11104986-<b>G</b>,"4 x 10-9",,'-,42.3,'-,[7.95–225.10],RNU1-117P,"Tafenoquine efficacy in P. vivax malaria (recurrence by 4 months)","Plasmodium vivax malaria, disease recurrence, response to tafenoquine",GCST010502,12:88657857
rs4917014-<b>?</b>,"8 x 10-11",,'-,2,'-,[1.43-2.50],IKZF1,"Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe mucosal involvement","Stevens-Johnson syndrome, toxic epidermal necrolysis, response to cold medicine",GCST002779,7:50266267
rs78310016-<b>G</b>,"4 x 10-8",,0.0726,'-,"1.052 unit increase",NR,"PRELID3BP7, PRELID3BP6","Weight gain in amisulpride-treated first-episode psychosis","psychosis, longitudinal BMI measurement, response to amisulpride",GCST010007,5:42949533
rs57818938-<b>T</b>,"1 x 10-6",,0.0611,'-,"0.9321 unit increase",NR,"EBF1, Y_RNA","Weight gain in amisulpride-treated first-episode psychosis","psychosis, longitudinal BMI measurement, response to amisulpride",GCST010007,5:2277955
rs10278819-<b>C</b>,"2 x 10-6",,0.1023,'-,"0.873 unit increase",NR,TMBIM7P,"Weight gain in amisulpride-treated first-episode psychosis","psychosis, longitudinal BMI measurement, response to amisulpride",GCST010007,7:92428006
rs7024062-<b>A</b>,"2 x 10-6",,0.1931,'-,"0.5885 unit decrease",NR,TJP2,"Weight gain in amisulpride-treated first-episode psychosis","psychosis, longitudinal BMI measurement, response to amisulpride",GCST010007,9:69130157
rs10070777-<b>A</b>,"4 x 10-6",,0.0743,'-,"0.8786 unit increase",NR,TMEM161B,"Weight gain in amisulpride-treated first-episode psychosis","psychosis, longitudinal BMI measurement, response to amisulpride",GCST010007,5:88128948
rs13230004-<b>A</b>,"4 x 10-6",,0.2724,'-,"0.5336 unit increase",NR,SLC29A4,"Weight gain in amisulpride-treated first-episode psychosis","psychosis, longitudinal BMI measurement, response to amisulpride",GCST010007,7:5305719
rs1048163-<b>G</b>,"5 x 10-6",,0.3383,'-,"0.4495 unit increase",NR,"BUB1B-PAK6, C15orf56, PAK6","Weight gain in amisulpride-treated first-episode psychosis","psychosis, longitudinal BMI measurement, response to amisulpride",GCST010007,15:40251022
rs927899-<b>C</b>,"9 x 10-6",,NR,'-,"0.7423 unit increase",NR,"TNNI1, PHLDA3","Weight gain in amisulpride-treated first-episode psychosis","psychosis, longitudinal BMI measurement, response to amisulpride",GCST010007,1:201459425
rs2129108-<b>A</b>,"8 x 10-6",,NR,'-,"0.7948 unit increase",NR,TTN,"Weight gain in amisulpride-treated first-episode psychosis","psychosis, longitudinal BMI measurement, response to amisulpride",GCST010007,2:178810202
rs9836481-<b>A</b>,"8 x 10-6",,NR,'-,"0.9768 unit increase",NR,MRPS31P1,"Weight gain in amisulpride-treated first-episode psychosis","psychosis, longitudinal BMI measurement, response to amisulpride",GCST010007,3:41148232
rs41501-<b>A</b>,"8 x 10-6",,NR,'-,"0.5127 unit increase",NR,"LINC02112, TAS2R1","Weight gain in amisulpride-treated first-episode psychosis","psychosis, longitudinal BMI measurement, response to amisulpride",GCST010007,5:9663747
rs28800-<b>A</b>,"5 x 10-6",,NR,'-,"0.5223 unit increase",NR,"LINC02112, TAS2R1","Weight gain in amisulpride-treated first-episode psychosis","psychosis, longitudinal BMI measurement, response to amisulpride",GCST010007,5:9666433
rs28716841-<b>C</b>,"9 x 10-6",,NR,'-,"0.8716 unit increase",NR,FSTL4,"Weight gain in amisulpride-treated first-episode psychosis","psychosis, longitudinal BMI measurement, response to amisulpride",GCST010007,5:133397775
rs11979775-<b>C</b>,"5 x 10-6",,NR,'-,"0.5007 unit increase",NR,SLC29A4,"Weight gain in amisulpride-treated first-episode psychosis","psychosis, longitudinal BMI measurement, response to amisulpride",GCST010007,7:5302782
rs112045010-<b>C</b>,"5 x 10-6",,NR,'-,"0.9056 unit increase",NR,C12orf56,"Weight gain in amisulpride-treated first-episode psychosis","psychosis, longitudinal BMI measurement, response to amisulpride",GCST010007,12:64331934
rs17834779-<b>A</b>,"7 x 10-6",,NR,'-,"0.4471 unit increase",NR,"KCNH5, ATP5F1AP4","Weight gain in amisulpride-treated first-episode psychosis","psychosis, longitudinal BMI measurement, response to amisulpride",GCST010007,14:62656081
rs1048164-<b>A</b>,"9 x 10-6",,NR,'-,"0.4365 unit increase",NR,"C15orf56, PAK6, BUB1B-PAK6","Weight gain in amisulpride-treated first-episode psychosis","psychosis, longitudinal BMI measurement, response to amisulpride",GCST010007,15:40250903
rs76356591-<b>T</b>,"6 x 10-6",,NR,'-,"0.5878 unit increase",NR,"SRL, ADCY9","Weight gain in amisulpride-treated first-episode psychosis","psychosis, longitudinal BMI measurement, response to amisulpride",GCST010007,16:4137064
rs17546654-<b>A</b>,"7 x 10-6",,NR,'-,"0.5526 unit increase",NR,"GFAP, KIF18B","Weight gain in amisulpride-treated first-episode psychosis","psychosis, longitudinal BMI measurement, response to amisulpride",GCST010007,17:44917727
rs8092589-<b>A</b>,"9 x 10-6",,NR,'-,"0.4724 unit increase",NR,SLC14A2,"Weight gain in amisulpride-treated first-episode psychosis","psychosis, longitudinal BMI measurement, response to amisulpride",GCST010007,18:45649289
rs10426669-<b>G</b>,"6 x 10-6",,NR,'-,"0.7649 unit increase",NR,SEMA6B,"Weight gain in amisulpride-treated first-episode psychosis","psychosis, longitudinal BMI measurement, response to amisulpride",GCST010007,19:4564769
rs6453204-<b>?</b>,"6 x 10-8",,NR,3.3,'-,[NR],SV2C,"Response to chemotherapy in breast cancer (hypertension) (bevacizumab)","response to bevacizumab, breast carcinoma, chemotherapy-induced hypertension",GCST002567,5:76143375
rs130318-<b>?</b>,"4 x 10-6",,NR,1.72,'-,[NR],PARVB,"Response to chemotherapy in breast cancer (hypertension) (bevacizumab)","response to bevacizumab, breast carcinoma, chemotherapy-induced hypertension",GCST002567,22:44080184
rs1943466-<b>?</b>,"1 x 10-6",,NR,1.82,'-,[NR],GRAMD1B,"Response to chemotherapy in breast cancer (hypertension) (bevacizumab)","response to bevacizumab, breast carcinoma, chemotherapy-induced hypertension",GCST002567,11:123393934
rs10916661-<b>A</b>,"7 x 10-6","(conditional on rs749671,CYP2C9*2 and CYP2C9*3, Brazilians)",0.326,4.426,'-,[NR],"OTUD3, RNF186","Warfarin maintenance dose","response to anticoagulant",GCST003085,1:19875286
rs6675828-<b>A</b>,"7 x 10-6","(conditional on rs749671,CYP2C9*2 and CYP2C9*3, Brazilians)",0.296,5.457,'-,[NR],BCL9,"Warfarin maintenance dose","response to anticoagulant",GCST003085,1:147615167
rs34707540-<b>C</b>,"8 x 10-6","(conditional on rs749671,CYP2C9*2 and CYP2C9*3, Brazilians)",0.631,4.56621,'-,[NR],Y_RNA,"Warfarin maintenance dose","response to anticoagulant",GCST003085,2:143884221
rs6897106-<b>C</b>,"1 x 10-6","(conditional on rs749671,CYP2C9*2 and CYP2C9*3, Brazilians)",0.354,5.653,'-,[NR],CAMK4,"Warfarin maintenance dose","response to anticoagulant",GCST003085,5:111434090
rs2065415-<b>G</b>,"2 x 10-6","(conditional on rs749671,CYP2C9*2 and CYP2C9*3, Brazilians)",0.889,12.913,'-,[NR],ADTRP,"Warfarin maintenance dose","response to anticoagulant",GCST003085,6:169037250
rs6904125-<b>G</b>,"8 x 10-6","(conditional on rs749671,CYP2C9*2 and CYP2C9*3, Brazilians)",0.471,5.4945054,'-,[NR],"SLC35F1, RPL12P23","Warfarin maintenance dose","response to anticoagulant",GCST003085,6:170191780
rs245880-<b>A</b>,"8 x 10-6","(conditional on rs749671,CYP2C9*2 and CYP2C9*3, Brazilians)",0.531,4.6948357,'-,[NR],"CHN2, CPVL","Warfarin maintenance dose","response to anticoagulant",GCST003085,7:29146640
rs1123970-<b>T</b>,"4 x 10-6","(conditional on rs749671,CYP2C9*2 and CYP2C9*3, Brazilians)",0.816,7.3529406,'-,[NR],"VLDLR-AS1, RN7SL592P","Warfarin maintenance dose","response to anticoagulant",GCST003085,9:2328213
rs878939-<b>G</b>,"9 x 10-7","(conditional on rs749671,CYP2C9*2 and CYP2C9*3, Brazilians)",0.208,6.431,'-,[NR],"SLC25A28, NKX2-3","Warfarin maintenance dose","response to anticoagulant",GCST003085,10:99583184
rs11022131-<b>C</b>,"3 x 10-6","(conditional on rs749671,CYP2C9*2 and CYP2C9*3, Brazilians)",0.761,6.535948,'-,[NR],LINC02547,"Warfarin maintenance dose","response to anticoagulant",GCST003085,11:12050666
rs72739921-<b>A</b>,"3 x 10-6","(conditional on rs749671,CYP2C9*2 and CYP2C9*3, Brazilians)",0.831,6.9930067,'-,[NR],"FOXB1, NMNAT1P5","Warfarin maintenance dose","response to anticoagulant",GCST003085,15:59978551
rs200639-<b>G</b>,"9 x 10-6","(conditional on rs749671,CYP2C9*2 and CYP2C9*3, Brazilians)",0.646,4.157,'-,[NR],TSHZ2,"Warfarin maintenance dose","response to anticoagulant",GCST003085,20:53289738
rs157089-<b>T</b>,"3 x 10-6","(conditional on rs749671,CYP2C9*2 and CYP2C9*3, Brazilians)",0.745,5.714286,'-,[NR],PMEPA1,"Warfarin maintenance dose","response to anticoagulant",GCST003085,20:57675887
rs68043594-<b>T</b>,"1 x 10-7","(conditional on rs749671,CYP2C9*2 and CYP2C9*3, Brazilians)",0.925,55.555557,'-,[NR],'-,"Warfarin maintenance dose","response to anticoagulant",GCST003085,22:27597456
rs749671-<b>G</b>,"1 x 10-33",(Brazilian),'-,20.4,'-,[14.3-29.0],ZNF646,"Warfarin maintenance dose","response to anticoagulant",GCST003085,16:31077026
rs4918798-<b>C</b>,"2 x 10-13",(Brazilian),'-,6.22,'-,'-,"CYP2C9, CYP2C59P","Warfarin maintenance dose","response to anticoagulant",GCST003085,10:94990786
rs9923231-<b>T</b>,"3 x 10-181",,0.40,'-,"0.97 mg/week decrease",[0.91-1.02],"BCKDK, VKORC1","Warfarin maintenance dose","response to anticoagulant",GCST000360,16:31096368
rs1799853-<b>?</b>,"1 x 10-31",,0.11,'-,"0.54 mg/week decrease",[0.45-0.63],CYP2C9,"Warfarin maintenance dose","response to anticoagulant",GCST000360,10:94942290
rs2108622-<b>?</b>,"3 x 10-10",,0.24,'-,"0.21 mg/week increase",[0.14-0.27],CYP4F2,"Warfarin maintenance dose","response to anticoagulant",GCST000360,19:15879621
rs1057910-<b>?</b>,"3 x 10-79",,0.07,'-,"1.11 mg/week decrease",[1.00-1.22],CYP2C9,"Warfarin maintenance dose","response to anticoagulant",GCST000360,10:94981296
rs10871454-<b>?</b>,"5 x 10-34",,NR,'-,'-,'-,STX4,"Warfarin maintenance dose","response to anticoagulant",GCST000204,16:31036758
rs4086116-<b>?</b>,"6 x 10-12",,NR,'-,'-,'-,CYP2C9,"Warfarin maintenance dose","response to anticoagulant",GCST000204,10:94947445
rs216013-<b>?</b>,"9 x 10-7",,NR,'-,'-,'-,CACNA1C,"Warfarin maintenance dose","response to anticoagulant",GCST000204,12:2620466
CYP2C19*2-<b>?</b>,"1 x 10-16",,NR,'-,'-,'-,'-,"Response to clopidogrel therapy","platelet reactivity measurement, response to clopidogrel",GCST004266,"Mapping not available"
rs78087832-<b>?</b>,"6 x 10-7",,'-,2.731,'-,[1.933-3.857],CUL3,"Response to bupropion and depression","unipolar depression, response to bupropion, mood disorder",GCST003806,2:224600060
rs73425402-<b>?</b>,"1 x 10-6",,'-,20.833332,'-,[8.26-52.63],NAV3,"Response to bupropion and depression","unipolar depression, response to bupropion, mood disorder",GCST003806,12:77503518
rs112538845-<b>?</b>,"6 x 10-7",,'-,1.637,'-,[1.366-1.961],"STOX2, ENPP6","Response to bupropion and depression","unipolar depression, response to bupropion, mood disorder",GCST003806,4:184084475
rs112106319-<b>?</b>,"1 x 10-6",,'-,2.3255813,'-,[1.59-3.4],"TNC, DELEC1","Response to bupropion and depression","unipolar depression, response to bupropion, mood disorder",GCST003806,9:115094539
rs190783615-<b>?</b>,"2 x 10-17",,'-,15.18,'-,[3.095-74.439],'-,"Non-response to bupropion and depression","unipolar depression, response to bupropion, mood disorder",GCST003804,X:142772620
rs201203751-<b>?</b>,"5 x 10-7",,'-,4.009,'-,[2.537-6.336],FYB1,"Non-response to bupropion and depression","unipolar depression, response to bupropion, mood disorder",GCST003804,5:39203496
rs183124483-<b>?</b>,"6 x 10-7",,'-,14.925372,'-,[6.85-32.26],NLK,"Non-response to bupropion and depression","unipolar depression, response to bupropion, mood disorder",GCST003804,17:28110028
rs56388524-<b>?</b>,"7 x 10-7",,'-,1.798,'-,[1.451-2.228],HCN1,"Non-response to bupropion and depression","unipolar depression, response to bupropion, mood disorder",GCST003804,5:45757459
rs143405544-<b>?</b>,"7 x 10-7",,'-,6.711409,'-,[2.44-18.52],ADAMTS6,"Non-response to bupropion and depression","unipolar depression, response to bupropion, mood disorder",GCST003804,5:65459777
rs183042538-<b>?</b>,"8 x 10-7",,'-,1.431,'-,[1.249-1.638],ZHX3,"Non-response to bupropion and depression","unipolar depression, response to bupropion, mood disorder",GCST003804,20:41197420
rs200855945-<b>?</b>,"4 x 10-7",,'-,4.929,'-,[2.35-10.34],"SSPN, BHLHE41","Response to bupropion and depression","unipolar depression, response to bupropion, mood disorder",GCST003806,12:26124961
rs1908557-<b>T</b>,"3 x 10-8",,'-,1.348,'-,[1.213-1.497],'-,"Response to bupropion in depression","unipolar depression, response to bupropion, mood disorder",GCST003800,4:89500202
rs77945277-<b>?</b>,"2 x 10-7",,'-,11.111111,'-,[3.83-32.26],BAZ1A,"Response to bupropion in depression","unipolar depression, response to bupropion, mood disorder",GCST003800,14:34840969
rs4839421-<b>?</b>,"5 x 10-7",,'-,1.249,'-,[1.146-1.362],"CYMP, PROK1","Response to bupropion in depression","unipolar depression, response to bupropion, mood disorder",GCST003800,1:110479338
rs75995702-<b>?</b>,"7 x 10-7",,'-,12.857,'-,[3.496-47.288],'-,"Response to bupropion in depression","unipolar depression, response to bupropion, mood disorder",GCST003800,11:42785177
rs34102224-<b>?</b>,"1 x 10-6",,'-,1.354,'-,[1.197-1.531],'-,"Response to bupropion in depression","unipolar depression, response to bupropion, mood disorder",GCST003800,8:5364506
rs6691722-<b>?</b>,"6 x 10-6",,0.5191,2.37,'-,[NR],GRHL3,"Response to interferon beta in multiple sclerosis","multiple sclerosis, response to interferon beta",GCST003193,1:24347376
rs16898029-<b>?</b>,"2 x 10-6",,0.8798,4.69,'-,[NR],LINC02357,"Response to interferon beta in multiple sclerosis","multiple sclerosis, response to interferon beta",GCST003193,4:19045994
rs12957214-<b>C</b>,"6 x 10-6",,0.1305,4.1219,'-,[NR],MIR924HG,"Response to interferon beta in multiple sclerosis","multiple sclerosis, response to interferon beta",GCST003193,18:39355576
rs7549785-<b>?</b>,"5 x 10-7","(endpoint 6, East Asian)",'-,8.22,'-,[NR],FCER1A,"Peginterferon alfa-2a treatment response in chronic hepatitis B infection","response to peginterferon alfa-2a, chronic hepatitis B virus infection",GCST008514,1:159308078
rs9287655-<b>?</b>,"1 x 10-6","(endpoint 4, additive)",'-,1.5151515,'-,[NR],NBAS,"Peginterferon alfa-2a treatment response in chronic hepatitis B infection","response to peginterferon alfa-2a, chronic hepatitis B virus infection",GCST008514,2:15245360
rs9287655-<b>?</b>,"1 x 10-6","(endpoint 5, additive)",'-,1.5625,'-,[NR],NBAS,"Peginterferon alfa-2a treatment response in chronic hepatitis B infection","response to peginterferon alfa-2a, chronic hepatitis B virus infection",GCST008514,2:15245360
rs1550116-<b>?</b>,"8 x 10-6","(endpoint 5, East Asian, additive)",'-,1.7857143,'-,[NR],CENPO,"Peginterferon alfa-2a treatment response in chronic hepatitis B infection","response to peginterferon alfa-2a, chronic hepatitis B virus infection",GCST008514,2:24799729
rs2082881-<b>?</b>,"7 x 10-6","(endpoint 5, East Asian, additive)",'-,1.7857143,'-,[NR],CENPO,"Peginterferon alfa-2a treatment response in chronic hepatitis B infection","response to peginterferon alfa-2a, chronic hepatitis B virus infection",GCST008514,2:24815399
rs1550115-<b>?</b>,"7 x 10-6","(endpoint 5, East Asian, additive)",'-,1.7857143,'-,[NR],CENPO,"Peginterferon alfa-2a treatment response in chronic hepatitis B infection","response to peginterferon alfa-2a, chronic hepatitis B virus infection",GCST008514,2:24818751
rs1040084-<b>?</b>,"4 x 10-6","(endpoint 3, additive)",'-,2.37,'-,[NR],"LNX1-AS1, LNX1","Peginterferon alfa-2a treatment response in chronic hepatitis B infection","response to peginterferon alfa-2a, chronic hepatitis B virus infection",GCST008514,4:53544057
rs1913484-<b>?</b>,"4 x 10-6","(endpoint 3, dominant)",'-,2.36,'-,[NR],"LNX1, LNX1-AS1","Peginterferon alfa-2a treatment response in chronic hepatitis B infection","response to peginterferon alfa-2a, chronic hepatitis B virus infection",GCST008514,4:53544157
rs2803073-<b>?</b>,"3 x 10-6","(endpoint 4, additive)",'-,1.5,'-,[NR],PRKN,"Peginterferon alfa-2a treatment response in chronic hepatitis B infection","response to peginterferon alfa-2a, chronic hepatitis B virus infection",GCST008514,6:162541796
rs10236906-<b>?</b>,"8 x 10-6","(endpoint 4, dominant)",'-,1.754386,'-,[NR],HDAC9,"Peginterferon alfa-2a treatment response in chronic hepatitis B infection","response to peginterferon alfa-2a, chronic hepatitis B virus infection",GCST008514,7:18700047
rs9691873-<b>?</b>,"9 x 10-6","(endpoint 5, East Asian)",'-,'-,'-,[NR],CREB5,"Peginterferon alfa-2a treatment response in chronic hepatitis B infection","response to peginterferon alfa-2a, chronic hepatitis B virus infection",GCST008514,7:28690392
rs2370220-<b>?</b>,"8 x 10-6","(endpoint 5, dominant)",'-,1.75,'-,[NR],DMRT1,"Peginterferon alfa-2a treatment response in chronic hepatitis B infection","response to peginterferon alfa-2a, chronic hepatitis B virus infection",GCST008514,9:917667
rs10814834-<b>?</b>,"7 x 10-6","(endpoint 6, dominant)",'-,2.173913,'-,[NR],GLIS3,"Peginterferon alfa-2a treatment response in chronic hepatitis B infection","response to peginterferon alfa-2a, chronic hepatitis B virus infection",GCST008514,9:4086370
rs7042473-<b>?</b>,"5 x 10-6","(endpoint 4, dominant)",'-,1.71,'-,[NR],CDC14B,"Peginterferon alfa-2a treatment response in chronic hepatitis B infection","response to peginterferon alfa-2a, chronic hepatitis B virus infection",GCST008514,9:96584288
rs10491723-<b>?</b>,"5 x 10-6","(endpoint 6, additive)",'-,2.11,'-,[NR],CORO2A,"Peginterferon alfa-2a treatment response in chronic hepatitis B infection","response to peginterferon alfa-2a, chronic hepatitis B virus infection",GCST008514,9:98165350
rs1411283-<b>?</b>,"9 x 10-6","(endpoint 1, dominant)",'-,2.0408163,'-,[NR],ANKRD26,"Peginterferon alfa-2a treatment response in chronic hepatitis B infection","response to peginterferon alfa-2a, chronic hepatitis B virus infection",GCST008514,10:27013843
rs2279519-<b>?</b>,"8 x 10-6","(endpoint 5, dominant)",'-,1.75,'-,[NR],GRAMD1B,"Peginterferon alfa-2a treatment response in chronic hepatitis B infection","response to peginterferon alfa-2a, chronic hepatitis B virus infection",GCST008514,11:123606644
rs216312-<b>?</b>,"5 x 10-6","(endpoint 5, dominant)",'-,1.5151515,'-,[NR],VWF,"Peginterferon alfa-2a treatment response in chronic hepatitis B infection","response to peginterferon alfa-2a, chronic hepatitis B virus infection",GCST008514,12:6019818
rs7968170-<b>?</b>,"5 x 10-6","(endpoint 4, East Asian, dominant)",'-,2.0408163,'-,[NR],DERA,"Peginterferon alfa-2a treatment response in chronic hepatitis B infection","response to peginterferon alfa-2a, chronic hepatitis B virus infection",GCST008514,12:15996401
rs7968170-<b>?</b>,"5 x 10-6","(endpoint 5, East Asian, dominant)",'-,2.173913,'-,[NR],DERA,"Peginterferon alfa-2a treatment response in chronic hepatitis B infection","response to peginterferon alfa-2a, chronic hepatitis B virus infection",GCST008514,12:15996401
rs8012912-<b>?</b>,"7 x 10-6","(endpoint 5, East Asian, additive)",'-,1.62,'-,[NR],SMOC1,"Peginterferon alfa-2a treatment response in chronic hepatitis B infection","response to peginterferon alfa-2a, chronic hepatitis B virus infection",GCST008514,14:70007490
rs11158827-<b>?</b>,"8 x 10-6","(endpoint 5, East Asian, additive)",'-,1.62,'-,[NR],SMOC1,"Peginterferon alfa-2a treatment response in chronic hepatitis B infection","response to peginterferon alfa-2a, chronic hepatitis B virus infection",GCST008514,14:70012457
rs6576456-<b>?</b>,"8 x 10-6","(endpoint 3, dominant)",'-,2.4390244,'-,[NR],ATP10A,"Peginterferon alfa-2a treatment response in chronic hepatitis B infection","response to peginterferon alfa-2a, chronic hepatitis B virus infection",GCST008514,15:25764093
rs2899723-<b>?</b>,"3 x 10-6","(endpoint 3, additive)",'-,2.04,'-,[NR],"IQCH, IQCH-AS1","Peginterferon alfa-2a treatment response in chronic hepatitis B infection","response to peginterferon alfa-2a, chronic hepatitis B virus infection",GCST008514,15:67443685
rs646097-<b>?</b>,"9 x 10-6","(endpoint 2, dominant)",'-,2.173913,'-,[NR],LASP1,"Peginterferon alfa-2a treatment response in chronic hepatitis B infection","response to peginterferon alfa-2a, chronic hepatitis B virus infection",GCST008514,17:38920078
rs10760490-<b>A</b>,"7 x 10-6",,0.03,2.93,'-,[1.80-4.77],NIBAN2,"Motor fluctuations in levodopa treated Parkinson's disease","Parkinson's disease, motor function measurement, response to levodopa",GCST011066,9:127573139
rs150380018-<b>G</b>,"8 x 10-6",,0.01,6.53,'-,[2.54-16.79],SNX29,"Motor fluctuations in levodopa treated Parkinson's disease","Parkinson's disease, motor function measurement, response to levodopa",GCST011066,16:12475931
rs10051838-<b>A</b>,"9 x 10-6",,0.09,2.09,'-,[1.50-2.91],C5orf52,"Motor fluctuations in levodopa treated Parkinson's disease","Parkinson's disease, motor function measurement, response to levodopa",GCST011066,5:157675151
rs77462941-<b>C</b>,"9 x 10-6",0.13,'-,0.5,'-,[0.36-0.68],STK10,"Motor fluctuations in levodopa treated Parkinson's disease","Parkinson's disease, motor function measurement, response to levodopa",GCST011066,5:172171430
rs11868362-<b>?</b>,"4 x 10-6","(endpoint 2, East Asian)",'-,2.9411764,'-,[NR],MSI2,"Peginterferon alfa-2a treatment response in chronic hepatitis B infection","response to peginterferon alfa-2a, chronic hepatitis B virus infection",GCST008514,17:57420875
rs16943470-<b>?</b>,"5 x 10-6","(endpoint 6, dominant)",'-,2.97,'-,[NR],YPEL2,"Peginterferon alfa-2a treatment response in chronic hepatitis B infection","response to peginterferon alfa-2a, chronic hepatitis B virus infection",GCST008514,17:59369227
rs4835796-<b>G</b>,"6 x 10-7","(phenotype 1)",NR,2.89,'-,[NR],REEP2,"Response to abacavir-containing treatment in HIV-1 infection (virologic failure)","HIV-1 infection, virologic response measurement, response to abacavir",GCST002769,5:138446426
rs7623430-<b>G</b>,"7 x 10-6","(phenotype 1)",NR,3.03,'-,[NR],RFC3P1,"Response to abacavir-containing treatment in HIV-1 infection (virologic failure)","HIV-1 infection, virologic response measurement, response to abacavir",GCST002769,3:36169851
rs11714574-<b>T</b>,"9 x 10-6","(phenotype 1)",NR,2.38,'-,[NR],PXK,"Response to abacavir-containing treatment in HIV-1 infection (virologic failure)","HIV-1 infection, virologic response measurement, response to abacavir",GCST002769,3:58394738
rs4869908-<b>G</b>,"8 x 10-6","(phenotype 1)",NR,2.5,'-,[NR],IYD,"Response to abacavir-containing treatment in HIV-1 infection (virologic failure)","HIV-1 infection, virologic response measurement, response to abacavir",GCST002769,6:150423701
rs4726279-<b>T</b>,"9 x 10-6","(phenotype 1)",NR,2.7,'-,[NR],LINC01287,"Response to abacavir-containing treatment in HIV-1 infection (virologic failure)","HIV-1 infection, virologic response measurement, response to abacavir",GCST002769,7:153359535
rs30388-<b>T</b>,"1 x 10-6","(phenotype 1)",NR,2.88,'-,[NR],MAF,"Response to abacavir-containing treatment in HIV-1 infection (virologic failure)","HIV-1 infection, virologic response measurement, response to abacavir",GCST002769,16:79580219
rs12953285-<b>C</b>,"3 x 10-6","(phenotype 1)",NR,5.88,'-,[NR],SEPTIN9-DT,"Response to abacavir-containing treatment in HIV-1 infection (virologic failure)","HIV-1 infection, virologic response measurement, response to abacavir",GCST002769,17:77261905
rs11803434-<b>G</b>,"2 x 10-6","(phenotype 2)",NR,3.57,'-,[NR],"PTP4A2, SPOCD1","Response to abacavir-containing treatment in HIV-1 infection (virologic failure)","HIV-1 infection, virologic response measurement, response to abacavir",GCST002769,1:31862344
rs7576600-<b>G</b>,"3 x 10-7","(phenotype 2)",NR,5.26,'-,[NR],LINC01794,"Response to abacavir-containing treatment in HIV-1 infection (virologic failure)","HIV-1 infection, virologic response measurement, response to abacavir",GCST002769,2:40840846
rs10516173-<b>T</b>,"5 x 10-6","(phenotype 2)",NR,2.85,'-,[NR],STK32B,"Response to abacavir-containing treatment in HIV-1 infection (virologic failure)","HIV-1 infection, virologic response measurement, response to abacavir",GCST002769,4:5151418
rs1913633-<b>A</b>,"4 x 10-6","(phenotype 2)",NR,3.84,'-,[NR],LARP1BP1,"Response to abacavir-containing treatment in HIV-1 infection (virologic failure)","HIV-1 infection, virologic response measurement, response to abacavir",GCST002769,4:63448265
rs6594357-<b>T</b>,"8 x 10-7","(phenotype 2)",NR,3.33,'-,[NR],FER,"Response to abacavir-containing treatment in HIV-1 infection (virologic failure)","HIV-1 infection, virologic response measurement, response to abacavir",GCST002769,5:109205522
rs61501627-<b>C</b>,"4 x 10-6","(phenotype 2)",NR,4.35,'-,[NR],LINC02694,"Response to abacavir-containing treatment in HIV-1 infection (virologic failure)","HIV-1 infection, virologic response measurement, response to abacavir",GCST002769,15:38932685
rs1491976-<b>G</b>,"5 x 10-6","(phenotype 3)",NR,2.33,'-,[NR],"IGSF10, MRPL42P6","Response to abacavir-containing treatment in HIV-1 infection (virologic failure)","HIV-1 infection, virologic response measurement, response to abacavir",GCST002769,3:151465283
rs17169-<b>T</b>,"1 x 10-7","(phenotype 3)",NR,2.97,'-,[NR],"LINC00299, LINC00298","Response to abacavir-containing treatment in HIV-1 infection (virologic failure)","HIV-1 infection, virologic response measurement, response to abacavir",GCST002769,2:8037334
rs13064773-<b>A</b>,"8 x 10-7","(phenotype 3)",NR,2.26,'-,[NR],"GPR79, IQCJ-SCHIP1","Response to abacavir-containing treatment in HIV-1 infection (virologic failure)","HIV-1 infection, virologic response measurement, response to abacavir",GCST002769,3:158893105
rs9358749-<b>T</b>,"5 x 10-6","(phenotype 3)",NR,3.27,'-,[NR],"HNRNPA1P58, NRSN1","Response to abacavir-containing treatment in HIV-1 infection (virologic failure)","HIV-1 infection, virologic response measurement, response to abacavir",GCST002769,6:24077829
rs608114-<b>A</b>,"3 x 10-7","(phenotype 3)",NR,4.84,'-,[NR],KRT18P50,"Response to abacavir-containing treatment in HIV-1 infection (virologic failure)","HIV-1 infection, virologic response measurement, response to abacavir",GCST002769,6:95928822
rs62432346-<b>A</b>,"5 x 10-6","(phenotype 3)",NR,4.6,'-,[NR],TSTD3,"Response to abacavir-containing treatment in HIV-1 infection (virologic failure)","HIV-1 infection, virologic response measurement, response to abacavir",GCST002769,6:99541358
rs538174-<b>C</b>,"5 x 10-6","(phenotype 3)",NR,2.44,'-,[NR],OPRM1,"Response to abacavir-containing treatment in HIV-1 infection (virologic failure)","HIV-1 infection, virologic response measurement, response to abacavir",GCST002769,6:154131402
rs16933829-<b>C</b>,"1 x 10-6","(phenotype 3)",NR,4.76,'-,[NR],PIK3C2A,"Response to abacavir-containing treatment in HIV-1 infection (virologic failure)","HIV-1 infection, virologic response measurement, response to abacavir",GCST002769,11:17094129
rs117526668-<b>T</b>,"9 x 10-6","(phenotype 3)",NR,3.19,'-,[NR],ALX4,"Response to abacavir-containing treatment in HIV-1 infection (virologic failure)","HIV-1 infection, virologic response measurement, response to abacavir",GCST002769,11:44263881
rs16966918-<b>A</b>,"5 x 10-6","(phenotype 3)",NR,4.01,'-,[NR],DAOA-AS1,"Response to abacavir-containing treatment in HIV-1 infection (virologic failure)","HIV-1 infection, virologic response measurement, response to abacavir",GCST002769,13:105595684
rs11649112-<b>A</b>,"1 x 10-6","(phenotype 3)",NR,2.49,'-,[NR],SHISA9,"Response to abacavir-containing treatment in HIV-1 infection (virologic failure)","HIV-1 infection, virologic response measurement, response to abacavir",GCST002769,16:13267554
rs74976893-<b>T</b>,"4 x 10-6","(phenotype 3)",NR,4.18,'-,[NR],'-,"Response to abacavir-containing treatment in HIV-1 infection (virologic failure)","HIV-1 infection, virologic response measurement, response to abacavir",GCST002769,17:71733784
rs9961574-<b>G</b>,"3 x 10-6","(phenotype 3)",NR,2.33,'-,[NR],"THEMIS3P, AKR1B1P6","Response to abacavir-containing treatment in HIV-1 infection (virologic failure)","HIV-1 infection, virologic response measurement, response to abacavir",GCST002769,18:8536118
rs62096106-<b>G</b>,"9 x 10-6","(phenotype 3)",NR,3.57,'-,[NR],PIGN,"Response to abacavir-containing treatment in HIV-1 infection (virologic failure)","HIV-1 infection, virologic response measurement, response to abacavir",GCST002769,18:62171686
rs830884-<b>?</b>,"2 x 10-6",,NR,3.13,'-,[1.85-5.26],ITGA1,"Response to platinum-based agents","response to platinum based chemotherapy",GCST001291,5:52724562
rs760816-<b>A</b>,"1 x 10-7",,NR,'-,"13.7849 unit decrease",[8.92-18.65],"MROH9, AJAP1","Response to haloperidol in schizophrenia","schizophrenia, response to haloperidol",GCST006298,1:4796871
rs929255-<b>C</b>,"8 x 10-7",,NR,'-,"14.7695 unit increase",[9.11-20.43],"NPVF, U3","Response to haloperidol in schizophrenia","schizophrenia, response to haloperidol",GCST006298,7:25233001
rs13338060-<b>G</b>,"6 x 10-6",,NR,'-,"11.0966 unit decrease",[6.43-15.76],CNTNAP4,"Response to haloperidol in schizophrenia","schizophrenia, response to haloperidol",GCST006298,16:76494737
rs73770737-<b>G</b>,"6 x 10-6",,NR,'-,"13.4294 unit increase",[7.78-19.08],MIR3660,"Response to haloperidol in schizophrenia","schizophrenia, response to haloperidol",GCST006298,5:89917211
rs138126300-<b>A</b>,"7 x 10-6",,NR,'-,"11.6948 unit increase",[6.75-16.63],ZNF665,"Response to haloperidol in schizophrenia","schizophrenia, response to haloperidol",GCST006298,19:53167698
rs1885572-<b>A</b>,"9 x 10-6",,NR,'-,"12.6252 unit decrease",[7.2-18.05],"Y_RNA, SNRPB2","Response to haloperidol in schizophrenia","schizophrenia, response to haloperidol",GCST006298,20:16679517
rs75165563-<b>C</b>,"7 x 10-7",,0.070,3.28,'-,[2.02-5.33],EXOC5,"Response to ranibizumab in age-related macular degeneration (exudative)","response to ranibizumab, wet macular degeneration",GCST006277,14:57220928
rs76150532-<b>A</b>,"2 x 10-6",,0.086,2.6,'-,[1.74-3.88],"KCNMA1, KCNMA1-AS3","Response to ranibizumab in age-related macular degeneration (exudative)","response to ranibizumab, wet macular degeneration",GCST006277,10:77371216
rs17822656-<b>G</b>,"2 x 10-6",,0.098,2.66,'-,[1.76-4.00],ZPLD1,"Response to ranibizumab in age-related macular degeneration (exudative)","response to ranibizumab, wet macular degeneration",GCST006277,3:102470325
rs17296444-<b>T</b>,"7 x 10-6",,0.102,2.43,'-,[1.64-3.59],"RN7SKP263, PLXNC1","Response to ranibizumab in age-related macular degeneration (exudative)","response to ranibizumab, wet macular degeneration",GCST006277,12:94056796
A*33:01-B*14:02-C*08:02-<b>?</b>,"1 x 10-10",,0.009,49.2,'-,'-,'-,"Drug-induced liver injury (terbinafine)","drug-induced liver injury, response to terbinafine",GCST004078,"Mapping not available"
rs7572081-<b>?</b>,"5 x 10-7",,'-,'-,'-,'-,NBAS,"Response to platinum-based chemotherapy (carboplatin)","response to carboplatin",GCST001204,2:15369022
rs2518590-<b>?</b>,"8 x 10-6",,'-,'-,'-,'-,"QDPR, RPS7P6","Response to platinum-based chemotherapy (carboplatin)","response to carboplatin",GCST001204,4:17433467
rs4326884-<b>?</b>,"8 x 10-7",,'-,'-,'-,'-,PDE3A,"Response to platinum-based chemotherapy (carboplatin)","response to carboplatin",GCST001204,12:20383437
rs3893319-<b>?</b>,"1 x 10-6",,'-,'-,'-,'-,IFNLR1,"Response to platinum-based chemotherapy (carboplatin)","response to carboplatin",GCST001204,1:24179559
rs9263567-<b>?</b>,"2 x 10-6",,'-,'-,'-,'-,"RNU6-1133P, C6orf15","Response to platinum-based chemotherapy (carboplatin)","response to carboplatin",GCST001204,6:31101750
rs1381451-<b>?</b>,"7 x 10-6",,'-,'-,'-,'-,"RN7SKP142, LINC01571","Response to platinum-based chemotherapy (carboplatin)","response to carboplatin",GCST001204,16:51681964
rs12457254-<b>?</b>,"5 x 10-6",,'-,'-,'-,'-,"LINC01897, HMGN1P30","Response to platinum-based chemotherapy (carboplatin)","response to carboplatin",GCST001204,18:57970480
rs11574583-<b>?</b>,"6 x 10-6",,'-,'-,'-,'-,LILRB4,"Response to platinum-based chemotherapy (carboplatin)","response to carboplatin",GCST001204,19:54667327
rs17059531-<b>?</b>,"6 x 10-6",,'-,'-,'-,'-,'-,"Response to platinum-based chemotherapy (carboplatin)","response to carboplatin",GCST001204,9:73877511
rs2279168-<b>?</b>,"9 x 10-6",,'-,'-,'-,'-,AKAP13,"Response to platinum-based chemotherapy (carboplatin)","response to carboplatin",GCST001204,15:85533958
rs1155410-<b>?</b>,"2 x 10-6",,'-,'-,'-,'-,'-,"Response to platinum-based chemotherapy (carboplatin)","response to carboplatin",GCST001204,11:96796409
rs7668874-<b>?</b>,"6 x 10-6",,'-,'-,'-,'-,KRT18P21,"Response to platinum-based chemotherapy (carboplatin)","response to carboplatin",GCST001204,4:115920168
rs255788-<b>?</b>,"2 x 10-6",,'-,'-,'-,'-,'-,"Response to platinum-based chemotherapy (carboplatin)","response to carboplatin",GCST001204,5:120081372
rs7758889-<b>?</b>,"9 x 10-7",,'-,'-,'-,'-,NHSL1,"Response to platinum-based chemotherapy (carboplatin)","response to carboplatin",GCST001204,6:138600907
rs13232006-<b>?</b>,"4 x 10-6",,'-,'-,'-,'-,"XRCC2, ATP5PBP3","Response to platinum-based chemotherapy (carboplatin)","response to carboplatin",GCST001204,7:152694814
rs244899-<b>?</b>,"1 x 10-6",,'-,'-,'-,'-,"WWC1, RARS1","Response to platinum-based chemotherapy (carboplatin)","response to carboplatin",GCST001204,5:168484035
rs6758334-<b>?</b>,"9 x 10-6",,'-,'-,'-,'-,PDE1A,"Response to platinum-based chemotherapy (carboplatin)","response to carboplatin",GCST001204,2:182257311
rs1144815-<b>?</b>,"9 x 10-6",,'-,'-,'-,'-,OR14L1P,"Response to platinum-based chemotherapy (carboplatin)","response to carboplatin",GCST001204,1:247618267
rs1517114-<b>C</b>,"9 x 10-6",(G3D),0.12,4.1,'-,[2.10-8.00],C8orf34,"Response to irinotecan in non-small-cell lung cancer","response to irinotecan, non-small cell lung carcinoma",GCST001558,8:68476982
rs2745761-<b>C</b>,"6 x 10-6",(G3D),0.072,4.8,'-,[2.30-10.0],PLCB1,"Response to irinotecan in non-small-cell lung cancer","response to irinotecan, non-small cell lung carcinoma",GCST001558,20:8297296
rs16950650-<b>T</b>,"2 x 10-7","(Dominant model)",NR,30.2,'-,[8.4-109.0],ABCC4,"Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer","response to irinotecan, non-small cell lung carcinoma",GCST001901,13:95123178
rs344924-<b>?</b>,"3 x 10-7","(Recessive model)",NR,4.9,'-,[2.70-9.0],"RN7SL392P, RNU6-1031P","Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer","response to irinotecan, non-small cell lung carcinoma",GCST001901,1:67639770
rs11622887-<b>?</b>,"3 x 10-7","(Recessive model)",NR,3.5,'-,[2.20-5.60],SYNE3,"Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer","response to irinotecan, non-small cell lung carcinoma",GCST001901,14:95476110
rs13398721-<b>?</b>,"2 x 10-7","(Recessive model)",NR,7.1,'-,[3.40-14.70],"OSR1, LINC01808","Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer","response to irinotecan, non-small cell lung carcinoma",GCST001901,2:19429543
rs17635492-<b>?</b>,"4 x 10-7","(Dominant model)",NR,7.6,'-,[3.50-16.70],"RAP1BP3, DCBLD1","Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer","response to irinotecan, non-small cell lung carcinoma",GCST001901,6:117450114
rs2018683-<b>T</b>,"8 x 10-7","(Recessive model)",NR,7.8,'-,[3.4-17.7],"CPVL, TRIL","Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer","response to irinotecan, non-small cell lung carcinoma",GCST001901,7:28974579
rs7186128-<b>G</b>,"4 x 10-7","(Additive model)",NR,2.5,'-,[1.70-3.50],LMF1,"Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer","response to irinotecan, non-small cell lung carcinoma",GCST001901,16:16864058
rs7542939-<b>A</b>,"7 x 10-7",,NR,'-,"4.97 unit decrease",[2.81-7.13],"PRDM2, KAZN","Left ventricular function change in anthracycline treatment","left ventricular function, response to anthracycline-based chemotherapy",GCST004353,1:13866181
rs17530621-<b>T</b>,"4 x 10-6",,0.107,'-,'-,'-,BEND4,"Anthracycline-induced cardiotoxicity in early breast cancer","breast carcinoma, cardiotoxicity, response to anthracycline-based chemotherapy",GCST010456,4:42225480
rs6804462-<b>C</b>,"3 x 10-6",,0.039,'-,'-,'-,'-,"Anthracycline-induced cardiotoxicity in early breast cancer","breast carcinoma, cardiotoxicity, response to anthracycline-based chemotherapy",GCST010456,3:103342570
rs11894115-<b>T</b>,"5 x 10-6",(adjusted),0.395,'-,'-,'-,MPP4,"Anthracycline-induced cardiotoxicity in early breast cancer","breast carcinoma, cardiotoxicity, response to anthracycline-based chemotherapy",GCST010456,2:201647726
rs58328254-<b>A</b>,"6 x 10-6",(adjusted),0.194,'-,'-,'-,RPL7,"Anthracycline-induced cardiotoxicity in early breast cancer","breast carcinoma, cardiotoxicity, response to anthracycline-based chemotherapy",GCST010456,8:73291487
rs2113374-<b>T</b>,"1 x 10-6",,0.061,'-,'-,'-,LINC01982,"Anthracycline-induced cardiotoxicity in early breast cancer","breast carcinoma, cardiotoxicity, response to anthracycline-based chemotherapy",GCST010456,17:52431359
rs117299725-<b>A</b>,"3 x 10-6",,0.055,'-,'-,'-,"PRUNE2, PCA3","Anthracycline-induced cardiotoxicity in early breast cancer","breast carcinoma, cardiotoxicity, response to anthracycline-based chemotherapy",GCST010456,9:76808695
rs147631684-<b>A</b>,"5 x 10-6",,0.03,'-,'-,'-,CDH13,"Anthracycline-induced cardiotoxicity in early breast cancer","breast carcinoma, cardiotoxicity, response to anthracycline-based chemotherapy",GCST010456,16:83599215
rs7624766-<b>G</b>,"4 x 10-7",,0.30,2.28,'-,[1.66-3.15],"PPM1L, SNORA72","Response to methotrexate in rheumatoid arthritis","response to methotrexate, rheumatoid arthritis",GCST002375,3:160712081
rs6506569-<b>G</b>,"7 x 10-6",,0.54,1.98,'-,[1.46-2.67],PTPRM,"Response to methotrexate in rheumatoid arthritis","response to methotrexate, rheumatoid arthritis",GCST002375,18:8275859
rs7158782-<b>?</b>,"8 x 10-7",,0.11,2.13,'-,[1.58-2.87],"TCL1B, TCL1A","Adverse response to aromatase inhibitors","response to aromatase inhibitor",GCST000813,14:95702794
rs140721383-<b>?</b>,"1 x 10-8",,'-,'-,"3.4627 unit decrease",[NR],BAIAP2,"Serum uric acid levels in response to allopurinol in gout","response to allopurinol, gout, uric acid measurement",GCST004751,17:81071259
rs2725271-<b>?</b>,"1 x 10-7",,'-,'-,"0.2376 unit decrease",[NR],ABCG2,"Serum uric acid levels in response to allopurinol in gout","response to allopurinol, gout, uric acid measurement",GCST004751,4:88170035
rs7555340-<b>?</b>,"4 x 10-7",,'-,'-,"0.5635 unit decrease",[NR],ZMYM6,"Serum uric acid levels in response to allopurinol in gout","response to allopurinol, gout, uric acid measurement",GCST004751,1:35015950
rs116568708-<b>?</b>,"4 x 10-7",,'-,'-,"2.6169 unit decrease",[NR],"KCNA1, KCNA5","Serum uric acid levels in response to allopurinol in gout","response to allopurinol, gout, uric acid measurement",GCST004751,12:4988312
rs17621578-<b>?</b>,"5 x 10-7",,'-,'-,"1.488 unit decrease",[NR],NALCN,"Serum uric acid levels in response to allopurinol in gout","response to allopurinol, gout, uric acid measurement",GCST004751,13:101144683
rs62015197-<b>?</b>,"8 x 10-7",,'-,'-,"0.6263 unit decrease",[NR],MAPK6,"Serum uric acid levels in response to allopurinol in gout","response to allopurinol, gout, uric acid measurement",GCST004751,15:52048569
rs13100165-<b>?</b>,"9 x 10-7",,'-,'-,"0.2282 unit increase",[NR],"RNU6-1270P, CCDC75P1","Serum uric acid levels in response to allopurinol in gout","response to allopurinol, gout, uric acid measurement",GCST004751,3:73225138
rs2311126-<b>?</b>,"1 x 10-6",,'-,'-,"0.2314 unit increase",[NR],RAB27B,"Serum uric acid levels in response to allopurinol in gout","response to allopurinol, gout, uric acid measurement",GCST004751,18:54876130
rs13374145-<b>?</b>,"2 x 10-6",,'-,'-,"0.7635 unit decrease",[NR],FAAHP1,"Serum uric acid levels in response to allopurinol in gout","response to allopurinol, gout, uric acid measurement",GCST004751,1:46464760
rs56126557-<b>?</b>,"2 x 10-6",,'-,'-,"0.6787 unit increase",[NR],WWOX,"Serum uric acid levels in response to allopurinol in gout","response to allopurinol, gout, uric acid measurement",GCST004751,16:78744762
rs75510224-<b>?</b>,"3 x 10-6",,'-,'-,"2.5675 unit decrease",[NR],"OR8D4, OR4D5","Serum uric acid levels in response to allopurinol in gout","response to allopurinol, gout, uric acid measurement",GCST004751,11:123909685
rs57248949-<b>?</b>,"3 x 10-6",,'-,'-,"2.3533 unit decrease",[NR],"PLAAT1, VEZF1P1","Serum uric acid levels in response to allopurinol in gout","response to allopurinol, gout, uric acid measurement",GCST004751,3:193161335
rs114363471-<b>?</b>,"3 x 10-6",,'-,'-,"1.5006 unit decrease",[NR],"CYP4F34P, SNX18P26","Serum uric acid levels in response to allopurinol in gout","response to allopurinol, gout, uric acid measurement",GCST004751,13:18792141
rs74415766-<b>?</b>,"3 x 10-6",,'-,'-,"1.1992 unit decrease",[NR],"RN7SL496P, CDK13","Serum uric acid levels in response to allopurinol in gout","response to allopurinol, gout, uric acid measurement",GCST004751,7:39945012
rs77467703-<b>?</b>,"4 x 10-6",,NR,'-,"1.2586 unit decrease",'-,PKNOX2,"Serum uric acid levels in response to allopurinol in gout","response to allopurinol, gout, uric acid measurement",GCST004751,11:125227371
rs114789419-<b>?</b>,"3 x 10-6",,NR,'-,"2.5372 unit decrease",'-,"OR6M1, OR6M2P","Serum uric acid levels in response to allopurinol in gout","response to allopurinol, gout, uric acid measurement",GCST004751,11:123834718
rs75544042-<b>?</b>,"2 x 10-7",,NR,'-,"0.298 unit increase",'-,ABCG2,"Serum uric acid levels in response to allopurinol in gout","response to allopurinol, gout, uric acid measurement",GCST004751,4:88124179
rs2231142-<b>?</b>,"3 x 10-7",,'-,'-,"0.2978 unit decrease",'-,ABCG2,"Serum uric acid levels in response to allopurinol in gout","response to allopurinol, gout, uric acid measurement",GCST004751,4:88131171
rs10011796-<b>?</b>,"2 x 10-8",(EA),'-,'-,"0.2799 unit increase",[0.18-0.38],ABCG2,"Serum uric acid levels in response to allopurinol in gout","response to allopurinol, gout, uric acid measurement",GCST004751,4:88169725
rs17211056-<b>?</b>,"4 x 10-7",(EA),'-,'-,"0.6488 unit increase",[0.4-0.9],SMIM21,"Serum uric acid levels in response to allopurinol in gout","response to allopurinol, gout, uric acid measurement",GCST004751,18:75471506
rs11152031-<b>?</b>,"2 x 10-6",(EA),'-,'-,"0.2519 unit decrease",[0.15-0.35],RAB27B,"Serum uric acid levels in response to allopurinol in gout","response to allopurinol, gout, uric acid measurement",GCST004751,18:54865807
rs3762427-<b>?</b>,"2 x 10-6",(EA),'-,'-,"0.4158 unit increase",[0.25-0.59],THEM4,"Serum uric acid levels in response to allopurinol in gout","response to allopurinol, gout, uric acid measurement",GCST004751,1:151895084
rs12922040-<b>?</b>,"5 x 10-6",(EA),'-,'-,"0.2415 unit increase",[0.14-0.34],MYH11,"Serum uric acid levels in response to allopurinol in gout","response to allopurinol, gout, uric acid measurement",GCST004751,16:15775609
rs12486903-<b>?</b>,"6 x 10-6",(EA),'-,'-,"0.2336 unit decrease",[0.13-0.33],"RNU6-1270P, CCDC75P1","Serum uric acid levels in response to allopurinol in gout","response to allopurinol, gout, uric acid measurement",GCST004751,3:73227801
rs34720592-<b>?</b>,"7 x 10-6",(EA),'-,'-,"0.5237 unit decrease",[0.3-0.75],ANO2,"Serum uric acid levels in response to allopurinol in gout","response to allopurinol, gout, uric acid measurement",GCST004751,12:5770243
rs13139451-<b>?</b>,"9 x 10-6",(EA),'-,'-,"0.2559 unit decrease",[0.14-0.37],'-,"Serum uric acid levels in response to allopurinol in gout","response to allopurinol, gout, uric acid measurement",GCST004751,4:115481897
rs1934341-<b>T</b>,"3 x 10-6",,NR,'-,"0.162 mg/dL decrease",[0.093-0.231],GREM2,"Response to allopurinol in gout (change in serum uric acid levels)","response to allopurinol, gout, uric acid measurement",GCST008148,1:240558252
rs2231142-<b>T</b>,"8 x 10-11",,NR,'-,"0.293 mg/dL increase",[0.19-0.39],ABCG2,"Response to allopurinol in gout (change in serum uric acid levels)","response to allopurinol, gout, uric acid measurement",GCST008147,4:88131171
rs4320241-<b>C</b>,"1 x 10-6",,NR,'-,"20.0689 unit increase",[12.16-27.98],"RPL27AP5, GCNT4","Response to ziprazidone in schizophrenia","schizophrenia, response to ziprasidone",GCST006296,5:75003319
rs183547317-<b>T</b>,"1 x 10-6",,NR,'-,"24.2758 unit increase",[14.58-33.97],'-,"Response to ziprazidone in schizophrenia","schizophrenia, response to ziprasidone",GCST006296,4:11562007
rs3862662-<b>A</b>,"3 x 10-6",,NR,'-,"9.0566 unit increase",[5.34-12.77],ZP1,"Response to ziprazidone in schizophrenia","schizophrenia, response to ziprasidone",GCST006296,11:60868357
rs59730210-<b>G</b>,"3 x 10-6",,NR,'-,"34.625 unit increase",[20.37-48.88],GRXCR1,"Response to ziprazidone in schizophrenia","schizophrenia, response to ziprasidone",GCST006296,4:138789275
rs56080959-<b>A</b>,"3 x 10-6",,NR,'-,"8.8291 unit decrease",[5.17-12.49],"LINC00303, SOX13","Response to ziprazidone in schizophrenia","schizophrenia, response to ziprasidone",GCST006296,1:204053289
rs12567918-<b>T</b>,"7 x 10-7",,NR,'-,"9.2903 unit decrease",[5.67-12.91],"SOX13, LINC00303","Response to ziprazidone in schizophrenia","schizophrenia, response to ziprasidone",GCST006296,1:204057325
rs737724-<b>G</b>,"2 x 10-7",,NR,'-,"10.6228 unit decrease",[6.68-14.56],LINC01656,"Response to ziprazidone in schizophrenia","schizophrenia, response to ziprasidone",GCST006296,22:44437202
rs10012947-<b>C</b>,"8 x 10-7",,NR,'-,"9.1431 unit decrease",[5.56-12.73],'-,"Response to ziprazidone in schizophrenia","schizophrenia, response to ziprasidone",GCST006296,4:30491805
rs12133007-<b>T</b>,"9 x 10-7",,NR,'-,"9.2915 unit decrease",[5.64-12.94],LINC00303,"Response to ziprazidone in schizophrenia","schizophrenia, response to ziprasidone",GCST006296,1:204039811
rs56343172-<b>T</b>,"8 x 10-8",(trend),0.031,5.15,'-,[2.65-10.01],PHLDB2,"Thionamide-induced agranulocytosis in Graves' disease","response to thioamide, Graves disease, Drug-induced agranulocytosis",GCST003018,3:111868398
rs9263688-<b>G</b>,"5 x 10-21",(trend),0.053,8.06,'-,[4.86-13.37],PSORS1C1,"Thionamide-induced agranulocytosis in Graves' disease","response to thioamide, Graves disease, Drug-induced agranulocytosis",GCST003018,6:31124190
rs7768644-<b>A</b>,"3 x 10-13",(trend),0.091,5.01,'-,[3.1-8.1],MUC22,"Thionamide-induced agranulocytosis in Graves' disease","response to thioamide, Graves disease, Drug-induced agranulocytosis",GCST003018,6:31034324
rs9262631-<b>A</b>,"6 x 10-19",(trend),0.063,7.09,'-,[4.32-11.63],HCG22,"Thionamide-induced agranulocytosis in Graves' disease","response to thioamide, Graves disease, Drug-induced agranulocytosis",GCST003018,6:31056824
rs17193122-<b>A</b>,"4 x 10-27",(trend),0.047,9.59,'-,[5.78-15.90],"RNU6-283P, DHFRP2","Thionamide-induced agranulocytosis in Graves' disease","response to thioamide, Graves disease, Drug-induced agranulocytosis",GCST003018,6:31367559
rs2596449-<b>A</b>,"2 x 10-13",(trend),0.047,6.35,'-,[3.68-10.96],HCP5,"Thionamide-induced agranulocytosis in Graves' disease","response to thioamide, Graves disease, Drug-induced agranulocytosis",GCST003018,6:31470613
rs17201248-<b>T</b>,"3 x 10-7",(trend),0.092,3.48,'-,[2.09-5.81],SNHG32,"Thionamide-induced agranulocytosis in Graves' disease","response to thioamide, Graves disease, Drug-induced agranulocytosis",GCST003018,6:31835353
rs116869525-<b>T</b>,"1 x 10-8",(trend),0.083,4.16,'-,[2.50-6.90],"TSBP1-AS1, HLA-DRA","Thionamide-induced agranulocytosis in Graves' disease","response to thioamide, Graves disease, Drug-induced agranulocytosis",GCST003018,6:32421366
rs2228391-<b>C</b>,"4 x 10-7",(trend),0.108,3.32,'-,[2.02-5.46],TAP2,"Thionamide-induced agranulocytosis in Graves' disease","response to thioamide, Graves disease, Drug-induced agranulocytosis",GCST003018,6:32829996
rs76755915-<b>?</b>,"5 x 10-7",,NR,4.5454545,'-,NR,'-,"Response to interferon treatment in hepatitis C virus genotype 3","response to interferon, hepatitis C virus infection",GCST008517,4:97038456
rs2492965-<b>?</b>,"1 x 10-6",,NR,2.857143,'-,NR,RIMS1,"Response to interferon treatment in hepatitis C virus genotype 3","response to interferon, hepatitis C virus infection",GCST008517,6:72445473
rs7332270-<b>?</b>,"1 x 10-6",,NR,1.6393442,'-,NR,Metazoa_SRP,"Response to interferon treatment in hepatitis C virus genotype 3","response to interferon, hepatitis C virus infection",GCST008517,13:34857816
rs6445096-<b>?</b>,"3 x 10-7",,NR,1.57,'-,NR,SPATA16,"Response to interferon treatment in hepatitis C virus genotype 3","response to interferon, hepatitis C virus infection",GCST008517,3:173063177
rs74597329-<b>?</b>,"2 x 10-7",,NR,1.59,'-,NR,IFNL4,"Response to interferon treatment in hepatitis C virus genotype 3","response to interferon, hepatitis C virus infection",GCST008517,19:39248515
rs13401937-<b>?</b>,"9 x 10-7",,NR,1.94,'-,NR,RTN4,"Response to interferon treatment in hepatitis C virus genotype 3","response to interferon, hepatitis C virus infection",GCST008517,2:55025078
rs75707332-<b>?</b>,"1 x 10-6",,NR,2.56,'-,NR,"CMAS, ABCC9","Response to interferon treatment in hepatitis C virus genotype 3","response to interferon, hepatitis C virus infection",GCST008517,12:22022003
rs72799981-<b>?</b>,"1 x 10-6",,NR,6.64,'-,NR,ARHGAP26,"Response to interferon treatment in hepatitis C virus genotype 3","response to interferon, hepatitis C virus infection",GCST008517,5:143150821
rs2562519-<b>A</b>,"5 x 10-6",,0.5,'-,'-,'-,POLR3G,"Nevirapine-induced rash","response to reverse transcriptase inhibitor",GCST001186,5:90485154
rs6545803-<b>G</b>,"6 x 10-6",,0.50,'-,'-,'-,MIR4432HG,"Nevirapine-induced rash","response to reverse transcriptase inhibitor",GCST001186,2:60307064
rs1265112-<b>G</b>,"1 x 10-8",,0.06,4.36,'-,[2.58-7.36],'-,"Nevirapine-induced rash","response to reverse transcriptase inhibitor",GCST001186,"Mapping not available"
rs79729634-<b>?</b>,"2 x 10-7",,'-,'-,'-,'-,MROH9,"Response to dolutegravir (body weight gain)","response to reverse transcriptase inhibitor, body weight gain",GCST011960,1:171011948
rs7590091-<b>?</b>,"4 x 10-8",,NR,'-,'-,'-,TMEM163,"Response to dolutegravir (body weight gain)","response to reverse transcriptase inhibitor, body weight gain",GCST011960,2:134523562
rs7712513-<b>C</b>,"2 x 10-7",,0.35,1.39,'-,[1.23-1.57],LINC02201,"Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy","diffuse large B-cell lymphoma, event free survival time, response to immunochemotherapy",GCST003178,5:122582513
rs7765004-<b>C</b>,"7 x 10-7",,0.33,1.38,'-,[1.22-1.57],'-,"Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy","diffuse large B-cell lymphoma, event free survival time, response to immunochemotherapy",GCST003178,6:113750518
rs6453204-<b>?</b>,"5 x 10-8",,NR,2.2,'-,[NR],SV2C,"Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab)","cumulative dose response to bevacizumab, breast carcinoma, chemotherapy-induced hypertension",GCST002566,5:76143375
rs130318-<b>?</b>,"4 x 10-7",,NR,1.7,'-,[NR],PARVB,"Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab)","cumulative dose response to bevacizumab, chemotherapy-induced hypertension, breast carcinoma",GCST002566,22:44080184
rs1943466-<b>?</b>,"6 x 10-7",,NR,1.69,'-,[NR],GRAMD1B,"Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab)","cumulative dose response to bevacizumab, breast carcinoma, chemotherapy-induced hypertension",GCST002566,11:123393934
rs11685222-<b>?</b>,"4 x 10-6",,NR,1.98,'-,[NR],"RPL27P7, PTPN4","Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab)","cumulative dose response to bevacizumab, breast carcinoma, chemotherapy-induced hypertension",GCST002566,2:119990995
rs12467348-<b>?</b>,"9 x 10-6",,NR,2.05,'-,[NR],KCNS3,"Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab)","cumulative dose response to bevacizumab, breast carcinoma, chemotherapy-induced hypertension",GCST002566,2:18106253
rs3773651-<b>?</b>,"7 x 10-6",,NR,2.15,'-,[NR],TGFBR2,"Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab)","cumulative dose response to bevacizumab, breast carcinoma, chemotherapy-induced hypertension",GCST002566,3:30677040
rs2731620-<b>?</b>,"7 x 10-6",,NR,1.59,'-,[NR],RNU1-146P,"Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab)","cumulative dose response to bevacizumab, breast carcinoma, chemotherapy-induced hypertension",GCST002566,12:19774866
rs6878584-<b>?</b>,"7 x 10-6",,NR,2.27,'-,[NR],"NSG2, LINC01411","Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab)","cumulative dose response to bevacizumab, breast carcinoma, chemotherapy-induced hypertension",GCST002566,5:174280232
rs2496589-<b>?</b>,"5 x 10-6",,NR,1.7,'-,[NR],"AIG1, ADAT2","Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab)","cumulative dose response to bevacizumab, breast carcinoma, chemotherapy-induced hypertension",GCST002566,6:143412439
rs1962073-<b>?</b>,"2 x 10-6",,NR,1.69,'-,[NR],MSRA,"Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab)","cumulative dose response to bevacizumab, breast carcinoma, chemotherapy-induced hypertension",GCST002566,8:10403043
rs11786541-<b>?</b>,"2 x 10-6",,NR,1.65,'-,[NR],MIR124-1HG,"Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab)","cumulative dose response to bevacizumab, breast carcinoma, chemotherapy-induced hypertension",GCST002566,8:9932039
rs11257188-<b>?</b>,"9 x 10-6",,NR,2.19,'-,[NR],PFKFB3,"Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab)","cumulative dose response to bevacizumab, breast carcinoma, chemotherapy-induced hypertension",GCST002566,10:6195193
rs479825-<b>?</b>,"6 x 10-6",,NR,1.64,'-,[NR],MAML2,"Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab)","cumulative dose response to bevacizumab, breast carcinoma, chemotherapy-induced hypertension",GCST002566,11:96198321
HLA-A*31:01-<b>?</b>,"2 x 10-9",,0.02,12.9,'-,[5.58-29.78],'-,"Carbamazepine-induced reaction with eosinophilia and systemic symptoms","drug hypersensitivity syndrome, response to carbamazepine",GCST008384,"Mapping not available"
HLA-B*51:01-<b>?</b>,"6 x 10-6",,NR,5.72,'-,[2.69-12.16],'-,"Carbamazepine-induced reaction with eosinophilia and systemic symptoms","drug hypersensitivity syndrome, response to carbamazepine",GCST008384,"Mapping not available"
rs187926838-<b>?</b>,"1 x 10-6",,NR,18.2,'-,[5.2-63.72],ALK,"Carbamazepine-induced reaction with eosinophilia and systemic symptoms","drug hypersensitivity syndrome, response to carbamazepine",GCST008384,2:29595425
rs116071718-<b>?</b>,"2 x 10-6","(conditioned on rs192543598)",NR,3.99,'-,[2.25-7.05],MUC22,"Carbamazepine-induced serious cutaneous adverse reaction","severe cutaneous adverse reaction, response to carbamazepine",GCST008386,6:31022304
rs192543598-<b>G</b>,"2 x 10-12",,0.01,18.11,'-,[8.03-40.88],"HLA-W, MICD","Carbamazepine-induced serious cutaneous adverse reaction","severe cutaneous adverse reaction, response to carbamazepine",GCST008386,6:29963568
rs187926838-<b>G</b>,"5 x 10-8",,0.007,12.1,'-,[4.94-29.8],ALK,"Carbamazepine-induced serious cutaneous adverse reaction","severe cutaneous adverse reaction, response to carbamazepine",GCST008386,2:29595425
rs10510829-<b>?</b>,"7 x 10-7",(LTG),NR,'-,'-,'-,FHIT,"Adverse response to lamotrigine and phenytoin","response to anticonvulsant",GCST001431,3:60137795
rs275380-<b>?</b>,"1 x 10-6",(LTG),NR,'-,'-,'-,ADAMTS20,"Adverse response to lamotrigine and phenytoin","response to anticonvulsant",GCST001431,12:43536193
rs6990917-<b>?</b>,"2 x 10-6",(LTG),NR,'-,'-,'-,"NDUFS5P6, PREX2","Adverse response to lamotrigine and phenytoin","response to anticonvulsant",GCST001431,8:67887142
rs285406-<b>?</b>,"5 x 10-6",(LTG),NR,'-,'-,'-,ATP6V0D2,"Adverse response to lamotrigine and phenytoin","response to anticonvulsant",GCST001431,8:86012784
rs183266-<b>?</b>,"5 x 10-6",(LTG),NR,'-,'-,'-,"LINC02288, IRF2BPL","Adverse response to lamotrigine and phenytoin","response to anticonvulsant",GCST001431,14:77031632
rs12230440-<b>?</b>,"3 x 10-6",(PHT),NR,'-,'-,'-,ADIPOR2,"Adverse response to lamotrigine and phenytoin","response to anticonvulsant",GCST001431,12:1747787
rs8083432-<b>?</b>,"6 x 10-6",(PHT),NR,'-,'-,'-,ZNF521,"Adverse response to lamotrigine and phenytoin","response to anticonvulsant",GCST001431,18:25151396
rs7798500-<b>?</b>,"6 x 10-6",(PHT),NR,'-,'-,'-,PRKAR2B,"Adverse response to lamotrigine and phenytoin","response to anticonvulsant",GCST001431,7:107021638
rs17002253-<b>?</b>,"7 x 10-6",(PHT),NR,'-,'-,'-,"SHROOM3-AS1, SOWAHB","Adverse response to lamotrigine and phenytoin","response to anticonvulsant",GCST001431,4:76850192
rs3853240-<b>?</b>,"1 x 10-6","(Total LTG and PHT)",NR,'-,'-,'-,LINC01947,"Adverse response to lamotrigine and phenytoin","response to anticonvulsant",GCST001431,5:166891185
rs9919839-<b>?</b>,"2 x 10-6","(Total LTG and PHT)",NR,'-,'-,'-,DACH1,"Adverse response to lamotrigine and phenytoin","response to anticonvulsant",GCST001431,13:71600221
rs4569005-<b>?</b>,"5 x 10-6","(Total LTG and PHT)",NR,'-,'-,'-,NELL1,"Adverse response to lamotrigine and phenytoin","response to anticonvulsant",GCST001431,11:21037185
HLA-<b>A*3101</b>,"1 x 10-16",,0.13,9.5,'-,[5.6-16.3],'-,"Adverse response to carbamazepine","response to anticonvulsant",GCST000912,"Mapping not available"
rs365836-<b>A</b>,"2 x 10-6",,NR,4.79,'-,[2.38-9.64],CUX1,"Response to antidepressants","response to antidepressant",GCST001528,7:102166571
rs6812281-<b>T</b>,"9 x 10-9",,0.18,2.37,'-,[1.77-3.18],'-,"Response to platinum-based neoadjuvant chemotherapy in cervical cancer","cervical carcinoma, response to platinum-based neoadjuvant chemotherapy",GCST004097,4:179391655
rs1742101-<b>G</b>,"7 x 10-6",,0.5,1.92,'-,[1.45-2.56],TTC7B,"Response to platinum-based neoadjuvant chemotherapy in cervical cancer","cervical carcinoma, response to platinum-based neoadjuvant chemotherapy",GCST004097,14:90698719
rs1364121-<b>A</b>,"3 x 10-6",,0.25,1.98,'-,[1.49-2.64],CDH13,"Response to platinum-based neoadjuvant chemotherapy in cervical cancer","cervical carcinoma, response to platinum-based neoadjuvant chemotherapy",GCST004097,16:83706502
rs11766298-<b>T</b>,"4 x 10-9","(VLDL diameter)",NR,'-,"4.41 unit increase",[2.96-5.86],AHCYL2,"Response to fenofibrate","response to fenofibrate",GCST001632,7:129365006
rs10952132-<b>T</b>,"1 x 10-6","(LDL diameter)",NR,'-,"0.31 unit increase",[-0.94440-1.56440],CCDC71L,"Response to fenofibrate","response to fenofibrate",GCST001632,7:9027190
rs519595-<b>G</b>,"2 x 10-6","(LDL diameter)",NR,'-,"0.6 unit decrease",[0.36-0.84],PDE10A,"Response to fenofibrate","response to fenofibrate",GCST001632,6:165521933
rs11574703-<b>T</b>,"8 x 10-8","(HDL diameter)",NR,'-,"3.72 unit decrease",[2.39-5.05],CD36,"Response to fenofibrate","response to fenofibrate",GCST001632,7:80657592
rs9285640-<b>G</b>,"3 x 10-7","(HDL diameter)",NR,'-,"29.95 unit decrease",[18.62-41.28],PPARGC1B,"Response to fenofibrate","response to fenofibrate",GCST001632,5:149762504
rs10428959-<b>T</b>,"1 x 10-7","(VLDL diameter)",NR,'-,"6 unit increase",[3.79-8.21],DOCK4,"Response to fenofibrate","response to fenofibrate",GCST001632,7:112037851
rs10952132-<b>T</b>,"7 x 10-6","(Large LDL)",NR,'-,"0.29 unit increase",[-0.98400-1.56400],CCDC71L,"Response to fenofibrate","response to fenofibrate",GCST001632,7:9027190
rs10995485-<b>G</b>,"2 x 10-6","(LDL diameter)",NR,'-,"1.18 unit decrease",[0.69-1.67],JMJD1C,"Response to fenofibrate","response to fenofibrate",GCST001632,10:63267098
rs5001812-<b>T</b>,"2 x 10-7","(HDL diameter)",NR,'-,"4.67 unit decrease",[2.93-6.41],'-,"Response to fenofibrate","response to fenofibrate",GCST001632,"Mapping not available"
rs519595-<b>G</b>,"5 x 10-6","(Large LDL)",NR,'-,"0.58 unit decrease",[0.33-0.83],PDE10A,"Response to fenofibrate","response to fenofibrate",GCST001632,6:165521933
rs114633080-<b>?</b>,"1 x 10-6",,NR,'-,'-,'-,'-,"Response to mepolizumab in severe asthma","response to mepolizumab, asthma",GCST005115,6:145083119
rs10811516-<b>?</b>,"1 x 10-6",,NR,'-,'-,'-,"IFNA22P, IFNA14","Response to mepolizumab in severe asthma","response to mepolizumab, asthma",GCST005115,9:21255050
rs13239071-<b>G</b>,"2 x 10-6",,NR,'-,"16.8758 unit decrease",[10.21-23.54],"TFAMP1, ELFN1","Response to perphenazine in schizophrenia","schizophrenia, response to perphenazine",GCST006297,7:1624714
rs7116879-<b>T</b>,"3 x 10-6",,NR,'-,"14.6983 unit decrease",[8.72-20.68],DKK3,"Response to perphenazine in schizophrenia","schizophrenia, response to perphenazine",GCST006297,11:11992266
rs75953396-<b>A</b>,"5 x 10-6",,NR,'-,"16.3291 unit increase",[9.52-23.13],"LGI1, FRA10AC1","Response to perphenazine in schizophrenia","schizophrenia, response to perphenazine",GCST006297,10:93748796
rs77989818-<b>G</b>,"7 x 10-6",,NR,'-,"26.962 unit decrease",[15.57-38.36],'-,"Response to perphenazine in schizophrenia","schizophrenia, response to perphenazine",GCST006297,5:44968962
rs7358476-<b>A</b>,"9 x 10-6",,NR,'-,"11.4794 unit decrease",[6.55-16.41],'-,"Response to perphenazine in schizophrenia","schizophrenia, response to perphenazine",GCST006297,11:87481582
rs2239063-<b>A</b>,"1 x 10-8",,NR,'-,"7.04 unit increase",[4.63-9.45],CACNA1C,"Response to olanzapine in schizophrenia","schizophrenia, response to olanzapine",GCST006293,12:2402665
rs1731240-<b>A</b>,"3 x 10-6",,NR,'-,"6.9 unit increase",[4.02-9.78],CIB4,"Response to olanzapine in schizophrenia","schizophrenia, response to olanzapine",GCST006293,2:26614527
rs551966-<b>?</b>,"1 x 10-6",,'-,'-,"9.7472 unit decrease",[5.89-13.61],'-,"Response to esketamine in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011398,10:29185269
rs77609995-<b>?</b>,"3 x 10-6",,'-,'-,"34.2748 unit decrease",[20.16-48.39],SORCS1,"Response to esketamine in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011398,10:106586194
rs117717236-<b>?</b>,"5 x 10-6",,'-,'-,"27.4409 unit decrease",[15.81-39.07],"NANOS1, LDHAP5","Response to esketamine in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011398,10:118939899
rs11052682-<b>?</b>,"5 x 10-6",,'-,'-,"20.1464 unit decrease",[11.57-28.72],SYT10,"Response to esketamine in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011398,12:33400846
rs11465988-<b>?</b>,"4 x 10-8",,'-,'-,"51.5905 unit decrease",[33.52-69.66],IRAK3,"Response to esketamine in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011398,12:66248033
rs1092013-<b>?</b>,"9 x 10-6",,'-,'-,"10.7514 unit decrease",[6.04-15.46],SLC35F4,"Response to esketamine in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011398,14:57735711
rs116975924-<b>?</b>,"7 x 10-6",,'-,'-,"35.0775 unit decrease",[19.89-50.27],"DIO2-AS1, DIO2","Response to esketamine in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011398,14:80346020
rs77861730-<b>?</b>,"4 x 10-6",,'-,'-,"23.8526 unit increase",[13.8-33.91],LINC01169,"Response to esketamine in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011398,15:66628157
rs111384268-<b>?</b>,"8 x 10-6",,'-,'-,"11.3007 unit increase",[6.39-16.21],TMEM266,"Response to esketamine in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011398,15:76174302
rs7191671-<b>?</b>,"9 x 10-6",,'-,'-,"11.7671 unit decrease",[6.63-16.91],SNX29,"Response to esketamine in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011398,16:12378793
rs79490404-<b>?</b>,"7 x 10-6",,'-,'-,"32.6871 unit decrease",[18.54-46.83],XPO6,"Response to esketamine in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011398,16:28200424
rs116974145-<b>?</b>,"5 x 10-6",,'-,'-,"38.5584 unit decrease",[22.16-54.96],"ZFHX3, LINC01568","Response to esketamine in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011398,16:73399546
rs56853567-<b>?</b>,"1 x 10-7",,'-,'-,"52.5556 unit decrease",[33.38-71.73],'-,"Response to esketamine in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011398,18:15091840
psy_rs112341441-<b>?</b>,"7 x 10-6",,'-,'-,"24.4593 unit decrease",[13.89-35.03],'-,"Response to esketamine in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011398,"Mapping not available"
exm2273047-<b>?</b>,"4 x 10-6",,'-,'-,"6.4963 unit increase",[3.77-9.22],'-,"Response to esketamine in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011398,"Mapping not available"
rs113784139-<b>?</b>,"5 x 10-6",,'-,7.8275,'-,[6.94-8.71],"RPL27AP4, RPS21P2","Response to esketamine (responder status) in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011397,2:106292093
rs76151810-<b>?</b>,"6 x 10-6",,'-,6.8437,'-,[6.01-7.67],OR5H14,"Response to esketamine (responder status) in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011397,3:98149189
rs10957273-<b>?</b>,"8 x 10-7",,'-,0.3297,'-,[-0.1111-0.7705],"TTPA, TARDBPP4","Response to esketamine (responder status) in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011397,8:63116532
rs4621851-<b>?</b>,"3 x 10-6",,'-,0.3408,'-,[-0.11372-0.79532],SNTB1,"Response to esketamine (responder status) in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011397,8:120843272
rs12778632-<b>?</b>,"8 x 10-6",,'-,5.5519,'-,[4.8-6.31],TNKS2,"Response to esketamine (responder status) in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011397,10:91808653
rs7191671-<b>?</b>,"4 x 10-6",,'-,4.9988,'-,[4.31-5.69],SNX29,"Response to esketamine (responder status) in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011397,16:12378793
rs57202603-<b>?</b>,"3 x 10-6",,'-,22.9068,'-,[21.6-24.21],ALOX12B,"Response to esketamine (responder status) in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011397,17:8082544
rs6004421-<b>?</b>,"2 x 10-6",,'-,4.2574,'-,[3.66-4.86],KIAA1671,"Response to esketamine (responder status) in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011397,22:25069861
rs9607045-<b>?</b>,"5 x 10-6",,'-,0.3586,'-,[-0.08181-0.79901],LARGE1,"Response to esketamine (responder status) in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011397,22:33428461
exm2273047-<b>?</b>,"8 x 10-6",,'-,0.3053,'-,[-0.21606-0.82666],'-,"Response to esketamine (responder status) in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011397,"Mapping not available"
rs147333636-<b>?</b>,"8 x 10-6",,'-,'-,"46.9233 unit increase",[26.52-67.33],DAB1,"Response to esketamine in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011398,1:57634958
rs115141868-<b>?</b>,"8 x 10-7",,'-,'-,"46.7739 unit decrease",[28.46-65.09],"TGFA, ADD2","Response to esketamine in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011398,2:70589473
rs113784139-<b>?</b>,"3 x 10-6",,'-,'-,"17.3441 unit decrease",[10.16-24.53],"RPL27AP4, RPS21P2","Response to esketamine in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011398,2:106292093
rs76281048-<b>?</b>,"9 x 10-6",,'-,'-,"42.9841 unit decrease",[24.16-61.81],"MIR5703, RNU6-627P","Response to esketamine in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011398,2:163332850
rs74833943-<b>?</b>,"3 x 10-6",,'-,'-,"9.7351 unit increase",[5.69-13.78],SCN11A,"Response to esketamine in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011398,3:38881542
rs116374079-<b>?</b>,"5 x 10-6",,'-,'-,"28.8083 unit decrease",[16.52-41.1],SAMMSON,"Response to esketamine in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011398,3:70116547
rs113873241-<b>?</b>,"2 x 10-6",,'-,'-,"37.1242 unit decrease",[21.88-52.37],MBNL1,"Response to esketamine in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011398,3:152280042
rs13141139-<b>?</b>,"2 x 10-6",,'-,'-,"52.0532 unit decrease",[30.69-73.41],MAEA,"Response to esketamine in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011398,4:1317139
rs150512710-<b>?</b>,"2 x 10-6",,'-,'-,"35.9753 unit decrease",[21.29-50.66],"EVC, CRMP1","Response to esketamine in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011398,4:5801387
rs141153844-<b>?</b>,"2 x 10-6",,'-,'-,"27.5742 unit decrease",[16.29-38.86],"PACRGL, SLIT2","Response to esketamine in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011398,4:20653548
rs137976722-<b>?</b>,"2 x 10-6",,'-,'-,"31.4511 unit decrease",[18.58-44.32],EEF1A1P21,"Response to esketamine in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011398,4:29742673
rs151184257-<b>?</b>,"5 x 10-7",,'-,'-,"40.4986 unit decrease",[24.97-56.03],CXXC4-AS1,"Response to esketamine in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011398,4:104793600
rs79939184-<b>?</b>,"7 x 10-6",,'-,'-,"38.3288 unit decrease",[21.76-54.9],MARCHF11,"Response to esketamine in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011398,5:16157247
rs72759613-<b>?</b>,"7 x 10-6",,'-,'-,"14.3869 unit decrease",[8.16-20.61],PDZD2,"Response to esketamine in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011398,5:31957178
rs67702993-<b>?</b>,"3 x 10-6",,'-,'-,"7.7028 unit decrease",[4.53-10.88],MROH2B,"Response to esketamine in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011398,5:41030620
rs199699215-<b>?</b>,"9 x 10-6",,'-,'-,"25.1097 unit decrease",[14.14-36.08],"NR3C1, ARHGAP26","Response to esketamine in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011398,5:143260638
rs142489926-<b>?</b>,"5 x 10-6",,'-,'-,"42.1954 unit decrease",[24.25-60.14],"PNISR, USP45","Response to esketamine in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011398,6:99431370
7_9352308-<b>?</b>,"7 x 10-6",,'-,'-,"40.4638 unit decrease",[22.95-57.98],'-,"Response to esketamine in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011398,"Mapping not available"
rs4276687-<b>?</b>,"4 x 10-6",,'-,'-,"6.8847 unit decrease",[4-9.77],NKAIN3,"Response to esketamine in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011398,8:62872146
YTHDF3-<b>AS1</b>,"6 x 10-8",,'-,'-,"7.4888 unit increase",[4.82-10.16],"TTPA, TARDBPP4","Response to esketamine in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011398,8:63122188
rs76381578-<b>?</b>,"2 x 10-6",,'-,'-,"15.2371 unit decrease",[9.05-21.42],MMP16,"Response to esketamine in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011398,8:88144744
rs202236734-<b>?</b>,"9 x 10-7",,'-,'-,"7.8351 unit increase",[4.74-10.93],SNTB1,"Response to esketamine in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011398,8:120845353
rs138256067-<b>?</b>,"6 x 10-6",,'-,'-,"43.956 unit decrease",[25.11-62.8],DOCK8,"Response to esketamine in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011398,9:339720
rs189749048-<b>?</b>,"9 x 10-6",,'-,'-,"41.4729 unit decrease",[23.39-59.55],"ZDHHC21, CDCA4P1","Response to esketamine in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011398,9:14595487
rs143769938-<b>?</b>,"4 x 10-6",,'-,'-,"45.7384 unit increase",[26.58-64.9],'-,"Response to esketamine in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011398,9:103509163
rs2133627-<b>?</b>,"1 x 10-5",,'-,2.9914,'-,[2.51-3.48],FOXP1,"Response to esketamine (responder status) in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011397,3:71502719
rs7105146-<b>?</b>,"2 x 10-6",,'-,2.216,'-,[1.89-2.54],PPFIBP2,"Response to esketamine (remission) in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011396,11:7546770
rs114035480-<b>?</b>,"3 x 10-6",,'-,0.3902,'-,[-0.00611-0.78651],METTL8,"Response to esketamine (remission) in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011396,2:171381449
rs146423616-<b>?</b>,"4 x 10-6",,'-,0.3912,'-,[-0.00629-0.78869],KRT18P24,"Response to esketamine (remission) in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011396,9:79101991
rs57279992-<b>?</b>,"6 x 10-6",,'-,0.4654,'-,[0.13-0.8],LINC02436,"Response to esketamine (remission) in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011396,4:185085185
rs62218079-<b>?</b>,"1 x 10-5",,'-,2.7539,'-,[2.3-3.2],"LINC02891, CCDC188","Response to esketamine (remission) in treatment resistant depression","treatment resistant depression, response to ketamine",GCST011396,22:20165339
rs17169-<b>T</b>,"1 x 10-7","(phenotype 1)",NR,2.97,'-,[NR],"LINC00299, LINC00298","Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)","HIV-1 infection, response to efavirenz, virologic response measurement",GCST002771,2:8037334
rs1491976-<b>G</b>,"5 x 10-6","(phenotype 1)",NR,2.3255813,'-,[NR],"IGSF10, MRPL42P6","Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)","HIV-1 infection, response to efavirenz, virologic response measurement",GCST002771,3:151465283
rs61550741-<b>G</b>,"1 x 10-6","(phenotype 2)",NR,2.27,'-,[NR],TIAM1,"Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)","HIV-1 infection, response to efavirenz, virologic response measurement",GCST002771,21:31133966
rs9358749-<b>T</b>,"5 x 10-6","(phenotype 1)",NR,3.27,'-,[NR],"HNRNPA1P58, NRSN1","Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)","HIV-1 infection, response to efavirenz, virologic response measurement",GCST002771,6:24077829
rs34975555-<b>C</b>,"5 x 10-6","(phenotype 3)",NR,2.08,'-,[NR],PCM1,"Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)","HIV-1 infection, response to efavirenz, virologic response measurement",GCST002771,8:18000788
rs9314308-<b>C</b>,"9 x 10-6","(phenotype 3)",NR,1.55,'-,[NR],'-,"Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)","HIV-1 infection, response to efavirenz, virologic response measurement",GCST002771,8:25687163
rs538174-<b>C</b>,"5 x 10-6","(phenotype 1)",NR,2.44,'-,[NR],OPRM1,"Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)","HIV-1 infection, response to efavirenz, virologic response measurement",GCST002771,6:154131402
rs59824868-<b>A</b>,"5 x 10-6","(phenotype 3)",NR,2.12,'-,[NR],"FRA10AC1, LGI1","Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)","HIV-1 infection, response to efavirenz, virologic response measurement",GCST002771,10:93717593
rs117526668-<b>T</b>,"9 x 10-6","(phenotype 1)",NR,3.19,'-,[NR],ALX4,"Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)","HIV-1 infection, response to efavirenz, virologic response measurement",GCST002771,11:44263881
rs12306296-<b>G</b>,"4 x 10-6","(phenotype 3)",NR,1.67,'-,[NR],LINC00944,"Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)","HIV-1 infection, response to efavirenz, virologic response measurement",GCST002771,12:126763839
rs10892324-<b>G</b>,"1 x 10-6","(phenotype 2)",NR,1.64,'-,[NR],"SLC37A4, HYOU1","Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)","HIV-1 infection, response to efavirenz, virologic response measurement",GCST002771,11:119032329
rs116002988-<b>C</b>,"8 x 10-6","(phenotype 2)",NR,2.04,'-,[NR],RPL3P4,"Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)","HIV-1 infection, response to efavirenz, virologic response measurement",GCST002771,14:98991100
rs7174156-<b>A</b>,"7 x 10-6","(phenotype 2)",NR,1.6,'-,[NR],"TUBAP12, PGAM1P12","Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)","HIV-1 infection, response to efavirenz, virologic response measurement",GCST002771,15:96416625
rs1663189-<b>T</b>,"6 x 10-6","(phenotype 2)",NR,1.79,'-,[NR],LINC01979,"Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)","HIV-1 infection, response to efavirenz, virologic response measurement",GCST002771,17:79915256
rs13064773-<b>A</b>,"8 x 10-7","(phenotype 1)",NR,2.26,'-,[NR],"GPR79, IQCJ-SCHIP1","Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)","HIV-1 infection, response to efavirenz, virologic response measurement",GCST002771,3:158893105
rs2910490-<b>C</b>,"9 x 10-6","(phenotype 3)",NR,1.49,'-,[NR],LINCR-0003,"Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)","HIV-1 infection, response to efavirenz, virologic response measurement",GCST002771,5:57626258
rs608114-<b>A</b>,"3 x 10-7","(phenotype 1)",NR,4.84,'-,[NR],KRT18P50,"Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)","HIV-1 infection, response to efavirenz, virologic response measurement",GCST002771,6:95928822
rs62432346-<b>A</b>,"5 x 10-6","(phenotype 1)",NR,4.6,'-,[NR],TSTD3,"Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)","HIV-1 infection, response to efavirenz, virologic response measurement",GCST002771,6:99541358
rs6471393-<b>A</b>,"7 x 10-6","(phenotype 3)",NR,1.57,'-,[NR],CIBAR1,"Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)","HIV-1 infection, response to efavirenz, virologic response measurement",GCST002771,8:93703063
rs16933829-<b>C</b>,"1 x 10-6","(phenotype 1)",NR,4.7619047,'-,[NR],PIK3C2A,"Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)","HIV-1 infection, response to efavirenz, virologic response measurement",GCST002771,11:17094129
rs12414342-<b>A</b>,"3 x 10-6","(phenotype 3)",NR,1.79,'-,[NR],'-,"Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)","HIV-1 infection, response to efavirenz, virologic response measurement",GCST002771,10:131491642
rs16966918-<b>A</b>,"5 x 10-6","(phenotype 1)",NR,4.01,'-,[NR],DAOA-AS1,"Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)","HIV-1 infection, response to efavirenz, virologic response measurement",GCST002771,13:105595684
rs11649112-<b>A</b>,"1 x 10-6","(phenotype 1)",NR,2.49,'-,[NR],SHISA9,"Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)","HIV-1 infection, response to efavirenz, virologic response measurement",GCST002771,16:13267554
rs74976893-<b>T</b>,"4 x 10-6","(phenotype 1)",NR,4.18,'-,[NR],'-,"Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)","HIV-1 infection, response to efavirenz, virologic response measurement",GCST002771,17:71733784
rs9961574-<b>G</b>,"3 x 10-6","(phenotype 1)",NR,2.33,'-,[NR],"THEMIS3P, AKR1B1P6","Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)","HIV-1 infection, response to efavirenz, virologic response measurement",GCST002771,18:8536118
rs62096106-<b>G</b>,"9 x 10-6","(phenotype 1)",NR,3.57,'-,[NR],PIGN,"Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)","HIV-1 infection, response to efavirenz, virologic response measurement",GCST002771,18:62171686
rs142039564-<b>C</b>,"6 x 10-6","(phenotype 2)",NR,1.79,'-,[NR],'-,"Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)","HIV-1 infection, response to efavirenz, virologic response measurement",GCST002771,1:118513635
rs7560018-<b>A</b>,"6 x 10-6","(phenotype 2)",NR,1.71,'-,[NR],"MCFD2, LINC01119","Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)","HIV-1 infection, response to efavirenz, virologic response measurement",GCST002771,2:46880193
rs1512777-<b>T</b>,"4 x 10-6","(phenotype 2)",NR,1.92,'-,[NR],ESYT3,"Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)","HIV-1 infection, response to efavirenz, virologic response measurement",GCST002771,3:144736294
rs11918665-<b>G</b>,"9 x 10-6","(phenotype 2)",NR,2.7,'-,[NR],"CRYGS, LINC02052","Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)","HIV-1 infection, response to efavirenz, virologic response measurement",GCST002771,3:186495995
rs17436410-<b>G</b>,"4 x 10-6","(phenotype 2)",NR,2,'-,[NR],SKAP2,"Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)","HIV-1 infection, response to efavirenz, virologic response measurement",GCST002771,7:26954548
rs7458938-<b>A</b>,"2 x 10-7","(phenotype 2)",NR,1.96,'-,[NR],'-,"Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)","HIV-1 infection, response to efavirenz, virologic response measurement",GCST002771,7:125820594
rs17742757-<b>C</b>,"8 x 10-6","(phenotype 2)",NR,1.64,'-,[NR],FAM167A,"Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)","HIV-1 infection, response to efavirenz, virologic response measurement",GCST002771,8:11472832
rs45479699-<b>A</b>,"8 x 10-6","(phenotype 2)",NR,5.62,'-,[NR],CAMK1D,"Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)","HIV-1 infection, response to efavirenz, virologic response measurement",GCST002771,10:12707063
rs73206853-<b>A</b>,"4 x 10-6","(phenotype 2)",NR,1.88,'-,[NR],"IFT81, ATP2A2","Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)","HIV-1 infection, response to efavirenz, virologic response measurement",GCST002771,12:110270941
rs72696020-<b>?</b>,"6 x 10-8",,'-,7.8,'-,3.52-14.66,"KCNK10, LINC01146","Drug-induced liver injury (nitrofurantoin)","response to nitrofurantoin, drug-induced liver injury",GCST004082,14:88105563
rs6694270-<b>?</b>,"2 x 10-7",,'-,2.59,'-,1.81-3.71,"TAS1R2, PAX7","Drug-induced liver injury (nitrofurantoin)","response to nitrofurantoin, drug-induced liver injury",GCST004082,1:18793883
rs10404821-<b>?</b>,"2 x 10-7",,'-,2.56,'-,1.80-3.65,C19orf81,"Drug-induced liver injury (nitrofurantoin)","response to nitrofurantoin, drug-induced liver injury",GCST004082,19:50657831
rs61858823-<b>?</b>,"5 x 10-7",,'-,5.63,'-,2.88-11.02,"MYL6P3, NEK4P3","Drug-induced liver injury (nitrofurantoin)","response to nitrofurantoin, drug-induced liver injury",GCST004082,10:65095495
rs114811931-<b>?</b>,"3 x 10-9",,NR,6.59,'-,3.54-12.28,GABRB2,"Drug-induced liver injury (diclofenac)","response to diclofenac, drug-induced liver injury",GCST004083,5:161257724
rs113206698-<b>?</b>,"6 x 10-7",,NR,3.79,'-,2.25-6.39,EXOC6,"Drug-induced liver injury (diclofenac)","response to diclofenac, drug-induced liver injury",GCST004083,10:92818147
rs115266745-<b>?</b>,"7 x 10-7",,'-,6.8,'-,3.19-14.48,LINC01266,"Drug-induced liver injury (diclofenac)","response to diclofenac, drug-induced liver injury",GCST004083,3:779530
rs149014830-<b>?</b>,"7 x 10-7",,NR,6.04,'-,2.96-12.3,RPL23AP44,"Drug-induced liver injury (diclofenac)","response to diclofenac, drug-induced liver injury",GCST004083,5:121540642
rs186920977-<b>?</b>,"1 x 10-7",,'-,7.22,'-,3.47-15.01,CCDC85A,"Drug-induced liver injury (fluoroquinolones)","response to fluoroquinolones, drug-induced liver injury",GCST004085,2:56422795
rs191153876-<b>?</b>,"2 x 10-7",,'-,7.33,'-,3.46-15.5,CCDC14,"Drug-induced liver injury (fluoroquinolones)","response to fluoroquinolones, drug-induced liver injury",GCST004085,3:123918335
rs116606120-<b>?</b>,"3 x 10-7",,'-,8.6,'-,3.79-19.5,RNU6-909P,"Drug-induced liver injury (fluoroquinolones)","response to fluoroquinolones, drug-induced liver injury",GCST004085,5:28665845
rs112655218-<b>?</b>,"3 x 10-7",,'-,4.54,'-,'-,RAB31,"Drug-induced liver injury (fluoroquinolones)","response to fluoroquinolones, drug-induced liver injury",GCST004085,18:9841518
rs150634721-<b>C</b>,"4 x 10-7",,NR,'-,"26.0032 unit increase",[16.13-35.88],IGF1,"Response to quetiapine in schizophrenia","schizophrenia, response to quetiapine",GCST006295,12:102492363
rs2802383-<b>G</b>,"8 x 10-7",,NR,'-,"9.507 unit decrease",[5.8-13.21],"SYF2P2, C9orf131","Response to quetiapine in schizophrenia","schizophrenia, response to quetiapine",GCST006295,9:35020439
rs9554958-<b>A</b>,"1 x 10-6",,NR,'-,"8.9266 unit decrease",[5.4-12.46],"ATP6V1G1P7, LINC00343","Response to quetiapine in schizophrenia","schizophrenia, response to quetiapine",GCST006295,13:103448176
rs76694263-<b>G</b>,"1 x 10-6",,NR,'-,"12.474 unit decrease",[7.49-17.46],GALNT10,"Response to quetiapine in schizophrenia","schizophrenia, response to quetiapine",GCST006295,5:154286206
rs16834649-<b>T</b>,"2 x 10-6",,NR,'-,"16.6214 unit increase",[9.85-23.4],"RGS13, RPS27AP5","Response to quetiapine in schizophrenia","schizophrenia, response to quetiapine",GCST006295,1:192698757
rs642296-<b>T</b>,"3 x 10-6",,NR,'-,"9.0135 unit decrease",[5.31-12.72],"RN7SL338P, VCP","Response to quetiapine in schizophrenia","schizophrenia, response to quetiapine",GCST006295,9:35051272
rs7088969-<b>T</b>,"3 x 10-6",,NR,'-,"8.7002 unit decrease",[5.11-12.29],LINC02674,"Response to quetiapine in schizophrenia","schizophrenia, response to quetiapine",GCST006295,10:117774246
rs34624213-<b>A</b>,"4 x 10-6",,NR,'-,"16.2055 unit increase",[9.46-22.95],"RPS27AP5, RGS2","Response to quetiapine in schizophrenia","schizophrenia, response to quetiapine",GCST006295,1:192734842
rs28533249-<b>G</b>,"4 x 10-6",,NR,'-,"8.8627 unit decrease",[5.16-12.56],LINC01310,"Response to quetiapine in schizophrenia","schizophrenia, response to quetiapine",GCST006295,22:48894738
rs3753947-<b>T</b>,"5 x 10-6",,NR,'-,"16.0195 unit increase",[9.27-22.77],"RGS2, RPS27AP5","Response to quetiapine in schizophrenia","schizophrenia, response to quetiapine",GCST006295,1:192745941
rs30419-<b>T</b>,"6 x 10-6",,NR,'-,"14.8543 unit increase",[8.53-21.18],"LINC01949, MIR4280HG","Response to quetiapine in schizophrenia","schizophrenia, response to quetiapine",GCST006295,5:87168783
rs4879848-<b>T</b>,"6 x 10-6",,NR,'-,"8.8412 unit decrease",[5.07-12.61],DNAJB5,"Response to quetiapine in schizophrenia","schizophrenia, response to quetiapine",GCST006295,9:34992077
rs986359-<b>A</b>,"7 x 10-6",,NR,'-,"16.4643 unit decrease",[9.37-23.56],SPOCK1,"Response to quetiapine in schizophrenia","schizophrenia, response to quetiapine",GCST006295,5:137311415
rs568300-<b>T</b>,"9 x 10-6",,NR,'-,"8.421 unit decrease",[4.76-12.08],PIGO,"Response to quetiapine in schizophrenia","schizophrenia, response to quetiapine",GCST006295,9:35093023
rs630961-<b>C</b>,"9 x 10-6",,NR,'-,"8.3966 unit decrease",[4.74-12.05],"FAM214B, STOML2","Response to quetiapine in schizophrenia","schizophrenia, response to quetiapine",GCST006295,9:35103725
rs9833094-<b>T</b>,"5 x 10-7","(East Asian)",0.1683,2.95,'-,[1.88-4.64],ABI3BP,"Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)","urticaria, response to non-steroidal anti-inflammatory, angioedema",GCST002263,3:100872081
rs9323624-<b>A</b>,"1 x 10-6","(East Asian)",0.6436,2.88,'-,[1.84-4.51],IFT43,"Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)","urticaria, response to non-steroidal anti-inflammatory, angioedema",GCST002263,14:76033960
rs9833094-<b>?</b>,"2 x 10-6",,'-,'-,'-,'-,ABI3BP,"Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)","urticaria, response to non-steroidal anti-inflammatory, angioedema",GCST002263,3:100872081
rs890448-<b>?</b>,"8 x 10-6",,'-,'-,'-,'-,BANK1,"Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)","urticaria, response to non-steroidal anti-inflammatory, angioedema",GCST002263,4:101511545
rs9323624-<b>?</b>,"1 x 10-6",,'-,'-,'-,'-,IFT43,"Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)","urticaria, response to non-steroidal anti-inflammatory, angioedema",GCST002263,14:76033960
rs4617927-<b>?</b>,"4 x 10-6",,'-,'-,'-,'-,HLF,"Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)","urticaria, response to non-steroidal anti-inflammatory, angioedema",GCST002263,17:55278765
rs8008961-<b>A</b>,"6 x 10-6",(EA),0.2944,2.44,'-,[1.67-3.56],RAD51B,"Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)","urticaria, response to non-steroidal anti-inflammatory, angioedema",GCST002263,14:68285926
rs2249625-<b>C</b>,"5 x 10-6",(EA),0.3821,2.24,'-,[1.55-3.24],RIMS1,"Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)","urticaria, response to non-steroidal anti-inflammatory, angioedema",GCST002263,6:72197050
rs461409-<b>?</b>,"3 x 10-6",(EA),NR,'-,'-,'-,"DDX18P4, CTBP2P4","Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)","urticaria, response to non-steroidal anti-inflammatory, angioedema",GCST002263,5:98594262
rs6493487-<b>G</b>,"8 x 10-6","(AA-glucose response)",0.09,'-,"5.96 mg/dL increase",[3.35-8.57],"MIR4713HG, CYP19A1","Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, fasting blood glucose measurement",GCST001859,15:51221532
rs1551678-<b>C</b>,"9 x 10-6","(EA-glucose response)",0.37,'-,"2.65 mg/dL increase",[1.49-3.81],ADAM12,"Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, fasting blood glucose measurement",GCST001859,10:126140443
rs2686586-<b>T</b>,"6 x 10-8","(AA-triglyceride response)",0.47,'-,"18.93 mg/dL increase",[11.89-25.97],"EGFEM1P, GOLIM4","Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, triglyceride measurement",GCST001859,3:168180033
rs2274788-<b>C</b>,"1 x 10-6","(EA-triglyceride response)",0.25,'-,"23.07 mg/dL decrease",[13.8-32.34],ARHGAP29,"Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, triglyceride measurement",GCST001859,1:94209170
rs12307997-<b>G</b>,"6 x 10-7","(AA-triglyceride response)",0.22,'-,"22.11 mg/dL increase",[13.41-30.81],"GDF3, DPPA3","Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, triglyceride measurement",GCST001859,12:7702675
rs2980003-<b>T</b>,"5 x 10-6","(EA-triglyceride response)",0.27,'-,"22.07 mg/dL increase",[12.6-31.54],RPL31P41,"Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, triglyceride measurement",GCST001859,8:65087728
rs10508921-<b>T</b>,"9 x 10-7","(AA-triglyceride response)",0.13,'-,"25.7 mg/dL decrease",[15.47-35.93],ASAH2,"Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, triglyceride measurement",GCST001859,10:50250948
rs10943724-<b>A</b>,"7 x 10-6","(EA-triglyceride response)",0.31,'-,"19.77 mg/dL decrease",[11.15-28.39],'-,"Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, triglyceride measurement",GCST001859,6:80593088
rs9420790-<b>A</b>,"2 x 10-6","(AA-triglyceride response)",0.08,'-,"34.63 mg/dL decrease",[20.46-48.8],SEC31B,"Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, triglyceride measurement",GCST001859,10:100496440
rs11077614-<b>G</b>,"3 x 10-6","(EA-glucose response)",0.49,'-,"3.25 mg/dL decrease",[1.92-4.58],LINC00511,"Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, fasting blood glucose measurement",GCST001859,17:72598490
rs2613514-<b>G</b>,"3 x 10-6","(AA-triglyceride response)",0.22,'-,"20.12 mg/dL decrease",[11.65-28.59],TMC6,"Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, triglyceride measurement",GCST001859,17:78114437
rs11810574-<b>G</b>,"4 x 10-6","(AA-triglyceride response)",0.15,'-,"23.12 mg/dL decrease",[13.34-32.9],FMN2,"Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, triglyceride measurement",GCST001859,1:240120436
rs7203315-<b>T</b>,"4 x 10-6","(AA-triglyceride response)",0.34,'-,"15.83 mg/dL increase",[9.13-22.53],GRIN2A,"Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, triglyceride measurement",GCST001859,16:10094203
rs878131-<b>A</b>,"4 x 10-6","(AA-triglyceride response)",0.25,'-,"17.21 mg/dL increase",[9.92-24.5],EYA2,"Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, triglyceride measurement",GCST001859,20:47051863
rs225675-<b>G</b>,"1 x 10-7","(AA-glucose response)",0.19,'-,"5.29 mg/dL decrease",[3.35-7.23],VTA1,"Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, fasting blood glucose measurement",GCST001859,6:142190999
rs9788333-<b>G</b>,"4 x 10-6","(AA-triglyceride response)",0.11,'-,"28.65 mg/dL decrease",[16.46-40.84],MIPEPP3,"Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, triglyceride measurement",GCST001859,13:21301957
rs7801534-<b>G</b>,"7 x 10-7","(AA-glucose response)",0.17,'-,"4.96 mg/dL increase",[3.02-6.9],DDX43P2,"Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, fasting blood glucose measurement",GCST001859,7:49290084
rs6870564-<b>A</b>,"4 x 10-6","(EA-glucose response)",0.13,'-,"3.84 mg/dL increase",[2.21-5.47],"RNU6-660P, BASP1","Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, fasting blood glucose measurement",GCST001859,5:17002976
rs12507634-<b>G</b>,"4 x 10-6","(AA-glucose response)",0.19,'-,"4.84 mg/dL decrease",[2.78-6.9],LINC02268,"Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, fasting blood glucose measurement",GCST001859,4:174150451
rs1974942-<b>A</b>,"4 x 10-6","(EA-glucose response)",0.1,'-,"5.29 mg/dL decrease",[3.04-7.54],"JADRR, JADE1","Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, fasting blood glucose measurement",GCST001859,4:128775066
rs10778699-<b>A</b>,"4 x 10-6","(AA-glucose response)",0.24,'-,"4.28 mg/dL increase",[2.46-6.1],"OTOGL, RNU7-106P","Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, fasting blood glucose measurement",GCST001859,12:80069304
rs1511453-<b>A</b>,"5 x 10-6","(EA-glucose response)",0.08,'-,"4.95 mg/dL increase",[2.83-7.07],RFPL4AP3,"Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, fasting blood glucose measurement",GCST001859,4:23586839
rs13402330-<b>A</b>,"6 x 10-6","(AA-glucose response)",0.19,'-,"5.27 mg/dL decrease",[3-7.54],TMEM182,"Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, fasting blood glucose measurement",GCST001859,2:102895834
rs7762018-<b>A</b>,"8 x 10-6","(EA-glucose response)",0.13,'-,"3.65 mg/dL increase",[2.06-5.24],PHF10,"Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, fasting blood glucose measurement",GCST001859,6:169713148
rs16951120-<b>T</b>,"6 x 10-6","(AA-glucose response)",0.15,'-,"4.49 mg/dL increase",[2.55-6.43],CA10,"Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, fasting blood glucose measurement",GCST001859,17:52216278
rs6859974-<b>T</b>,"8 x 10-6","(EA-glucose response)",0.14,'-,"3.67 mg/dL increase",[2.06-5.28],"MGAT1, OR2Y1","Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, fasting blood glucose measurement",GCST001859,5:180778938
rs12279250-<b>C</b>,"7 x 10-9","(AA-triglyceride response)",0.15,'-,"28.2 mg/dL increase",[18.67-37.73],NELL1,"Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, triglyceride measurement",GCST001859,11:21543533
rs17560407-<b>G</b>,"5 x 10-7","(EA-triglyceride response)",0.27,'-,"23.23 mg/dL decrease",[14.14-32.32],"MEF2C, MEF2C-AS1","Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, triglyceride measurement",GCST001859,5:88887834
rs12455924-<b>T</b>,"3 x 10-7","(AA-triglyceride response)",0.36,'-,"17.88 mg/dL decrease",[11.04-24.72],PIEZO2,"Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, triglyceride measurement",GCST001859,18:11064410
rs11216831-<b>A</b>,"4 x 10-6","(EA-triglyceride response)",0.07,'-,"42.47 mg/dL increase",[24.4-60.54],MPZL3,"Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, triglyceride measurement",GCST001859,11:118246303
rs10152811-<b>A</b>,"8 x 10-7","(AA-triglyceride response)",0.69,'-,"18.81 mg/dL decrease",[11.32-26.3],"AGBL1-AS1, AGBL1","Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, triglyceride measurement",GCST001859,15:86311359
rs11648716-<b>G</b>,"7 x 10-6","(EA-triglyceride response)",0.08,'-,"39.68 mg/dL decrease",[22.37-56.99],"IRF8, COX4I1","Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, triglyceride measurement",GCST001859,16:85873010
rs12127679-<b>T</b>,"1 x 10-6","(AA-triglyceride response)",0.19,'-,"22.31 mg/dL increase",[13.24-31.38],LINC02774,"Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, triglyceride measurement",GCST001859,1:244004499
rs17183114-<b>T</b>,"8 x 10-6","(EA-triglyceride response)",0.14,'-,"26.49 mg/dL increase",[14.89-38.09],LINC02500,"Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, triglyceride measurement",GCST001859,4:181301574
rs10985375-<b>A</b>,"2 x 10-6","(AA-triglyceride response)",0.1,'-,"33.94 mg/dL decrease",[19.81-48.07],"DAB2IP, TTLL11","Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, triglyceride measurement",GCST001859,9:121787363
rs4722750-<b>T</b>,"9 x 10-6","(EA-triglyceride response)",0.1,'-,"31.88 mg/dL decrease",[17.85-45.91],JAZF1,"Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, triglyceride measurement",GCST001859,7:27964579
rs2116940-<b>G</b>,"3 x 10-6","(AA-triglyceride response)",0.19,'-,"19.71 mg/dL decrease",[11.4-28.02],DNMT1,"Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, triglyceride measurement",GCST001859,19:10199716
rs12303914-<b>A</b>,"6 x 10-6","(EA-triglyceride response)",0.35,'-,"20.39 mg/dL increase",[11.51-29.27],KLRD1,"Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, triglyceride measurement",GCST001859,12:10318451
rs1559759-<b>A</b>,"9 x 10-6","(EA-triglyceride response)",0.15,'-,"25.59 mg/dL increase",[14.3-36.88],"CD44, PDHX","Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, triglyceride measurement",GCST001859,11:35101504
rs166881-<b>C</b>,"4 x 10-6","(AA-triglyceride response)",0.18,'-,"22.26 mg/dL decrease",[12.79-31.73],SLC35F1,"Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, triglyceride measurement",GCST001859,6:118297818
rs7077606-<b>T</b>,"5 x 10-7","(AA-glucose response)",0.12,'-,"5.44 mg/dL decrease",[3.32-7.56],'-,"Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, fasting blood glucose measurement",GCST001859,10:53647331
rs17668704-<b>A</b>,"9 x 10-6","(AA-glucose response)",0.61,'-,"3.38 mg/dL decrease",[1.89-4.87],"LINC01572, PMFBP1","Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, fasting blood glucose measurement",GCST001859,16:72223800
rs7964748-<b>G</b>,"3 x 10-6","(AA-glucose response)",0.28,'-,"4.06 mg/dL increase",[2.37-5.75],IGF1,"Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, fasting blood glucose measurement",GCST001859,12:102571551
rs427576-<b>C</b>,"4 x 10-6","(EA-glucose response)",0.43,'-,"2.62 mg/dL decrease",[1.5-3.74],ZFHX3,"Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, fasting blood glucose measurement",GCST001859,16:73795371
rs11785622-<b>T</b>,"4 x 10-6","(AA-glucose response)",0.07,'-,"7.21 mg/dL decrease",[4.15-10.27],"NIPAL2, STK3","Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, fasting blood glucose measurement",GCST001859,8:98305511
rs1669070-<b>T</b>,"4 x 10-6","(EA-glucose response)",0.4,'-,"3.02 mg/dL decrease",[1.73-4.31],ARMC9,"Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, fasting blood glucose measurement",GCST001859,2:231327593
rs11599315-<b>T</b>,"5 x 10-6","(AA-glucose response)",0.37,'-,"3.88 mg/dL decrease",[2.21-5.55],ADARB2,"Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, fasting blood glucose measurement",GCST001859,10:1300822
rs10989824-<b>T</b>,"7 x 10-6","(EA-glucose response)",0.06,'-,"5.85 mg/dL decrease",[3.3-8.4],ARL2BPP7,"Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, fasting blood glucose measurement",GCST001859,9:102105556
rs7965364-<b>T</b>,"6 x 10-6","(AA-glucose response)",0.37,'-,"3.79 mg/dL increase",[2.14-5.44],"KRAS, RNU4-67P","Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, fasting blood glucose measurement",GCST001859,12:25331259
rs890749-<b>C</b>,"8 x 10-6","(EA-glucose response)",0.19,'-,"3.25 mg/dL decrease",[1.82-4.68],"ZNF474, LOX","Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, fasting blood glucose measurement",GCST001859,5:122100901
rs4808260-<b>C</b>,"7 x 10-6","(AA-glucose response)",0.3,'-,"3.71 mg/dL decrease",[2.08-5.34],"ZNF626, VN1R79P","Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, fasting blood glucose measurement",GCST001859,19:20663465
rs2944755-<b>A</b>,"8 x 10-6","(AA-glucose response)",0.06,'-,"9.45 mg/dL decrease",[5.31-13.59],AGO2,"Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, fasting blood glucose measurement",GCST001859,8:140564095
rs2460504-<b>C</b>,"5 x 10-6","(AA-triglyceride response)",0.18,'-,"24.57 mg/dL decrease",[14.06-35.08],"S100Z, RNU6ATAC36P","Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, triglyceride measurement",GCST001859,5:76928346
rs7147996-<b>A</b>,"6 x 10-6","(AA-triglyceride response)",0.12,'-,"28.09 mg/dL decrease",[15.96-40.22],EFCAB11,"Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, triglyceride measurement",GCST001859,14:89930230
rs17133858-<b>T</b>,"6 x 10-6","(AA-triglyceride response)",0.14,'-,"20.99 mg/dL decrease",[11.92-30.06],ARRB1,"Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, triglyceride measurement",GCST001859,11:75260513
rs12904863-<b>C</b>,"6 x 10-6","(AA-triglyceride response)",0.08,'-,"30.31 mg/dL decrease",[17.22-43.4],THSD4,"Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, triglyceride measurement",GCST001859,15:71131670
rs12498735-<b>T</b>,"8 x 10-6","(AA-triglyceride response)",0.25,'-,"19.13 mg/dL increase",[10.74-27.52],STOX2,"Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, triglyceride measurement",GCST001859,4:184000146
rs2099077-<b>A</b>,"8 x 10-6","(AA-triglyceride response)",0.29,'-,"16.53 mg/dL decrease",[9.26-23.8],"SNORD29, PDZPH1P","Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, triglyceride measurement",GCST001859,5:103428347
rs6928289-<b>G</b>,"9 x 10-6","(AA-triglyceride response)",0.45,'-,"15.56 mg/dL decrease",[8.68-22.44],'-,"Thiazide-induced adverse metabolic effects in hypertensive patients","response to hydrochlorothiazide, triglyceride measurement",GCST001859,6:137352165
rs59532114-<b>A</b>,"2 x 10-8",,0.04,'-,'-,'-,BCL2,"Response to adalimumab in hidradenitis suppurativa (abscess and inflammatory nodule count increase)","response to TNF antagonist, hidradenitis suppurativa",GCST009601,18:63162799
rs7046653-<b>A</b>,"5 x 10-7",,0.26,'-,'-,'-,MOB3B,"Response to TNF antagonist treatment","response to TNF antagonist",GCST000211,9:27490969
rs13393173-<b>A</b>,"4 x 10-6",,0.12,'-,'-,'-,CERS6,"Response to TNF antagonist treatment","response to TNF antagonist",GCST000211,2:168532581
rs6138150-<b>T</b>,"3 x 10-6",,0.84,'-,'-,'-,"CST5, CST2","Response to TNF antagonist treatment","response to TNF antagonist",GCST000211,20:23866372
rs983332-<b>A</b>,"5 x 10-6",,0.21,'-,'-,'-,PKN2-AS1,"Response to TNF antagonist treatment","response to TNF antagonist",GCST000211,1:87666697
rs437943-<b>G</b>,"4 x 10-6",,0.33,'-,'-,'-,'-,"Response to TNF antagonist treatment","response to TNF antagonist",GCST000211,4:35370476
rs854555-<b>A</b>,"2 x 10-6",,0.34,'-,'-,'-,PON1,"Response to TNF antagonist treatment","response to TNF antagonist",GCST000211,7:95301079
rs10945919-<b>G</b>,"3 x 10-7",,0.32,'-,'-,'-,RN7SL366P,"Response to TNF antagonist treatment","response to TNF antagonist",GCST000211,6:163765645
rs6028945-<b>T</b>,"2 x 10-7",,0.12,'-,'-,'-,'-,"Response to TNF antagonist treatment","response to TNF antagonist",GCST000211,20:40192165
rs4707930-<b>?</b>,"6 x 10-6",,NR,6.603,'-,[NR],RNU4-66P,"Response to anti-TNF alpha therapy in inflammatory bowel disease","response to TNF antagonist",GCST000748,6:71696616
rs1155848-<b>?</b>,"5 x 10-7",,NR,35.73,'-,[NR],RBM26,"Response to anti-TNF alpha therapy in inflammatory bowel disease","response to TNF antagonist",GCST000748,13:79314341
rs1592749-<b>?</b>,"1 x 10-6",,NR,5.949,'-,[NR],"MIR3142HG, ATP10B","Response to anti-TNF alpha therapy in inflammatory bowel disease","response to TNF antagonist",GCST000748,5:160545014
rs765132-<b>?</b>,"1 x 10-6",,NR,35,'-,[NR],"MIR106A, LARP1BP3","Response to anti-TNF alpha therapy in inflammatory bowel disease","response to TNF antagonist",GCST000748,X:134188574
rs12646351-<b>?</b>,"2 x 10-7",,NR,25,'-,[3.03-100],ZNF827,"Severe skin toxicity response to cetuximab in colorectal cancer","colorectal cancer, skin disease, response to cetuximab",GCST007259,4:145819473
rs17806780-<b>?</b>,"3 x 10-7",,NR,25,'-,[2.86-100],ZNF827,"Severe skin toxicity response to cetuximab in colorectal cancer","colorectal cancer, skin disease, response to cetuximab",GCST007259,4:145811502
rs7692430-<b>?</b>,"4 x 10-7",,NR,4.57,'-,[2.46-8.49],EPHA5,"Severe skin toxicity response to cetuximab in colorectal cancer","colorectal cancer, skin disease, response to cetuximab",GCST007259,4:65354979
chr2:3625175-<b>?</b>,"1 x 10-6",,NR,7.142857,'-,[2.56-20],'-,"Severe skin toxicity response to cetuximab in colorectal cancer","colorectal cancer, skin disease, response to cetuximab",GCST007259,"Mapping not available"
rs11183750-<b>?</b>,"2 x 10-6",,NR,7.142857,'-,[2.5-20],PCED1B,"Severe skin toxicity response to cetuximab in colorectal cancer","colorectal cancer, skin disease, response to cetuximab",GCST007259,12:47123912
rs7012009-<b>?</b>,"2 x 10-6",,NR,25,'-,[2.7-100],"SLCO5A1, Metazoa_SRP","Severe skin toxicity response to cetuximab in colorectal cancer","colorectal cancer, skin disease, response to cetuximab",GCST007259,8:69841638
rs2422088-<b>?</b>,"2 x 10-6",,NR,5.882353,'-,[0.075-0.41],"POLE4, TACR1","Severe skin toxicity response to cetuximab in colorectal cancer","colorectal cancer, skin disease, response to cetuximab",GCST007259,2:75024234
rs13155752-<b>?</b>,"2 x 10-6",,NR,3.82,'-,[2.11-6.92],"RN7SL383P, LINC02224","Severe skin toxicity response to cetuximab in colorectal cancer","colorectal cancer, skin disease, response to cetuximab",GCST007259,5:44680585
11:92331394:A_AT-<b>?</b>,"2 x 10-8",(AA),NR,'-,'-,'-,'-,"Change in glucose in response to thiazide diuretic treatment in hypertension","response to thiazide, hypertension, glucose measurement",GCST005577,"Mapping not available"
12:52807944-<b>?</b>,"1 x 10-7",(EA),'-,'-,'-,'-,'-,"Change in glucose in response to thiazide diuretic treatment in hypertension","response to thiazide, hypertension, glucose measurement",GCST005577,"Mapping not available"
6:5337596-<b>?</b>,"2 x 10-7",(EA),'-,'-,'-,'-,'-,"Change in glucose in response to thiazide diuretic treatment in hypertension","response to thiazide, hypertension, glucose measurement",GCST005577,"Mapping not available"
rs9943291-<b>G</b>,"4 x 10-8",(AA),0.0637,'-,"10.01 unit increase",[NR],HMGCS2,"Change in glucose in response to thiazide diuretic treatment in hypertension","response to thiazide, hypertension, glucose measurement",GCST005577,1:119749667
6:131801262-<b>?</b>,"6 x 10-7",(EA),'-,'-,'-,'-,'-,"Change in glucose in response to thiazide diuretic treatment in hypertension","response to thiazide, hypertension, glucose measurement",GCST005577,"Mapping not available"
rs61824877-<b>A</b>,"5 x 10-8",(AA),0.0606,'-,"9.08 unit increase",[NR],LINC00862,"Change in glucose in response to thiazide diuretic treatment in hypertension","response to thiazide, hypertension, glucose measurement",GCST005577,1:200273504
rs281508-<b>?</b>,"1 x 10-6","(Recessive model)",NR,'-,"0.77 unit increase",'-,PRKCE,"Response to zileuton treatment in asthma (FEV1 change interaction)","FEV change measurement, response to zileuton, asthma",GCST002951,2:46184068
rs2193412-<b>?</b>,"4 x 10-6","(Recessive model)",NR,'-,"0.6 unit increase",'-,NRXN1,"Response to zileuton treatment in asthma (FEV1 change interaction)","FEV change measurement, response to zileuton, asthma",GCST002951,2:50909664
rs12991650-<b>?</b>,"3 x 10-6","(Additive model)",NR,'-,"0.41 unit decrease",'-,'-,"Response to zileuton treatment in asthma (FEV1 change interaction)","FEV change measurement, response to zileuton, asthma",GCST002951,2:210976104
rs6790709-<b>?</b>,"3 x 10-6","(Additive model)",NR,'-,"0.36 unit decrease",'-,RBMS3,"Response to zileuton treatment in asthma (FEV1 change interaction)","FEV change measurement, response to zileuton, asthma",GCST002951,3:29005953
rs4689355-<b>?</b>,"5 x 10-7","(Recessive model)",NR,'-,"0.61 unit increase",'-,"JAKMIP1, C4orf50","Response to zileuton treatment in asthma (FEV1 change interaction)","FEV change measurement, response to zileuton, asthma",GCST002951,4:6175408
rs4689318-<b>?</b>,"7 x 10-6","(Recessive model)",NR,'-,"0.74 unit decrease",'-,C4orf50,"Response to zileuton treatment in asthma (FEV1 change interaction)","FEV change measurement, response to zileuton, asthma",GCST002951,4:6017164
rs3812141-<b>?</b>,"8 x 10-7","(Additive model)",NR,'-,"0.5 unit decrease",'-,PRSS35,"Response to zileuton treatment in asthma (FEV1 change interaction)","FEV change measurement, response to zileuton, asthma",GCST002951,6:83524425
rs6929584-<b>?</b>,"5 x 10-6","(Dominant model)",NR,'-,"0.66 unit increase",'-,LMBRD1,"Response to zileuton treatment in asthma (FEV1 change interaction)","FEV change measurement, response to zileuton, asthma",GCST002951,6:69672978
rs3093009-<b>?</b>,"4 x 10-7","(Additive model)",NR,'-,"0.38 unit decrease",'-,CCR6,"Response to zileuton treatment in asthma (FEV1 change interaction)","FEV change measurement, response to zileuton, asthma",GCST002951,6:167135989
rs7777754-<b>?</b>,"6 x 10-6","(Recessive model)",NR,'-,"0.76 unit decrease",'-,GRB10,"Response to zileuton treatment in asthma (FEV1 change interaction)","FEV change measurement, response to zileuton, asthma",GCST002951,7:50598336
rs2720499-<b>?</b>,"3 x 10-7","(Recessive model)",NR,'-,"2.42 unit decrease",'-,SLC7A2,"Response to zileuton treatment in asthma (FEV1 change interaction)","FEV change measurement, response to zileuton, asthma",GCST002951,8:17534848
rs2741335-<b>?</b>,"8 x 10-6","(Additive model)",NR,'-,"0.28 unit decrease",'-,"EPHX2, CHRNA2","Response to zileuton treatment in asthma (FEV1 change interaction)","FEV change measurement, response to zileuton, asthma",GCST002951,8:27480274
rs11812286-<b>?</b>,"3 x 10-6","(Recessive model)",NR,'-,"2.27 unit decrease",'-,FAM13C,"Response to zileuton treatment in asthma (FEV1 change interaction)","FEV change measurement, response to zileuton, asthma",GCST002951,10:59313854
rs1910505-<b>?</b>,"4 x 10-6","(Additive model)",NR,'-,"0.3 unit increase",'-,LINC02752,"Response to zileuton treatment in asthma (FEV1 change interaction)","FEV change measurement, response to zileuton, asthma",GCST002951,11:11087692
rs517020-<b>?</b>,"7 x 10-7","(Additive model)",NR,'-,"0.43 unit decrease",'-,GLT1D1,"Response to zileuton treatment in asthma (FEV1 change interaction)","FEV change measurement, response to zileuton, asthma",GCST002951,12:128978158
rs7976838-<b>?</b>,"4 x 10-7","(Recessive model)",NR,'-,"2.32 unit decrease",'-,SLC16A7,"Response to zileuton treatment in asthma (FEV1 change interaction)","FEV change measurement, response to zileuton, asthma",GCST002951,12:59692425
rs12436663-<b>?</b>,"6 x 10-8","(Recessive model)",NR,'-,"1.54 unit decrease",'-,PRORP,"Response to zileuton treatment in asthma (FEV1 change interaction)","FEV change measurement, response to zileuton, asthma",GCST002951,14:35169914
rs1872085-<b>?</b>,"2 x 10-6","(Recessive model)",NR,'-,"0.69 unit increase",'-,SDK2,"Response to zileuton treatment in asthma (FEV1 change interaction)","FEV change measurement, response to zileuton, asthma",GCST002951,17:73531941
rs9952762-<b>?</b>,"5 x 10-7","(Dominant model)",NR,'-,"0.64 unit increase",'-,LINC01898,"Response to zileuton treatment in asthma (FEV1 change interaction)","FEV change measurement, response to zileuton, asthma",GCST002951,18:75689695
rs917063-<b>?</b>,"1 x 10-6","(Additive model)",NR,'-,"0.34 unit decrease",'-,PCNX1,"Response to zileuton treatment in asthma (FEV1 change interaction)","FEV change measurement, response to zileuton, asthma",GCST002951,14:71181355
rs2899832-<b>?</b>,"6 x 10-6","(Recessive model)",NR,'-,"1.47 unit decrease",'-,PRORP,"Response to zileuton treatment in asthma (FEV1 change interaction)","FEV change measurement, response to zileuton, asthma",GCST002951,14:35271735
rs1333973-<b>A</b>,"1 x 10-10",,0.32,'-,'-,'-,IFI44L,"Immune response to measles vaccine (measles-specific neutralising antibody titre)","response to vaccine",GCST004269,1:78628396
rs2724384-<b>A</b>,"3 x 10-9",,0.23,'-,'-,'-,CD46,"Immune response to measles vaccine (measles-specific neutralising antibody titre)","response to vaccine",GCST004269,1:207756858
rs6669384-<b>C</b>,"1 x 10-8",,0.22,'-,'-,'-,MIR29B2CHG,"Immune response to measles vaccine (measles-specific neutralising antibody titre)","response to vaccine",GCST004269,1:207852581
rs2724374-<b>G</b>,"5 x 10-9",(EA),0.23,'-,'-,'-,CD46,"Immune response to measles vaccine (measles-specific neutralising antibody titre)","response to vaccine",GCST004269,1:207767846
rs1333973-<b>A</b>,"2 x 10-8",(EA),0.33,'-,'-,'-,IFI44L,"Immune response to measles vaccine (measles-specific neutralising antibody titre)","response to vaccine",GCST004269,1:78628396
rs6669384-<b>C</b>,"4 x 10-8",(EA),0.23,'-,'-,'-,MIR29B2CHG,"Immune response to measles vaccine (measles-specific neutralising antibody titre)","response to vaccine",GCST004269,1:207852581
rs316274-<b>?</b>,"8 x 10-7",(AA),'-,'-,'-,'-,RASAL2,"Immune response to smallpox vaccine (IL-6)","response to vaccine",GCST001491,1:178173073
rs11786194-<b>?</b>,"9 x 10-7",(AA),'-,'-,'-,'-,VENTXP5,"Immune response to smallpox vaccine (IL-6)","response to vaccine",GCST001491,8:33815493
rs12256830-<b>?</b>,"2 x 10-10",(Hispanic),'-,'-,'-,'-,'-,"Immune response to smallpox vaccine (IL-6)","response to vaccine",GCST001491,10:53624983
rs7394570-<b>?</b>,"1 x 10-6",(EA),'-,'-,'-,'-,LINC02740,"Immune response to smallpox vaccine (IL-6)","response to vaccine",GCST001491,11:42294336
rs12425131-<b>?</b>,"2 x 10-6",(EA),'-,'-,'-,'-,TMTC2,"Immune response to smallpox vaccine (IL-6)","response to vaccine",GCST001491,12:82591100
rs359965-<b>?</b>,"2 x 10-6",(EA),'-,'-,'-,'-,LINC00608,"Immune response to smallpox vaccine (IL-6)","response to vaccine",GCST001491,2:218976169
rs2836770-<b>?</b>,"3 x 10-6",(EA),'-,'-,'-,'-,"LINC01700, RPSAP64","Immune response to smallpox vaccine (IL-6)","response to vaccine",GCST001491,21:38942780
rs11115322-<b>?</b>,"3 x 10-6",(EA),'-,'-,'-,'-,TMTC2,"Immune response to smallpox vaccine (IL-6)","response to vaccine",GCST001491,12:82625409
rs11723261-<b>?</b>,"4 x 10-6",(EA),'-,'-,'-,'-,ZNF732,"Immune response to smallpox vaccine (IL-6)","response to vaccine",GCST001491,4:288710
rs4955826-<b>?</b>,"5 x 10-6",(EA),'-,'-,'-,'-,CACNA2D3,"Immune response to smallpox vaccine (IL-6)","response to vaccine",GCST001491,3:55001847
rs13388915-<b>?</b>,"8 x 10-6",(EA),'-,'-,'-,'-,RAB10,"Immune response to smallpox vaccine (IL-6)","response to vaccine",GCST001491,2:26049733
rs9608102-<b>?</b>,"8 x 10-6",(EA),'-,'-,'-,'-,BCR,"Immune response to smallpox vaccine (IL-6)","response to vaccine",GCST001491,22:23302607
rs10489759-<b>?</b>,"8 x 10-8",(EA),'-,'-,'-,'-,RNA5SP73,"Immune response to smallpox vaccine (IL-6)","response to vaccine",GCST001491,1:189620209
rs10108684-<b>?</b>,"1 x 10-8",(AA),'-,'-,'-,'-,ZHX2,"Immune response to smallpox vaccine (IL-6)","response to vaccine",GCST001491,8:122960828
rs9959145-<b>?</b>,"3 x 10-8",(AA),'-,'-,'-,'-,SPIRE1,"Immune response to smallpox vaccine (IL-6)","response to vaccine",GCST001491,18:12606464
rs10495471-<b>?</b>,"2 x 10-7",(AA),'-,'-,'-,'-,GREM2,"Immune response to smallpox vaccine (IL-6)","response to vaccine",GCST001491,1:240542807
rs17070309-<b>?</b>,"5 x 10-7",(AA),'-,'-,'-,'-,CSMD1,"Immune response to smallpox vaccine (IL-6)","response to vaccine",GCST001491,8:4442361
rs2834655-<b>?</b>,"5 x 10-7",(AA),'-,'-,'-,'-,RUNX1,"Immune response to smallpox vaccine (IL-6)","response to vaccine",GCST001491,21:34866210
rs1322846-<b>?</b>,"6 x 10-7",(AA),'-,'-,'-,'-,RBM24,"Immune response to smallpox vaccine (IL-6)","response to vaccine",GCST001491,6:17240923
rs7140601-<b>?</b>,"7 x 10-7",(AA),'-,'-,'-,'-,LINC01550,"Immune response to smallpox vaccine (IL-6)","response to vaccine",GCST001491,14:97996820
rs1940973-<b>?</b>,"8 x 10-7",(AA),'-,'-,'-,'-,SPIRE1,"Immune response to smallpox vaccine (IL-6)","response to vaccine",GCST001491,18:12550748
rs10508727-<b>?</b>,"1 x 10-10",(AA),'-,'-,'-,'-,MKX,"Immune response to smallpox vaccine (IL-6)","response to vaccine",GCST001491,10:27736842
rs10503951-<b>?</b>,"3 x 10-9",(AA),'-,'-,'-,'-,VENTXP5,"Immune response to smallpox vaccine (IL-6)","response to vaccine",GCST001491,8:33808162
rs12775535-<b>?</b>,"4 x 10-9",(AA),'-,'-,'-,'-,"GPN3P1, GPR158","Immune response to smallpox vaccine (IL-6)","response to vaccine",GCST001491,10:25629950
rs2860975-<b>?</b>,"2 x 10-7",(Hispanic),'-,'-,'-,'-,CYP2C59P,"Immune response to smallpox vaccine (IL-6)","response to vaccine",GCST001491,10:95007177
rs3135363-<b>?</b>,"7 x 10-22",,NR,1.53,'-,[1.35-1.74],'-,"Hepatitis B vaccine response","response to vaccine",GCST001162,"Mapping not available"
rs9267665-<b>?</b>,"1 x 10-17",,NR,2.05,'-,[1.64-2.57],C2,"Hepatitis B vaccine response","response to vaccine",GCST001162,6:31903079
rs4469412-<b>?</b>,"9 x 10-7",(AA),'-,'-,'-,'-,"BUD31P1, RN7SL457P","Immune response to smallpox vaccine (IL-6)","response to vaccine",GCST001491,8:33707860
rs3804795-<b>?</b>,"1 x 10-6",(AA),'-,'-,'-,'-,IL5RA,"Immune response to smallpox vaccine (IL-6)","response to vaccine",GCST001491,3:3088961
rs12282-<b>?</b>,"3 x 10-7",(Hispanic),'-,'-,'-,'-,GOLGA3,"Immune response to smallpox vaccine (IL-6)","response to vaccine",GCST001491,12:132769223
rs1934953-<b>?</b>,"5 x 10-7",(Hispanic),'-,'-,'-,'-,CYP2C8,"Immune response to smallpox vaccine (IL-6)","response to vaccine",GCST001491,10:95037713
rs6081597-<b>?</b>,"7 x 10-7",(Hispanic),'-,'-,'-,'-,PDYN-AS1,"Immune response to smallpox vaccine (IL-6)","response to vaccine",GCST001491,20:2014888
rs2553218-<b>?</b>,"8 x 10-7",(Hispanic),'-,'-,'-,'-,UNC13C,"Immune response to smallpox vaccine (IL-6)","response to vaccine",GCST001491,15:54576470
rs9835812-<b>?</b>,"8 x 10-7",(Hispanic),'-,'-,'-,'-,'-,"Immune response to smallpox vaccine (IL-6)","response to vaccine",GCST001491,3:3334100
rs10512697-<b>?</b>,"9 x 10-7",(Hispanic),'-,'-,'-,'-,"IRX1, LINC01019","Immune response to smallpox vaccine (IL-6)","response to vaccine",GCST001491,5:3558424
rs2548621-<b>?</b>,"9 x 10-7",(Hispanic),'-,'-,'-,'-,SNX18,"Immune response to smallpox vaccine (IL-6)","response to vaccine",GCST001491,5:54606509
rs12148329-<b>?</b>,"9 x 10-7",(Hispanic),'-,'-,'-,'-,ABHD17C,"Immune response to smallpox vaccine (IL-6)","response to vaccine",GCST001491,15:80708937
rs4748153-<b>?</b>,"3 x 10-8",(Hispanic),'-,'-,'-,'-,PRKCQ,"Immune response to smallpox vaccine (IL-6)","response to vaccine",GCST001491,10:6564579
rs9380880-<b>?</b>,"1 x 10-7",(Hispanic),'-,'-,'-,'-,KIF6,"Immune response to smallpox vaccine (IL-6)","response to vaccine",GCST001491,6:39561206
rs3736995-<b>?</b>,"3 x 10-7","(IFN gamma response)",'-,'-,'-,'-,CDK8,"Immune response to measles-mumps-rubella vaccine","response to vaccine",GCST002441,13:26349428
rs1982955-<b>?</b>,"4 x 10-7","(IFN gamma response)",'-,'-,'-,'-,MIR4719,"Immune response to measles-mumps-rubella vaccine","response to vaccine",GCST002441,16:76935701
rs7218761-<b>?</b>,"1 x 10-7","(IL-6 response)",'-,'-,'-,'-,DNAH9,"Immune response to measles-mumps-rubella vaccine","response to vaccine",GCST002441,17:11790270
kgp4580976-<b>?</b>,"3 x 10-7","(IFN gamma response)",'-,'-,'-,'-,'-,"Immune response to measles-mumps-rubella vaccine","response to vaccine",GCST002441,"Mapping not available"
rs10813374-<b>?</b>,"3 x 10-8","(IFN gamma response)",'-,'-,'-,'-,"RPS26P2, FTLP4","Immune response to measles-mumps-rubella vaccine","response to vaccine",GCST002441,9:30879677
rs9806400-<b>?</b>,"2 x 10-7","(IFN gamma response)",'-,'-,'-,'-,NR2F2-AS1,"Immune response to measles-mumps-rubella vaccine","response to vaccine",GCST002441,15:96198191
rs6112821-<b>?</b>,"3 x 10-7","(IFN gamma response)",'-,'-,'-,'-,"STK35, RPL7P2","Immune response to measles-mumps-rubella vaccine","response to vaccine",GCST002441,20:2093677
rs16928280-<b>?</b>,"3 x 10-10","(IFN gamma response)",'-,'-,'-,'-,PTPRD,"Immune response to measles-mumps-rubella vaccine","response to vaccine",GCST002441,9:8695233
rs1243704-<b>?</b>,"7 x 10-7","(IFN gamma response)",'-,'-,'-,'-,"RNASE9, SETP1","Immune response to measles-mumps-rubella vaccine","response to vaccine",GCST002441,14:20536903
rs1430246-<b>?</b>,"2 x 10-7","(IFN gamma response)",'-,'-,'-,'-,'-,"Immune response to measles-mumps-rubella vaccine","response to vaccine",GCST002441,2:221314147
rs4140752-<b>?</b>,"8 x 10-7","(IL-6 response)",'-,'-,'-,'-,'-,"Immune response to measles-mumps-rubella vaccine","response to vaccine",GCST002441,2:41259931
rs16921385-<b>A</b>,"4 x 10-8",,NR,'-,"6.8 unit increase",[4.37-9.23],SLC1A1,"Response to risperidone in schizophrenia","schizophrenia, response to risperidone",GCST006294,9:4507513
rs7925908-<b>?</b>,"5 x 10-7",,NR,'-,'-,'-,NTM,"Glucocorticoid-induced osteonecrosis (age 10 years and older)","response to glucocorticoid, osteonecrosis",GCST003081,11:131276855
rs10989692-<b>A</b>,"1 x 10-6",,0.0905,2.07,'-,[1.59-2.7],'-,"Glucocorticoid-induced osteonecrosis (age 10 years and older)","response to glucocorticoid, osteonecrosis",GCST003081,9:101912273
rs1388941-<b>?</b>,"2 x 10-6",,NR,'-,'-,'-,CSGALNACT1,"Glucocorticoid-induced osteonecrosis (age 10 years and older)","response to glucocorticoid, osteonecrosis",GCST003081,8:19757960
rs80131293-<b>?</b>,"3 x 10-6",,NR,'-,'-,'-,CWC27,"Glucocorticoid-induced osteonecrosis (age 10 years and older)","response to glucocorticoid, osteonecrosis",GCST003081,5:64854707
rs1696756-<b>?</b>,"3 x 10-6",,NR,'-,'-,'-,"CBX4, LINC01979","Glucocorticoid-induced osteonecrosis (age 10 years and older)","response to glucocorticoid, osteonecrosis",GCST003081,17:79854174
rs192462116-<b>?</b>,"3 x 10-6",,NR,'-,'-,'-,"PPP1R9A, PPP1R9A-AS1","Glucocorticoid-induced osteonecrosis (age 10 years and older)","response to glucocorticoid, osteonecrosis",GCST003081,7:95138094
rs7445608-<b>?</b>,"4 x 10-6",,NR,'-,'-,'-,'-,"Glucocorticoid-induced osteonecrosis (age 10 years and older)","response to glucocorticoid, osteonecrosis",GCST003081,5:27646712
rs74446409-<b>?</b>,"4 x 10-6",,NR,'-,'-,'-,"KLF14, TSGA13","Glucocorticoid-induced osteonecrosis (age 10 years and older)","response to glucocorticoid, osteonecrosis",GCST003081,7:130711940
rs2400362-<b>?</b>,"4 x 10-6",,NR,'-,'-,'-,"PAG1, ZNF704","Glucocorticoid-induced osteonecrosis (age 10 years and older)","response to glucocorticoid, osteonecrosis",GCST003081,8:80937071
rs11770772-<b>?</b>,"4 x 10-6",,NR,'-,'-,'-,RAPGEF5,"Glucocorticoid-induced osteonecrosis (age 10 years and older)","response to glucocorticoid, osteonecrosis",GCST003081,7:22147462
rs1509911-<b>?</b>,"5 x 10-6",,NR,'-,'-,'-,'-,"Glucocorticoid-induced osteonecrosis (age 10 years and older)","response to glucocorticoid, osteonecrosis",GCST003081,7:81175859
rs11212617-<b>C</b>,"3 x 10-9",,0.44,1.35,'-,[1.22-1.49],C11orf65,"Response to metformin in type 2 diabetes (glycemic)","response to metformin",GCST000927,11:108412434
rs1459148-<b>?</b>,"2 x 10-6",(SAS),NR,'-,'-,'-,RN7SL714P,"Response to antipsychotic therapy (extrapyramidal side effects)","response to antipsychotic drug",GCST000514,14:98374106
rs7669317-<b>?</b>,"8 x 10-8",(AIMS),NR,'-,'-,'-,"ARHGEF38, ATP5F1EP1","Response to antipsychotic therapy (extrapyramidal side effects)","response to antipsychotic drug",GCST000514,4:105536173
rs2251301-<b>?</b>,"1 x 10-6",(BARS),NR,'-,'-,'-,LINC00529,"Response to antipsychotic therapy (extrapyramidal side effects)","response to antipsychotic drug",GCST000514,8:11261528
rs1494373-<b>?</b>,"6 x 10-6",(SAS),NR,'-,'-,'-,MTARC2,"Response to antipsychotic therapy (extrapyramidal side effects)","response to antipsychotic drug",GCST000514,1:220756014
rs17119280-<b>?</b>,"7 x 10-6",(SAS),NR,'-,'-,'-,FGGY,"Response to antipsychotic therapy (extrapyramidal side effects)","response to antipsychotic drug",GCST000514,1:59333489
rs6743931-<b>?</b>,"2 x 10-6",(AIMS),NR,'-,'-,'-,HDAC4-AS1,"Response to antipsychotic therapy (extrapyramidal side effects)","response to antipsychotic drug",GCST000514,2:239496966
rs876347-<b>?</b>,"2 x 10-6",(SAS),NR,'-,'-,'-,'-,"Response to antipsychotic therapy (extrapyramidal side effects)","response to antipsychotic drug",GCST000514,9:118268751
rs2126709-<b>?</b>,"4 x 10-7",(SAS),NR,'-,'-,'-,ZNF202,"Response to antipsychotic therapy (extrapyramidal side effects)","response to antipsychotic drug",GCST000514,11:123725219
rs4837752-<b>?</b>,"6 x 10-6",(SAS),NR,'-,'-,'-,"MIR147A, CDK5RAP2","Response to antipsychotic therapy (extrapyramidal side effects)","response to antipsychotic drug",GCST000514,9:120294359
rs12625057-<b>?</b>,"7 x 10-6",(SAS),NR,'-,'-,'-,ZNF831,"Response to antipsychotic therapy (extrapyramidal side effects)","response to antipsychotic drug",GCST000514,20:59215381
rs7928794-<b>?</b>,"8 x 10-6",(SAS),NR,'-,'-,'-,TRIM44,"Response to antipsychotic therapy (extrapyramidal side effects)","response to antipsychotic drug",GCST000514,11:35679688
rs12147450-<b>?</b>,"6 x 10-7",(BARS),NR,'-,'-,'-,"RNASE10, PNP","Response to antipsychotic therapy (extrapyramidal side effects)","response to antipsychotic drug",GCST000514,14:20489274
rs10811771-<b>?</b>,"8 x 10-7",(SAS),NR,'-,'-,'-,LINC01239,"Response to antipsychotic therapy (extrapyramidal side effects)","response to antipsychotic drug",GCST000514,9:22770887
rs17022444-<b>?</b>,"1 x 10-10",(SAS),NR,'-,'-,'-,MTND4P25,"Response to antipsychotic therapy (extrapyramidal side effects)","response to antipsychotic drug",GCST000514,2:82802345
rs337161-<b>?</b>,"3 x 10-6",(SAS),NR,'-,'-,'-,"MTARC2, C1orf115","Response to antipsychotic therapy (extrapyramidal side effects)","response to antipsychotic drug",GCST000514,1:220741578
rs9302841-<b>?</b>,"2 x 10-6",(AIMS),NR,'-,'-,'-,RBFOX1,"Response to antipsychotic therapy (extrapyramidal side effects)","response to antipsychotic drug",GCST000514,16:7177121
rs16996151-<b>?</b>,"6 x 10-6",(SAS),NR,'-,'-,'-,FAM13A,"Response to antipsychotic therapy (extrapyramidal side effects)","response to antipsychotic drug",GCST000514,4:89057649
rs286913-<b>?</b>,"7 x 10-8","(Ziprasidone, vigilance)",0.05,'-,'-,'-,EHF,"Response to antipsychotic treatment","response to antipsychotic drug",GCST000884,11:34633816
rs11240594-<b>?</b>,"1 x 10-7","(Olanzapine, processing speed)",0.19,'-,'-,'-,SLC26A9,"Response to antipsychotic treatment","response to antipsychotic drug",GCST000884,1:205927107
rs8091660-<b>?</b>,"9 x 10-6",,NR,'-,'-,'-,CTIF,"Response to carboplatin in ovarian cancer (MTT IC50)","response to platinum based chemotherapy, ovarian carcinoma, cytotoxicity measurement",GCST003440,18:48561565
rs150303591-<b>?</b>,"6 x 10-7",,NR,'-,'-,'-,FRAS1,"Response to carboplatin in ovarian cancer (MTT IC50)","response to platinum based chemotherapy, ovarian carcinoma, cytotoxicity measurement",GCST003440,4:78088155
rs201083182-<b>?</b>,"2 x 10-6",,NR,'-,'-,'-,EYS,"Response to paclitaxel in ovarian cancer (Caspase 3/7 EC50)","response to platinum based chemotherapy, ovarian carcinoma, cytotoxicity measurement",GCST003439,6:65027022
rs3842595-<b>?</b>,"3 x 10-7",,NR,'-,'-,'-,"MGC32805, SNCAIP","Response to paclitaxel in ovarian cancer (Caspase 3/7 EC50)","response to platinum based chemotherapy, ovarian carcinoma, cytotoxicity measurement",GCST003439,5:122442912
rs7461108-<b>G</b>,"4 x 10-7",(EA),0.7,'-,"2.68 bpm increase",[1.68-3.68],RPL23AP56,"Heart rate response to beta blockers (atenolol monotherapy)","response to beta blocker, heart rate",GCST005521,8:134945091
rs2830261-<b>T</b>,"3 x 10-6",(AA),0.13,'-,"5.53 bpm increase",[3.3-7.76],"CYYR1-AS1, CYYR1","Heart rate response to beta blockers (atenolol monotherapy)","response to beta blocker, heart rate",GCST005521,21:26501576
rs2823008-<b>T</b>,"8 x 10-6",(AA),0.89,'-,"5.24 bpm decrease",[3.03-7.45],NRIP1,"Heart rate response to beta blockers (atenolol monotherapy)","response to beta blocker, heart rate",GCST005521,21:15015582
rs2823005-<b>A</b>,"8 x 10-6",(AA),0.89,'-,"5.23 bpm decrease",[3.02-7.44],NRIP1,"Heart rate response to beta blockers (atenolol monotherapy)","response to beta blocker, heart rate",GCST005521,21:15008108
rs4780091-<b>C</b>,"5 x 10-6",(EA),0.86,'-,"3.32 bpm decrease",[1.95-4.69],FMN1,"Heart rate response to beta blockers (atenolol monotherapy)","response to beta blocker, heart rate",GCST005521,15:33192136
rs723730-<b>A</b>,"4 x 10-8",(EA),0.93,'-,"5.29 bpm decrease",[3.49-7.09],MARCHF1,"Heart rate response to beta blockers (atenolol add-on therapy)","response to beta blocker, heart rate",GCST005520,4:164154356
rs6835078-<b>C</b>,"4 x 10-8",(EA),0.93,'-,"5.29 bpm decrease",[3.49-7.09],MARCHF1,"Heart rate response to beta blockers (atenolol add-on therapy)","response to beta blocker, heart rate",GCST005520,4:164155752
rs6840738-<b>A</b>,"4 x 10-8",(EA),0.93,'-,"5.29 bpm decrease",[3.49-7.09],MARCHF1,"Heart rate response to beta blockers (atenolol add-on therapy)","response to beta blocker, heart rate",GCST005520,4:164156275
rs3002655-<b>T</b>,"3 x 10-6",(AA),0.76,'-,"4.21 bpm decrease",[2.52-5.9],RGL1,"Heart rate response to beta blockers (atenolol monotherapy)","response to beta blocker, heart rate",GCST005521,1:183796672
rs804136-<b>C</b>,"8 x 10-6",(AA),0.22,'-,"4.06 bpm increase",[2.34-5.78],KAZN,"Heart rate response to beta blockers (atenolol monotherapy)","response to beta blocker, heart rate",GCST005521,1:14807172
rs9991538-<b>T</b>,"5 x 10-8",(EA),0.93,'-,"5.27 bpm decrease",[3.45-7.09],MARCHF1,"Heart rate response to beta blockers (atenolol add-on therapy)","response to beta blocker, heart rate",GCST005520,4:164159680
rs10002082-<b>A</b>,"5 x 10-8",(EA),0.93,'-,"5.27 bpm decrease",[3.45-7.09],MARCHF1,"Heart rate response to beta blockers (atenolol add-on therapy)","response to beta blocker, heart rate",GCST005520,4:164159753
rs12619068-<b>C</b>,"8 x 10-6",(AA),0.47,'-,"3.46 bpm decrease",[2.01-4.91],"SPR, EXOC6B","Heart rate response to beta blockers (atenolol monotherapy)","response to beta blocker, heart rate",GCST005521,2:72842170
rs7593084-<b>C</b>,"8 x 10-6",(AA),0.47,'-,"3.46 bpm decrease",[1.99-4.93],EXOC6B,"Heart rate response to beta blockers (atenolol monotherapy)","response to beta blocker, heart rate",GCST005521,2:72786707
rs1430999-<b>G</b>,"6 x 10-8",(EA),0.93,'-,"5.26 bpm decrease",[3.44-7.08],MARCHF1,"Heart rate response to beta blockers (atenolol add-on therapy)","response to beta blocker, heart rate",GCST005520,4:164164750
rs1120384-<b>G</b>,"6 x 10-8",(EA),0.93,'-,"5.26 bpm decrease",[3.44-7.08],MARCHF1,"Heart rate response to beta blockers (atenolol add-on therapy)","response to beta blocker, heart rate",GCST005520,4:164161744
rs6713372-<b>A</b>,"9 x 10-6",(AA),0.93,'-,"6.44 bpm decrease",[3.7-9.18],'-,"Heart rate response to beta blockers (atenolol monotherapy)","response to beta blocker, heart rate",GCST005521,2:150979869
rs4315759-<b>C</b>,"7 x 10-6",(AA),0.94,'-,"8.53 bpm decrease",[4.96-12.1],TMEM131L,"Heart rate response to beta blockers (atenolol monotherapy)","response to beta blocker, heart rate",GCST005521,4:153589424
rs7673540-<b>G</b>,"4 x 10-7",(EA),0.93,'-,"5.03 bpm decrease",[3.15-6.91],MARCHF1,"Heart rate response to beta blockers (atenolol add-on therapy)","response to beta blocker, heart rate",GCST005520,4:164177450
rs6470258-<b>C</b>,"6 x 10-7",(AA),0.8,'-,"5.63 bpm decrease",[3.51-7.75],MTSS1,"Heart rate response to beta blockers (atenolol monotherapy)","response to beta blocker, heart rate",GCST005521,8:124670801
rs6470259-<b>A</b>,"7 x 10-6",(AA),0.78,'-,"4.21 bpm decrease",[2.45-5.97],MTSS1,"Heart rate response to beta blockers (atenolol monotherapy)","response to beta blocker, heart rate",GCST005521,8:124670942
rs10115550-<b>C</b>,"3 x 10-6",(AA),0.84,'-,"4.48 bpm decrease",[2.66-6.3],MAPKAP1,"Heart rate response to beta blockers (atenolol monotherapy)","response to beta blocker, heart rate",GCST005521,9:125445955
rs2804864-<b>A</b>,"5 x 10-6",(AA),0.93,'-,"6.17 bpm decrease",[3.62-8.72],LINC02628,"Heart rate response to beta blockers (atenolol monotherapy)","response to beta blocker, heart rate",GCST005521,10:33506985
rs11034161-<b>A</b>,"1 x 10-6",(AA),0.88,'-,"5.08 bpm decrease",[3.1-7.06],'-,"Heart rate response to beta blockers (atenolol monotherapy)","response to beta blocker, heart rate",GCST005521,11:37475966
rs16930242-<b>G</b>,"7 x 10-6",(AA),0.93,'-,"6.49 bpm decrease",[3.77-9.21],'-,"Heart rate response to beta blockers (atenolol monotherapy)","response to beta blocker, heart rate",GCST005521,11:37419117
rs3730662-<b>C</b>,"1 x 10-7",(AA),0.92,'-,"6.4 bpm decrease",[4.15-8.65],"POLI, MBD2","Heart rate response to beta blockers (atenolol monotherapy)","response to beta blocker, heart rate",GCST005521,18:54268905
rs3730810-<b>T</b>,"1 x 10-7",(AA),0.92,'-,"6.4 bpm decrease",[4.15-8.65],POLI,"Heart rate response to beta blockers (atenolol monotherapy)","response to beta blocker, heart rate",GCST005521,18:54292131
rs17662631-<b>T</b>,"2 x 10-6",(AA),0.95,'-,"7.52 bpm decrease",[4.52-10.52],MIR924HG,"Heart rate response to beta blockers (atenolol monotherapy)","response to beta blocker, heart rate",GCST005521,18:39145929
rs1006609-<b>A</b>,"3 x 10-6",(AA),0.92,'-,"6.6 bpm decrease",[3.95-9.25],"LINC01915, EIF4A3P1","Heart rate response to beta blockers (atenolol monotherapy)","response to beta blocker, heart rate",GCST005521,18:24534093
rs11082886-<b>A</b>,"3 x 10-6",(AA),0.77,'-,"4.41 bpm decrease",[2.63-6.19],RPS8P3,"Heart rate response to beta blockers (atenolol monotherapy)","response to beta blocker, heart rate",GCST005521,18:51748195
rs4132831-<b>G</b>,"5 x 10-6",(EA),0.66,'-,"2.44 bpm increase",[1.42-3.46],RPL23AP56,"Heart rate response to beta blockers (atenolol monotherapy)","response to beta blocker, heart rate",GCST005521,8:134943565
rs11072312-<b>A</b>,"2 x 10-6",(EA),0.86,'-,"3.37 bpm decrease",[2.02-4.72],FMN1,"Heart rate response to beta blockers (atenolol monotherapy)","response to beta blocker, heart rate",GCST005521,15:33189743
rs6822628-<b>G</b>,"4 x 10-8",(EA),0.93,'-,"5.29 bpm decrease",[3.49-7.09],MARCHF1,"Heart rate response to beta blockers (atenolol add-on therapy)","response to beta blocker, heart rate",GCST005520,4:164148204
rs17044565-<b>T</b>,"4 x 10-8",(EA),0.93,'-,"5.29 bpm decrease",[3.49-7.09],MARCHF1,"Heart rate response to beta blockers (atenolol add-on therapy)","response to beta blocker, heart rate",GCST005520,4:164148585
rs7255998-<b>A</b>,"8 x 10-6",(EA),0.88,'-,"3.25 bpm decrease",[1.88-4.62],ZNF444,"Heart rate response to beta blockers (atenolol monotherapy)","response to beta blocker, heart rate",GCST005521,19:56145644
rs547441-<b>A</b>,"2 x 10-6",(AA),0.54,'-,"3.69 bpm increase",[2.22-5.16],EFCAB2,"Heart rate response to beta blockers (atenolol monotherapy)","response to beta blocker, heart rate",GCST005521,1:245060665
rs985676-<b>T</b>,"4 x 10-8",(EA),0.93,'-,"5.29 bpm decrease",[3.49-7.09],MARCHF1,"Heart rate response to beta blockers (atenolol add-on therapy)","response to beta blocker, heart rate",GCST005520,4:164156960
rs17044630-<b>T</b>,"5 x 10-8",(EA),0.93,'-,"5.28 bpm decrease",[3.46-7.1],MARCHF1,"Heart rate response to beta blockers (atenolol add-on therapy)","response to beta blocker, heart rate",GCST005520,4:164157441
rs11930019-<b>T</b>,"5 x 10-8",(EA),0.93,'-,"5.28 bpm decrease",[3.46-7.1],MARCHF1,"Heart rate response to beta blockers (atenolol add-on therapy)","response to beta blocker, heart rate",GCST005520,4:164159224
rs6685658-<b>C</b>,"8 x 10-6",(AA),0.9,'-,"5.57 bpm decrease",[3.22-7.92],DPYD,"Heart rate response to beta blockers (atenolol monotherapy)","response to beta blocker, heart rate",GCST005521,1:97524780
rs11943491-<b>G</b>,"5 x 10-8",(EA),0.93,'-,"5.27 bpm decrease",[3.45-7.09],MARCHF1,"Heart rate response to beta blockers (atenolol add-on therapy)","response to beta blocker, heart rate",GCST005520,4:164159378
rs11931264-<b>T</b>,"5 x 10-8",(EA),0.93,'-,"5.27 bpm decrease",[3.45-7.09],MARCHF1,"Heart rate response to beta blockers (atenolol add-on therapy)","response to beta blocker, heart rate",GCST005520,4:164160251
rs1431001-<b>A</b>,"6 x 10-8",(EA),0.93,'-,"5.26 bpm decrease",[3.44-7.08],MARCHF1,"Heart rate response to beta blockers (atenolol add-on therapy)","response to beta blocker, heart rate",GCST005520,4:164164637
rs16829119-<b>G</b>,"8 x 10-6",(AA),0.3,'-,"3.78 bpm increase",[2.17-5.39],EPC2,"Heart rate response to beta blockers (atenolol monotherapy)","response to beta blocker, heart rate",GCST005521,2:148650670
rs1430998-<b>A</b>,"2 x 10-7",(EA),0.93,'-,"5.17 bpm decrease",[3.31-7.03],MARCHF1,"Heart rate response to beta blockers (atenolol add-on therapy)","response to beta blocker, heart rate",GCST005520,4:164164966
rs10517800-<b>C</b>,"4 x 10-7",(EA),0.93,'-,"5.04 bpm decrease",[3.16-6.92],MARCHF1,"Heart rate response to beta blockers (atenolol add-on therapy)","response to beta blocker, heart rate",GCST005520,4:164174438
rs17044711-<b>C</b>,"4 x 10-7",(EA),0.93,'-,"5.04 bpm decrease",[3.16-6.92],MARCHF1,"Heart rate response to beta blockers (atenolol add-on therapy)","response to beta blocker, heart rate",GCST005520,4:164172004
rs13435288-<b>A</b>,"4 x 10-7",(EA),0.93,'-,"5.03 bpm decrease",[3.15-6.91],MARCHF1,"Heart rate response to beta blockers (atenolol add-on therapy)","response to beta blocker, heart rate",GCST005520,4:164169729
rs4274995-<b>C</b>,"1 x 10-6",(AA),0.13,'-,"5.95 bpm increase",[3.68-8.22],MRPL57P6,"Heart rate response to beta blockers (atenolol monotherapy)","response to beta blocker, heart rate",GCST005521,5:162971455
rs7659131-<b>G</b>,"4 x 10-7",(EA),0.93,'-,"5.03 bpm decrease",[3.15-6.91],MARCHF1,"Heart rate response to beta blockers (atenolol add-on therapy)","response to beta blocker, heart rate",GCST005520,4:164180839
rs1835507-<b>A</b>,"4 x 10-7",(EA),0.93,'-,"5.03 bpm decrease",[3.15-6.91],MARCHF1,"Heart rate response to beta blockers (atenolol add-on therapy)","response to beta blocker, heart rate",GCST005520,4:164190521
rs12952770-<b>A</b>,"2 x 10-6",(EA),0.87,'-,"3.54 bpm decrease",[2.13-4.95],DNAH17,"Heart rate response to beta blockers (atenolol add-on therapy)","response to beta blocker, heart rate",GCST005520,17:78456913
rs12130603-<b>C</b>,"3 x 10-6",(AA),0.9,'-,"7.11 bpm decrease",[4.29-9.93],"KAZN, KAZN-AS1","Heart rate response to beta blockers (atenolol add-on therapy)","response to beta blocker, heart rate",GCST005520,1:14418293
rs13118928-<b>A</b>,"9 x 10-6",(AA),0.87,'-,"5.44 bpm decrease",[3.15-7.73],KRT18P51,"Heart rate response to beta blockers (atenolol add-on therapy)","response to beta blocker, heart rate",GCST005520,4:144565237
rs9385619-<b>C</b>,"8 x 10-6",(AA),0.72,'-,"4.35 bpm increase",[2.53-6.17],TAAR2,"Heart rate response to beta blockers (atenolol add-on therapy)","response to beta blocker, heart rate",GCST005520,6:132623384
rs16917667-<b>G</b>,"1 x 10-7",(AA),0.93,'-,"8.83 bpm decrease",[5.77-11.89],C8orf37-AS1,"Heart rate response to beta blockers (atenolol add-on therapy)","response to beta blocker, heart rate",GCST005520,8:95439600
rs1392797-<b>C</b>,"4 x 10-6",(AA),0.91,'-,"7.17 bpm decrease",[4.29-10.05],C8orf37-AS1,"Heart rate response to beta blockers (atenolol add-on therapy)","response to beta blocker, heart rate",GCST005520,8:95440624
rs1017660-<b>C</b>,"8 x 10-6",(AA),0.43,'-,"4 bpm increase",[2.31-5.69],"PPM1AP1, RPL32P19","Heart rate response to beta blockers (atenolol add-on therapy)","response to beta blocker, heart rate",GCST005520,8:15845741
rs2658796-<b>A</b>,"9 x 10-6",(AA),0.31,'-,"4.27 bpm increase",[2.47-6.07],"SMCO4, DEUP1","Heart rate response to beta blockers (atenolol add-on therapy)","response to beta blocker, heart rate",GCST005520,11:93477650
rs10142635-<b>A</b>,"6 x 10-7",(AA),0.88,'-,"6.61 bpm decrease",[4.16-9.06],EGLN3,"Heart rate response to beta blockers (atenolol add-on therapy)","response to beta blocker, heart rate",GCST005520,14:34423401
rs8035503-<b>A</b>,"4 x 10-6",(AA),0.91,'-,"6.7 bpm decrease",[3.98-9.42],GABRB3,"Heart rate response to beta blockers (atenolol add-on therapy)","response to beta blocker, heart rate",GCST005520,15:26748512
rs2000887-<b>A</b>,"3 x 10-6",(AA),0.08,'-,"7.01 bpm increase",[4.21-9.81],CCBE1,"Heart rate response to beta blockers (atenolol add-on therapy)","response to beta blocker, heart rate",GCST005520,18:59552172
rs17117817-<b>G</b>,"2 x 10-9",(AA),NR,'-,"5.53 bpm decrease",NR,"OR10P1, OR6U2P","Heart rate response to beta blockers","response to beta blocker, heart rate",GCST005519,12:55629199
rs2364349-<b>A</b>,"1 x 10-8",(AA),0.18,'-,"3.5 bpm decrease",NR,SNX9,"Heart rate response to beta blockers","response to beta blocker, heart rate",GCST005519,6:157939659
rs79206939-<b>A</b>,"1 x 10-8",,0.015,4.3,'-,[2.50-7.40],FTO,"Thiopurine-induced leukopenia in inflammatory bowel disease","leukopenia, response to thiopurine, inflammatory bowel disease",GCST003603,16:53826140
rs116855232-<b>C</b>,"1 x 10-22",,0.05,3.9,'-,[2.90-5.30],NUDT15,"Thiopurine-induced leukopenia in inflammatory bowel disease","leukopenia, response to thiopurine, inflammatory bowel disease",GCST003603,13:48045719
rs116855232-<b>T</b>,"5 x 10-94",,0.04,35.63,'-,[22.47-56.51],NUDT15,"Thiopurine-induced early leukopenia in Crohn's disease","leukopenia, response to thiopurine, Crohn's disease",GCST007229,13:48045719
rs6011368-<b>?</b>,"8 x 10-7",(AUC),NR,'-,'-,'-,"MYT1, PCMTD2","Clozapine-induced cytotoxicity","cytotoxicity measurement, response to clozapine",GCST002777,20:64255151
rs17739794-<b>?</b>,"6 x 10-6",(AUC),NR,'-,'-,'-,DLGAP2,"Clozapine-induced cytotoxicity","cytotoxicity measurement, response to clozapine",GCST002777,8:862946
rs320209-<b>?</b>,"4 x 10-7",(clozapine-glucose),0.068,'-,'-,'-,RNU6-329P,"Response to antipsychotic treatment","response to clozapine",GCST000618,9:102182473
rs2994684-<b>?</b>,"3 x 10-7",(clozapine-triglycerides),0.155,'-,'-,'-,ZNF438,"Response to antipsychotic treatment","response to clozapine",GCST000618,10:31077342
rs17216786-<b>?</b>,"1 x 10-6",(clozapine-triglycerides),0.054,'-,'-,'-,CDH13,"Response to antipsychotic treatment","response to clozapine",GCST000618,16:83453866
rs399885-<b>?</b>,"5 x 10-7","(clozapine-heart rate)",0.327,'-,'-,'-,CTNNA2,"Response to antipsychotic treatment","response to clozapine",GCST000618,2:79460126
rs1577917-<b>?</b>,"3 x 10-6",(clozapine-triglycerides),0.21,'-,'-,'-,"TCP11, RNU4-12P","Response to antipsychotic treatment","response to clozapine",GCST000618,6:85982222
rs7570469-<b>?</b>,"6 x 10-7","(clozapine-heart rate)",0.418,'-,'-,'-,CTNNA2,"Response to antipsychotic treatment","response to clozapine",GCST000618,2:79482228
rs1534238-<b>?</b>,"3 x 10-6",(clozapine-triglycerides),0.381,'-,'-,'-,ST6GALNAC2P1,"Response to antipsychotic treatment","response to clozapine",GCST000618,2:84123793
rs9658108-<b>?</b>,"5 x 10-7",(clozapine-glucose),0.052,'-,'-,'-,PPARD,"Response to antipsychotic treatment","response to clozapine",GCST000618,6:35395980
rs17661538-<b>?</b>,"1 x 10-6",(clozapine-triglycerides),0.138,'-,'-,'-,"CACNB2, SLC39A12","Response to antipsychotic treatment","response to clozapine",GCST000618,10:18108318
rs620875-<b>?</b>,"3 x 10-6",(clozapine-triglycerides),0.101,'-,'-,'-,KIRREL3,"Response to antipsychotic treatment","response to clozapine",GCST000618,11:126989261
rs10499504-<b>?</b>,"4 x 10-7","(clozapine-total cholesterol)",0.11,'-,'-,'-,LINC02889,"Response to antipsychotic treatment","response to clozapine",GCST000618,7:17521959
rs17385675-<b>?</b>,"3 x 10-6",(clozapine-triglycerides),0.069,'-,'-,'-,"RNU6-440P, FZD7","Response to antipsychotic treatment","response to clozapine",GCST000618,2:201942473
rs13224682-<b>?</b>,"6 x 10-8",(clozapine-triglycerides),0.072,'-,'-,'-,"PRKAR2B-AS1, PRKAR2B","Response to antipsychotic treatment","response to clozapine",GCST000618,7:107122773
rs6490957-<b>?</b>,"3 x 10-6",,0.966536,5.0805006,'-,[2.58-10],TPTE2P6,"Angiotensin-converting enzyme inhibitor intolerance","response to angiotensin-converting enzyme inhibitor",GCST004029,13:24595069
rs77880822-<b>?</b>,"6 x 10-6",,0.901215,1.764241,'-,[1.38-2.26],PSMF1,"Angiotensin-converting enzyme inhibitor intolerance","response to angiotensin-converting enzyme inhibitor",GCST004029,20:1167932
rs9988636-<b>?</b>,"9 x 10-7",,0.860735,1.4610485,'-,[1.26-1.7],PKN2-AS1,"Angiotensin-converting enzyme inhibitor intolerance","response to angiotensin-converting enzyme inhibitor",GCST004029,1:87602425
rs55787219-<b>?</b>,"6 x 10-6",,0.642367,1.4299707,'-,[1.22-1.67],ATP6V0E2,"Angiotensin-converting enzyme inhibitor intolerance","response to angiotensin-converting enzyme inhibitor",GCST004029,7:149900188
rs4981211-<b>?</b>,"2 x 10-6",,0.572083,1.3267844,'-,[1.18-1.49],"RNASE10, PNP","Angiotensin-converting enzyme inhibitor intolerance","response to angiotensin-converting enzyme inhibitor",GCST004029,14:20489897
rs2317621-<b>?</b>,"6 x 10-6",,0.7316,1.3132718,'-,[1.17-1.48],ACOT11,"Angiotensin-converting enzyme inhibitor intolerance","response to angiotensin-converting enzyme inhibitor",GCST004029,1:54634286
chr5:112080825-<b>?</b>,"7 x 10-6",,0.5278229999999999,1.3069708,'-,[1.16-1.47],'-,"Angiotensin-converting enzyme inhibitor intolerance","response to angiotensin-converting enzyme inhibitor",GCST004029,"Mapping not available"
rs139500482-<b>?</b>,"7 x 10-6",,0.5909800000000001,1.3031371,'-,[1.16-1.46],"SLA, TG","Angiotensin-converting enzyme inhibitor intolerance","response to angiotensin-converting enzyme inhibitor",GCST004029,8:133067867
rs9897443-<b>?</b>,"9 x 10-6",,0.616646,1.2877936,'-,[1.15-1.44],SOX9-AS1,"Angiotensin-converting enzyme inhibitor intolerance","response to angiotensin-converting enzyme inhibitor",GCST004029,17:72221025
rs59800292-<b>?</b>,"3 x 10-6",,0.5621940000000001,1.2875596,'-,[1.16-1.43],CNTNAP2,"Angiotensin-converting enzyme inhibitor intolerance","response to angiotensin-converting enzyme inhibitor",GCST004029,7:148181278
rs619426-<b>?</b>,"4 x 10-6",,0.468888,1.276973,'-,[1.151436-1.416198],LARGE1,"Angiotensin-converting enzyme inhibitor intolerance","response to angiotensin-converting enzyme inhibitor",GCST004029,22:33778807
rs6580082-<b>?</b>,"3 x 10-6",,0.468246,1.297159,'-,[1.162544-1.447362],SAP30L,"Angiotensin-converting enzyme inhibitor intolerance","response to angiotensin-converting enzyme inhibitor",GCST004029,5:154450098
rs1056265-<b>?</b>,"6 x 10-6",,0.298392,1.302217,'-,[1.161181-1.460382],PIP5K1B,"Angiotensin-converting enzyme inhibitor intolerance","response to angiotensin-converting enzyme inhibitor",GCST004029,9:68943461
rs4720575-<b>?</b>,"1 x 10-6",,0.380062,1.313155,'-,[1.176686-1.465451],MRPL42P4,"Angiotensin-converting enzyme inhibitor intolerance","response to angiotensin-converting enzyme inhibitor",GCST004029,7:47047207
chr1:99192765-<b>?</b>,"6 x 10-6",,0.343142,1.330366,'-,[1.176052-1.504928],'-,"Angiotensin-converting enzyme inhibitor intolerance","response to angiotensin-converting enzyme inhibitor",GCST004029,"Mapping not available"
rs10946364-<b>T</b>,"4 x 10-8",,0.399228,1.347209,'-,[1.211477-1.498147],MBOAT1,"Angiotensin-converting enzyme inhibitor intolerance","response to angiotensin-converting enzyme inhibitor",GCST004029,6:20176991
rs16964713-<b>?</b>,"2 x 10-6",,0.197082,1.38197,'-,[1.208836-1.579902],"Metazoa_SRP, MEIS2","Angiotensin-converting enzyme inhibitor intolerance","response to angiotensin-converting enzyme inhibitor",GCST004029,15:37130625
rs1648053-<b>?</b>,"9 x 10-6",,0.140188,1.402716,'-,[1.20778-1.629115],ANAPC10,"Angiotensin-converting enzyme inhibitor intolerance","response to angiotensin-converting enzyme inhibitor",GCST004029,4:144957432
rs66670561-<b>?</b>,"6 x 10-7",,0.412353,1.420046,'-,[1.23795-1.628927],COP1,"Angiotensin-converting enzyme inhibitor intolerance","response to angiotensin-converting enzyme inhibitor",GCST004029,1:176091360
chr7:9060460-<b>?</b>,"9 x 10-6",,0.182056,1.467579,'-,[1.239048-1.73826],'-,"Angiotensin-converting enzyme inhibitor intolerance","response to angiotensin-converting enzyme inhibitor",GCST004029,"Mapping not available"
rs34984545-<b>?</b>,"6 x 10-7",,0.121595,1.506737,'-,[1.283176-1.769246],"RPS23P4, OTUD4","Angiotensin-converting enzyme inhibitor intolerance","response to angiotensin-converting enzyme inhibitor",GCST004029,4:145190605
rs2061538-<b>G</b>,"6 x 10-9",,0.160098,1.527849,'-,[1.324419-1.762525],RBFOX3,"Angiotensin-converting enzyme inhibitor intolerance","response to angiotensin-converting enzyme inhibitor",GCST004029,17:79116480
rs12504213-<b>?</b>,"4 x 10-6",,0.080258,1.570069,'-,[1.295642-1.902623],"ANAPC10, HHIP","Angiotensin-converting enzyme inhibitor intolerance","response to angiotensin-converting enzyme inhibitor",GCST004029,4:144801156
rs7960581-<b>?</b>,"3 x 10-7",,0.088001,1.633271,'-,[1.353663-1.970635],ANKS1B,"Angiotensin-converting enzyme inhibitor intolerance","response to angiotensin-converting enzyme inhibitor",GCST004029,12:98825958
rs17782805-<b>?</b>,"7 x 10-7",,0.058917,1.836717,'-,[1.444594-2.33528],ASIC2,"Angiotensin-converting enzyme inhibitor intolerance","response to angiotensin-converting enzyme inhibitor",GCST004029,17:33568429
rs77652464-<b>?</b>,"9 x 10-6",,0.072725,1.858855,'-,[1.414607-2.442616],C5orf64,"Angiotensin-converting enzyme inhibitor intolerance","response to angiotensin-converting enzyme inhibitor",GCST004029,5:61806954
chr4:95284543-<b>?</b>,"8 x 10-7",,0.113883,1.905864,'-,[1.475983-2.460948],'-,"Angiotensin-converting enzyme inhibitor intolerance","response to angiotensin-converting enzyme inhibitor",GCST004029,"Mapping not available"
rs188832927-<b>?</b>,"7 x 10-6",,0.073287,2.131358,'-,[1.533736-2.961844],'-,"Angiotensin-converting enzyme inhibitor intolerance","response to angiotensin-converting enzyme inhibitor",GCST004029,2:221181621
rs79497550-<b>?</b>,"4 x 10-6",,0.037046,2.219817,'-,[1.579697-3.119324],RN7SL101P,"Angiotensin-converting enzyme inhibitor intolerance","response to angiotensin-converting enzyme inhibitor",GCST004029,4:28631128
chr18:47092527-<b>?</b>,"2 x 10-6",,0.036689,2.247996,'-,[1.612571-3.133807],'-,"Angiotensin-converting enzyme inhibitor intolerance","response to angiotensin-converting enzyme inhibitor",GCST004029,"Mapping not available"
rs192613545-<b>T</b>,"3 x 10-8",,0.078457,2.338445,'-,[1.734515-3.152654],SH2B1,"Angiotensin-converting enzyme inhibitor intolerance","response to angiotensin-converting enzyme inhibitor",GCST004029,16:28852580
rs79779463-<b>?</b>,"1 x 10-6",,0.037813,2.366938,'-,[1.67426-3.34619],'-,"Angiotensin-converting enzyme inhibitor intolerance","response to angiotensin-converting enzyme inhibitor",GCST004029,4:28518026
chr16:55574507-<b>?</b>,"3 x 10-6",,0.041648,2.536248,'-,[1.713451-3.754151],'-,"Angiotensin-converting enzyme inhibitor intolerance","response to angiotensin-converting enzyme inhibitor",GCST004029,"Mapping not available"
rs78740289-<b>?</b>,"8 x 10-6",,0.051144,2.829821,'-,[1.790824-4.471621],"PNLIPRP3, RNU6-1090P","Angiotensin-converting enzyme inhibitor intolerance","response to angiotensin-converting enzyme inhibitor",GCST004029,10:116532643
rs957322-<b>?</b>,"9 x 10-6",,0.044117,2.94359,'-,[1.830155-4.73442],FAM135B,"Angiotensin-converting enzyme inhibitor intolerance","response to angiotensin-converting enzyme inhibitor",GCST004029,8:138483259
rs144785229-<b>?</b>,"6 x 10-6",,0.061337,3.038123,'-,[1.876171-4.919696],TESK2,"Angiotensin-converting enzyme inhibitor intolerance","response to angiotensin-converting enzyme inhibitor",GCST004029,1:45372365
chr16:57243985-<b>?</b>,"1 x 10-6",,0.042096,3.042745,'-,[1.940995-4.769872],'-,"Angiotensin-converting enzyme inhibitor intolerance","response to angiotensin-converting enzyme inhibitor",GCST004029,"Mapping not available"
chr17:1910627-<b>?</b>,"6 x 10-6",,0.035278,3.12877,'-,[1.911702-5.120673],'-,"Angiotensin-converting enzyme inhibitor intolerance","response to angiotensin-converting enzyme inhibitor",GCST004029,"Mapping not available"
rs77370934-<b>G</b>,"8 x 10-9",,0.037258,3.166316,'-,[2.141682-4.681161],GABRG2,"Angiotensin-converting enzyme inhibitor intolerance","response to angiotensin-converting enzyme inhibitor",GCST004029,5:162177248
rs7708945-<b>?</b>,"9 x 10-6",,0.030749,3.666179,'-,[2.066661-6.503664],'-,"Angiotensin-converting enzyme inhibitor intolerance","response to angiotensin-converting enzyme inhibitor",GCST004029,5:26402141
chr8:29593493-<b>?</b>,"8 x 10-6",,0.03265,3.888525,'-,[2.143968-7.052636],'-,"Angiotensin-converting enzyme inhibitor intolerance","response to angiotensin-converting enzyme inhibitor",GCST004029,"Mapping not available"
chr6:147433571-<b>?</b>,"9 x 10-6",,0.029546,4.195447,'-,[2.230761-7.89048],'-,"Angiotensin-converting enzyme inhibitor intolerance","response to angiotensin-converting enzyme inhibitor",GCST004029,"Mapping not available"
chr3:23991028-<b>?</b>,"3 x 10-6",,0.016755,8.99483,'-,[3.590002-22.536747],'-,"Angiotensin-converting enzyme inhibitor intolerance","response to angiotensin-converting enzyme inhibitor",GCST004029,"Mapping not available"
chr10:71805625-<b>?</b>,"1 x 10-7",,0.025127,9.773455,'-,[2.838659-22.690645],'-,"Angiotensin-converting enzyme inhibitor intolerance","response to angiotensin-converting enzyme inhibitor",GCST004029,"Mapping not available"
rs141951987-<b>?</b>,"7 x 10-8",,0.014782,16.498344,'-,[5.965522-45.628087],LINC01945,"Angiotensin-converting enzyme inhibitor intolerance","response to angiotensin-converting enzyme inhibitor",GCST004029,2:131954620
rs79755914-<b>?</b>,"3 x 10-6",,NR,6.49,'-,[2.97-14.18],SLC38A6,"Cough in response to angiotensin-converting enzyme inhibitor drugs","response to angiotensin-converting enzyme inhibitor, Cough",GCST004049,14:60998402
rs118096318-<b>?</b>,"2 x 10-6",,NR,5.06,'-,[2.61-9.8],TGFBR1,"Cough in response to angiotensin-converting enzyme inhibitor drugs","response to angiotensin-converting enzyme inhibitor, Cough",GCST004049,9:99130744
rs61753726-<b>?</b>,"2 x 10-6",,NR,5.16,'-,[2.62-10.19],VPS13B,"Cough in response to angiotensin-converting enzyme inhibitor drugs","response to angiotensin-converting enzyme inhibitor, Cough",GCST004049,8:99853454
rs117173564-<b>?</b>,"2 x 10-6",,NR,6.07,'-,[2.88-12.82],WRN,"Cough in response to angiotensin-converting enzyme inhibitor drugs","response to angiotensin-converting enzyme inhibitor, Cough",GCST004049,8:31153953
rs79070520-<b>?</b>,"9 x 10-7",,NR,8.73,'-,[3.68-20.71],TGFA,"Cough in response to angiotensin-converting enzyme inhibitor drugs","response to angiotensin-converting enzyme inhibitor, Cough",GCST004049,2:70532529
rs2695743-<b>?</b>,"6 x 10-7",,NR,2.2727273,'-,[1.64-3.12],PDE11A,"Cough in response to angiotensin-converting enzyme inhibitor drugs","response to angiotensin-converting enzyme inhibitor, Cough",GCST004049,2:177980216
rs114834275-<b>?</b>,"2 x 10-6",,NR,3.84,'-,[2.21-6.69],GALNTL6,"Cough in response to angiotensin-converting enzyme inhibitor drugs","response to angiotensin-converting enzyme inhibitor, Cough",GCST004049,4:171747426
rs145207197-<b>?</b>,"4 x 10-6",,NR,5.54,'-,[2.67-11.5],ABCB5,"Cough in response to angiotensin-converting enzyme inhibitor drugs","response to angiotensin-converting enzyme inhibitor, Cough",GCST004049,7:20704124
rs62151096-<b>?</b>,"1 x 10-7",,NR,3.54,'-,[3.54-2.22],CLASP1,"Cough in response to angiotensin-converting enzyme inhibitor drugs","response to angiotensin-converting enzyme inhibitor, Cough",GCST004049,2:121498964
rs62151109-<b>?</b>,"1 x 10-9",,NR,3.97,'-,[2.39-6.59],CLASP1,"Cough in response to angiotensin-converting enzyme inhibitor drugs","response to angiotensin-converting enzyme inhibitor, Cough",GCST004049,2:121644122
rs139928095-<b>?</b>,"4 x 10-6",,NR,9.07,'-,[3.57-23.03],DNAJC16,"Cough in response to angiotensin-converting enzyme inhibitor drugs","response to angiotensin-converting enzyme inhibitor, Cough",GCST004049,1:15562716
rs34199165-<b>?</b>,"4 x 10-7",,NR,6.11,'-,[3.03-12.31],NIBAN1,"Cough in response to angiotensin-converting enzyme inhibitor drugs","response to angiotensin-converting enzyme inhibitor, Cough",GCST004049,1:184861124
rs73085377-<b>?</b>,"2 x 10-7",,NR,4.22,'-,[2.44-7.3],GYS2,"Cough in response to angiotensin-converting enzyme inhibitor drugs","response to angiotensin-converting enzyme inhibitor, Cough",GCST004049,12:21561840
rs10256342-<b>?</b>,"4 x 10-6",,NR,2.44,'-,[1.67-3.58],ACTR3B,"Cough in response to angiotensin-converting enzyme inhibitor drugs","response to angiotensin-converting enzyme inhibitor, Cough",GCST004049,7:152898722
rs115863790-<b>?</b>,"5 x 10-7",,NR,8.75,'-,[3.77-20.33],"RNU1-64P, NEDD9","Cough in response to angiotensin-converting enzyme inhibitor drugs","response to angiotensin-converting enzyme inhibitor, Cough",GCST004049,6:11438722
rs144023814-<b>?</b>,"4 x 10-7",,NR,7.35,'-,[3.4-15.92],"CACNG4, CACNG1","Cough in response to angiotensin-converting enzyme inhibitor drugs","response to angiotensin-converting enzyme inhibitor, Cough",GCST004049,17:67043327
rs150996375-<b>?</b>,"3 x 10-6",,NR,3.51,'-,[2.07-5.96],KCNA5,"Cough in response to angiotensin-converting enzyme inhibitor drugs","response to angiotensin-converting enzyme inhibitor, Cough",GCST004049,12:5034431
rs151256649-<b>?</b>,"3 x 10-7",,NR,16.11,'-,[5.53-46.92],LINC01819,"Cough in response to angiotensin-converting enzyme inhibitor drugs","response to angiotensin-converting enzyme inhibitor, Cough",GCST004049,2:42955614
rs181221928-<b>?</b>,"2 x 10-6",,NR,8.56,'-,[3.51-20.88],MIR646HG,"Cough in response to angiotensin-converting enzyme inhibitor drugs","response to angiotensin-converting enzyme inhibitor, Cough",GCST004049,20:60441709
rs186568962-<b>?</b>,"2 x 10-6",,NR,18.19,'-,[5.52-59.9],"Y_RNA, ASXL2","Cough in response to angiotensin-converting enzyme inhibitor drugs","response to angiotensin-converting enzyme inhibitor, Cough",GCST004049,2:25699730
rs187974900-<b>?</b>,"4 x 10-6",,NR,17.54,'-,[5.18-59.44],"NAALADL2, TNFSF10","Cough in response to angiotensin-converting enzyme inhibitor drugs","response to angiotensin-converting enzyme inhibitor, Cough",GCST004049,3:174436702
rs189601688-<b>?</b>,"1 x 10-8",,NR,11.96,'-,[4.43-32.26],"NDUFB4P4, KIF3C","Cough in response to angiotensin-converting enzyme inhibitor drugs","response to angiotensin-converting enzyme inhibitor, Cough",GCST004049,2:25914035
rs2349007-<b>?</b>,"3 x 10-7",,NR,2.79,'-,[1.89-4.12],SPOCK1,"Cough in response to angiotensin-converting enzyme inhibitor drugs","response to angiotensin-converting enzyme inhibitor, Cough",GCST004049,5:137568737
rs2978336-<b>?</b>,"4 x 10-6",,NR,3.31,'-,[1.99-5.5],'-,"Cough in response to angiotensin-converting enzyme inhibitor drugs","response to angiotensin-converting enzyme inhibitor, Cough",GCST004049,8:2826812
rs561569797-<b>?</b>,"4 x 10-6",,NR,16.91,'-,[5.08-56.3],"CYP26B1, EXOC6B","Cough in response to angiotensin-converting enzyme inhibitor drugs","response to angiotensin-converting enzyme inhibitor, Cough",GCST004049,2:72161566
rs78139826-<b>?</b>,"2 x 10-6",,NR,8.47,'-,[3.5-20.5],'-,"Cough in response to angiotensin-converting enzyme inhibitor drugs","response to angiotensin-converting enzyme inhibitor, Cough",GCST004049,10:57122880
rs9596009-<b>?</b>,"3 x 10-6",,NR,2.63,'-,[1.75-3.95],PSME2P2,"Cough in response to angiotensin-converting enzyme inhibitor drugs","response to angiotensin-converting enzyme inhibitor, Cough",GCST004049,13:48793144
rs115510347-<b>?</b>,"8 x 10-7",,NR,6.45,'-,[3.07-13.53],"KCNMB2, KCNMB2-AS1","Cough in response to angiotensin-converting enzyme inhibitor drugs","response to angiotensin-converting enzyme inhibitor, Cough",GCST004049,3:178786479
rs143725757-<b>?</b>,"8 x 10-7",,NR,8.09,'-,[3.53-18.57],LINC00290,"Cough in response to angiotensin-converting enzyme inhibitor drugs","response to angiotensin-converting enzyme inhibitor, Cough",GCST004049,4:181113853
rs556450158-<b>?</b>,"3 x 10-6",,NR,10.07,'-,[3.84-26.41],MMP16,"Cough in response to angiotensin-converting enzyme inhibitor drugs","response to angiotensin-converting enzyme inhibitor, Cough",GCST004049,8:88107164
rs1038679-<b>?</b>,"3 x 10-6",,NR,1.95,'-,[1.47-2.57],PBX1,"Cough in response to angiotensin-converting enzyme inhibitor drugs","response to angiotensin-converting enzyme inhibitor, Cough",GCST004049,1:164730485
rs62053173-<b>?</b>,"2 x 10-6",,NR,5.12,'-,[2.6-10.08],PKD1L2,"Cough in response to angiotensin-converting enzyme inhibitor drugs","response to angiotensin-converting enzyme inhibitor, Cough",GCST004049,16:81139451
rs4369272-<b>G</b>,"5 x 10-6",,0.2554,'-,"0.2719 unit increase",[0.16-0.39],ST6GALNAC3,"Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,1:76397851
rs4949715-<b>A</b>,"5 x 10-6",,0.2557,'-,"0.2716 unit increase",[0.16-0.39],ST6GALNAC3,"Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,1:76398384
rs6715187-<b>G</b>,"8 x 10-8",,0.1826,'-,"0.3644 unit increase",[0.23-0.5],"ALPP, ECEL1P3","Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,2:232353879
rs6715387-<b>A</b>,"9 x 10-8",,0.1829,'-,"0.3641 unit increase",[0.23-0.5],"ECEL1P3, ALPP","Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,2:232353864
rs6729965-<b>C</b>,"9 x 10-8",,0.183,'-,"0.3641 unit increase",[0.23-0.5],"ECEL1P3, ALPP","Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,2:232353552
rs55738617-<b>T</b>,"9 x 10-8",,0.1812,'-,"0.3646 unit increase",[0.23-0.5],"ECEL1P3, ALPP","Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,2:232352849
rs1065643-<b>G</b>,"1 x 10-6",,0.09075,'-,"0.4449 unit increase",[0.27-0.62],"HAAO, FTOP1","Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,2:42794053
rs10519881-<b>G</b>,"4 x 10-6",,0.3156,'-,"0.2607 unit increase",[0.15-0.37],RPSAP37,"Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,5:126046631
rs12658330-<b>G</b>,"5 x 10-6",,0.0207,'-,"0.902 unit increase",[0.52-1.28],SEMA5A,"Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,5:9317600
rs7724529-<b>T</b>,"5 x 10-6",,0.3159,'-,"0.2597 unit increase",[0.15-0.37],RPSAP37,"Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,5:126045975
rs62482803-<b>A</b>,"3 x 10-6",,0.2132,'-,"0.3058 unit decrease",[0.18-0.43],ATXN7L1,"Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,7:105858521
rs11769266-<b>G</b>,"3 x 10-6",,0.3817,'-,"0.2495 unit increase",[0.15-0.35],GALNT17,"Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,7:71534157
rs4557585-<b>G</b>,"3 x 10-6",,0.3817,'-,"0.2495 unit increase",[0.15-0.35],GALNT17,"Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,7:71534123
rs80082057-<b>T</b>,"5 x 10-7",,0.0276,'-,"0.7723 unit decrease",[0.47-1.07],SVIL,"Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,10:29652692
rs75690380-<b>G</b>,"6 x 10-7",,0.0277,'-,"0.7692 unit decrease",[0.47-1.07],SVIL,"Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,10:29647954
rs78721916-<b>T</b>,"2 x 10-6",,0.0224,'-,"0.8776 unit decrease",[0.52-1.23],SVIL,"Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,10:29655323
rs12598355-<b>C</b>,"1 x 10-7",,0.1193,'-,"0.4221 unit increase",[0.27-0.58],SLC38A7,"Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,16:58669872
rs11639682-<b>A</b>,"8 x 10-7",,0.1204,'-,"0.3938 unit increase",[0.24-0.55],SLC38A7,"Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,16:58673228
rs2280398-<b>T</b>,"2 x 10-6",,0.1213,'-,"0.3795 unit increase",[0.23-0.53],SLC38A7,"Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,16:58678226
rs11643617-<b>C</b>,"2 x 10-6",,0.1234,'-,"0.3767 unit increase",[0.22-0.53],"SLC38A7, GOT2","Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,16:58698951
rs2280399-<b>A</b>,"2 x 10-6",,0.1214,'-,"0.3752 unit increase",[0.22-0.53],SLC38A7,"Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,16:58677628
rs73549255-<b>A</b>,"2 x 10-6",,0.1236,'-,"0.3777 unit increase",[0.22-0.53],"SLC38A7, GOT2","Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,16:58701769
rs60388585-<b>C</b>,"3 x 10-6",,0.1454,'-,"0.3447 unit increase",[0.2-0.49],"CNOT1, SLC38A7","Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,16:58659688
rs59234479-<b>A</b>,"3 x 10-6",,0.1178,'-,"0.3738 unit increase",[0.22-0.53],SLC38A7,"Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,16:58673724
rs11647748-<b>G</b>,"3 x 10-6",,0.1185,'-,"0.3743 unit increase",[0.22-0.53],"SLC38A7, GOT2","Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer","response to aromatase inhibitor, estrogen-receptor positive breast cancer",GCST007664,16:58697980
rs522308-<b>T</b>,"2 x 10-15",,0.25,2.6,'-,[2.05-3.29],"HLA-DRB1, HLA-DQA1","Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies)","multiple sclerosis, response to interferon beta, anti-drug antibody measurement",GCST005706,6:32614145
rs2454138-<b>A</b>,"5 x 10-19",,0.22,'-,"0.41 unit increase",[0.31-0.51],"HLA-DRB1, HLA-DQA1","Neutralising antibody response to interferon beta therapy in multiple sclerosis (mean antibody levels)","multiple sclerosis, response to interferon beta, anti-drug antibody measurement",GCST005707,6:32602624
rs2454138-<b>A</b>,"8 x 10-19",,0.22,'-,"0.41 unit increase",[0.31-0.51],"HLA-DRB1, HLA-DQA1","Neutralising antibody response to interferon beta therapy in multiple sclerosis (area under the curve for the first two years)","multiple sclerosis, response to interferon beta, anti-drug antibody measurement",GCST005708,6:32602624
rs2454138-<b>A</b>,"1 x 10-18",,0.22,'-,"0.41 unit increase",'-,"HLA-DRB1, HLA-DQA1","Neutralising antibody response to interferon beta therapy in multiple sclerosis (maximum antibody levels)","multiple sclerosis, response to interferon beta, anti-drug antibody measurement",GCST005709,6:32602624
rs144125291-<b>T</b>,"8 x 10-9",,0.07,5.45,'-,[2.87-10.33],"GALNT14, CAPN13","Levodopa-induced dyskinesia in levodopa treated Parkinson's disease","drug-Induced dyskinesia, Parkinson's disease, response to levodopa",GCST011065,2:30883189
rs139221627-<b>T</b>,"1 x 10-7",,0.07,4.68,'-,[2.51-8.73],UBBP4,"Levodopa-induced dyskinesia in levodopa treated Parkinson's disease","drug-Induced dyskinesia, Parkinson's disease, response to levodopa",GCST011065,17:22189093
rs208892-<b>A</b>,"6 x 10-7",,0.4,1.9,'-,[1.47-2.45],LINC01549,"Levodopa-induced dyskinesia in levodopa treated Parkinson's disease","drug-Induced dyskinesia, Parkinson's disease, response to levodopa",GCST011065,21:17441172
rs10495912-<b>A</b>,"6 x 10-7",,0.07,4.03,'-,[2.24-7.24],"LRPPRC, RNU6-566P","Levodopa-induced dyskinesia in levodopa treated Parkinson's disease","drug-Induced dyskinesia, Parkinson's disease, response to levodopa",GCST011065,2:44078322
rs150854091-<b>A</b>,"1 x 10-6",,0.08,3.64,'-,[2.10-6.33],CBFA2T3,"Levodopa-induced dyskinesia in levodopa treated Parkinson's disease","drug-Induced dyskinesia, Parkinson's disease, response to levodopa",GCST011065,16:88962376
rs1531246-<b>G</b>,"2 x 10-6",,0.18,2.28,'-,[1.62-3.21],TMEM132C,"Levodopa-induced dyskinesia in levodopa treated Parkinson's disease","drug-Induced dyskinesia, Parkinson's disease, response to levodopa",GCST011065,12:128514576
rs953169-<b>G</b>,"3 x 10-6",,0.45,1.8,'-,[1.41-2.31],"NPM1P35, SCGB1D4","Levodopa-induced dyskinesia in levodopa treated Parkinson's disease","drug-Induced dyskinesia, Parkinson's disease, response to levodopa",GCST011065,11:62316070
rs118109628-<b>A</b>,"4 x 10-6",,0.03,9.35,'-,[2.96-29.55],"TMEM158, U3","Levodopa-induced dyskinesia in levodopa treated Parkinson's disease","drug-Induced dyskinesia, Parkinson's disease, response to levodopa",GCST011065,3:45238031
rs12185607-<b>T</b>,"5 x 10-6",,0.1,2.86,'-,[1.79-4.57],"RNU6-566P, LRPPRC","Levodopa-induced dyskinesia in levodopa treated Parkinson's disease","drug-Induced dyskinesia, Parkinson's disease, response to levodopa",GCST011065,2:44069141
rs118049686-<b>A</b>,"7 x 10-6",,0.06,4.07,'-,[2.11-7.86],ADAM10,"Levodopa-induced dyskinesia in levodopa treated Parkinson's disease","drug-Induced dyskinesia, Parkinson's disease, response to levodopa",GCST011065,15:58603521
rs17031893-<b>G</b>,"7 x 10-6",,0.08,3.24,'-,[1.89-5.55],"RNU6-566P, LRPPRC","Levodopa-induced dyskinesia in levodopa treated Parkinson's disease","drug-Induced dyskinesia, Parkinson's disease, response to levodopa",GCST011065,2:44056033
rs73564758-<b>G</b>,"9 x 10-6",,0.05,4.58,'-,[2.20-9.52],EXTL3,"Levodopa-induced dyskinesia in levodopa treated Parkinson's disease","drug-Induced dyskinesia, Parkinson's disease, response to levodopa",GCST011065,8:28664344
rs566103-<b>G</b>,"6 x 10-6",(EA),0.235,'-,"0.12 unit decrease",[NR],"RN7SKP189, CYCSP44","Response to simvastatin treatment (PCSK9 protein level change)","response to simvastatin, PCSK9 protein measurement",GCST002642,X:145127999
rs72648866-<b>?</b>,"4 x 10-6",,NR,3.37,'-,[2.13-5.34],TBX21,"Simvastatin-induced myopathy","response to simvastatin, myopathy",GCST008551,17:47735928
rs138591431-<b>?</b>,"9 x 10-6",,NR,3.92,'-,[2.22-6.93],CSPG4,"Simvastatin-induced myopathy","response to simvastatin, myopathy",GCST008551,15:75697275
rs148352615-<b>?</b>,"7 x 10-6",,NR,3.94,'-,[2.23-6.97],"PPIAP47, DNM1P35","Simvastatin-induced myopathy","response to simvastatin, myopathy",GCST008551,15:75740948
rs12508927-<b>?</b>,"6 x 10-6",,NR,5.02,'-,[2.29-11.0],STX18-AS1,"Simvastatin-induced myopathy","response to simvastatin, myopathy",GCST008551,4:4603786
rs117119573-<b>?</b>,"8 x 10-6",,NR,9.07,'-,[1.96-41.93],XKR6,"Simvastatin-induced myopathy","response to simvastatin, myopathy",GCST008551,8:11028343
rs77180504-<b>?</b>,"6 x 10-6",,NR,14.9,'-,[3.99-55.6],ZNF561-AS1,"Simvastatin-induced myopathy","response to simvastatin, myopathy",GCST008551,19:9623491
rs184787123-<b>?</b>,"6 x 10-6",,NR,15.8,'-,[4.64-53.9],LCOR,"Simvastatin-induced myopathy","response to simvastatin, myopathy",GCST008551,10:96947432
rs190668351-<b>?</b>,"7 x 10-6",,NR,22.3,'-,[5.27-94.1],"LINC02179, C16orf78","Simvastatin-induced myopathy","response to simvastatin, myopathy",GCST008551,16:49412462
rs149208014-<b>?</b>,"7 x 10-6",,NR,35.7,'-,[4.06-314.6],"NUDT7, LINC02131","Simvastatin-induced myopathy","response to simvastatin, myopathy",GCST008551,16:77648576
rs190206717-<b>?</b>,"9 x 10-6",,NR,43.9,'-,[4.84-398.9],"HNRNPA1P64, LINC01781","Simvastatin-induced myopathy","response to simvastatin, myopathy",GCST008551,1:80480922
rs77051277-<b>?</b>,"4 x 10-7",,NR,50.9,'-,[10.6-243.6],"PLEKHO1, RN7SL480P","Simvastatin-induced myopathy","response to simvastatin, myopathy",GCST008551,1:150167075
rs140854723-<b>?</b>,"1 x 10-6",,NR,66.1,'-,[10.6-414.0],EVC2,"Simvastatin-induced myopathy","response to simvastatin, myopathy",GCST008551,4:5634585
rs2861137-<b>?</b>,"5 x 10-6",,NR,'-,'-,[0.001-1092],KIAA1328,"Simvastatin-induced myopathy","response to simvastatin, myopathy",GCST008551,18:37141725
rs6454721-<b>?</b>,"9 x 10-6",,NR,4,'-,[1.85-8.33],RNGTT,"Simvastatin-induced myopathy","response to simvastatin, myopathy",GCST008551,6:88769294
rs61865606-<b>?</b>,"3 x 10-7",,NR,2.564103,'-,[1.39-4.76],"PWWP2B, LINC02870","Simvastatin-induced myopathy","response to simvastatin, myopathy",GCST008551,10:132440647
rs10872257-<b>?</b>,"1 x 10-6",,NR,2.173913,'-,[1.56-3.03],CLVS2,"Simvastatin-induced myopathy","response to simvastatin, myopathy",GCST008551,6:122969896
rs10795948-<b>?</b>,"5 x 10-6",,NR,2.1276596,'-,[1.54-2.94],"CDC123, RN7SL198P","Simvastatin-induced myopathy","response to simvastatin, myopathy",GCST008551,10:12308135
rs187058151-<b>?</b>,"5 x 10-6",,NR,1.94,'-,[1.40-2.68],CCDC91,"Simvastatin-induced myopathy","response to simvastatin, myopathy",GCST008551,12:28675079
rs62131018-<b>?</b>,"5 x 10-6",,NR,1.99,'-,[1.46-2.71],ALK,"Simvastatin-induced myopathy","response to simvastatin, myopathy",GCST008551,2:29828498
rs11155111-<b>?</b>,"6 x 10-6",,NR,2.03,'-,[1.49-2.75],'-,"Simvastatin-induced myopathy","response to simvastatin, myopathy",GCST008551,6:140380286
rs145427387-<b>?</b>,"4 x 10-6",,NR,2.33,'-,[1.66-3.29],'-,"Simvastatin-induced myopathy","response to simvastatin, myopathy",GCST008551,13:70725683
rs11519272-<b>?</b>,"3 x 10-6",,NR,2.37,'-,[1.68-3.36],SLCO1B1,"Simvastatin-induced myopathy","response to simvastatin, myopathy",GCST008551,12:21209458
rs116168042-<b>?</b>,"9 x 10-6",,NR,2.76,'-,[1.71-4.46],ADTRP,"Simvastatin-induced myopathy","response to simvastatin, myopathy",GCST008551,6:11754825
rs56027559-<b>?</b>,"8 x 10-6",,NR,2.77,'-,[1.86-4.12],"TBC1D21, INSYN1-AS1","Simvastatin-induced myopathy","response to simvastatin, myopathy",GCST008551,15:73858742
rs41558212-<b>?</b>,"9 x 10-6",,NR,3.18,'-,[2.01-5.05],ERCC1,"Simvastatin-induced myopathy","response to simvastatin, myopathy",GCST008551,19:45414987
rs79980568-<b>?</b>,"6 x 10-6",,NR,3.21,'-,[2.02-5.08],KPNB1,"Simvastatin-induced myopathy","response to simvastatin, myopathy",GCST008551,17:47671302
rs333114-<b>?</b>,"2 x 10-6",,NR,3.22,'-,[1.72-6.05],"SPNS3, SPNS2","Simvastatin-induced myopathy","response to simvastatin, myopathy",GCST008551,17:4495991
rs7779564-<b>?</b>,"2 x 10-6",,NR,3.37,'-,[1.82-6.22],"ABCA13, LINC02838","Simvastatin-induced myopathy","response to simvastatin, myopathy",GCST008551,7:48686597
undefined,"7 x 10-28",,'-,'-,"0.351 unit increase",0.032,'-,"Lipoprotein (a) levels in response to niacin in statin-treated individuals","response to statin, lipoprotein A measurement, response to vitamin B3",GCST009881,"Mapping not available"
rs3764261-<b>?</b>,"2 x 10-8",,0.28,'-,"0.178 unit increase",'-,"HERPUD1, CETP","HDL cholesterol change in response to niacin in statin-treated individuals","HDL cholesterol change measurement, response to statin, response to vitamin B3",GCST009880,16:56959412
rs10455872-<b>G</b>,"4 x 10-30",,0.068,'-,"0.179 unit increase",[0.15-0.21],LPA,"Response to statins (LDL cholesterol percent change)","response to statin, LDL cholesterol change measurement",GCST009821,6:160589086
rs58310495-<b>T</b>,"7 x 10-12",,0.179,'-,"0.069 unit increase",[0.049-0.089],SLCO1B1,"Response to statins (LDL cholesterol percent change)","response to statin, LDL cholesterol change measurement",GCST009821,12:21204777
rs7412-<b>T</b>,"1 x 10-36",,0.07,'-,"0.202 unit decrease",[0.17-0.23],APOE,"Response to statins (LDL cholesterol percent change)","response to statin, LDL cholesterol change measurement",GCST009821,19:44908822
rs7528419-<b>G</b>,"4 x 10-6",,0.198,'-,"0.046 unit decrease",[0.026-0.066],CELSR2,"Response to statins (LDL cholesterol percent change)","response to statin, LDL cholesterol change measurement",GCST009821,1:109274570
rs7528419-<b>G</b>,"1 x 10-17",,0.198,'-,"0.019 unit decrease",[0.015-0.023],CELSR2,"Response to statins (LDL cholesterol change)","response to statin, LDL cholesterol change measurement",GCST010338,1:109274570
rs1713222-<b>A</b>,"5 x 10-8",,0.145,'-,"0.013 unit decrease",[0.0091-0.0169],"TDRD15, APOB","Response to statins (LDL cholesterol change)","response to statin, LDL cholesterol change measurement",GCST010338,2:21048451
rs10455872-<b>G</b>,"1 x 10-33",,0.068,'-,"0.042 unit increase",[0.036-0.048],LPA,"Response to statins (LDL cholesterol change)","response to statin, LDL cholesterol change measurement",GCST010338,6:160589086
rs58310495-<b>T</b>,"5 x 10-11",,0.179,'-,"0.015 unit increase",[0.011-0.019],SLCO1B1,"Response to statins (LDL cholesterol change)","response to statin, LDL cholesterol change measurement",GCST010338,12:21204777
rs67337506-<b>C</b>,"3 x 10-8",,0.25,'-,"0.012 unit decrease",[0.0081-0.0159],LDLR,"Response to statins (LDL cholesterol change)","response to statin, LDL cholesterol change measurement",GCST010338,19:11097306
rs7412-<b>T</b>,"1 x 10-78",,0.07,'-,"0.068 unit decrease",[0.06-0.076],APOE,"Response to statins (LDL cholesterol change)","response to statin, LDL cholesterol change measurement",GCST010338,19:44908822
rs73089338-<b>?</b>,"2 x 10-7",,NR,4.63,'-,[2.7-7.96],CDCP1,"Statin-induced myopathy (severe)","response to statin, myopathy",GCST008553,3:45114350
rs504365-<b>?</b>,"3 x 10-6",,NR,1.25,'-,[2.27-14.29],RASGRF2,"Statin-induced myopathy (severe)","response to statin, myopathy",GCST008553,5:81012056
rs2247256-<b>?</b>,"2 x 10-6",,NR,6.25,'-,[0.023-16.667],ERICH1,"Statin-induced myopathy (severe)","response to statin, myopathy",GCST008553,8:666484
rs4149056-<b>?</b>,"3 x 10-9",,NR,5.15,'-,[3.13-8.45],SLCO1B1,"Statin-induced myopathy (severe)","response to statin, myopathy",GCST008553,12:21178615
rs4149000-<b>?</b>,"3 x 10-6",,NR,3.94,'-,[2.36-6.57],SLCO1A2,"Statin-induced myopathy (severe)","response to statin, myopathy",GCST008553,12:21295063
rs28447350-<b>?</b>,"5 x 10-7",,NR,3.66,'-,[2.23-6.0],"ELF1, LGMNP1","Statin-induced myopathy (severe)","response to statin, myopathy",GCST008553,13:64923076
rs55902659-<b>?</b>,"5 x 10-6",,NR,2.2727273,'-,[1.52-3.23],"FBN2, SLC12A2","Statin-induced myopathy","response to statin, myopathy",GCST008552,5:128209813
rs79860430-<b>?</b>,"8 x 10-6",,NR,2.59,'-,[1.75-3.83],"FBXO34, COX5AP1","Statin-induced myopathy","response to statin, myopathy",GCST008552,14:55255145
rs11591147-<b>?</b>,"5 x 10-9","(baseline LDL-C)",NR,'-,"5 mg/dL decrease",[3.43-6.57],PCSK9,"Response to statins (LDL cholesterol change)","response to statin, LDL cholesterol change measurement",GCST001408,1:55039974
rs10455872-<b>?</b>,"5 x 10-15","(fractional LDL-C reduction)",NR,'-,"6.8 % increase",[4.45-9.15],LPA,"Response to statins (LDL cholesterol change)","response to statin, LDL cholesterol change measurement",GCST001408,6:160589086
rs1481012-<b>?</b>,"2 x 10-15","(fractional LDL-C reduction)",NR,'-,"5.1 % decrease",[3.34-6.86],ABCG2,"Response to statins (LDL cholesterol change)","response to statin, LDL cholesterol change measurement",GCST001408,4:88117930
rs7412-<b>?</b>,"2 x 10-47","(baseline LDL-C)",NR,'-,"6.2 mg/dL decrease",[5.42-6.98],APOE,"Response to statins (LDL cholesterol change)","response to statin, LDL cholesterol change measurement",GCST001408,19:44908822
rs6924995-<b>?</b>,"5 x 10-7","(absolute LDL-C reduction)",NR,'-,"4.1 mg/dL increase",[2.73-5.47],"MYLIP, MRPL42P2","Response to statins (LDL cholesterol change)","response to statin, LDL cholesterol change measurement",GCST001408,6:16161194
rs7769153-<b>?</b>,"2 x 10-7","(fractional LDL-C reduction)",NR,'-,"10.3 % increase",[6.77-13.83],EPB41L2,"Response to statins (LDL cholesterol change)","response to statin, LDL cholesterol change measurement",GCST001408,6:130935224
rs1875620-<b>?</b>,"7 x 10-7","(absolute LDL-C reduction)",NR,'-,"2.8 mg/dL increase",[1.62-3.98],'-,"Response to statins (LDL cholesterol change)","response to statin, LDL cholesterol change measurement",GCST001408,"Mapping not available"
rs931608-<b>?</b>,"3 x 10-7","(absolute LDL-C reduction)",NR,'-,"4.2 mg/dL increase",[2.44-5.96],ZNF98,"Response to statins (LDL cholesterol change)","response to statin, LDL cholesterol change measurement",GCST001408,19:22431320
rs11559024-<b>G</b>,"4 x 10-16",,0.010,'-,"0.501 unit decrease",[0.38-0.62],CKM,"Creatine kinase levels in statin users","response to statin, creatine kinase measurement",GCST002603,19:45317925
rs2361797-<b>T</b>,"2 x 10-10",,0.443,'-,"0.08 unit increase",[0.055-0.105],LILRB5,"Creatine kinase levels in statin users","response to statin, creatine kinase measurement",GCST002603,19:54249685
rs729397-<b>C</b>,"8 x 10-6","(chol, sum)",0.26,'-,'-,'-,LINC02645,"Response to statin therapy","response to statin",GCST000635,10:2489827
rs1535-<b>G</b>,"7 x 10-6","(HDL, sum)",0.32,'-,'-,'-,FADS2,"Response to statin therapy","response to statin",GCST000635,11:61830500
rs16839962-<b>T</b>,"9 x 10-6","(HDL, sum)",0.13,'-,'-,'-,LINC01876,"Response to statin therapy","response to statin",GCST000635,2:156068774
rs174583-<b>T</b>,"3 x 10-6","(Triglyceride, sum)",0.34,'-,'-,'-,FADS2,"Response to statin therapy","response to statin",GCST000635,11:61842278
rs16909449-<b>C</b>,"1 x 10-6","(Triglyceride, sum)",0.25,'-,'-,'-,'-,"Response to statin therapy","response to statin",GCST000635,9:120099019
rs2954038-<b>C</b>,"7 x 10-6","(Triglyceride, sum)",0.32,'-,'-,'-,TRIB1,"Response to statin therapy","response to statin",GCST000635,8:125495147
rs3757057-<b>T</b>,"4 x 10-6","(Triglyceride, sum)",0.05,'-,'-,'-,ADGRB3,"Response to statin therapy","response to statin",GCST000635,6:69364340
rs1431005-<b>A</b>,"2 x 10-7","(LDL, diff)",0.4,'-,'-,'-,LINC02515,"Response to statin therapy","response to statin",GCST000635,4:187424214
rs10950821-<b>G</b>,"7 x 10-6","(chol, sum)",0.26,'-,'-,'-,"ABCB5, EEF1A1P27","Response to statin therapy","response to statin",GCST000635,7:20607392
rs646776-<b>C</b>,"4 x 10-6","(chol, sum)",0.19,'-,'-,'-,"CELSR2, PSRC1","Response to statin therapy","response to statin",GCST000635,1:109275908
rs6588480-<b>A</b>,"8 x 10-6","(chol, sum)",0.15,'-,'-,'-,GLIS1,"Response to statin therapy","response to statin",GCST000635,1:53512446
rs10746514-<b>A</b>,"1 x 10-6","(LDL, sum)",0.42,'-,'-,'-,DISC1,"Response to statin therapy","response to statin",GCST000635,1:232110281
rs541041-<b>G</b>,"8 x 10-6","(LDL, sum)",0.16,'-,'-,'-,"TDRD15, APOB","Response to statin therapy","response to statin",GCST000635,2:21072103
rs4684585-<b>G</b>,"9 x 10-7","(LDL, sum)",0.43,'-,'-,'-,LINC01266,"Response to statin therapy","response to statin",GCST000635,3:842168
rs10266483-<b>A</b>,"8 x 10-6","(LDL, sum)",0.35,'-,'-,'-,"ZNF736, ZNF679","Response to statin therapy","response to statin",GCST000635,7:64272953
rs10091038-<b>A</b>,"3 x 10-8","(HDL, sum)",0.43,'-,'-,'-,'-,"Response to statin therapy","response to statin",GCST000635,8:29502788
rs10123041-<b>T</b>,"6 x 10-6","(HDL, sum)",0.16,'-,'-,'-,SLC28A3,"Response to statin therapy","response to statin",GCST000635,9:84307121
rs7584099-<b>G</b>,"5 x 10-7","(Triglyceride, diff)",0.41,'-,'-,'-,RNA5SP106,"Response to statin therapy","response to statin",GCST000635,2:147720767
rs16883019-<b>C</b>,"7 x 10-7","(Triglyceride, sum)",0.04,'-,'-,'-,'-,"Response to statin therapy","response to statin",GCST000635,6:19969407
rs9305406-<b>G</b>,"8 x 10-6","(Triglyceride, sum)",0.2,'-,'-,'-,GRIK1,"Response to statin therapy","response to statin",GCST000635,21:30013925
rs2053302-<b>T</b>,"4 x 10-6","(chol, sum)",0.18,'-,'-,'-,LINC01720,"Response to statin therapy","response to statin",GCST000635,1:190872543
rs13390159-<b>A</b>,"2 x 10-7","(LDL, diff)",0.16,'-,'-,'-,ASB18,"Response to statin therapy","response to statin",GCST000635,2:236247906
rs17540621-<b>C</b>,"2 x 10-6","(chol, sum)",0.06,'-,'-,'-,TTC7A,"Response to statin therapy","response to statin",GCST000635,2:47002700
rs10270805-<b>A</b>,"9 x 10-6","(chol, sum)",0.07,'-,'-,'-,CRPPA,"Response to statin therapy","response to statin",GCST000635,7:16460517
rs13148903-<b>G</b>,"3 x 10-6","(LDL, sum)",0.25,'-,'-,'-,F11-AS1,"Response to statin therapy","response to statin",GCST000635,4:186336422
rs8014194-<b>A</b>,"2 x 10-8","(chol, diff)",0.24,'-,'-,'-,CLMN,"Response to statin therapy","response to statin",GCST000635,14:95254341
rs6658356-<b>A</b>,"2 x 10-6","(chol, sum)",0.06,'-,'-,'-,PRDM16,"Response to statin therapy","response to statin",GCST000635,1:3363689
rs6070116-<b>G</b>,"4 x 10-6","(chol, sum)",0.25,'-,'-,'-,"RBM38, HMGB1P1","Response to statin therapy","response to statin",GCST000635,20:57469128
rs35964523-<b>T</b>,"8 x 10-6","(chol, sum)",0.42,'-,'-,'-,LINC01266,"Response to statin therapy","response to statin",GCST000635,3:856978
rs12527253-<b>G</b>,"1 x 10-6","(LDL, sum)",0.34,'-,'-,'-,RNGTT,"Response to statin therapy","response to statin",GCST000635,6:88584026
rs7900909-<b>C</b>,"8 x 10-6","(LDL, sum)",0.15,'-,'-,'-,"RPL17P35, CYP2C61P","Response to statin therapy","response to statin",GCST000635,10:64688715
rs11641231-<b>G</b>,"8 x 10-6","(HDL, sum)",0.23,'-,'-,'-,LINC00917,"Response to statin therapy","response to statin",GCST000635,16:86347578
rs7979575-<b>C</b>,"2 x 10-6","(Triglyceride, sum)",0.16,'-,'-,'-,SOX5,"Response to statin therapy","response to statin",GCST000635,12:24125887
rs2901331-<b>A</b>,"6 x 10-6","(Triglyceride, sum)",0.31,'-,'-,'-,CNTNAP5,"Response to statin therapy","response to statin",GCST000635,2:124570373
rs1218282-<b>C</b>,"5 x 10-6","(Triglyceride, sum)",0.06,'-,'-,'-,"CCT5P2, HSPD1P8","Response to statin therapy","response to statin",GCST000635,13:78881697
rs10221833-<b>C</b>,"6 x 10-6","(Triglyceride, sum)",0.09,'-,'-,'-,COBLL1,"Response to statin therapy","response to statin",GCST000635,2:164720654
rs7244245-<b>?</b>,"1 x 10-6",(EA),'-,5.365,'-,[NR],"RPS4XP19, MTCL1","Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy)","response to reverse transcriptase inhibitor, HIV-1 infection, peripheral neuropathy",GCST002366,18:8931654
rs817565-<b>?</b>,"3 x 10-6",(EA),'-,3.779,'-,[NR],MAP2K6,"Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy)","response to reverse transcriptase inhibitor, HIV-1 infection, peripheral neuropathy",GCST002366,17:69436244
rs17169635-<b>?</b>,"6 x 10-6",(EA),'-,3.526,'-,[NR],CALD1,"Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy)","response to reverse transcriptase inhibitor, HIV-1 infection, peripheral neuropathy",GCST002366,7:134805711
rs10216322-<b>?</b>,"8 x 10-6",(EA),'-,4.776,'-,[NR],RNA5SP228,"Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy)","response to reverse transcriptase inhibitor, HIV-1 infection, peripheral neuropathy",GCST002366,7:24067707
rs4722585-<b>?</b>,"5 x 10-6",(AA),'-,5,'-,[NR],NFE2L3,"Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy)","response to reverse transcriptase inhibitor, HIV-1 infection, peripheral neuropathy",GCST002366,7:26143746
rs11189867-<b>?</b>,"7 x 10-6",(AA),'-,26.8,'-,[NR],HPSE2,"Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy)","response to reverse transcriptase inhibitor, HIV-1 infection, peripheral neuropathy",GCST002366,10:98922691
rs10784285-<b>?</b>,"9 x 10-6",(AA),'-,4.1,'-,[NR],TAFA2,"Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy)","response to reverse transcriptase inhibitor, HIV-1 infection, peripheral neuropathy",GCST002366,12:62164533
rs3826795-<b>?</b>,"3 x 10-6",(Hispanic),'-,12.8,'-,[NR],HIF3A,"Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy)","response to reverse transcriptase inhibitor, HIV-1 infection, peripheral neuropathy",GCST002366,19:46297176
rs4899685-<b>?</b>,"4 x 10-6",(Hispanic),'-,14,'-,[NR],ADCK1,"Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy)","response to reverse transcriptase inhibitor, HIV-1 infection, peripheral neuropathy",GCST002366,14:77954715
rs502716-<b>?</b>,"4 x 10-6",(Hispanic),'-,14,'-,[NR],"RSPO4, ANGPT4","Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy)","response to reverse transcriptase inhibitor, HIV-1 infection, peripheral neuropathy",GCST002366,20:945754
rs11707293-<b>?</b>,"5 x 10-6",(Hispanic),'-,14.2,'-,[NR],STXBP5L,"Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy)","response to reverse transcriptase inhibitor, HIV-1 infection, peripheral neuropathy",GCST002366,3:121365620
rs575134-<b>?</b>,"6 x 10-6",(Hispanic),NR,'-,'-,'-,"BSCL2, HNRNPUL2-BSCL2","Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy)","response to reverse transcriptase inhibitor, HIV-1 infection, peripheral neuropathy",GCST002363,11:62693757
rs13333308-<b>?</b>,"6 x 10-6",(AA),NR,32.3,'-,[NR],LITAF,"Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy)","response to reverse transcriptase inhibitor, HIV-1 infection, peripheral neuropathy",GCST002363,16:11607793
rs1776368-<b>?</b>,"6 x 10-6",(Hispanic),NR,'-,'-,'-,NUFIP1P1,"Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy)","response to reverse transcriptase inhibitor, HIV-1 infection, peripheral neuropathy",GCST002363,6:66117392
rs266095-<b>?</b>,"8 x 10-9",(EA),'-,56.3,'-,[NR],"LINC02881, CXCL12","Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy)","response to reverse transcriptase inhibitor, HIV-1 infection, peripheral neuropathy",GCST002363,10:44368720
rs9827908-<b>?</b>,"6 x 10-8",(AA),'-,48.5,'-,[NR],LRIG1,"Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy)","response to reverse transcriptase inhibitor, HIV-1 infection, peripheral neuropathy",GCST002363,3:66395177
rs12722486-<b>?</b>,"2 x 10-9",(EA),'-,38.2,'-,[NR],IL2RA,"Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy)","response to reverse transcriptase inhibitor, HIV-1 infection, peripheral neuropathy",GCST002363,10:6061799
rs9501753-<b>?</b>,"1 x 10-8",(EA),'-,'-,'-,[NR],"DUSP22, CICP18","Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy)","response to reverse transcriptase inhibitor, HIV-1 infection, peripheral neuropathy",GCST002363,6:221146
rs17108344-<b>?</b>,"3 x 10-8",(EA),'-,25.3,'-,[NR],PTPRB,"Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy)","response to reverse transcriptase inhibitor, HIV-1 infection, peripheral neuropathy",GCST002363,12:70560684
rs7554182-<b>?</b>,"6 x 10-8",(AA),'-,48.5,'-,[NR],ZNF648,"Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy)","response to reverse transcriptase inhibitor, HIV-1 infection, peripheral neuropathy",GCST002363,1:182052148
rs9636436-<b>?</b>,"2 x 10-7",(AA),'-,11.1,'-,[NR],RNU6-439P,"Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy)","response to reverse transcriptase inhibitor, HIV-1 infection, peripheral neuropathy",GCST002363,2:49270867
rs1514687-<b>?</b>,"2 x 10-7",(AA),'-,16.8,'-,[NR],TPO,"Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy)","response to reverse transcriptase inhibitor, HIV-1 infection, peripheral neuropathy",GCST002363,2:1434216
rs10495970-<b>?</b>,"5 x 10-7",(AA),'-,10.3,'-,[NR],RNU6-439P,"Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy)","response to reverse transcriptase inhibitor, HIV-1 infection, peripheral neuropathy",GCST002363,2:49264671
rs7568498-<b>?</b>,"2 x 10-8",(Hispanic),'-,'-,'-,[NR],TANK,"Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy)","response to reverse transcriptase inhibitor, HIV-1 infection, peripheral neuropathy",GCST002363,2:161172602
rs801350-<b>?</b>,"2 x 10-8",(Hispanic),'-,'-,'-,[NR],"Metazoa_SRP, LINC01790","Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy)","response to reverse transcriptase inhibitor, HIV-1 infection, peripheral neuropathy",GCST002363,2:194682669
rs801378-<b>?</b>,"2 x 10-8",(Hispanic),'-,'-,'-,[NR],"Metazoa_SRP, LINC01790","Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy)","response to reverse transcriptase inhibitor, HIV-1 infection, peripheral neuropathy",GCST002363,2:194695273
rs213273-<b>?</b>,"2 x 10-8",(Hispanic),'-,'-,'-,[NR],HDAC9,"Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy)","response to reverse transcriptase inhibitor, HIV-1 infection, peripheral neuropathy",GCST002363,7:18464885
rs6557786-<b>?</b>,"5 x 10-6",(Hispanic),NR,23.2,'-,[NR],"NEFL, NEFM","Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy)","response to reverse transcriptase inhibitor, HIV-1 infection, peripheral neuropathy",GCST002365,8:24942229
rs6637197-<b>?</b>,"1 x 10-6",(EA),'-,14.9,'-,[NR],RRM2P4,"Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy)","response to reverse transcriptase inhibitor, HIV-1 infection, peripheral neuropathy",GCST002365,X:144281548
rs7985891-<b>?</b>,"2 x 10-7",(EA),'-,38.2,'-,[NR],GPC6,"Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy)","response to reverse transcriptase inhibitor, HIV-1 infection, peripheral neuropathy",GCST002365,13:93226778
rs10509586-<b>?</b>,"4 x 10-7",(EA),'-,9.3,'-,[NR],LINC01374,"Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy)","response to reverse transcriptase inhibitor, HIV-1 infection, peripheral neuropathy",GCST002365,10:89981680
rs2708973-<b>?</b>,"3 x 10-6",(EA),'-,31.7,'-,[NR],"IL37, XIAPP3","Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy)","response to reverse transcriptase inhibitor, HIV-1 infection, peripheral neuropathy",GCST002365,2:112906296
rs28489712-<b>?</b>,"3 x 10-6",(EA),'-,31.7,'-,[NR],WDHD1,"Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy)","response to reverse transcriptase inhibitor, HIV-1 infection, peripheral neuropathy",GCST002365,14:55017068
rs4722585-<b>?</b>,"5 x 10-6",(AA),'-,5,'-,[NR],NFE2L3,"Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy)","response to reverse transcriptase inhibitor, HIV-1 infection, peripheral neuropathy",GCST002365,7:26143746
rs1346751-<b>?</b>,"8 x 10-6",(AA),'-,10,'-,[NR],CYRIA,"Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy)","response to reverse transcriptase inhibitor, HIV-1 infection, peripheral neuropathy",GCST002365,2:16458298
rs502716-<b>?</b>,"3 x 10-8",(Hispanic),'-,28,'-,[NR],"RSPO4, ANGPT4","Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy)","response to reverse transcriptase inhibitor, HIV-1 infection, peripheral neuropathy",GCST002365,20:945754
rs1330950-<b>?</b>,"8 x 10-7",(Hispanic),'-,17.5,'-,[NR],LINC00551,"Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy)","response to reverse transcriptase inhibitor, HIV-1 infection, peripheral neuropathy",GCST002365,13:106686453
rs1062746-<b>?</b>,"2 x 10-6",(Hispanic),'-,15.6,'-,[NR],FBXO31,"Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy)","response to reverse transcriptase inhibitor, HIV-1 infection, peripheral neuropathy",GCST002365,16:87331044
rs717423-<b>?</b>,"4 x 10-6",(Hispanic),'-,14.1,'-,[NR],GLIS3,"Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy)","response to reverse transcriptase inhibitor, HIV-1 infection, peripheral neuropathy",GCST002365,9:3844061
rs8192282-<b>?</b>,"5 x 10-6",(Hispanic),'-,23.2,'-,[NR],IL6R,"Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy)","response to reverse transcriptase inhibitor, HIV-1 infection, peripheral neuropathy",GCST002365,1:154429203
rs141860749-<b>A</b>,"4 x 10-7",,0.01,8.9,'-,[NR],SYT2,"Epilepsy and lamotrigine-induced maculopapular eruptions","response to lamotrigine, maculopapular eruption, epilepsy",GCST002949,1:202668176
rs62270313-<b>?</b>,"1 x 10-7",,0.05,4.6,'-,[NR],EPHB1,"Epilepsy and lamotrigine-induced maculopapular eruptions","response to lamotrigine, maculopapular eruption, epilepsy",GCST002949,3:134930924
rs631844-<b>T</b>,"7 x 10-8",,0.05,4.9,'-,[NR],LINC02109,"Epilepsy and lamotrigine-induced maculopapular eruptions","response to lamotrigine, maculopapular eruption, epilepsy",GCST002949,5:29054513
rs71568191-<b>A</b>,"3 x 10-9",,0.01,8.9,'-,[NR],HCG27,"Epilepsy and lamotrigine-induced maculopapular eruptions","response to lamotrigine, maculopapular eruption, epilepsy",GCST002949,6:104230957
rs1178326-<b>C</b>,"2 x 10-7",,0.01,8.1,'-,[NR],HDAC9,"Epilepsy and lamotrigine-induced maculopapular eruptions","response to lamotrigine, maculopapular eruption, epilepsy",GCST002949,7:18195234
rs12668095-<b>C</b>,"5 x 10-7",,0.22,3.4,'-,[NR],MRPL42P4,"Epilepsy and lamotrigine-induced maculopapular eruptions","response to lamotrigine, maculopapular eruption, epilepsy",GCST002949,7:47036178
rs7461897-<b>?</b>,"5 x 10-7",,0.08,4.1,'-,[NR],MIR548H4,"Epilepsy and lamotrigine-induced maculopapular eruptions","response to lamotrigine, maculopapular eruption, epilepsy",GCST002949,8:27037027
rs13287547-<b>?</b>,"7 x 10-7",,0.04,4.8,'-,[NR],C9orf92,"Epilepsy and lamotrigine-induced maculopapular eruptions","response to lamotrigine, maculopapular eruption, epilepsy",GCST002949,9:16286892
rs74912790-<b>A</b>,"1 x 10-9",,0.01,10.7,'-,[NR],"IFNA6, IFNA13","Epilepsy and lamotrigine-induced maculopapular eruptions","response to lamotrigine, maculopapular eruption, epilepsy",GCST002949,9:21354067
rs75078187-<b>?</b>,"2 x 10-7",,0.01,8.1,'-,[NR],'-,"Epilepsy and lamotrigine-induced maculopapular eruptions","response to lamotrigine, maculopapular eruption, epilepsy",GCST002949,9:26064687
rs74308953-<b>A</b>,"2 x 10-10",,0.12,4.6,'-,[NR],LINC02578,"Epilepsy and lamotrigine-induced maculopapular eruptions","response to lamotrigine, maculopapular eruption, epilepsy",GCST002949,9:118668911
rs146173241-<b>?</b>,"1 x 10-7",,0.02,7.3,'-,[NR],"CCDC172, GFRA1","Epilepsy and lamotrigine-induced maculopapular eruptions","response to lamotrigine, maculopapular eruption, epilepsy",GCST002949,10:116285226
rs139427007-<b>?</b>,"4 x 10-7",,0.01,11,'-,[NR],LINC02409,"Epilepsy and lamotrigine-induced maculopapular eruptions","response to lamotrigine, maculopapular eruption, epilepsy",GCST002949,12:97202325
rs7328626-<b>?</b>,"8 x 10-9",,0.01,9.7,'-,[NR],'-,"Epilepsy and lamotrigine-induced maculopapular eruptions","response to lamotrigine, maculopapular eruption, epilepsy",GCST002949,13:53576772
rs9596837-<b>?</b>,"4 x 10-9",,0.01,10.1,'-,[NR],'-,"Epilepsy and lamotrigine-induced maculopapular eruptions","response to lamotrigine, maculopapular eruption, epilepsy",GCST002949,13:53683928
rs9596863-<b>G</b>,"8 x 10-11",,0.01,15.2,'-,[NR],LINC00558,"Epilepsy and lamotrigine-induced maculopapular eruptions","response to lamotrigine, maculopapular eruption, epilepsy",GCST002949,13:53860512
rs118166657-<b>?</b>,"1 x 10-7",,0.02,7.2,'-,[NR],"GCATP1, PPP2R5E","Epilepsy and lamotrigine-induced maculopapular eruptions","response to lamotrigine, maculopapular eruption, epilepsy",GCST002949,14:63580544
rs7495694-<b>G</b>,"1 x 10-9",,0.02,7.6,'-,[NR],"NPM1P42, ADPGK-AS1","Epilepsy and lamotrigine-induced maculopapular eruptions","response to lamotrigine, maculopapular eruption, epilepsy",GCST002949,15:72833651
rs79007183-<b>A</b>,"3 x 10-10",,0.01,14,'-,[NR],CRAMP1,"Epilepsy and lamotrigine-induced maculopapular eruptions","response to lamotrigine, maculopapular eruption, epilepsy",GCST002949,16:1655793
rs1429264-<b>?</b>,"9 x 10-7",,0.01,8.4,'-,[NR],COTL1,"Epilepsy and lamotrigine-induced maculopapular eruptions","response to lamotrigine, maculopapular eruption, epilepsy",GCST002949,16:84589878
rs11663316-<b>?</b>,"6 x 10-7",,0.07,4.2,'-,[NR],"RPS4XP19, NDUFV2","Epilepsy and lamotrigine-induced maculopapular eruptions","response to lamotrigine, maculopapular eruption, epilepsy",GCST002949,18:9027916
rs17084405-<b>A</b>,"1 x 10-7",,0.01,12.1,'-,[NR],LINC01541,"Epilepsy and lamotrigine-induced maculopapular eruptions","response to lamotrigine, maculopapular eruption, epilepsy",GCST002949,18:71429162
rs970510-<b>?</b>,"7 x 10-7",,0.02,6.5,'-,[NR],LINC01899,"Epilepsy and lamotrigine-induced maculopapular eruptions","response to lamotrigine, maculopapular eruption, epilepsy",GCST002949,18:71812685
rs150435906-<b>?</b>,"6 x 10-7",,0.01,8.6,'-,[NR],DNAJC5B,"Epilepsy and lamotrigine-induced maculopapular eruptions","response to lamotrigine, maculopapular eruption, epilepsy",GCST002949,8:65952103
rs2930491-<b>?</b>,"5 x 10-7",,0.07,4,'-,[NR],ABRA,"Epilepsy and lamotrigine-induced maculopapular eruptions","response to lamotrigine, maculopapular eruption, epilepsy",GCST002949,8:106830066
rs143543475-<b>?</b>,"4 x 10-7",,0.01,11,'-,[NR],"PTCHD3, RAB18","Epilepsy and lamotrigine-induced maculopapular eruptions","response to lamotrigine, maculopapular eruption, epilepsy",GCST002949,10:27419100
rs55949311-<b>?</b>,"8 x 10-9",,0.01,9.7,'-,[NR],'-,"Epilepsy and lamotrigine-induced maculopapular eruptions","response to lamotrigine, maculopapular eruption, epilepsy",GCST002949,13:53557781
rs12600394-<b>?</b>,"2 x 10-6",,'-,'-,'-,'-,RPS18P12,"Response to platinum-based chemotherapy (cisplatin)","response to cisplatin",GCST001201,17:14614150
rs11148708-<b>?</b>,"3 x 10-6",,'-,'-,'-,'-,PCDH9,"Response to platinum-based chemotherapy (cisplatin)","response to cisplatin",GCST001201,13:66586549
rs9527419-<b>?</b>,"6 x 10-6",,'-,'-,'-,'-,'-,"Response to platinum-based chemotherapy (cisplatin)","response to cisplatin",GCST001201,13:55584874
rs7210837-<b>?</b>,"6 x 10-7",,'-,'-,'-,'-,"COTL1P1, TBC1D27P","Response to platinum-based chemotherapy (cisplatin)","response to cisplatin",GCST001201,17:16861664
rs1520896-<b>?</b>,"1 x 10-6",,'-,'-,'-,'-,DBX1,"Response to platinum-based chemotherapy (cisplatin)","response to cisplatin",GCST001201,11:20247844
rs6698365-<b>?</b>,"1 x 10-6",,'-,'-,'-,'-,IFNLR1,"Response to platinum-based chemotherapy (cisplatin)","response to cisplatin",GCST001201,1:24171333
rs7605235-<b>?</b>,"7 x 10-6",,'-,'-,'-,'-,DTNB,"Response to platinum-based chemotherapy (cisplatin)","response to cisplatin",GCST001201,2:25431180
rs9263567-<b>?</b>,"5 x 10-6",,'-,'-,'-,'-,"RNU6-1133P, C6orf15","Response to platinum-based chemotherapy (cisplatin)","response to cisplatin",GCST001201,6:31101750
rs2833197-<b>?</b>,"9 x 10-6",,'-,'-,'-,'-,KRTAP19-8,"Response to platinum-based chemotherapy (cisplatin)","response to cisplatin",GCST001201,21:31034797
rs9960150-<b>?</b>,"5 x 10-6",,'-,'-,'-,'-,"RPLP0P11, MAPK4","Response to platinum-based chemotherapy (cisplatin)","response to cisplatin",GCST001201,18:50482070
rs10164289-<b>?</b>,"7 x 10-6",,'-,'-,'-,'-,ARHGAP35,"Response to platinum-based chemotherapy (cisplatin)","response to cisplatin",GCST001201,19:46980665
rs2997105-<b>?</b>,"4 x 10-6",,'-,'-,'-,'-,'-,"Response to platinum-based chemotherapy (cisplatin)","response to cisplatin",GCST001201,13:55804290
rs1340490-<b>?</b>,"3 x 10-6",,'-,'-,'-,'-,'-,"Response to platinum-based chemotherapy (cisplatin)","response to cisplatin",GCST001201,13:63490455
rs4860223-<b>?</b>,"1 x 10-6",,'-,'-,'-,'-,'-,"Response to platinum-based chemotherapy (cisplatin)","response to cisplatin",GCST001201,4:66748851
rs12105510-<b>?</b>,"6 x 10-6",,'-,'-,'-,'-,"MRPL19, U3","Response to platinum-based chemotherapy (cisplatin)","response to cisplatin",GCST001201,2:75642702
rs10518159-<b>?</b>,"1 x 10-6",,'-,'-,'-,'-,"SOWAHB, SHROOM3-AS1","Response to platinum-based chemotherapy (cisplatin)","response to cisplatin",GCST001201,4:76842845
rs11115148-<b>?</b>,"2 x 10-6",,'-,'-,'-,'-,LINC02426,"Response to platinum-based chemotherapy (cisplatin)","response to cisplatin",GCST001201,12:81995345
rs7191751-<b>?</b>,"2 x 10-6",,'-,'-,'-,'-,'-,"Response to platinum-based chemotherapy (cisplatin)","response to cisplatin",GCST001201,"Mapping not available"
rs7758889-<b>?</b>,"7 x 10-7",,'-,'-,'-,'-,NHSL1,"Response to platinum-based chemotherapy (cisplatin)","response to cisplatin",GCST001201,6:138600907
rs1254774-<b>?</b>,"4 x 10-6",,'-,'-,'-,'-,LPP,"Response to platinum-based chemotherapy (cisplatin)","response to cisplatin",GCST001201,3:188701738
rs4545955-<b>?</b>,"7 x 10-6",,'-,'-,'-,'-,LINC01937,"Response to platinum-based chemotherapy (cisplatin)","response to cisplatin",GCST001201,2:238729659
rs6593803-<b>?</b>,"2 x 10-7",,'-,3.13,'-,[NR],"GJA5, RN7SL261P","Methotrexate-induced interstitial lung disease in rheumatoid arthritis","response to methotrexate, rheumatoid arthritis, interstitial lung disease",GCST004358,1:147733635
rs9299346-<b>?</b>,"2 x 10-6",,'-,2.76,'-,[NR],GRIN3A,"Methotrexate-induced interstitial lung disease in rheumatoid arthritis","response to methotrexate, rheumatoid arthritis, interstitial lung disease",GCST004358,9:101611505
rs1624005-<b>?</b>,"7 x 10-6",,'-,2.59,'-,[NR],'-,"Methotrexate-induced interstitial lung disease in rheumatoid arthritis","response to methotrexate, rheumatoid arthritis, interstitial lung disease",GCST004358,14:42913159
rs2229774-<b>A</b>,"6 x 10-8",,0.064,4.7,'-,[2.7-8.3],RARG,"Anthracycline-induced cardiotoxicity in childhood cancer","childhood cancer, cardiotoxicity, response to anthracycline-based chemotherapy",GCST003062,12:53211761
rs2229774-<b>A</b>,"8 x 10-8",(EA),0.076,5.4,'-,[2.9-10.3],RARG,"Anthracycline-induced cardiotoxicity in childhood cancer","childhood cancer, cardiotoxicity, response to anthracycline-based chemotherapy",GCST003062,12:53211761
rs12652364-<b>A</b>,"6 x 10-7",(PhysVAS),NR,'-,"1.45 unit decrease",[0.88-2.02],'-,"Response to methotrexate in juvenile idiopathic arthritis","response to methotrexate, juvenile idiopathic arthritis",GCST002408,5:30835972
rs757278-<b>T</b>,"5 x 10-7",(ParVAS),NR,'-,"1.32 unit increase",[0.81-1.83],CTTNBP2,"Response to methotrexate in juvenile idiopathic arthritis","response to methotrexate, juvenile idiopathic arthritis",GCST002408,7:117737591
rs7800668-<b>C</b>,"6 x 10-6",(ACR-pedi),NR,'-,"1.34 unit decrease",[0.75-1.93],CTTNBP2,"Response to methotrexate in juvenile idiopathic arthritis","response to methotrexate, juvenile idiopathic arthritis",GCST002408,7:117818989
rs4395908-<b>C</b>,"1 x 10-6",(CHAQ),NR,'-,"0.27 unit decrease",[0.17-0.37],CSMD1,"Response to methotrexate in juvenile idiopathic arthritis","response to methotrexate, juvenile idiopathic arthritis",GCST002408,8:4168122
rs10113213-<b>T</b>,"3 x 10-6",(AJC),NR,'-,"1.99 unit decrease",[1.15-2.83],LINC02235,"Response to methotrexate in juvenile idiopathic arthritis","response to methotrexate, juvenile idiopathic arthritis",GCST002408,8:81976373
rs7839040-<b>G</b>,"2 x 10-6",(LJC),NR,'-,"1.81 unit decrease",[1.07-2.55],LINC02235,"Response to methotrexate in juvenile idiopathic arthritis","response to methotrexate, juvenile idiopathic arthritis",GCST002408,8:81982071
rs10956445-<b>C</b>,"5 x 10-7",(AJC),NR,'-,"2.73 unit decrease",[1.67-3.79],CCDC26,"Response to methotrexate in juvenile idiopathic arthritis","response to methotrexate, juvenile idiopathic arthritis",GCST002408,8:128775730
rs10128264-<b>C</b>,"1 x 10-6",(ParVAS),NR,'-,"1.18 unit decrease",[0.71-1.65],ZMIZ1,"Response to methotrexate in juvenile idiopathic arthritis","response to methotrexate, juvenile idiopathic arthritis",GCST002408,10:79200216
rs2802369-<b>C</b>,"7 x 10-6",(ESR),NR,'-,"9.37 unit decrease",[5.33-13.41],ZMIZ1,"Response to methotrexate in juvenile idiopathic arthritis","response to methotrexate, juvenile idiopathic arthritis",GCST002408,10:79201071
rs66861122-<b>G</b>,"5 x 10-6",(ParVAS),NR,'-,"1.82 unit increase",[1.06-2.58],ANO4,"Response to methotrexate in juvenile idiopathic arthritis","response to methotrexate, juvenile idiopathic arthritis",GCST002408,12:100990180
rs11113818-<b>T</b>,"4 x 10-6",(ParVAS),NR,'-,"1.16 unit increase",[0.67-1.65],CMKLR1,"Response to methotrexate in juvenile idiopathic arthritis","response to methotrexate, juvenile idiopathic arthritis",GCST002408,12:108324152
rs144444502-<b>A</b>,"6 x 10-6",(LJC),NR,'-,"2.27 unit decrease",[1.29-3.25],CCDC26,"Response to methotrexate in juvenile idiopathic arthritis","response to methotrexate, juvenile idiopathic arthritis",GCST002408,8:128761289
rs11225055-<b>C</b>,"1 x 10-6",(LJC),NR,'-,"3.49 unit decrease",[2.08-4.90],ANGPTL5,"Response to methotrexate in juvenile idiopathic arthritis","response to methotrexate, juvenile idiopathic arthritis",GCST002408,11:101900702
rs61996546-<b>C</b>,"3 x 10-6",(PhysVAS),NR,'-,"0.78 unit decrease",[0.47-1.09],GABRB3,"Response to methotrexate in juvenile idiopathic arthritis","response to methotrexate, juvenile idiopathic arthritis",GCST002408,15:26558984
rs6506122-<b>C</b>,"5 x 10-6",(LJC),NR,'-,"1.82 unit increase",[1.06-2.58],"IGLJCOR18, LINC01895","Response to methotrexate in juvenile idiopathic arthritis","response to methotrexate, juvenile idiopathic arthritis",GCST002408,18:3394451
rs10084630-<b>G</b>,"9 x 10-6",(ParVAS),NR,'-,"1.13 unit increase",[0.64-1.62],CYTH4,"Response to methotrexate in juvenile idiopathic arthritis","response to methotrexate, juvenile idiopathic arthritis",GCST002408,22:37283446
rs2294369-<b>A</b>,"9 x 10-8",(AJC),NR,'-,"2.77 unit increase",[1.77-3.77],CACNA1I,"Response to methotrexate in juvenile idiopathic arthritis","response to methotrexate, juvenile idiopathic arthritis",GCST002408,22:39679395
rs60624478-<b>A</b>,"6 x 10-6",(PhysVAS),NR,'-,"1.17 unit increase",[0.66-1.68],LMX1A,"Response to methotrexate in juvenile idiopathic arthritis","response to methotrexate, juvenile idiopathic arthritis",GCST002408,1:165138742
rs6871559-<b>?</b>,"5 x 10-6",,NR,'-,'-,'-,RNU1-76P,"Response to antiepileptic drugs in genetic generalized epilepsy","generalised epilepsy, response to anticonvulsant",GCST010296,5:8047596
rs13179734-<b>?</b>,"9 x 10-6",,NR,'-,'-,'-,LINC02064,"Response to antiepileptic drugs in genetic generalized epilepsy","generalised epilepsy, response to anticonvulsant",GCST010296,5:29350574
rs7457112-<b>?</b>,"9 x 10-6",,NR,'-,'-,'-,CNTNAP2,"Response to antiepileptic drugs in genetic generalized epilepsy","generalised epilepsy, response to anticonvulsant",GCST010296,7:147179410
rs1277731-<b>?</b>,"9 x 10-6",,NR,'-,'-,'-,CACNB2,"Response to antiepileptic drugs in genetic generalized epilepsy","generalised epilepsy, response to anticonvulsant",GCST010296,10:18275056
rs78269837-<b>?</b>,"5 x 10-6",,NR,'-,'-,'-,WDR41,"Response to valproic acid in genetic generalized epilepsy","generalised epilepsy, response to anticonvulsant",GCST010295,5:77513656
rs4292046-<b>?</b>,"5 x 10-6",,NR,'-,'-,'-,"COL6A3, EXOC6B","Response to valproic acid in genetic generalized epilepsy","generalised epilepsy, response to anticonvulsant",GCST010295,2:237241061
rs6046489-<b>?</b>,"7 x 10-6",,NR,'-,'-,'-,RIN2,"Response to valproic acid in genetic generalized epilepsy","generalised epilepsy, response to anticonvulsant",GCST010295,20:19964849
rs17650998-<b>?</b>,"9 x 10-7",,NR,'-,'-,'-,"KCNMB2, KCNMB2-AS1","Response to lamotrigine in genetic generalized epilepsy","generalised epilepsy, response to anticonvulsant",GCST010294,3:178595905
rs10206521-<b>?</b>,"3 x 10-6",,NR,'-,'-,'-,TDRD15,"Response to lamotrigine in genetic generalized epilepsy","generalised epilepsy, response to anticonvulsant",GCST010294,2:21197956
rs1291861-<b>?</b>,"6 x 10-6",,NR,'-,'-,'-,CELF2,"Response to lamotrigine in genetic generalized epilepsy","generalised epilepsy, response to anticonvulsant",GCST010294,10:11069836
rs11794033-<b>?</b>,"8 x 10-6",,NR,'-,'-,'-,RN7SKP120,"Response to lamotrigine in genetic generalized epilepsy","generalised epilepsy, response to anticonvulsant",GCST010294,9:25100018
rs17676256-<b>?</b>,"1 x 10-7",,NR,'-,'-,'-,ANK2,"Response to levetiracetam in genetic generalized epilepsy","generalised epilepsy, response to anticonvulsant",GCST010293,4:113140380
rs12320526-<b>?</b>,"2 x 10-6",,NR,'-,'-,'-,NAV3,"Response to levetiracetam in genetic generalized epilepsy","generalised epilepsy, response to anticonvulsant",GCST010293,12:77558903
rs12734159-<b>?</b>,"3 x 10-6",,NR,'-,'-,'-,"RN7SL854P, LEPR","Response to levetiracetam in genetic generalized epilepsy","generalised epilepsy, response to anticonvulsant",GCST010293,1:65719775
rs7956831-<b>?</b>,"3 x 10-6",,NR,'-,'-,'-,"CD69, CLECL1","Response to levetiracetam in genetic generalized epilepsy","generalised epilepsy, response to anticonvulsant",GCST010293,12:9736561
rs1014085-<b>?</b>,"4 x 10-6",,NR,'-,'-,'-,'-,"Response to levetiracetam in genetic generalized epilepsy","generalised epilepsy, response to anticonvulsant",GCST010293,8:56731439
rs3756744-<b>?</b>,"4 x 10-6",,NR,'-,'-,'-,"ISOC1, SLC27A6","Response to levetiracetam in genetic generalized epilepsy","generalised epilepsy, response to anticonvulsant",GCST010293,5:129093029
rs7515154-<b>?</b>,"4 x 10-6",,NR,'-,'-,'-,"C1orf52, SYDE2","Response to levetiracetam in genetic generalized epilepsy","generalised epilepsy, response to anticonvulsant",GCST010293,1:85238752
rs72765466-<b>?</b>,"6 x 10-6",,NR,'-,'-,'-,NID1,"Response to levetiracetam in genetic generalized epilepsy","generalised epilepsy, response to anticonvulsant",GCST010293,1:236054704
rs17124115-<b>?</b>,"7 x 10-6",,NR,'-,'-,'-,"LINC02395, LINC02396","Response to levetiracetam in genetic generalized epilepsy","generalised epilepsy, response to anticonvulsant",GCST010293,12:49911807
rs1922809-<b>?</b>,"8 x 10-7",,NR,'-,'-,'-,LRRTM4,"Response to lamotrigine and valproic acid in genetic generalized epilepsy","generalised epilepsy, response to anticonvulsant",GCST010292,2:77459975
rs78723182-<b>?</b>,"2 x 10-6",,NR,'-,'-,'-,MAGI2,"Response to lamotrigine and valproic acid in genetic generalized epilepsy","generalised epilepsy, response to anticonvulsant",GCST010292,7:78891976
rs4416719-<b>?</b>,"2 x 10-6",,NR,'-,'-,'-,F13A1,"Response to lamotrigine and valproic acid in genetic generalized epilepsy","generalised epilepsy, response to anticonvulsant",GCST010292,6:6163975
rs1479876-<b>?</b>,"4 x 10-6",,NR,'-,'-,'-,CLSTN2,"Response to lamotrigine and valproic acid in genetic generalized epilepsy","generalised epilepsy, response to anticonvulsant",GCST010292,3:140325167
rs7705566-<b>?</b>,"4 x 10-6",,NR,'-,'-,'-,CDH6,"Response to lamotrigine and valproic acid in genetic generalized epilepsy","generalised epilepsy, response to anticonvulsant",GCST010292,5:31259022
rs8003775-<b>?</b>,"6 x 10-6",,NR,'-,'-,'-,LINC00639,"Response to lamotrigine and valproic acid in genetic generalized epilepsy","generalised epilepsy, response to anticonvulsant",GCST010292,14:38866611
rs1061235-<b>?</b>,"1 x 10-7",,NR,9.12,'-,[4.03-20.65],HLA-A,"Adverse response to carbamazepine","response to anticonvulsant",GCST001014,6:29945521
rs875858-<b>?</b>,"2 x 10-8",,NR,3.6,'-,[2.21-5.84],VAC14,"Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer","peripheral neuropathy, response to docetaxel, metastatic prostate cancer",GCST003672,16:70741552
rs11017056-<b>?</b>,"4 x 10-7",,NR,2.61,'-,[1.77-3.84],C10orf143,"Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer","peripheral neuropathy, response to docetaxel, metastatic prostate cancer",GCST003672,10:130032376
rs1326116-<b>?</b>,"2 x 10-6",,NR,2.77,'-,[1.79-4.27],ATP8A2,"Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer","peripheral neuropathy, response to docetaxel, metastatic prostate cancer",GCST003672,13:25800908
rs8089250-<b>?</b>,"2 x 10-6",,NR,2.72,'-,[1.78-4.17],'-,"Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer","peripheral neuropathy, response to docetaxel, metastatic prostate cancer",GCST003672,18:4772808
rs6436559-<b>?</b>,"3 x 10-6",,NR,3.34,'-,[1.95-5.71],NYAP2,"Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer","peripheral neuropathy, response to docetaxel, metastatic prostate cancer",GCST003672,2:225488082
rs1566691-<b>?</b>,"4 x 10-6",,NR,3.64,'-,[2.03-6.52],'-,"Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer","peripheral neuropathy, response to docetaxel, metastatic prostate cancer",GCST003672,5:3727065
rs1027796-<b>?</b>,"4 x 10-6",,NR,2.38,'-,[1.62-3.48],OPCML,"Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer","peripheral neuropathy, response to docetaxel, metastatic prostate cancer",GCST003672,11:132887775
rs2213920-<b>?</b>,"5 x 10-6",,NR,2.63,'-,[1.70-4.06],'-,"Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer","peripheral neuropathy, response to docetaxel, metastatic prostate cancer",GCST003672,9:115509305
rs4438470-<b>?</b>,"5 x 10-6",,NR,2.71,'-,[1.73-4.25],SPHKAP,"Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer","peripheral neuropathy, response to docetaxel, metastatic prostate cancer",GCST003672,2:228150003
rs17815605-<b>?</b>,"6 x 10-6",,NR,2.886,'-,[NR],MIR7515HG,"Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer","peripheral neuropathy, response to docetaxel, metastatic prostate cancer",GCST003672,2:6637697
rs11740657-<b>?</b>,"9 x 10-6",,NR,2.776,'-,[NR],TRPC7,"Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer","peripheral neuropathy, response to docetaxel, metastatic prostate cancer",GCST003672,5:136245971
rs10997287-<b>?</b>,"9 x 10-6",,NR,4.0816326,'-,[NR],CTNNA3,"Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer","peripheral neuropathy, response to docetaxel, metastatic prostate cancer",GCST003672,10:66659088
rs7562732-<b>?</b>,"2 x 10-6",,NR,5,'-,NR,'-,"Depression in response to interferon-based therapy in chronic hepatitis C","chronic hepatitis C virus infection, response to interferon, depressive symptom measurement",GCST003824,2:118328332
rs1863918-<b>T</b>,"8 x 10-8",,NR,2.55,'-,[1.8-3.61],ADAMTS2,"Depression in response to interferon-based therapy in chronic hepatitis C","chronic hepatitis C virus infection, response to interferon, depressive symptom measurement",GCST003824,5:179112381
rs9386749-<b>?</b>,"9 x 10-6",,NR,2.173913,'-,NR,LINC00222,"Depression in response to interferon-based therapy in chronic hepatitis C","chronic hepatitis C virus infection, response to interferon, depressive symptom measurement",GCST003824,6:108752513
rs2779180-<b>?</b>,"1 x 10-6",,NR,2.564103,'-,NR,PLIN3,"Depression in response to interferon-based therapy in chronic hepatitis C","chronic hepatitis C virus infection, response to interferon, depressive symptom measurement",GCST003824,19:4841139
rs1202179-<b>C</b>,"4 x 10-8",,'-,4.05,'-,[2.46-6.67],ABCB1,"Persistent chemotherapy-induced alopecia in breast cancer","chemotherapy-induced alopecia, response to docetaxel, breast carcinoma",GCST011316,7:87574963
rs16964543-<b>T</b>,"4 x 10-7",,0.67,'-,"0.37 unit decrease",'-,ZNF536,"Myocardial infarction in hypertension (calcium channel blocker interaction)","hypertension, response to calcium channel blocker, myocardial infarction",GCST003206,19:30694303
rs11595500-<b>?</b>,"4 x 10-8",,NR,'-,"0.212 unit decrease",[NR],'-,"Paclitaxel-induced cytotoxicity","cytotoxicity measurement, response to paclitaxel",GCST002924,10:2818886
rs264124-<b>?</b>,"7 x 10-7",,NR,'-,"0.146 unit increase",[NR],RNU7-53P,"Paclitaxel-induced cytotoxicity","cytotoxicity measurement, response to paclitaxel",GCST002924,5:130312328
rs3892315-<b>?</b>,"9 x 10-7",,NR,'-,"0.207 unit increase",[NR],AIPL1,"Paclitaxel-induced cytotoxicity","cytotoxicity measurement, response to paclitaxel",GCST002924,17:6423425
rs11059635-<b>G</b>,"2 x 10-7",(Dominant),0.67,6.63,'-,[2.95-14.9],TMEM132C,"Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel)","chemotherapy-induced alopecia, response to paclitaxel",GCST002179,12:128297477
rs3844412-<b>A</b>,"4 x 10-7",(Dominant),0.11,5.22,'-,[2.67-10.2],CDH13,"Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel)","chemotherapy-induced alopecia, response to paclitaxel",GCST002179,16:82612728
rs163818-<b>C</b>,"6 x 10-7",(Dominant),0.02,11.5,'-,[3.37-39.3],"TRIO, DNAH5","Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel)","chemotherapy-induced alopecia, response to paclitaxel",GCST002179,5:14071948
rs698813-<b>C</b>,"1 x 10-6",(Allelic),0.52,4.27,'-,[2.35-7.76],CAMKMT,"Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel)","chemotherapy-induced alopecia, response to paclitaxel",GCST002179,2:44478476
rs2838088-<b>A</b>,"1 x 10-6",(Dominant),0.12,4.48,'-,[2.32-8.66],"LINC00111, PCSEAT","Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel)","chemotherapy-induced alopecia, response to paclitaxel",GCST002179,21:41672041
rs548726-<b>?</b>,"5 x 10-7",,NR,'-,'-,'-,MIR4689,"Response to taxane treatment (placlitaxel)","response to paclitaxel",GCST001694,1:5853561
rs12657996-<b>?</b>,"9 x 10-6",,NR,'-,'-,'-,LINC01845,"Response to taxane treatment (placlitaxel)","response to paclitaxel",GCST001694,5:159477305
rs6967385-<b>?</b>,"6 x 10-6",,NR,'-,'-,'-,VWDE,"Response to taxane treatment (placlitaxel)","response to paclitaxel",GCST001694,7:12351693
rs2787702-<b>?</b>,"9 x 10-6",,NR,'-,'-,'-,TMEM26-AS1,"Response to taxane treatment (placlitaxel)","response to paclitaxel",GCST001694,10:61547717
rs1350172-<b>?</b>,"4 x 10-7",,NR,'-,'-,'-,CABCOCO1,"Response to taxane treatment (placlitaxel)","response to paclitaxel",GCST001694,10:61589009
rs1227969-<b>?</b>,"6 x 10-7",,NR,'-,'-,'-,TSPAN15,"Response to taxane treatment (placlitaxel)","response to paclitaxel",GCST001694,10:69503508
rs4936613-<b>?</b>,"6 x 10-6",,NR,'-,'-,'-,"BMPR1AP2, SC5D","Response to taxane treatment (placlitaxel)","response to paclitaxel",GCST001694,11:121333892
rs184234-<b>?</b>,"1 x 10-6",,NR,'-,'-,'-,ASB7,"Response to taxane treatment (placlitaxel)","response to paclitaxel",GCST001694,15:100711514
rs4787484-<b>?</b>,"1 x 10-6",,NR,'-,'-,'-,SEZ6L2,"Response to taxane treatment (placlitaxel)","response to paclitaxel",GCST001694,16:29895225
rs9895585-<b>?</b>,"9 x 10-6",,NR,'-,'-,'-,PYY,"Response to taxane treatment (placlitaxel)","response to paclitaxel",GCST001694,17:43987619
rs7260598-<b>?</b>,"6 x 10-6",,NR,'-,'-,'-,ZNF254,"Response to taxane treatment (placlitaxel)","response to paclitaxel",GCST001694,19:24039984
rs915832-<b>?</b>,"7 x 10-6",,NR,'-,'-,'-,PRDM15,"Response to taxane treatment (placlitaxel)","response to paclitaxel",GCST001694,21:41855386
rs10521792-<b>?</b>,"2 x 10-7",,NR,'-,'-,'-,FGF13,"Response to taxane treatment (placlitaxel)","response to paclitaxel",GCST001694,X:139035247
rs17348202-<b>G</b>,"1 x 10-6",,0.05,4.85,'-,[2.57-9.13],'-,"Paclitaxel-induced neuropathy","brain serotonin transporter measurement, response to paclitaxel",GCST002074,2:221207458
rs4141404-<b>A</b>,"3 x 10-6",,0.25,2.41,'-,[1.66-3.48],LIMK2,"Paclitaxel-induced neuropathy","brain serotonin transporter measurement, response to paclitaxel",GCST002074,22:31279199
rs275456-<b>A</b>,"3 x 10-6",,0.24,2.26,'-,[1.60-3.18],LINC02236,"Paclitaxel-induced neuropathy","brain serotonin transporter measurement, response to paclitaxel",GCST002074,5:6813824
rs1165472-<b>G</b>,"4 x 10-6",,0.30,2.36,'-,[1.64-3.40],'-,"Paclitaxel-induced neuropathy","brain serotonin transporter measurement, response to paclitaxel",GCST002074,1:55642931
rs10065203-<b>A</b>,"4 x 10-6",,0.40,2.51,'-,[1.69-3.71],TRIO,"Paclitaxel-induced neuropathy","brain serotonin transporter measurement, response to paclitaxel",GCST002074,5:14393512
rs10512385-<b>G</b>,"6 x 10-6",,0.14,2.58,'-,[1.71-3.89],'-,"Paclitaxel-induced neuropathy","brain serotonin transporter measurement, response to paclitaxel",GCST002074,9:108693295
rs3181157-<b>A</b>,"4 x 10-6",,0.10,3.22,'-,[1.96-5.29],"VWF, CD9","Paclitaxel-induced neuropathy","brain serotonin transporter measurement, response to paclitaxel",GCST002074,12:6199357
rs10090117-<b>G</b>,"4 x 10-6",,0.21,2.38,'-,[1.64-3.44],PSD3,"Paclitaxel-induced neuropathy","brain serotonin transporter measurement, response to paclitaxel",GCST002074,8:18523725
rs2947253-<b>G</b>,"4 x 10-6",,0.11,3.38,'-,[2.01-5.68],DPH6-DT,"Paclitaxel-induced neuropathy","brain serotonin transporter measurement, response to paclitaxel",GCST002074,15:35757291
rs12699683-<b>A</b>,"7 x 10-6",,0.09,3.66,'-,[2.08-6.45],'-,"Paclitaxel-induced neuropathy","brain serotonin transporter measurement, response to paclitaxel",GCST002074,7:15093502
HLA-A*31:01-<b>?</b>,"1 x 10-10",(EA),0.02,5.5,'-,[3.0-10],'-,"Carbamazepine-induced maculopapular exanthema","maculopapular eruption, response to carbamazepine",GCST005198,"Mapping not available"
rs11057864-<b>?</b>,"6 x 10-7",,NR,'-,'-,'-,SCARB1,"Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis","response to cyclophosphamide, systemic lupus erythematosus, lupus nephritis",GCST003445,12:124851404
rs7692514-<b>?</b>,"9 x 10-7",,NR,'-,'-,'-,"EPHA5, LINC02835","Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis","response to cyclophosphamide, systemic lupus erythematosus, lupus nephritis",GCST003445,4:65276878
rs1108131-<b>?</b>,"9 x 10-7",,NR,'-,'-,'-,CAMK1D,"Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis","response to cyclophosphamide, systemic lupus erythematosus, lupus nephritis",GCST003445,10:12455748
rs958476-<b>?</b>,"1 x 10-6",,NR,'-,'-,'-,BARX2,"Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis","response to cyclophosphamide, systemic lupus erythematosus, lupus nephritis",GCST003445,11:129451923
rs8009420-<b>?</b>,"2 x 10-6",,NR,'-,'-,'-,LINC02331,"Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis","response to cyclophosphamide, systemic lupus erythematosus, lupus nephritis",GCST003445,14:53797133
rs6696619-<b>?</b>,"2 x 10-6",,NR,'-,'-,'-,LINC01739,"Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis","response to cyclophosphamide, systemic lupus erythematosus, lupus nephritis",GCST003445,1:62987118
rs12589674-<b>?</b>,"2 x 10-6",,NR,'-,'-,'-,LINC02331,"Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis","response to cyclophosphamide, systemic lupus erythematosus, lupus nephritis",GCST003445,14:53779635
rs710987-<b>?</b>,"2 x 10-6",,NR,'-,'-,'-,LINC01019,"Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis","response to cyclophosphamide, systemic lupus erythematosus, lupus nephritis",GCST003445,5:3525326
rs1534618-<b>?</b>,"4 x 10-6",,NR,'-,'-,'-,LINC02439,"Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis","response to cyclophosphamide, systemic lupus erythematosus, lupus nephritis",GCST003445,12:118865390
rs10992211-<b>?</b>,"5 x 10-6",,NR,'-,'-,'-,"OR7E31P, IL6RP1","Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis","response to cyclophosphamide, systemic lupus erythematosus, lupus nephritis",GCST003445,9:90129733
rs10954650-<b>?</b>,"6 x 10-6",,NR,'-,'-,'-,HIPK2,"Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis","response to cyclophosphamide, systemic lupus erythematosus, lupus nephritis",GCST003445,7:139641806
rs10142203-<b>?</b>,"7 x 10-6",,NR,'-,'-,'-,TMX1,"Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis","response to cyclophosphamide, systemic lupus erythematosus, lupus nephritis",GCST003445,14:51238072
rs4149228-<b>?</b>,"7 x 10-6",,NR,'-,'-,'-,EPHX1,"Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis","response to cyclophosphamide, systemic lupus erythematosus, lupus nephritis",GCST003445,1:225844976
rs6697139-<b>?</b>,"3 x 10-8",,NR,'-,'-,'-,"Y_RNA, RPL31P11","Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis","response to cyclophosphamide, systemic lupus erythematosus, lupus nephritis",GCST003445,1:161690906
rs17450029-<b>T</b>,"3 x 10-6","(Tri-Tetra/cyclic antidepressants)",0.23,'-,'-,'-,DPH5,"QT interval (drug interaction)","QT interval, response to tricyclic antidepressant",GCST001890,1:101075443
rs3217869-<b>A</b>,"4 x 10-6","(Tri-Tetra/cyclic antidepressants)",0.41,'-,'-,'-,CCND2,"QT interval (drug interaction)","QT interval, response to tricyclic antidepressant",GCST001890,12:4290804
rs2708240-<b>A</b>,"4 x 10-6","(Tri-Tetra/cyclic antidepressants)",0.51,'-,'-,'-,CNTNAP2,"QT interval (drug interaction)","QT interval, response to tricyclic antidepressant",GCST001890,7:147880445
rs6755560-<b>T</b>,"2 x 10-6","(Tri-Tetra/cyclic antidepressants)",0.32,'-,'-,'-,"CPO, FASTKD2","QT interval (drug interaction)","QT interval, response to tricyclic antidepressant",GCST001890,2:206853059
rs9375225-<b>T</b>,"6 x 10-6","(Tri-Tetra/cyclic antidepressants)",0.48,'-,'-,'-,EIF4EBP2P3,"QT interval (drug interaction)","QT interval, response to tricyclic antidepressant",GCST001890,6:98140878
rs1718641-<b>?</b>,"6 x 10-6",,'-,2.5,'-,[1.69-3.70],LINC01808,"Oxcarbazepine-induced hyponatremia in epilepsy","response to oxcarbazepine, oxcarbazepine-induced hyponatremia, epilepsy",GCST007812,2:19499850
rs763780-<b>G</b>,"3 x 10-8",,NR,3.3,'-,[2.10-5.10],IL17F,"Response to gemcitabine in pancreatic cancer","response to gemcitabine, pancreatic carcinoma",GCST001346,6:52236941
rs2900174-<b>G</b>,"1 x 10-6",,NR,3.3,'-,[2.00-5.50],"PRB1, PRB2","Response to gemcitabine in pancreatic cancer","response to gemcitabine, pancreatic carcinoma",GCST001346,12:11394598
rs11062040-<b>A</b>,"8 x 10-6",,NR,1.4,'-,[1.20-1.70],"CACNA1C, DCP1B","Response to gemcitabine in pancreatic cancer","response to gemcitabine, pancreatic carcinoma",GCST001346,12:1982091
rs1901440-<b>C</b>,"3 x 10-6",(Recessive),0.20,34,'-,[4.29-269.48],RN7SKP93,"Response to gemcitabine in pancreatic cancer","response to gemcitabine, pancreatic carcinoma",GCST001390,2:133680388
rs11141915-<b>T</b>,"1 x 10-6",(Allelic),0.62,4.1,'-,[2.21-7.62],DAPK1,"Response to gemcitabine in pancreatic cancer","response to gemcitabine, pancreatic carcinoma",GCST001390,9:87620879
rs2799083-<b>?</b>,"2 x 10-6",,NR,2.27,'-,[1.61-3.19],TGFB2,"Gemcitabine-induced early high-grade neutropenia in pancreatic cancer","neutropenia, response to gemcitabine, pancreatic carcinoma",GCST007643,1:218408275
rs9835060-<b>?</b>,"5 x 10-6",,NR,2.59,'-,[1.7-3.94],UPK1B,"Gemcitabine-induced early high-grade neutropenia in pancreatic cancer","neutropenia, response to gemcitabine, pancreatic carcinoma",GCST007643,3:119189379
rs12526817-<b>?</b>,"3 x 10-6",,NR,2.22,'-,[1.57-3.14],NT5DC1,"Gemcitabine-induced early high-grade neutropenia in pancreatic cancer","neutropenia, response to gemcitabine, pancreatic carcinoma",GCST007643,6:116188473
rs17117434-<b>?</b>,"5 x 10-6",,NR,2.86,'-,[1.78-4.6],'-,"Gemcitabine-induced early high-grade neutropenia in pancreatic cancer","neutropenia, response to gemcitabine, pancreatic carcinoma",GCST007643,8:13768307
rs7915425-<b>?</b>,"4 x 10-6",,NR,2.34,'-,[1.62-3.39],"RPS26P39, LINC02641","Gemcitabine-induced early high-grade neutropenia in pancreatic cancer","neutropenia, response to gemcitabine, pancreatic carcinoma",GCST007643,10:123256985
rs1941238-<b>?</b>,"7 x 10-6",,NR,2.34,'-,[1.6-3.43],RN7SL97P,"Gemcitabine-induced early high-grade neutropenia in pancreatic cancer","neutropenia, response to gemcitabine, pancreatic carcinoma",GCST007643,18:25864505
rs117491755-<b>?</b>,"1 x 10-7",,'-,3.92,'-,2.35-6.51,ASTN2,"Drug-induced liver injury (anti-tuberculosis drugs)","response to anti-tuberculosis drug, drug-induced liver injury",GCST004084,9:116881377
rs143575776-<b>?</b>,"2 x 10-7",,'-,4.96,'-,2.70-9.09,PTPRD,"Drug-induced liver injury (anti-tuberculosis drugs)","response to anti-tuberculosis drug, drug-induced liver injury",GCST004084,9:9593742
rs73122578-<b>?</b>,"5 x 10-7",,NR,2.42,'-,1.71-3.40,ROBO1,"Drug-induced liver injury (anti-tuberculosis drugs)","response to anti-tuberculosis drug, drug-induced liver injury",GCST004084,3:79310483
rs149232047-<b>G</b>,"5 x 10-9",,0.0075,4.9,'-,[2.86-8.33],"PPP1R14BP5, CENPW","Diarrhoea in darapladib-treated cardiovascular disease (time to event)","response to darapladib, Diarrhea, acute coronary syndrome, coronary artery disease",GCST004962,6:126276990
rs16999497-<b>C</b>,"6 x 10-9",,0.0385,4.08,'-,[2.56-6.67],"APLN, OCRL","Diarrhoea in darapladib-treated cardiovascular disease (time to event)","response to darapladib, Diarrhea, acute coronary syndrome, coronary artery disease",GCST004962,X:129601222
rs151269874-<b>T</b>,"2 x 10-9",,0.0111,4.18,'-,[2.63-6.67],TMEM231,"Diarrhoea in darapladib-treated cardiovascular disease (time to event)","response to darapladib, Diarrhea, acute coronary syndrome, coronary artery disease",GCST004962,16:75549741
rs11915606-<b>G</b>,"4 x 10-8",,0.0071,7.23,'-,[3.58-14.62],BTD,"Moderate or severe diarrhoea in darapladib-treated cardiovascular disease (time to event)","response to darapladib, Diarrhea, acute coronary syndrome, coronary artery disease",GCST004967,3:15633655
rs148121703-<b>C</b>,"3 x 10-8",,0.0116,14.93,'-,[5.75-38.76],GABRB1,"Moderate or severe diarrhoea in darapladib-treated cardiovascular disease (time to event)","response to darapladib, Diarrhea, acute coronary syndrome, coronary artery disease",GCST004967,4:47371654
rs201394051-<b>AAT</b>,"2 x 10-8",,0.0442,2.72,'-,[1.91-3.86],LINC02147,"Moderate or severe diarrhoea in darapladib-treated cardiovascular disease (time to event)","response to darapladib, Diarrhea, acute coronary syndrome, coronary artery disease",GCST004967,5:117697919
rs4357117-<b>T</b>,"3 x 10-8",,0.0105,6.19,'-,[3.25-11.81],'-,"Moderate or severe diarrhoea in darapladib-treated cardiovascular disease (time to event)","response to darapladib, Diarrhea, acute coronary syndrome, coronary artery disease",GCST004967,6:66873865
rs145044782-<b>A</b>,"3 x 10-8",,0.0062,10.88,'-,[4.67-25.38],GLCCI1,"Moderate or severe diarrhoea in darapladib-treated cardiovascular disease (time to event)","response to darapladib, Diarrhea, acute coronary syndrome, coronary artery disease",GCST004967,7:7995866
rs144610116-<b>C</b>,"7 x 10-9",,0.0083,89.29,'-,[19.61-400],FAM114A1,"Moderate or severe diarrhoea in darapladib-treated cardiovascular disease (time to event)","response to darapladib, Diarrhea, acute coronary syndrome, coronary artery disease",GCST004967,4:38941227
rs62568141-<b>T</b>,"7 x 10-11",,0.0303,3.36,'-,[2.34-4.84],"LYPLA2P3, FOXB2","Moderate or severe diarrhoea in darapladib-treated cardiovascular disease (time to event)","response to darapladib, Diarrhea, acute coronary syndrome, coronary artery disease",GCST004967,9:77012344
rs74497159-<b>?</b>,"4 x 10-7",,'-,'-,"0.591 unit increase",[NR],LINC01307,"Sensory peripheral neuropathy in microtubule targeting agent-treated breast cancer","peripheral neuropathy, breast carcinoma, response to antimicrotubule agent",GCST010732,1:101409030
rs3110366-<b>?</b>,"1 x 10-6",,'-,'-,"0.394 unit decrease",[NR],ZFPM2,"Sensory peripheral neuropathy in microtubule targeting agent-treated breast cancer","peripheral neuropathy, breast carcinoma, response to antimicrotubule agent",GCST010732,8:105277293
rs77526807-<b>?</b>,"2 x 10-6",,'-,'-,"0.818 unit increase",[NR],"LINC01503, RN7SL159P","Sensory peripheral neuropathy in microtubule targeting agent-treated breast cancer","peripheral neuropathy, breast carcinoma, response to antimicrotubule agent",GCST010732,9:129361675
rs17076837-<b>?</b>,"2 x 10-6",,'-,'-,"0.578 unit increase",[NR],'-,"Sensory peripheral neuropathy in microtubule targeting agent-treated breast cancer","peripheral neuropathy, breast carcinoma, response to antimicrotubule agent",GCST010732,13:83495035
rs61963755-<b>?</b>,"2 x 10-6",,'-,'-,"0.674 unit increase",[NR],KLHL1,"Sensory peripheral neuropathy in microtubule targeting agent-treated breast cancer","peripheral neuropathy, breast carcinoma, response to antimicrotubule agent",GCST010732,13:69848530
rs2342780-<b>?</b>,"2 x 10-6",,'-,'-,"0.788 unit decrease",[NR],ZFPM2,"Sensory peripheral neuropathy in microtubule targeting agent-treated breast cancer","peripheral neuropathy, breast carcinoma, response to antimicrotubule agent",GCST010732,8:105251146
rs10771973-<b>?</b>,"2 x 10-6",,'-,'-,"0.451 unit increase",[NR],FGD4,"Sensory peripheral neuropathy in microtubule targeting agent-treated breast cancer","peripheral neuropathy, breast carcinoma, response to antimicrotubule agent",GCST010732,12:32640040
rs2342791-<b>?</b>,"3 x 10-6",,'-,'-,"0.414 unit decrease",[NR],ZFPM2,"Sensory peripheral neuropathy in microtubule targeting agent-treated breast cancer","peripheral neuropathy, breast carcinoma, response to antimicrotubule agent",GCST010732,8:105275744
rs11076190-<b>?</b>,"3 x 10-6",,'-,'-,"0.738 unit increase",[NR],"CCL17, CX3CL1","Sensory peripheral neuropathy in microtubule targeting agent-treated breast cancer","peripheral neuropathy, breast carcinoma, response to antimicrotubule agent",GCST010732,16:57393024
rs78777495-<b>?</b>,"3 x 10-6",,'-,'-,"0.602 unit increase",[NR],"LINC01450, SUGCT","Sensory peripheral neuropathy in microtubule targeting agent-treated breast cancer","peripheral neuropathy, breast carcinoma, response to antimicrotubule agent",GCST010732,7:40927299
rs9623812-<b>?</b>,"3 x 10-6",,'-,'-,"0.34 unit decrease",[NR],SCUBE1,"Sensory peripheral neuropathy in microtubule targeting agent-treated breast cancer","peripheral neuropathy, breast carcinoma, response to antimicrotubule agent",GCST010732,22:43328680
rs2060717-<b>?</b>,"3 x 10-6",,'-,'-,"0.496 unit increase",[NR],CALU,"Sensory peripheral neuropathy in microtubule targeting agent-treated breast cancer","peripheral neuropathy, breast carcinoma, response to antimicrotubule agent",GCST010732,7:128740695
rs6788186-<b>?</b>,"5 x 10-6",,'-,'-,"0.282 unit increase",[NR],LINC01326,"Sensory peripheral neuropathy in microtubule targeting agent-treated breast cancer","peripheral neuropathy, breast carcinoma, response to antimicrotubule agent",GCST010732,3:166544100
rs78017515-<b>?</b>,"6 x 10-6",,'-,'-,"0.621 unit increase",[NR],"SUGCT, LINC01450","Sensory peripheral neuropathy in microtubule targeting agent-treated breast cancer","peripheral neuropathy, breast carcinoma, response to antimicrotubule agent",GCST010732,7:40947421
rs13168251-<b>?</b>,"7 x 10-6",,'-,'-,"0.295 unit increase",[NR],'-,"Sensory peripheral neuropathy in microtubule targeting agent-treated breast cancer","peripheral neuropathy, breast carcinoma, response to antimicrotubule agent",GCST010732,5:92138315
rs777619-<b>?</b>,"8 x 10-6",,'-,'-,"0.416 unit increase",[NR],LINC02549,"Sensory peripheral neuropathy in microtubule targeting agent-treated breast cancer","peripheral neuropathy, breast carcinoma, response to antimicrotubule agent",GCST010732,6:68149055
rs2188156-<b>?</b>,"8 x 10-6",,'-,'-,"0.8 unit increase",[NR],"LINC00895, SEPTIN5","Sensory peripheral neuropathy in microtubule targeting agent-treated breast cancer","peripheral neuropathy, breast carcinoma, response to antimicrotubule agent",GCST010732,22:19651952
rs57940640-<b>?</b>,"9 x 10-6",,'-,'-,"0.552 unit increase",[NR],CNGB1,"Sensory peripheral neuropathy in microtubule targeting agent-treated breast cancer","peripheral neuropathy, breast carcinoma, response to antimicrotubule agent",GCST010732,16:57925334
rs2158962-<b>A</b>,"1 x 10-7",,0.54,4.94,'-,[2.65-9.24],TRAP1,"Infliximab-induced mucosal healing in Crohn's disease","response to TNF antagonist, Crohn's disease",GCST008397,16:3688026
rs284515-<b>G</b>,"7 x 10-7","(GEE model, response at both 3 and 6 months)",0.17,'-,"0.35 unit increase",[0.21-0.49],MAP3K7,"Response to anti-TNF therapy in rheumatoid arthritis","rheumatoid arthritis, response to TNF antagonist",GCST003329,6:90499109
rs75908454-<b>C</b>,"6 x 10-7","(GEE model, response at both 3 and 6 months)",0.1,'-,"0.42 unit increase",[0.26-0.59],WDR27,"Response to anti-TNF therapy in rheumatoid arthritis","rheumatoid arthritis, response to TNF antagonist",GCST003329,6:169570527
rs1679568-<b>?</b>,"8 x 10-7","(GEE model, response at both 3 and 6 months)",0.15,'-,"0.35 unit increase",[0.21-0.49],GFRA1,"Response to anti-TNF therapy in rheumatoid arthritis","rheumatoid arthritis, response to TNF antagonist",GCST003329,10:116058040
rs284511-<b>C</b>,"3 x 10-8","(response at 6 months)",0.33,'-,"0.41 unit increase",[NR],MAP3K7,"Response to anti-TNF therapy in rheumatoid arthritis","rheumatoid arthritis, response to TNF antagonist",GCST003329,6:90498823
rs1679568-<b>A</b>,"5 x 10-6","(response at 6 months)",0.15,'-,"0.44 unit increase",[NR],GFRA1,"Response to anti-TNF therapy in rheumatoid arthritis","rheumatoid arthritis, response to TNF antagonist",GCST003329,10:116058040
rs923880-<b>C</b>,"8 x 10-6","(GEE model, both 3 and 6 months)",0.43,'-,"0.25 unit decrease",[0.14-0.36],CSMD2,"Response to anti-TNF therapy in rheumatoid arthritis","rheumatoid arthritis, response to TNF antagonist",GCST003329,1:33522178
rs41005-<b>T</b>,"4 x 10-6","(GEE model, both 3 and 6 months)",0.33,'-,"0.27 unit increase","[0.16, 0.39]",LINC00298,"Response to anti-TNF therapy in rheumatoid arthritis","rheumatoid arthritis, response to TNF antagonist",GCST003329,2:7971100
rs13015080-<b>A</b>,"3 x 10-6","(GEE model, both 3 and 6 months)",0.31,'-,"0.28 unit decrease",[0.16-0.40],RPL37A,"Response to anti-TNF therapy in rheumatoid arthritis","rheumatoid arthritis, response to TNF antagonist",GCST003329,2:216519759
rs1079467-<b>C</b>,"2 x 10-6","(GEE model, both 3 and 6 months)",0.26,'-,"0.29 unit increase","[0.17, 0.41]","NLRP10, OR10A3","Response to anti-TNF therapy in rheumatoid arthritis","rheumatoid arthritis, response to TNF antagonist",GCST003329,11:7948164
rs16973500-<b>T</b>,"9 x 10-6","(GEE model, both 3 and 6 months)",0.38,'-,"0.24 unit increase","[0.13, 0.34]",PKD1L3,"Response to anti-TNF therapy in rheumatoid arthritis","rheumatoid arthritis, response to TNF antagonist",GCST003329,16:71931293
rs13015080-<b>A</b>,"1 x 10-6","(moderate and severe, GEE model, both 3 and 6 months)",0.31,'-,"0.3 unit decrease",[0.18-0.43],RPL37A,"Response to anti-TNF therapy in rheumatoid arthritis","rheumatoid arthritis, response to TNF antagonist",GCST003329,2:216519759
rs1498103-<b>A</b>,"6 x 10-6","(moderate and severe, GEE model, both 3 and 6 months)",0.46,'-,"0.26 unit increase","[0.15, 0.38]",CDH18,"Response to anti-TNF therapy in rheumatoid arthritis","rheumatoid arthritis, response to TNF antagonist",GCST003329,5:19839394
rs10520789-<b>?</b>,"6 x 10-7","(Change in DAS28)",NR,'-,'-,'-,LINC00924,"Response to TNF-alpha inhibitors in rheumatoid arthritis","rheumatoid arthritis, response to TNF antagonist",GCST001510,15:95598638
rs11870477-<b>?</b>,"3 x 10-6","(Change in DAS28)",NR,'-,'-,'-,LINC01483,"Response to TNF-alpha inhibitors in rheumatoid arthritis","rheumatoid arthritis, response to TNF antagonist",GCST001510,17:69806211
rs885814-<b>?</b>,"6 x 10-6","(Change in DAS28)",NR,'-,'-,'-,ALPL,"Response to TNF-alpha inhibitors in rheumatoid arthritis","rheumatoid arthritis, response to TNF antagonist",GCST001510,1:21549423
rs1539909-<b>?</b>,"4 x 10-6","(Relative change in DAS28)",NR,'-,'-,'-,LINC01541,"Response to TNF-alpha inhibitors in rheumatoid arthritis","rheumatoid arthritis, response to TNF antagonist",GCST001510,18:71581359
rs960902-<b>?</b>,"8 x 10-6","(Relative change in DAS28)",NR,'-,'-,'-,RNU6-1116P,"Response to TNF-alpha inhibitors in rheumatoid arthritis","rheumatoid arthritis, response to TNF antagonist",GCST001510,2:37504522
rs17679567-<b>?</b>,"9 x 10-6","(Relative change in DAS28)",NR,'-,'-,'-,MIR4719,"Response to TNF-alpha inhibitors in rheumatoid arthritis","rheumatoid arthritis, response to TNF antagonist",GCST001510,16:76856229
rs11045392-<b>?</b>,"2 x 10-6","(EULAR response)",NR,3.3,'-,[1.90-5.60],PDE3A,"Response to TNF-alpha inhibitors in rheumatoid arthritis","rheumatoid arthritis, response to TNF antagonist",GCST001510,12:20687905
rs3794271-<b>?</b>,"4 x 10-6","(EULAR response)",NR,3.2,'-,[1.90-5.50],SLCO1C1,"Response to TNF-alpha inhibitors in rheumatoid arthritis","rheumatoid arthritis, response to TNF antagonist",GCST001510,12:20707159
rs12777823-<b>?</b>,"5 x 10-12",,NR,'-,'-,'-,"CTBP2P2, HELLS","Warfarin maintenance dose","response to anticoagulant",GCST002061,10:94645745
rs4736253-<b>?</b>,"5 x 10-8",(EA),NR,'-,"5.448 z score increase",'-,'-,"Response to lurasidone in schizophrenia","schizophrenia, response to antipsychotic drug",GCST006248,8:139342742
rs10895475-<b>A</b>,"2 x 10-7",(EA),0.357,'-,"5.167 z score decrease",'-,'-,"Response to lurasidone in schizophrenia","schizophrenia, response to antipsychotic drug",GCST006248,11:103593113
rs10180106-<b>A</b>,"5 x 10-7",(EA),0.2813,'-,"5.03 z score increase",'-,CTNNA2,"Response to lurasidone in schizophrenia","schizophrenia, response to antipsychotic drug",GCST006248,2:79994772
rs511841-<b>C</b>,"2 x 10-7",(AA),NR,'-,"5.185 z score decrease",'-,"STXBP5L, LINC02049","Response to lurasidone in schizophrenia","schizophrenia, response to antipsychotic drug",GCST006248,3:120896668
rs7620938-<b>?</b>,"3 x 10-7",(AA),NR,'-,"5.116 z score decrease",'-,STXBP5L,"Response to lurasidone in schizophrenia","schizophrenia, response to antipsychotic drug",GCST006248,3:121172743
rs4736253-<b>?</b>,"2 x 10-6",,NR,'-,"4.718 z score increase",'-,'-,"Response to lurasidone in schizophrenia","schizophrenia, response to antipsychotic drug",GCST006248,8:139342742
rs10180106-<b>A</b>,"2 x 10-6",,NR,'-,"4.719 z score increase",'-,CTNNA2,"Response to lurasidone in schizophrenia","schizophrenia, response to antipsychotic drug",GCST006248,2:79994772
rs642516-<b>A</b>,"2 x 10-6",,0.6926,'-,"4.803 z score increase",'-,TENM4,"Response to lurasidone in schizophrenia","schizophrenia, response to antipsychotic drug",GCST006248,11:79289084
rs4507566-<b>A</b>,"2 x 10-6",,0.5584,'-,"4.756 z score decrease",'-,EYS,"Response to lurasidone in schizophrenia","schizophrenia, response to antipsychotic drug",GCST006248,6:65552163
rs60354593-<b>T</b>,"5 x 10-6",,0.1435,'-,"4.557 z score decrease",'-,"ATP5MGP4, TET2","Response to lurasidone in schizophrenia","schizophrenia, response to antipsychotic drug",GCST006248,4:148673270
rs26193-<b>A</b>,"8 x 10-6",,0.3048,'-,"4.475 z score increase",'-,U3,"Response to lurasidone in schizophrenia","schizophrenia, response to antipsychotic drug",GCST006248,5:35363807
rs12857574-<b>A</b>,"9 x 10-6",,0.3397,'-,"4.441 z score increase",'-,"LINC00460, RPL35P9","Response to lurasidone in schizophrenia","schizophrenia, response to antipsychotic drug",GCST006248,13:106409080
rs524045-<b>A</b>,"9 x 10-7",,0.1151,'-,"4.918 z score increase",'-,"RNU6-210P, RN7SKP123","Response to lurasidone in schizophrenia","schizophrenia, response to antipsychotic drug",GCST006248,1:93024470
rs2240395-<b>?</b>,"3 x 10-7",,'-,1.84,'-,1.45-2.31,TBXAS1,"Drug-induced liver injury (nonsteroidal anti-inflammatory drugs)","response to non-steroidal anti-inflammatory, drug-induced liver injury",GCST004087,7:140018347
rs185305928-<b>?</b>,"3 x 10-7",,'-,4.55,'-,2.55-8.11,CAMTA1,"Drug-induced liver injury (nonsteroidal anti-inflammatory drugs)","response to non-steroidal anti-inflammatory, drug-induced liver injury",GCST004087,1:6845651
rs597480-<b>?</b>,"4 x 10-7",,'-,1.84,'-,1.45-2.32,SYTL2,"Drug-induced liver injury (nonsteroidal anti-inflammatory drugs)","response to non-steroidal anti-inflammatory, drug-induced liver injury",GCST004087,11:85725825
rs2025009-<b>?</b>,"7 x 10-7",,'-,1.81,'-,1.43-2.29,RAD51B,"Drug-induced liver injury (nonsteroidal anti-inflammatory drugs)","response to non-steroidal anti-inflammatory, drug-induced liver injury",GCST004087,14:68376888
rs79645820-<b>?</b>,"5 x 10-6",,NR,2.8465698,'-,NR,"ARHGAP15, KYNU","Response to SSRI (symptom remission)","response to selective serotonin reuptake inhibitor",GCST007060,2:143086939
rs12044299-<b>?</b>,"4 x 10-6",,NR,2.1362956,'-,NR,KAZN,"Response to SSRI (symptom remission)","response to selective serotonin reuptake inhibitor",GCST007060,1:13961624
rs12644500-<b>?</b>,"5 x 10-6",,NR,1.6038493,'-,NR,LINC01378,"Response to SSRI (symptom remission)","response to selective serotonin reuptake inhibitor",GCST007060,4:117586197
rs7482428-<b>?</b>,"4 x 10-7",,NR,1.4643433,'-,NR,"OR51B5, HBG2, HBE1","Response to SSRI (symptom remission)","response to selective serotonin reuptake inhibitor",GCST007060,11:5321196
rs1102156-<b>?</b>,"2 x 10-6",,NR,1.4518,'-,NR,"KCTD15, RN7SL150P","Response to SSRI (symptom remission)","response to selective serotonin reuptake inhibitor",GCST007060,19:33847882
rs3935545-<b>?</b>,"3 x 10-6",,NR,1.6929,'-,NR,"NOC4L, LINC02361","Response to SSRI (symptom remission)","response to selective serotonin reuptake inhibitor",GCST007060,12:132181579
rs4352485-<b>?</b>,"2 x 10-6",,NR,1.9615,'-,NR,TBC1D1,"Response to SSRI (symptom remission)","response to selective serotonin reuptake inhibitor",GCST007060,4:37975567
rs17768250-<b>?</b>,"7 x 10-7",,NR,2.3758,'-,NR,ZFAT,"Response to SSRI (symptom remission)","response to selective serotonin reuptake inhibitor",GCST007060,8:134558431
rs114465512-<b>?</b>,"5 x 10-7",,'-,12.987013,'-,[3.98-43.48],"IGLVIV-66-1, IGLV10-67","Response to selective serotonin reuptake inhibitors in depression","unipolar depression, response to selective serotonin reuptake inhibitor, mood disorder",GCST003801,22:22047895
rs117198528-<b>?</b>,"9 x 10-7",,'-,1.823,'-,[1.437-2.313],"ACAA2, SMUG1P1","Response to selective serotonin reuptake inhibitors in depression","unipolar depression, response to selective serotonin reuptake inhibitor, mood disorder",GCST003801,18:49694188
rs141746753-<b>?</b>,"1 x 10-6",,'-,3.2467532,'-,[1.84-5.71],"RNU6-13P, BPNT2","Response to selective serotonin reuptake inhibitors and depression","unipolar depression, response to selective serotonin reuptake inhibitor, mood disorder",GCST003809,8:56934154
rs6545694-<b>?</b>,"2 x 10-6",,'-,1.096,'-,[1.056-1.137],LINC01122,"Response to selective serotonin reuptake inhibitors and depression","unipolar depression, response to selective serotonin reuptake inhibitor, mood disorder",GCST003809,2:58620818
rs113378111-<b>?</b>,"7 x 10-7",,'-,1.579,'-,[1.303-1.912],"RNU4-73P, TAF1B","Non-response to selective serotonin reuptake inhibitors and depression","unipolar depression, response to selective serotonin reuptake inhibitor, mood disorder",GCST003808,2:9788024
rs80164876-<b>?</b>,"4 x 10-7",,'-,2.09,'-,[1.551-2.815],EGFLAM,"Response to selective serotonin reuptake inhibitors in depression","unipolar depression, response to selective serotonin reuptake inhibitor, mood disorder",GCST003801,5:38464142
rs35863382-<b>?</b>,"7 x 10-7",,'-,1.540832,'-,[1.3-1.83],PPP4R3A,"Response to selective serotonin reuptake inhibitors in depression","unipolar depression, response to selective serotonin reuptake inhibitor, mood disorder",GCST003801,14:91472532
rs150175932-<b>?</b>,"1 x 10-7",,'-,15.22,'-,[3.318-69.804],DCLK2,"Response to selective serotonin reuptake inhibitors and depression","unipolar depression, response to selective serotonin reuptake inhibitor, mood disorder",GCST003809,4:150101495
rs138472420-<b>?</b>,"1 x 10-6",,'-,5.628,'-,[2.692-11.767],BICRA,"Response to selective serotonin reuptake inhibitors in depression","unipolar depression, response to selective serotonin reuptake inhibitor, mood disorder",GCST003801,19:47657765
rs73720034-<b>?</b>,"1 x 10-6",,'-,1.256,'-,[1.142-1.381],'-,"Response to selective serotonin reuptake inhibitors and depression","unipolar depression, response to selective serotonin reuptake inhibitor, mood disorder",GCST003809,7:125794995
rs61519662-<b>?</b>,"2 x 10-6",,'-,1.1013216,'-,[1.06-1.15],'-,"Response to selective serotonin reuptake inhibitors and depression","unipolar depression, response to selective serotonin reuptake inhibitor, mood disorder",GCST003809,2:2696619
rs1994321-<b>?</b>,"5 x 10-7",,'-,1.1547344,'-,[1.09-1.22],"MICAL2, LINC02547","Non-response to selective serotonin reuptake inhibitors and depression","unipolar depression, response to selective serotonin reuptake inhibitor, mood disorder",GCST003808,11:12065766
rs73788091-<b>?</b>,"1 x 10-6",,'-,3.011,'-,[2.044-4.437],FSTL4,"Non-response to selective serotonin reuptake inhibitors and depression","unipolar depression, response to selective serotonin reuptake inhibitor, mood disorder",GCST003808,5:133429517
rs9951011-<b>?</b>,"2 x 10-6",,'-,1.1806375,'-,[1.1-1.26],'-,"Non-response to selective serotonin reuptake inhibitors and depression","unipolar depression, response to selective serotonin reuptake inhibitor, mood disorder",GCST003808,18:67366441
rs78620960-<b>?</b>,"2 x 10-6",,'-,1.2033695,'-,[1.12-1.3],LINC01720,"Non-response to selective serotonin reuptake inhibitors and depression","unipolar depression, response to selective serotonin reuptake inhibitor, mood disorder",GCST003808,1:190812369
rs148071215-<b>A</b>,"4 x 10-7",,0.0217,4.3652,'-,[3.80-4.93],LINC02301,"Clozapine-induced agranulocytosis","Drug-induced agranulocytosis, response to clozapine",GCST002595,14:82806309
rs111703385-<b>A</b>,"6 x 10-7",,0.0419,3.6248,'-,[3.12-4.13],"CLDN23, RN7SL178P","Clozapine-induced agranulocytosis","Drug-induced agranulocytosis, response to clozapine",GCST002595,8:8642006
rs12993904-<b>G</b>,"9 x 10-7",,0.4783,1.93,'-,[1.67-2.19],SILC1,"Clozapine-induced agranulocytosis","Drug-induced agranulocytosis, response to clozapine",GCST002595,2:5999574
rs144803255-<b>A</b>,"9 x 10-7",,0.0241,4.1709,'-,[3.60-4.74],TEX9,"Clozapine-induced agranulocytosis","Drug-induced agranulocytosis, response to clozapine",GCST002595,15:56403547
rs41314643-<b>C</b>,"1 x 10-6",,0.0159,5.2714815,'-,[4.6-5.95],NMNAT2,"Clozapine-induced agranulocytosis","Drug-induced agranulocytosis, response to clozapine",GCST002595,1:183286773
rs11211480-<b>G</b>,"2 x 10-6",,0.5253,1.9278966,'-,[1.66-2.2],TAL1,"Clozapine-induced agranulocytosis","Drug-induced agranulocytosis, response to clozapine",GCST002595,1:47227548
rs61800638-<b>G</b>,"2 x 10-6",,0.0438,3.387534,'-,[2.88-3.89],"LINC02795, COL24A1","Clozapine-induced agranulocytosis","Drug-induced agranulocytosis, response to clozapine",GCST002595,1:86241900
rs10865924-<b>G</b>,"3 x 10-6",,0.3018,1.84,'-,[1.59-2.09],"ACKR2, KRBOX1","Clozapine-induced agranulocytosis","Drug-induced agranulocytosis, response to clozapine",GCST002595,3:42852935
rs12809497-<b>C</b>,"4 x 10-6",,0.4449,2.09,'-,[1.78-2.40],"LINC02441, LINC00508","Clozapine-induced agranulocytosis","Drug-induced agranulocytosis, response to clozapine",GCST002595,12:128016467
rs17156371-<b>A</b>,"5 x 10-6",,0.1115,2.1463,'-,[1.82-2.47],"NMT2, FAM171A1","Clozapine-induced agranulocytosis","Drug-induced agranulocytosis, response to clozapine",GCST002595,10:15171101
rs114397494-<b>G0.0414</b>,"5 x 10-6",,0.0414,2.96,'-,[2.49-3.43],XRCC4,"Clozapine-induced agranulocytosis","Drug-induced agranulocytosis, response to clozapine",GCST002595,5:83114977
rs3123012-<b>T</b>,"5 x 10-6",,0.0901,2.3069,'-,[1.95-2.67],LINC01707,"Clozapine-induced agranulocytosis","Drug-induced agranulocytosis, response to clozapine",GCST002595,1:69092456
rs112511621-<b>T</b>,"6 x 10-6",,0.1762,2.4087,'-,[2.03-2.79],TMTC3,"Clozapine-induced agranulocytosis","Drug-induced agranulocytosis, response to clozapine",GCST002595,12:88254303
rs62204504-<b>C</b>,"6 x 10-6",,0.0355,3.22,'-,[2.71-3.73],JPH2,"Clozapine-induced agranulocytosis","Drug-induced agranulocytosis, response to clozapine",GCST002595,20:44166408
rs6546043-<b>A</b>,"7 x 10-6",,0.7116,2.079,'-,[1.76-2.40],VPS54,"Clozapine-induced agranulocytosis","Drug-induced agranulocytosis, response to clozapine",GCST002595,2:63980311
rs10510921-<b>G</b>,"7 x 10-6",,0.02,3.52,'-,[2.97-4.07],ADAMTS9-AS2,"Clozapine-induced agranulocytosis","Drug-induced agranulocytosis, response to clozapine",GCST002595,3:64926476
rs9513373-<b>C</b>,"8 x 10-6",,0.02,4.18,'-,[3.55-4.81],FARP1,"Clozapine-induced agranulocytosis","Drug-induced agranulocytosis, response to clozapine",GCST002595,13:98214742
rs73201717-<b>T</b>,"8 x 10-6",,0.159,2.08,'-,[1.76-2.40],RN7SL474P,"Clozapine-induced agranulocytosis","Drug-induced agranulocytosis, response to clozapine",GCST002595,8:16825237
rs2808382-<b>C</b>,"8 x 10-6",,0.0469,2.7742,'-,[2.33-3.22],"INTS7, LPGAT1-AS1","Clozapine-induced agranulocytosis","Drug-induced agranulocytosis, response to clozapine",GCST002595,1:211918606
rs7428297-<b>T</b>,"8 x 10-6",,0.125,2.0602,'-,[1.74-2.38],LINC02016,"Clozapine-induced agranulocytosis","Drug-induced agranulocytosis, response to clozapine",GCST002595,3:127359497
rs115384187-<b>A</b>,"9 x 10-6",,0.0125,6.4585,'-,[5.64-7.28],"CHI3L1, CHIT1","Clozapine-induced agranulocytosis","Drug-induced agranulocytosis, response to clozapine",GCST002595,1:203195061
rs116688600-<b>C</b>,"9 x 10-6",,0.0196,5.07,'-,[4.35-5.79],CCNB3P1,"Clozapine-induced agranulocytosis","Drug-induced agranulocytosis, response to clozapine",GCST002595,5:26746274
rs17312438-<b>C</b>,"9 x 10-6",,0.0116,8.37,'-,[7.43-9.31],'-,"Clozapine-induced agranulocytosis","Drug-induced agranulocytosis, response to clozapine",GCST002595,7:85937160
rs2068666-<b>G</b>,"9 x 10-6",,0.0813,2.38,'-,[2.00-2.76],NFASC,"Clozapine-induced agranulocytosis","Drug-induced agranulocytosis, response to clozapine",GCST002595,1:204948452
rs6978272-<b>?</b>,"7 x 10-6",,NR,3.448276,'-,[2-5.88],EXOC4,"Response to selective serotonin reuptake inhibitors in depression","unipolar depression, response to selective serotonin reuptake inhibitor",GCST006267,7:133403285
rs7954376-<b>?</b>,"4 x 10-6",,NR,3.448276,'-,[2.04-5.88],GRIN2B,"Response to selective serotonin reuptake inhibitors in depression","unipolar depression, response to selective serotonin reuptake inhibitor",GCST006267,12:13481181
rs4810894-<b>?</b>,"3 x 10-6",,NR,2.7,'-,[1.78-4.10],"ARFGEF2, PREX1","Response to selective serotonin reuptake inhibitors in depression","unipolar depression, response to selective serotonin reuptake inhibitor",GCST006267,20:48916462
rs77554113-<b>?</b>,"1 x 10-6",,NR,4.81,'-,[2.54-9.13],TSHZ3,"Remission after SSRI treatment in major depression","unipolar depression, response to selective serotonin reuptake inhibitor",GCST006266,19:31140034
rs2814778-<b>C</b>,"4 x 10-21",,0.8838,'-,"0.856 unit decrease",[0.68-1.03],"ACKR1, CADM3-AS1","Neutrophil level response to clozapine in treatment-resistant schizophrenia","neutrophil count, treatment refractory schizophrenia, response to clozapine",GCST006987,1:159204893
rs77198048-<b>T</b>,"9 x 10-9",,0.107,'-,"1.625 unit increase",[1.07-2.18],ZNF618,"Neutrophil level response to clozapine in treatment-resistant schizophrenia","neutrophil count, treatment refractory schizophrenia, response to clozapine",GCST006987,9:114026974
nsv831124-<b>?</b>,"3 x 10-6",,0.54,1.4285715,'-,'-,'-,"Treatment resistant depression","treatment resistant depression, response to antidepressant",GCST007665,"Mapping not available"
nsv527355-<b>A</b>,"5 x 10-6",,0.47,1.44,'-,[1.28-1.6],'-,"Treatment resistant depression","treatment resistant depression, response to antidepressant",GCST007665,"Mapping not available"
rs242999-<b>C</b>,"1 x 10-6",,0.39,1.85,'-,[1.44-2.37],LINC01643,"Treatment resistant depression","treatment resistant depression, response to antidepressant",GCST007667,22:34109914
rs73837957-<b>A</b>,"2 x 10-6",,0.15,2.73,'-,[1.81-4.11],CCSER1,"Treatment resistant depression","treatment resistant depression, response to antidepressant",GCST007667,4:91682958
rs9895559-<b>A</b>,"2 x 10-6",,0.45,1.85,'-,[1.43-2.38],"SLC13A5, RPL23AP73","Treatment resistant depression","treatment resistant depression, response to antidepressant",GCST007667,17:6732054
rs80080484-<b>?</b>,"4 x 10-6",,0.97,5.882353,'-,[2.7-12.5],"LARP7P3, LINC01910","Treatment resistant depression","treatment resistant depression, response to antidepressant",GCST007667,18:70403190
rs12745534-<b>?</b>,"5 x 10-6",,0.87,2.2222223,'-,[1.59-3.12],HIVEP3,"Treatment resistant depression","treatment resistant depression, response to antidepressant",GCST007667,1:41890579
rs12564480-<b>?</b>,"9 x 10-7",,0.88,2.4390244,'-,[1.72-3.57],"WDR64, OPN3","Treatment resistant depression","treatment resistant depression, response to antidepressant",GCST007667,1:241666284
rs1841915-<b>?</b>,"1 x 10-6",,0.61,1.8518518,'-,[1.45-2.33],"ZNF385D-AS1, ZNF385D","Treatment resistant depression","treatment resistant depression, response to antidepressant",GCST007667,3:21573947
rs952614-<b>A</b>,"2 x 10-6",,0.31,'-,"0.08 unit increase",[0.041-0.119],'-,"Depressive symptom improvement","depressive symptom measurement, response to antidepressant",GCST007666,13:109577461
rs12564480-<b>C</b>,"4 x 10-7",,0.12,'-,"0.12 unit increase",[0.081-0.159],"WDR64, OPN3","Depressive symptom improvement","depressive symptom measurement, response to antidepressant",GCST007666,1:241666284
rs8086741-<b>C</b>,"7 x 10-7",,0.01,'-,"0.37 unit decrease",[0.23-0.51],LDLRAD4,"Depressive symptom improvement","depressive symptom measurement, response to antidepressant",GCST007666,18:13357230
rs79035215-<b>T</b>,"7 x 10-7",,0.01,'-,"0.31 unit decrease",[0.19-0.43],ZDHHC3,"Depressive symptom improvement","depressive symptom measurement, response to antidepressant",GCST007666,3:44954646
rs1991346-<b>G</b>,"7 x 10-7",,0.42,'-,"0.08 unit decrease",[0.041-0.119],SGCZ,"Depressive symptom improvement","depressive symptom measurement, response to antidepressant",GCST007666,8:14293973
rs1334063-<b>T</b>,"9 x 10-7",,0.33,'-,"0.08 unit increase",[0.041-0.119],RFX3-AS1,"Depressive symptom improvement","depressive symptom measurement, response to antidepressant",GCST007666,9:3652155
rs73837957-<b>A</b>,"1 x 10-6",,0.15,'-,"0.12 unit decrease",[0.081-0.159],CCSER1,"Depressive symptom improvement","depressive symptom measurement, response to antidepressant",GCST007666,4:91682958
rs2075855-<b>A</b>,"1 x 10-6",,0.08,'-,"0.14 unit increase",[0.081-0.199],MUC5B,"Depressive symptom improvement","depressive symptom measurement, response to antidepressant",GCST007666,11:1227730
rs138362018-<b>G</b>,"2 x 10-6",,0.01,'-,"0.31 unit decrease",[0.17-0.45],TGM4,"Depressive symptom improvement","depressive symptom measurement, response to antidepressant",GCST007666,3:44908534
rs10514108-<b>T</b>,"1 x 10-6",,0.1,'-,"0.13 unit decrease",[0.071-0.189],ARSB,"Depressive symptom improvement","depressive symptom measurement, response to antidepressant",GCST007666,5:78809524
rs112534819-<b>T</b>,"2 x 10-6",,0.02,'-,"0.37 unit increase",[0.21-0.53],"LINC02224, RN7SL383P","Depressive symptom improvement","depressive symptom measurement, response to antidepressant",GCST007666,5:44712640
rs188509130-<b>T</b>,"3 x 10-6",,0.01,'-,"0.34 unit increase",[0.2-0.48],DPY19L1P1,"Depressive symptom improvement","depressive symptom measurement, response to antidepressant",GCST007666,7:32643161
rs10860592-<b>T</b>,"3 x 10-6",,0.19,'-,"0.09 unit decrease",[0.051-0.129],'-,"Depressive symptom improvement","depressive symptom measurement, response to antidepressant",GCST007666,12:78554754
rs72865845-<b>C</b>,"4 x 10-6",,0.22,'-,"0.09 unit increase",[0.051-0.129],EVPL,"Depressive symptom improvement","depressive symptom measurement, response to antidepressant",GCST007666,17:76019315
rs144150047-<b>T</b>,"5 x 10-6",,0.04,'-,"0.25 unit increase",[0.15-0.35],'-,"Depressive symptom improvement","depressive symptom measurement, response to antidepressant",GCST007666,X:125515825
rs151126591-<b>T</b>,"5 x 10-6",,0.01,'-,"0.35 unit increase",[0.19-0.51],STK3,"Depressive symptom improvement","depressive symptom measurement, response to antidepressant",GCST007666,8:98460061
rs12080794-<b>?</b>,"9 x 10-6",,NR,1.75,'-,[1.33-2.27],"SLC2A5, GPR157","Response to antidepressant treatment (citalopram)","response to antidepressant",GCST002046,1:9091266
rs7816924-<b>A</b>,"2 x 10-7",,NR,2.14,'-,[1.53-2.99],CSGALNACT1,"Response to antidepressant treatment (citalopram)","response to antidepressant",GCST002046,8:19682127
rs10492002-<b>?</b>,"4 x 10-6",,NR,1.64,'-,[1.33-2.00],ACSS3,"Response to antidepressant treatment (citalopram)","response to antidepressant",GCST002046,12:81150757
rs7239368-<b>?</b>,"9 x 10-6",(remission),0.42,1.45,'-,[1.22-1.69],NOL4,"Response to citalopram treatment","response to antidepressant",GCST000509,18:34065415
rs6966038-<b>?</b>,"5 x 10-7",(response),0.19,1.64,'-,[1.35-1.99],"MNX1-AS1, UBE3C","Response to citalopram treatment","response to antidepressant",GCST000509,7:157087704
rs6127921-<b>?</b>,"3 x 10-6",(response),0.82,1.64,'-,[1.33-2.04],'-,"Response to citalopram treatment","response to antidepressant",GCST000509,20:57063694
rs809736-<b>?</b>,"8 x 10-6",(response),0.17,1.52,'-,[1.27-1.83],RORA,"Response to citalopram treatment","response to antidepressant",GCST000509,15:61037589
rs6127921-<b>?</b>,"1 x 10-6",(remission),0.81,1.75,'-,[1.39-2.17],'-,"Response to citalopram treatment","response to antidepressant",GCST000509,20:57063694
rs6966038-<b>?</b>,"4 x 10-7",(remission),0.20,1.68,'-,[1.37-2.04],"MNX1-AS1, UBE3C","Response to citalopram treatment","response to antidepressant",GCST000509,7:157087704
rs2830840-<b>?</b>,"5 x 10-6",(remission),0.46,1.47,'-,[1.23-1.72],EIF4A1P1,"Response to citalopram treatment","response to antidepressant",GCST000509,21:27293028
rs7715172-<b>G</b>,"3 x 10-6","(EA + AA - GSE)",0.071,'-,'-,'-,EGFLAM,"Response to citalopram treatment","response to antidepressant",GCST001591,5:38452792
rs17135437-<b>A</b>,"3 x 10-8","(EA + AA - Vision\hearing)",0.019,'-,'-,'-,COL26A1,"Response to citalopram treatment","response to antidepressant",GCST001591,7:101472713
rs3810046-<b>T</b>,"5 x 10-7","(EA + AA - Overall tolerability)",0.456,'-,'-,'-,"RNU6-916P, LAMA1","Response to citalopram treatment","response to antidepressant",GCST001591,18:6941663
rs13430864-<b>G</b>,"5 x 10-7","(EA + AA - Dizziness)",0.04,'-,'-,'-,"AOX2P, BZW1-AS1","Response to citalopram treatment","response to antidepressant",GCST001591,2:200783916
rs6040399-<b>T</b>,"7 x 10-7","(EA + AA - Dizziness)",0.308,'-,'-,'-,'-,"Response to citalopram treatment","response to antidepressant",GCST001591,20:11176363
rs17135437-<b>A</b>,"3 x 10-6","(AA - Vision\hearing)",NR,'-,'-,'-,COL26A1,"Response to citalopram treatment","response to antidepressant",GCST001591,7:101472713
rs6040399-<b>T</b>,"1 x 10-6","(AA - Dizziness)",NR,'-,'-,'-,'-,"Response to citalopram treatment","response to antidepressant",GCST001591,20:11176363
rs11935103-<b>T</b>,"1 x 10-6","(EA + AA - GSE)",0.262,'-,'-,'-,F11-AS1,"Response to citalopram treatment","response to antidepressant",GCST001591,4:186417181
rs2903308-<b>A</b>,"2 x 10-6","(EA + AA - Overall tolerability)",0.461,'-,'-,'-,'-,"Response to citalopram treatment","response to antidepressant",GCST001591,16:13563028
rs4502542-<b>T</b>,"2 x 10-6","(EA + AA - GSE)",0.017,'-,'-,'-,FHIT,"Response to citalopram treatment","response to antidepressant",GCST001591,3:59935294
rs6563353-<b>A</b>,"2 x 10-6","(EA + AA - GSE)",0.177,'-,'-,'-,'-,"Response to citalopram treatment","response to antidepressant",GCST001591,13:83556097
rs16965962-<b>T</b>,"3 x 10-7","(EA + AA - GSE)",0.03,'-,'-,'-,'-,"Response to citalopram treatment","response to antidepressant",GCST001591,13:105154672
rs6646773-<b>C</b>,"1 x 10-6","(EA + AA - GSE)",0.076,'-,'-,'-,'-,"Response to citalopram treatment","response to antidepressant",GCST001591,X:117088295
rs6764050-<b>G</b>,"9 x 10-7","(EA + AA - GSE)",0.023,'-,'-,'-,"SST, RTP2","Response to citalopram treatment","response to antidepressant",GCST001591,3:187696203
rs4398173-<b>G</b>,"4 x 10-6","(EA - Overall tolerability)",NR,'-,'-,'-,"LAMA1, RNU6-916P","Response to citalopram treatment","response to antidepressant",GCST001591,18:6941109
rs16965962-<b>T</b>,"3 x 10-7","(AA - GSE)",NR,'-,'-,'-,'-,"Response to citalopram treatment","response to antidepressant",GCST001591,13:105154672
rs11935103-<b>T</b>,"2 x 10-6","(EA - GSE)",NR,'-,'-,'-,F11-AS1,"Response to citalopram treatment","response to antidepressant",GCST001591,4:186417181
rs148114323-<b>?</b>,"8 x 10-6","(adjusted for CYP2C19*2)",0.01,'-,"0.78 unit decrease",NR,LINC02240,"Platelet reactivity in response to clopidogrel treatment","platelet reactivity measurement, response to clopidogrel",GCST010485,5:163280338
rs7584466-<b>?</b>,"2 x 10-6",,0.29186,2.3175902,'-,NR,RPS20P10,"Cardiovascular death or myocardial infarction in response to clopidogrel treatment","response to clopidogrel, cardiovascular event measurement",GCST010482,2:71884400
rs142225302-<b>?</b>,"8 x 10-6","(adjusted for CYP2C19*2)",0.02,'-,"0.5 unit increase",NR,VRK1,"Platelet reactivity in response to clopidogrel treatment","platelet reactivity measurement, response to clopidogrel",GCST010485,14:97014377
rs11035623-<b>T</b>,"7 x 10-6",,0.929568,2.7592254,'-,NR,'-,"Cardiovascular death or myocardial infarction in response to clopidogrel treatment","response to clopidogrel, cardiovascular event measurement",GCST010482,11:39949536
rs74952072-<b>?</b>,"1 x 10-6","(adjusted for CYP2C19*2)",0.04,'-,"0.32 unit increase",NR,PDE10A,"Platelet reactivity in response to clopidogrel treatment","platelet reactivity measurement, response to clopidogrel",GCST010485,6:165694839
rs139496757-<b>A</b>,"3 x 10-6",,0.990879,7.530715,'-,NR,CDC42BPA,"Cardiovascular death or myocardial infarction in response to clopidogrel treatment","response to clopidogrel, cardiovascular event measurement",GCST010482,1:227236411
rs9399096-<b>?</b>,"4 x 10-6","(adjusted for CYP2C19*2)",0.07,'-,"0.25 unit decrease",NR,LINC01010,"Platelet reactivity in response to clopidogrel treatment","platelet reactivity measurement, response to clopidogrel",GCST010485,6:134418922
rs1219603-<b>?</b>,"6 x 10-6","(adjusted for CYP2C19*2)",0.15,'-,"0.18 unit increase",NR,'-,"Platelet reactivity in response to clopidogrel treatment","platelet reactivity measurement, response to clopidogrel",GCST010485,10:36254386
rs10505836-<b>?</b>,"7 x 10-6","(adjusted for CYP2C19*2)",0.16,'-,"0.17 unit increase",NR,PLEKHA5,"Platelet reactivity in response to clopidogrel treatment","platelet reactivity measurement, response to clopidogrel",GCST010485,12:19135574
rs57908830-<b>C</b>,"3 x 10-6","(adjusted for CYP2C19*2)",0.973036,'-,"0.39621 unit increase",[0.23-0.56],LINC02554,"Platelet reactivity in response to clopidogrel treatment","platelet reactivity measurement, response to clopidogrel",GCST010485,22:27363217
rs1516568-<b>G</b>,"3 x 10-6","(adjusted for CYP2C19*2)",0.885066,'-,"0.199481 unit decrease",[0.12-0.28],GRM7,"Platelet reactivity in response to clopidogrel treatment","platelet reactivity measurement, response to clopidogrel",GCST010485,3:6907543
rs13118022-<b>T</b>,"1 x 10-6","(adjusted for CYP2C19*2)",0.605871,'-,"0.135527 unit decrease",[0.081-0.19],NR3C2,"Platelet reactivity in response to clopidogrel treatment","platelet reactivity measurement, response to clopidogrel",GCST010485,4:148424435
rs1546044-<b>T</b>,"1 x 10-6","(adjusted for CYP2C19*2)",0.72993,'-,"0.149735 unit decrease",[0.09-0.209],NR3C2,"Platelet reactivity in response to clopidogrel treatment","platelet reactivity measurement, response to clopidogrel",GCST010485,4:148411792
rs6901676-<b>?</b>,"5 x 10-6",,0.236,7.11475,'-,NR,"CAHM, PACRG-AS1","Stent thrombosis in response to clopidogrel treatment","response to clopidogrel, cardiovascular event measurement",GCST010484,6:163351472
rs303500-<b>?</b>,"4 x 10-6",,0.294685,5.559621,'-,NR,"LIPM, RCBTB2P1","Stent thrombosis in response to clopidogrel treatment","response to clopidogrel, cardiovascular event measurement",GCST010484,10:88793660
rs4738080-<b>G</b>,"7 x 10-7",,0.909321,4.4665666,'-,NR,NCOA2,"Stent thrombosis in response to clopidogrel treatment","response to clopidogrel, cardiovascular event measurement",GCST010484,8:70217578
rs71546150-<b>T</b>,"7 x 10-6",,0.973446,6.5332203,'-,NR,'-,"Stent thrombosis in response to clopidogrel treatment","response to clopidogrel, cardiovascular event measurement",GCST010484,7:54085846
rs72661666-<b>C</b>,"7 x 10-6",,0.988771,12.519281,'-,NR,PPM1K,"Stent thrombosis in response to clopidogrel treatment","response to clopidogrel, cardiovascular event measurement",GCST010484,4:88275046
rs185315165-<b>A</b>,"1 x 10-6",,0.997048,38.516624,'-,NR,"R3HCC1L, CRTAC1","Stent thrombosis in response to clopidogrel treatment","response to clopidogrel, cardiovascular event measurement",GCST010484,10:98071581
rs35835168-<b>C</b>,"4 x 10-35",,0.827305,'-,"0.453913 unit decrease",[0.38-0.52],CYP2C18,"Platelet reactivity in response to clopidogrel treatment","platelet reactivity measurement, response to clopidogrel",GCST010485,10:94727550
rs28399513-<b>T</b>,"1 x 10-33",,0.831002,'-,"0.447534 unit decrease",[0.38-0.52],CYP2C19,"Platelet reactivity in response to clopidogrel treatment","platelet reactivity measurement, response to clopidogrel",GCST010485,10:94842641
rs35464072-<b>?</b>,"3 x 10-7","(adjusted for CYP2C19*2)",0.45,'-,"0.14 unit increase",NR,NR3C2,"Platelet reactivity in response to clopidogrel treatment","platelet reactivity measurement, response to clopidogrel",GCST010485,4:148405084
rs151216272-<b>A</b>,"2 x 10-7","(adjusted for CYP2C19*2)",0.988336,'-,"0.635567 unit decrease",[0.4-0.87],LINGO2,"Platelet reactivity in response to clopidogrel treatment","platelet reactivity measurement, response to clopidogrel",GCST010485,9:28118947
rs12598219-<b>?</b>,"2 x 10-6",,0.1383,4.0172997,'-,NR,"KRT18P18, ZFHX3","Cardiovascular death or myocardial infarction in response to clopidogrel treatment","response to clopidogrel, cardiovascular event measurement",GCST010482,16:72743326
rs76180455-<b>?</b>,"7 x 10-6","(adjusted for CYP2C19*2)",0.02,'-,"0.4 unit decrease",NR,PLCE1,"Platelet reactivity in response to clopidogrel treatment","platelet reactivity measurement, response to clopidogrel",GCST010485,10:94234751
rs13147128-<b>C</b>,"3 x 10-6",,0.607027,1.9768566,'-,NR,"SLC10A7, REELD1","Cardiovascular death or myocardial infarction in response to clopidogrel treatment","response to clopidogrel, cardiovascular event measurement",GCST010482,4:146249405
rs140497518-<b>?</b>,"9 x 10-6","(adjusted for CYP2C19*2)",0.02,'-,"0.49 unit increase",NR,VRK1,"Platelet reactivity in response to clopidogrel treatment","platelet reactivity measurement, response to clopidogrel",GCST010485,14:97016874
rs55670713-<b>T</b>,"6 x 10-6",,0.973647,4.1872745,'-,NR,"CER1, FREM1","Cardiovascular death or myocardial infarction in response to clopidogrel treatment","response to clopidogrel, cardiovascular event measurement",GCST010482,9:14723628
rs61670395-<b>?</b>,"6 x 10-6","(adjusted for CYP2C19*2)",0.06,'-,"0.25 unit decrease",NR,SYT4,"Platelet reactivity in response to clopidogrel treatment","platelet reactivity measurement, response to clopidogrel",GCST010485,18:43305596
rs115346894-<b>G</b>,"2 x 10-6",,0.991113,7.707701,'-,NR,CDC42BPA,"Cardiovascular death or myocardial infarction in response to clopidogrel treatment","response to clopidogrel, cardiovascular event measurement",GCST010482,1:227120115
rs151062494-<b>C</b>,"4 x 10-7",,0.992037,10.044749,'-,NR,'-,"Cardiovascular death or myocardial infarction in response to clopidogrel treatment","response to clopidogrel, cardiovascular event measurement",GCST010482,7:86058899
rs112858730-<b>T</b>,"2 x 10-6",,0.99373,10.931953,'-,NR,SOCS5P1,"Cardiovascular death or myocardial infarction in response to clopidogrel treatment","response to clopidogrel, cardiovascular event measurement",GCST010482,7:86193546
rs2479921-<b>?</b>,"3 x 10-6","(adjusted for CYP2C19*2)",0.18,'-,"0.16 unit increase",NR,ATXN8OS,"Platelet reactivity in response to clopidogrel treatment","platelet reactivity measurement, response to clopidogrel",GCST010485,13:70175037
rs7276140-<b>?</b>,"4 x 10-6","(adjusted for CYP2C19*2)",0.44,'-,"0.12 unit decrease",NR,SYNJ1,"Platelet reactivity in response to clopidogrel treatment","platelet reactivity measurement, response to clopidogrel",GCST010485,21:32632890
rs117956006-<b>?</b>,"6 x 10-6","(adjusted for CYP2C19*2)",NR,'-,"1.19 unit increase",NR,MBNL2,"Platelet reactivity in response to clopidogrel treatment","platelet reactivity measurement, response to clopidogrel",GCST010485,13:97266674
rs6924808-<b>?</b>,"7 x 10-16",,'-,'-,'-,'-,'-,"Response to inhaled glucocorticoid treatment in asthma (change in FEV1)","FEV change measurement, response to glucocorticoid, asthma",GCST002754,6:97910699
rs1353649-<b>?</b>,"6 x 10-11",,'-,'-,'-,'-,"RAB38, DBX1","Response to inhaled glucocorticoid treatment in asthma (change in FEV1)","FEV change measurement, response to glucocorticoid, asthma",GCST002754,11:20232053
rs10989692-<b>A</b>,"4 x 10-7",,0.1,2.03,'-,[1.55-2.66],'-,"Glucocorticoid-induced osteonecrosis (time dependent analysis)","response to glucocorticoid, osteonecrosis",GCST003083,9:101912273
rs7925908-<b>C</b>,"1 x 10-6",,0.341,'-,'-,'-,NTM,"Glucocorticoid-induced osteonecrosis (time dependent analysis)","response to glucocorticoid, osteonecrosis",GCST003083,11:131276855
rs10989692-<b>A</b>,"2 x 10-6",(European),0.089,2.22,'-,[1.64-2.99],'-,"Glucocorticoid-induced osteonecrosis (time dependent analysis)","response to glucocorticoid, osteonecrosis",GCST003083,9:101912273
rs10989692-<b>A</b>,"3 x 10-8",,0.106,'-,'-,'-,'-,"Glucocorticoid-induced osteonecrosis","response to glucocorticoid, osteonecrosis",GCST003084,9:101912273
rs2154490-<b>A</b>,"1 x 10-6",,0.222,'-,'-,'-,"BACH1, GRIK1","Glucocorticoid-induced osteonecrosis","response to glucocorticoid, osteonecrosis",GCST003084,21:29543641
rs72733993-<b>A</b>,"3 x 10-6",,0.156,'-,'-,'-,'-,"Glucocorticoid-induced osteonecrosis","response to glucocorticoid, osteonecrosis",GCST003084,5:18408799
rs11144550-<b>A</b>,"3 x 10-6",,0.137,'-,'-,'-,OTX2P1,"Glucocorticoid-induced osteonecrosis","response to glucocorticoid, osteonecrosis",GCST003084,9:75646632
rs1536407-<b>A</b>,"4 x 10-6",,0.646,'-,'-,'-,"LINC00347, LINC00381","Glucocorticoid-induced osteonecrosis","response to glucocorticoid, osteonecrosis",GCST003084,13:74521430
rs4789693-<b>C</b>,"6 x 10-6",,0.274,'-,'-,'-,NARF,"Glucocorticoid-induced osteonecrosis","response to glucocorticoid, osteonecrosis",GCST003084,17:82463994
rs6797178-<b>A</b>,"6 x 10-6",,0.39,'-,'-,'-,RNA5SP142,"Glucocorticoid-induced osteonecrosis","response to glucocorticoid, osteonecrosis",GCST003084,3:137534871
rs10849004-<b>C</b>,"6 x 10-6",,0.819,'-,'-,'-,"HSPA8P5, CCND2-AS1","Glucocorticoid-induced osteonecrosis","response to glucocorticoid, osteonecrosis",GCST003084,12:4183696
rs11594258-<b>A</b>,"9 x 10-6",,0.822,'-,'-,'-,KCNMA1,"Glucocorticoid-induced osteonecrosis","response to glucocorticoid, osteonecrosis",GCST003084,10:77458272
rs2229288-<b>C</b>,"1 x 10-6",,0.0022,'-,'-,'-,ZFHX3,"Glucocorticoid-induced osteonecrosis","response to glucocorticoid, osteonecrosis",GCST003084,16:72794405
rs4401379-<b>T</b>,"4 x 10-6",,0.128,'-,'-,'-,SATB1-AS1,"glucocorticoid receptor gene expression in B-cell precursor acute lymphoblastic leukaemia","B-cell acute lymphoblastic leukemia, response to glucocorticoid",GCST011998,3:18888633
rs7675928-<b>T</b>,"7 x 10-6",,0.064,'-,'-,'-,"TBC1D14, KIAA0232","glucocorticoid receptor gene expression in B-cell precursor acute lymphoblastic leukaemia","B-cell acute lymphoblastic leukemia, response to glucocorticoid",GCST011998,4:6889210
rs4565182-<b>?</b>,"4 x 10-6",,NR,'-,'-,'-,'-,"glucocorticoid receptor gene expression in B-cell precursor acute lymphoblastic leukaemia","B-cell acute lymphoblastic leukemia, response to glucocorticoid",GCST011998,5:26372454
rs11975522-<b>A</b>,"6 x 10-8",,0.064,'-,'-,'-,PLEKHA8,"glucocorticoid receptor gene expression in B-cell precursor acute lymphoblastic leukaemia","B-cell acute lymphoblastic leukemia, response to glucocorticoid",GCST011998,7:30089509
rs3824145-<b>?</b>,"3 x 10-6",,NR,'-,'-,'-,POP1,"glucocorticoid receptor gene expression in B-cell precursor acute lymphoblastic leukaemia","B-cell acute lymphoblastic leukemia, response to glucocorticoid",GCST011998,8:98128434
rs10982218-<b>?</b>,"6 x 10-6",,NR,'-,'-,'-,WHRN,"glucocorticoid receptor gene expression in B-cell precursor acute lymphoblastic leukaemia","B-cell acute lymphoblastic leukemia, response to glucocorticoid",GCST011998,9:114437860
rs9332146-<b>A</b>,"3 x 10-6",,0.012,'-,'-,'-,CYP2C9,"glucocorticoid receptor gene expression in B-cell precursor acute lymphoblastic leukaemia","B-cell acute lymphoblastic leukemia, response to glucocorticoid",GCST011998,10:94962487
rs12421832-<b>G</b>,"9 x 10-6",,0.01,'-,'-,'-,GUCY1A2,"glucocorticoid receptor gene expression in B-cell precursor acute lymphoblastic leukaemia","B-cell acute lymphoblastic leukemia, response to glucocorticoid",GCST011998,11:106594812
rs2852835-<b>C</b>,"6 x 10-6",,0.267,'-,'-,'-,"RNU6-256P, MIR100HG","glucocorticoid receptor gene expression in B-cell precursor acute lymphoblastic leukaemia","B-cell acute lymphoblastic leukemia, response to glucocorticoid",GCST011998,11:122009230
rs7975754-<b>C</b>,"9 x 10-6",,0.25,'-,'-,'-,SLC41A2,"glucocorticoid receptor gene expression in B-cell precursor acute lymphoblastic leukaemia","B-cell acute lymphoblastic leukemia, response to glucocorticoid",GCST011998,12:104934421
rs7136734-<b>?</b>,"3 x 10-6",,NR,'-,'-,'-,"TMEM132C, SLC15A4","glucocorticoid receptor gene expression in B-cell precursor acute lymphoblastic leukaemia","B-cell acute lymphoblastic leukemia, response to glucocorticoid",GCST011998,12:128738576
rs11842690-<b>G</b>,"1 x 10-6",,0.207,'-,'-,'-,RIOK3P1,"glucocorticoid receptor gene expression in B-cell precursor acute lymphoblastic leukaemia","B-cell acute lymphoblastic leukemia, response to glucocorticoid",GCST011998,13:74741736
rs7187736-<b>G</b>,"8 x 10-6",,0.087,'-,'-,'-,HNRNPA1P48,"glucocorticoid receptor gene expression in B-cell precursor acute lymphoblastic leukaemia","B-cell acute lymphoblastic leukemia, response to glucocorticoid",GCST011998,16:51454295
rs10485674-<b>G</b>,"8 x 10-6",,0.017,'-,'-,'-,MAFB,"glucocorticoid receptor gene expression in B-cell precursor acute lymphoblastic leukaemia","B-cell acute lymphoblastic leukemia, response to glucocorticoid",GCST011998,20:40665192
rs219649-<b>A</b>,"2 x 10-6",,0.3,'-,'-,'-,CYYR1-AS1,"glucocorticoid receptor gene expression in B-cell precursor acute lymphoblastic leukaemia","B-cell acute lymphoblastic leukemia, response to glucocorticoid",GCST011998,21:26451966
rs3763969-<b>?</b>,"1 x 10-5",,NR,'-,'-,'-,'-,"glucocorticoid receptor gene expression in B-cell precursor acute lymphoblastic leukaemia","B-cell acute lymphoblastic leukemia, response to glucocorticoid",GCST011998,"Mapping not available"
rs7601541-<b>?</b>,"2 x 10-8",,NR,6.78,'-,[3.49-13.15],"STEAP3, RN7SL468P","Severe skin toxicity response to cetuximab in stage 3 colon cancer","skin disease, colon carcinoma, response to cetuximab",GCST011795,2:119184520
rs78201730-<b>?</b>,"6 x 10-9",,NR,3.98,'-,[2.50-6.33],WIPF2,"Severe skin toxicity response to cetuximab in stage 3 colon cancer","skin disease, colon carcinoma, response to cetuximab",GCST011795,17:40276973
rs13014982-<b>?</b>,"7 x 10-6","(variant homozygote model)",'-,'-,'-,'-,'-,"Platinum-induced myelosuppression in non-small cell lung cancer","myelosuppression, response to platinum based chemotherapy, non-small cell lung carcinoma",GCST002833,2:163470244
rs1878022-<b>?</b>,"5 x 10-7",,NR,1.33,'-,[1.19-1.48],CMKLR1,"Response to platinum-based chemotherapy in non-small-cell lung cancer","response to platinum based chemotherapy, non-small cell lung carcinoma",GCST001035,12:108305255
chr19:40405886-<b>?</b>,"4 x 10-6",(European),NR,'-,"0.09072 unit decrease",[0.027-0.154],'-,"Response to fenofibrate (triglyceride levels)","triglyceride change measurement, response to fenofibrate",GCST003488,"Mapping not available"
chr16:52684158-<b>?</b>,"4 x 10-6",(European),NR,'-,"0.06533 unit decrease",[0.029-0.102],'-,"Response to fenofibrate (triglyceride levels)","triglyceride change measurement, response to fenofibrate",GCST003488,"Mapping not available"
chr3:169196390-<b>?</b>,"5 x 10-6",(European),NR,'-,"0.1086 unit decrease",[0.052-0.166],'-,"Response to fenofibrate (triglyceride levels)","triglyceride change measurement, response to fenofibrate",GCST003488,"Mapping not available"
chr20:16968502-<b>?</b>,"4 x 10-6",(European),NR,'-,"0.1242 unit increase",[0.031-0.217],'-,"Response to fenofibrate (triglyceride levels)","triglyceride change measurement, response to fenofibrate",GCST003488,"Mapping not available"
chr6:51672610-<b>?</b>,"7 x 10-6",(European),NR,'-,"0.08754 unit increase",[0.039-0.136],'-,"Response to fenofibrate (triglyceride levels)","triglyceride change measurement, response to fenofibrate",GCST003488,"Mapping not available"
chr6:7500085-<b>?</b>,"3 x 10-6",(European),NR,'-,"0.08284 unit increase",[0.044-0.122],'-,"Response to fenofibrate (triglyceride levels)","triglyceride change measurement, response to fenofibrate",GCST003488,"Mapping not available"
chr6:134385092-<b>?</b>,"5 x 10-6",(European),NR,'-,"0.0595 unit decrease",[0.0075-0.1115],'-,"Response to fenofibrate (triglyceride levels)","triglyceride change measurement, response to fenofibrate",GCST003488,"Mapping not available"
chr3:4427796-<b>?</b>,"9 x 10-6",(European),NR,'-,"0.06138 unit decrease",[0.027-0.096],'-,"Response to fenofibrate (triglyceride levels)","triglyceride change measurement, response to fenofibrate",GCST003488,"Mapping not available"
chr6:144671771-<b>?</b>,"8 x 10-6",(European),NR,'-,"0.04137 unit increase",[0.011-0.072],'-,"Response to fenofibrate (triglyceride levels)","triglyceride change measurement, response to fenofibrate",GCST003488,"Mapping not available"
chr10:31371073-<b>?</b>,"2 x 10-6",(European),NR,'-,"0.041 unit decrease",[0.01-0.072],'-,"Response to fenofibrate (triglyceride levels)","triglyceride change measurement, response to fenofibrate",GCST003488,"Mapping not available"
chr15:63598430-<b>?</b>,"8 x 10-6",(European),NR,'-,"0.06271 unit decrease",[0.034-0.091],'-,"Response to fenofibrate (triglyceride levels)","triglyceride change measurement, response to fenofibrate",GCST003488,"Mapping not available"
chr1:162879470-<b>?</b>,"2 x 10-6",(European),NR,'-,"0.05183 unit decrease",[0.022-0.081],'-,"Response to fenofibrate (triglyceride levels)","triglyceride change measurement, response to fenofibrate",GCST003488,"Mapping not available"
chr15:100786202-<b>?</b>,"6 x 10-6",(European),NR,'-,"0.05739 unit increase",[0.027-0.088],'-,"Response to fenofibrate (triglyceride levels)","triglyceride change measurement, response to fenofibrate",GCST003488,"Mapping not available"
chr13:77383216-<b>?</b>,"9 x 10-6",(European),NR,'-,"0.0919 unit decrease",[0.032-0.152],'-,"Response to fenofibrate (triglyceride levels)","triglyceride change measurement, response to fenofibrate",GCST003488,"Mapping not available"
chr11:84250557-<b>?</b>,"9 x 10-6",(European),NR,'-,"0.1089 unit increase",[0.044-0.174],'-,"Response to fenofibrate (triglyceride levels)","triglyceride change measurement, response to fenofibrate",GCST003488,"Mapping not available"
rs7911500-<b>?</b>,"5 x 10-9","(hsCRP-IL6 pattern prefenofibrate)",NR,'-,'-,'-,"IL15RA, IL2RA","Inflammatory biomarkers","response to fenofibrate",GCST001371,10:5995763
rs12532960-<b>?</b>,"3 x 10-7","(hsCRP-IL6 pattern prefenofibrate)",NR,'-,'-,'-,GLI3,"Inflammatory biomarkers","response to fenofibrate",GCST001371,7:42286026
rs6728440-<b>?</b>,"2 x 10-7","(hsCRP-IL6 pattern postfenofibrate)",NR,'-,'-,'-,CISD1P1,"Inflammatory biomarkers","response to fenofibrate",GCST001371,2:19799585
rs13122273-<b>?</b>,"9 x 10-7","(C-reactive protein)",NR,'-,'-,'-,U6,"Inflammatory biomarkers","response to fenofibrate",GCST001371,4:13100727
rs17460823-<b>?</b>,"2 x 10-6","(C-reactive protein)",NR,'-,'-,'-,NPAS3,"Inflammatory biomarkers","response to fenofibrate",GCST001371,14:33117357
rs10888935-<b>?</b>,"7 x 10-7",(Interleukin-6),NR,'-,'-,'-,'-,"Inflammatory biomarkers","response to fenofibrate",GCST001371,1:55595278
rs4513299-<b>?</b>,"4 x 10-6",(Interleukin-6),NR,'-,'-,'-,SEPHS1P7,"Inflammatory biomarkers","response to fenofibrate",GCST001371,2:114292241
rs6517147-<b>?</b>,"7 x 10-7","(Interleukin-2 soluble receptor-a)",NR,'-,'-,'-,LINC01548,"Inflammatory biomarkers","response to fenofibrate",GCST001371,21:33170482
rs11661856-<b>?</b>,"1 x 10-6","(Interleukin-2 soluble receptor-a)",NR,'-,'-,'-,"RNA5SP461, LINC01029","Inflammatory biomarkers","response to fenofibrate",GCST001371,18:77941567
rs17556665-<b>?</b>,"1 x 10-6","(Tumor necrosis factor-a)",NR,'-,'-,'-,SPON1,"Inflammatory biomarkers","response to fenofibrate",GCST001371,11:14076935
rs11979476-<b>?</b>,"2 x 10-6","(Tumor necrosis factor-a)",NR,'-,'-,'-,AHCYL2,"Inflammatory biomarkers","response to fenofibrate",GCST001371,7:129353915
rs12220898-<b>?</b>,"1 x 10-6","(Monocyte chemoattractant protein-1)",NR,'-,'-,'-,DRGX,"Inflammatory biomarkers","response to fenofibrate",GCST001371,10:49368588
rs4909764-<b>?</b>,"2 x 10-6","(Monocyte chemoattractant protein-1)",NR,'-,'-,'-,FAM135B,"Inflammatory biomarkers","response to fenofibrate",GCST001371,8:138243675
rs3764563-<b>?</b>,"3 x 10-7","(MCP1-TNF-a pattern prefenofibrate)",NR,'-,'-,'-,"RPL23AP2, CYP4F8","Inflammatory biomarkers","response to fenofibrate",GCST001371,19:15613392
rs786870-<b>?</b>,"5 x 10-7","(MCP1-TNF-a pattern prefenofibrate)",NR,'-,'-,'-,APBB1IP,"Inflammatory biomarkers","response to fenofibrate",GCST001371,10:26485765
rs17564315-<b>?</b>,"7 x 10-7","(MCP1-TNF-a pattern prefenofibrate)",NR,'-,'-,'-,CISD1P1,"Inflammatory biomarkers","response to fenofibrate",GCST001371,2:19758735
rs1396485-<b>?</b>,"7 x 10-7","(MCP1-TNF-a pattern prefenofibrate)",NR,'-,'-,'-,COMMD10,"Inflammatory biomarkers","response to fenofibrate",GCST001371,5:116176655
rs12722605-<b>?</b>,"3 x 10-7","(MCP1-TNF-a pattern postfenofibrate)",NR,'-,'-,'-,IL2RA,"Inflammatory biomarkers","response to fenofibrate",GCST001371,10:6011200
rs391317-<b>?</b>,"5 x 10-7","(MCP1-TNF-a pattern postfenofibrate)",NR,'-,'-,'-,'-,"Inflammatory biomarkers","response to fenofibrate",GCST001371,11:36990987
rs12481680-<b>?</b>,"2 x 10-7",(Baseline),NR,'-,"0.22 ng/dL increase",[0.14-0.30],'-,"Response to fenofibrate (adiponectin levels)","response to fenofibrate",GCST001738,20:57853649
rs525304-<b>?</b>,"3 x 10-6",(Response),NR,'-,"0.04 ng/dL increase",[0.024-0.056],SHANK2,"Response to fenofibrate (adiponectin levels)","response to fenofibrate",GCST001738,11:70660101
rs950027-<b>?</b>,"5 x 10-6",(Response),NR,'-,"0.04 ng/dL decrease",[0.024-0.056],SLC30A4,"Response to fenofibrate (adiponectin levels)","response to fenofibrate",GCST001738,15:45508837
rs5751452-<b>?</b>,"2 x 10-6",(Baseline),NR,'-,"0.31 ng/dL decrease",[0.19-0.43],SCUBE1,"Response to fenofibrate (adiponectin levels)","response to fenofibrate",GCST001738,22:43239567
rs1716403-<b>?</b>,"2 x 10-6",(Baseline),NR,'-,"0.14 ng/dL decrease",[0.081-0.199],RFLNA,"Response to fenofibrate (adiponectin levels)","response to fenofibrate",GCST001738,12:124035299
rs2384207-<b>?</b>,"5 x 10-8",(Response),NR,'-,"0.06 ng/dL increase",[0.040-0.080],DDX54,"Response to fenofibrate (adiponectin levels)","response to fenofibrate",GCST001738,12:113169697
rs12199015-<b>?</b>,"5 x 10-6",(Response),NR,'-,"0.09 ng/dL increase",[0.051-0.129],ENPP3,"Response to fenofibrate (adiponectin levels)","response to fenofibrate",GCST001738,6:131737807
rs10746997-<b>?</b>,"1 x 10-6",(Baseline),NR,'-,"0.14 ng/dL decrease",[0.081-0.199],PCSK5,"Response to fenofibrate (adiponectin levels)","response to fenofibrate",GCST001738,9:76226485
rs12999373-<b>?</b>,"3 x 10-6",(Baseline),NR,'-,"0.14 ng/dL decrease",[0.081-0.199],TMEM18,"Response to fenofibrate (adiponectin levels)","response to fenofibrate",GCST001738,2:663483
rs8053728-<b>?</b>,"6 x 10-6",(Baseline),NR,'-,"0.18 ng/dL decrease",[0.10-0.26],'-,"Response to fenofibrate (adiponectin levels)","response to fenofibrate",GCST001738,16:82451646
rs7443270-<b>?</b>,"5 x 10-6",(Response),NR,'-,"0.04 ng/dL increase",[0.022-0.058],C6,"Response to fenofibrate (adiponectin levels)","response to fenofibrate",GCST001738,5:41233944
rs16925187-<b>?</b>,"5 x 10-6",(Response),NR,'-,"0.1 ng/dL increase",[0.061-0.139],KDM4C,"Response to fenofibrate (adiponectin levels)","response to fenofibrate",GCST001738,9:7043455
rs10417097-<b>?</b>,"3 x 10-6","(paternal & maternal alleles modelled separately)",'-,'-,'-,'-,PBX4,"Triglyceride levels in response to fenofibrate treatment (parental genotype effect)","triglyceride measurement, response to fenofibrate, parental genotype effect measurement",GCST007660,19:19609015
rs10417097-<b>?</b>,"7 x 10-6","(difference between paternal and maternal transmissions)",'-,'-,'-,'-,PBX4,"Triglyceride levels in response to fenofibrate treatment (parental genotype effect)","triglyceride measurement, response to fenofibrate, parental genotype effect measurement",GCST007660,19:19609015
rs10417097-<b>?</b>,"9 x 10-7","(paternal effect)",'-,'-,'-,'-,PBX4,"Triglyceride levels in response to fenofibrate treatment (parental genotype effect)","triglyceride measurement, response to fenofibrate, parental genotype effect measurement",GCST007660,19:19609015
rs117829974-<b>?</b>,"2 x 10-7",,NR,2.1,'-,[1.6-2.7],"CADPS, LINC00698","Thiopurine-induced leukopenia in inflammatory bowel disease","leukopenia, response to thiopurine, inflammatory bowel disease",GCST006201,3:62886233
rs116855232-<b>?</b>,"1 x 10-33",,NR,5.8,'-,[4.4-7.7],NUDT15,"Thiopurine-induced leukopenia in inflammatory bowel disease","leukopenia, response to thiopurine, inflammatory bowel disease",GCST006201,13:48045719
rs2501846-<b>?</b>,"1 x 10-6",,NR,1.94,'-,[1.49-2.52],"BATF3, LINC02773","Thiopurine-induced leukopenia in inflammatory bowel disease (conditioned on rs116855232)","leukopenia, response to thiopurine, inflammatory bowel disease",GCST006202,1:212668592
rs116855232-<b>?</b>,"1 x 10-8",,NR,'-,'-,'-,NUDT15,"Thiopurine-induced severe leukopenia in inflammatory bowel disease","leukopenia, response to thiopurine, inflammatory bowel disease",GCST006204,13:48045719
rs116855232-<b>?</b>,"1 x 10-8",,NR,'-,'-,'-,NUDT15,"Thiopurine-induced acute severe leukopenia in inflammatory bowel disease","leukopenia, response to thiopurine, inflammatory bowel disease",GCST006205,13:48045719
rs75466870-<b>?</b>,"5 x 10-7",,NR,4.5,'-,[2.5-8.0],"GRAMD2B, SV2C","Thiopurine-induced alopecia in inflammatory bowel disease","Alopecia, response to thiopurine, inflammatory bowel disease",GCST006206,5:126346163
rs117927258-<b>?</b>,"2 x 10-7",,NR,6.5,'-,[3.2-13.2],ADGRF1,"Thiopurine-induced alopecia in inflammatory bowel disease","Alopecia, response to thiopurine, inflammatory bowel disease",GCST006206,6:47108781
rs145080284-<b>?</b>,"1 x 10-6",,NR,3.8,'-,[2.2-6.5],"CYP2C18, CTBP2P2","Thiopurine-induced alopecia in inflammatory bowel disease","Alopecia, response to thiopurine, inflammatory bowel disease",GCST006206,10:94662973
rs78844412-<b>?</b>,"6 x 10-7",,NR,6.9,'-,[3.2-14.8],LINC02745,"Thiopurine-induced alopecia in inflammatory bowel disease","Alopecia, response to thiopurine, inflammatory bowel disease",GCST006206,11:42131190
rs116855232-<b>?</b>,"4 x 10-29",,NR,10.4,'-,[6.9-15.6],NUDT15,"Thiopurine-induced alopecia in inflammatory bowel disease","Alopecia, response to thiopurine, inflammatory bowel disease",GCST006206,13:48045719
rs116855232-<b>?</b>,"1 x 10-8",,NR,'-,'-,'-,NUDT15,"Thiopurine-induced severe alopecia in inflammatory bowel disease","Alopecia, response to thiopurine, inflammatory bowel disease",GCST006207,13:48045719
rs4437130-<b>?</b>,"2 x 10-7",,NR,6.8,'-,[3.3-14.1],RN7SKP144,"Thiopurine-induced pancreatitis in inflammatory bowel disease","pancreatitis, response to thiopurine, inflammatory bowel disease",GCST006208,3:2035283
rs62561366-<b>?</b>,"5 x 10-7",,NR,7,'-,[3.3-14.8],PTCH1,"Thiopurine-induced pancreatitis in inflammatory bowel disease","pancreatitis, response to thiopurine, inflammatory bowel disease",GCST006208,9:95555669
rs117506642-<b>?</b>,"5 x 10-7",,NR,13.3,'-,[4.9-36.3],'-,"Thiopurine-induced acute severe leukopenia in inflammatory bowel disease (conditioned on rs116855232)","leukopenia, response to thiopurine, inflammatory bowel disease",GCST006215,2:195143585
rs11969064-<b>?</b>,"5 x 10-9",,NR,2.3,'-,[1.7-3.1],NHLRC1,"Thiopurine-induced myelosuppression in inflammatory bowel disease","myelosuppression, response to thiopurine, inflammatory bowel disease",GCST008801,6:18104864
rs2819742-<b>G</b>,"2 x 10-7",,0.62,2.08,'-,[1.59-2.78],RYR2,"Cerivastatin-induced rhabdomyolysis","response to statin, rhabdomyolysis",GCST001002,1:237826822
rs10455872-<b>A</b>,"1 x 10-9",,NR,'-,"0.28 mmol/L decrease",[0.20-0.36],LPA,"Response to statin therapy","response to statin",GCST001425,6:160589086
rs129963-<b>T</b>,"9 x 10-6",(Thiazides),0.42,'-,'-,'-,CREBBP,"QT interval (drug interaction)","response to thiazide, QT interval",GCST001890,16:3746146
rs10906189-<b>A</b>,"6 x 10-6",(Thiazides),0.58,'-,'-,'-,CAMK1D,"QT interval (drug interaction)","response to thiazide, QT interval",GCST001890,10:12633062
rs1978746-<b>A</b>,"8 x 10-6",(Thiazides),0.79,'-,'-,'-,ADAMTSL1,"QT interval (drug interaction)","response to thiazide, QT interval",GCST001890,9:18761101
rs192597095-<b>T</b>,"2 x 10-7","(Tetracyclines [J01AA])",0.005,8.5,'-,'-,GLS2,"Adverse response to drug","adverse effect, response to drug",GCST009028,12:56486375
rs34180124-<b>A</b>,"2 x 10-7","(Proton pump inhibitors [A02BC])",0.044,2.03,'-,'-,EHD4,"Adverse response to drug","adverse effect, response to drug",GCST009028,15:41908697
rs146425640-<b>C</b>,"3 x 10-7","(First-generation cephalosporins [J01DB])",0.017,5.34,'-,'-,NAV2,"Adverse response to drug","adverse effect, response to drug",GCST009028,11:19823052
rs1882642-<b>A</b>,"5 x 10-7","(Sulfonamides, plain [C03CA])",0.135,2.1,'-,'-,LRP1B,"Adverse response to drug","adverse effect, response to drug",GCST009028,2:141104341
rs72700531-<b>T</b>,"4 x 10-7","(Beta blocking agents, selective [C07AB])",0.056,2.05,'-,'-,NFIB,"Adverse response to drug","adverse effect, response to drug",GCST009028,9:14346344
rs7048567-<b>A</b>,"5 x 10-7","(Beta blocking agents, selective [C07AB])",0.336,1.54,'-,'-,ABCA2,"Adverse response to drug","adverse effect, response to drug",GCST009028,9:137009585
rs67134687-<b>G</b>,"7 x 10-7","(Dihydropyridine derivatives [C08CA])",0.052,2.45,'-,'-,MTAP,"Adverse response to drug","adverse effect, response to drug",GCST009028,9:21845309
rs12232685-<b>T</b>,"9 x 10-9","(Macrolides [J01FA])",0.008,3.82,'-,'-,LDLRAD4,"Adverse response to drug","adverse effect, response to drug",GCST009028,18:13437028
rs72656469-<b>T</b>,"3 x 10-7","(Fluoroquinolones [J01MA])",0.019,3.38,'-,'-,CYP7B1,"Adverse response to drug","adverse effect, response to drug",GCST009028,8:64701356
rs2267078-<b>A</b>,"7 x 10-8","(Fluoroquinolones [J01MA])",0.045,2.66,'-,'-,CRYBB2,"Adverse response to drug","adverse effect, response to drug",GCST009028,22:25220484
rs78512431-<b>C</b>,"2 x 10-7","(Imidazole derivatives [J01XD])",0.073,2.93,'-,'-,AGPAT3,"Adverse response to drug","adverse effect, response to drug",GCST009028,21:43970856
rs76456255-<b>A</b>,"2 x 10-7","(Acetic acid derivatives and related substances [M01AB])",0.098,1.75,'-,'-,HMGA2,"Adverse response to drug","adverse effect, response to drug",GCST009028,12:65950114
rs4767831-<b>G</b>,"8 x 10-9","(Acetic acid derivatives and related substances [M01AB])",0.393,1.56,'-,'-,TMEM233,"Adverse response to drug","adverse effect, response to drug",GCST009028,12:119601623
rs114830967-<b>T</b>,"4 x 10-7","(Oxicams [M01AC])",0.06,2.07,'-,'-,DPP10,"Adverse response to drug","adverse effect, response to drug",GCST009028,2:115820465
rs75495219-<b>G</b>,"8 x 10-7","(Oxicams [M01AC])",0.09,1.84,'-,'-,CTNNA3,"Adverse response to drug","adverse effect, response to drug",GCST009028,10:67151138
chr2:88905846-<b>A</b>,"1 x 10-9","(Propionic acid derivatives [M01AE])",0.202,1.89,'-,'-,'-,"Adverse response to drug","adverse effect, response to drug",GCST009028,"Mapping not available"
rs139840509-<b>A</b>,"8 x 10-7","(Propionic acid derivatives [M01AE])",0.025,2.72,'-,'-,LAMA1,"Adverse response to drug","adverse effect, response to drug",GCST009028,18:6953581
rs3775578-<b>C</b>,"2 x 10-7","(Coxibs [M01AH])",0.11,1.93,'-,'-,IRF2,"Adverse response to drug","adverse effect, response to drug",GCST009028,4:184451980
chr14:69045021-<b>A</b>,"3 x 10-7","(Imidazole derivatives [G01AF])",0.011,5.19,'-,'-,'-,"Adverse response to drug","adverse effect, response to drug",GCST009028,"Mapping not available"
rs12118495-<b>T</b>,"4 x 10-7","(Other antiinflammatory and antirheumatic agents, non-steroids [M01AX])",0.071,2.24,'-,'-,SOX13,"Adverse response to drug","adverse effect, response to drug",GCST009028,1:204077651
rs1790634-<b>A</b>,"3 x 10-7","(Glucocorticoids [H02AB])",0.448,1.74,'-,'-,FHOD3,"Adverse response to drug","adverse effect, response to drug",GCST009028,18:36419450
rs190508378-<b>C</b>,"4 x 10-7","(Other antiinflammatory and antirheumatic agents, non-steroids [M01AX])",0.011,4.85,'-,'-,SCAF4,"Adverse response to drug","adverse effect, response to drug",GCST009028,21:31697608
rs186555016-<b>C</b>,"5 x 10-7","(Antiinflammatory preparations, non-steroids for topical use [M02AA])",0.025,2.86,'-,'-,"TLCD4, TLCD4-RWDD3","Adverse response to drug","adverse effect, response to drug",GCST009028,1:95161598
rs61806081-<b>A</b>,"8 x 10-7","(Antiinflammatory preparations, non-steroids for topical use [M02AA])",0.039,2.46,'-,'-,KIFAP3,"Adverse response to drug","adverse effect, response to drug",GCST009028,1:169931786
rs138288216-<b>T</b>,"3 x 10-7","(Antiinflammatory preparations, non-steroids for topical use [M02AA])",0.009,4.26,'-,'-,NLGN1,"Adverse response to drug","adverse effect, response to drug",GCST009028,3:174250679
rs73184656-<b>C</b>,"7 x 10-7","(Other centrally acting agents [M03BX])",0.2,2.06,'-,'-,BCL6,"Adverse response to drug","adverse effect, response to drug",GCST009028,3:187724028
rs56837599-<b>A</b>,"1 x 10-7","(Proton pump inhibitors [A02BC])",0.053,1.95,'-,'-,"STON1-GTF2A1L, STON1","Adverse response to drug","adverse effect, response to drug",GCST009028,2:48571883
rs142897541-<b>T</b>,"5 x 10-8","(First-generation cephalosporins [J01DB])",0.034,3.65,'-,'-,TMEFF2,"Adverse response to drug","adverse effect, response to drug",GCST009028,2:192095144
rs77063336-<b>T</b>,"8 x 10-7","(Other cardiac preparations [C01EB])",0.047,3.07,'-,'-,ASTN2,"Adverse response to drug","adverse effect, response to drug",GCST009028,9:116932295
rs116264298-<b>C</b>,"5 x 10-7","(Macrolides [J01FA])",0.039,2.09,'-,'-,CENPC,"Adverse response to drug","adverse effect, response to drug",GCST009028,4:67496237
rs151068302-<b>T</b>,"1 x 10-6","(Macrolides [J01FA])",0.08,1.73,'-,'-,CAAP1,"Adverse response to drug","adverse effect, response to drug",GCST009028,9:26883048
rs73391993-<b>T</b>,"2 x 10-8","(Macrolides [J01FA])",0.008,3.99,'-,'-,STAB2,"Adverse response to drug","adverse effect, response to drug",GCST009028,12:103592748
rs7087342-<b>A</b>,"5 x 10-8","(Dihydropyridine derivatives [C08CA])",0.011,5.39,'-,'-,ADARB2,"Adverse response to drug","adverse effect, response to drug",GCST009028,10:1613599
rs1882642-<b>A</b>,"2 x 10-9","(ACE inhibitors, plain [C09AA])",0.146,2.1,'-,'-,LRP1B,"Adverse response to drug","adverse effect, response to drug",GCST009028,2:141104341
rs142630661-<b>G</b>,"8 x 10-7","(ACE inhibitors, plain [C09AA])",0.009,5.24,'-,'-,"FAM86C1P, ALG1L9P","Adverse response to drug","adverse effect, response to drug",GCST009028,11:71794579
rs117451620-<b>A</b>,"2 x 10-7","(ACE inhibitors and diuretics [C09BA])",0.011,7.4,'-,'-,LARGE1,"Adverse response to drug","adverse effect, response to drug",GCST009028,22:33873469
rs1394432-<b>C</b>,"1 x 10-7","(Angiotensin II antagonists, plain [C09CA])",0.323,2.19,'-,'-,VWA3B,"Adverse response to drug","adverse effect, response to drug",GCST009028,2:98279575
rs7721607-<b>A</b>,"3 x 10-7","(Angiotensin II antagonists, plain [C09CA])",0.165,2.21,'-,'-,FBXL7,"Adverse response to drug","adverse effect, response to drug",GCST009028,5:15652449
chr5:39159863-<b>T</b>,"6 x 10-7","(HMG CoA reductase inhibitors [C10AA])",0.016,4.11,'-,'-,'-,"Adverse response to drug","adverse effect, response to drug",GCST009028,"Mapping not available"
rs10505380-<b>G</b>,"9 x 10-7","(HMG CoA reductase inhibitors [C10AA])",0.195,1.87,'-,'-,COL14A1,"Adverse response to drug","adverse effect, response to drug",GCST009028,8:120314234
rs116502295-<b>C</b>,"9 x 10-7","(HMG CoA reductase inhibitors [C10AA])",0.006,6.52,'-,'-,ETS1,"Adverse response to drug","adverse effect, response to drug",GCST009028,11:128462620
rs180822335-<b>C</b>,"7 x 10-7","(Imidazole and triazole derivatives [D01AC])",0.027,3.8,'-,'-,COL13A1,"Adverse response to drug","adverse effect, response to drug",GCST009028,10:69950109
rs12539913-<b>A</b>,"8 x 10-8","(Imidazole derivatives [G01AF])",0.059,2.77,'-,'-,MAGI2,"Adverse response to drug","adverse effect, response to drug",GCST009028,7:79143230
rs192238733-<b>A</b>,"2 x 10-7","(Imidazole derivatives [G01AF])",0.005,8.02,'-,'-,CELF2,"Adverse response to drug","adverse effect, response to drug",GCST009028,10:11109944
rs184429573-<b>C</b>,"6 x 10-8","(Imidazole derivatives [G01AF])",0.009,6.18,'-,'-,CCDC91,"Adverse response to drug","adverse effect, response to drug",GCST009028,12:28504235
rs9962013-<b>T</b>,"5 x 10-7","(Coxibs [M01AH])",0.847,2.5,'-,'-,RIT2,"Adverse response to drug","adverse effect, response to drug",GCST009028,18:42914972
rs12232685-<b>T</b>,"2 x 10-8","(Glucocorticoids [H02AB])",0.007,6.99,'-,'-,LDLRAD4,"Adverse response to drug","adverse effect, response to drug",GCST009028,18:13437028
chr7:140125839-<b>A</b>,"3 x 10-7","(Other antiinflammatory and antirheumatic agents, non-steroids [M01AX])",0.044,3.14,'-,'-,'-,"Adverse response to drug","adverse effect, response to drug",GCST009028,"Mapping not available"
rs189131320-<b>G</b>,"8 x 10-7","(Tetracyclines [J01AA])",0.011,4.72,'-,'-,RUNX3,"Adverse response to drug","adverse effect, response to drug",GCST009028,1:24951485
rs78147979-<b>A</b>,"3 x 10-7","(Tetracyclines [J01AA])",0.013,5.01,'-,'-,ST14,"Adverse response to drug","adverse effect, response to drug",GCST009028,11:130175205
chr17:79041626-<b>T</b>,"4 x 10-8","(Other centrally acting agents [M03BX])",0.011,6.97,'-,'-,'-,"Adverse response to drug","adverse effect, response to drug",GCST009028,"Mapping not available"
rs2284147-<b>A</b>,"2 x 10-7","(Other centrally acting agents [M03BX])",0.485,2.01,'-,'-,USF2,"Adverse response to drug","adverse effect, response to drug",GCST009028,19:35274138
rs57997684-<b>C</b>,"5 x 10-7","(Benzodiazepine related drugs [N05CF])",0.019,3.12,'-,'-,ELOVL2,"Adverse response to drug","adverse effect, response to drug",GCST009028,6:11014323
rs211437-<b>C</b>,"8 x 10-7","(Selective serotonin reuptake inhibitors [N06AB])",0.017,3.79,'-,'-,EYA4,"Adverse response to drug","adverse effect, response to drug",GCST009028,6:133292270
rs139465532-<b>G</b>,"4 x 10-7","(Other antidepressants [N06AX])",0.009,5.67,'-,'-,PLCB1,"Adverse response to drug","adverse effect, response to drug",GCST009028,20:8348184
rs140255439-<b>T</b>,"7 x 10-7","(Other antidepressants [N07CA])",0.007,9.16,'-,'-,PAFAH1B1,"Adverse response to drug","adverse effect, response to drug",GCST009028,17:2638960
chr1:97819216-<b>T</b>,"7 x 10-7","(Corticosteroids (nasal) [R01AD])",0.012,4.19,'-,'-,'-,"Adverse response to drug","adverse effect, response to drug",GCST009028,"Mapping not available"
rs150859230-<b>T</b>,"5 x 10-7","(Corticosteroids (nasal) [R01AD])",0.013,4.63,'-,'-,ESRRG,"Adverse response to drug","adverse effect, response to drug",GCST009028,1:216675108
rs149325996-<b>A</b>,"4 x 10-7","(Corticosteroids (nasal) [R01AD])",0.013,4.55,'-,'-,CTDP1,"Adverse response to drug","adverse effect, response to drug",GCST009028,18:79735872
rs3800917-<b>A</b>,"4 x 10-7","(Other antihistamines for systemic use [R06AX])",0.35,2.1,'-,'-,MAD1L1,"Adverse response to drug","adverse effect, response to drug",GCST009028,7:2128304
rs55797039-<b>A</b>,"6 x 10-7","(Other antihistamines for systemic use [R06AX])",0.016,5.32,'-,'-,SCNN1A,"Adverse response to drug","adverse effect, response to drug",GCST009028,12:6363586
HLA-B*27:05-<b>?</b>,"1 x 10-11",,NR,3.24,'-,[2·31-4·55],'-,"Non-chemotherapy drug induced agranulocytosis","response to drug, Drug-induced agranulocytosis",GCST003526,"Mapping not available"
HLA-B*08:01-<b>?</b>,"1 x 10-7","(adjusted for HLA-B*27:05)",NR,2.14,'-,[1·61-2·84],'-,"Non-chemotherapy drug induced agranulocytosis","response to drug, Drug-induced agranulocytosis",GCST003526,"Mapping not available"
HLA-B*39:01-<b>?</b>,"7 x 10-6","(adjusted for HLA-B*27:05, HLA-B*08:01)",NR,'-,'-,'-,'-,"Non-chemotherapy drug induced agranulocytosis","response to drug, Drug-induced agranulocytosis",GCST003526,"Mapping not available"
rs114291795-<b>?</b>,"2 x 10-15",,NR,3.57,'-,[2·61-4·90],MICA,"Non-chemotherapy drug induced agranulocytosis","response to drug, Drug-induced agranulocytosis",GCST003526,6:31409863
rs1811197-<b>?</b>,"9 x 10-13","(adjusted for rs114291795)",NR,2.4,'-,[1.89-3.06],"HLA-B, DHFRP2","Non-chemotherapy drug induced agranulocytosis","response to drug, Drug-induced agranulocytosis",GCST003526,6:31359883
rs1915279-<b>?</b>,"2 x 10-6","(GG vs. not GG)",NR,'-,'-,'-,'-,"Treatment response for severe sepsis","response to drug",GCST001402,1:238912414
rs1829975-<b>?</b>,"6 x 10-6","(AG vs. not AG)",NR,'-,'-,'-,RN7SL423P,"Treatment response for severe sepsis","response to drug",GCST001402,2:160928658
rs4723738-<b>?</b>,"6 x 10-6","(AG vs. not AG)",NR,'-,'-,'-,STARD3NL,"Treatment response for severe sepsis","response to drug",GCST001402,7:38201307
rs13273073-<b>?</b>,"7 x 10-6","(GT vs. not GT)",NR,'-,'-,'-,NKX2-6,"Treatment response for severe sepsis","response to drug",GCST001402,8:23726713
rs12159200-<b>?</b>,"6 x 10-7","(AA vs. not AA)",NR,'-,'-,'-,"GAPDHP37, MRTFA","Treatment response for severe sepsis","response to drug",GCST001402,22:40646087
rs2716601-<b>?</b>,"1 x 10-6","(TT vs. not TT)",NR,'-,'-,'-,PSMD7-DT,"Treatment response for severe sepsis","response to drug",GCST001402,16:74042353
rs12652255-<b>?</b>,"8 x 10-6","(CC vs. not CC)",NR,'-,'-,'-,ARL2BPP6,"Treatment response for severe sepsis","response to drug",GCST001402,5:175334092
rs17513961-<b>?</b>,"1 x 10-7","(TT vs. not TT)",NR,'-,'-,'-,'-,"Treatment response for severe sepsis","response to drug",GCST001402,7:46352969
rs564148-<b>?</b>,"9 x 10-6",(SF10),NR,'-,'-,'-,CSMD2,"Response to amphetamines","response to drug",GCST001651,1:33708220
rs4476553-<b>?</b>,"3 x 10-6",(SF5),NR,'-,'-,'-,STX18-AS1,"Response to amphetamines","response to drug",GCST001651,4:4702287
rs9312648-<b>?</b>,"6 x 10-6",(SF6),NR,'-,'-,'-,LINC02283,"Response to amphetamines","response to drug",GCST001651,4:54375414
rs7676384-<b>?</b>,"8 x 10-6",(SF4),NR,'-,'-,'-,'-,"Response to amphetamines","response to drug",GCST001651,4:161252328
rs12646107-<b>?</b>,"4 x 10-6",(SF8),NR,'-,'-,'-,HAND2-AS1,"Response to amphetamines","response to drug",GCST001651,4:173594531
rs74347767-<b>?</b>,"7 x 10-7",(SF1),NR,'-,'-,'-,'-,"Response to amphetamines","response to drug",GCST001651,"Mapping not available"
rs111649495-<b>?</b>,"2 x 10-6",(SF4),NR,'-,'-,'-,"DMXL1, RNU6-373P","Response to amphetamines","response to drug",GCST001651,5:119020720
rs6894216-<b>?</b>,"4 x 10-6",(SF2),NR,'-,'-,'-,"RNU7-53P, ARL2BPP4","Response to amphetamines","response to drug",GCST001651,5:130456441
rs1438949-<b>?</b>,"6 x 10-6",(SF8),NR,'-,'-,'-,LINC01470,"Response to amphetamines","response to drug",GCST001651,5:153125369
rs4710654-<b>?</b>,"8 x 10-7",(SF2),NR,'-,'-,'-,"RNU6-280P, RNA5SP208","Response to amphetamines","response to drug",GCST001651,6:67471804
rs2213553-<b>?</b>,"5 x 10-6",(SF9),NR,'-,'-,'-,'-,"Response to amphetamines","response to drug",GCST001651,6:98489270
rs875033-<b>?</b>,"8 x 10-6",(SF2),NR,'-,'-,'-,"RNU6-280P, Y_RNA","Response to amphetamines","response to drug",GCST001651,6:67617137
rs58810682-<b>?</b>,"8 x 10-6",(SF9),NR,'-,'-,'-,'-,"Response to amphetamines","response to drug",GCST001651,8:43840091
rs35820208-<b>?</b>,"3 x 10-6",(SF7),NR,'-,'-,'-,PDP1,"Response to amphetamines","response to drug",GCST001651,8:93903875
rs12554707-<b>?</b>,"2 x 10-6",(SF5),NR,'-,'-,'-,LINC01239,"Response to amphetamines","response to drug",GCST001651,9:22842203
rs79460104-<b>?</b>,"4 x 10-6",(SF10),NR,'-,'-,'-,"FOXB2, LYPLA2P3","Response to amphetamines","response to drug",GCST001651,9:76995712
rs10841397-<b>?</b>,"9 x 10-6",(SF6),NR,'-,'-,'-,TCP1P3,"Response to amphetamines","response to drug",GCST001651,12:19911034
rs55874825-<b>?</b>,"3 x 10-7",(SF5),NR,'-,'-,'-,"PSMB3P1, METTL7B","Response to amphetamines","response to drug",GCST001651,12:55676884
rs7304057-<b>?</b>,"4 x 10-6",(SF6),NR,'-,'-,'-,"STX2, RNU6-1077P","Response to amphetamines","response to drug",GCST001651,12:130868017
rs17641529-<b>?</b>,"9 x 10-6",(SF7),NR,'-,'-,'-,KCTD8,"Response to amphetamines","response to drug",GCST001651,4:44210148
rs2325244-<b>?</b>,"8 x 10-7",(SF3),NR,'-,'-,'-,KLHL1,"Response to amphetamines","response to drug",GCST001651,13:69855961
rs1870584-<b>?</b>,"5 x 10-6",(SF2),NR,'-,'-,'-,MAP2K4,"Response to amphetamines","response to drug",GCST001651,17:12144227
rs33993717-<b>?</b>,"5 x 10-6",(SF4),NR,'-,'-,'-,MFSD9,"Response to amphetamines","response to drug",GCST001651,2:102718982
rs549476-<b>?</b>,"3 x 10-6",(SF5),NR,'-,'-,'-,NEDD4L,"Response to amphetamines","response to drug",GCST001651,18:58143501
rs61883261-<b>?</b>,"9 x 10-6",(SF2),NR,'-,'-,'-,NELL1,"Response to amphetamines","response to drug",GCST001651,11:20962659
rs10017238-<b>?</b>,"7 x 10-6",(SF4),NR,'-,'-,'-,TENM3,"Response to amphetamines","response to drug",GCST001651,4:182766636
rs2236824-<b>?</b>,"2 x 10-6",(SF10),NR,'-,'-,'-,PAX7,"Response to amphetamines","response to drug",GCST001651,1:18705778
rs3827886-<b>?</b>,"7 x 10-6",(SF9),NR,'-,'-,'-,PLBD1,"Response to amphetamines","response to drug",GCST001651,12:14507250
rs12049671-<b>?</b>,"7 x 10-6",(SF10),NR,'-,'-,'-,PTPRE,"Response to amphetamines","response to drug",GCST001651,10:127939367
rs4909189-<b>?</b>,"3 x 10-6",(SF9),NR,'-,'-,'-,PTPRN2,"Response to amphetamines","response to drug",GCST001651,7:158344294
rs2574975-<b>?</b>,"5 x 10-6",(SF6),NR,'-,'-,'-,SGMS1,"Response to amphetamines","response to drug",GCST001651,10:50359537
rs472402-<b>?</b>,"3 x 10-7",(SF2),NR,'-,'-,'-,SRD5A1,"Response to amphetamines","response to drug",GCST001651,5:6635478
rs14978-<b>?</b>,"7 x 10-6",(SF3),NR,'-,'-,'-,TMEM106B,"Response to amphetamines","response to drug",GCST001651,7:12233526
rs17713676-<b>?</b>,"8 x 10-6",(SF3),NR,'-,'-,'-,WWOX,"Response to amphetamines","response to drug",GCST001651,16:79039524
rs12123383-<b>?</b>,"4 x 10-6",(SF1),NR,'-,'-,'-,UBR4,"Response to amphetamines","response to drug",GCST001651,1:19060091
rs214034-<b>?</b>,"7 x 10-6",(SF2),NR,'-,'-,'-,"SMC6, MSGN1","Response to amphetamines","response to drug",GCST001651,2:17807391
rs7600259-<b>?</b>,"1 x 10-6",(SF9),NR,'-,'-,'-,RN7SL602P,"Response to amphetamines","response to drug",GCST001651,2:34868226
rs12467847-<b>?</b>,"5 x 10-6",(SF4),NR,'-,'-,'-,"IL36G, CDK8P2","Response to amphetamines","response to drug",GCST001651,2:112933827
rs6754521-<b>?</b>,"5 x 10-6",(SF10),NR,'-,'-,'-,"FZD7, RNU6-440P","Response to amphetamines","response to drug",GCST001651,2:201994894
rs4382726-<b>?</b>,"4 x 10-6",(SF4),NR,'-,'-,'-,TFDP1P1,"Response to amphetamines","response to drug",GCST001651,1:209160872
rs583464-<b>?</b>,"3 x 10-6",(SF2),NR,'-,'-,'-,"ATP6V1G1P7, LINC01309","Response to amphetamines","response to drug",GCST001651,13:103439195
rs3884558-<b>?</b>,"5 x 10-6",(SF10),NR,'-,'-,'-,'-,"Response to amphetamines","response to drug",GCST001651,15:61410580
rs8073390-<b>?</b>,"7 x 10-6",(SF3),NR,'-,'-,'-,"RNF126P1, SCPEP1","Response to amphetamines","response to drug",GCST001651,17:57042633
16-78042454-<b>?</b>,"4 x 10-7",(SF1),NR,'-,'-,'-,'-,"Response to amphetamines","response to drug",GCST001651,"Mapping not available"
rs2458179-<b>?</b>,"7 x 10-6",(SF9),NR,'-,'-,'-,"ARL17B, MAPK8IP1P1","Response to amphetamines","response to drug",GCST001651,17:46257341
rs9650199-<b>?</b>,"6 x 10-6",(SF3),NR,'-,'-,'-,LINC01301,"Response to amphetamines","response to drug",GCST001651,8:60433638
rs10959672-<b>?</b>,"5 x 10-7",(SF1),NR,'-,'-,'-,PTPRD,"Response to amphetamines","response to drug",GCST001651,9:11257448
rs11243437-<b>?</b>,"7 x 10-6",(SF4),NR,'-,'-,'-,"RAPGEF1, PRRT1B","Response to amphetamines","response to drug",GCST001651,9:131574686
rs72820627-<b>?</b>,"7 x 10-6",(SF8),NR,'-,'-,'-,"CYP2C8, PAWRP1","Response to amphetamines","response to drug",GCST001651,10:95092933
rs11059374-<b>?</b>,"2 x 10-6",(SF5),NR,'-,'-,'-,LINC02393,"Response to amphetamines","response to drug",GCST001651,12:127819873
rs977102-<b>?</b>,"2 x 10-6",(SF7),NR,'-,'-,'-,"SUCLG2, MIR4272","Response to amphetamines","response to drug",GCST001651,3:67323553
rs6054906-<b>?</b>,"3 x 10-6",(SF4),NR,'-,'-,'-,"LINC01706, LINC01751","Response to amphetamines","response to drug",GCST001651,20:7314256
rs9813712-<b>?</b>,"2 x 10-6",(SF1),NR,'-,'-,'-,COL6A4P2,"Response to amphetamines","response to drug",GCST001651,3:130252258
rs932425-<b>?</b>,"5 x 10-6",(SF4),NR,'-,'-,'-,"LINC01734, ATG3P1","Response to amphetamines","response to drug",GCST001651,20:39244967
rs1490075-<b>?</b>,"2 x 10-6",(SF9),NR,'-,'-,'-,LINC01208,"Response to amphetamines","response to drug",GCST001651,3:176704864
rs6532271-<b>?</b>,"3 x 10-6",(SF7),NR,'-,'-,'-,CCSER1,"Response to amphetamines","response to drug",GCST001651,4:91082746
rs4732957-<b>?</b>,"7 x 10-6",(SF8),NR,'-,'-,'-,ADRA1A,"Response to amphetamines","response to drug",GCST001651,8:26861363
rs4704187-<b>?</b>,"6 x 10-6",(SF6),NR,'-,'-,'-,ANKRD31,"Response to amphetamines","response to drug",GCST001651,5:75184463
rs80171647-<b>?</b>,"2 x 10-6",(SF3),NR,'-,'-,'-,FHIT,"Response to amphetamines","response to drug",GCST001651,3:60522607
rs12540771-<b>?</b>,"5 x 10-6",(SF9),NR,'-,'-,'-,CCDC146,"Response to amphetamines","response to drug",GCST001651,7:77133634
rs13429458-<b>?</b>,"6 x 10-6",(SF4),NR,'-,'-,'-,THADA,"Response to amphetamines","response to drug",GCST001651,2:43411699
rs10810790-<b>?</b>,"6 x 10-6",(SF7),NR,'-,'-,'-,CNTLN,"Response to amphetamines","response to drug",GCST001651,9:17458874
rs9837561-<b>?</b>,"3 x 10-6",(SF9),NR,'-,'-,'-,SUMF1,"Response to amphetamines","response to drug",GCST001651,3:3608555
rs7193230-<b>?</b>,"5 x 10-6",(SF6),NR,'-,'-,'-,CNTNAP4,"Response to amphetamines","response to drug",GCST001651,16:76284645
rs17439560-<b>?</b>,"4 x 10-6",(SF10),NR,'-,'-,'-,"MEIS2, Metazoa_SRP","Response to amphetamines","response to drug",GCST001651,15:37157418
rs113154706-<b>?</b>,"7 x 10-6",(SF5),NR,'-,'-,'-,"PGAM1P12, RN7SKP254","Response to amphetamines","response to drug",GCST001651,15:96475503
rs73317122-<b>?</b>,"4 x 10-6",(SF8),NR,'-,'-,'-,PDLIM1P3,"Response to amphetamines","response to drug",GCST001651,17:26993863
rs13380637-<b>?</b>,"5 x 10-6",(SF4),NR,'-,'-,'-,"PABPC1P13, ABCD1P3","Response to amphetamines","response to drug",GCST001651,16:32469603
rs4800843-<b>?</b>,"3 x 10-6",(SF7),NR,'-,'-,'-,CDH2,"Response to amphetamines","response to drug",GCST001651,18:28193052
rs11767191-<b>?</b>,"1 x 10-6",(SF7),NR,'-,'-,'-,LINC02838,"Response to amphetamines","response to drug",GCST001651,7:48778369
rs73001827-<b>?</b>,"1 x 10-6",(SF7),NR,'-,'-,'-,RPL23AP39,"Response to amphetamines","response to drug",GCST001651,3:1700081
rs74529274-<b>?</b>,"9 x 10-6",(SF8),NR,'-,'-,'-,"RN7SKP164, RN7SKP203","Response to amphetamines","response to drug",GCST001651,2:76532449
rs11904006-<b>?</b>,"6 x 10-6",(SF1),NR,'-,'-,'-,"SCN1A, SCN1A-AS1","Response to amphetamines","response to drug",GCST001651,2:166085630
rs12618573-<b>?</b>,"8 x 10-6",(SF6),NR,'-,'-,'-,NDUFA10,"Response to amphetamines","response to drug",GCST001651,2:239904221
rs10502675-<b>?</b>,"3 x 10-6",(SF9),NR,'-,'-,'-,"CELF4, MIR4318","Response to amphetamines","response to drug",GCST001651,18:37618333
rs1017745-<b>?</b>,"6 x 10-6",(SF6),NR,'-,'-,'-,'-,"Response to amphetamines","response to drug",GCST001651,18:75815681
rs66591657-<b>?</b>,"4 x 10-6",(SF7),NR,'-,'-,'-,'-,"Response to amphetamines","response to drug",GCST001651,18:78655450
rs112553552-<b>?</b>,"3 x 10-6",(SF8),NR,'-,'-,'-,"PDCL3P4, RPL24","Response to amphetamines","response to drug",GCST001651,3:101693134
rs6103489-<b>?</b>,"4 x 10-6",(SF7),NR,'-,'-,'-,"RNU6-639P, LINC01728","Response to amphetamines","response to drug",GCST001651,20:43858564
rs9878522-<b>?</b>,"6 x 10-6",(SF3),NR,'-,'-,'-,LINC01322,"Response to amphetamines","response to drug",GCST001651,3:165407371
rs12480534-<b>?</b>,"9 x 10-6",(SF2),NR,'-,'-,'-,"CD40, CDH22","Response to amphetamines","response to drug",GCST001651,20:46132846
rs2070997-<b>?</b>,"8 x 10-6",(SF6),NR,'-,'-,'-,ABL1,"Response to amphetamines","response to drug",GCST001651,9:130872696
rs9556893-<b>?</b>,"6 x 10-6",(SF6),NR,'-,'-,'-,FARP1,"Response to amphetamines","response to drug",GCST001651,13:98179341
rs11242661-<b>?</b>,"1 x 10-6",(SF9),NR,'-,'-,'-,FBXL17,"Response to amphetamines","response to drug",GCST001651,5:108065750
rs10957125-<b>?</b>,"4 x 10-6",(SF7),NR,'-,'-,'-,"LINC01301, CA8","Response to amphetamines","response to drug",GCST001651,8:60281611
rs2160050-<b>?</b>,"9 x 10-6",(SF3),NR,'-,'-,'-,IGSF11,"Response to amphetamines","response to drug",GCST001651,3:119027089
rs3784943-<b>?</b>,"5 x 10-8",(SF1),NR,'-,'-,'-,CDH13,"Response to amphetamines","response to drug",GCST001651,16:83678830
rs6992848-<b>?</b>,"7 x 10-6",(SF10),NR,'-,'-,'-,TRAPPC9,"Response to amphetamines","response to drug",GCST001651,8:140140070
rs11582540-<b>?</b>,"3 x 10-6",(SF5),NR,'-,'-,'-,"RPL21P24, ATP6V0E1P4","Response to amphetamines","response to drug",GCST001651,1:47544325
rs7838490-<b>?</b>,"6 x 10-8",(BMI),NR,'-,'-,[NR],'-,"Body mass index and cholesterol (psychopharmacological treatment)","response to drug, body mass index",GCST001440,8:88572819
rs11615274-<b>?</b>,"9 x 10-8",(HDL-C),NR,'-,'-,[NR],LINC02444,"Body mass index and cholesterol (psychopharmacological treatment)","total cholesterol measurement, response to drug",GCST001440,12:73207352
rs12165173-<b>?</b>,"5 x 10-6","(adjusted for dose, GFR & AST)",NR,'-,"1.06 unit decrease",'-,'-,"Carboplatin disposition in epthelial ovarian cancer","Malignant epithelial tumor of ovary, response to carboplatin",GCST005351,2:217010416
rs12412836-<b>?</b>,"4 x 10-6","(adjusted for dose, GFR & AST)",NR,'-,"0.75 unit decrease",'-,COL13A1,"Carboplatin disposition in epthelial ovarian cancer","Malignant epithelial tumor of ovary, response to carboplatin",GCST005351,10:69910197
rs12571637-<b>?</b>,"7 x 10-6","(adjusted for dose, GFR & AST)",NR,'-,"1.59 unit decrease",'-,'-,"Carboplatin disposition in epthelial ovarian cancer","Malignant epithelial tumor of ovary, response to carboplatin",GCST005351,10:85041429
rs17280534-<b>?</b>,"6 x 10-6","(adjusted for dose, GFR & AST)",NR,'-,"1.49 unit decrease",'-,LINC02299,"Carboplatin disposition in epthelial ovarian cancer","Malignant epithelial tumor of ovary, response to carboplatin",GCST005351,14:96778118
rs17635967-<b>?</b>,"6 x 10-6","(adjusted for dose, GFR & AST)",NR,'-,"1.49 unit decrease",'-,RHEB,"Carboplatin disposition in epthelial ovarian cancer","Malignant epithelial tumor of ovary, response to carboplatin",GCST005351,7:151487834
rs2202766-<b>?</b>,"7 x 10-6","(adjusted for dose, GFR & AST)",NR,'-,"1.47 unit decrease",'-,'-,"Carboplatin disposition in epthelial ovarian cancer","Malignant epithelial tumor of ovary, response to carboplatin",GCST005351,6:105789630
rs4313770-<b>?</b>,"6 x 10-6","(adjusted for dose, GFR & AST)",NR,'-,"1.49 unit decrease",'-,RASGRP1,"Carboplatin disposition in epthelial ovarian cancer","Malignant epithelial tumor of ovary, response to carboplatin",GCST005351,15:38490292
rs4692174-<b>?</b>,"7 x 10-6","(adjusted for dose, GFR & AST)",NR,'-,"0.88 unit decrease",'-,LINC02261,"Carboplatin disposition in epthelial ovarian cancer","Malignant epithelial tumor of ovary, response to carboplatin",GCST005351,4:27184810
rs5741804-<b>?</b>,"9 x 10-6","(adjusted for dose, GFR & AST)",NR,'-,"1.49 unit decrease",'-,BPI,"Carboplatin disposition in epthelial ovarian cancer","Malignant epithelial tumor of ovary, response to carboplatin",GCST005351,20:38323940
rs7102974-<b>?</b>,"6 x 10-6","(adjusted for dose, GFR & AST)",NR,'-,"1.49 unit decrease",'-,TMEM258,"Carboplatin disposition in epthelial ovarian cancer","Malignant epithelial tumor of ovary, response to carboplatin",GCST005351,11:61792563
rs7230264-<b>?</b>,"9 x 10-7","(adjusted for dose, GFR & AST)",NR,'-,"0.65 unit decrease",'-,UBA52P9,"Carboplatin disposition in epthelial ovarian cancer","Malignant epithelial tumor of ovary, response to carboplatin",GCST005351,18:27347470
rs7909167-<b>?</b>,"6 x 10-6","(adjusted for dose, GFR & AST)",NR,'-,"1.49 unit decrease",'-,"GPN3P1, GPR158","Carboplatin disposition in epthelial ovarian cancer","Malignant epithelial tumor of ovary, response to carboplatin",GCST005351,10:25602315
rs8187707-<b>?</b>,"5 x 10-6","(adjusted for dose, GFR & AST)",NR,'-,"1.21 unit decrease",'-,ABCC2,"Carboplatin disposition in epthelial ovarian cancer","Malignant epithelial tumor of ovary, response to carboplatin",GCST005351,10:99850776
rs9982086-<b>?</b>,"9 x 10-6","(adjusted for dose, GFR & AST)",NR,'-,"1.06 unit decrease",'-,"MRPL39, JAM2","Carboplatin disposition in epthelial ovarian cancer","Malignant epithelial tumor of ovary, response to carboplatin",GCST005351,21:25631797
rs9558996-<b>?</b>,"5 x 10-6",,NR,'-,"1.285 unit increase",'-,FAM155A,"Carboplatin disposition in epthelial ovarian cancer","Malignant epithelial tumor of ovary, response to carboplatin",GCST005351,13:107290084
rs11130471-<b>?</b>,"9 x 10-6",,NR,'-,"1.641 unit decrease",'-,"LINC02030, WNT5A","Carboplatin disposition in epthelial ovarian cancer","Malignant epithelial tumor of ovary, response to carboplatin",GCST005351,3:55376983
rs17806780-<b>?</b>,"9 x 10-6",,NR,'-,"1.484 unit increase",'-,ZNF827,"Carboplatin disposition in epthelial ovarian cancer","Malignant epithelial tumor of ovary, response to carboplatin",GCST005351,4:145811502
rs12516561-<b>?</b>,"4 x 10-6",,NR,'-,"1.671 unit increase",'-,"WNT8A, NME5","Carboplatin disposition in epthelial ovarian cancer","Malignant epithelial tumor of ovary, response to carboplatin",GCST005351,5:138109311
rs62283056-<b>C</b>,"5 x 10-8",,NR,'-,"5.438 z score decrease",'-,WFS1,"Cisplatin-induced ototoxicity","ototoxicity, response to cisplatin",GCST003898,4:6274903
rs62137541-<b>T</b>,"1 x 10-7",,NR,'-,"5.28 z score decrease",'-,"RNU6-242P, LINC02590","Cisplatin-induced ototoxicity","ototoxicity, response to cisplatin",GCST003898,2:43088349
rs7562946-<b>A</b>,"4 x 10-7",,NR,'-,"5.053 z score decrease",'-,"LINC02580, RNU6-242P","Cisplatin-induced ototoxicity","ototoxicity, response to cisplatin",GCST003898,2:43091570
rs12156238-<b>C</b>,"5 x 10-7",,NR,'-,"5.032 z score increase",'-,"FAM167A-AS1, FAM167A","Cisplatin-induced ototoxicity","ototoxicity, response to cisplatin",GCST003898,8:11427626
rs3179891-<b>A</b>,"5 x 10-7",,NR,'-,"5.026 z score increase",'-,LINC02580,"Cisplatin-induced ototoxicity","ototoxicity, response to cisplatin",GCST003898,2:43092840
rs7578467-<b>T</b>,"5 x 10-7",,NR,'-,"5.019 z score increase",'-,"LINC02590, RNU6-242P","Cisplatin-induced ototoxicity","ototoxicity, response to cisplatin",GCST003898,2:43088710
rs10829534-<b>T</b>,"5 x 10-6",,NR,'-,"4.582 z score decrease",'-,LINC02667,"Cisplatin-induced ototoxicity","ototoxicity, response to cisplatin",GCST003898,10:128974127
rs2143582-<b>T</b>,"5 x 10-6",,NR,'-,"4.554 z score decrease",'-,ST6GALNAC5,"Cisplatin-induced ototoxicity","ototoxicity, response to cisplatin",GCST003898,1:76987908
rs13148643-<b>T</b>,"5 x 10-6",,NR,'-,"4.554 z score increase",'-,MIR548AG1,"Cisplatin-induced ototoxicity","ototoxicity, response to cisplatin",GCST003898,4:60987687
rs1000083-<b>T</b>,"5 x 10-6",,NR,'-,"4.55 z score decrease",'-,LIX1-AS1,"Cisplatin-induced ototoxicity","ototoxicity, response to cisplatin",GCST003898,5:97197765
rs12615153-<b>T</b>,"6 x 10-6",,NR,'-,"4.529 z score decrease",'-,LINC02580,"Cisplatin-induced ototoxicity","ototoxicity, response to cisplatin",GCST003898,2:43093990
rs13067896-<b>A</b>,"7 x 10-6",,NR,'-,"4.494 z score decrease",'-,"RPL21P17, RN7SKP144","Cisplatin-induced ototoxicity","ototoxicity, response to cisplatin",GCST003898,3:2005081
rs35367356-<b>A</b>,"7 x 10-6",,NR,'-,"4.492 z score decrease",'-,"RN7SKP144, RPL21P17","Cisplatin-induced ototoxicity","ototoxicity, response to cisplatin",GCST003898,3:2002712
rs10850703-<b>A</b>,"8 x 10-6",,NR,'-,"4.472 z score increase",'-,SPRING1,"Cisplatin-induced ototoxicity","ototoxicity, response to cisplatin",GCST003898,12:116702884
rs1466045-<b>A</b>,"8 x 10-6",,NR,'-,"4.46 z score increase",'-,OSBPL5,"Cisplatin-induced ototoxicity","ototoxicity, response to cisplatin",GCST003898,11:3128167
rs7746807-<b>A</b>,"8 x 10-6",,NR,'-,"4.46 z score increase",'-,"H3C9P, H4C8","Cisplatin-induced ototoxicity","ototoxicity, response to cisplatin",GCST003898,6:26293110
rs3888233-<b>A</b>,"9 x 10-6",,NR,'-,"4.451 z score increase",'-,FAF2,"Cisplatin-induced ototoxicity","ototoxicity, response to cisplatin",GCST003898,5:176485993
rs1906073-<b>A</b>,"9 x 10-6",,NR,'-,"4.438 z score increase",'-,MIR548AG1,"Cisplatin-induced ototoxicity","ototoxicity, response to cisplatin",GCST003898,4:60971415
rs7399018-<b>T</b>,"9 x 10-6",,NR,'-,"4.438 z score increase",'-,POU6F1,"Cisplatin-induced ototoxicity","ototoxicity, response to cisplatin",GCST003898,12:51216581
rs73807529-<b>A</b>,"9 x 10-6",,NR,'-,"4.435 z score decrease",'-,RN7SKP144,"Cisplatin-induced ototoxicity","ototoxicity, response to cisplatin",GCST003898,3:2006661
rs4543825-<b>A</b>,"2 x 10-6",,0.212,'-,"0.1678 unit decrease",[0.099-0.236],LINC01358,"Serum platinum levels after completion of cisplatin chemotherapy","response to cisplatin, platinum measurement",GCST008756,1:59091175
rs115440456-<b>C</b>,"7 x 10-6",,0.0495,'-,"0.3291 unit decrease",[0.19-0.47],INTS7,"Serum platinum levels after completion of cisplatin chemotherapy","response to cisplatin, platinum measurement",GCST008756,1:211962728
rs6759709-<b>G</b>,"3 x 10-7",,0.2572,'-,"0.1671 unit increase",[0.1-0.23],MYT1L,"Serum platinum levels after completion of cisplatin chemotherapy","response to cisplatin, platinum measurement",GCST008756,2:2043625
rs7568939-<b>T</b>,"5 x 10-6",,0.0203,'-,"0.5003 unit increase",[0.29-0.71],FBXO11,"Serum platinum levels after completion of cisplatin chemotherapy","response to cisplatin, platinum measurement",GCST008756,2:47842905
rs115487787-<b>T</b>,"7 x 10-6",,0.0463,'-,"0.3084 unit increase",[0.17-0.44],NRXN1,"Serum platinum levels after completion of cisplatin chemotherapy","response to cisplatin, platinum measurement",GCST008756,2:50193619
rs7587256-<b>A</b>,"4 x 10-6",,0.0396,'-,"0.3333 unit increase",[0.19-0.47],RPS20P10,"Serum platinum levels after completion of cisplatin chemotherapy","response to cisplatin, platinum measurement",GCST008756,2:71929572
rs114985352-<b>T</b>,"6 x 10-6",,0.0153,'-,"0.5881 unit increase",[0.34-0.84],RPRM,"Serum platinum levels after completion of cisplatin chemotherapy","response to cisplatin, platinum measurement",GCST008756,2:153509761
rs7579510-<b>C</b>,"4 x 10-6",,0.012,'-,"0.6159 unit increase",[0.36-0.88],'-,"Serum platinum levels after completion of cisplatin chemotherapy","response to cisplatin, platinum measurement",GCST008756,2:155713678
rs10469688-<b>G</b>,"8 x 10-6",,0.0264,'-,"0.4037 unit increase",[0.23-0.58],'-,"Serum platinum levels after completion of cisplatin chemotherapy","response to cisplatin, platinum measurement",GCST008756,2:163401427
rs114949804-<b>C</b>,"4 x 10-6",,0.01,'-,"0.7073 unit increase",[0.41-1.01],"OTOS, U3","Serum platinum levels after completion of cisplatin chemotherapy","response to cisplatin, platinum measurement",GCST008756,2:240237625
rs563551865-<b>T</b>,"2 x 10-6",,0.0126,'-,"0.6234 unit decrease",[0.37-0.88],PLSCR2,"Serum platinum levels after completion of cisplatin chemotherapy","response to cisplatin, platinum measurement",GCST008756,3:146429826
rs9289856-<b>C</b>,"9 x 10-6",,0.0283,'-,"0.3856 unit increase",[0.22-0.55],AADACL2-AS1,"Serum platinum levels after completion of cisplatin chemotherapy","response to cisplatin, platinum measurement",GCST008756,3:151791956
rs17506814-<b>G</b>,"7 x 10-6",,0.0131,'-,"0.6165 unit increase",[0.35-0.88],LINC02006,"Serum platinum levels after completion of cisplatin chemotherapy","response to cisplatin, platinum measurement",GCST008756,3:153616961
rs75979836-<b>G</b>,"4 x 10-6",,0.0547,'-,"0.3189 unit increase",[0.18-0.45],"ECT2, NCEH1","Serum platinum levels after completion of cisplatin chemotherapy","response to cisplatin, platinum measurement",GCST008756,3:172744684
rs111649035-<b>C</b>,"6 x 10-6",,0.0114,'-,"0.6144 unit increase",[0.35-0.88],"TRA2B, IGF2BP2","Serum platinum levels after completion of cisplatin chemotherapy","response to cisplatin, platinum measurement",GCST008756,3:185887160
rs138013532-<b>T</b>,"1 x 10-6",,0.0107,'-,"0.7147 unit increase",[0.43-1],TENM3,"Serum platinum levels after completion of cisplatin chemotherapy","response to cisplatin, platinum measurement",GCST008756,4:182631880
rs80184476-<b>T</b>,"2 x 10-6",,0.0349,'-,"0.3691 unit increase",[0.22-0.52],"LINC01847, ADRA1B","Serum platinum levels after completion of cisplatin chemotherapy","response to cisplatin, platinum measurement",GCST008756,5:159914068
rs76903139-<b>G</b>,"9 x 10-6",,0.043,'-,"0.3411 unit increase",[0.19-0.49],'-,"Serum platinum levels after completion of cisplatin chemotherapy","response to cisplatin, platinum measurement",GCST008756,6:16951395
rs144939408-<b>T</b>,"8 x 10-6",,0.0106,'-,"0.6703 unit increase",[0.38-0.96],MLN,"Serum platinum levels after completion of cisplatin chemotherapy","response to cisplatin, platinum measurement",GCST008756,6:97750641
rs9484827-<b>G</b>,"2 x 10-6",,0.0133,'-,"0.5719 unit increase",[0.34-0.81],ZC2HC1B,"Serum platinum levels after completion of cisplatin chemotherapy","response to cisplatin, platinum measurement",GCST008756,6:143903175
rs10252204-<b>A</b>,"3 x 10-6",,0.4261,'-,"0.1349 unit decrease",[0.079-0.191],CCDC146,"Serum platinum levels after completion of cisplatin chemotherapy","response to cisplatin, platinum measurement",GCST008756,7:77191483
rs150691387-<b>G</b>,"4 x 10-7",,0.0135,'-,"0.63 unit increase",[0.39-0.87],SEM1,"Serum platinum levels after completion of cisplatin chemotherapy","response to cisplatin, platinum measurement",GCST008756,7:96538498
rs10949698-<b>C</b>,"6 x 10-6",,0.3239,'-,"0.1383 unit increase",[0.079-0.198],PTPRN2,"Serum platinum levels after completion of cisplatin chemotherapy","response to cisplatin, platinum measurement",GCST008756,7:158137551
rs183748570-<b>A</b>,"3 x 10-6",,0.0147,'-,"0.6129 unit increase",[0.36-0.87],CSMD1,"Serum platinum levels after completion of cisplatin chemotherapy","response to cisplatin, platinum measurement",GCST008756,8:4055538
rs73653973-<b>T</b>,"9 x 10-6",,0.0425,'-,"0.3189 unit increase",[0.18-0.46],"SPATA31C1, SPATA31E1","Serum platinum levels after completion of cisplatin chemotherapy","response to cisplatin, platinum measurement",GCST008756,9:87889799
rs78280308-<b>A</b>,"8 x 10-6",,0.0325,'-,"0.3793 unit increase",[0.21-0.54],"SARDH, VAV2","Serum platinum levels after completion of cisplatin chemotherapy","response to cisplatin, platinum measurement",GCST008756,9:133748501
rs11200804-<b>G</b>,"2 x 10-6",,0.1573,'-,"0.1899 unit increase",[0.11-0.27],"RNU1-65P, HMGN2P8","Serum platinum levels after completion of cisplatin chemotherapy","response to cisplatin, platinum measurement",GCST008756,10:84018619
rs61878760-<b>A</b>,"8 x 10-7",,0.0896,'-,"0.2499 unit increase",[0.15-0.35],TEAD1,"Serum platinum levels after completion of cisplatin chemotherapy","response to cisplatin, platinum measurement",GCST008756,11:12785642
rs501630-<b>G</b>,"5 x 10-6",,0.5545,'-,"0.1299 unit decrease",[0.074-0.186],EFEMP2,"Serum platinum levels after completion of cisplatin chemotherapy","response to cisplatin, platinum measurement",GCST008756,11:65869802
rs36116683-<b>G</b>,"1 x 10-6",,0.2011,'-,"0.1746 unit increase",[0.11-0.24],"LINC02204, LINC02205","Serum platinum levels after completion of cisplatin chemotherapy","response to cisplatin, platinum measurement",GCST008756,15:70518645
rs75276171-<b>G</b>,"4 x 10-6",,0.0611,'-,"0.2797 unit increase",[0.16-0.4],ACAA2,"Serum platinum levels after completion of cisplatin chemotherapy","response to cisplatin, platinum measurement",GCST008756,18:49783170
rs1377817-<b>G</b>,"5 x 10-8",,0.1299,'-,"0.2303 unit decrease",[0.15-0.31],MYH14,"Serum platinum levels after completion of cisplatin chemotherapy","response to cisplatin, platinum measurement",GCST008756,19:50300809
rs13047590-<b>T</b>,"1 x 10-6",,0.1363,'-,"0.1998 unit increase",[0.12-0.28],ADARB1,"Serum platinum levels after completion of cisplatin chemotherapy","response to cisplatin, platinum measurement",GCST008756,21:45143905
rs1512114-<b>G</b>,"8 x 10-6",,'-,3.676,'-,[NR],"PLEKHA6, PPP1R15B","Multiple severe cisplatin-induced neurotixicitiies in testicular cancer survivors","testicular carcinoma, response to cisplatin",GCST011637,1:204390636
rs1484309-<b>A</b>,"9 x 10-6",,'-,5.944,'-,[NR],LINC01709,"Multiple severe cisplatin-induced neurotixicitiies in testicular cancer survivors","testicular carcinoma, response to cisplatin",GCST011637,1:101559434
rs12829696-<b>T</b>,"9 x 10-7",,'-,0.1076,'-,[NR],TMEM132C,"Multiple severe cisplatin-induced neurotixicitiies in testicular cancer survivors","testicular carcinoma, response to cisplatin",GCST011637,12:128699887
rs34832729-<b>G</b>,"1 x 10-6",,'-,5.554,'-,[NR],"ATP11AUN, SLITRK6","Multiple severe cisplatin-induced neurotixicitiies in testicular cancer survivors","testicular carcinoma, response to cisplatin",GCST011637,13:85811977
rs1223889-<b>G</b>,"8 x 10-6",,'-,0.2677,'-,[NR],"LINC02352, TRPM1","Multiple severe cisplatin-induced neurotixicitiies in testicular cancer survivors","testicular carcinoma, response to cisplatin",GCST011637,15:31179269
"rs317689-<b>?</b>, rs7297610-<b>?</b>, rs315135-<b>?</b>","3 x 10-7",(blacks),NR,'-,'-,'-,"C1GALT1P1 - LYZ; No mapped genes; No mapped genes","Response to diuretic therapy","response to diuretic",GCST000208,12:69333410
rs13260300-<b>?</b>,"2 x 10-7",,'-,1.64,'-,[1.35-2.00],"MIR2052HG, MIR5681A","Breast cancer-free interval (treatment with aromatase inhibitor)","disease recurrence, response to aromatase inhibitor, breast carcinoma",GCST003816,8:74567389
rs254271-<b>?</b>,"4 x 10-7",(EA),NR,'-,'-,'-,PRPF31,"Change in HbA1c levels in response to metformin treatment in type 2 diabetes","HbA1c measurement, type II diabetes mellitus, response to metformin",GCST005753,19:54127382
rs185229225-<b>?</b>,"2 x 10-7",,NR,'-,'-,'-,BOD1L1,"Response to paclitaxel in ovarian cancer (MTT IC50)","ovarian carcinoma, cytotoxicity measurement, response to paclitaxel",GCST003441,4:13607505
rs4751538-<b>?</b>,"8 x 10-7",,NR,'-,'-,'-,"FOXI2, BUB1P1","Response to lamotrigine and valproic acid in genetic generalized epilepsy","generalised epilepsy, response to anticonvulsant",GCST010292,10:127837644
rs78835388-<b>G</b>,"7 x 10-9",,0.021,'-,"6.6 unit decrease",NR,THSD7A,"Response to antiepileptic mood-stabilizing treatment in bipolar disorder","bipolar disorder, response to anticonvulsant",GCST010579,7:11774419
rs114872993-<b>G</b>,"3 x 10-8",,0.029,'-,"4.5 unit decrease",NR,"SLC35F3, COA6-AS1","Response to antiepileptic mood-stabilizing treatment in bipolar disorder","bipolar disorder, response to anticonvulsant",GCST010579,1:234346906
rs34701716-<b>C</b>,"2 x 10-6",,0.14,'-,"1.8 unit increase",NR,DISP1,"Response to antiepileptic mood-stabilizing treatment in bipolar disorder","bipolar disorder, response to anticonvulsant",GCST010579,1:222940467
rs13353016-<b>T</b>,"2 x 10-6",,0.028,'-,"4.7 unit decrease",NR,VAV3,"Response to antiepileptic mood-stabilizing treatment in bipolar disorder","bipolar disorder, response to anticonvulsant",GCST010579,1:107856873
rs875740-<b>C</b>,"2 x 10-6",,0.34,'-,"1.3 unit decrease",NR,ABCC1,"Response to antiepileptic mood-stabilizing treatment in bipolar disorder","bipolar disorder, response to anticonvulsant",GCST010579,16:16029191
rs924607-<b>T</b>,"6 x 10-9",,NR,2.43,'-,[1.70-3.49],"CEP72, MIR4456","Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia","peripheral neuropathy, acute lymphoblastic leukemia, response to vincristine",GCST002792,5:609978
rs17032980-<b>?</b>,"1 x 10-8",,NR,3.17,'-,[1.95-5.17],LINC01828,"Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia","peripheral neuropathy, acute lymphoblastic leukemia, response to vincristine",GCST002792,2:67075611
rs12786200-<b>?</b>,"3 x 10-8",,NR,4.35,'-,[2.50-7.69],FAT3,"Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia","peripheral neuropathy, acute lymphoblastic leukemia, response to vincristine",GCST002792,11:92245852
rs4463516-<b>?</b>,"3 x 10-8",,NR,2.89,'-,[1.90-4.39],"Y_RNA, APTX","Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia","peripheral neuropathy, acute lymphoblastic leukemia, response to vincristine",GCST002792,9:32867483
rs7818688-<b>?</b>,"4 x 10-8",,NR,4.26,'-,[2.45-7.42],NDUFAF6,"Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia","peripheral neuropathy, acute lymphoblastic leukemia, response to vincristine",GCST002792,8:95011854
rs4986811-<b>G</b>,"5 x 10-8",,0.20504,'-,'-,'-,WT1,"Rubella-specific interleukin-6 secretion","interleukin-6 measurement, response to vaccine",GCST005176,11:32429547
rs140973961-<b>C</b>,"1 x 10-6",,0.34,'-,'-,'-,HLA-DRB5,"Immune response to measles vaccine (measles-induced IFN gamma)","response to vaccine",GCST004268,6:32520210
rs9277535-<b>?</b>,"3 x 10-12",,NR,1.39,'-,[1.23-1.59],HLA-DPB1,"Hepatitis B vaccine response","response to vaccine",GCST001162,6:33087084
rs477515-<b>T</b>,"3 x 10-19",,0.442,2.05,'-,[1.75-2.41],"HLA-DRB1, HLA-DQA1","Hepatitis B vaccine response","response to vaccine",GCST002297,6:32601914
rs3135363-<b>?</b>,"8 x 10-7",,NR,1.51,'-,[1.28-1.78],'-,"Hepatitis B vaccine response","response to vaccine",GCST002297,"Mapping not available"
rs11121382-<b>C</b>,"4 x 10-6",,NR,'-,"0.099 unit decrease",[0.056-0.142],SPSB1,"Immune response to anthrax vaccine","response to vaccine",GCST001547,1:9351410
rs634308-<b>G</b>,"4 x 10-6",,NR,'-,"0.1 unit decrease",[0.057-0.143],C5orf66,"Immune response to anthrax vaccine","response to vaccine",GCST001547,5:135227467
rs6478282-<b>A</b>,"6 x 10-6",,NR,'-,"0.101 unit increase",[0.058-0.144],ASTN2,"Immune response to anthrax vaccine","response to vaccine",GCST001547,9:117162816
rs732949-<b>C</b>,"8 x 10-6",,NR,'-,"0.166 unit increase",[0.093-0.239],"OLFM4, PCDH8","Immune response to anthrax vaccine","response to vaccine",GCST001547,13:52943749
rs7230711-<b>C</b>,"1 x 10-6",,NR,'-,"0.162 unit decrease",[0.097-0.227],"MEX3C, SRSF10P1","Immune response to anthrax vaccine","response to vaccine",GCST001547,18:51164249
rs2647264-<b>G</b>,"9 x 10-6",,NR,'-,"0.165 unit increase",[0.092-0.238],"PPA2, RN7SL89P","Immune response to anthrax vaccine","response to vaccine",GCST001547,4:105347437
rs3104402-<b>A</b>,"6 x 10-6",,NR,'-,"0.165 unit decrease",[0.094-0.236],"MTCO3P1, HLA-DQB3","Immune response to anthrax vaccine","response to vaccine",GCST001547,6:32713899
rs10758161-<b>G</b>,"8 x 10-6",,NR,'-,"0.159 unit decrease",[0.088-0.230],"TMEM215, SNRPCP1","Immune response to anthrax vaccine","response to vaccine",GCST001547,9:32755030
rs11265263-<b>?</b>,"3 x 10-6",(wheezing),0.04,'-,'-,'-,"DUSP23, CRP","Vaccine-related adverse events","response to vaccine",GCST001016,1:159740727
rs6593122-<b>?</b>,"4 x 10-6",(influenza),0.11,'-,'-,'-,'-,"Vaccine-related adverse events","response to vaccine",GCST001016,7:54114239
rs7105056-<b>A</b>,"1 x 10-8",(EA),'-,'-,'-,'-,BCO2,"Immune reponse to smallpox (secreted IL-12p40)","response to vaccine, cytokine measurement",GCST001537,11:112193708
rs17331151-<b>A</b>,"2 x 10-9",(AA),'-,'-,'-,'-,"ITIH4, ITIH3","Immune reponse to smallpox (secreted IL-2)","response to vaccine, cytokine measurement",GCST001535,3:52810518
rs17231212-<b>G</b>,"2 x 10-8",(AA),'-,'-,'-,'-,"AGBL3, CYREN","Immune reponse to smallpox (secreted IL-10)","response to vaccine, cytokine measurement",GCST001534,7:135100989
rs1584468-<b>A</b>,"9 x 10-8",(EA),'-,'-,'-,'-,PRR16,"Immune reponse to smallpox (secreted IL-12p40)","response to vaccine, cytokine measurement",GCST001537,5:120601996
rs10055544-<b>A</b>,"1 x 10-7",(AA),'-,'-,'-,'-,'-,"Immune reponse to smallpox (secreted IL-10)","response to vaccine, cytokine measurement",GCST001534,5:92222904
rs3736638-<b>A</b>,"3 x 10-7",(EA),'-,'-,'-,'-,COL1A2,"Immune reponse to smallpox (secreted IL-12p40)","response to vaccine, cytokine measurement",GCST001537,7:94417954
rs13111850-<b>G</b>,"3 x 10-11",(AA),'-,'-,'-,'-,RN7SL776P,"Immune reponse to smallpox (secreted IL-10)","response to vaccine, cytokine measurement",GCST001534,4:167343098
rs6943090-<b>A</b>,"3 x 10-7",(AA),'-,'-,'-,'-,FKBP6,"Immune reponse to smallpox (secreted IL-12p40)","response to vaccine, cytokine measurement",GCST001537,7:73332645
rs7771911-<b>A</b>,"2 x 10-12",(EA),'-,'-,'-,'-,'-,"Immune reponse to smallpox (secreted IL-12p40)","response to vaccine, cytokine measurement",GCST001537,6:23437448
rs17000918-<b>A</b>,"4 x 10-9",(AA),'-,'-,'-,'-,C22orf34,"Immune reponse to smallpox (secreted IL-1beta)","response to vaccine, cytokine measurement",GCST001533,22:49418853
rs11223581-<b>G</b>,"9 x 10-9",(AA),'-,'-,'-,'-,CNTN5,"Immune reponse to smallpox (secreted IL-2)","response to vaccine, cytokine measurement",GCST001535,11:100302805
rs16850885-<b>A</b>,"7 x 10-9",(EA),'-,'-,'-,'-,"EPGN, MTHFD2L","Immune reponse to smallpox (secreted IL-1beta)","response to vaccine, cytokine measurement",GCST001533,4:74304423
rs16948200-<b>A</b>,"2 x 10-8",(AA),'-,'-,'-,'-,"LINC02075, NGFR","Immune reponse to smallpox (secreted IL-2)","response to vaccine, cytokine measurement",GCST001535,17:49488950
rs1403155-<b>A</b>,"2 x 10-8",(EA),'-,'-,'-,'-,'-,"Immune reponse to smallpox (secreted IL-2)","response to vaccine, cytokine measurement",GCST001535,7:68585426
rs10432496-<b>A</b>,"6 x 10-8",(AA),'-,'-,'-,'-,"FAM8A3P, LYPD6B","Immune reponse to smallpox (secreted IL-2)","response to vaccine, cytokine measurement",GCST001535,2:149290764
rs1473500-<b>A</b>,"3 x 10-7",(EA),'-,'-,'-,'-,FRMD1,"Immune reponse to smallpox (secreted IL-2)","response to vaccine, cytokine measurement",GCST001535,6:168110336
rs10513432-<b>G</b>,"4 x 10-7",(EA),'-,'-,'-,'-,"P2RY1, ATP5MGP5","Immune reponse to smallpox (secreted IL-2)","response to vaccine, cytokine measurement",GCST001535,3:152817576
rs4827947-<b>A</b>,"3 x 10-7",(AA),'-,'-,'-,'-,'-,"Immune reponse to smallpox (secreted IL-1beta)","response to vaccine, cytokine measurement",GCST001533,X:98609356
rs11845208-<b>G</b>,"1 x 10-7",(AA),'-,'-,'-,'-,'-,"Immune reponse to smallpox (secreted IL-2)","response to vaccine, cytokine measurement",GCST001535,14:48994281
rs10998624-<b>A</b>,"1 x 10-9",(EA),'-,'-,'-,'-,"SUPV3L1, VPS26A","Immune reponse to smallpox (secreted IL-1beta)","response to vaccine, cytokine measurement",GCST001533,10:69180045
rs1392089-<b>A</b>,"4 x 10-7",(AA),'-,'-,'-,'-,'-,"Immune reponse to smallpox (secreted IL-2)","response to vaccine, cytokine measurement",GCST001535,6:119544976
rs17299841-<b>C</b>,"2 x 10-7",(AA),'-,'-,'-,'-,"LINC02536, THEMIS","Immune response to smallpox vaccine (IL-6)","response to vaccine, cytokine measurement",GCST001532,6:127700658
rs3796352-<b>A</b>,"5 x 10-7",(AA),'-,'-,'-,'-,"STIMATE-MUSTN1, STIMATE","Immune reponse to smallpox (secreted IL-2)","response to vaccine, cytokine measurement",GCST001535,3:52879263
rs17444059-<b>G</b>,"2 x 10-8",(AA),'-,'-,'-,'-,PDE4D,"Immune response to smallpox vaccine (IL-6)","response to vaccine, cytokine measurement",GCST001532,5:59264891
rs13088281-<b>A</b>,"3 x 10-11",(AA),'-,'-,'-,'-,RFT1,"Immune reponse to smallpox (secreted IL-2)","response to vaccine, cytokine measurement",GCST001535,3:53113560
rs908327-<b>C</b>,"5 x 10-10",(AA),'-,'-,'-,'-,RN7SL668P,"Immune reponse to smallpox (secreted IL-2)","response to vaccine, cytokine measurement",GCST001535,1:234956853
rs7658486-<b>A</b>,"1 x 10-8",(EA),'-,'-,'-,'-,ARHGAP10,"Immune reponse to smallpox (secreted IL-12p40)","response to vaccine, cytokine measurement",GCST001537,4:147963038
rs11242417-<b>C</b>,"6 x 10-8",(EA),'-,'-,'-,'-,GFRA3,"Immune reponse to smallpox (secreted IL-12p40)","response to vaccine, cytokine measurement",GCST001537,5:138263645
rs16970881-<b>A</b>,"1 x 10-7",(EA),'-,'-,'-,'-,DNAH3,"Immune reponse to smallpox (secreted IL-10)","response to vaccine, cytokine measurement",GCST001534,16:21101951
rs11034653-<b>A</b>,"2 x 10-7",(EA),'-,'-,'-,'-,LRRC6P1,"Immune reponse to smallpox (secreted IL-12p40)","response to vaccine, cytokine measurement",GCST001537,11:38267043
rs6679454-<b>G</b>,"3 x 10-7",(AA),'-,'-,'-,'-,DAB1,"Immune reponse to smallpox (secreted IL-10)","response to vaccine, cytokine measurement",GCST001534,1:57901564
rs859267-<b>C</b>,"3 x 10-7",(AA),'-,'-,'-,'-,"ADORA2B, SPECC1P1","Immune reponse to smallpox (secreted IL-12p40)","response to vaccine, cytokine measurement",GCST001537,17:15922707
rs13231718-<b>C</b>,"5 x 10-9",(AA),'-,'-,'-,'-,DYNC1I1,"Immune reponse to smallpox (secreted IL-10)","response to vaccine, cytokine measurement",GCST001534,7:95971056
rs11564024-<b>C</b>,"3 x 10-8",(AA),'-,'-,'-,'-,"RPL35P4, HNRNPA1P73","Immune reponse to smallpox (secreted IL-1beta)","response to vaccine, cytokine measurement",GCST001533,7:27295942
rs17142462-<b>A</b>,"3 x 10-9",(EA),'-,'-,'-,'-,"LINC02476, RNU1-29P","Immune reponse to smallpox (secreted IL-12p40)","response to vaccine, cytokine measurement",GCST001537,7:119966578
rs16850864-<b>A</b>,"7 x 10-9",(EA),'-,'-,'-,'-,MTHFD2L,"Immune reponse to smallpox (secreted IL-1beta)","response to vaccine, cytokine measurement",GCST001533,4:74295107
rs2268118-<b>A</b>,"1 x 10-8",(EA),'-,'-,'-,'-,GRIN2B,"Immune reponse to smallpox (secreted IL-2)","response to vaccine, cytokine measurement",GCST001535,12:13719110
rs17168526-<b>G</b>,"6 x 10-8",(AA),'-,'-,'-,'-,COL28A1,"Immune reponse to smallpox (secreted IL-1beta)","response to vaccine, cytokine measurement",GCST001533,7:7531789
rs9582259-<b>C</b>,"3 x 10-8",(EA),'-,'-,'-,'-,SLC15A1,"Immune reponse to smallpox (secreted IL-1beta)","response to vaccine, cytokine measurement",GCST001533,13:98733736
rs9883650-<b>C</b>,"4 x 10-7",(EA),'-,'-,'-,'-,MECOM,"Immune reponse to smallpox (secreted IL-1beta)","response to vaccine, cytokine measurement",GCST001533,3:169362397
rs12247397-<b>G</b>,"3 x 10-9",(AA),'-,'-,'-,'-,LINC00709,"Immune reponse to smallpox (secreted IL-1beta)","response to vaccine, cytokine measurement",GCST001533,10:9321914
rs12542677-<b>A</b>,"2 x 10-7",(AA),'-,'-,'-,'-,XKR4,"Immune reponse to smallpox (secreted IL-1beta)","response to vaccine, cytokine measurement",GCST001533,8:55255499
rs1372791-<b>A</b>,"4 x 10-7",(EA),'-,'-,'-,'-,RNA5SP38,"Immune reponse to smallpox (secreted IL-2)","response to vaccine, cytokine measurement",GCST001535,13:106132916
rs9835973-<b>A</b>,"7 x 10-8",(EA),'-,'-,'-,'-,RAB6B,"Immune reponse to smallpox (secreted IL-1beta)","response to vaccine, cytokine measurement",GCST001533,3:133870480
rs4963243-<b>A</b>,"2 x 10-7",(AA),'-,'-,'-,'-,DAGLA,"Immune reponse to smallpox (secreted IL-2)","response to vaccine, cytokine measurement",GCST001535,11:61726855
rs902464-<b>A</b>,"3 x 10-7",(EA),'-,'-,'-,'-,DCHS2,"Immune reponse to smallpox (secreted IL-1beta)","response to vaccine, cytokine measurement",GCST001533,4:154394970
rs7224438-<b>G</b>,"4 x 10-7",(AA),'-,'-,'-,'-,BCAS3,"Immune reponse to smallpox (secreted IL-2)","response to vaccine, cytokine measurement",GCST001535,17:60889177
rs8096445-<b>A</b>,"9 x 10-9",(AA),'-,'-,'-,'-,MEX3C,"Immune response to smallpox vaccine (IL-6)","response to vaccine, cytokine measurement",GCST001532,18:51186670
rs9389316-<b>A</b>,"7 x 10-13",(EA),'-,'-,'-,'-,LINC00271,"Immune reponse to smallpox (secreted IL-2)","response to vaccine, cytokine measurement",GCST001535,6:135679865
rs6728021-<b>G</b>,"4 x 10-8",(AA),'-,'-,'-,'-,LINC00486,"Immune response to smallpox vaccine (IL-6)","response to vaccine, cytokine measurement",GCST001532,2:32896437
rs13181561-<b>G</b>,"3 x 10-14",(EA),'-,'-,'-,'-,SMIM33,"Immune reponse to smallpox (secreted IFN-alpha)","response to vaccine, cytokine measurement",GCST001538,5:139471320
rs2048161-<b>A</b>,"6 x 10-12",(AA),'-,'-,'-,'-,ZNF827,"Immune reponse to smallpox (secreted IFN-alpha)","response to vaccine, cytokine measurement",GCST001538,4:145932013
rs6573333-<b>A</b>,"3 x 10-10",(EA),'-,'-,'-,'-,MNAT1,"Immune reponse to smallpox (secreted IFN-alpha)","response to vaccine, cytokine measurement",GCST001538,14:60841619
rs11171846-<b>A</b>,"6 x 10-10",(AA),'-,'-,'-,'-,TIMELESS,"Immune reponse to smallpox (secreted IFN-alpha)","response to vaccine, cytokine measurement",GCST001538,12:56434272
rs2272205-<b>G</b>,"3 x 10-9",(AA),'-,'-,'-,'-,COL4A4,"Immune reponse to smallpox (secreted IFN-alpha)","response to vaccine, cytokine measurement",GCST001538,2:227051208
rs9408928-<b>G</b>,"4 x 10-9",(AA),'-,'-,'-,'-,RAB14,"Immune reponse to smallpox (secreted IFN-alpha)","response to vaccine, cytokine measurement",GCST001538,9:121189639
rs6576443-<b>A</b>,"6 x 10-9",(EA),'-,'-,'-,'-,"ATP10A, LINC02250","Immune reponse to smallpox (secreted IFN-alpha)","response to vaccine, cytokine measurement",GCST001538,15:25649511
rs4713226-<b>A</b>,"2 x 10-8",(AA),'-,'-,'-,'-,UBDP1,"Immune reponse to smallpox (secreted IFN-alpha)","response to vaccine, cytokine measurement",GCST001538,6:29466637
rs9408926-<b>A</b>,"4 x 10-8",(AA),'-,'-,'-,'-,CNTRL,"Immune reponse to smallpox (secreted IFN-alpha)","response to vaccine, cytokine measurement",GCST001538,9:121152596
rs210359-<b>A</b>,"8 x 10-8",(AA),'-,'-,'-,'-,LINC02331,"Immune reponse to smallpox (secreted IFN-alpha)","response to vaccine, cytokine measurement",GCST001538,14:53700754
rs261532-<b>A</b>,"3 x 10-7",(EA),'-,'-,'-,'-,UBE2D2,"Immune reponse to smallpox (secreted IFN-alpha)","response to vaccine, cytokine measurement",GCST001538,5:139569777
rs5925760-<b>A</b>,"1 x 10-7",(AA),'-,'-,'-,'-,PTCHD1,"Immune reponse to smallpox (secreted IFN-alpha)","response to vaccine, cytokine measurement",GCST001538,X:23365327
rs17221323-<b>G</b>,"1 x 10-7",(AA),'-,'-,'-,'-,DIP2C,"Immune reponse to smallpox (secreted IFN-alpha)","response to vaccine, cytokine measurement",GCST001538,10:572745
rs4839431-<b>A</b>,"2 x 10-7",(AA),'-,'-,'-,'-,CYMP,"Immune reponse to smallpox (secreted IFN-alpha)","response to vaccine, cytokine measurement",GCST001538,1:110491187
rs10517025-<b>A</b>,"2 x 10-7",(AA),'-,'-,'-,'-,ATP8A1,"Immune reponse to smallpox (secreted IFN-alpha)","response to vaccine, cytokine measurement",GCST001538,4:42451236
rs9493873-<b>G</b>,"4 x 10-7",(AA),'-,'-,'-,'-,SGK1,"Immune reponse to smallpox (secreted IFN-alpha)","response to vaccine, cytokine measurement",GCST001538,6:134255373
rs3095748-<b>G</b>,"5 x 10-7",(AA),'-,'-,'-,'-,DAPK1,"Immune reponse to smallpox (secreted IFN-alpha)","response to vaccine, cytokine measurement",GCST001538,9:87594222
rs2043599-<b>G</b>,"5 x 10-7",(AA),'-,'-,'-,'-,"NLRP13, NLRP8","Immune reponse to smallpox (secreted IFN-alpha)","response to vaccine, cytokine measurement",GCST001538,19:55939683
rs1516489-<b>C</b>,"8 x 10-8",(AA),'-,'-,'-,'-,'-,"Immune response to smallpox vaccine (IL-6)","response to vaccine, cytokine measurement",GCST001532,3:191804063
rs17290760-<b>G</b>,"1 x 10-7",(AA),'-,'-,'-,'-,"NDUFB6, SMIM27","Immune response to smallpox vaccine (IL-6)","response to vaccine, cytokine measurement",GCST001532,9:32556382
rs2501276-<b>A</b>,"2 x 10-7",(AA),'-,'-,'-,'-,"CDC42, CDC42-AS1","Immune response to smallpox vaccine (IL-6)","response to vaccine, cytokine measurement",GCST001532,1:22047131
rs2255327-<b>A</b>,"3 x 10-7",(AA),'-,'-,'-,'-,BLK,"Immune response to smallpox vaccine (IL-6)","response to vaccine, cytokine measurement",GCST001532,8:11552483
rs2973662-<b>A</b>,"5 x 10-7",(AA),'-,'-,'-,'-,TENM2,"Immune response to smallpox vaccine (IL-6)","response to vaccine, cytokine measurement",GCST001532,5:167783467
rs11889798-<b>A</b>,"4 x 10-7",(EA),'-,'-,'-,'-,C2orf83,"Immune reponse to smallpox (secreted TNF-alpha)","response to vaccine, cytokine measurement",GCST001536,2:227616703
rs13414205-<b>A</b>,"7 x 10-8",(AA),'-,'-,'-,'-,CAMKMT,"Immune reponse to smallpox (secreted TNF-alpha)","response to vaccine, cytokine measurement",GCST001536,2:44435336
rs738968-<b>C</b>,"8 x 10-8",(EA),'-,'-,'-,'-,'-,"Immune reponse to smallpox (secreted TNF-alpha)","response to vaccine, cytokine measurement",GCST001536,22:34493105
rs13006863-<b>A</b>,"5 x 10-7",(EA),'-,'-,'-,'-,SLC4A5,"Immune reponse to smallpox (secreted TNF-alpha)","response to vaccine, cytokine measurement",GCST001536,2:74236439
rs758386-<b>A</b>,"2 x 10-7",(AA),'-,'-,'-,'-,SLC6A20,"Immune reponse to smallpox (secreted TNF-alpha)","response to vaccine, cytokine measurement",GCST001536,3:45775926
rs4251424-<b>A</b>,"2 x 10-8",(AA),'-,'-,'-,'-,IRAK4,"Immune reponse to smallpox (secreted TNF-alpha)","response to vaccine, cytokine measurement",GCST001536,12:43760023
rs542631-<b>A</b>,"1 x 10-7",(EA),'-,'-,'-,'-,LTBP1,"Immune reponse to smallpox (secreted IFN-alpha)","response to vaccine, cytokine measurement",GCST001538,2:33076880
rs13067593-<b>G</b>,"8 x 10-8",(AA),'-,'-,'-,'-,LPP,"Immune reponse to smallpox (secreted IFN-alpha)","response to vaccine, cytokine measurement",GCST001538,3:188866891
rs7060947-<b>G</b>,"1 x 10-7",(AA),'-,'-,'-,'-,TENM1,"Immune reponse to smallpox (secreted IFN-alpha)","response to vaccine, cytokine measurement",GCST001538,X:124939813
rs8127571-<b>A</b>,"2 x 10-7",(AA),'-,'-,'-,'-,PCBP3,"Immune reponse to smallpox (secreted IFN-alpha)","response to vaccine, cytokine measurement",GCST001538,21:45745515
rs381365-<b>A</b>,"2 x 10-12",(AA),'-,'-,'-,'-,ANKRD11P2,"Immune reponse to smallpox (secreted IFN-alpha)","response to vaccine, cytokine measurement",GCST001538,X:146667390
rs17252936-<b>G</b>,"6 x 10-10",(AA),'-,'-,'-,'-,MAMLD1,"Immune reponse to smallpox (secreted IFN-alpha)","response to vaccine, cytokine measurement",GCST001538,X:150467029
rs12044963-<b>A</b>,"9 x 10-10",(AA),'-,'-,'-,'-,KCND3,"Immune reponse to smallpox (secreted IFN-alpha)","response to vaccine, cytokine measurement",GCST001538,1:111849738
rs6778194-<b>C</b>,"2 x 10-9",(AA),'-,'-,'-,'-,"LINC02006, LINC02877","Immune reponse to smallpox (secreted IFN-alpha)","response to vaccine, cytokine measurement",GCST001538,3:153466867
rs1540283-<b>G</b>,"9 x 10-9",(AA),'-,'-,'-,'-,PHEX,"Immune reponse to smallpox (secreted IFN-alpha)","response to vaccine, cytokine measurement",GCST001538,X:22129934
rs17007761-<b>A</b>,"1 x 10-8",(AA),'-,'-,'-,'-,'-,"Immune reponse to smallpox (secreted IFN-alpha)","response to vaccine, cytokine measurement",GCST001538,2:122468047
rs10195263-<b>G</b>,"3 x 10-8",(EA),'-,'-,'-,'-,'-,"Immune reponse to smallpox (secreted IFN-alpha)","response to vaccine, cytokine measurement",GCST001538,2:150869278
rs9807334-<b>A</b>,"2 x 10-7",(AA),'-,'-,'-,'-,"ELAC1, SMAD4","Immune reponse to smallpox (secreted IFN-alpha)","response to vaccine, cytokine measurement",GCST001538,18:50997791
rs17714988-<b>G</b>,"3 x 10-7",(AA),'-,'-,'-,'-,LINC00381,"Immune reponse to smallpox (secreted IFN-alpha)","response to vaccine, cytokine measurement",GCST001538,13:74421523
rs4078978-<b>A</b>,"2 x 10-18",(AA),'-,'-,'-,'-,WDR92,"Immune reponse to smallpox (secreted IFN-alpha)","response to vaccine, cytokine measurement",GCST001538,2:68132765
rs76425237-<b>?</b>,"4 x 10-8",,NR,'-,'-,'-,PIWIL1,"B cell lymphocyte profile difference (1 day post influenza vaccination)","lymphocyte count, response to vaccine",GCST011885,12:130360022
rs75504175-<b>?</b>,"2 x 10-9",,NR,'-,'-,[NR],B4GALT4-AS1,"B cell lymphocyte profile difference (7 days post influenza vaccination)","lymphocyte count, response to vaccine",GCST011884,3:119278858
rs12611599-<b>?</b>,"8 x 10-9",,NR,'-,'-,[NR],"RPL12P17, CRYGEP","B cell lymphocyte profile difference (7 days post influenza vaccination)","lymphocyte count, response to vaccine",GCST011884,2:208096304
rs4668882-<b>?</b>,"3 x 10-8",,NR,'-,'-,[NR],NBAS,"B cell lymphocyte profile difference (7 days post influenza vaccination)","lymphocyte count, response to vaccine",GCST011884,2:15194127
rs35806-<b>?</b>,"3 x 10-8",,NR,'-,'-,[NR],KCNMA1,"B cell lymphocyte profile difference (7 days post influenza vaccination)","lymphocyte count, response to vaccine",GCST011884,10:77406072
rs76280036-<b>?</b>,"4 x 10-8",,NR,'-,'-,[NR],ARHGAP26,"B cell lymphocyte profile difference (7 days post influenza vaccination)","lymphocyte count, response to vaccine",GCST011884,5:142897219
rs78509568-<b>?</b>,"2 x 10-8",,NR,'-,'-,[NR],HECW2,"B cell lymphocyte profile difference (90 days post influenza vaccination)","lymphocyte count, response to vaccine",GCST011883,2:196533476
rs9851822-<b>?</b>,"5 x 10-8",,NR,'-,'-,[NR],"SELENOT, ERICH6","B cell lymphocyte profile difference (90 days post influenza vaccination)","lymphocyte count, response to vaccine",GCST011883,3:150646577
rs8073989-<b>?</b>,"3 x 10-8",,NR,'-,'-,'-,"PMP22, TEKT3","T cell lymphocyte profile difference (1 day post influenza vaccination)","lymphocyte count, response to vaccine",GCST011881,17:15291407
rs9919764-<b>?</b>,"4 x 10-9",,NR,'-,'-,'-,LINC01559,"T cell lymphocyte profile difference (7 days post influenza vaccination)","lymphocyte count, response to vaccine",GCST011880,12:13339770
rs39426-<b>?</b>,"8 x 10-10",,NR,'-,'-,[NR],"OSBPL3, CYCS","T cell lymphocyte profile difference (90 days post influenza vaccination)","lymphocyte count, response to vaccine",GCST011879,7:25066677
rs55914228-<b>?</b>,"3 x 10-8",,NR,'-,'-,[NR],MRPS21P6,"T cell lymphocyte profile difference (90 days post influenza vaccination)","lymphocyte count, response to vaccine",GCST011879,10:125208106
rs11920819-<b>?</b>,"5 x 10-8",,NR,'-,'-,[NR],HNRNPA3P8,"T cell lymphocyte profile difference (90 days post influenza vaccination)","lymphocyte count, response to vaccine",GCST011879,3:80219886
rs10740455-<b>A</b>,"7 x 10-6",,0.08,'-,'-,[NR],LRMDA,"Methotrexate phramacokinetics (acute lymphoblastic leukemia)","response to antineoplastic agent",GCST000523,10:76151274
rs564816-<b>C</b>,"3 x 10-7",,0.04,'-,'-,[NR],GLIS3,"Methotrexate phramacokinetics (acute lymphoblastic leukemia)","response to antineoplastic agent",GCST000523,9:4015370
rs2479768-<b>G</b>,"6 x 10-6",,0.03,'-,'-,[NR],MTUS2,"Methotrexate phramacokinetics (acute lymphoblastic leukemia)","response to antineoplastic agent",GCST000523,13:29046517
rs16923647-<b>T</b>,"2 x 10-6",,0.1,'-,'-,[NR],SLCO1A2,"Methotrexate phramacokinetics (acute lymphoblastic leukemia)","response to antineoplastic agent",GCST000523,12:21298461
rs11045818-<b>G</b>,"7 x 10-7",,0.14,'-,"9.3 mL/min/m2 decrease",[5.7-12.9],SLCO1B1,"Methotrexate phramacokinetics (acute lymphoblastic leukemia)","response to antineoplastic agent",GCST000523,12:21176827
rs10841753-<b>T</b>,"7 x 10-6",,0.19,'-,"7.1 mL/min/m2 decrease",[4.0-10.2],SLCO1B1,"Methotrexate phramacokinetics (acute lymphoblastic leukemia)","response to antineoplastic agent",GCST000523,12:21168436
rs11045879-<b>T</b>,"8 x 10-11",,0.16,'-,"1.8 mL/min/m2 increase",[7.6-14.0],SLCO1B1,"Methotrexate phramacokinetics (acute lymphoblastic leukemia)","response to antineoplastic agent",GCST000523,12:21229685
rs495524-<b>T</b>,"2 x 10-6",,0.42,'-,'-,[NR],METTL11B,"Methotrexate phramacokinetics (acute lymphoblastic leukemia)","response to antineoplastic agent",GCST000523,1:170159467
rs7523455-<b>A</b>,"2 x 10-7",,0.19,'-,'-,[NR],"UBR4, IFFO2","Methotrexate phramacokinetics (acute lymphoblastic leukemia)","response to antineoplastic agent",GCST000523,1:19005582
rs16862426-<b>C</b>,"9 x 10-8",,0.03,'-,'-,[NR],"IFFO2, UBR4","Methotrexate phramacokinetics (acute lymphoblastic leukemia)","response to antineoplastic agent",GCST000523,1:18995001
rs4387258-<b>G</b>,"4 x 10-6",,0.14,'-,'-,[NR],LYZL1,"Methotrexate phramacokinetics (acute lymphoblastic leukemia)","response to antineoplastic agent",GCST000523,10:29198436
rs4129601-<b>G</b>,"2 x 10-6",,0.03,'-,'-,[NR],'-,"Methotrexate phramacokinetics (acute lymphoblastic leukemia)","response to antineoplastic agent",GCST000523,11:42852452
rs7312122-<b>G</b>,"9 x 10-6",,0.16,'-,'-,[NR],RPH3A,"Methotrexate phramacokinetics (acute lymphoblastic leukemia)","response to antineoplastic agent",GCST000523,12:112721033
rs276000-<b>C</b>,"7 x 10-7",,0.02,'-,'-,[NR],"LINC02448, RNU6-871P","Methotrexate phramacokinetics (acute lymphoblastic leukemia)","response to antineoplastic agent",GCST000523,12:59455896
rs16951021-<b>T</b>,"3 x 10-7",,0.01,'-,'-,[NR],CASC22,"Methotrexate phramacokinetics (acute lymphoblastic leukemia)","response to antineoplastic agent",GCST000523,16:52288064
rs16842994-<b>C</b>,"2 x 10-6",,0.02,'-,'-,[NR],'-,"Methotrexate phramacokinetics (acute lymphoblastic leukemia)","response to antineoplastic agent",GCST000523,2:139869162
rs6543610-<b>C</b>,"1 x 10-7",,0.02,'-,'-,[NR],GALNT14,"Methotrexate phramacokinetics (acute lymphoblastic leukemia)","response to antineoplastic agent",GCST000523,2:31153788
rs7742587-<b>C</b>,"3 x 10-7",,0.02,'-,'-,[NR],"RPS3AP23, RN7SKP106","Methotrexate phramacokinetics (acute lymphoblastic leukemia)","response to antineoplastic agent",GCST000523,6:141535997
rs6570465-<b>C</b>,"4 x 10-7",,0.02,'-,'-,[NR],"RN7SKP106, MTHFD1L","Methotrexate phramacokinetics (acute lymphoblastic leukemia)","response to antineoplastic agent",GCST000523,6:141535457
rs4145130-<b>A</b>,"1 x 10-7",,0.06,'-,'-,[NR],'-,"Methotrexate phramacokinetics (acute lymphoblastic leukemia)","response to antineoplastic agent",GCST000523,6:94712900
rs16904316-<b>C</b>,"2 x 10-6",,0.03,'-,'-,[NR],'-,"Methotrexate phramacokinetics (acute lymphoblastic leukemia)","response to antineoplastic agent",GCST000523,8:130605604
rs4925540-<b>?</b>,"2 x 10-6",,NR,'-,'-,'-,"ZNF670, ZNF670-ZNF695","Response to taxane treatment (docetaxel)","response to antineoplastic agent",GCST001692,1:247051576
rs17624523-<b>?</b>,"8 x 10-6",,NR,'-,'-,'-,LINC01102,"Response to taxane treatment (docetaxel)","response to antineoplastic agent",GCST001692,2:104542180
rs6790433-<b>?</b>,"1 x 10-6",,NR,'-,'-,'-,SLC6A6,"Response to taxane treatment (docetaxel)","response to antineoplastic agent",GCST001692,3:14439270
rs11748684-<b>?</b>,"3 x 10-6",,NR,'-,'-,'-,'-,"Response to taxane treatment (docetaxel)","response to antineoplastic agent",GCST001692,5:42288491
rs258671-<b>?</b>,"1 x 10-6",,NR,'-,'-,'-,CACNA2D1,"Response to taxane treatment (docetaxel)","response to antineoplastic agent",GCST001692,7:82102130
rs1412259-<b>?</b>,"4 x 10-6",,NR,'-,'-,'-,'-,"Response to taxane treatment (docetaxel)","response to antineoplastic agent",GCST001692,9:1456797
rs923175-<b>?</b>,"7 x 10-6",,NR,'-,'-,'-,LINC02547,"Response to taxane treatment (docetaxel)","response to antineoplastic agent",GCST001692,11:12050956
rs2130017-<b>?</b>,"8 x 10-6",,NR,'-,'-,'-,"TRIM64DP, UBTFL2","Response to taxane treatment (docetaxel)","response to antineoplastic agent",GCST001692,11:89769208
rs2586502-<b>?</b>,"1 x 10-6",,NR,'-,'-,'-,"SUMO2P7, COL1A1","Response to taxane treatment (docetaxel)","response to antineoplastic agent",GCST001692,17:50211709
rs12954803-<b>?</b>,"8 x 10-6",,NR,'-,'-,'-,LINC01915,"Response to taxane treatment (docetaxel)","response to antineoplastic agent",GCST001692,18:24556605
rs1944582-<b>?</b>,"4 x 10-6",,NR,'-,'-,'-,ZBTB7C,"Response to taxane treatment (docetaxel)","response to antineoplastic agent",GCST001692,18:48289046
rs11668609-<b>?</b>,"3 x 10-6",,NR,'-,'-,'-,ZNF254,"Response to taxane treatment (docetaxel)","response to antineoplastic agent",GCST001692,19:24172691
rs10423754-<b>?</b>,"9 x 10-6",,NR,'-,'-,'-,'-,"Response to taxane treatment (docetaxel)","response to antineoplastic agent",GCST001692,"Mapping not available"
rs10874322-<b>?</b>,"2 x 10-6",,NR,'-,'-,'-,'-,"Response to taxane treatment (docetaxel)","response to antineoplastic agent",GCST001692,1:82589116
rs1478912-<b>?</b>,"6 x 10-6",,NR,'-,'-,'-,RYR2,"Response to taxane treatment (docetaxel)","response to antineoplastic agent",GCST001692,1:237457939
rs6044112-<b>?</b>,"7 x 10-7",,NR,'-,'-,'-,KIF16B,"Response to taxane treatment (docetaxel)","response to antineoplastic agent",GCST001692,20:16555769
rs10509373-<b>C</b>,"6 x 10-9",,0.024,4.51,'-,[2.72-7.51],LRMDA,"Response to tamoxifen in breast cancer","response to antineoplastic agent",GCST001357,10:76397814
rs576523-<b>?</b>,"2 x 10-7",,NR,'-,'-,'-,"SLAMF7, LY9","Capecitabine sensitivity","response to antineoplastic agent",GCST001368,1:160776286
rs1249675-<b>?</b>,"7 x 10-6",,NR,'-,'-,'-,SLC44A5,"Capecitabine sensitivity","response to antineoplastic agent",GCST001368,1:75304940
rs6771019-<b>?</b>,"2 x 10-6",,NR,'-,'-,'-,OSBPL11,"Capecitabine sensitivity","response to antineoplastic agent",GCST001368,3:59368432
rs11941399-<b>?</b>,"1 x 10-6",,NR,'-,'-,'-,'-,"Capecitabine sensitivity","response to antineoplastic agent",GCST001368,4:166534341
rs4702484-<b>?</b>,"6 x 10-7",,NR,'-,'-,'-,ADCY2,"Capecitabine sensitivity","response to antineoplastic agent",GCST001368,5:7649747
rs361433-<b>?</b>,"9 x 10-7",,NR,'-,'-,'-,'-,"Capecitabine sensitivity","response to antineoplastic agent",GCST001368,"Mapping not available"
rs2882834-<b>?</b>,"1 x 10-6",,NR,'-,'-,'-,'-,"Capecitabine sensitivity","response to antineoplastic agent",GCST001368,7:10325096
rs6971109-<b>?</b>,"7 x 10-6",,NR,'-,'-,'-,RN7SL542P,"Capecitabine sensitivity","response to antineoplastic agent",GCST001368,7:21183171
rs2863344-<b>?</b>,"2 x 10-6",,NR,'-,'-,'-,PDE4DIP,"Capecitabine sensitivity","response to antineoplastic agent",GCST001368,1:148892307
rs4848143-<b>?</b>,"9 x 10-6",,NR,'-,'-,'-,Y_RNA,"Capecitabine sensitivity","response to antineoplastic agent",GCST001368,2:121054648
rs9824150-<b>?</b>,"7 x 10-6",,NR,'-,'-,'-,LINC01192,"Capecitabine sensitivity","response to antineoplastic agent",GCST001368,3:163116513
rs3106136-<b>?</b>,"7 x 10-6",,NR,'-,'-,'-,SMARCAD1,"Capecitabine sensitivity","response to antineoplastic agent",GCST001368,4:94232198
rs2524276-<b>?</b>,"6 x 10-6",,NR,'-,'-,'-,"MICA, LINC01149","Capecitabine sensitivity","response to antineoplastic agent",GCST001368,6:31440488
rs12198063-<b>?</b>,"8 x 10-6",,NR,'-,'-,'-,LINC02540,"Capecitabine sensitivity","response to antineoplastic agent",GCST001368,6:76581082
rs705469-<b>?</b>,"7 x 10-6",,NR,'-,'-,'-,'-,"Capecitabine sensitivity","response to antineoplastic agent",GCST001368,10:3616727
rs6586111-<b>?</b>,"7 x 10-6",,NR,'-,'-,'-,SH2D4B,"Capecitabine sensitivity","response to antineoplastic agent",GCST001368,10:80617834
rs16932455-<b>?</b>,"2 x 10-6",,NR,'-,'-,'-,SOX6,"Capecitabine sensitivity","response to antineoplastic agent",GCST001368,11:16018629
rs9953852-<b>?</b>,"3 x 10-6",,NR,'-,'-,'-,"GALNT1, INO80C","Capecitabine sensitivity","response to antineoplastic agent",GCST001368,18:35517996
rs4702484-<b>?</b>,"5 x 10-8",(EA),NR,'-,'-,'-,ADCY2,"Capecitabine sensitivity","response to antineoplastic agent",GCST001368,5:7649747
rs705471-<b>?</b>,"7 x 10-6",,NR,'-,'-,'-,'-,"Capecitabine sensitivity","response to antineoplastic agent",GCST001368,10:3625534
rs6490525-<b>?</b>,"4 x 10-6",,NR,'-,'-,'-,"GJA3, PPIAP28","Capecitabine sensitivity","response to antineoplastic agent",GCST001368,13:20162077
rs8101143-<b>?</b>,"2 x 10-7",,NR,'-,'-,'-,"ZNF100, BRI3BPP1","Capecitabine sensitivity","response to antineoplastic agent",GCST001368,19:21773334
rs438034-<b>T</b>,"5 x 10-6",,NR,1.88,'-,[1.44-2.46],CENPF,"Response to antineoplastic agents","response to antineoplastic agent",GCST001095,1:214657274
rs2793086-<b>C</b>,"9 x 10-6",,NR,3.01,'-,[1.51-6.01],"TSNAX-DISC1, DISC1","Response to antineoplastic agents","response to antineoplastic agent",GCST001095,1:231763958
rs6785504-<b>T</b>,"7 x 10-6",,NR,2.11,'-,[1.51-2.94],'-,"Response to antineoplastic agents","response to antineoplastic agent",GCST001095,3:152954990
rs9883654-<b>T</b>,"2 x 10-6",,NR,2.2,'-,[1.57-3.08],HMGN2P13,"Response to antineoplastic agents","response to antineoplastic agent",GCST001095,3:153004186
rs1949733-<b>A</b>,"8 x 10-7",,NR,2.36,'-,[1.60-3.47],"GPR78, TRMT44","Response to antineoplastic agents","response to antineoplastic agent",GCST001095,4:8501632
rs10958369-<b>?</b>,"2 x 10-6",,NR,2.33,'-,[1.64-3.33],MAPK6P1,"Response to antineoplastic agents","response to antineoplastic agent",GCST001095,8:53497648
rs1342899-<b>?</b>,"8 x 10-7",,NR,3.13,'-,[1.85-5.26],CYLC2,"Response to antineoplastic agents","response to antineoplastic agent",GCST001095,9:102972913
rs1168987-<b>A</b>,"5 x 10-6",,NR,2.27,'-,[0.31-0.63],BRMS1L,"Response to antineoplastic agents","response to antineoplastic agent",GCST001095,14:35928474
rs11158493-<b>?</b>,"9 x 10-7",,NR,2,'-,[1.56-2.56],PPP2R5E,"Response to antineoplastic agents","response to antineoplastic agent",GCST001095,14:63486804
rs17047200-<b>T</b>,"3 x 10-8",,'-,2.37,'-,[1.74-3.23],TLL1,"Hepatocellular carcinoma in post hepatitis C eradication by interferon therapy","response to interferon, hepatocellular carcinoma, virologic response measurement",GCST004160,4:166008836
rs9833158-<b>?</b>,"1 x 10-6",,'-,1.6393442,'-,[1.35-2.04],"CDYLP1, PLCL2","Carbamazepine-induced hyponatremia in epilepsy","carbamazepine-induced hyponatremia, epilepsy, response to carbamazepine",GCST007811,3:16742882
rs57143981-<b>?</b>,"2 x 10-6",,'-,1.98,'-,[1.50-2.62],BTBD11,"Carbamazepine-induced hyponatremia in epilepsy","carbamazepine-induced hyponatremia, epilepsy, response to carbamazepine",GCST007811,12:107644147
rs4817405-<b>?</b>,"2 x 10-6",,'-,1.6129031,'-,[1.33-1.96],"FBXW11P1, TIAM1","Carbamazepine-induced hyponatremia in epilepsy","carbamazepine-induced hyponatremia, epilepsy, response to carbamazepine",GCST007811,21:31562069
rs11817796-<b>?</b>,"4 x 10-6",,'-,1.74,'-,[1.37-2.19],'-,"Carbamazepine-induced hyponatremia in epilepsy","carbamazepine-induced hyponatremia, epilepsy, response to carbamazepine",GCST007811,10:56719055
rs35648408-<b>?</b>,"4 x 10-6",,'-,1.7857143,'-,[1.39-2.27],RUNDC3B,"Carbamazepine-induced hyponatremia in epilepsy","carbamazepine-induced hyponatremia, epilepsy, response to carbamazepine",GCST007811,7:87761845
rs12743242-<b>?</b>,"6 x 10-6",,'-,1.68,'-,[1.34-2.11],LINC01141,"Carbamazepine-induced hyponatremia in epilepsy","carbamazepine-induced hyponatremia, epilepsy, response to carbamazepine",GCST007811,1:20408608
rs6033092-<b>?</b>,"7 x 10-6",,'-,1.55,'-,[1.28-1.87],RPS11P1,"Carbamazepine-induced hyponatremia in epilepsy","carbamazepine-induced hyponatremia, epilepsy, response to carbamazepine",GCST007811,20:11292509
rs822127-<b>A</b>,"7 x 10-6",(EA),0.37,'-,"0.6 mmHg decrease",[NR],PLCXD3,"Diastolic blood pressure response to hydrochlorothiazide in hypertension","response to hydrochlorothiazide, diastolic blood pressure change measurement, hypertension",GCST003805,5:41546857
rs9370524-<b>A</b>,"9 x 10-6",(EA),0.36,'-,"0.58 mmHg increase",[NR],COL21A1,"Diastolic blood pressure response to hydrochlorothiazide in hypertension","response to hydrochlorothiazide, diastolic blood pressure change measurement, hypertension",GCST003805,6:56354955
rs10951933-<b>T</b>,"3 x 10-6",(EA),0.2,'-,"0.75 mmHg increase",[NR],PKD1L1,"Diastolic blood pressure response to hydrochlorothiazide in hypertension","response to hydrochlorothiazide, diastolic blood pressure change measurement, hypertension",GCST003805,7:47867616
rs2198596-<b>C</b>,"8 x 10-7",(EA),0.91,'-,"1.3 mmHg decrease",[NR],SGCZ,"Diastolic blood pressure response to hydrochlorothiazide in hypertension","response to hydrochlorothiazide, diastolic blood pressure change measurement, hypertension",GCST003805,8:15143257
rs11784910-<b>A</b>,"4 x 10-7",(EA),0.95,'-,"1.48 mmHg increase",[NR],ZDHHC2,"Diastolic blood pressure response to hydrochlorothiazide in hypertension","response to hydrochlorothiazide, diastolic blood pressure change measurement, hypertension",GCST003805,8:17217746
rs17755650-<b>T</b>,"6 x 10-6",(EA),0.9,'-,"1.17 mmHg increase",[NR],"RN7SL151P, MTAP","Diastolic blood pressure response to hydrochlorothiazide in hypertension","response to hydrochlorothiazide, diastolic blood pressure change measurement, hypertension",GCST003805,9:21780038
rs177848-<b>A</b>,"6 x 10-6",(EA),0.59,'-,"0.6 mmHg decrease",[NR],TTC6,"Diastolic blood pressure response to hydrochlorothiazide in hypertension","response to hydrochlorothiazide, diastolic blood pressure change measurement, hypertension",GCST003805,14:37634801
rs11657217-<b>C</b>,"5 x 10-6",(EA),0.69,'-,"0.7 mmHg decrease",[NR],ENPP7,"Diastolic blood pressure response to hydrochlorothiazide in hypertension","response to hydrochlorothiazide, diastolic blood pressure change measurement, hypertension",GCST003805,17:79735540
rs7565329-<b>T</b>,"7 x 10-6",(EA),0.09,'-,"1.7 mmHg decrease",[NR],LINC01812,"Systolic blood pressure response to hydrochlorothiazide in hypertension","response to hydrochlorothiazide, hypertension, systolic blood pressure change measurement",GCST003807,2:67878704
rs12642634-<b>A</b>,"5 x 10-6",(EA),0.78,'-,"1.1 mmHg increase",[NR],LINC01095,"Systolic blood pressure response to hydrochlorothiazide in hypertension","response to hydrochlorothiazide, hypertension, systolic blood pressure change measurement",GCST003807,4:146064475
rs11750990-<b>A</b>,"8 x 10-6",(EA),0.96,'-,"2.44 mmHg increase",[NR],"RNU2-8P, SLC25A5P7","Systolic blood pressure response to hydrochlorothiazide in hypertension","response to hydrochlorothiazide, hypertension, systolic blood pressure change measurement",GCST003807,6:121614456
rs2876449-<b>T</b>,"7 x 10-6",(EA),0.03,'-,"2.8 mmHg decrease",[NR],"MIR4465, RPS3AP24","Systolic blood pressure response to hydrochlorothiazide in hypertension","response to hydrochlorothiazide, hypertension, systolic blood pressure change measurement",GCST003807,6:140736804
rs11784910-<b>A</b>,"4 x 10-7",(EA),0.95,'-,"2.31 mmHg increase",[NR],ZDHHC2,"Systolic blood pressure response to hydrochlorothiazide in hypertension","response to hydrochlorothiazide, hypertension, systolic blood pressure change measurement",GCST003807,8:17217746
rs2925663-<b>T</b>,"7 x 10-6",(EA),0.12,'-,"1.4 mmHg decrease",[NR],UBXN2B,"Systolic blood pressure response to hydrochlorothiazide in hypertension","response to hydrochlorothiazide, hypertension, systolic blood pressure change measurement",GCST003807,8:58349310
rs13253998-<b>T</b>,"7 x 10-6",(EA),0.51,'-,"0.9 mmHg decrease",[NR],'-,"Systolic blood pressure response to hydrochlorothiazide in hypertension","response to hydrochlorothiazide, hypertension, systolic blood pressure change measurement",GCST003807,8:77622326
rs7960884-<b>A</b>,"4 x 10-6",(EA),0.27,'-,"1.09 mmHg increase",[NR],MREGP1,"Systolic blood pressure response to hydrochlorothiazide in hypertension","response to hydrochlorothiazide, hypertension, systolic blood pressure change measurement",GCST003807,12:31207706
rs16962897-<b>A</b>,"3 x 10-7",(EA),0.12,'-,"1.7 mmHg decrease",[NR],DNAAF1,"Systolic blood pressure response to hydrochlorothiazide in hypertension","response to hydrochlorothiazide, hypertension, systolic blood pressure change measurement",GCST003807,16:84175474
rs4150161-<b>T</b>,"1 x 10-6",(EA),0.86,'-,"1.53 mmHg increase",[NR],TAF1C,"Systolic blood pressure response to hydrochlorothiazide in hypertension","response to hydrochlorothiazide, hypertension, systolic blood pressure change measurement",GCST003807,16:84180630
rs17137701-<b>?</b>,"6 x 10-8",,NR,'-,'-,'-,"CTNNA1P1, CCDC112","Response to tenofovir alafenamide (body weight gain)","response to tenofovir, body weight gain",GCST011959,5:115379792
rs76794506-<b>?</b>,"9 x 10-8",,NR,'-,'-,'-,LINC01515,"Response to tenofovir alafenamide (body weight gain)","response to tenofovir, body weight gain",GCST011959,10:65557138
rs76771105-<b>?</b>,"1 x 10-7",,NR,'-,'-,'-,PIPOX,"Response to tenofovir disoproxil fumarate (body weight gain)","response to tenofovir, body weight gain",GCST011958,17:29015034
rs140142800-<b>?</b>,"6 x 10-8",(adalimumab),'-,'-,"0.79 unit decrease",[0.5-1.08],LINC00845,"Response to TNF inhibitor in rheumatoid arthritis (erythrocyte sedimentation rate)","rheumatoid arthritis, response to TNF antagonist, blood sedimentation",GCST006607,10:61036479
rs150537045-<b>?</b>,"2 x 10-8","(All TNF inhibitors combined)",'-,'-,"0.5 unit decrease",[0.32-0.68],CSMD3,"Response to TNF inhibitor in rheumatoid arthritis (change in swollen 28-joint count)","rheumatoid arthritis, response to TNF antagonist, joint damage measurement",GCST006606,8:113394871
rs140825531-<b>?</b>,"6 x 10-10",(Infliximab),'-,'-,"1.44 unit decrease",[0.99-1.89],RAD51B,"Response to TNF inhibitor in rheumatoid arthritis (change in swollen 28-joint count)","rheumatoid arthritis, response to TNF antagonist, joint damage measurement",GCST006606,14:68021957
rs10097964-<b>?</b>,"4 x 10-8",(Infliximab),'-,'-,"1.28 unit decrease",[0.83-1.73],'-,"Response to TNF inhibitor in rheumatoid arthritis (change in swollen 28-joint count)","rheumatoid arthritis, response to TNF antagonist, joint damage measurement",GCST006606,8:21125392
rs114456288-<b>?</b>,"5 x 10-8",(Infliximab),'-,'-,"1.1 unit decrease",[0.71-1.49],"LINC02070, RN7SKP284","Response to TNF inhibitor in rheumatoid arthritis (change in swollen 28-joint count)","rheumatoid arthritis, response to TNF antagonist, joint damage measurement",GCST006606,3:86448244
rs76668869-<b>?</b>,"2 x 10-11",(Etanercept),'-,'-,"0.75 unit decrease",[0.53-0.97],"LINC01781, HNRNPA1P64","Response to TNF inhibitor in rheumatoid arthritis (change in swollen 28-joint count)","rheumatoid arthritis, response to TNF antagonist, joint damage measurement",GCST006606,1:80513736
rs78078856-<b>?</b>,"2 x 10-8",(Etanercept),'-,'-,"0.91 unit decrease",[0.6-1.22],"CENPUP1, FAR1","Response to TNF inhibitor in rheumatoid arthritis (change in swollen 28-joint count)","rheumatoid arthritis, response to TNF antagonist, joint damage measurement",GCST006606,11:13737245
rs2295463-<b>?</b>,"3 x 10-8",(Adalimumab),'-,'-,"0.84 unit decrease",[0.55-1.13],PRORP,"Response to TNF inhibitor in rheumatoid arthritis (change in swollen 28-joint count)","rheumatoid arthritis, response to TNF antagonist, joint damage measurement",GCST006606,14:35267067
rs117214796-<b>?</b>,"4 x 10-8",(Adalimumab),'-,'-,"0.86 unit decrease",[0.55-1.17],DLG2,"Response to TNF inhibitor in rheumatoid arthritis (change in swollen 28-joint count)","rheumatoid arthritis, response to TNF antagonist, joint damage measurement",GCST006606,11:85160633
rs74807419-<b>?</b>,"6 x 10-8",(Adalimumab),'-,'-,"0.66 unit decrease",[0.42-0.9],NEBL,"Response to TNF inhibitor in rheumatoid arthritis (change in swollen 28-joint count)","rheumatoid arthritis, response to TNF antagonist, joint damage measurement",GCST006606,10:21051164
rs34619498-<b>?</b>,"8 x 10-8",(Adalimumab),'-,'-,"0.64 unit decrease",[0.4-0.88],EMCN,"Response to TNF inhibitor in rheumatoid arthritis (change in swollen 28-joint count)","rheumatoid arthritis, response to TNF antagonist, joint damage measurement",GCST006606,4:100505575
rs7195994-<b>?</b>,"1 x 10-8",(Infliximab),'-,'-,"0.48 unit decrease",[0.32-0.64],FTO,"Response to TNF inhibitor in rheumatoid arthritis (change in swollen 28-joint count)","rheumatoid arthritis, response to TNF antagonist, joint damage measurement",GCST006606,16:54026293
rs10739537-<b>?</b>,"9 x 10-8",(Adalimumab),'-,'-,"0.21 unit decrease",[0.13-0.29],BRINP1,"Response to TNF inhibitor in rheumatoid arthritis (change in swollen 28-joint count)","rheumatoid arthritis, response to TNF antagonist, joint damage measurement",GCST006606,9:119426326
rs150537045-<b>?</b>,"8 x 10-6",(Adalimumab),'-,'-,"0.56 unit decrease",[NR],CSMD3,"Response to TNF inhibitor in rheumatoid arthritis (change in swollen 28-joint count)","rheumatoid arthritis, response to TNF antagonist, joint damage measurement",GCST006606,8:113394871
rs948138-<b>?</b>,"8 x 10-8",(Etanercept),'-,'-,"0.25 unit increase",[-0.24-0.74],"MMP20, MMP27","Response to TNF inhibitor in rheumatoid arthritis (change in patient global heath assessment score)","rheumatoid arthritis, self rated health, response to TNF antagonist",GCST006608,11:102630934
rs78368496-<b>?</b>,"4 x 10-8",(Etanercept),'-,'-,"0.69 unit decrease",[0.44-0.94],NAV2,"Response to TNF inhibitor in rheumatoid arthritis (change in tender 28-joint count)","rheumatoid arthritis, response to TNF antagonist, joint damage measurement",GCST006609,11:19962783
rs147859879-<b>?</b>,"4 x 10-9",(Adalimumab),'-,'-,"0.1 unit decrease",[-0.2332-0.4332],"MRPL36, MIR4277","Response to TNF inhibitor in rheumatoid arthritis (change in tender 28-joint count)","rheumatoid arthritis, response to TNF antagonist, joint damage measurement",GCST006609,5:1729673
rs337527-<b>?</b>,"7 x 10-8",(Adalimumab),'-,'-,"0.98 unit decrease",[0.63-1.33],GABBR2,"Response to TNF inhibitor in rheumatoid arthritis (change in tender 28-joint count)","rheumatoid arthritis, response to TNF antagonist, joint damage measurement",GCST006609,9:98685681
rs11599217-<b>?</b>,"7 x 10-8",(Infliximab),'-,'-,"0.29 unit decrease",[0.19-0.39],"DOCK1, C10orf90","Response to TNF inhibitor in rheumatoid arthritis (change in tender 28-joint count)","rheumatoid arthritis, response to TNF antagonist, joint damage measurement",GCST006609,10:126878395
rs2187874-<b>?</b>,"7 x 10-8","(All TNF inhibitors combined)",'-,'-,"0.19 unit decrease",[0.11-0.27],ZNF595,"Response to TNF inhibitor in rheumatoid arthritis (change in tender 28-joint count)","rheumatoid arthritis, response to TNF antagonist, joint damage measurement",GCST006609,4:82429
rs76668869-<b>?</b>,"8 x 10-6",(Etanercept),'-,'-,"0.61 unit decrease",[NR],"LINC01781, HNRNPA1P64","Response to TNF inhibitor in rheumatoid arthritis (change in tender 28-joint count)","rheumatoid arthritis, response to TNF antagonist, joint damage measurement",GCST006609,1:80513736
rs78078856-<b>?</b>,"7 x 10-6",(Etanercept),'-,'-,"0.9 unit decrease",[NR],"CENPUP1, FAR1","Response to TNF inhibitor in rheumatoid arthritis (change in tender 28-joint count)","rheumatoid arthritis, response to TNF antagonist, joint damage measurement",GCST006609,11:13737245
rs11599217-<b>?</b>,"5 x 10-6",,'-,'-,"0.29 unit decrease",[NR],"DOCK1, C10orf90","Response to TNF inhibitor in rheumatoid arthritis (change in disease activity score)","rheumatoid arthritis, response to TNF antagonist, arthritis disease activity score measurement",GCST006610,10:126878395
rs9828223-<b>A</b>,"2 x 10-9",,0.10,15.87,'-,[4.38-57.49],CD96,"Anti-adalimumab antibody production in response to treatment in Crohn's disease","response to TNF antagonist, Crohn's disease",GCST008271,3:111506078
rs7528419-<b>G</b>,"8 x 10-9",,0.17701,'-,"0.4227 unit decrease",[-0.5965-1.4419],CELSR2,"Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease","response to darapladib, acute coronary syndrome, lipoprotein-associated phospholipase A(2) change measurement, coronary artery disease",GCST004966,1:109274570
rs76863441-<b>A</b>,"8 x 10-47",,0.01019,'-,"0.2355 unit decrease",[-4.3313-4.8023],PLA2G7,"Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease","response to darapladib, acute coronary syndrome, lipoprotein-associated phospholipase A(2) change measurement, coronary artery disease",GCST004966,6:46709361
rs7412-<b>T</b>,"2 x 10-27",,0.06071,'-,"0.04 unit decrease",[-1.5672-1.6472],APOE,"Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease","response to darapladib, acute coronary syndrome, lipoprotein-associated phospholipase A(2) change measurement, coronary artery disease",GCST004966,19:44908822
rs201052613-<b>?</b>,"4 x 10-9",,0.012,3.21,'-,[2.17-4.76],TNFSF18,"Myocardial infarction in darapladib-treated cardiovascular disease (time to event)","response to darapladib, acute coronary syndrome, myocardial infarction, coronary artery disease",GCST004964,1:173026503
rs117714106-<b>T</b>,"5 x 10-10",,0.007,3.79,'-,[2.5-5.88],'-,"Myocardial infarction in darapladib-treated cardiovascular disease (time to event)","response to darapladib, acute coronary syndrome, myocardial infarction, coronary artery disease",GCST004964,14:84338144
rs138741635-<b>A</b>,"2 x 10-6",,0.019,'-,'-,'-,FHIT,"Major coronary event in cardiovascular disease (time to event) (darapladib treatment interaction)","response to darapladib, acute coronary syndrome, cardiovascular event measurement, coronary artery disease",GCST004958,3:60942161
rs192427471-<b>T</b>,"2 x 10-6",,0.024,'-,'-,'-,"ANKRD50, LINC02516","Major coronary event in cardiovascular disease (time to event) (darapladib treatment interaction)","response to darapladib, acute coronary syndrome, cardiovascular event measurement, coronary artery disease",GCST004958,4:124644124
rs181937009-<b>G</b>,"1 x 10-7",,0.224,'-,'-,'-,RNA5SP220,"Major coronary event in cardiovascular disease (time to event) (darapladib treatment interaction)","response to darapladib, acute coronary syndrome, cardiovascular event measurement, coronary artery disease",GCST004958,6:140064258
rs12290663-<b>A</b>,"4 x 10-6",,0.013,'-,'-,'-,ANO3,"Major coronary event in cardiovascular disease (time to event) (darapladib treatment interaction)","response to darapladib, acute coronary syndrome, cardiovascular event measurement, coronary artery disease",GCST004958,11:26141193
rs147204125-<b>G</b>,"2 x 10-6",,0.008,'-,'-,'-,"ACOT4, ACOT6","Major coronary event in cardiovascular disease (time to event) (darapladib treatment interaction)","response to darapladib, acute coronary syndrome, cardiovascular event measurement, coronary artery disease",GCST004958,14:73609035
rs192427471-<b>T</b>,"6 x 10-9",,0.024,2.04,'-,[1.61-2.56],"ANKRD50, LINC02516","Major coronary event in darapladib-treated cardiovascular disease (time to event)","response to darapladib, acute coronary syndrome, cardiovascular event measurement, coronary artery disease",GCST004957,4:124644124
rs12290663-<b>A</b>,"3 x 10-8",,0.013,2.11,'-,[1.61-2.78],ANO3,"Major coronary event in darapladib-treated cardiovascular disease (time to event)","response to darapladib, acute coronary syndrome, cardiovascular event measurement, coronary artery disease",GCST004957,11:26141193
rs117714106-<b>T</b>,"2 x 10-6",,0.007,'-,'-,'-,'-,"Myocardial infarction in cardiovascular disease (time to event) (darapladib treatment interaction)","response to darapladib, acute coronary syndrome, myocardial infarction, coronary artery disease",GCST004959,14:84338144
rs201933111-<b>?</b>,"1 x 10-6",,NR,'-,"1.4628 unit decrease",[0.92-2.00],"GNE, CLTA","Frequency of relapse in mepolizumab-treated eosinophilic granulomatosis with polyangiitis","Churg-Strauss syndrome, response to mepolizumab, disease progression measurement",GCST009999,9:36231131
rs8057024-<b>?</b>,"3 x 10-6",,NR,'-,"1.4127 unit decrease",[0.83-1.99],PMM2,"Frequency of relapse in mepolizumab-treated eosinophilic granulomatosis with polyangiitis","Churg-Strauss syndrome, response to mepolizumab, disease progression measurement",GCST009999,16:8814954
rs60731826-<b>?</b>,"9 x 10-6",,NR,'-,"0.9781 unit decrease",[0.58-1.37],KLHL20,"Average oral glucocorticoid dose in mepolizumab-treated eosinophilic granulomatosis with polyangiitis","Churg-Strauss syndrome, response to mepolizumab, Glucocorticoid use measurement",GCST009998,1:209087883
rs6748896-<b>?</b>,"5 x 10-6",,NR,'-,"1.0261 unit decrease",[0.63-1.42],'-,"Average oral glucocorticoid dose in mepolizumab-treated eosinophilic granulomatosis with polyangiitis","Churg-Strauss syndrome, response to mepolizumab, Glucocorticoid use measurement",GCST009998,2:220159818
rs138754151-<b>?</b>,"5 x 10-6",,NR,'-,"1.2345 unit decrease",[0.75-1.71],"GAPDHP50, ICE2P2","Average oral glucocorticoid dose in mepolizumab-treated eosinophilic granulomatosis with polyangiitis","Churg-Strauss syndrome, response to mepolizumab, Glucocorticoid use measurement",GCST009998,3:89032462
rs71648192-<b>?</b>,"4 x 10-6",,NR,'-,"1.0477 unit increase",[0.65-1.45],"C1QTNF7-AS1, CPEB2","Average oral glucocorticoid dose in mepolizumab-treated eosinophilic granulomatosis with polyangiitis","Churg-Strauss syndrome, response to mepolizumab, Glucocorticoid use measurement",GCST009998,4:15035212
rs58722526-<b>?</b>,"6 x 10-6",,NR,'-,"1.1664 unit decrease",[0.71-1.63],MCUB,"Average oral glucocorticoid dose in mepolizumab-treated eosinophilic granulomatosis with polyangiitis","Churg-Strauss syndrome, response to mepolizumab, Glucocorticoid use measurement",GCST009998,4:109648695
rs13176353-<b>?</b>,"6 x 10-6",,NR,'-,"1.0022 unit increase",[0.61-1.4],MRPL36,"Average oral glucocorticoid dose in mepolizumab-treated eosinophilic granulomatosis with polyangiitis","Churg-Strauss syndrome, response to mepolizumab, Glucocorticoid use measurement",GCST009998,5:1801312
rs5877241-<b>?</b>,"2 x 10-6",,NR,'-,"0.8202 unit increase",[0.51-1.13],COL19A1,"Average oral glucocorticoid dose in mepolizumab-treated eosinophilic granulomatosis with polyangiitis","Churg-Strauss syndrome, response to mepolizumab, Glucocorticoid use measurement",GCST009998,6:70148926
rs79825511-<b>?</b>,"5 x 10-6",,NR,'-,"1.5068 unit decrease",[0.92-2.09],FGF19,"Average oral glucocorticoid dose in mepolizumab-treated eosinophilic granulomatosis with polyangiitis","Churg-Strauss syndrome, response to mepolizumab, Glucocorticoid use measurement",GCST009998,11:69700928
rs3018529-<b>?</b>,"4 x 10-6",,NR,'-,"0.7885 unit decrease",[0.48-1.09],"OR10D3, OR8F1P","Average oral glucocorticoid dose in mepolizumab-treated eosinophilic granulomatosis with polyangiitis","Churg-Strauss syndrome, response to mepolizumab, Glucocorticoid use measurement",GCST009998,11:124205080
rs3782788-<b>?</b>,"9 x 10-6",,NR,'-,"0.8059 unit increase",[0.48-1.13],TSPAN9,"Average oral glucocorticoid dose in mepolizumab-treated eosinophilic granulomatosis with polyangiitis","Churg-Strauss syndrome, response to mepolizumab, Glucocorticoid use measurement",GCST009998,12:3248826
rs670142-<b>?</b>,"2 x 10-6",,NR,'-,"0.8528 unit increase",[0.54-1.17],KRT73-AS1,"Average oral glucocorticoid dose in mepolizumab-treated eosinophilic granulomatosis with polyangiitis","Churg-Strauss syndrome, response to mepolizumab, Glucocorticoid use measurement",GCST009998,12:52607203
rs12971298-<b>?</b>,"7 x 10-6",,NR,'-,"1.0665 unit increase",[0.65-1.49],"IGFL1P2, HIF3A","Average oral glucocorticoid dose in mepolizumab-treated eosinophilic granulomatosis with polyangiitis","Churg-Strauss syndrome, response to mepolizumab, Glucocorticoid use measurement",GCST009998,19:46272899
rs72751931-<b>?</b>,"4 x 10-7",,NR,'-,"0.9796 unit increase",[0.64-1.32],RHOU,"Accrued duration of remission in mepolizumab-treated eosinophilic granulomatosis with polyangiitis","disease free survival, Churg-Strauss syndrome, response to mepolizumab",GCST010000,1:228751382
rs11681484-<b>?</b>,"3 x 10-6",,NR,'-,"0.763 unit increase",[0.47-1.05],CTNNA2,"Accrued duration of remission in mepolizumab-treated eosinophilic granulomatosis with polyangiitis","disease free survival, Churg-Strauss syndrome, response to mepolizumab",GCST010000,2:79741032
rs9869380-<b>?</b>,"4 x 10-6",,NR,'-,"0.9182 unit increase",[0.57-1.27],"RN7SKP227, NBPF21P","Accrued duration of remission in mepolizumab-treated eosinophilic granulomatosis with polyangiitis","disease free survival, Churg-Strauss syndrome, response to mepolizumab",GCST010000,3:36669806
rs891193-<b>?</b>,"6 x 10-6",,NR,'-,"0.8882 unit increase",[0.54-1.24],'-,"Accrued duration of remission in mepolizumab-treated eosinophilic granulomatosis with polyangiitis","disease free survival, Churg-Strauss syndrome, response to mepolizumab",GCST010000,5:4662408
rs6450419-<b>?</b>,"6 x 10-6",,NR,'-,"0.8618 unit decrease",[0.52-1.2],Y_RNA,"Accrued duration of remission in mepolizumab-treated eosinophilic granulomatosis with polyangiitis","disease free survival, Churg-Strauss syndrome, response to mepolizumab",GCST010000,5:57160768
rs36094591-<b>?</b>,"2 x 10-6",,NR,'-,"0.8653 unit increase",[0.54-1.19],LCP2,"Accrued duration of remission in mepolizumab-treated eosinophilic granulomatosis with polyangiitis","disease free survival, Churg-Strauss syndrome, response to mepolizumab",GCST010000,5:170274013
rs12682188-<b>?</b>,"8 x 10-6",,NR,'-,"0.8264 unit increase",[0.49-1.16],"TUSC3, PPM1AP1","Accrued duration of remission in mepolizumab-treated eosinophilic granulomatosis with polyangiitis","disease free survival, Churg-Strauss syndrome, response to mepolizumab",GCST010000,8:15772149
rs2978233-<b>?</b>,"4 x 10-7",,NR,'-,"0.8597 unit decrease",[0.56-1.16],"LINC01592, C8orf34","Accrued duration of remission in mepolizumab-treated eosinophilic granulomatosis with polyangiitis","disease free survival, Churg-Strauss syndrome, response to mepolizumab",GCST010000,8:68829081
rs2243951-<b>?</b>,"3 x 10-6",,NR,'-,"0.7938 unit decrease",[0.49-1.1],CELF2-DT,"Accrued duration of remission in mepolizumab-treated eosinophilic granulomatosis with polyangiitis","disease free survival, Churg-Strauss syndrome, response to mepolizumab",GCST010000,10:10444248
rs569630056-<b>?</b>,"9 x 10-6",,NR,'-,"0.9931 unit decrease",[0.59-1.4],PWRN1,"Accrued duration of remission in mepolizumab-treated eosinophilic granulomatosis with polyangiitis","disease free survival, Churg-Strauss syndrome, response to mepolizumab",GCST010000,15:24373321
rs7209938-<b>?</b>,"4 x 10-6",,NR,'-,"0.8148 unit increase",[0.5-1.13],HS3ST3A1,"Accrued duration of remission in mepolizumab-treated eosinophilic granulomatosis with polyangiitis","disease free survival, Churg-Strauss syndrome, response to mepolizumab",GCST010000,17:13490565
rs3136644-<b>?</b>,"7 x 10-7",,NR,'-,"1.1388 unit decrease",[0.74-1.54],NFKBIB,"Accrued duration of remission in mepolizumab-treated eosinophilic granulomatosis with polyangiitis","disease free survival, Churg-Strauss syndrome, response to mepolizumab",GCST010000,19:38907991
rs61138008-<b>?</b>,"4 x 10-6",,NR,'-,"1.5243 unit decrease",[0.94-2.11],"AVP, RN7SL555P","Accrued duration of remission in mepolizumab-treated eosinophilic granulomatosis with polyangiitis","disease free survival, Churg-Strauss syndrome, response to mepolizumab",GCST010000,20:3086608
rs2076380-<b>?</b>,"8 x 10-6",,NR,'-,"0.9316 unit decrease",[0.56-1.31],TGM2,"Accrued duration of remission in mepolizumab-treated eosinophilic granulomatosis with polyangiitis","disease free survival, Churg-Strauss syndrome, response to mepolizumab",GCST010000,20:38165127
rs7665833-<b>A</b>,"1 x 10-7",,0.14,2.03,'-,[1.78-2.28],"LINC02479, PGBD4P4","Treatment resistant depression","treatment resistant depression, response to antidepressant",GCST007665,4:130459962
rs7735612-<b>C</b>,"6 x 10-7",,0.4,1.63,'-,[1.43-1.83],SLIT3,"Treatment resistant depression","treatment resistant depression, response to antidepressant",GCST007665,5:169082727
rs2898168-<b>?</b>,"2 x 10-6",,0.68,1.6666665,'-,'-,"KRTAP13-1, KRTAP13-3","Treatment resistant depression","treatment resistant depression, response to antidepressant",GCST007665,21:30410284
rs4863995-<b>T</b>,"4 x 10-6",,0.22,1.67,'-,[1.45-1.89],"PGBD4P4, GAPDHP56","Treatment resistant depression","treatment resistant depression, response to antidepressant",GCST007665,4:130496927
rs6852702-<b>A</b>,"4 x 10-6",,0.09,2.07,'-,[1.76-2.38],GAPDHP56,"Treatment resistant depression","treatment resistant depression, response to antidepressant",GCST007665,4:130515632
rs12006913-<b>A</b>,"4 x 10-6",,0.12,2.13,'-,[1.82-2.44],PTCHD1,"Treatment resistant depression","treatment resistant depression, response to antidepressant",GCST007665,X:23358454
rs17382228-<b>?</b>,"2 x 10-6",,NR,'-,"0.044 unit decrease",NR,SORCS2,"Response to antidepressants (symptom improvement)","response to antidepressant",GCST007059,4:7741408
rs6878462-<b>?</b>,"2 x 10-6",,NR,'-,"0.1196 unit decrease",NR,CTNND2,"Response to antidepressants (symptom improvement)","response to antidepressant",GCST007059,5:11198225
rs112687359-<b>?</b>,"5 x 10-6",,NR,'-,"0.068 unit decrease",NR,ADGRE3,"Response to antidepressants (symptom improvement)","response to antidepressant",GCST007059,19:14647800
rs59689479-<b>?</b>,"4 x 10-6",,NR,'-,"0.1674 unit decrease",NR,CSGALNACT1,"Response to antidepressants (symptom improvement)","response to antidepressant",GCST007059,8:19663020
rs61924290-<b>?</b>,"3 x 10-6",,NR,'-,"0.1183 unit decrease",NR,'-,"Response to antidepressants (symptom improvement)","response to antidepressant",GCST007059,12:23388296
rs116692768-<b>?</b>,"2 x 10-6",,NR,'-,"0.1261 unit decrease",NR,ITGA9,"Response to antidepressants (symptom improvement)","response to antidepressant",GCST007059,3:37498991
rs298207-<b>?</b>,"5 x 10-6",,NR,'-,"0.0651 unit increase",NR,"MIR124-2HG, LINC01414","Response to antidepressants (symptom improvement)","response to antidepressant",GCST007059,8:64370040
rs12034885-<b>?</b>,"3 x 10-6",,NR,'-,"0.0401 unit decrease",NR,"RN7SKP19, KRT8P21","Response to antidepressants (symptom improvement)","response to antidepressant",GCST007059,1:73185836
rs56060088-<b>?</b>,"3 x 10-6",,NR,'-,"0.0402 unit decrease",NR,LINC01360,"Response to antidepressants (symptom improvement)","response to antidepressant",GCST007059,1:73429085
rs76191705-<b>?</b>,"2 x 10-6",,NR,'-,"0.1863 unit decrease",NR,NRXN3,"Response to antidepressants (symptom improvement)","response to antidepressant",GCST007059,14:79252119
rs72819868-<b>?</b>,"1 x 10-6",,NR,'-,"0.0974 unit decrease",NR,'-,"Response to antidepressants (symptom improvement)","response to antidepressant",GCST007059,2:81703501
rs11813481-<b>?</b>,"4 x 10-6",,NR,'-,"0.0451 unit increase",NR,"NEURL1, NEURL1-AS1","Response to antidepressants (symptom improvement)","response to antidepressant",GCST007059,10:103515993
rs117379618-<b>?</b>,"2 x 10-6",,NR,'-,"0.1741 unit decrease",NR,"CHIAP3, HIGD1AP12","Response to antidepressants (symptom improvement)","response to antidepressant",GCST007059,1:111371132
rs116503642-<b>?</b>,"5 x 10-6",,NR,'-,"0.1432 unit increase",NR,"TICAM2, FEM1C","Response to antidepressants (symptom improvement)","response to antidepressant",GCST007059,5:115575963
rs3935545-<b>?</b>,"5 x 10-6",,NR,'-,"0.0593 unit decrease",NR,"NOC4L, LINC02361","Response to antidepressants (symptom improvement)","response to antidepressant",GCST007059,12:132181579
rs11167062-<b>?</b>,"3 x 10-6",,NR,'-,"0.0448 unit increase",NR,MROH5,"Response to antidepressants (symptom improvement)","response to antidepressant",GCST007059,8:141448932
rs78940746-<b>?</b>,"3 x 10-6",,NR,'-,"0.1018 unit decrease",NR,"KCNMB3, ZNF639","Response to antidepressants (symptom improvement)","response to antidepressant",GCST007059,3:179321943
rs4658888-<b>?</b>,"4 x 10-6",,NR,'-,"0.0594 unit increase",NR,DISC1,"Response to antidepressants (symptom improvement)","response to antidepressant",GCST007059,1:231869381
rs10784781-<b>?</b>,"4 x 10-6",,NR,1.5360984,'-,NR,"LINC02373, RPS26P45","Response to antidepressants (symptom remission)","response to antidepressant",GCST007061,12:69434256
rs1102156-<b>?</b>,"3 x 10-6",,NR,1.4086,'-,NR,"KCTD15, RN7SL150P","Response to antidepressants (symptom remission)","response to antidepressant",GCST007061,19:33847882
rs11733276-<b>?</b>,"5 x 10-7",,NR,1.61577,'-,NR,LINC01378,"Response to antidepressants (symptom remission)","response to antidepressant",GCST007061,4:117580003
rs17768250-<b>?</b>,"7 x 10-7",,NR,2.1933,'-,NR,ZFAT,"Response to antidepressants (symptom remission)","response to antidepressant",GCST007061,8:134558431
rs35551581-<b>?</b>,"4 x 10-6",,NR,1.600512,'-,NR,"NPBWR1, RB1CC1","Response to antidepressants (symptom remission)","response to antidepressant",GCST007061,8:52844839
rs3849106-<b>?</b>,"3 x 10-6",,NR,1.4394,'-,NR,MYO10,"Response to antidepressants (symptom remission)","response to antidepressant",GCST007061,5:16705806
rs4352485-<b>?</b>,"3 x 10-6",,NR,1.8042,'-,NR,TBC1D1,"Response to antidepressants (symptom remission)","response to antidepressant",GCST007061,4:37975567
rs7420310-<b>?</b>,"4 x 10-6",,NR,1.4220706,'-,NR,"RN7SKP203, USP21P2","Response to antidepressants (symptom remission)","response to antidepressant",GCST007061,2:76356110
rs74442120-<b>?</b>,"2 x 10-6",,NR,3.9588277,'-,NR,MYT1L,"Response to antidepressants (symptom remission)","response to antidepressant",GCST007061,2:2404302
rs7482428-<b>?</b>,"2 x 10-7",,NR,1.440507,'-,NR,"OR51B5, HBG2, HBE1","Response to antidepressants (symptom remission)","response to antidepressant",GCST007061,11:5321196
rs76756809-<b>?</b>,"1 x 10-6",,NR,1.7205782,'-,NR,'-,"Response to antidepressants (symptom remission)","response to antidepressant",GCST007061,16:65917379
SLC22A8-<b>?</b>,"2 x 10-6","(bupropion + escitalopram)",NR,'-,'-,'-,'-,"Response to antidepressants in depression","unipolar depression, response to antidepressant",GCST006817,"Mapping not available"
rs10769025-<b>?</b>,"1 x 10-7","(escitalopram + placebo)",NR,'-,'-,'-,ALX4,"Response to antidepressants in depression","unipolar depression, response to antidepressant",GCST006817,11:44267885
LYPD6B-<b>?</b>,"5 x 10-6","(escitalopram + placebo)",NR,'-,'-,'-,'-,"Response to antidepressants in depression","unipolar depression, response to antidepressant",GCST006817,"Mapping not available"
downstreamRASGEF1B-<b>?</b>,"2 x 10-6","(venlafaxine + mirtazapine)",NR,'-,'-,'-,'-,"Response to antidepressants in depression","unipolar depression, response to antidepressant",GCST006817,"Mapping not available"
PPP5C-<b>?</b>,"5 x 10-6","(venlafaxine + mirtazapine)",NR,'-,'-,'-,'-,"Response to antidepressants in depression","unipolar depression, response to antidepressant",GCST006817,"Mapping not available"
rs190544851-<b>?</b>,"3 x 10-7",,'-,14.29,'-,[3.555-57.454],"ERG, LINC01423","Non-response to antidepressants and depression","unipolar depression, mood disorder, response to antidepressant",GCST003812,21:38360474
rs57043326-<b>?</b>,"8 x 10-7",,'-,2.65252,'-,[1.69-4.17],C6orf99,"Non-response to antidepressants and depression","unipolar depression, mood disorder, response to antidepressant",GCST003812,6:158893901
rs12068879-<b>?</b>,"1 x 10-6",,'-,2.221,'-,[1.667-2.958],KAZN,"Non-response to antidepressants and depression","unipolar depression, mood disorder, response to antidepressant",GCST003812,1:14959860
rs1322281-<b>?</b>,"1 x 10-6",,'-,1.242,'-,[1.139-1.354],PTPRD,"Non-response to antidepressants and depression","unipolar depression, mood disorder, response to antidepressant",GCST003812,9:10582445
rs13418410-<b>?</b>,"2 x 10-6",,'-,1.212,'-,[1.121-1.311],"FAM98A, RASGRP3","Non-response to antidepressants and depression","unipolar depression, mood disorder, response to antidepressant",GCST003812,2:33575832
rs1375194-<b>?</b>,"2 x 10-7",,'-,1.2578616,'-,[1.15-1.37],"ATP6V0E1P3, FAM98A","Response to antidepressants in depression","unipolar depression, mood disorder, response to antidepressant",GCST003803,2:33601810
rs190662943-<b>?</b>,"7 x 10-7",,'-,14.419,'-,[5.177-40.161],DPP10,"Response to antidepressants in depression","unipolar depression, mood disorder, response to antidepressant",GCST003803,2:115195009
rs75507262-<b>?</b>,"1 x 10-6",,'-,2.3255813,'-,[1.69-3.21],"TMEM78, LINC02814","Response to antidepressants in depression","unipolar depression, mood disorder, response to antidepressant",GCST003803,1:229213737
rs10847303-<b>?</b>,"2 x 10-6",,'-,1.242236,'-,[1.14-1.36],LINC02376,"Response to antidepressants in depression","unipolar depression, mood disorder, response to antidepressant",GCST003803,12:127251320
rs73086581-<b>?</b>,"2 x 10-6",,'-,1.299,'-,[1.169-1.444],RNF24,"Response to antidepressants in depression","unipolar depression, mood disorder, response to antidepressant",GCST003803,20:3996678
rs34807503-<b>?</b>,"5 x 10-7",,'-,1.0905125,'-,[1.05-1.13],"SLC4A8, SCN8A","Response to antidepressants and depression","unipolar depression, mood disorder, response to antidepressant",GCST003813,12:51525350
rs2402960-<b>?</b>,"8 x 10-7",,'-,1.098901,'-,[1.06-1.14],"NRF1, MIR182","Response to antidepressants and depression","unipolar depression, mood disorder, response to antidepressant",GCST003813,7:129765934
rs200312707-<b>?</b>,"1 x 10-6",,'-,1.0881393,'-,[1.05-1.13],CDH8,"Response to antidepressants and depression","unipolar depression, mood disorder, response to antidepressant",GCST003813,16:62031776
rs400736-<b>?</b>,"2 x 10-6",,'-,1.0857763,'-,[1.05-1.12],ERRFI1,"Response to antidepressants and depression","unipolar depression, mood disorder, response to antidepressant",GCST003813,1:8018249
rs35265457-<b>?</b>,"2 x 10-6",,'-,1.508,'-,[1.261-1.803],NDC1,"Response to antidepressants and depression","unipolar depression, mood disorder, response to antidepressant",GCST003813,1:53807606
rs1126757-<b>?</b>,"3 x 10-6",(escitalopram),0.48,'-,"10.4 unit increase",[NR],IL11,"Response to antidepressants","response to antidepressant",GCST000643,19:55368504
rs2136093-<b>?</b>,"4 x 10-7","(whole sample)",0.31,'-,"8.3 unit decrease",[NR],'-,"Response to antidepressants","response to antidepressant",GCST000643,1:90410331
rs16920624-<b>?</b>,"7 x 10-7","(whole sample)",0.07,'-,"16 unit decrease",[NR],MIR4675,"Response to antidepressants","response to antidepressant",GCST000643,10:20521596
rs2500535-<b>A</b>,"9 x 10-6","(genotype x drug)",0.06,'-,"29.7 unit decrease",[NR],UST,"Response to antidepressants","response to antidepressant",GCST000643,6:149008131
rs4651156-<b>?</b>,"3 x 10-6",(nortriptyline),0.29,'-,"12.6 unit decrease",[NR],RGL1,"Response to antidepressants","response to antidepressant",GCST000643,1:183867898
rs11666579-<b>?</b>,"3 x 10-6","(genotype x drug)",0.48,'-,"14.4 unit increase",[NR],SLC27A1,"Response to antidepressants","response to antidepressant",GCST000643,19:17479472
rs1013696-<b>?</b>,"4 x 10-6","(genotype x drug)",0.22,'-,"17.8 unit decrease",[NR],"ASXL3, NOL4","Response to antidepressants","response to antidepressant",GCST000643,18:33840046
rs2500535-<b>A</b>,"4 x 10-8",(nortriptyline),0.06,'-,"27 unit decrease",[NR],UST,"Response to antidepressants","response to antidepressant",GCST000643,6:149008131
rs3768939-<b>A</b>,"9 x 10-7",(EA),0.19,'-,"0.35 unit decrease",'-,AGAP1,"Cardiovascular disease in hypertension (calcium channel blocker interaction)","hypertension, cardiovascular disease, response to calcium channel blocker",GCST003205,2:236081413
rs7751419-<b>T</b>,"3 x 10-6",(EA),0.29,'-,"0.26 unit increase",'-,"KCNK5, SAYSD1","Cardiovascular disease in hypertension (calcium channel blocker interaction)","hypertension, cardiovascular disease, response to calcium channel blocker",GCST003205,6:39147637
rs2461451-<b>A</b>,"3 x 10-7",,NR,'-,"7320 unit decrease",'-,"SAP130, AMMECR1L","Antipsychotic drug-induced QTc interval change in schizophrenia","schizophrenia, heart rate variability measurement, response to antipsychotic drug",GCST004987,2:127927687
rs4662592-<b>T</b>,"3 x 10-7",,NR,'-,"8370 unit decrease",'-,"UGGT1, Y_RNA","Antipsychotic drug-induced QTc interval change in schizophrenia","schizophrenia, heart rate variability measurement, response to antipsychotic drug",GCST004987,2:128076730
rs737191-<b>T</b>,"3 x 10-7",,NR,'-,"9050 unit decrease",'-,HS6ST1,"Antipsychotic drug-induced QTc interval change in schizophrenia","schizophrenia, heart rate variability measurement, response to antipsychotic drug",GCST004987,2:128259316
rs7924197-<b>C</b>,"3 x 10-7",,NR,'-,"6160 unit decrease",'-,JAKMIP3,"Antipsychotic drug-induced QTc interval change in schizophrenia","schizophrenia, heart rate variability measurement, response to antipsychotic drug",GCST004987,10:132100221
rs10829461-<b>A</b>,"7 x 10-7",,NR,'-,"1600 unit decrease",'-,'-,"Antipsychotic drug-induced QTc interval change in schizophrenia","schizophrenia, heart rate variability measurement, response to antipsychotic drug",GCST004987,10:128646955
rs12625774-<b>T</b>,"9 x 10-7",,NR,'-,"4550 unit increase",'-,"RBM38, HMGB1P1","Antipsychotic drug-induced QTc interval change in schizophrenia","schizophrenia, heart rate variability measurement, response to antipsychotic drug",GCST004987,20:57412108
rs7793239-<b>C</b>,"9 x 10-7",,NR,'-,"1960 unit increase",'-,CEP41,"Antipsychotic drug-induced QTc interval change in schizophrenia","schizophrenia, heart rate variability measurement, response to antipsychotic drug",GCST004987,7:130394854
rs17454013-<b>A</b>,"2 x 10-6",,NR,'-,"3710 unit decrease",'-,GPR12,"Antipsychotic drug-induced QTc interval change in schizophrenia","schizophrenia, heart rate variability measurement, response to antipsychotic drug",GCST004987,13:26774997
rs7229439-<b>T</b>,"2 x 10-6",,NR,'-,"2660 unit increase",'-,SLC14A2,"Antipsychotic drug-induced QTc interval change in schizophrenia","schizophrenia, heart rate variability measurement, response to antipsychotic drug",GCST004987,18:45380719
rs12039371-<b>C</b>,"2 x 10-6",,NR,'-,"3500 unit decrease",'-,COLGALT2,"Antipsychotic drug-induced QTc interval change in schizophrenia","schizophrenia, heart rate variability measurement, response to antipsychotic drug",GCST004987,1:184016669
rs9425326-<b>C</b>,"2 x 10-6",,NR,'-,"3340 unit decrease",'-,RGL1,"Antipsychotic drug-induced QTc interval change in schizophrenia","schizophrenia, heart rate variability measurement, response to antipsychotic drug",GCST004987,1:183869871
rs1163825-<b>A</b>,"2 x 10-6",,NR,'-,"29700 unit increase",'-,'-,"Antipsychotic drug-induced QTc interval change in schizophrenia","schizophrenia, heart rate variability measurement, response to antipsychotic drug",GCST004987,13:111491360
rs11025109-<b>A</b>,"3 x 10-6",,NR,'-,"2720 unit decrease",'-,"NAV2-IT1, NAV2","Antipsychotic drug-induced QTc interval change in schizophrenia","schizophrenia, heart rate variability measurement, response to antipsychotic drug",GCST004987,11:19383945
rs10105578-<b>A</b>,"3 x 10-6",,NR,'-,"4280 unit decrease",'-,CSMD1,"Antipsychotic drug-induced QTc interval change in schizophrenia","schizophrenia, heart rate variability measurement, response to antipsychotic drug",GCST004987,8:3658097
rs11025120-<b>T</b>,"3 x 10-6",,NR,'-,"3630 unit decrease",'-,NAV2,"Antipsychotic drug-induced QTc interval change in schizophrenia","schizophrenia, heart rate variability measurement, response to antipsychotic drug",GCST004987,11:19403687
rs1423688-<b>G</b>,"3 x 10-6",,NR,'-,"6110 unit decrease",'-,RICTOR,"Antipsychotic drug-induced QTc interval change in schizophrenia","schizophrenia, heart rate variability measurement, response to antipsychotic drug",GCST004987,5:39072514
rs2278326-<b>C</b>,"3 x 10-6",,NR,'-,"6610 unit decrease",'-,OSMR,"Antipsychotic drug-induced QTc interval change in schizophrenia","schizophrenia, heart rate variability measurement, response to antipsychotic drug",GCST004987,5:38881251
rs2914244-<b>T</b>,"3 x 10-6",,NR,'-,"7650 unit decrease",'-,LIFR-AS1,"Antipsychotic drug-induced QTc interval change in schizophrenia","schizophrenia, heart rate variability measurement, response to antipsychotic drug",GCST004987,5:38655151
rs9293983-<b>G</b>,"4 x 10-6",,NR,'-,"6730 unit decrease",'-,'-,"Antipsychotic drug-induced QTc interval change in schizophrenia","schizophrenia, heart rate variability measurement, response to antipsychotic drug",GCST004987,6:74851875
rs4337869-<b>A</b>,"4 x 10-6",,NR,'-,"4990 unit decrease",'-,OSMR-AS1,"Antipsychotic drug-induced QTc interval change in schizophrenia","schizophrenia, heart rate variability measurement, response to antipsychotic drug",GCST004987,5:38728116
rs777948-<b>C</b>,"4 x 10-6",,NR,'-,"3180 unit decrease",'-,'-,"Antipsychotic drug-induced QTc interval change in schizophrenia","schizophrenia, heart rate variability measurement, response to antipsychotic drug",GCST004987,3:104732323
rs10829470-<b>A</b>,"4 x 10-6",,NR,'-,"1800 unit decrease",'-,'-,"Antipsychotic drug-induced QTc interval change in schizophrenia","schizophrenia, heart rate variability measurement, response to antipsychotic drug",GCST004987,10:128678844
rs9642793-<b>A</b>,"4 x 10-6",,NR,'-,"531 unit decrease",'-,"ADI1P2, GASAL1","Antipsychotic drug-induced QTc interval change in schizophrenia","schizophrenia, heart rate variability measurement, response to antipsychotic drug",GCST004987,8:102721404
rs793278-<b>T</b>,"5 x 10-6",,NR,'-,"2480 unit decrease",'-,"CSRP3-AS1, E2F8","Antipsychotic drug-induced QTc interval change in schizophrenia","schizophrenia, heart rate variability measurement, response to antipsychotic drug",GCST004987,11:19224307
rs515103-<b>T</b>,"5 x 10-6",,NR,'-,"2260 unit decrease",'-,COL12A1,"Antipsychotic drug-induced QTc interval change in schizophrenia","schizophrenia, heart rate variability measurement, response to antipsychotic drug",GCST004987,6:75100605
rs2491441-<b>C</b>,"5 x 10-6",,NR,'-,"5060 unit decrease",'-,RGL1,"Antipsychotic drug-induced QTc interval change in schizophrenia","schizophrenia, heart rate variability measurement, response to antipsychotic drug",GCST004987,1:183833125
rs1190460-<b>C</b>,"6 x 10-6",,NR,'-,"6260 unit decrease",'-,"PRSS56, ECEL1","Antipsychotic drug-induced QTc interval change in schizophrenia","schizophrenia, heart rate variability measurement, response to antipsychotic drug",GCST004987,2:232502030
rs11132911-<b>T</b>,"7 x 10-6",,NR,'-,"4500 unit decrease",'-,LINC02174,"Antipsychotic drug-induced QTc interval change in schizophrenia","schizophrenia, heart rate variability measurement, response to antipsychotic drug",GCST004987,4:171565714
rs17834760-<b>G</b>,"7 x 10-6",,NR,'-,"1520 unit decrease",'-,KHDRBS2-OT1,"Antipsychotic drug-induced QTc interval change in schizophrenia","schizophrenia, heart rate variability measurement, response to antipsychotic drug",GCST004987,6:61668740
rs9542550-<b>C</b>,"7 x 10-6",,NR,'-,"2730 unit decrease",'-,"LINC00348, MTCL1P1","Antipsychotic drug-induced QTc interval change in schizophrenia","schizophrenia, heart rate variability measurement, response to antipsychotic drug",GCST004987,13:70973380
rs9378078-<b>T</b>,"7 x 10-6",,NR,'-,"6700 unit decrease",'-,'-,"Antipsychotic drug-induced QTc interval change in schizophrenia","schizophrenia, heart rate variability measurement, response to antipsychotic drug",GCST004987,6:61213337
rs1928480-<b>A</b>,"7 x 10-6",,NR,'-,"2500 unit decrease",'-,"RFC5P1, ATP5MFP3","Antipsychotic drug-induced QTc interval change in schizophrenia","schizophrenia, heart rate variability measurement, response to antipsychotic drug",GCST004987,9:77071521
rs9363882-<b>T</b>,"7 x 10-6",,NR,'-,"5350 unit decrease",'-,KHDRBS2,"Antipsychotic drug-induced QTc interval change in schizophrenia","schizophrenia, heart rate variability measurement, response to antipsychotic drug",GCST004987,6:62150634
rs998808-<b>A</b>,"7 x 10-6",,NR,'-,"6910 unit decrease",'-,KHDRBS2,"Antipsychotic drug-induced QTc interval change in schizophrenia","schizophrenia, heart rate variability measurement, response to antipsychotic drug",GCST004987,6:61997852
rs72790443-<b>T</b>,"1 x 10-9",,0.09,'-,"5.64 unit decrease",[3.82-7.46],MEGF10,"Response to antipsychotic treatment in schizophrenia","schizophrenia, response to antipsychotic drug",GCST006292,5:127455149
rs1471786-<b>G</b>,"2 x 10-9",,0.42,'-,"3.35 unit decrease",[2.25-4.45],"SPATA6L, SLC1A1","Response to antipsychotic treatment in schizophrenia","schizophrenia, response to antipsychotic drug",GCST006292,9:4576774
rs9291547-<b>A</b>,"3 x 10-9",,0.48,'-,"3.18 unit decrease",[2.12-4.24],PCDH7,"Response to antipsychotic treatment in schizophrenia","schizophrenia, response to antipsychotic drug",GCST006292,4:30748032
rs12711680-<b>G</b>,"2 x 10-8",,0.36,'-,"3.18 unit increase",[2.06-4.3],CNTNAP5,"Response to antipsychotic treatment in schizophrenia","schizophrenia, response to antipsychotic drug",GCST006292,2:124546458
rs6444970-<b>T</b>,"5 x 10-8",,0.11,'-,"4.8 unit decrease",[3.08-6.52],TNIK,"Response to antipsychotic treatment in schizophrenia","schizophrenia, response to antipsychotic drug",GCST006292,3:171192653
rs77685948-<b>G</b>,"7 x 10-8",,0.32,'-,"3.14 unit decrease",[2-4.28],PCDH7,"Response to antipsychotic treatment in schizophrenia","schizophrenia, response to antipsychotic drug",GCST006292,4:30653520
rs301440-<b>C</b>,"2 x 10-7",,0.35,'-,"3.07 unit decrease",[1.91-4.23],SPATA6L,"Response to antipsychotic treatment in schizophrenia","schizophrenia, response to antipsychotic drug",GCST006292,9:4590305
rs150192045-<b>C</b>,"2 x 10-6",,0.04,'-,"6.64 unit decrease",[3.92-9.36],"MEGF10, HNRNPKP1","Response to antipsychotic treatment in schizophrenia","schizophrenia, response to antipsychotic drug",GCST006292,5:127477772
rs4848939-<b>G</b>,"4 x 10-6",,0.3,'-,"2.75 unit increase",[1.57-3.93],CNTNAP5,"Response to antipsychotic treatment in schizophrenia","schizophrenia, response to antipsychotic drug",GCST006292,2:124558127
rs9544382-<b>C</b>,"9 x 10-6",,0.34,'-,"2.52 unit increase",[1.4-3.64],NBEA,"Response to antipsychotic treatment in schizophrenia","schizophrenia, response to antipsychotic drug",GCST006292,13:35449873
rs199650082-<b>T</b>,"2 x 10-6",,0.03,18.2,'-,[7.1-46.9],ERN1,"Liver injury in anti-retroviral drug treated HIV","response to efavirenz, HIV infection, drug-induced liver injury",GCST004261,17:64044166
rs10990032-<b>G</b>,"2 x 10-6",(European),0.94,'-,"0.155 unit decrease",[0.077-0.233],RNU6-329P,"Response to fenofibrate (triglyceride levels)","triglyceride change measurement, response to fenofibrate",GCST003488,9:102353919
rs73199626-<b>T</b>,"8 x 10-7",(European),0.86,'-,"0.084 unit decrease",[0.045-0.123],OSTN,"Response to fenofibrate (triglyceride levels)","triglyceride change measurement, response to fenofibrate",GCST003488,3:191170774
chr20:60546575-<b>?</b>,"9 x 10-6",(European),NR,'-,"0.04218 unit increase",[0.012-0.073],'-,"Response to fenofibrate (LDL cholesterol levels)","LDL cholesterol change measurement, response to fenofibrate",GCST003486,"Mapping not available"
chr9:16979194-<b>?</b>,"9 x 10-6",(European),NR,'-,"0.02482 unit decrease",[-0.00078-0.05042],'-,"Response to fenofibrate (HDL cholesterol levels)","HDL cholesterol change measurement, response to fenofibrate",GCST003485,"Mapping not available"
chr12:12727200-<b>?</b>,"9 x 10-6",(European),NR,'-,"0.0487 unit increase",[0.028-0.069],'-,"Response to fenofibrate (HDL cholesterol levels)","HDL cholesterol change measurement, response to fenofibrate",GCST003485,"Mapping not available"
chr1:91944137-<b>?</b>,"3 x 10-6",(European),NR,'-,"0.03538 unit decrease",[0.0092-0.0615],'-,"Response to fenofibrate (HDL cholesterol levels)","HDL cholesterol change measurement, response to fenofibrate",GCST003485,"Mapping not available"
chr7:27614112-<b>?</b>,"3 x 10-6",(European),NR,'-,"0.01886 unit decrease",[0.0045-0.0332],'-,"Response to fenofibrate (HDL cholesterol levels)","HDL cholesterol change measurement, response to fenofibrate",GCST003485,"Mapping not available"
chr13:71763633-<b>?</b>,"6 x 10-6",(European),NR,'-,"0.02145 unit decrease",[0.00032-0.04258],'-,"Response to fenofibrate (HDL cholesterol levels)","HDL cholesterol change measurement, response to fenofibrate",GCST003485,"Mapping not available"
chr19:30263509-<b>?</b>,"9 x 10-6",(European),NR,'-,"0.01489 unit increase",[0.0052-0.0246],'-,"Response to fenofibrate (total cholesterol levels)","total cholesterol change measurement, response to fenofibrate",GCST003487,"Mapping not available"
chr1:81874455-<b>?</b>,"9 x 10-6",(European),NR,'-,"0.03997 unit decrease",[0.013-0.067],'-,"Response to fenofibrate (HDL cholesterol levels)","HDL cholesterol change measurement, response to fenofibrate",GCST003485,"Mapping not available"
chr18:50464126-<b>?</b>,"2 x 10-6",(European),NR,'-,"0.01694 unit increase",[0.0044-0.0295],'-,"Response to fenofibrate (total cholesterol levels)","total cholesterol change measurement, response to fenofibrate",GCST003487,"Mapping not available"
chr3:18404279-<b>?</b>,"6 x 10-6",(European),NR,'-,"0.04321 unit increase",[0.021-0.066],'-,"Response to fenofibrate (HDL cholesterol levels)","HDL cholesterol change measurement, response to fenofibrate",GCST003485,"Mapping not available"
chr5:128000893-<b>?</b>,"5 x 10-6",(European),NR,'-,"0.009154 unit decrease",[0.0027-0.0156],'-,"Response to fenofibrate (total cholesterol levels)","total cholesterol change measurement, response to fenofibrate",GCST003487,"Mapping not available"
chr18:8858808-<b>?</b>,"7 x 10-7",(European),NR,'-,"0.03304 unit decrease",[0.015-0.051],'-,"Response to fenofibrate (HDL cholesterol levels)","HDL cholesterol change measurement, response to fenofibrate",GCST003485,"Mapping not available"
rs72744354-<b>G</b>,"5 x 10-7",(European),0.96,'-,"0.066 unit decrease",[0.046-0.086],"MIR4713HG, TNFAIP8L3","Response to fenofibrate (HDL cholesterol levels)","HDL cholesterol change measurement, response to fenofibrate",GCST003485,15:51060678
chr15:51473345-<b>?</b>,"5 x 10-7",(European),NR,'-,"0.06432 unit decrease",[0.038-0.091],'-,"Response to fenofibrate (HDL cholesterol levels)","HDL cholesterol change measurement, response to fenofibrate",GCST003485,"Mapping not available"
rs62041965-<b>G</b>,"3 x 10-7",(European),0.95,'-,"0.064 unit increase",[0.044-0.084],"MAF, RBFOX1","Response to fenofibrate (HDL cholesterol levels)","HDL cholesterol change measurement, response to fenofibrate",GCST003485,16:79517330
chr12:19956384-<b>?</b>,"7 x 10-7",(European),NR,'-,"0.04454 unit decrease",[0.024-0.065],'-,"Response to fenofibrate (LDL cholesterol levels)","LDL cholesterol change measurement, response to fenofibrate",GCST003486,"Mapping not available"
chr19:45422160-<b>?</b>,"1 x 10-6",(European),NR,'-,"0.07956 unit increase",[0.038-0.121],'-,"Response to fenofibrate (LDL cholesterol levels)","LDL cholesterol change measurement, response to fenofibrate",GCST003486,"Mapping not available"
rs3841260-<b>AGCC</b>,"2 x 10-8",(European),0.92,'-,"0.067 unit decrease",[0.028-0.106],ATP13A1,"Response to fenofibrate (LDL cholesterol levels)","LDL cholesterol change measurement, response to fenofibrate",GCST003486,19:19645265
chr4:99251006-<b>?</b>,"8 x 10-6",(European),NR,'-,"0.01758 unit increase",[0.0081-0.027],'-,"Response to fenofibrate (total cholesterol levels)","total cholesterol change measurement, response to fenofibrate",GCST003487,"Mapping not available"
chr12:54422052-<b>?</b>,"9 x 10-6",(European),NR,'-,"0.09434 unit decrease",[0.025-0.164],'-,"Response to fenofibrate (LDL cholesterol levels)","LDL cholesterol change measurement, response to fenofibrate",GCST003486,"Mapping not available"
chr10:29554568-<b>?</b>,"9 x 10-6",(European),NR,'-,"0.1407 unit increase",[0.088-0.193],'-,"Response to fenofibrate (LDL cholesterol levels)","LDL cholesterol change measurement, response to fenofibrate",GCST003486,"Mapping not available"
chr15:78075910-<b>?</b>,"3 x 10-6",(European),NR,'-,"0.03257 unit decrease",[0.013-0.052],'-,"Response to fenofibrate (LDL cholesterol levels)","LDL cholesterol change measurement, response to fenofibrate",GCST003486,"Mapping not available"
rs150268548-<b>G</b>,"2 x 10-8",(European),0.92,'-,"0.05 unit decrease",[0.011-0.089],"GATAD2A, MAU2","Response to fenofibrate (LDL cholesterol levels)","LDL cholesterol change measurement, response to fenofibrate",GCST003486,19:19383674
chr15:51235835-<b>?</b>,"5 x 10-7",(European),NR,'-,"0.06143 unit decrease",[0.036-0.087],'-,"Response to fenofibrate (HDL cholesterol levels)","HDL cholesterol change measurement, response to fenofibrate",GCST003485,"Mapping not available"
chr7:147841618-<b>?</b>,"6 x 10-6",(European),NR,'-,"0.05601 unit decrease",[0.0056-0.1065],'-,"Response to fenofibrate (LDL cholesterol levels)","LDL cholesterol change measurement, response to fenofibrate",GCST003486,"Mapping not available"
chr9:107725470-<b>?</b>,"7 x 10-6",(European),NR,'-,"0.009843 unit decrease",[0.0048-0.0149],'-,"Response to fenofibrate (total cholesterol levels)","total cholesterol change measurement, response to fenofibrate",GCST003487,"Mapping not available"
chr5:15420132-<b>?</b>,"2 x 10-6",(European),NR,'-,"0.02593 unit decrease",[0.011-0.041],'-,"Response to fenofibrate (total cholesterol levels)","total cholesterol change measurement, response to fenofibrate",GCST003487,"Mapping not available"
chr20:49493745-<b>?</b>,"7 x 10-6",(European),NR,'-,"0.03604 unit decrease",[0.018-0.055],'-,"Response to fenofibrate (total cholesterol levels)","total cholesterol change measurement, response to fenofibrate",GCST003487,"Mapping not available"
chr10:71500935-<b>?</b>,"2 x 10-6",(European),NR,'-,"0.01503 unit increase",[0.0085-0.0216],'-,"Response to fenofibrate (total cholesterol levels)","total cholesterol change measurement, response to fenofibrate",GCST003487,"Mapping not available"
chr11:8398757-<b>?</b>,"2 x 10-6",(European),NR,'-,"0.05053 unit decrease",[0.024-0.077],'-,"Response to fenofibrate (HDL cholesterol levels)","HDL cholesterol change measurement, response to fenofibrate",GCST003485,"Mapping not available"
chr7:3070897-<b>?</b>,"4 x 10-6",(European),NR,'-,"0.01082 unit decrease",[0.0049-0.0167],'-,"Response to fenofibrate (total cholesterol levels)","total cholesterol change measurement, response to fenofibrate",GCST003487,"Mapping not available"
chr17:6437220-<b>?</b>,"7 x 10-6",(European),NR,'-,"0.04826 unit decrease",[0.02-0.076],'-,"Response to fenofibrate (HDL cholesterol levels)","HDL cholesterol change measurement, response to fenofibrate",GCST003485,"Mapping not available"
chr18:4129594-<b>?</b>,"5 x 10-6",(European),NR,'-,"0.01383 unit increase",[0.0078-0.0198],'-,"Response to fenofibrate (total cholesterol levels)","total cholesterol change measurement, response to fenofibrate",GCST003487,"Mapping not available"
chr8:8219349-<b>?</b>,"9 x 10-6",(European),NR,'-,"0.02634 unit decrease",[0.013-0.04],'-,"Response to fenofibrate (HDL cholesterol levels)","HDL cholesterol change measurement, response to fenofibrate",GCST003485,"Mapping not available"
chr5:15524470-<b>?</b>,"4 x 10-6",(European),NR,'-,"0.02374 unit decrease",[0.0088-0.0387],'-,"Response to fenofibrate (total cholesterol levels)","total cholesterol change measurement, response to fenofibrate",GCST003487,"Mapping not available"
rs10090104-<b>G</b>,"1 x 10-6",(European),0.83,'-,"0.01781 unit decrease",[0.011-0.025],GPR20,"Response to fenofibrate (total cholesterol levels)","total cholesterol change measurement, response to fenofibrate",GCST003487,8:141360762
chr3:7468858-<b>?</b>,"7 x 10-6",(European),NR,'-,"0.009073 unit decrease",[0.0037-0.0145],'-,"Response to fenofibrate (total cholesterol levels)","total cholesterol change measurement, response to fenofibrate",GCST003487,"Mapping not available"
chr6:77497321-<b>?</b>,"7 x 10-6",(European),NR,'-,"0.01386 unit decrease",[0.0063-0.0215],'-,"Response to fenofibrate (total cholesterol levels)","total cholesterol change measurement, response to fenofibrate",GCST003487,"Mapping not available"
chr14:87488179-<b>?</b>,"3 x 10-6",(European),NR,'-,"0.01247 unit increase",[0.0043-0.0206],'-,"Response to fenofibrate (total cholesterol levels)","total cholesterol change measurement, response to fenofibrate",GCST003487,"Mapping not available"
chr9:140323098-<b>?</b>,"4 x 10-6",(European),NR,'-,"0.06597 unit decrease",[0.023-0.109],'-,"Response to fenofibrate (total cholesterol levels)","total cholesterol change measurement, response to fenofibrate",GCST003487,"Mapping not available"
chr5:103538711-<b>?</b>,"9 x 10-6",(European),NR,'-,"0.01521 unit increase",[0.0074-0.023],'-,"Response to fenofibrate (total cholesterol levels)","total cholesterol change measurement, response to fenofibrate",GCST003487,"Mapping not available"
chr2:17702456-<b>?</b>,"5 x 10-6",(European),NR,'-,"0.01537 unit decrease",[0.0077-0.023],'-,"Response to fenofibrate (total cholesterol levels)","total cholesterol change measurement, response to fenofibrate",GCST003487,"Mapping not available"
chr2:197094718-<b>?</b>,"1 x 10-7",(European),NR,'-,"0.05933 unit increase",[0.024-0.095],'-,"Response to fenofibrate (LDL cholesterol levels)","LDL cholesterol change measurement, response to fenofibrate",GCST003486,"Mapping not available"
chr15:80016523-<b>?</b>,"5 x 10-6",(European),NR,'-,"0.07612 unit decrease",[0.032-0.12],'-,"Response to fenofibrate (LDL cholesterol levels)","LDL cholesterol change measurement, response to fenofibrate",GCST003486,"Mapping not available"
chr1:88642627-<b>?</b>,"5 x 10-6",(European),NR,'-,"0.03745 unit decrease",[0.018-0.057],'-,"Response to fenofibrate (LDL cholesterol levels)","LDL cholesterol change measurement, response to fenofibrate",GCST003486,"Mapping not available"
rs28404156-<b>A</b>,"2 x 10-7",(EA),0.072,'-,"3.6 unit decrease",[2.25-4.95],BST1,"Response to beta blocker use in hypertension (systolic blood pressure)","hypertension, systolic blood pressure change measurement, response to beta blocker",GCST008736,4:15736109
rs2959223-<b>A</b>,"4 x 10-7",,0.3,5.55,'-,[1.44-21.26],SIX2,"Clozapine-induced myocarditis in schizophrenia","myocarditis, schizophrenia, response to clozapine",GCST009817,2:45018026
rs9463787-<b>G</b>,"8 x 10-7",,0.13,7.67,'-,[2.63-22.36],EFHC1,"Clozapine-induced myocarditis in schizophrenia","myocarditis, schizophrenia, response to clozapine",GCST009817,6:52431785
rs117188076-<b>T</b>,"3 x 10-7",,0.03,13.74,'-,[3.68-51.22],ADAM7,"Clozapine-induced myocarditis in schizophrenia","myocarditis, schizophrenia, response to clozapine",GCST009817,8:24543885
rs74675399-<b>A</b>,"1 x 10-7",,0.07,6.36,'-,[2.28-17.8],"GNA15, GNA15-DT","Clozapine-induced myocarditis in schizophrenia","myocarditis, schizophrenia, response to clozapine",GCST009817,19:3148871
rs2328386-<b>C</b>,"5 x 10-8",,NR,3.030303,'-,[1.82-5],HIVEP2,"Adverse response to inhaled corticosteroid treatment x age interaction in asthma","response to corticosteroid, age at assessment, asthma",GCST010039,6:142823821
rs6500715-<b>G</b>,"4 x 10-7",,NR,2.1276596,'-,[1.54-2.94],RBFOX1,"Adverse response to inhaled corticosteroid treatment x age interaction in asthma","response to corticosteroid, age at assessment, asthma",GCST010039,16:5734291
rs509061-<b>C</b>,"2 x 10-7",,NR,2.08,'-,[1.5-2.89],"SPRR2G, LELP1","Adverse response to inhaled corticosteroid treatment x age interaction in asthma","response to corticosteroid, age at assessment, asthma",GCST010039,1:153160647
rs34338452-<b>A</b>,"4 x 10-7",,NR,2.24,'-,[1.57-3.19],SAMD12,"Adverse response to inhaled corticosteroid treatment x age interaction in asthma","response to corticosteroid, age at assessment, asthma",GCST010039,8:118461550
rs34631960-<b>C</b>,"4 x 10-8",,NR,2.33,'-,[1.61-3.38],THSD4,"Adverse response to inhaled corticosteroid treatment x age interaction in asthma","response to corticosteroid, age at assessment, asthma",GCST010039,15:71540730
rs290119-<b>A</b>,"6 x 10-8",,NR,2.38,'-,[1.6-3.53],"RNU6-168P, LSM1P2","Adverse response to inhaled corticosteroid treatment x age interaction in asthma","response to corticosteroid, age at assessment, asthma",GCST010039,5:163841095
rs290122-<b>T</b>,"6 x 10-8",,NR,2.38,'-,[1.6-3.53],"RNU6-168P, LSM1P2","Adverse response to inhaled corticosteroid treatment x age interaction in asthma","response to corticosteroid, age at assessment, asthma",GCST010039,5:163841300
rs58836160-<b>TA</b>,"6 x 10-8",,NR,2.38,'-,[1.6-3.53],"RNU6-168P, LSM1P2","Adverse response to inhaled corticosteroid treatment x age interaction in asthma","response to corticosteroid, age at assessment, asthma",GCST010039,5:163841781
chr12:121988899-<b>T</b>,"1 x 10-7",,NR,2.38,'-,[1.62-3.48],'-,"Adverse response to inhaled corticosteroid treatment x age interaction in asthma","response to corticosteroid, age at assessment, asthma",GCST010039,"Mapping not available"
rs72755727-<b>T</b>,"3 x 10-7",,NR,2.67,'-,[1.71-4.17],"PGAM1P1, P4HA2-AS1","Adverse response to inhaled corticosteroid treatment x age interaction in asthma","response to corticosteroid, age at assessment, asthma",GCST010039,5:58230875
rs12658947-<b>G</b>,"2 x 10-7",,NR,2.69,'-,[1.72-4.2],PGAM1P1,"Adverse response to inhaled corticosteroid treatment x age interaction in asthma","response to corticosteroid, age at assessment, asthma",GCST010039,5:58256637
rs12659412-<b>C</b>,"2 x 10-7",,NR,2.69,'-,[1.72-4.2],PGAM1P1,"Adverse response to inhaled corticosteroid treatment x age interaction in asthma","response to corticosteroid, age at assessment, asthma",GCST010039,5:58256888
rs6892109-<b>T</b>,"1 x 10-7",,NR,2.7,'-,[1.73-4.22],PGAM1P1,"Adverse response to inhaled corticosteroid treatment x age interaction in asthma","response to corticosteroid, age at assessment, asthma",GCST010039,5:58254269
rs1477347-<b>A</b>,"2 x 10-7",,NR,2.71,'-,[1.73-4.24],PGAM1P1,"Adverse response to inhaled corticosteroid treatment x age interaction in asthma","response to corticosteroid, age at assessment, asthma",GCST010039,5:58237135
rs72755734-<b>G</b>,"2 x 10-7",,NR,2.72,'-,[1.74-4.26],PGAM1P1,"Adverse response to inhaled corticosteroid treatment x age interaction in asthma","response to corticosteroid, age at assessment, asthma",GCST010039,5:58242927
rs2052548-<b>C</b>,"2 x 10-7",,NR,2.73,'-,[1.74-4.27],PGAM1P1,"Adverse response to inhaled corticosteroid treatment x age interaction in asthma","response to corticosteroid, age at assessment, asthma",GCST010039,5:58240905
rs524887-<b>G</b>,"4 x 10-7",,NR,2.23,'-,[1.58-3.14],"LELP1, SPRR2G","Adverse response to inhaled corticosteroid treatment x age interaction in asthma","response to corticosteroid, age at assessment, asthma",GCST010039,1:153164031
rs149104283-<b>T</b>,"2 x 10-8",,0.0152,4.3198,'-,'-,SLCO1B3-SLCO1B7,"Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia","treatment refractory schizophrenia, Drug-induced agranulocytosis, response to clozapine",GCST003628,12:20930928
rs80208670-<b>C</b>,"2 x 10-7",,0.0124,4.6904316,'-,'-,SLITRK1,"Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia","treatment refractory schizophrenia, Drug-induced agranulocytosis, response to clozapine",GCST003628,13:83863953
rs184597564-<b>A</b>,"8 x 10-7",,0.0282,3.0647,'-,'-,ADGRL2,"Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia","treatment refractory schizophrenia, Drug-induced agranulocytosis, response to clozapine",GCST003628,1:81770721
rs78900159-<b>A</b>,"2 x 10-6",,0.0244,2.7947,'-,'-,GSAP,"Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia","treatment refractory schizophrenia, Drug-induced agranulocytosis, response to clozapine",GCST003628,7:77339061
rs16916041-<b>T</b>,"2 x 10-6",,0.0973,1.9778,'-,'-,TMEM26,"Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia","treatment refractory schizophrenia, Drug-induced agranulocytosis, response to clozapine",GCST003628,10:61386789
rs11649311-<b>T</b>,"2 x 10-6",,0.3413,1.6818029,'-,'-,"AQP8, RN7SL557P","Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia","treatment refractory schizophrenia, Drug-induced agranulocytosis, response to clozapine",GCST003628,16:25214699
rs117202297-<b>T</b>,"5 x 10-6",,0.0122,4.9702,'-,'-,TMEM100,"Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia","treatment refractory schizophrenia, Drug-induced agranulocytosis, response to clozapine",GCST003628,17:55691674
rs80282661-<b>T</b>,"5 x 10-6",,0.0121,4.1666,'-,'-,LINC02093,"Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia","treatment refractory schizophrenia, Drug-induced agranulocytosis, response to clozapine",GCST003628,17:13348756
rs185053659-<b>A</b>,"8 x 10-6",,0.0142,3.7968,'-,'-,"LINC02778, FCGR3A","Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia","treatment refractory schizophrenia, Drug-induced agranulocytosis, response to clozapine",GCST003628,1:60238578
rs143888465-<b>?</b>,"4 x 10-6","ANC <1000/mm3",NR,4.94,'-,NR,SCN8A,"Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia","treatment refractory schizophrenia, Drug-induced agranulocytosis, response to clozapine",GCST003628,12:51616324
rs7003550-<b>?</b>,"1 x 10-8",,'-,'-,'-,'-,NCRNA00250,"Bone mineral accretion in asthma (oral corticosteroid dose interaction)","bone mineral accretion measurement, response to corticosteroid, asthma",GCST002926,8:134838655
rs9896933-<b>?</b>,"3 x 10-8",,'-,'-,'-,'-,TBCD,"Bone mineral accretion in asthma (oral corticosteroid dose interaction)","bone mineral accretion measurement, response to corticosteroid, asthma",GCST002926,17:82940212
rs7599706-<b>?</b>,"4 x 10-8",,'-,'-,'-,'-,'-,"Bone mineral accretion in asthma (oral corticosteroid dose interaction)","bone mineral accretion measurement, response to corticosteroid, asthma",GCST002926,2:236897044
rs12447718-<b>?</b>,"4 x 10-8",,'-,'-,'-,'-,ZFPM1,"Bone mineral accretion in asthma (oral corticosteroid dose interaction)","bone mineral accretion measurement, response to corticosteroid, asthma",GCST002926,16:88503726
rs4368243-<b>?</b>,"6 x 10-8",,'-,'-,'-,'-,'-,"Bone mineral accretion in asthma (oral corticosteroid dose interaction)","bone mineral accretion measurement, response to corticosteroid, asthma",GCST002926,18:40803519
rs2316527-<b>?</b>,"8 x 10-8",,'-,'-,'-,'-,DPP6,"Bone mineral accretion in asthma (oral corticosteroid dose interaction)","bone mineral accretion measurement, response to corticosteroid, asthma",GCST002926,7:154830747
rs4484658-<b>?</b>,"8 x 10-8",,'-,'-,'-,'-,"PLEKHF2, C8orf37-AS1","Bone mineral accretion in asthma (oral corticosteroid dose interaction)","bone mineral accretion measurement, response to corticosteroid, asthma",GCST002926,8:95196498
rs7506840-<b>?</b>,"9 x 10-8",,'-,'-,'-,'-,LINC01387,"Bone mineral accretion in asthma (oral corticosteroid dose interaction)","bone mineral accretion measurement, response to corticosteroid, asthma",GCST002926,18:6522757
rs10485681-<b>?</b>,"1 x 10-7",,'-,'-,'-,'-,'-,"Bone mineral accretion in asthma (oral corticosteroid dose interaction)","bone mineral accretion measurement, response to corticosteroid, asthma",GCST002926,20:41864432
rs7785360-<b>?</b>,"2 x 10-8",,NR,'-,'-,'-,AUTS2,"Response to serotonin reuptake inhibitors in non-psychotic unipolar depression","unipolar depression, response to selective serotonin reuptake inhibitor",GCST003118,7:69944392
rs10924309-<b>?</b>,"6 x 10-6",,NR,'-,'-,'-,KIF26B,"Response to serotonin reuptake inhibitors in non-psychotic unipolar depression","unipolar depression, response to selective serotonin reuptake inhibitor",GCST003118,1:245699920
rs3749448-<b>A</b>,"2 x 10-6",,0.2,2.96,'-,[2.52-3.4],GRM7,"Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia","treatment refractory schizophrenia, Drug-induced agranulocytosis, response to clozapine",GCST003450,3:7146429
rs1800625-<b>G</b>,"3 x 10-9",,0.084,3.78,'-,[3.34-4.22],"AGER, PBX2","Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia","treatment refractory schizophrenia, Drug-induced agranulocytosis, response to clozapine",GCST003450,6:32184665
rs2472297-<b>T</b>,"4 x 10-10",,NR,'-,"0.073 unit increase",[0.049-0.097],"CYP1A2, CYP1A1","Clozapine concentration in schizophrenia","schizophrenia, response to clozapine",GCST010565,15:74735539
rs3732218-<b>A</b>,"7 x 10-9",,NR,'-,"0.095 unit increase",[0.064-0.126],"UGT1A9, UGT1A10, UGT1A6, UGT1A7, UGT1A5, UGT1A8","N-desmethylclozapine concentration in schizophrenia","schizophrenia, response to clozapine",GCST010564,2:233718658
rs10000284-<b>T</b>,"4 x 10-20",,NR,'-,"0.14 unit decrease",[0.11-0.17],UGT2B10,"N-desmethylclozapine concentration in schizophrenia","schizophrenia, response to clozapine",GCST010564,4:68803465
rs10023464-<b>T</b>,"2 x 10-91",,NR,'-,"0.177 unit decrease",[0.16-0.19],UGT2B10,"Clozapine-to-N-desmethylclozapine metabolic ratio in schizophrenia","schizophrenia, response to clozapine",GCST010563,4:68794020
rs12767583-<b>T</b>,"1 x 10-16",,NR,'-,"0.063 unit decrease",[0.047-0.079],CYP2C19,"Clozapine-to-N-desmethylclozapine metabolic ratio in schizophrenia","schizophrenia, response to clozapine",GCST010563,10:94787706
rs2388639-<b>?</b>,"9 x 10-9",,0.19,'-,"0.878 unit increase",[NR],"LINC02183, LINC02140","Asthma (corticosteroid response)","response to corticosteroid, asthma",GCST002342,16:54455881
rs10044254-<b>?</b>,"9 x 10-8",,0.18,'-,"1.19 unit increase",[NR],FBXL7,"Asthma (corticosteroid response)","response to corticosteroid, asthma",GCST002342,5:15783487
rs11123610-<b>?</b>,"4 x 10-7",,'-,'-,"0.367 unit increase",[NR],ALLC,"Response to inhaled corticosteroid treatment in asthma (change in FEV1)","FEV change measurement, response to corticosteroid, asthma",GCST002432,2:3675436
rs6440972-<b>?</b>,"8 x 10-7",,'-,'-,"0.353 unit increase",[NR],"PLCH1, PABPC1P10","Response to inhaled corticosteroid treatment in asthma (change in FEV1)","FEV change measurement, response to corticosteroid, asthma",GCST002432,3:155327641
rs1323555-<b>?</b>,"2 x 10-6",,'-,'-,"0.343 unit increase",[NR],CYSLTR2,"Response to inhaled corticosteroid treatment in asthma (change in FEV1)","FEV change measurement, response to corticosteroid, asthma",GCST002432,13:48676861
rs1930336-<b>?</b>,"3 x 10-6",,'-,'-,"0.346 unit increase",[NR],'-,"Response to inhaled corticosteroid treatment in asthma (change in FEV1)","FEV change measurement, response to corticosteroid, asthma",GCST002432,13:80488806
rs6601306-<b>?</b>,"4 x 10-6",,'-,'-,"0.338 unit increase",[NR],RNU6-526P,"Response to inhaled corticosteroid treatment in asthma (change in FEV1)","FEV change measurement, response to corticosteroid, asthma",GCST002432,8:9407201
rs11835157-<b>?</b>,"6 x 10-6",,'-,'-,"0.324 unit increase",[NR],ELK3,"Response to inhaled corticosteroid treatment in asthma (change in FEV1)","FEV change measurement, response to corticosteroid, asthma",GCST002432,12:96240427
rs2811670-<b>?</b>,"7 x 10-6",,'-,'-,"0.053 unit increase",[NR],'-,"Response to inhaled corticosteroid treatment in asthma (change in FEV1)","FEV change measurement, response to corticosteroid, asthma",GCST002432,6:91246945
rs2434364-<b>?</b>,"7 x 10-6",,'-,'-,"0.326 unit increase",[NR],KIAA0825,"Response to inhaled corticosteroid treatment in asthma (change in FEV1)","FEV change measurement, response to corticosteroid, asthma",GCST002432,5:94362147
rs4884502-<b>?</b>,"9 x 10-6",,'-,'-,"0.32 unit increase",[NR],LINC00395,"Response to inhaled corticosteroid treatment in asthma (change in FEV1)","FEV change measurement, response to corticosteroid, asthma",GCST002432,13:63636265
rs1074145-<b>?</b>,"2 x 10-16","(S-DCT/S-CT ratio)",0.162,'-,'-,'-,"CYP2C9, RPL7AP52","Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels)","unipolar depression, response to selective serotonin reuptake inhibitor",GCST002549,10:94922089
rs1074145-<b>?</b>,"4 x 10-9","(S-CT concentration)",0.162,'-,'-,'-,"CYP2C9, RPL7AP52","Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels)","unipolar depression, response to selective serotonin reuptake inhibitor",GCST002549,10:94922089
rs9747992-<b>?</b>,"2 x 10-7","(S-DCT concentration)",0.086,'-,'-,'-,"LINC01977, CBX4","Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels)","unipolar depression, response to selective serotonin reuptake inhibitor",GCST002549,17:79831041
rs2059865-<b>?</b>,"3 x 10-7","(S-DCT concentration)",0.235,'-,'-,'-,PDZD2,"Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels)","unipolar depression, response to selective serotonin reuptake inhibitor",GCST002549,5:31766326
rs55734731-<b>?</b>,"4 x 10-7","(S-CT concentration, adjusted for CYP2C19)",0.124,'-,'-,'-,"HSPE1P1, LINC01370","Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels)","unipolar depression, response to selective serotonin reuptake inhibitor",GCST002549,20:39943772
rs71607999-<b>?</b>,"7 x 10-9","(S-DCT/S-CT ratio, adjusted for CYP2C19)",0.165,'-,'-,'-,'-,"Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels)","unipolar depression, response to selective serotonin reuptake inhibitor",GCST002549,4:188269957
rs11934750-<b>?</b>,"1 x 10-7","(S-DCT/S-CT ratio, adjusted for CYP2C19)",0.160,'-,'-,'-,'-,"Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels)","unipolar depression, response to selective serotonin reuptake inhibitor",GCST002549,4:27962783
rs77724872-<b>?</b>,"7 x 10-7","(S-DCT concentration, adjusted for CYP2C19)",0.047,'-,'-,'-,"CHST11, TXNRD1","Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels)","unipolar depression, response to selective serotonin reuptake inhibitor",GCST002549,12:104360722
rs8102150-<b>?</b>,"7 x 10-7","(S-DCT concentration, adjusted for CYP2C19)",0.028,'-,'-,'-,"CPT1C, TSKS","Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels)","unipolar depression, response to selective serotonin reuptake inhibitor",GCST002549,19:49727070
rs1722229-<b>?</b>,"1 x 10-6","(S-CT concentration, adjusted for CYP2C19)",0.034,'-,'-,'-,MYL10,"Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels)","unipolar depression, response to selective serotonin reuptake inhibitor",GCST002549,7:101642897
rs117020818-<b>?</b>,"7 x 10-7","(S-DCT concentration)",0.046,'-,'-,'-,RASSF10,"Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels)","unipolar depression, response to selective serotonin reuptake inhibitor",GCST002549,11:13107616
rs1058172-<b>?</b>,"2 x 10-16","(S-DDCT concentration)",0.155,'-,'-,'-,SEPTIN3,"Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels)","unipolar depression, response to selective serotonin reuptake inhibitor",GCST002549,22:41996807
rs1058172-<b>?</b>,"8 x 10-16","(S-DDCT/S-DCT ratio)",0.155,'-,'-,'-,"NDUFA6-DT, CYP2D6","Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels)","unipolar depression, response to selective serotonin reuptake inhibitor",GCST002549,22:42127526
rs1065852-<b>?</b>,"2 x 10-16","(S-DDCT concentration)",0.215,'-,'-,'-,"NDUFA6-DT, CYP2D6","Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels)","unipolar depression, response to selective serotonin reuptake inhibitor",GCST002549,22:42130692
rs1065852-<b>?</b>,"8 x 10-16","(S-DDCT/S-DCT ratio)",0.215,'-,'-,'-,"NDUFA6-DT, CYP2D6","Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels)","unipolar depression, response to selective serotonin reuptake inhibitor",GCST002549,22:42130692
rs6889896-<b>?</b>,"5 x 10-7","(% Change in score)",NR,'-,"0.17 unit decrease",[NR],LINC02240,"Response to serotonin reuptake inhibitors in major depressive disorder","unipolar depression, response to selective serotonin reuptake inhibitor",GCST002868,5:125363546
rs35806662-<b>?</b>,"6 x 10-7","(% Change in score)",NR,'-,"0.2 unit decrease",[NR],UPP2,"Response to serotonin reuptake inhibitors in major depressive disorder","unipolar depression, response to selective serotonin reuptake inhibitor",GCST002868,2:157933913
rs73069924-<b>?</b>,"8 x 10-7","(% Change in score)",NR,'-,"0.44 unit decrease",[NR],MTMR12,"Response to serotonin reuptake inhibitors in major depressive disorder","unipolar depression, response to selective serotonin reuptake inhibitor",GCST002868,5:32278127
rs4615376-<b>?</b>,"1 x 10-6","(% Change in score)",NR,'-,"0.16 unit decrease",[NR],PHACTR1,"Response to serotonin reuptake inhibitors in major depressive disorder","unipolar depression, response to selective serotonin reuptake inhibitor",GCST002868,6:13070841
rs2566255-<b>?</b>,"2 x 10-6","(% Change in score)",NR,'-,"0.26 unit increase",[NR],OR52I2,"Response to serotonin reuptake inhibitors in major depressive disorder","unipolar depression, response to selective serotonin reuptake inhibitor",GCST002868,11:4583965
rs910039-<b>?</b>,"2 x 10-6","(% Change in score)",NR,'-,"0.13 unit increase",[NR],CAP2,"Response to serotonin reuptake inhibitors in major depressive disorder","unipolar depression, response to selective serotonin reuptake inhibitor",GCST002868,6:17505713
rs17068112-<b>?</b>,"3 x 10-6","(% Change in score)",NR,'-,"0.26 unit increase",[NR],REPS1,"Response to serotonin reuptake inhibitors in major depressive disorder","unipolar depression, response to selective serotonin reuptake inhibitor",GCST002868,6:138928988
rs7485210-<b>?</b>,"3 x 10-6","(% Change in score)",NR,'-,"0.14 unit increase",[NR],"ADGRD1, LINC01257","Response to serotonin reuptake inhibitors in major depressive disorder","unipolar depression, response to selective serotonin reuptake inhibitor",GCST002868,12:131154308
rs74378198-<b>?</b>,"4 x 10-6","(% Change in score)",NR,'-,"0.43 unit decrease",[NR],OSMR,"Response to serotonin reuptake inhibitors in major depressive disorder","unipolar depression, response to selective serotonin reuptake inhibitor",GCST002868,5:38870806
rs4236420-<b>?</b>,"4 x 10-6","(% Change in score)",NR,'-,"0.13 unit increase",[NR],PER3P1,"Response to serotonin reuptake inhibitors in major depressive disorder","unipolar depression, response to selective serotonin reuptake inhibitor",GCST002868,7:9648479
rs2456568-<b>?</b>,"5 x 10-8",(Response),NR,1.36,'-,[NR],HPRT1P3,"Response to serotonin reuptake inhibitors in major depressive disorder","unipolar depression, response to selective serotonin reuptake inhibitor",GCST002868,11:93958166
rs113889867-<b>?</b>,"9 x 10-7",(Response),NR,1.96,'-,[NR],STMN2,"Response to serotonin reuptake inhibitors in major depressive disorder","unipolar depression, response to selective serotonin reuptake inhibitor",GCST002868,8:79644265
rs10954808-<b>?</b>,"1 x 10-6",(Response),NR,1.37,'-,[NR],"NRG1, RNA5SP261","Response to serotonin reuptake inhibitors in major depressive disorder","unipolar depression, response to selective serotonin reuptake inhibitor",GCST002868,8:31622107
rs506546-<b>?</b>,"1 x 10-6",(Response),NR,1.32,'-,[NR],CSMD2,"Response to serotonin reuptake inhibitors in major depressive disorder","unipolar depression, response to selective serotonin reuptake inhibitor",GCST002868,1:33973693
rs74546197-<b>?</b>,"3 x 10-6",(Response),NR,2.17,'-,[NR],"PM20D1, SLC26A9","Response to serotonin reuptake inhibitors in major depressive disorder","unipolar depression, response to selective serotonin reuptake inhibitor",GCST002868,1:205911051
rs72772787-<b>?</b>,"4 x 10-6",(Response),NR,2.34,'-,[NR],"TRIM58, OR11L1","Response to serotonin reuptake inhibitors in major depressive disorder","unipolar depression, response to selective serotonin reuptake inhibitor",GCST002868,1:247853076
rs2043144-<b>?</b>,"4 x 10-6",(Response),NR,2.63,'-,[NR],TRPM3,"Response to serotonin reuptake inhibitors in major depressive disorder","unipolar depression, response to selective serotonin reuptake inhibitor",GCST002868,9:71336039
rs291028-<b>?</b>,"5 x 10-6",(Response),NR,1.64,'-,[NR],'-,"Response to serotonin reuptake inhibitors in major depressive disorder","unipolar depression, response to selective serotonin reuptake inhibitor",GCST002868,15:95072557
rs7051085-<b>?</b>,"6 x 10-6",(Response),NR,1.59,'-,[NR],PTCHD1,"Response to serotonin reuptake inhibitors in major depressive disorder","unipolar depression, response to selective serotonin reuptake inhibitor",GCST002868,X:23356860
rs1210638-<b>?</b>,"6 x 10-6",(Response),NR,1.33,'-,[NR],DGCR5,"Response to serotonin reuptake inhibitors in major depressive disorder","unipolar depression, response to selective serotonin reuptake inhibitor",GCST002868,22:18994050
rs41549217-<b>T</b>,"2 x 10-7",,0.0288,4.6582,'-,[4.08-5.24],HLA-B,"Clozapine-induced agranulocytosis","Drug-induced agranulocytosis, response to clozapine",GCST002595,6:31356108
rs45495792-<b>G</b>,"1 x 10-6",,0.1706,2.11,'-,[1.81-2.41],RAD23A,"Clozapine-induced agranulocytosis","Drug-induced agranulocytosis, response to clozapine",GCST002595,19:12951613
rs118067775-<b>C</b>,"1 x 10-6",,0.0348,4.12,'-,[3.55-4.69],KANSL2,"Clozapine-induced agranulocytosis","Drug-induced agranulocytosis, response to clozapine",GCST002595,12:48679011
rs425283-<b>A</b>,"9 x 10-6",,0.1616,1.9644,'-,[1.67-2.26],LILRB4,"Clozapine-induced agranulocytosis","Drug-induced agranulocytosis, response to clozapine",GCST002595,19:54660297
rs4947962-<b>G</b>,"1 x 10-6",,0.11,1.35,'-,[NR],EGFR,"Subjective response to lithium treatment","bipolar disorder, response to lithium ion",GCST003158,7:55008114
rs146727601-<b>?</b>,"1 x 10-8",,0.01,3.98,'-,[NR],PTS,"Objective response to lithium treatment","bipolar disorder, response to lithium ion",GCST003159,11:112247868
rs6138892-<b>?</b>,"3 x 10-7","(CTJC , EA, RF-)",0.15,'-,"10.93 unit increase",[NR],"RPL19P1, EBF4","Response to tocilizumab in rheumatoid arthritis","rheumatoid arthritis, response to drug",GCST001476,20:2774842
rs6774280-<b>?</b>,"9 x 10-7","(CSJC , EA, RF-)",0.23,'-,"5.5 unit decrease",[NR],'-,"Response to tocilizumab in rheumatoid arthritis","rheumatoid arthritis, response to drug",GCST001476,3:6214310
rs11121380-<b>?</b>,"5 x 10-8","(CSJC , EA, RF-)",0.07,'-,"11.11 unit increase",[NR],SPSB1,"Response to tocilizumab in rheumatoid arthritis","rheumatoid arthritis, response to drug",GCST001476,1:9348900
rs1809529-<b>?</b>,"3 x 10-7","(CHAQ, RF-)",0.34,'-,"0.28 unit increase",[NR],SLC6A11,"Response to tocilizumab in rheumatoid arthritis","rheumatoid arthritis, response to drug",GCST001476,3:10835926
rs9604529-<b>?</b>,"7 x 10-7","(CHAQ, RF-)",0.19,'-,"0.35 unit increase",[NR],LINC00452,"Response to tocilizumab in rheumatoid arthritis","rheumatoid arthritis, response to drug",GCST001476,13:113919624
SNP2-179127489-<b>?</b>,"4 x 10-7","(CSJC, RF-)",0.017,'-,"23.66 unit decrease",[NR],'-,"Response to tocilizumab in rheumatoid arthritis","rheumatoid arthritis, response to drug",GCST001476,"Mapping not available"
rs1914816-<b>?</b>,"7 x 10-7","(CDAS28, EA, RF-)",0.3,'-,"0.87 unit increase",[NR],ETFA,"Response to tocilizumab in rheumatoid arthritis","rheumatoid arthritis, response to drug",GCST001476,15:76254592
rs16906916-<b>?</b>,"8 x 10-7","(CSJC, EA, RF+)",0.03,'-,"14 unit increase",[NR],PCDH15,"Response to tocilizumab in rheumatoid arthritis","rheumatoid arthritis, response to drug",GCST001476,10:55089225
GA009635-<b>?</b>,"7 x 10-7","(CSJC, RF-)",0.034,'-,"12.51 unit decrease",[NR],'-,"Response to tocilizumab in rheumatoid arthritis","rheumatoid arthritis, response to drug",GCST001476,"Mapping not available"
rs1329568-<b>?</b>,"8 x 10-7","(CSJC, RF-)",0.029,'-,"19.64 unit increase",[NR],'-,"Response to tocilizumab in rheumatoid arthritis","rheumatoid arthritis, response to drug",GCST001476,"Mapping not available"
rs16977065-<b>?</b>,"1 x 10-7","(CSJC , EA, RF+)",0.044,'-,"33.72 unit increase",[NR],RIT2,"Response to tocilizumab in rheumatoid arthritis","rheumatoid arthritis, response to drug",GCST001476,18:42857686
rs4942242-<b>?</b>,"2 x 10-7","(CHAQ, RF+)",0.47,'-,"0.13 unit decrease",[NR],ENOX1,"Response to tocilizumab in rheumatoid arthritis","rheumatoid arthritis, response to drug",GCST001476,13:43642928
rs17118552-<b>?</b>,"2 x 10-7","(CTJC , EA, RF+)",0.014,'-,"17.19 unit increase",[NR],MDGA2,"Response to tocilizumab in rheumatoid arthritis","rheumatoid arthritis, response to drug",GCST001476,14:47405354
rs6500395-<b>?</b>,"6 x 10-7","(CSJC, RF+)",0.35,'-,"2.2 unit increase",[NR],N4BP1,"Response to tocilizumab in rheumatoid arthritis","rheumatoid arthritis, response to drug",GCST001476,16:48587491
rs1406428-<b>?</b>,"2 x 10-7","(CSJC , RF+)",0.28,'-,"2.74 unit increase",[NR],KNOP1P3,"Response to tocilizumab in rheumatoid arthritis","rheumatoid arthritis, response to drug",GCST001476,2:51509856
rs6026990-<b>?</b>,"6 x 10-7","(CHAQ , EA, RF-)",0.086,'-,"0.63 unit increase",[NR],PHACTR3,"Response to tocilizumab in rheumatoid arthritis","rheumatoid arthritis, response to drug",GCST001476,20:59602560
rs12565755-<b>?</b>,"5 x 10-8","(CHAQ, EA, RF-)",0.14,'-,"0.39 unit decrease",[NR],LINC01748,"Response to tocilizumab in rheumatoid arthritis","rheumatoid arthritis, response to drug",GCST001476,1:60576203
rs16938910-<b>?</b>,"4 x 10-7","(CSJC , EA, RF+)",0.011,'-,"28.66 unit increase",[NR],GDAP1,"Response to tocilizumab in rheumatoid arthritis","rheumatoid arthritis, response to drug",GCST001476,8:74461713
rs12901682-<b>?</b>,"4 x 10-8","(CSJC , EA, RF-)",0.017,'-,"135.02 unit decrease",[NR],PSMA4,"Response to tocilizumab in rheumatoid arthritis","rheumatoid arthritis, response to drug",GCST001476,15:78540881
rs13137105-<b>?</b>,"9 x 10-7","(CTJC, RF-)",0.38,'-,"6.39 unit decrease",[NR],RCHY1,"Response to tocilizumab in rheumatoid arthritis","rheumatoid arthritis, response to drug",GCST001476,4:75491177
rs11937061-<b>?</b>,"2 x 10-7","(CTJC, RF-)",0.36,'-,"6.7 unit decrease",[NR],CCNG2,"Response to tocilizumab in rheumatoid arthritis","rheumatoid arthritis, response to drug",GCST001476,4:77215780
rs7164176-<b>?</b>,"5 x 10-7","(CHAQ, RF-)",0.43,'-,"0.28 unit decrease",[NR],"CRAT37, THRAP3P2","Response to tocilizumab in rheumatoid arthritis","rheumatoid arthritis, response to drug",GCST001476,15:91668544
rs800586-<b>?</b>,"2 x 10-7","(CTJC , EA, RF-)",0.38,'-,"9.78 unit decrease",[NR],TRPS1,"Response to tocilizumab in rheumatoid arthritis","rheumatoid arthritis, response to drug",GCST001476,8:115801679
rs72991-<b>?</b>,"5 x 10-7","(CSJC, RF+)",0.25,'-,"2.45 unit decrease",[NR],"BMPR1AP2, SORL1","Response to tocilizumab in rheumatoid arthritis","rheumatoid arthritis, response to drug",GCST001476,11:121373007
SNP3-186373264-<b>?</b>,"2 x 10-7","(CSJC, RF-)",0.1,'-,"7.4 unit decrease",[NR],'-,"Response to tocilizumab in rheumatoid arthritis","rheumatoid arthritis, response to drug",GCST001476,"Mapping not available"
rs1543922-<b>?</b>,"3 x 10-7","(CSJC, EA, RF-)",0.036,'-,"34.48 unit increase",[NR],ZNF175,"Response to tocilizumab in rheumatoid arthritis","rheumatoid arthritis, response to drug",GCST001476,19:51581583
rs7940423-<b>?</b>,"1 x 10-7","(CSJC, RF+)",0.011,'-,"10.9 unit decrease",[NR],GALNT18,"Response to tocilizumab in rheumatoid arthritis","rheumatoid arthritis, response to drug",GCST001476,11:11482681
rs1273516-<b>?</b>,"9 x 10-7","(CSJC , EA, RF-)",0.39,'-,"4.26 unit decrease",[NR],CYP4F23P,"Response to tocilizumab in rheumatoid arthritis","rheumatoid arthritis, response to drug",GCST001476,19:15566899
rs12109285-<b>?</b>,"1 x 10-7","(CSJC , EA, RF+)",0.011,'-,"130.2 unit decrease",[NR],CDH12,"Response to tocilizumab in rheumatoid arthritis","rheumatoid arthritis, response to drug",GCST001476,5:21749239
rs11051970-<b>?</b>,"1 x 10-6","(CSJC, RF+)",0.34,'-,"2.08 unit decrease",[NR],"Y_RNA, BICD1","Response to tocilizumab in rheumatoid arthritis","rheumatoid arthritis, response to drug",GCST001476,12:32384554
rs1898036-<b>?</b>,"2 x 10-7","(CSJC , EA, RF-)",0.1,'-,"7.73 unit decrease",[NR],LINC02853,"Response to tocilizumab in rheumatoid arthritis","rheumatoid arthritis, response to drug",GCST001476,15:36057645
rs1142345-<b>?</b>,"9 x 10-61",,NR,'-,"7.69 unit decrease",'-,TPMT,"Thiopurine methyltransferase activity in acute lymphoblastic leukemia patients treated with mercaptopurines","thiopurine methyltransferase activity measurement, response to mercaptopurine, acute lymphoblastic leukemia",GCST003609,6:18130687
rs10949482-<b>T</b>,"1 x 10-20",,NR,'-,'-,'-,NHLRC1,"Erythrocyte methylated 6-mercaptopurine metabolite concentration in 6-mercaptopurine-treated acute lymphoblastic leukaemia","thiopurine metabolite measurement, response to mercaptopurine, acute lymphoblastic leukemia",GCST007149,6:18121083
rs79050301-<b>C</b>,"8 x 10-10",,NR,'-,'-,'-,TPMT,"DNA-incorporated thioguanine levels in 6-mercaptopurine-treated acute lymphoblastic leukaemia","thiopurine metabolite measurement, response to mercaptopurine, acute lymphoblastic leukemia",GCST007150,6:18151959
rs10949482-<b>T</b>,"1 x 10-33",,NR,'-,'-,'-,NHLRC1,"Erythrocyte thioguanine concentration in 6-mercaptopurine-treated acute lymphoblastic leukaemia","thiopurine metabolite measurement, response to mercaptopurine, acute lymphoblastic leukemia",GCST007148,6:18121083
rs1442118-<b>A</b>,"2 x 10-8",(EA),NR,'-,"3.89 unit increase",NR,LINC02163,"Systolic blood pressure response to thiazide and thiazide-like diuretics in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009645,5:104354615
rs79944011-<b>A</b>,"5 x 10-8",(AA),NR,'-,"19.13 unit increase",NR,"AKR1B1, SLC35B4","Systolic blood pressure response to thiazide and thiazide-like diuretics in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009645,7:134355236
rs79237970-<b>T</b>,"8 x 10-9",(AA),NR,'-,"12.02 unit decrease",NR,WDR92,"Diastolic blood pressure response to thiazide and thiazide-like diuretics in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009646,2:68123598
rs118131161-<b>G</b>,"1 x 10-8",(EA),NR,'-,"7.3599 unit increase",NR,"COL4A1, RN7SL783P","Diastolic blood pressure response to thiazide and thiazide-like diuretics in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009646,13:110131585
rs2400940-<b>T</b>,"4 x 10-8",(EA),NR,'-,"2.5285 unit increase",NR,"MEG3, DLK1","Diastolic blood pressure response to thiazide and thiazide-like diuretics in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009646,14:100758585
rs118140307-<b>C</b>,"5 x 10-8",(EA),NR,'-,"7.1643 unit increase",NR,LRRC4C,"Diastolic blood pressure response to thiazide and thiazide-like diuretics in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009646,11:40895426
chr1:218216863-<b>A</b>,"1 x 10-6",(AA),0.028,'-,"15.71 unit increase",[9.67-21.75],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr3:190369649-<b>G</b>,"1 x 10-6",(AA),0.073,'-,"11.49 unit decrease",[7.02-15.96],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr22:19342329-<b>C</b>,"2 x 10-6",(AA),0.017,'-,"20.28 unit decrease",[12.26-28.3],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr13:33831026-<b>A</b>,"2 x 10-6",(AA),0.176,'-,"6.24 unit increase",[3.77-8.71],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr6:45490690-<b>T</b>,"2 x 10-6",(AA),0.034,'-,"14.74 unit increase",[8.88-20.6],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr14:46568609-<b>A</b>,"3 x 10-6",(AA),0.021,'-,"21.21 unit increase",[12.66-29.76],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr4:140544936-<b>A</b>,"3 x 10-6",(AA),0.29,'-,"4.85 unit increase",[2.89-6.81],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr14:68773739-<b>T</b>,"3 x 10-6",(AA),0.244,'-,"5.63 unit increase",[3.36-7.9],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr11:21259199-<b>T</b>,"4 x 10-6",(AA),0.257,'-,"6.22 unit increase",[3.69-8.75],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr5:156144905-<b>G</b>,"4 x 10-6",(AA),0.012,'-,"24.79 unit increase",[14.72-34.86],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr14:97468972-<b>C</b>,"4 x 10-6",(AA),0.425,'-,"5.02 unit increase",[2.98-7.06],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr2:40645825-<b>A</b>,"4 x 10-6",(AA),0.14,'-,"6.55 unit increase",[3.88-9.22],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr6:158195695-<b>G</b>,"4 x 10-6",(AA),0.288,'-,"4.98 unit decrease",[2.94-7.02],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr7:137230391-<b>C</b>,"4 x 10-6",(AA),0.031,'-,"15.06 unit increase",[8.89-21.23],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr1:205796021-<b>C</b>,"4 x 10-6",(AA),0.068,'-,"10.53 unit decrease",[6.2-14.86],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr13:92244167-<b>T</b>,"5 x 10-6",(AA),0.031,'-,"14.42 unit increase",[8.48-20.36],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr5:76411774-<b>T</b>,"5 x 10-6",(AA),0.037,'-,"12.72 unit decrease",[7.47-17.97],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr7:55729814-<b>C</b>,"5 x 10-6",(AA),0.347,'-,"4.86 unit decrease",[2.86-6.86],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr2:60002943-<b>GC</b>,"6 x 10-6",(AA),0.18,'-,"5.86 unit increase",[3.43-8.29],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr1:28452553-<b>T</b>,"6 x 10-6",(AA),0.019,'-,"17.5 unit increase",[10.23-24.77],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr18:29665179-<b>G</b>,"6 x 10-6",(AA),0.014,'-,"21.45 unit increase",[12.49-30.41],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr1:4550104-<b>A</b>,"6 x 10-6",(AA),0.149,'-,"5.93 unit decrease",[3.46-8.4],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr15:42938962-<b>A</b>,"7 x 10-6",(AA),0.367,'-,"4.53 unit decrease",[2.63-6.43],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr3:70984708-<b>C</b>,"7 x 10-6",(AA),0.025,'-,"15.05 unit increase",[8.74-21.36],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr16:4200277-<b>T</b>,"7 x 10-6",(AA),0.028,'-,"15.14 unit decrease",[8.79-21.49],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr21:30014690-<b>A</b>,"7 x 10-6",(AA),0.116,'-,"7.09 unit increase",[4.11-10.07],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr20:52774427-<b>G</b>,"7 x 10-6",(AA),0.409,'-,"5 unit increase",[2.9-7.1],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr3:39754820-<b>C</b>,"7 x 10-6",(AA),0.359,'-,"4.63 unit decrease",[2.69-6.57],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr7:133636770-<b>A</b>,"8 x 10-6",(AA),0.032,'-,"12.59 unit increase",[7.28-17.9],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr7:134039988-<b>A</b>,"8 x 10-6",(AA),0.012,'-,"20.96 unit increase",[12.1-29.82],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr17:70810958-<b>G</b>,"9 x 10-6",(AA),0.057,'-,"10.34 unit increase",[5.95-14.73],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr3:68603582-<b>G</b>,"9 x 10-6",(AA),0.366,'-,"4.52 unit decrease",[2.6-6.44],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr10:13468298-<b>G</b>,"9 x 10-6",(AA),0.036,'-,"12.73 unit increase",[7.32-18.14],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr16:7504546-<b>G</b>,"9 x 10-6",(AA),0.162,'-,"6.53 unit decrease",[3.75-9.31],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr12:70421583-<b>C</b>,"7 x 10-7",(EA),0.479,'-,"2.67 unit decrease",[1.65-3.69],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr20:47032395-<b>A</b>,"2 x 10-6",(EA),0.134,'-,"5.42 unit decrease",[3.26-7.58],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr6:26045367-<b>TTA</b>,"2 x 10-6",(EA),0.045,'-,"8.66 unit decrease",[5.19-12.13],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr16:56697867-<b>G</b>,"3 x 10-6",(EA),0.126,'-,"5.53 unit decrease",[3.3-7.76],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr18:66520811-<b>AT</b>,"3 x 10-6",(EA),0.024,'-,"10.69 unit increase",[6.36-15.02],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr5:1688900-<b>A</b>,"3 x 10-6",(EA),0.041,'-,"5.46 unit decrease",[3.25-7.67],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr20:10244172-<b>C</b>,"4 x 10-6",(EA),0.041,'-,"6.35 unit decrease",[3.72-8.98],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr17:42821246-<b>C</b>,"5 x 10-6",(EA),0.01,'-,"16.99 unit decrease",[9.93-24.05],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr4:144288418-<b>A</b>,"6 x 10-6",(EA),0.009,'-,"13.28 unit decrease",[7.71-18.85],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr14:104359310-<b>T</b>,"6 x 10-6",(EA),0.037,'-,"8.1 unit decrease",[4.69-11.51],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr15:62437471-<b>C</b>,"6 x 10-6",(EA),0.01,'-,"14.23 unit decrease",[8.25-20.21],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr11:127223995-<b>C</b>,"6 x 10-6",(EA),0.377,'-,"2.62 unit decrease",[1.52-3.72],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr20:61032694-<b>T</b>,"6 x 10-6",(EA),0.081,'-,"4.85 unit increase",[2.81-6.89],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr2:148156515-<b>T</b>,"7 x 10-6",(EA),0.029,'-,"11.32 unit decrease",[6.54-16.1],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr21:15364317-<b>A</b>,"7 x 10-6",(EA),0.017,'-,"13.57 unit decrease",[7.83-19.31],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr3:37276320-<b>T</b>,"7 x 10-6",(EA),0.284,'-,"2.61 unit increase",[1.51-3.71],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr9:18139412-<b>G</b>,"7 x 10-6",(EA),0.235,'-,"2.65 unit increase",[1.53-3.77],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr1:115464269-<b>CA</b>,"7 x 10-6",(EA),0.353,'-,"2.78 unit increase",[1.6-3.96],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr15:38626475-<b>C</b>,"8 x 10-6",(EA),0.102,'-,"4.16 unit decrease",[2.4-5.92],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr5:38751223-<b>C</b>,"8 x 10-6",(EA),0.414,'-,"2.19 unit decrease",[1.25-3.13],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr19:10408439-<b>C</b>,"8 x 10-6",(EA),0.035,'-,"8.44 unit decrease",[4.83-12.05],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr2:34319717-<b>A</b>,"8 x 10-6",(EA),0.359,'-,"2.2 unit increase",[1.26-3.14],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr3:65620508-<b>G</b>,"8 x 10-6",(EA),0.025,'-,"7.47 unit decrease",[4.28-10.66],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr16:65929016-<b>G</b>,"9 x 10-6",(EA),0.46,'-,"2.2 unit increase",[1.26-3.14],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr14:95912388-<b>A</b>,"9 x 10-6",(EA),0.076,'-,"3.92 unit decrease",[2.23-5.61],'-,"Systolic blood pressure response to chlorthalidone in hypertension","response to diuretic, hypertension, systolic blood pressure change measurement",GCST009644,"Mapping not available"
chr9:106700069-<b>T</b>,"2 x 10-7",(AA),0.028,'-,"10.07 unit decrease",[6.48-13.66],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr5:50624217-<b>G</b>,"2 x 10-7",(AA),0.02,'-,"12.5 unit decrease",[8.03-16.97],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr14:48940347-<b>T</b>,"2 x 10-7",(AA),0.011,'-,"18.36 unit decrease",[11.74-24.98],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr5:58418501-<b>A</b>,"3 x 10-7",(AA),0.085,'-,"6.74 unit increase",[4.31-9.17],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr13:106475443-<b>T</b>,"3 x 10-7",(AA),0.018,'-,"12.6 unit decrease",[8.01-17.19],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr11:2913938-<b>T</b>,"4 x 10-7",(AA),0.011,'-,"18.32 unit decrease",[11.56-25.08],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr4:180442771-<b>C</b>,"4 x 10-7",(AA),0.024,'-,"11.38 unit decrease",[7.19-15.57],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr21:45737605-<b>T</b>,"1 x 10-6",(AA),0.026,'-,"11.46 unit decrease",[7.07-15.85],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr8:81977545-<b>C</b>,"1 x 10-6",(AA),0.016,'-,"13.25 unit decrease",[8.17-18.33],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr2:158485292-<b>A</b>,"1 x 10-6",(AA),0.013,'-,"20.3 unit decrease",[12.44-28.16],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr8:89122108-<b>C</b>,"1 x 10-6",(AA),0.014,'-,"16.42 unit decrease",[10.07-22.77],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr7:10129002-<b>T</b>,"1 x 10-6",(AA),0.011,'-,"19.72 unit decrease",[12.08-27.36],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr17:47989987-<b>G</b>,"1 x 10-6",(AA),0.024,'-,"13.08 unit decrease",[7.98-18.18],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr10:76827323-<b>A</b>,"2 x 10-6",(AA),0.217,'-,"3.84 unit increase",[2.35-5.33],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr5:10515903-<b>G</b>,"2 x 10-6",(AA),0.035,'-,"8.76 unit decrease",[5.31-12.21],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr14:89369962-<b>A</b>,"2 x 10-6",(AA),0.02,'-,"9.68 unit decrease",[5.86-13.5],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr3:69281337-<b>G</b>,"2 x 10-6",(AA),0.48,'-,"3.59 unit decrease",[2.16-5.02],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr9:31295759-<b>A</b>,"3 x 10-6",(AA),0.027,'-,"10.88 unit decrease",[6.53-15.23],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr19:42342073-<b>A</b>,"3 x 10-6",(AA),0.026,'-,"12.79 unit decrease",[7.65-17.93],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr7:18282368-<b>A</b>,"3 x 10-6",(AA),0.012,'-,"15.18 unit decrease",[9.08-21.28],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr6:162192205-<b>A</b>,"3 x 10-6",(AA),0.017,'-,"13.71 unit decrease",[8.2-19.22],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr12:119779963-<b>T</b>,"3 x 10-6",(AA),0.015,'-,"17.29 unit decrease",[10.33-24.25],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr8:134743852-<b>T</b>,"3 x 10-6",(AA),0.015,'-,"14.94 unit decrease",[8.92-20.96],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr22:47691442-<b>T</b>,"3 x 10-6",(AA),0.02,'-,"13.15 unit decrease",[7.84-18.46],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr16:57510363-<b>A</b>,"3 x 10-6",(AA),0.014,'-,"14.31 unit decrease",[8.51-20.11],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr11:121771661-<b>A</b>,"3 x 10-6",(AA),0.011,'-,"13.12 unit decrease",[7.81-18.43],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr4:187490357-<b>G</b>,"4 x 10-6",(AA),0.427,'-,"3.09 unit decrease",[1.84-4.34],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr7:144890144-<b>C</b>,"4 x 10-6",(AA),0.026,'-,"9.93 unit decrease",[5.87-13.99],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr14:36281438-<b>C</b>,"4 x 10-6",(AA),0.013,'-,"15.42 unit decrease",[9.13-21.71],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr5:10489128-<b>T</b>,"4 x 10-6",(AA),0.019,'-,"13.7 unit decrease",[8.09-19.31],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr14:62849226-<b>G</b>,"4 x 10-6",(AA),0.055,'-,"5.9 unit decrease",[3.49-8.31],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr8:71365589-<b>T</b>,"4 x 10-6",(AA),0.017,'-,"13.25 unit decrease",[7.82-18.68],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr15:63923093-<b>C</b>,"5 x 10-6",(AA),0.092,'-,"5.81 unit decrease",[3.42-8.2],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr12:48800679-<b>A</b>,"5 x 10-6",(AA),0.011,'-,"17.06 unit decrease",[10.04-24.08],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr9:115570712-<b>T</b>,"5 x 10-6",(AA),0.062,'-,"6.91 unit decrease",[4.05-9.77],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr10:76167912-<b>A</b>,"9 x 10-6",(AA),0.271,'-,"4.31 unit increase",[2.47-6.15],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr19:55129569-<b>AAAAAAAG</b>,"9 x 10-6",(AA),0.072,'-,"6.54 unit increase",[3.76-9.32],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr5:27411608-<b>T</b>,"9 x 10-6",(AA),0.217,'-,"3.91 unit decrease",[2.24-5.58],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr12:70421583-<b>C</b>,"7 x 10-7",(EA),0.479,'-,"2.67 unit decrease",[1.65-3.69],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr20:47032395-<b>A</b>,"2 x 10-6",(EA),0.134,'-,"5.42 unit decrease",[3.26-7.58],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr6:26045367-<b>TTA</b>,"2 x 10-6",(EA),0.045,'-,"8.66 unit decrease",[5.19-12.13],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr16:56697867-<b>G</b>,"3 x 10-6",(EA),0.126,'-,"5.53 unit decrease",[3.3-7.76],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr18:66520811-<b>AT</b>,"3 x 10-6",(EA),0.024,'-,"10.69 unit increase",[6.36-15.02],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr5:1688900-<b>A</b>,"3 x 10-6",(EA),0.041,'-,"5.46 unit decrease",[3.25-7.67],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr20:10244172-<b>C</b>,"4 x 10-6",(EA),0.041,'-,"6.35 unit decrease",[3.72-8.98],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr17:42821246-<b>C</b>,"5 x 10-6",(EA),0.01,'-,"16.99 unit decrease",[9.93-24.05],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr4:144288418-<b>A</b>,"6 x 10-6",(EA),0.009,'-,"13.28 unit decrease",[7.71-18.85],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr14:104359310-<b>T</b>,"6 x 10-6",(EA),0.037,'-,"8.1 unit decrease",[4.69-11.51],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr15:62437471-<b>C</b>,"6 x 10-6",(EA),0.01,'-,"14.23 unit decrease",[8.25-20.21],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr11:127223995-<b>C</b>,"6 x 10-6",(EA),0.377,'-,"2.62 unit decrease",[1.52-3.72],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr20:61032694-<b>T</b>,"6 x 10-6",(EA),0.081,'-,"4.85 unit increase",[2.81-6.89],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr2:148156515-<b>T</b>,"7 x 10-6",(EA),0.029,'-,"11.32 unit decrease",[6.54-16.1],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr21:15364317-<b>A</b>,"7 x 10-6",(EA),0.017,'-,"13.57 unit decrease",[7.83-19.31],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr3:37276320-<b>T</b>,"7 x 10-6",(EA),0.284,'-,"2.61 unit increase",[1.51-3.71],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr9:18139412-<b>G</b>,"7 x 10-6",(EA),0.235,'-,"2.65 unit increase",[1.53-3.77],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr1:115464269-<b>CA</b>,"7 x 10-6",(EA),0.353,'-,"2.78 unit increase",[1.6-3.96],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr15:38626475-<b>C</b>,"8 x 10-6",(EA),0.102,'-,"4.16 unit decrease",[2.4-5.92],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr5:38751223-<b>C</b>,"8 x 10-6",(EA),0.414,'-,"2.19 unit decrease",[1.25-3.13],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr19:10408439-<b>C</b>,"8 x 10-6",(EA),0.035,'-,"8.44 unit decrease",[4.83-12.05],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr2:34319717-<b>A</b>,"8 x 10-6",(EA),0.359,'-,"2.2 unit increase",[1.26-3.14],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr22:41218683-<b>C</b>,"5 x 10-6",(AA),0.019,'-,"12.63 unit decrease",[7.4-17.86],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr6:88202550-<b>A</b>,"6 x 10-6",(AA),0.021,'-,"10.39 unit decrease",[6.08-14.7],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr2:68350730-<b>T</b>,"6 x 10-6",(AA),0.011,'-,"15.75 unit decrease",[9.2-22.3],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr10:33886562-<b>G</b>,"6 x 10-6",(AA),0.112,'-,"4.81 unit increase",[2.81-6.81],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr8:142574962-<b>T</b>,"6 x 10-6",(AA),0.184,'-,"4.29 unit decrease",[2.51-6.07],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr13:76825276-<b>A</b>,"6 x 10-6",(AA),0.024,'-,"8.75 unit decrease",[5.1-12.4],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr1:182097713-<b>C</b>,"6 x 10-6",(AA),0.034,'-,"9.18 unit decrease",[5.34-13.02],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr3:123014904-<b>T</b>,"6 x 10-6",(AA),0.023,'-,"12.66 unit decrease",[7.37-17.95],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr16:77814065-<b>A</b>,"7 x 10-6",(AA),0.031,'-,"9.01 unit decrease",[5.23-12.79],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr15:41901475-<b>C</b>,"7 x 10-6",(AA),0.033,'-,"8.51 unit decrease",[4.94-12.08],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr3:37843727-<b>AG</b>,"7 x 10-6",(AA),0.241,'-,"3.49 unit decrease",[2.02-4.96],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr22:19321745-<b>A</b>,"7 x 10-6",(AA),0.013,'-,"15.6 unit decrease",[9.03-22.17],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr15:24599180-<b>A</b>,"7 x 10-6",(AA),0.028,'-,"11.27 unit decrease",[6.53-16.01],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr8:51443231-<b>C</b>,"8 x 10-6",(AA),0.045,'-,"7.21 unit decrease",[4.17-10.25],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr11:2852309-<b>T</b>,"8 x 10-6",(AA),0.027,'-,"9.35 unit decrease",[5.41-13.29],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr16:5571510-<b>T</b>,"8 x 10-6",(AA),0.055,'-,"7.05 unit decrease",[4.07-10.03],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr14:47049146-<b>G</b>,"8 x 10-6",(AA),0.096,'-,"5.28 unit decrease",[3.05-7.51],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr1:23715978-<b>G</b>,"8 x 10-6",(AA),0.205,'-,"3.63 unit increase",[2.1-5.16],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr10:97987596-<b>C</b>,"8 x 10-6",(AA),0.011,'-,"15.92 unit decrease",[9.18-22.66],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr8:92693591-<b>T</b>,"9 x 10-6",(AA),0.034,'-,"8.29 unit decrease",[4.78-11.8],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr5:76449714-<b>G</b>,"9 x 10-6",(AA),0.046,'-,"7.86 unit decrease",[4.53-11.19],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr2:2870592-<b>G</b>,"9 x 10-6",(AA),0.032,'-,"8.85 unit decrease",[5.09-12.61],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr20:11017205-<b>C</b>,"9 x 10-6",(AA),0.012,'-,"18.31 unit decrease",[10.53-26.09],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr3:47580813-<b>T</b>,"9 x 10-6",(AA),0.123,'-,"4.88 unit decrease",[2.8-6.96],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr8:77343407-<b>G</b>,"9 x 10-6",(AA),0.197,'-,"3.96 unit decrease",[2.27-5.65],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr3:65620508-<b>G</b>,"8 x 10-6",(EA),0.025,'-,"7.47 unit decrease",[4.28-10.66],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr16:65929016-<b>G</b>,"9 x 10-6",(EA),0.46,'-,"2.2 unit increase",[1.26-3.14],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
chr14:95912388-<b>A</b>,"9 x 10-6",(EA),0.076,'-,"3.92 unit decrease",[2.23-5.61],'-,"Diastolic blood pressure response to chlorthalidone in hypertension","response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009643,"Mapping not available"
rs2273359-<b>C</b>,"6 x 10-8",,0.04,'-,"8.15 mm Hg increase",[NR],"NELFCD, CTSZ","Response to diuretic therapy in hypertension","response to diuretic",GCST002067,20:58987047
rs13279522-<b>?</b>,"5 x 10-7",,NR,1.59,'-,[1.33-1.92],DNAJC5B,"Coronary heart disease event reduction (statin therapy interaction)","response to statin, coronary artery disease",GCST001545,8:66062017
rs11604904-<b>?</b>,"7 x 10-6",,0.201249,3.5436242,'-,NR,MICAL2,"Cardiovascular death, myocardial infarction or stroke in response to clopidogrel treatment","stroke, response to clopidogrel, cardiovascular event measurement",GCST010483,11:12239165
rs35323955-<b>C</b>,"4 x 10-6",,0.542679,2.2579808,'-,NR,'-,"Cardiovascular death, myocardial infarction or stroke in response to clopidogrel treatment","stroke, response to clopidogrel, cardiovascular event measurement",GCST010483,8:137210487
rs7086422-<b>T</b>,"8 x 10-6",,0.737762,2.261929,'-,NR,PRKG1,"Cardiovascular death, myocardial infarction or stroke in response to clopidogrel treatment","stroke, response to clopidogrel, cardiovascular event measurement",GCST010483,10:51474417
rs4782918-<b>G</b>,"3 x 10-6",,0.522901,2.3190856,'-,NR,WFDC1,"Cardiovascular death, myocardial infarction or stroke in response to clopidogrel treatment","stroke, response to clopidogrel, cardiovascular event measurement",GCST010483,16:84305578
rs7714373-<b>G</b>,"8 x 10-6",,0.829285,2.4056714,'-,NR,LHFPL2,"Cardiovascular death, myocardial infarction or stroke in response to clopidogrel treatment","stroke, response to clopidogrel, cardiovascular event measurement",GCST010483,5:78725395
rs8017559-<b>?</b>,"5 x 10-6",,0.36822,2.478749,'-,NR,"TRDV2, TRAV41","Cardiovascular death, myocardial infarction or stroke in response to clopidogrel treatment","stroke, response to clopidogrel, cardiovascular event measurement",GCST010483,14:22395865
rs1606812-<b>?</b>,"3 x 10-7",(AA),NR,'-,"11.5 ms decrease",[7.19-15.81],LINC01911,"QT interval (sulfonylurea treatment interaction)","response to sulfonylurea, QT interval",GCST004031,2:146957758
rs10767455-<b>?</b>,"4 x 10-7",(AA),NR,'-,"2.1 ms increase",[1.32-2.88],LINC02699,"QRS interval (sulfonylurea treatment interaction)","QRS duration, response to sulfonylurea",GCST004033,11:25778731
rs7726558-<b>?</b>,"4 x 10-7",(AA),NR,'-,"6.2 ms decrease",[3.85-8.55],HSD17B4,"QT interval (sulfonylurea treatment interaction)","response to sulfonylurea, QT interval",GCST004031,5:119576903
rs985292-<b>?</b>,"1 x 10-6",(AA),NR,'-,"2.4 ms increase",[1.42-3.38],ARHGEF12,"QRS interval (sulfonylurea treatment interaction)","QRS duration, response to sulfonylurea",GCST004033,11:127807979
rs17081313-<b>?</b>,"2 x 10-7",,NR,'-,"11.2 ms increase",[7.08-15.32],LINC02353,"QT interval (sulfonylurea treatment interaction)","response to sulfonylurea, QT interval",GCST004031,4:32375105
rs4591595-<b>?</b>,"3 x 10-7",(EA),NR,'-,"2.8 ms decrease",[1.62-3.98],"COQ2, PLAC8","QRS interval (sulfonylurea treatment interaction)","QRS duration, response to sulfonylurea",GCST004033,4:83203287
rs6035275-<b>?</b>,"1 x 10-7",(EA),NR,'-,"12 ms decrease",[7.69-16.31],SLC24A3,"QT interval (sulfonylurea treatment interaction)","response to sulfonylurea, QT interval",GCST004031,20:19291566
rs4911179-<b>?</b>,"8 x 10-8",(EA),NR,'-,"1.7 ms decrease",[1.11-2.29],UQCC1,"QRS interval (sulfonylurea treatment interaction)","QRS duration, response to sulfonylurea",GCST004033,20:35385096
rs9966832-<b>?</b>,"2 x 10-8",(EA),NR,'-,"10.4 ms decrease",[6.68-14.12],RN7SL97P,"QT interval (sulfonylurea treatment interaction)","response to sulfonylurea, QT interval",GCST004031,18:25825224
rs830233-<b>?</b>,"3 x 10-12",(AA),NR,'-,"16.3 ms decrease",[11.79-20.81],RPL7P20,"QT interval (sulfonylurea treatment interaction)","response to sulfonylurea, QT interval",GCST004031,5:165976741
rs1890262-<b>?</b>,"8 x 10-7",(EA),NR,'-,"13.8 ms increase",[8.31-19.29],TM2D1,"QT interval (sulfonylurea treatment interaction)","response to sulfonylurea, QT interval",GCST004031,1:61648730
rs12132562-<b>?</b>,"4 x 10-7",(AA),NR,'-,"8.5 ms increase",[5.17-11.83],"PIGC, DNM3","QT interval (sulfonylurea treatment interaction)","response to sulfonylurea, QT interval",GCST004031,1:172384331
rs1388107-<b>?</b>,"5 x 10-7",(AA),NR,'-,"6.2 ms decrease",[3.85-8.55],HSD17B4,"JT interval (sulfonylurea treatment interaction)","JT interval, response to sulfonylurea",GCST004032,5:119573311
rs2182486-<b>?</b>,"1 x 10-7",(AA),NR,'-,"13.3 ms decrease",[8.4-18.2],DCLK1,"JT interval (sulfonylurea treatment interaction)","JT interval, response to sulfonylurea",GCST004032,13:35792945
rs9853921-<b>?</b>,"8 x 10-7",,NR,'-,"2.3 ms decrease",[1.32-3.28],'-,"JT interval (sulfonylurea treatment interaction)","JT interval, response to sulfonylurea",GCST004032,3:118240655
rs624896-<b>?</b>,"9 x 10-7",,NR,'-,"6 ms decrease",[3.65-8.35],"KCNN2, LINC01957","JT interval (sulfonylurea treatment interaction)","JT interval, response to sulfonylurea",GCST004032,5:114520357
rs200214-<b>?</b>,"4 x 10-7",,NR,'-,"3.6 ms decrease",[2.23-4.97],FARS2,"JT interval (sulfonylurea treatment interaction)","JT interval, response to sulfonylurea",GCST004032,6:5478560
rs17156495-<b>?</b>,"5 x 10-7",,NR,'-,"8.5 ms decrease",[5.17-11.83],'-,"JT interval (sulfonylurea treatment interaction)","JT interval, response to sulfonylurea",GCST004032,7:109123612
rs16895033-<b>?</b>,"1 x 10-6",(EA),NR,'-,"7.9 ms decrease",[4.76-11.04],RPL35AP19,"JT interval (sulfonylurea treatment interaction)","JT interval, response to sulfonylurea",GCST004032,8:121285201
rs17211409-<b>?</b>,"6 x 10-8",(Hispanic/Latino),NR,'-,"11.6 ms decrease",[7.48-15.72],ME3,"JT interval (sulfonylurea treatment interaction)","JT interval, response to sulfonylurea",GCST004032,11:86614845
rs17107548-<b>?</b>,"1 x 10-6",(Hispanic/Latino),NR,'-,"6.6 ms increase",[4.05-9.15],NRXN3,"JT interval (sulfonylurea treatment interaction)","JT interval, response to sulfonylurea",GCST004032,14:78425799
rs1890262-<b>?</b>,"2 x 10-8",(EA),NR,'-,"14.9 ms increase",[9.8-20],TM2D1,"JT interval (sulfonylurea treatment interaction)","JT interval, response to sulfonylurea",GCST004032,1:61648730
rs12468579-<b>?</b>,"5 x 10-8",(AA),NR,'-,"4.1 ms increase",[2.53-5.67],STAT1,"JT interval (sulfonylurea treatment interaction)","JT interval, response to sulfonylurea",GCST004032,2:190967538
rs1478173-<b>?</b>,"1 x 10-12",(AA),NR,'-,"15 ms decrease",[10.88-19.12],TOMM22P6,"JT interval (sulfonylurea treatment interaction)","JT interval, response to sulfonylurea",GCST004032,3:162558617
rs17281245-<b>?</b>,"5 x 10-9",(AA),NR,'-,"8.8 ms increase",[5.86-11.74],'-,"JT interval (sulfonylurea treatment interaction)","JT interval, response to sulfonylurea",GCST004032,4:181714136
rs7713675-<b>?</b>,"1 x 10-8",(AA),NR,'-,"12.2 ms decrease",[8.08-16.32],LINC02109,"JT interval (sulfonylurea treatment interaction)","JT interval, response to sulfonylurea",GCST004032,5:28750200
rs1106399-<b>?</b>,"3 x 10-7",(AA),NR,'-,"10.5 ms increase",[6.58-14.42],'-,"QT interval (sulfonylurea treatment interaction)","response to sulfonylurea, QT interval",GCST004031,2:200139114
rs10484885-<b>?</b>,"9 x 10-7",(AA),NR,'-,"3.5 ms increase",[2.13-4.87],MDN1,"QRS interval (sulfonylurea treatment interaction)","QRS duration, response to sulfonylurea",GCST004033,6:89685297
rs1439840-<b>?</b>,"7 x 10-7",,NR,'-,"4.7 ms decrease",[2.74-6.66],'-,"QT interval (sulfonylurea treatment interaction)","response to sulfonylurea, QT interval",GCST004031,2:122651367
rs4855537-<b>?</b>,"1 x 10-6",(AA),NR,'-,"4.6 ms decrease",[2.84-6.36],TAFA4,"QRS interval (sulfonylurea treatment interaction)","QRS duration, response to sulfonylurea",GCST004033,3:68906333
rs6718130-<b>?</b>,"8 x 10-8",(EA),NR,'-,"9.1 ms increase",[5.77-12.43],"LINC01830, KCNS3","QT interval (sulfonylurea treatment interaction)","response to sulfonylurea, QT interval",GCST004031,2:18451319
rs4362469-<b>?</b>,"7 x 10-7",(EA),NR,'-,"4.8 ms decrease",[2.84-6.76],"LINC02582, LINC02864","QRS interval (sulfonylurea treatment interaction)","QRS duration, response to sulfonylurea",GCST004033,18:73269323
rs17639063-<b>?</b>,"3 x 10-7",(Hispanic/Latino),NR,'-,"9.7 ms increase",[5.98-13.42],CADPS,"QT interval (sulfonylurea treatment interaction)","response to sulfonylurea, QT interval",GCST004031,3:62548760
rs1777084-<b>?</b>,"1 x 10-6",(Hispanic/Latino),NR,'-,"3.3 ms decrease",[1.93-4.67],YWHAQP1,"QRS interval (sulfonylurea treatment interaction)","QRS duration, response to sulfonylurea",GCST004033,14:42709204
rs2134953-<b>?</b>,"8 x 10-8",,NR,'-,"7.8 ms decrease",[5.06-10.54],CSMD1,"QRS interval (sulfonylurea treatment interaction)","QRS duration, response to sulfonylurea",GCST004033,8:4328031
rs7861565-<b>?</b>,"2 x 10-7",,NR,'-,"3.7 ms decrease",[2.33-5.07],CNTLN,"QRS interval (sulfonylurea treatment interaction)","QRS duration, response to sulfonylurea",GCST004033,9:17346857
rs3736352-<b>?</b>,"3 x 10-7",,NR,'-,"2.7 ms increase",[1.72-3.68],TINAG,"QRS interval (sulfonylurea treatment interaction)","QRS duration, response to sulfonylurea",GCST004033,6:54389791
rs10507540-<b>?</b>,"6 x 10-8",,NR,'-,"2.2 ms decrease",[1.42-2.98],LRRC63,"QRS interval (sulfonylurea treatment interaction)","QRS duration, response to sulfonylurea",GCST004033,13:46267417
rs1397988-<b>?</b>,"7 x 10-7",,NR,'-,"1.6 ms decrease",[1.01-2.19],LINC01478,"QRS interval (sulfonylurea treatment interaction)","QRS duration, response to sulfonylurea",GCST004033,18:44442837
rs6088791-<b>?</b>,"8 x 10-7",,NR,'-,"1.1 ms decrease",[0.71-1.49],UQCC1,"QRS interval (sulfonylurea treatment interaction)","QRS duration, response to sulfonylurea",GCST004033,20:35320106
rs7595140-<b>?</b>,"4 x 10-8",(EA),NR,'-,"5.7 ms decrease",[3.74-7.66],ZNF638,"QRS interval (sulfonylurea treatment interaction)","QRS duration, response to sulfonylurea",GCST004033,2:71324491
rs7861565-<b>?</b>,"6 x 10-8",(AA),NR,'-,"4 ms decrease",[2.63-5.37],CNTLN,"QRS interval (sulfonylurea treatment interaction)","QRS duration, response to sulfonylurea",GCST004033,9:17346857
rs1997103-<b>?</b>,"6 x 10-8",(AA),NR,'-,"9 ms decrease",[5.67-12.33],"LANCL2, CALM1P2","QRS interval (sulfonylurea treatment interaction)","QRS duration, response to sulfonylurea",GCST004033,7:55327697
rs12430683-<b>?</b>,"2 x 10-7",(AA),NR,'-,"3.2 ms decrease",[2.02-4.38],"SLC15A1, DOCK9","QRS interval (sulfonylurea treatment interaction)","QRS duration, response to sulfonylurea",GCST004033,13:98775476
rs10890920-<b>A</b>,"3 x 10-6","(Sulfonylurea Hypoglycemic agents)",0.57,'-,'-,'-,"RNU6-654P, DDX10","QT interval (drug interaction)","response to sulfonylurea, QT interval",GCST001890,11:109002392
rs1612141-<b>A</b>,"5 x 10-6","(Sulfonylurea Hypoglycemic agents)",0.21,'-,'-,'-,LINC02315,"QT interval (drug interaction)","response to sulfonylurea, QT interval",GCST001890,14:41233395
rs7006687-<b>T</b>,"2 x 10-6","(Sulfonylurea Hypoglycemic agents)",0.57,'-,'-,'-,"NATP, NAT2","QT interval (drug interaction)","response to sulfonylurea, QT interval",GCST001890,8:18376073
rs230014-<b>A</b>,"4 x 10-6","(Sulfonylurea Hypoglycemic agents)",0.48,'-,'-,'-,RPSAP1,"QT interval (drug interaction)","response to sulfonylurea, QT interval",GCST001890,20:51123323
rs10916248-<b>A</b>,"5 x 10-6","(Sulfonylurea Hypoglycemic agents)",0.8,'-,'-,'-,"RN7SKP49, SEPTIN7P13","QT interval (drug interaction)","response to sulfonylurea, QT interval",GCST001890,1:224068646
rs969088-<b>C</b>,"2 x 10-6","(Han Chinese)",NR,1.43,'-,[1.24-1.66],'-,"Response to platinum-based chemotherapy in non-small-cell lung cancer","response to platinum based chemotherapy, non-small cell lung carcinoma",GCST001629,5:26389153
rs41997-<b>A</b>,"4 x 10-7","(Han Chinese)",NR,1.52,'-,[1.28-1.79],ANKRD7,"Response to platinum-based chemotherapy in non-small-cell lung cancer","response to platinum based chemotherapy, non-small cell lung carcinoma",GCST001629,7:118351841
rs12000445-<b>A</b>,"7 x 10-6","(Han Chinese)",NR,1.49,'-,[1.25-1.75],'-,"Response to platinum-based chemotherapy in non-small-cell lung cancer","response to platinum based chemotherapy, non-small cell lung carcinoma",GCST001629,9:23426273
rs969088-<b>C</b>,"3 x 10-6","(Han Chinese + EA)",NR,1.4,'-,[1.22-1.61],'-,"Response to platinum-based chemotherapy in non-small-cell lung cancer","response to platinum based chemotherapy, non-small cell lung carcinoma",GCST001629,5:26389153
rs3850370-<b>C</b>,"4 x 10-6","(Han Chinese + EA)",NR,1.31,'-,[1.17-1.47],FXNP1,"Response to platinum-based chemotherapy in non-small-cell lung cancer","response to platinum based chemotherapy, non-small cell lung carcinoma",GCST001629,14:78068563
rs6935723-<b>C</b>,"1 x 10-21",,0.27,2.46,'-,[2.04-2.98],"MTCO3P1, HLA-DQB3","Response to thiopurine immunosuppressants in inflammatory bowel disease (pancreatitis) (azathioprine and mercaptopurine)","response to thiopurine, thiopurine immunosuppressant-induced pancreatitis, inflammatory bowel disease",GCST002607,6:32713892
rs12140361-<b>?</b>,"3 x 10-6","(adjusted for dose, GFR & AST)",NR,'-,"7.098 unit increase",'-,SDHC,"Paclitaxel disposition in epithelial ovarian cancer","Malignant epithelial tumor of ovary, response to paclitaxel",GCST005352,1:161352208
rs7566539-<b>?</b>,"3 x 10-6","(adjusted for dose, GFR & AST)",NR,'-,"7.171 unit increase",'-,'-,"Paclitaxel disposition in epithelial ovarian cancer","Malignant epithelial tumor of ovary, response to paclitaxel",GCST005352,2:122620366
rs9934640-<b>?</b>,"5 x 10-6","(adjusted for dose, GFR & AST)",NR,'-,"8.074 unit increase",'-,RNA5SP431,"Paclitaxel disposition in epithelial ovarian cancer","Malignant epithelial tumor of ovary, response to paclitaxel",GCST005352,16:79311795
rs9283636-<b>?</b>,"5 x 10-7","(adjusted for dose, GFR & AST)",NR,'-,"3.049 unit increase",'-,'-,"Paclitaxel disposition in epithelial ovarian cancer","Malignant epithelial tumor of ovary, response to paclitaxel",GCST005352,3:166315136
rs9302891-<b>?</b>,"7 x 10-6","(adjusted for dose, GFR & AST)",NR,'-,"6.616 unit increase",'-,ABCA10,"Paclitaxel disposition in epithelial ovarian cancer","Malignant epithelial tumor of ovary, response to paclitaxel",GCST005352,17:69228706
rs2483519-<b>?</b>,"2 x 10-6","(adjusted for dose, GFR & AST)",NR,'-,"2.729 unit increase",'-,ABLIM1,"Paclitaxel disposition in epithelial ovarian cancer","Malignant epithelial tumor of ovary, response to paclitaxel",GCST005352,10:114642349
rs16969611-<b>?</b>,"7 x 10-6","(adjusted for dose, GFR & AST)",NR,'-,"3.629 unit increase",'-,LINC00393,"Paclitaxel disposition in epithelial ovarian cancer","Malignant epithelial tumor of ovary, response to paclitaxel",GCST005352,13:107030239
rs1574560-<b>?</b>,"6 x 10-7","(adjusted for dose, GFR & AST)",NR,'-,"3.049 unit increase",'-,'-,"Paclitaxel disposition in epithelial ovarian cancer","Malignant epithelial tumor of ovary, response to paclitaxel",GCST005352,3:166329716
rs2056859-<b>?</b>,"2 x 10-6",,NR,'-,"11.03 unit increase",'-,"LINC01629, RN7SKP17","Paclitaxel disposition in epithelial ovarian cancer","Malignant epithelial tumor of ovary, response to paclitaxel",GCST005352,14:76937083
rs17741873-<b>?</b>,"8 x 10-6","(adjusted for dose, GFR & AST)",NR,'-,"2.888 unit increase",'-,"PLAU, CAMK2G","Paclitaxel disposition in epithelial ovarian cancer","Malignant epithelial tumor of ovary, response to paclitaxel",GCST005352,10:73894042
rs1851138-<b>?</b>,"6 x 10-6",,NR,'-,"6.833 unit increase",'-,ACTG1P22,"Paclitaxel disposition in epithelial ovarian cancer","Malignant epithelial tumor of ovary, response to paclitaxel",GCST005352,2:57804114
rs1614627-<b>?</b>,"6 x 10-7",,NR,'-,"7.424 unit increase",'-,"CDA, PINK1","Paclitaxel disposition in epithelial ovarian cancer","Malignant epithelial tumor of ovary, response to paclitaxel",GCST005352,1:20620263
rs9787692-<b>?</b>,"7 x 10-7","(adjusted for dose, GFR & AST)",NR,'-,"3.672 unit increase",'-,"KRT8P37, CHCHD3P1","Paclitaxel disposition in epithelial ovarian cancer","Malignant epithelial tumor of ovary, response to paclitaxel",GCST005352,10:8603200
rs4235212-<b>?</b>,"6 x 10-6",,NR,'-,"2.503 unit increase",'-,GLRA3,"Paclitaxel disposition in epithelial ovarian cancer","Malignant epithelial tumor of ovary, response to paclitaxel",GCST005352,4:174644094
rs10510382-<b>?</b>,"6 x 10-6",,NR,'-,"3.033 unit increase",'-,LMCD1-AS1,"Paclitaxel disposition in epithelial ovarian cancer","Malignant epithelial tumor of ovary, response to paclitaxel",GCST005352,3:7956266
rs9938946-<b>?</b>,"3 x 10-6",,NR,'-,"3.774 unit increase",'-,HS3ST4,"Paclitaxel disposition in epithelial ovarian cancer","Malignant epithelial tumor of ovary, response to paclitaxel",GCST005352,16:25955783
rs8083427-<b>?</b>,"3 x 10-6",,NR,'-,"5.467 unit increase",'-,KCTD1,"Paclitaxel disposition in epithelial ovarian cancer","Malignant epithelial tumor of ovary, response to paclitaxel",GCST005352,18:26521596
rs2505127-<b>?</b>,"6 x 10-6","(adjusted for dose, GFR & AST)",NR,'-,"5.005 unit increase",'-,JCAD,"Paclitaxel disposition in epithelial ovarian cancer","Malignant epithelial tumor of ovary, response to paclitaxel",GCST005352,10:30080931
rs17130142-<b>?</b>,"2 x 10-7",,NR,'-,"8.641 unit increase",'-,PKN2-AS1,"Paclitaxel disposition in epithelial ovarian cancer","Malignant epithelial tumor of ovary, response to paclitaxel",GCST005352,1:87773925
rs17131753-<b>?</b>,"7 x 10-6",,NR,'-,"7.784 unit increase",'-,RN7SKP247,"Paclitaxel disposition in epithelial ovarian cancer","Malignant epithelial tumor of ovary, response to paclitaxel",GCST005352,1:81208812
rs470903-<b>?</b>,"3 x 10-6","(adjusted for dose, GFR & AST)",NR,'-,"5.453 unit increase",'-,MBP,"Paclitaxel disposition in epithelial ovarian cancer","Malignant epithelial tumor of ovary, response to paclitaxel",GCST005352,18:77003313
rs11840576-<b>?</b>,"2 x 10-6",,NR,'-,"8.684 unit increase",'-,LINC00676,"Paclitaxel disposition in epithelial ovarian cancer","Malignant epithelial tumor of ovary, response to paclitaxel",GCST005352,13:109657033
rs12425791-<b>?</b>,"4 x 10-6",,NR,'-,"2.026 unit increase",'-,"NINJ2-AS1, LINC02455","Paclitaxel disposition in epithelial ovarian cancer","Malignant epithelial tumor of ovary, response to paclitaxel",GCST005352,12:674318
rs2205226-<b>?</b>,"5 x 10-6",,NR,'-,"4.956 unit increase",'-,NRXN3,"Paclitaxel disposition in epithelial ovarian cancer","Malignant epithelial tumor of ovary, response to paclitaxel",GCST005352,14:79888998
rs7013285-<b>?</b>,"3 x 10-6","(adjusted for dose, GFR & AST)",NR,'-,"3.067 unit increase",'-,OXR1,"Paclitaxel disposition in epithelial ovarian cancer","Malignant epithelial tumor of ovary, response to paclitaxel",GCST005352,8:106314611
rs2758596-<b>?</b>,"6 x 10-6",,NR,'-,"4.844 unit increase",'-,"PMF1-BGLAP, PMF1","Paclitaxel disposition in epithelial ovarian cancer","Malignant epithelial tumor of ovary, response to paclitaxel",GCST005352,1:156219495
rs17169015-<b>?</b>,"5 x 10-6",,NR,'-,"18.28 unit increase",'-,PTN,"Paclitaxel disposition in epithelial ovarian cancer","Malignant epithelial tumor of ovary, response to paclitaxel",GCST005352,7:137259485
rs16838233-<b>?</b>,"4 x 10-6",,NR,'-,"5.346 unit increase",'-,LINC01756,"Paclitaxel disposition in epithelial ovarian cancer","Malignant epithelial tumor of ovary, response to paclitaxel",GCST005352,1:29429306
rs17211649-<b>?</b>,"2 x 10-6",,NR,'-,"14.22 unit increase",'-,"EGILA, RNASE4, ANG","Paclitaxel disposition in epithelial ovarian cancer","Malignant epithelial tumor of ovary, response to paclitaxel",GCST005352,14:20698124
rs2241111-<b>?</b>,"6 x 10-6",,NR,'-,"4.844 unit increase",'-,"SEMA4A, SLC25A44","Paclitaxel disposition in epithelial ovarian cancer","Malignant epithelial tumor of ovary, response to paclitaxel",GCST005352,1:156193927
rs969348-<b>?</b>,"6 x 10-6",,NR,'-,"5.866 unit increase",'-,TMC3-AS1,"Paclitaxel disposition in epithelial ovarian cancer","Malignant epithelial tumor of ovary, response to paclitaxel",GCST005352,15:81554938
rs9862857-<b>C</b>,"6 x 10-8",,NR,'-,"0.7386 unit decrease",[NR],LINC01985,"Pharmacokinetics of olanzapine in severe mental disorder (concentration dose ratio)","unipolar depression, schizophrenia, bipolar disorder, response to olanzapine, concentration dose ratio",GCST002885,3:30453840
rs17673138-<b>C</b>,"6 x 10-8",,NR,'-,"0.4143 unit decrease",[NR],NRG1,"Pharmacokinetics of olanzapine in severe mental disorder (concentration dose ratio)","unipolar depression, schizophrenia, bipolar disorder, response to olanzapine, concentration dose ratio",GCST002885,8:32840440
rs10968749-<b>G</b>,"2 x 10-7",,NR,'-,"0.8345 unit decrease",[NR],LINGO2,"Pharmacokinetics of olanzapine in severe mental disorder (concentration dose ratio)","unipolar depression, schizophrenia, bipolar disorder, response to olanzapine, concentration dose ratio",GCST002885,9:28752486
rs10405744-<b>A</b>,"2 x 10-7",,NR,'-,"0.5736 unit decrease",[NR],ZNF93,"Pharmacokinetics of olanzapine in severe mental disorder (concentration dose ratio)","unipolar depression, schizophrenia, bipolar disorder, response to olanzapine, concentration dose ratio",GCST002885,19:19948684
rs11644916-<b>?</b>,"4 x 10-6",,'-,1.4,'-,[1.20-1.59],AXIN1,"Metastatic colorectal cancer survival in treatment with chemotherapy plus biologics","metastatic colorectal cancer, survival time, response to antineoplastic agent",GCST011584,16:309567
rs11246159-<b>?</b>,"6 x 10-6",,'-,1.47,'-,[1.24-1.75],ANO9,"Metastatic colorectal cancer survival in treatment with chemotherapy plus biologics","metastatic colorectal cancer, survival time, response to antineoplastic agent",GCST011584,11:436461
rs6139258-<b>C</b>,"6 x 10-7",,0.02,13.62,'-,[4.90-37.84],RNF24,"Nevirapine-induced hypersensitivity in HIV (drug-induced liver injury)","response to reverse transcriptase inhibitor, HIV infection, drug-induced liver injury",GCST004114,20:3977969
rs5010528-<b>G</b>,"8 x 10-8",,0.14,4.84,'-,[2.71-8.61],"HLA-C, USP8P1","Nevirapine-induced hypersensitivity in HIV (Stevens-Johnson syndrome or toxic epidermal necrosis)","response to reverse transcriptase inhibitor, Stevens-Johnson syndrome, toxic epidermal necrolysis, HIV infection",GCST004115,6:31273255
rs34213790-<b>A</b>,"7 x 10-7",,0.37,2.06,'-,[1.55-2.74],"HLA-B, LINC02571","Nevirapine-induced hypersensitivity in HIV","response to reverse transcriptase inhibitor, hypersensitivity reaction disease, HIV infection",GCST004118,6:31350802
rs8192675-<b>C</b>,"7 x 10-14",(EA),'-,'-,"0.17 unit increase",[0.13-0.21],SLC2A2,"Response to metformin in type 2 diabetes (HbA1c reduction)","HbA1c measurement, type II diabetes mellitus, response to metformin",GCST004522,3:171007094
rs4266947-<b>T</b>,"7 x 10-6",,NR,4.62,'-,[2.37-9.01],LGR6,"PEG-asparaginase hypersensitivity without enzyme activity in childhood acute lymphoblastic leukaemia","asparaginase hypersensitivity, acute lymphoblastic leukemia",GCST007540,1:202233110
rs60086424-<b>T</b>,"1 x 10-7",,NR,5.85,'-,[3.03-11.3],ZNF863P,"PEG-asparaginase hypersensitivity without enzyme activity in childhood acute lymphoblastic leukaemia","asparaginase hypersensitivity, acute lymphoblastic leukemia",GCST007540,2:52162981
rs2560504-<b>T</b>,"3 x 10-6",,NR,9.84,'-,[3.8-25.52],LINC00992,"PEG-asparaginase hypersensitivity without enzyme activity in childhood acute lymphoblastic leukaemia","asparaginase hypersensitivity, acute lymphoblastic leukemia",GCST007540,5:117472385
rs11748968-<b>C</b>,"3 x 10-6",,NR,3.69,'-,[2.13-6.4],"TCERG1, POU4F3","PEG-asparaginase hypersensitivity without enzyme activity in childhood acute lymphoblastic leukaemia","asparaginase hypersensitivity, acute lymphoblastic leukemia",GCST007540,5:146354070
rs9272131-<b>T</b>,"9 x 10-6",,0.11,3.01,'-,[1.85-4.91],HLA-DQA1,"PEG-asparaginase hypersensitivity without enzyme activity in childhood acute lymphoblastic leukaemia","asparaginase hypersensitivity, acute lymphoblastic leukemia",GCST007540,6:32632894
rs73195662-<b>G</b>,"1 x 10-6",,NR,3.52,'-,[2.12-5.85],CDHR3,"PEG-asparaginase hypersensitivity without enzyme activity in childhood acute lymphoblastic leukaemia","asparaginase hypersensitivity, acute lymphoblastic leukemia",GCST007540,7:106018014
rs77032081-<b>T</b>,"7 x 10-6",,NR,8.53,'-,[3.35-21.76],ARNTL,"PEG-asparaginase hypersensitivity without enzyme activity in childhood acute lymphoblastic leukaemia","asparaginase hypersensitivity, acute lymphoblastic leukemia",GCST007540,11:13341732
rs7973974-<b>C</b>,"3 x 10-6",,NR,2.71,'-,[1.78-4.11],BCAT1,"PEG-asparaginase hypersensitivity without enzyme activity in childhood acute lymphoblastic leukaemia","asparaginase hypersensitivity, acute lymphoblastic leukemia",GCST007540,12:24847276
rs60218192-<b>A</b>,"6 x 10-7",,NR,4.76,'-,[2.58-8.81],HS3ST4,"PEG-asparaginase hypersensitivity without enzyme activity in childhood acute lymphoblastic leukaemia","asparaginase hypersensitivity, acute lymphoblastic leukemia",GCST007540,16:25874649
rs73331351-<b>G</b>,"5 x 10-6",,NR,8.24,'-,[3.32-20.44],"ZNF232, ZFP3","PEG-asparaginase hypersensitivity without enzyme activity in childhood acute lymphoblastic leukaemia","asparaginase hypersensitivity, acute lymphoblastic leukemia",GCST007540,17:5101992
rs73062673-<b>C</b>,"5 x 10-8",,0.09,3.73,'-,[2.33-5.98],CNOT3,"PEG-asparaginase hypersensitivity without enzyme activity in childhood acute lymphoblastic leukaemia","asparaginase hypersensitivity, acute lymphoblastic leukemia",GCST007540,19:54151243
rs3130284-<b>C</b>,"7 x 10-6",,NR,1.464,'-,'-,AGPAT1,"Asparaginase hypersensitivity in acute lymphoblastic leukemia","asparaginase hypersensitivity, acute lymphoblastic leukemia",GCST002915,6:32172710
rs6021191-<b>T</b>,"4 x 10-8",,'-,3.109,'-,'-,NFATC2,"Asparaginase hypersensitivity in acute lymphoblastic leukemia","asparaginase hypersensitivity, acute lymphoblastic leukemia",GCST002915,20:51419700
rs17885382-<b>T</b>,"3 x 10-6",,'-,1.627,'-,'-,HLA-DRB1,"Asparaginase hypersensitivity in acute lymphoblastic leukemia","asparaginase hypersensitivity, acute lymphoblastic leukemia",GCST002915,6:32584318
rs7865267-<b>T</b>,"3 x 10-6",,'-,2.012,'-,'-,CACNA1B,"Asparaginase hypersensitivity in acute lymphoblastic leukemia","asparaginase hypersensitivity, acute lymphoblastic leukemia",GCST002915,9:138043623
rs3096696-<b>A</b>,"4 x 10-6",,'-,1.478,'-,'-,"PPT2, PPT2-EGFL8","Asparaginase hypersensitivity in acute lymphoblastic leukemia","asparaginase hypersensitivity, acute lymphoblastic leukemia",GCST002915,6:32154695
rs10260824-<b>C</b>,"5 x 10-6",,'-,1.749,'-,'-,BET1-AS1,"Asparaginase hypersensitivity in acute lymphoblastic leukemia","asparaginase hypersensitivity, acute lymphoblastic leukemia",GCST002915,7:94008313
rs1805465-<b>T</b>,"6 x 10-6",,'-,2.339,'-,'-,MIS12,"Asparaginase hypersensitivity in acute lymphoblastic leukemia","asparaginase hypersensitivity, acute lymphoblastic leukemia",GCST002915,17:5489769
rs821931-<b>G</b>,"9 x 10-6",,'-,1.587,'-,'-,SORCS1,"Asparaginase hypersensitivity in acute lymphoblastic leukemia","asparaginase hypersensitivity, acute lymphoblastic leukemia",GCST002915,10:106677881
rs55945116-<b>G</b>,"6 x 10-7",,0.7892,'-,"23.3347 unit increase",[14.59-32.08],SEC11A,"Response to ketamine in bipolar disorder or major depression (antidepressant effects)","unipolar depression, depressive symptom measurement, response to ketamine, bipolar disorder",GCST007316,15:84676882
rs112647602-<b>G</b>,"5 x 10-6",,0.7875,'-,"23.135 unit decrease",[13.6-32.67],KRASP1,"Response to ketamine in bipolar disorder or major depression (antidepressant effects)","unipolar depression, depressive symptom measurement, response to ketamine, bipolar disorder",GCST007316,6:54731957
rs1846786-<b>T</b>,"6 x 10-6",,0.6951,'-,"19.0893 unit decrease",[11.14-27.04],'-,"Response to ketamine in bipolar disorder or major depression (antidepressant effects)","unipolar depression, depressive symptom measurement, response to ketamine, bipolar disorder",GCST007316,4:130998547
rs5997786-<b>C</b>,"6 x 10-6",,0.7995,'-,"22.0315 unit increase",[12.83-31.23],OSBP2,"Response to ketamine in bipolar disorder or major depression (antidepressant effects)","unipolar depression, depressive symptom measurement, response to ketamine, bipolar disorder",GCST007316,22:30858049
rs1524145-<b>G</b>,"6 x 10-6",,0.5,'-,"17.3121 unit decrease",[10.07-24.55],'-,"Response to ketamine in bipolar disorder or major depression (antidepressant effects)","unipolar depression, depressive symptom measurement, response to ketamine, bipolar disorder",GCST007316,2:35897322
rs6689906-<b>C</b>,"7 x 10-6",,0.9364,'-,"35.6552 unit increase",[20.7-50.61],"LINC01779, MAB21L3","Response to ketamine in bipolar disorder or major depression (antidepressant effects)","unipolar depression, depressive symptom measurement, response to ketamine, bipolar disorder",GCST007316,1:116140919
rs79749176-<b>T</b>,"9 x 10-6",,0.9468,'-,"39.0894 unit increase",[22.49-55.69],LINC01649,"Response to ketamine in bipolar disorder or major depression (antidepressant effects)","unipolar depression, depressive symptom measurement, response to ketamine, bipolar disorder",GCST007316,1:115918397
rs17211233-<b>T</b>,"2 x 10-7",,0.939,'-,"26.9757 unit decrease",[17.75-36.2],RASGRF2,"Response to ketamine in bipolar disorder or major depression (dissociation effects)","unipolar depression, response to ketamine, dissociation measurement, bipolar disorder",GCST007317,5:81072944
rs1400237-<b>T</b>,"2 x 10-6",,0.0778,'-,"21.4345 unit increase",[13.27-29.6],ROBO2,"Response to ketamine in bipolar disorder or major depression (dissociation effects)","unipolar depression, response to ketamine, dissociation measurement, bipolar disorder",GCST007317,3:76123081
rs12236015-<b>C</b>,"3 x 10-6",,0.833,'-,"13.9838 unit decrease",[8.54-19.43],'-,"Response to ketamine in bipolar disorder or major depression (dissociation effects)","unipolar depression, response to ketamine, dissociation measurement, bipolar disorder",GCST007317,9:120055542
rs9713737-<b>A</b>,"5 x 10-6",,0.244,'-,"13.5351 unit increase",[8.15-18.92],ROBO2,"Response to ketamine in bipolar disorder or major depression (dissociation effects)","unipolar depression, response to ketamine, dissociation measurement, bipolar disorder",GCST007317,3:76248023
rs77987715-<b>A</b>,"5 x 10-6",,0.6547,'-,"11.7152 unit decrease",[7.04-16.39],KRT18P33,"Response to ketamine in bipolar disorder or major depression (dissociation effects)","unipolar depression, response to ketamine, dissociation measurement, bipolar disorder",GCST007317,2:65727945
rs3900502-<b>C</b>,"6 x 10-6",,0.4877,'-,"12.2832 unit decrease",[7.36-17.21],'-,"Response to ketamine in bipolar disorder or major depression (dissociation effects)","unipolar depression, response to ketamine, dissociation measurement, bipolar disorder",GCST007317,4:188948079
rs3018154-<b>C</b>,"6 x 10-6",,0.9111,'-,"19.9461 unit decrease",[11.92-27.98],"LINC02700, AMOTL1","Response to ketamine in bipolar disorder or major depression (dissociation effects)","unipolar depression, response to ketamine, dissociation measurement, bipolar disorder",GCST007317,11:94687142
rs1287071-<b>A</b>,"6 x 10-6",,0.7111,'-,"11.3492 unit decrease",[6.77-15.93],SHLD1,"Response to ketamine in bipolar disorder or major depression (dissociation effects)","unipolar depression, response to ketamine, dissociation measurement, bipolar disorder",GCST007317,20:5847729
rs11127199-<b>G</b>,"7 x 10-6",,0.6335,'-,"11.445 unit increase",[6.82-16.07],TOGARAM2,"Response to ketamine in bipolar disorder or major depression (dissociation effects)","unipolar depression, response to ketamine, dissociation measurement, bipolar disorder",GCST007317,2:28990695
rs4855976-<b>A</b>,"8 x 10-6",,0.0702,'-,"23.7477 unit increase",[14.02-33.48],ROBO2,"Response to ketamine in bipolar disorder or major depression (dissociation effects)","unipolar depression, response to ketamine, dissociation measurement, bipolar disorder",GCST007317,3:76218217
rs11907319-<b>T</b>,"9 x 10-6",,0.8099,'-,"14.3351 unit increase",[8.45-20.22],"FITM2, GDAP1L1","Response to ketamine in bipolar disorder or major depression (dissociation effects)","unipolar depression, response to ketamine, dissociation measurement, bipolar disorder",GCST007317,20:44294659
rs4558394-<b>A</b>,"9 x 10-6",,0.85,'-,"15.6495 unit decrease",[9.19-22.11],LINC00923,"Response to ketamine in bipolar disorder or major depression (dissociation effects)","unipolar depression, response to ketamine, dissociation measurement, bipolar disorder",GCST007317,15:97779155
rs6427528-<b>A</b>,"2 x 10-6","(Etanercept, EA)",0.08,'-,'-,'-,CD84,"Response to anti-TNF therapy in rheumatoid arthritis","response to TNF antagonist",GCST001926,1:160546518
rs4336372-<b>C</b>,"3 x 10-6","(infliximab, delta-DAS analysis)",0.34,'-,"0.34 unit decrease",[NR],'-,"Response to anti-TNF therapy in rheumatoid arthritis","rheumatoid arthritis, response to TNF antagonist",GCST001927,5:175184337
rs12570744-<b>T</b>,"2 x 10-7","(infliximab, delta-DAS analysis)",0.17,'-,"0.49 unit decrease",[NR],"LINP1, LINC00706","Response to anti-TNF therapy in rheumatoid arthritis","rheumatoid arthritis, response to TNF antagonist",GCST001927,10:6747501
rs7141276-<b>A</b>,"2 x 10-6","(all patients, EULAR response analysis)",0.41,'-,"0.37 unit increase",[NR],"RNU6-1261P, Metazoa_SRP","Response to anti-TNF therapy in rheumatoid arthritis","rheumatoid arthritis, response to TNF antagonist",GCST001927,14:34665980
rs4336372-<b>C</b>,"1 x 10-6","(infliximab, EULAR response analysis)",0.34,'-,"0.65 unit decrease",[NR],'-,"Response to anti-TNF therapy in rheumatoid arthritis","rheumatoid arthritis, response to TNF antagonist",GCST001927,5:175184337
rs2276314-<b>?</b>,"4 x 10-7","(all controls combined)",0.19,2,'-,[1.5-2.6],C18orf21,"Drug-induced torsades de pointes","torsades de pointes, response to drug",GCST002269,18:35977503
rs17067290-<b>T</b>,"6 x 10-6","(allelic model)",NR,8.4,'-,[NR],'-,"Uric acid elevation in response to thiazide-like diuretic in hypertension","response to diuretic, hypertension, uric acid measurement",GCST009319,4:179265397
rs2072883-<b>C</b>,"1 x 10-7","(recessive model)",NR,'-,'-,'-,"TTLL1, TTLL1-AS1","Uric acid elevation in response to thiazide-like diuretic in hypertension","response to diuretic, hypertension, uric acid measurement",GCST009319,22:43039662
"rs17445240-<b>G</b>, rs10173297-<b>A</b>, rs13384889-<b>C</b>, rs13031619-<b>G</b>, rs4849975-<b>G</b>, rs1965732-<b>G</b>, rs13418767-<b>T</b>, rs6754459-<b>T</b>, rs11902059-<b>A</b>, rs13395090-<b>T</b>, rs17017879-<b>C</b>, rs7558370-<b>C</b>","4 x 10-6",,0.093,'-,"0.329 unit increase",[NR],"COLEC11 - ALLC; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes","Response to inhaled corticosteroid treatment in asthma (change in FEV1)","FEV change measurement, response to corticosteroid, asthma",GCST002432,2:3655451
rs1495509-<b>C</b>,"2 x 10-9",,NR,1.23,'-,[1.15–1.32],KCNIP4,"Cough in response to angiotensin-converting enzyme inhibitor drugs","response to angiotensin-converting enzyme inhibitor, Cough",GCST003027,4:21391993
chr17:60904543-<b>C</b>,"3 x 10-6",(GLM),NR,'-,"26.3702 unit decrease",[NR],'-,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,"Mapping not available"
rs67357741-<b>?</b>,"3 x 10-6",(MLM),NR,'-,"0.556851 unit increase",[0.32-0.79],CA12,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,15:63378609
rs200136777-<b>GAC</b>,"3 x 10-6",(GLM),NR,'-,"4.3976 unit increase",[NR],NXN,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,17:913294
chr2:230347877-<b>T</b>,"4 x 10-6",(GLM),NR,'-,"27.2427 unit increase",[NR],'-,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,"Mapping not available"
rs11439302-<b>G</b>,"5 x 10-6",(GLM),NR,'-,"4.8086 unit decrease",[NR],LINC02246,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,21:14869414
chr16:8606507-<b>G</b>,"8 x 10-6",(GLM),NR,'-,"14.7557 unit increase",[NR],'-,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,"Mapping not available"
rs2429929-<b>?</b>,"8 x 10-6",(MLM),NR,'-,"0.6971282 unit increase",[0.39-1],TNRC6C,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,17:71725783
rs2560471-<b>A</b>,"8 x 10-6",(GLM),NR,'-,"5.8753 unit increase",[NR],'-,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,5:5811952
rs77301145-<b>C</b>,"8 x 10-6",(GLM),NR,'-,"8.4108 unit decrease",[NR],"ZC3HAV1L, KIAA1549","Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,7:139012454
rs181534711-<b>G</b>,"3 x 10-8",(GLM),NR,'-,"20.6563 unit decrease",[NR],"LINC00390, NRAD1","Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,13:44069329
rs147515995-<b>G</b>,"8 x 10-6",(GLM),NR,'-,"11.2777 unit increase",[NR],'-,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,19:28059504
rs115342620-<b>A</b>,"9 x 10-6",(GLM),NR,'-,"12.8016 unit decrease",[NR],"LNX1-AS1, LNX1","Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,4:53526544
rs8094969-<b>A</b>,"7 x 10-6",(GLM),NR,'-,"3.1476 unit increase",[NR],LINC01899,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,18:71833874
rs76131026-<b>G</b>,"8 x 10-8",(GLM),NR,'-,"30.5578 unit decrease",[NR],"KCNIP1, LINC01366","Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,5:170352321
rs4903318-<b>G</b>,"8 x 10-6",(GLM),NR,'-,"2.9084 unit increase",[NR],JDP2,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,14:75399932
rs7268897-<b>?</b>,"7 x 10-6",(MLM),NR,'-,"0.4867662 unit increase",[0.27-0.7],NFS1,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,20:35678548
rs34252091-<b>?</b>,"6 x 10-6",(MLM),NR,'-,"0.2247672 unit increase",[0.13-0.32],'-,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,1:189924464
rs117673608-<b>G</b>,"8 x 10-7",(GLM),NR,'-,"26.3182 unit decrease",[NR],PRKN,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,6:161931643
rs17093238-<b>A</b>,"2 x 10-6",(GLM),NR,'-,"8.986 unit decrease",[NR],PHF20,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,20:35913170
rs17093238-<b>?</b>,"2 x 10-6",(MLM),NR,'-,"0.5214499 unit increase",[0.31-0.74],PHF20,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,20:35913170
rs9993696-<b>T</b>,"8 x 10-6",(GLM),NR,'-,"6.3351 unit decrease",[NR],"POLN, HAUS3","Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,4:2185650
rs1923775-<b>?</b>,"9 x 10-6",(MLM),NR,'-,"0.1839497 unit increase",[0.1-0.26],"POLN, HAUS3","Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,4:2101369
rs4945082-<b>A</b>,"5 x 10-6",(GLM),NR,'-,"4.651 unit decrease",[NR],GVQW3,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,11:76401041
rs74370740-<b>C</b>,"6 x 10-6",(GLM),NR,'-,"8.9397 unit decrease",[NR],PRLR,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,5:35162774
rs2634458-<b>?</b>,"6 x 10-6",(MLM),NR,'-,"0.489852 unit decrease",[0.28-0.7],PSD3,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,8:18600936
rs73006788-<b>C</b>,"1 x 10-6",(GLM),NR,'-,"13.0042 unit decrease",[NR],NECTIN1,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,11:119793235
rs142794624-<b>?</b>,"4 x 10-6",(MLM),NR,'-,"0.5155792 unit increase",[0.3-0.73],RNA5SP214,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,6:117132166
rs1906727-<b>C</b>,"8 x 10-6",(GLM),NR,'-,"3.2907 unit increase",[NR],"MYO5A, SEPHS1P2","Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,15:93411839
rs4901536-<b>?</b>,"1 x 10-6",(MLM),NR,'-,"0.2108473 unit increase",[0.13-0.3],SAMD4A,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,14:54733816
rs62380867-<b>?</b>,"1 x 10-8",(MLM),NR,'-,"0.5614234 unit increase",[0.37-0.75],SGCD,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,5:156619236
rs62380867-<b>A</b>,"6 x 10-7",(GLM),NR,'-,"7.9915 unit decrease",[NR],SGCD,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,5:156619236
rs62382696-<b>A</b>,"1 x 10-6",(GLM),NR,'-,"7.5388 unit decrease",[NR],SGCD,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,5:156466557
rs11082490-<b>?</b>,"5 x 10-6",(MLM),NR,'-,"0.2760101 unit increase",[0.16-0.39],SIGLEC15,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,18:45832663
rs1447514-<b>?</b>,"5 x 10-6",(MLM),NR,'-,"0.2921513 unit increase",[0.17-0.42],SLC17A6,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,11:22340750
rs111527967-<b>G</b>,"7 x 10-6",(GLM),NR,'-,"12.4453 unit decrease",[NR],SLC5A10,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,17:19008954
rs59721556-<b>?</b>,"4 x 10-6",(MLM),NR,'-,"0.2285079 unit increase",[0.13-0.33],"COX6CP11, SPTLC2","Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,14:77646050
rs76989557-<b>G</b>,"1 x 10-6",(GLM),NR,'-,"9.38 unit decrease",[NR],LINC00898,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,22:47616362
rs12915820-<b>T</b>,"1 x 10-7",(GLM),NR,'-,"3.4619 unit decrease",[NR],'-,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,15:81716770
rs12915820-<b>?</b>,"2 x 10-6",(MLM),NR,'-,"0.1859238 unit increase",[0.11-0.26],'-,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,15:81716770
rs73249047-<b>?</b>,"8 x 10-6",(MLM),NR,'-,"0.4501463 unit increase",[0.25-0.65],TOX,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,8:58871645
rs111916630-<b>A</b>,"5 x 10-6",(GLM),NR,'-,"6.7737 unit decrease",[NR],NPM1P28,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,3:147592931
rs146460178-<b>C</b>,"9 x 10-6",(GLM),NR,'-,"15.8127 unit decrease",[NR],ZNF326,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,1:90109901
rs28785552-<b>?</b>,"9 x 10-6",(MLM),NR,'-,"0.1835087 unit increase",[0.1-0.26],ZNF611,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,19:52730908
rs138538719-<b>?</b>,"5 x 10-8",(MLM),NR,'-,'-,'-,SGCD,"Response to paliperidone in schizophrenia (Multivariate)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004043,5:156578156
rs80052780-<b>?</b>,"4 x 10-7",(MLM),NR,'-,'-,'-,LINC00499,"Response to paliperidone in schizophrenia (Multivariate)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004043,4:138346969
rs61854820-<b>?</b>,"4 x 10-7",(MLM),NR,'-,'-,'-,ZWINT,"Response to paliperidone in schizophrenia (Multivariate)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004043,10:56294881
rs74065827-<b>?</b>,"7 x 10-7",(MLM),NR,'-,'-,'-,ADCK1,"Response to paliperidone in schizophrenia (Multivariate)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004043,14:77902942
rs9815738-<b>?</b>,"7 x 10-7",(MLM),NR,'-,'-,'-,C3orf38,"Response to paliperidone in schizophrenia (Multivariate)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004043,3:88155583
rs61857276-<b>?</b>,"8 x 10-7",(MLM),NR,'-,'-,'-,ZWINT,"Response to paliperidone in schizophrenia (Multivariate)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004043,10:56434080
rs78547569-<b>?</b>,"2 x 10-6",(MLM),NR,'-,'-,'-,CCDC122,"Response to paliperidone in schizophrenia (Multivariate)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004043,13:43866062
rs59721556-<b>?</b>,"2 x 10-6",(MLM),NR,'-,'-,'-,"COX6CP11, SPTLC2","Response to paliperidone in schizophrenia (Multivariate)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004043,14:77646050
rs118106993-<b>?</b>,"3 x 10-6",(MLM),NR,'-,'-,'-,"OR10D3, OR10D1P","Response to paliperidone in schizophrenia (Multivariate)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004043,11:124166986
rs72706301-<b>?</b>,"3 x 10-6",(MLM),NR,'-,'-,'-,SERPINA1,"Response to paliperidone in schizophrenia (Multivariate)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004043,14:94385882
rs56175057-<b>?</b>,"3 x 10-6",(MLM),NR,'-,'-,'-,MIR3681HG,"Response to paliperidone in schizophrenia (Multivariate)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004043,2:12647004
rs7267005-<b>?</b>,"4 x 10-6",(MLM),NR,'-,'-,'-,PHF20,"Response to paliperidone in schizophrenia (Multivariate)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004043,20:35901643
rs145463728-<b>?</b>,"5 x 10-6",(MLM),NR,'-,'-,'-,ENOX1,"Response to paliperidone in schizophrenia (Multivariate)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004043,13:43665045
rs12323387-<b>?</b>,"6 x 10-6",(MLM),NR,'-,'-,'-,JDP2,"Response to paliperidone in schizophrenia (Multivariate)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004043,14:75398548
rs7963446-<b>?</b>,"6 x 10-6",(MLM),NR,'-,'-,'-,PTPN6,"Response to paliperidone in schizophrenia (Multivariate)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004043,12:6956243
rs464250-<b>?</b>,"6 x 10-6",(MLM),NR,'-,'-,'-,EFNA5,"Response to paliperidone in schizophrenia (Multivariate)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004043,5:107528014
rs10758913-<b>?</b>,"7 x 10-6",(MLM),NR,'-,'-,'-,DMAC1,"Response to paliperidone in schizophrenia (Multivariate)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004043,9:7887951
rs76297747-<b>?</b>,"7 x 10-6",(MLM),NR,'-,'-,'-,HDHD2,"Response to paliperidone in schizophrenia (Multivariate)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004043,18:47139286
rs77217161-<b>?</b>,"7 x 10-6",(MLM),NR,'-,'-,'-,'-,"Response to paliperidone in schizophrenia (Multivariate)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004043,10:56074184
rs7268897-<b>?</b>,"8 x 10-6",(MLM),NR,'-,'-,'-,NFS1,"Response to paliperidone in schizophrenia (Multivariate)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004043,20:35678548
rs6055808-<b>?</b>,"8 x 10-6",(MLM),NR,'-,'-,'-,PLCB1,"Response to paliperidone in schizophrenia (Multivariate)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004043,20:8426427
rs145252195-<b>?</b>,"8 x 10-6",(MLM),NR,'-,'-,'-,COL26A1,"Response to paliperidone in schizophrenia (Multivariate)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004043,7:101528955
rs55728704-<b>?</b>,"8 x 10-6",(MLM),NR,'-,'-,'-,IQGAP2,"Response to paliperidone in schizophrenia (Multivariate)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004043,5:76647574
rs80058639-<b>?</b>,"9 x 10-6",(MLM),NR,'-,'-,'-,DLGAP2,"Response to paliperidone in schizophrenia (Multivariate)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004043,8:1214070
rs202106186-<b>?</b>,"9 x 10-6",(MLM),NR,'-,'-,'-,"SMC5, KLF9","Response to paliperidone in schizophrenia (Multivariate)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004043,9:70368818
rs6566288-<b>?</b>,"9 x 10-6",(MLM),NR,'-,'-,'-,DSEL-AS1,"Response to paliperidone in schizophrenia (Multivariate)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004043,18:67518184
rs2685441-<b>?</b>,"2 x 10-6",(MLM),NR,'-,"0.1840039 unit decrease",[0.11-0.26],LINC01899,"Response to paliperidone in schizophrenia (CGI-S score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004039,18:71851474
rs644939-<b>?</b>,"6 x 10-7",(MLM),NR,'-,"0.2339642 unit increase",[0.14-0.33],ANO4,"Response to paliperidone in schizophrenia (CGI-S score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004039,12:101060211
rs59721556-<b>?</b>,"3 x 10-7",(MLM),NR,'-,"0.2564292 unit increase",[0.16-0.35],"COX6CP11, SPTLC2","Response to paliperidone in schizophrenia (CGI-S score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004039,14:77646050
rs11256768-<b>?</b>,"8 x 10-6",(MLM),NR,'-,"0.23322 unit increase",[0.13-0.34],'-,"Response to paliperidone in schizophrenia (CGI-S score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004039,10:10683500
rs17288586-<b>?</b>,"7 x 10-6",(MLM),NR,'-,"0.23989 unit increase",[0.14-0.34],CLIC5,"Response to paliperidone in schizophrenia (CGI-S score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004039,6:45852033
rs56374507-<b>?</b>,"3 x 10-8",(MLM),NR,'-,"0.3768625 unit increase",[0.24-0.51],ADCK1,"Response to paliperidone in schizophrenia (CGI-S score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004039,14:77914190
rs116144992-<b>?</b>,"6 x 10-6",(MLM),NR,'-,"0.3702252 unit decrease",[0.21-0.53],'-,"Response to paliperidone in schizophrenia (CGI-S score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004039,3:6254168
rs11624682-<b>?</b>,"9 x 10-6",(MLM),NR,'-,"0.4273234 unit increase",[0.24-0.62],VIPAS39,"Response to paliperidone in schizophrenia (CGI-S score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004039,14:77429295
rs7675231-<b>?</b>,"5 x 10-6",(MLM),NR,'-,"0.6654135 unit decrease",[0.38-0.95],RN7SL776P,"Response to paliperidone in schizophrenia (CGI-S score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004039,4:167404683
rs56240334-<b>A</b>,"8 x 10-8",(GLM),NR,'-,"0.3808 unit decrease",[NR],ADCK1,"Response to paliperidone in schizophrenia (CGI-S score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004039,14:77905060
rs72838804-<b>C</b>,"5 x 10-7",(GLM),NR,'-,"0.7565 unit decrease",[NR],B9D1,"Response to paliperidone in schizophrenia (CGI-S score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004039,17:19338052
rs8094969-<b>A</b>,"6 x 10-7",(GLM),NR,'-,"0.206 unit increase",[NR],LINC01899,"Response to paliperidone in schizophrenia (CGI-S score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004039,18:71833874
rs201061212-<b>TA</b>,"1 x 10-6",(GLM),NR,'-,"0.2113 unit increase",[NR],ZFAND6,"Response to paliperidone in schizophrenia (CGI-S score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004039,15:80091637
rs59721556-<b>G</b>,"2 x 10-6",(GLM),NR,'-,"0.2371 unit decrease",[NR],"COX6CP11, SPTLC2","Response to paliperidone in schizophrenia (CGI-S score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004039,14:77646050
rs183993610-<b>C</b>,"2 x 10-6",(GLM),NR,'-,"0.5537 unit decrease",[NR],"LNX1-AS1, LNX1","Response to paliperidone in schizophrenia (CGI-S score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004039,4:53540709
rs2127826-<b>A</b>,"3 x 10-6",(GLM),NR,'-,"0.2289 unit decrease",[NR],"PDE5A, SEPTIN7P14","Response to paliperidone in schizophrenia (CGI-S score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004039,4:119504060
rs111751755-<b>C</b>,"3 x 10-6",(GLM),NR,'-,"0.7606 unit decrease",[NR],SGCD,"Response to paliperidone in schizophrenia (CGI-S score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004039,5:156553408
rs17555185-<b>G</b>,"4 x 10-6",(GLM),NR,'-,"0.6987 unit decrease",[NR],SGCD,"Response to paliperidone in schizophrenia (CGI-S score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004039,5:156354547
chr3:67336707-<b>G</b>,"4 x 10-6",(GLM),NR,'-,"0.2255 unit decrease",[NR],'-,"Response to paliperidone in schizophrenia (CGI-S score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004039,"Mapping not available"
rs190585232-<b>C</b>,"6 x 10-6",(GLM),NR,'-,"0.5843 unit decrease",[NR],RASGRF2,"Response to paliperidone in schizophrenia (CGI-S score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004039,5:81060251
rs34804741-<b>C</b>,"7 x 10-6",(GLM),NR,'-,"0.5383 unit decrease",[NR],EVL,"Response to paliperidone in schizophrenia (CGI-S score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004039,14:100050504
rs502697-<b>G</b>,"7 x 10-6",(GLM),NR,'-,"0.2112 unit decrease",[NR],ANO4,"Response to paliperidone in schizophrenia (CGI-S score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004039,12:101057493
chr4:7352632-<b>C</b>,"6 x 10-6",(GLM),NR,'-,"0.21 unit increase",[NR],'-,"Response to paliperidone in schizophrenia (CGI-S score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004039,"Mapping not available"
rs10894895-<b>C</b>,"9 x 10-6",(GLM),NR,'-,"0.1931 unit decrease",[NR],LINC02697,"Response to paliperidone in schizophrenia (CGI-S score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004039,11:134882140
rs76008570-<b>G</b>,"9 x 10-6",(GLM),NR,'-,"0.274 unit decrease",[NR],MIR5702,"Response to paliperidone in schizophrenia (CGI-S score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004039,2:226611691
rs2944499-<b>T</b>,"9 x 10-6",(GLM),NR,'-,"0.1741 unit decrease",[NR],TCERG1L,"Response to paliperidone in schizophrenia (CGI-S score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004039,10:131235052
rs9900497-<b>G</b>,"4 x 10-6",(GLM),NR,'-,"0.1968 unit decrease",[NR],SLC47A2,"Response to paliperidone in schizophrenia (CGI-S score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004039,17:19714080
rs2560471-<b>A</b>,"5 x 10-6",(GLM),NR,'-,"0.3525 unit increase",[NR],'-,"Response to paliperidone in schizophrenia (CGI-S score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004039,5:5811952
rs61909487-<b>C</b>,"8 x 10-6",(GLM),NR,'-,"0.6787 unit increase",[NR],PRMT8,"Response to paliperidone in schizophrenia (CGI-S score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004039,12:3435254
rs113925979-<b>G</b>,"8 x 10-6",(GLM),NR,'-,"0.8082 unit increase",[NR],PTPN13,"Response to paliperidone in schizophrenia (CGI-S score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004039,4:86797215
rs73506161-<b>C</b>,"6 x 10-6",(GLM),NR,'-,"1.3697 unit increase",[NR],ADGRE3,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,19:14643177
rs111527967-<b>G</b>,"2 x 10-6",(GLM),NR,'-,"4.2893 unit decrease",[NR],SLC5A10,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,17:19008954
rs73309282-<b>T</b>,"3 x 10-6",(GLM),NR,'-,"1.9187 unit increase",[NR],OXR1,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,8:106483376
rs1451608-<b>G</b>,"7 x 10-6",(GLM),NR,'-,"3.2311 unit decrease",[NR],"GAPDHP70, CTSC","Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,11:88386364
rs145847018-<b>G</b>,"3 x 10-6",(GLM),NR,'-,"3.2111 unit decrease",[NR],"PPM1AP1, TUSC3","Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,8:15786716
rs75528631-<b>G</b>,"8 x 10-6",(GLM),NR,'-,"3.0592 unit decrease",[NR],'-,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,11:37269808
rs147692810-<b>C</b>,"5 x 10-6",(GLM),NR,'-,"2.9933 unit decrease",[NR],STEAP2-AS1,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,7:89924805
rs138538719-<b>C</b>,"3 x 10-7",(GLM),NR,'-,"2.5963 unit decrease",[NR],SGCD,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,5:156578156
rs5020196-<b>C</b>,"2 x 10-6",(GLM),NR,'-,"2.5638 unit decrease",[NR],RBFOX1,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,16:7718619
rs62382696-<b>A</b>,"7 x 10-7",(GLM),NR,'-,"2.514 unit decrease",[NR],SGCD,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,5:156466557
rs2532643-<b>C</b>,"9 x 10-7",(GLM),NR,'-,"2.4204 unit decrease",[NR],"PDZD8, EMX2OS","Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,10:117452370
rs4335177-<b>?</b>,"4 x 10-6",(MLM),NR,'-,"0.1834814 unit increase",[0.11-0.26],LINC01505,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,9:106581778
rs3006553-<b>?</b>,"8 x 10-6",(MLM),NR,'-,"0.186628 unit increase",[0.11-0.27],SVIL,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,10:29800065
rs4901536-<b>?</b>,"9 x 10-6",(MLM),NR,'-,"0.1919267 unit increase",[0.11-0.28],SAMD4A,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,14:54733816
rs59721556-<b>?</b>,"1 x 10-7",(MLM),NR,'-,"0.2615917 unit increase",[0.16-0.36],"COX6CP11, SPTLC2","Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,14:77646050
rs34252091-<b>?</b>,"1 x 10-6",(MLM),NR,'-,"0.2422166 unit increase",[0.15-0.34],'-,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,1:189924464
rs149053538-<b>?</b>,"6 x 10-6",(MLM),NR,'-,"0.247486 unit decrease",[0.14-0.35],PLD1,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,3:171750468
rs11082490-<b>?</b>,"2 x 10-6",(MLM),NR,'-,"0.2858119 unit increase",[0.17-0.4],SIGLEC15,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,18:45832663
rs74065827-<b>?</b>,"1 x 10-7",(MLM),NR,'-,"0.3707302 unit increase",[0.24-0.51],ADCK1,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,14:77902942
rs74405815-<b>?</b>,"3 x 10-6",(MLM),NR,'-,"0.3438862 unit increase",[0.2-0.49],CHCHD6,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,3:126800994
rs4903318-<b>G</b>,"4 x 10-7",(GLM),NR,'-,"1.0842 unit increase",[NR],JDP2,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,14:75399932
rs1906727-<b>C</b>,"7 x 10-6",(GLM),NR,'-,"1.086 unit increase",[NR],"MYO5A, SEPHS1P2","Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,15:93411839
rs6777098-<b>T</b>,"8 x 10-6",(GLM),NR,'-,"1.1964 unit increase",[NR],ZBBX,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,3:167260917
rs56161922-<b>?</b>,"4 x 10-6",(MLM),NR,'-,"0.3874831 unit decrease",[0.22-0.55],CR1,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,1:207636488
rs2532643-<b>?</b>,"1 x 10-6",(MLM),NR,'-,"0.4471507 unit increase",[0.27-0.63],"PDZD8, EMX2OS","Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,10:117452370
rs138538719-<b>?</b>,"7 x 10-9",(MLM),NR,'-,"0.5380868 unit increase",[0.36-0.72],SGCD,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,5:156578156
rs142794624-<b>?</b>,"8 x 10-6",(MLM),NR,'-,"0.4962775 unit increase",[0.28-0.71],RNA5SP214,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,6:117132166
rs72838804-<b>C</b>,"2 x 10-7",(GLM),NR,'-,"4.3391 unit decrease",[NR],B9D1,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,17:19338052
rs11984453-<b>G</b>,"7 x 10-6",(GLM),NR,'-,"1.8088 unit increase",[NR],CSMD1,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,8:4647009
rs147466853-<b>C</b>,"2 x 10-6",(GLM),NR,'-,"3.7236 unit decrease",[NR],LINC00898,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,22:47716296
rs10769859-<b>G</b>,"1 x 10-6",(GLM),NR,'-,"2.9542 unit increase",[NR],EIF3F,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,11:7979900
chr8:102010440-<b>T</b>,"6 x 10-6",(GLM),NR,'-,"3.6429 unit increase",[NR],'-,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,"Mapping not available"
rs77730715-<b>G</b>,"5 x 10-6",(GLM),NR,'-,"3.724 unit increase",[NR],CWH43,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,4:49027406
chr3:24752415-<b>C</b>,"6 x 10-6",(GLM),NR,'-,"4.5708 unit increase",[NR],'-,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,"Mapping not available"
rs3767510-<b>?</b>,"4 x 10-6",(MLM),NR,'-,"0.1748027 unit decrease",[0.1-0.25],CACNA1S,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,1:201075216
rs8008002-<b>?</b>,"8 x 10-7",(MLM),NR,'-,"0.1891768 unit decrease",[0.11-0.26],JDP2,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,14:75398980
rs28403489-<b>?</b>,"8 x 10-6",(MLM),NR,'-,"0.1723415 unit increase",[0.097-0.248],'-,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,15:81718161
rs9993696-<b>T</b>,"3 x 10-6",(GLM),NR,'-,"2.1804 unit decrease",[NR],"POLN, HAUS3","Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,4:2185650
rs56240334-<b>A</b>,"2 x 10-7",(GLM),NR,'-,"2.0543 unit decrease",[NR],ADCK1,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,14:77905060
rs6911131-<b>A</b>,"5 x 10-6",(GLM),NR,'-,"1.9021 unit decrease",[NR],PHACTR2,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,6:143544084
rs11439302-<b>G</b>,"8 x 10-7",(GLM),NR,'-,"1.6969 unit decrease",[NR],LINC02246,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,21:14869414
rs12434701-<b>C</b>,"1 x 10-6",(GLM),NR,'-,"1.3434 unit decrease",[NR],"COX6CP11, SPTLC2","Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,14:77643001
rs4102217-<b>G</b>,"7 x 10-6",(GLM),NR,'-,"1.2945 unit decrease",[NR],"MALAT1, LINC02736","Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,11:65496424
rs73878431-<b>G</b>,"4 x 10-7",(GLM),NR,'-,"1.248 unit decrease",[NR],'-,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,3:166933488
rs57425123-<b>A</b>,"8 x 10-6",(GLM),NR,'-,"1.1038 unit decrease",[NR],'-,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,7:25763634
rs3934047-<b>T</b>,"3 x 10-6",(GLM),NR,'-,"0.9856 unit decrease",[NR],'-,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,15:81715972
rs6440475-<b>C</b>,"6 x 10-6",(GLM),NR,'-,"0.9637 unit decrease",[NR],RPL21P71,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,3:147221219
rs3006553-<b>G</b>,"5 x 10-6",(GLM),NR,'-,"1.0728 unit increase",[NR],SVIL,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,10:29800065
rs6911131-<b>?</b>,"7 x 10-6",(MLM),NR,'-,"0.3302258 unit increase",[0.19-0.47],PHACTR2,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,6:143544084
rs9930542-<b>?</b>,"6 x 10-6",(MLM),NR,'-,"0.3371169 unit increase",[0.19-0.48],RBFOX1,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,16:7718742
rs139132350-<b>G</b>,"8 x 10-6",(GLM),NR,'-,"3.7624 unit decrease",[NR],MIR4432HG,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,2:60357702
rs45496701-<b>G</b>,"9 x 10-6",(GLM),NR,'-,"3.1538 unit decrease",[NR],ZNF362,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,1:33300620
rs141443024-<b>G</b>,"9 x 10-6",(GLM),NR,'-,"3.4524 unit decrease",[NR],TDRP,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,8:510240
rs1647768-<b>G</b>,"9 x 10-6",(GLM),NR,'-,"1.4641 unit decrease",[NR],PECR,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,2:216078567
rs34272020-<b>?</b>,"3 x 10-7",(MLM),NR,'-,"0.3507382 unit increase",[0.22-0.48],ADCK1,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,14:77907829
rs56240334-<b>A</b>,"9 x 10-7",(GLM),NR,'-,"5.936 unit decrease",[NR],ADCK1,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,14:77905060
rs2567700-<b>C</b>,"7 x 10-6",(GLM),NR,'-,"3.4596 unit decrease",[NR],AMBP,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,9:114076463
rs12344124-<b>?</b>,"8 x 10-6",(MLM),NR,'-,"0.3106994 unit increase",[0.17-0.45],AMBP,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,9:114075465
rs73105738-<b>G</b>,"5 x 10-6",(GLM),NR,'-,"19.8193 unit decrease",[NR],ARHGEF28,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,5:73931380
rs77584330-<b>G</b>,"3 x 10-6",(GLM),NR,'-,"9.5184 unit decrease",[NR],'-,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,13:70766522
rs72838804-<b>C</b>,"2 x 10-6",(GLM),NR,'-,"12.1314 unit decrease",[NR],B9D1,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,17:19338052
rs6443921-<b>C</b>,"7 x 10-6",(GLM),NR,'-,"3.3779 unit decrease",[NR],'-,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,3:166955476
rs141443024-<b>G</b>,"9 x 10-6",(GLM),NR,'-,"12.905 unit decrease",[NR],TDRP,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,8:510240
rs10247392-<b>?</b>,"5 x 10-6",(MLM),NR,'-,"0.1695217 unit decrease",[0.097-0.242],CALD1,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,7:134883505
rs10247392-<b>G</b>,"5 x 10-6",(GLM),NR,'-,"2.9047 unit increase",[NR],CALD1,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,7:134883505
rs182333180-<b>C</b>,"1 x 10-6",(GLM),NR,'-,"11.3945 unit decrease",[NR],CCDC122,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,13:43857773
rs115212412-<b>T</b>,"9 x 10-6",(GLM),NR,'-,"17.1602 unit decrease",[NR],"HSP90B3P, WDR82P2","Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,1:91544232
rs56161922-<b>?</b>,"7 x 10-6",(MLM),NR,'-,"0.3780124 unit decrease",[0.21-0.54],CR1,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,1:207636488
rs145712811-<b>A</b>,"2 x 10-6",(GLM),NR,'-,"13.4185 unit decrease",[NR],'-,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,8:113555989
rs55774002-<b>C</b>,"7 x 10-6",(GLM),NR,'-,"6.2895 unit decrease",[NR],CWH43,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,4:49037941
rs73506161-<b>C</b>,"5 x 10-6",(GLM),NR,'-,"4.1977 unit increase",[NR],ADGRE3,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,19:14643177
rs151233144-<b>C</b>,"5 x 10-6",(GLM),NR,'-,"9.3214 unit decrease",[NR],'-,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,22:47765137
rs144212837-<b>T</b>,"2 x 10-6",(GLM),NR,'-,"23.0292 unit decrease",[NR],IGLC7,"Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,22:22956986
rs192381152-<b>A</b>,"3 x 10-6",(GLM),NR,'-,"4.0968 unit decrease",[NR],"FLJ31104, ANKRD55","Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,5:56031173
rs201581573-<b>TA</b>,"2 x 10-6",(GLM),NR,'-,"10.6514 unit decrease",[NR],"TUSC3, PPM1AP1","Response to paliperidone in schizophrenia (PANSS score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004042,8:15777526
rs117858172-<b>G</b>,"2 x 10-6",(GLM),NR,'-,"3.8171 unit decrease",[NR],ETS1,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,11:128440905
rs7419486-<b>T</b>,"3 x 10-6",(GLM),NR,'-,"1.4142 unit decrease",[NR],DPP10,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,2:115672654
rs146790986-<b>C</b>,"3 x 10-6",(GLM),NR,'-,"3.6312 unit decrease",[NR],SGCZ,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,8:14810524
chr2:71975709-<b>C</b>,"3 x 10-6",(GLM),NR,'-,"7.5668 unit decrease",[NR],'-,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,"Mapping not available"
rs143325061-<b>A</b>,"3 x 10-6",(GLM),NR,'-,"2.7622 unit decrease",[NR],'-,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,10:56579595
rs76799118-<b>T</b>,"3 x 10-6",(GLM),NR,'-,"5.8703 unit decrease",[NR],FAP,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,2:162222501
rs146767487-<b>T</b>,"3 x 10-6",(GLM),NR,'-,"4.0595 unit decrease",[NR],LINC02152,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,16:8352071
rs182734081-<b>C</b>,"4 x 10-6",(GLM),NR,'-,"5.7984 unit decrease",[NR],"FSTL5, MTHFD2P4","Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,4:162231756
rs74757231-<b>G</b>,"4 x 10-6",(GLM),NR,'-,"3.7011 unit decrease",[NR],TENM2,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,5:168087215
rs189688109-<b>T</b>,"4 x 10-6",(GLM),NR,'-,"2.713 unit decrease",[NR],ENOX1,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,13:43442961
rs77561866-<b>A</b>,"4 x 10-6",(GLM),NR,'-,"4.5798 unit decrease",[NR],LINC02177,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,16:9282898
chr17:60904543-<b>C</b>,"4 x 10-6",(GLM),NR,'-,"6.9554 unit decrease",[NR],'-,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,"Mapping not available"
rs61854820-<b>C</b>,"5 x 10-6",(GLM),NR,'-,"2.4396 unit decrease",[NR],ZWINT,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,10:56294881
rs150863502-<b>G</b>,"5 x 10-6",(GLM),NR,'-,"5.6704 unit decrease",[NR],RSPH14,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,22:23029925
rs117612853-<b>C</b>,"6 x 10-6",(GLM),NR,'-,"3.4459 unit increase",[NR],"LINC00709, CACNB2","Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,10:9385373
rs117295891-<b>G</b>,"6 x 10-6",(GLM),NR,'-,"2.4809 unit decrease",[NR],VWC2,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,7:49691344
rs4562622-<b>C</b>,"6 x 10-6",(GLM),NR,'-,"1.6989 unit increase",[NR],CR1L,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,1:207703232
rs11956350-<b>A</b>,"6 x 10-6",(GLM),NR,'-,"4.9287 unit increase",[NR],LINC02223,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,5:17706242
rs77217161-<b>A</b>,"6 x 10-6",(GLM),NR,'-,"2.5732 unit decrease",[NR],'-,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,10:56074184
rs59000197-<b>T</b>,"6 x 10-6",(GLM),NR,'-,"2.5473 unit increase",[NR],HIBCH,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,2:190244144
rs56031646-<b>T</b>,"7 x 10-6",(GLM),NR,'-,"3.4102 unit decrease",[NR],'-,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,6:76863427
rs182020790-<b>G</b>,"7 x 10-6",(GLM),NR,'-,"4.7248 unit decrease",[NR],"PRG4, HMCN1","Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,1:186258139
rs116557595-<b>G</b>,"7 x 10-6",(GLM),NR,'-,"3.8348 unit decrease",[NR],FSTL5,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,4:161980073
rs188710179-<b>A</b>,"7 x 10-6",(GLM),NR,'-,"7.3835 unit decrease",[NR],MAILR,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,8:102985733
rs7554419-<b>C</b>,"8 x 10-6",(GLM),NR,'-,"0.9641 unit decrease",[NR],VPS45,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,1:150069348
rs2382999-<b>G</b>,"3 x 10-7",(GLM),NR,'-,"1.8534 unit decrease",[NR],"LINC00964, ZNF572","Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,8:124967335
rs188803409-<b>A</b>,"3 x 10-7",(GLM),NR,'-,"7.2424 unit decrease",[NR],RBFOX1,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,16:6990147
rs79862545-<b>C</b>,"3 x 10-7",(GLM),NR,'-,"6.1924 unit decrease",[NR],"U8, CLMP","Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,11:123278215
rs149776388-<b>C</b>,"5 x 10-7",(GLM),NR,'-,"6.7037 unit decrease",[NR],XKR6,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,8:11008861
rs7036881-<b>C</b>,"7 x 10-7",(GLM),NR,'-,"4.5047 unit decrease",[NR],CACNA1B,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,9:138076309
rs73177327-<b>C</b>,"7 x 10-7",(GLM),NR,'-,"3.781 unit decrease",[NR],NRAD1,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,13:43983531
rs138707712-<b>T</b>,"7 x 10-7",(GLM),NR,'-,"4.7564 unit decrease",[NR],OSCP1,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,1:36447523
rs141473550-<b>A</b>,"9 x 10-7",(GLM),NR,'-,"4.864 unit decrease",[NR],"SH3GL2, ADAMTSL1","Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,9:17878240
rs117673608-<b>G</b>,"1 x 10-6",(GLM),NR,'-,"6.9628 unit decrease",[NR],PRKN,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,6:161931643
rs73006788-<b>C</b>,"1 x 10-6",(GLM),NR,'-,"3.4802 unit decrease",[NR],NECTIN1,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,11:119793235
rs12001041-<b>A</b>,"1 x 10-6",(GLM),NR,'-,"1.2081 unit increase",[NR],"PAEPP1, GLT6D1","Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,9:135600269
rs182333180-<b>C</b>,"1 x 10-6",(GLM),NR,'-,"3.0708 unit decrease",[NR],CCDC122,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,13:43857773
rs180968789-<b>T</b>,"1 x 10-6",(GLM),NR,'-,"3.8855 unit increase",[NR],MIR3147,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,7:57356326
rs150202118-<b>G</b>,"1 x 10-6",(GLM),NR,'-,"7.3719 unit decrease",[NR],IQGAP2,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,5:76459601
rs201447509-<b>ATC</b>,"1 x 10-6",(GLM),NR,'-,"1.8871 unit decrease",[NR],NSMCE2,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,8:125236380
rs2083117-<b>G</b>,"1 x 10-6",(GLM),NR,'-,"2.1099 unit increase",[NR],Metazoa_SRP,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,15:96536103
rs147237795-<b>G</b>,"2 x 10-6",(GLM),NR,'-,"4.1116 unit decrease",[NR],'-,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,11:127546637
rs116939006-<b>C</b>,"2 x 10-6",(GLM),NR,'-,"3.5749 unit decrease",[NR],SGCZ,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,8:14416309
rs28425639-<b>T</b>,"2 x 10-6",(GLM),NR,'-,"3.0464 unit decrease",[NR],AFF3,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,2:99936050
rs78178087-<b>G</b>,"2 x 10-6",(GLM),NR,'-,"3.9925 unit decrease",[NR],CACNA1B,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,9:137974654
rs78309295-<b>A</b>,"2 x 10-6",(GLM),NR,'-,"6.5925 unit decrease",[NR],TRIB1,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,8:125516480
rs79886049-<b>A</b>,"2 x 10-6",(GLM),NR,'-,"2.8136 unit increase",[NR],PTPRT,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,20:42702075
rs79851935-<b>T</b>,"2 x 10-6",(GLM),NR,'-,"5.7487 unit decrease",[NR],'-,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,17:54257841
rs191581512-<b>G</b>,"2 x 10-6",(GLM),NR,'-,"4.7236 unit decrease",[NR],LINC00390,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,13:44105194
rs79533578-<b>?</b>,"4 x 10-6",(MLM),NR,'-,"0.5676763 unit increase",[0.33-0.81],RNF135,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,17:30998606
rs142996120-<b>?</b>,"3 x 10-6",(MLM),NR,'-,"0.702981 unit increase",[0.41-1],POMT2,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,14:77289119
rs2429928-<b>?</b>,"4 x 10-6",(MLM),NR,'-,"0.7148641 unit increase",[0.41-1.02],'-,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,17:71726064
rs76131026-<b>G</b>,"1 x 10-8",(GLM),NR,'-,"10.692 unit decrease",[NR],"KCNIP1, LINC01366","Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,5:170352321
rs200868329-<b>AT</b>,"3 x 10-6",(GLM),NR,'-,"7.5455 unit decrease",[NR],CTNNA3,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,10:66162055
chr12:106657179-<b>A</b>,"5 x 10-6",(GLM),NR,'-,"7.002 unit decrease",[NR],'-,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,"Mapping not available"
rs191581512-<b>G</b>,"6 x 10-8",(GLM),NR,'-,"6.736 unit decrease",[NR],LINC00390,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,13:44105194
rs117325373-<b>G</b>,"2 x 10-6",(GLM),NR,'-,"6.3469 unit decrease",[NR],PIM3,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,22:49963977
rs115449435-<b>T</b>,"7 x 10-6",(GLM),NR,'-,"6.1478 unit decrease",[NR],EGFEM1P,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,3:168747556
rs113353280-<b>A</b>,"8 x 10-6",(GLM),NR,'-,"5.8417 unit decrease",[NR],USP24,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,1:55180186
rs76540759-<b>G</b>,"9 x 10-6",(GLM),NR,'-,"5.6127 unit decrease",[NR],ACTN4P1,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,4:116607403
rs146460178-<b>C</b>,"7 x 10-6",(GLM),NR,'-,"5.2383 unit decrease",[NR],ZNF326,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,1:90109901
rs76289741-<b>A</b>,"8 x 10-6",(GLM),NR,'-,"5.1717 unit decrease",[NR],EGFEM1P,"Response to paliperidone in schizophrenia (positive Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004040,3:168633460
rs6545747-<b>?</b>,"6 x 10-6",(MLM),NR,'-,"0.1756764 unit increase",[0.1-0.251],RNA5SP94,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,2:59725711
rs7859245-<b>?</b>,"8 x 10-6",(MLM),NR,'-,"0.1832648 unit decrease",[0.1-0.26],"PAEPP1, GLT6D1","Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,9:135598751
rs10827221-<b>?</b>,"8 x 10-6",(MLM),NR,'-,"0.1877251 unit decrease",[0.11-0.27],NRP1,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,10:33256536
rs2634458-<b>?</b>,"7 x 10-6",(MLM),NR,'-,"0.4892784 unit decrease",[0.28-0.7],PSD3,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,8:18600936
rs61857276-<b>?</b>,"1 x 10-7",(MLM),NR,'-,"0.7002314 unit increase",[0.44-0.96],ZWINT,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,10:56434080
rs61854820-<b>?</b>,"6 x 10-8",(MLM),NR,'-,"0.724535 unit increase",[0.46-0.99],ZWINT,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,10:56294881
rs77217161-<b>?</b>,"9 x 10-7",(MLM),NR,'-,"0.6896701 unit increase",[0.42-0.96],'-,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,10:56074184
rs923806-<b>?</b>,"8 x 10-6",(MLM),NR,'-,"0.6283593 unit increase",[0.35-0.9],"DKK3, LINC02547","Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,11:12026851
rs78547569-<b>?</b>,"5 x 10-6",(MLM),NR,'-,"0.6972073 unit increase",[0.4-1],CCDC122,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,13:43866062
rs117752187-<b>G</b>,"6 x 10-11",(GLM),NR,'-,"7.9991 unit decrease",[NR],MIR100HG,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,11:122490175
rs76830538-<b>C</b>,"2 x 10-8",(GLM),NR,'-,"4.4144 unit decrease",[NR],TUSC3,"Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,8:15615416
rs117019455-<b>G</b>,"2 x 10-7",(GLM),NR,'-,"4.0451 unit decrease",[NR],"TUSC3, PPM1AP1","Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,8:15796634
rs75070487-<b>G</b>,"2 x 10-7",(GLM),NR,'-,"4.4176 unit decrease",[NR],"KCNIP1, KCNIP1-OT1","Response to paliperidone in schizophrenia (negative Marder score)","schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004041,5:170389767
rs247616-<b>T</b>,"9 x 10-13",,0.326,'-,"0.0071 unit increase",[0.0090-0.0130],"HERPUD1, CETP","Response to statins (HDL cholesterol change)","HDL cholesterol change measurement, response to statin",GCST003617,16:56955678
rs12916361-<b>?</b>,"5 x 10-6",,NR,'-,"0.0139 unit increase",[0.13-0.15],CEMIP,"Response to statins (HDL cholesterol change)","HDL cholesterol change measurement, response to statin",GCST003617,15:80945704
rs116561224-<b>?</b>,"7 x 10-9",,0.09,5.4,'-,3.0-9.5,RNU6-1037P,"Drug-induced liver injury (statins)","response to statin, drug-induced liver injury",GCST004080,18:66962261
rs147451859-<b>G</b>,"6 x 10-9",,0.07,1.74,'-,[NR],PPCDC,"Adverse response to chemotherapy (amenorrhea) in breast cancer","amenorrhea, breast carcinoma, response to antineoplastic agent",GCST009153,15:75039102
rs17587029-<b>G</b>,"3 x 10-8",,0.05,1.84,'-,[NR],"CHCHD5, SLC20A1","Adverse response to chemotherapy (amenorrhea) in breast cancer","amenorrhea, breast carcinoma, response to antineoplastic agent",GCST009153,2:112624477
rs6488809-<b>T</b>,"3 x 10-7",,0.06,1.74,'-,[NR],DERA,"Adverse response to chemotherapy (amenorrhea) in breast cancer","amenorrhea, breast carcinoma, response to antineoplastic agent",GCST009153,12:16001304
rs1410669-<b>G</b>,"5 x 10-7",,0.07,1.71,'-,[NR],RNU4-66P,"Adverse response to chemotherapy (amenorrhea) in breast cancer","amenorrhea, breast carcinoma, response to antineoplastic agent",GCST009153,6:71740732
rs11096688-<b>T</b>,"7 x 10-7",,0.1,1.45,'-,[NR],LINC02850,"Adverse response to chemotherapy (amenorrhea) in breast cancer","amenorrhea, breast carcinoma, response to antineoplastic agent",GCST009153,2:20885650
rs73419340-<b>A</b>,"8 x 10-7",,0.06,0.49,'-,[NR],"VPS50, CALCR","Adverse response to chemotherapy (amenorrhea) in breast cancer","amenorrhea, breast carcinoma, response to antineoplastic agent",GCST009153,7:93388705
rs1189020-<b>T</b>,"9 x 10-7",,0.06,1.61,'-,[NR],LINC02284,"Adverse response to chemotherapy (amenorrhea) in breast cancer","amenorrhea, breast carcinoma, response to antineoplastic agent",GCST009153,14:56410241
rs78264913-<b>C</b>,"1 x 10-6",,0.05,1.53,'-,[NR],TMTC1,"Adverse response to chemotherapy (amenorrhea) in breast cancer","amenorrhea, breast carcinoma, response to antineoplastic agent",GCST009153,12:29733920
rs77569618-<b>A</b>,"1 x 10-6",,0.09,1.48,'-,[NR],LINC02236,"Adverse response to chemotherapy (amenorrhea) in breast cancer","amenorrhea, breast carcinoma, response to antineoplastic agent",GCST009153,5:6784082
rs1119997-<b>G</b>,"1 x 10-6",,0.46,1.3,'-,[NR],ADCY8,"Adverse response to chemotherapy (amenorrhea) in breast cancer","amenorrhea, breast carcinoma, response to antineoplastic agent",GCST009153,8:131109670
rs7300446-<b>?</b>,"1 x 10-6",,'-,1.56,'-,[1.30-1.87],MGST1,"Metastatic colorectal cancer survival in treatment with chemotherapy plus biologics","metastatic colorectal cancer, survival time, response to antineoplastic agent",GCST011584,12:16521286
rs2461035-<b>?</b>,"5 x 10-6",,'-,0.72,'-,[0.62-0.83],"STMN2, HEY1","Metastatic colorectal cancer survival in treatment with chemotherapy plus biologics","metastatic colorectal cancer, survival time, response to antineoplastic agent",GCST011584,8:79677902
rs16985284-<b>?</b>,"5 x 10-6",,'-,1.56,'-,[1.29-1.89],RDH14,"Metastatic colorectal cancer survival in treatment with chemotherapy plus biologics","metastatic colorectal cancer, survival time, response to antineoplastic agent",GCST011584,2:18553898
rs898838-<b>?</b>,"8 x 10-6",,'-,0.74,'-,[0.65-0.85],"MSGN1, KCNS3","Metastatic colorectal cancer survival in treatment with chemotherapy plus biologics","metastatic colorectal cancer, survival time, response to antineoplastic agent",GCST011584,2:17858241
rs12144699-<b>A</b>,"6 x 10-7",,0.04,1.67,'-,[NR],"FGGY-DT, LINC01358","Subjective response to lithium treatment","bipolar disorder, response to lithium ion",GCST003158,1:59139525
rs9834970-<b>C</b>,"8 x 10-7",,0.5,1.22,'-,[NR],"LINC02033, HSPD1P6","Subjective response to lithium treatment","bipolar disorder, response to lithium ion",GCST003158,3:36814539
rs12493050-<b>G</b>,"9 x 10-7",,0.2,1.27,'-,[NR],LAMP3,"Subjective response to lithium treatment","bipolar disorder, response to lithium ion",GCST003158,3:183147285
rs73918339-<b>C</b>,"4 x 10-7",,0.09,1.79,'-,[NR],"RPL7P3, SLCO4A1","Subjective response to lithium treatment in bipolar disorder","bipolar disorder, response to lithium ion",GCST003160,20:62608205
rs7240206-<b>G</b>,"4 x 10-7",,0.91,1.67,'-,[NR],"ARL2BPP1, CCND3P2","Subjective response to lithium treatment in bipolar disorder","bipolar disorder, response to lithium ion",GCST003160,18:76723198
rs116927879-<b>G</b>,"5 x 10-7",,0.85,1.53,'-,[NR],"RNU6-326P, CICP20","Subjective response to lithium treatment in bipolar disorder","bipolar disorder, response to lithium ion",GCST003160,7:45825128
rs78295376-<b>C</b>,"7 x 10-7",,0.1,1.75,'-,[NR],"CDKL2, ODAPH","Subjective response to lithium treatment in bipolar disorder","bipolar disorder, response to lithium ion",GCST003160,4:75570281
rs116323614-<b>A</b>,"3 x 10-8",,0.03,3.14,'-,[NR],SESTD1,"Objective response to lithium treatment","bipolar disorder, response to lithium ion",GCST003159,2:179120817
rs77866734-<b>T</b>,"1 x 10-7",,0.02,3.7,'-,[NR],TCF3,"Objective response to lithium treatment","bipolar disorder, response to lithium ion",GCST003159,19:1637053
rs142643109-<b>G</b>,"4 x 10-7",,0.02,3.57,'-,[NR],"TBC1D3P2, EFCAB3","Objective response to lithium treatment","bipolar disorder, response to lithium ion",GCST003159,17:62310560
rs438475-<b>A</b>,"2 x 10-6",,0.12,2.04,'-,[NR],NOTCH4,"Objective response to lithium treatment in bipolar disorder","bipolar disorder, response to lithium ion",GCST003161,6:32218468
rs113262272-<b>A</b>,"4 x 10-6",,0.71,1.93,'-,[NR],CNTN5,"Objective response to lithium treatment in bipolar disorder","bipolar disorder, response to lithium ion",GCST003161,11:99428262
rs809-<b>T</b>,"4 x 10-6",,0.47,1.64,'-,[NR],"FXNP1, NRXN3","Objective response to lithium treatment in bipolar disorder","bipolar disorder, response to lithium ion",GCST003161,14:78090121
rs181812561-<b>A</b>,"6 x 10-6",,0.02,7.69,'-,[NR],'-,"Objective response to lithium treatment in bipolar disorder","bipolar disorder, response to lithium ion",GCST003161,6:74372527
rs12061999-<b>?</b>,"3 x 10-6",(Hispanic),'-,'-,'-,'-,"GPR157, SLC2A5","Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,1:9093570
rs4282783-<b>?</b>,"7 x 10-6",(Hispanic),'-,'-,'-,'-,EEF1DP6,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,1:4130625
rs113162402-<b>?</b>,"1 x 10-7",,'-,'-,'-,'-,"SEPTIN4-AS1, SEPTIN4","Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,17:58522103
rs1833170-<b>?</b>,"8 x 10-6",,'-,'-,'-,'-,GRIN2A,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,16:9728154
rs2586052-<b>?</b>,"2 x 10-7",,'-,'-,'-,'-,CUEDC1,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,17:57885718
rs3807044-<b>?</b>,"6 x 10-7",,'-,'-,'-,'-,KCNK16,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,6:39322933
rs17199679-<b>?</b>,"9 x 10-6",,'-,'-,'-,'-,"ACTL7B, RPL36AP35","Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,9:108830800
rs75158213-<b>?</b>,"3 x 10-7",(African),'-,'-,'-,'-,"SPINK8, FBXW12","Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,3:48345739
rs7640677-<b>?</b>,"3 x 10-7",(African),'-,'-,'-,'-,"SPINK8, FBXW12","Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,3:48340996
rs139231591-<b>?</b>,"3 x 10-7",(African),'-,'-,'-,'-,"SPINK8, FBXW12","Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,3:48342403
rs75281979-<b>?</b>,"2 x 10-6",(African),'-,'-,'-,'-,"MIR4443, CDC25A","Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,3:48194468
rs138708216-<b>?</b>,"2 x 10-6",(African),'-,'-,'-,'-,"MIR4443, CDC25A","Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,3:48195305
rs114356151-<b>?</b>,"2 x 10-6",(African),'-,'-,'-,'-,"CAMP, MIR4443","Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,3:48216832
rs7645101-<b>?</b>,"2 x 10-6",(African),'-,'-,'-,'-,CAMP,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,3:48224479
rs7645493-<b>?</b>,"3 x 10-6",(African),'-,'-,'-,'-,"CAMP, ZNF589","Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,3:48232141
rs7645493-<b>?</b>,"3 x 10-6",(African),'-,'-,'-,'-,"CAMP, ZNF589","Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,3:48232141
rs7618694-<b>?</b>,"3 x 10-6",(African),'-,'-,'-,'-,"CAMP, ZNF589","Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,3:48235481
rs79901854-<b>?</b>,"3 x 10-6",(African),'-,'-,'-,'-,"ZNF589, CAMP","Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,3:48236415
rs74358307-<b>?</b>,"3 x 10-6",(African),'-,'-,'-,'-,"ZNF589, CAMP","Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,3:48236590
rs6789249-<b>?</b>,"3 x 10-6",(African),'-,'-,'-,'-,"CAMP, ZNF589","Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,3:48238448
chr3:48283878-<b>?</b>,"3 x 10-6",(African),'-,'-,'-,'-,'-,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,"Mapping not available"
chr3:48285797-<b>?</b>,"3 x 10-6",(African),'-,'-,'-,'-,'-,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,"Mapping not available"
rs76227692-<b>?</b>,"3 x 10-6",(African),'-,'-,'-,'-,ZNF589,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,3:48244677
rs4282783-<b>?</b>,"7 x 10-6",(Hispanic),'-,'-,'-,'-,EEF1DP6,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,1:4130625
rs10912094-<b>?</b>,"9 x 10-6",(Hispanic),'-,'-,'-,'-,LINC01036,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,1:187555131
chr1:205412525-<b>?</b>,"9 x 10-6",(Hispanic),'-,'-,'-,'-,'-,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,"Mapping not available"
rs10912094-<b>?</b>,"9 x 10-6",(Hispanic),'-,'-,'-,'-,LINC01036,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,1:187555131
rs2141654-<b>?</b>,"7 x 10-6",(Hispanic),'-,'-,'-,'-,MAEA,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,4:1291100
rs11727297-<b>?</b>,"7 x 10-6",(Hispanic),'-,'-,'-,'-,MAEA,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,4:1292174
rs28660352-<b>?</b>,"7 x 10-6",(Hispanic),'-,'-,'-,'-,MAEA,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,4:1319132
rs13147602-<b>?</b>,"9 x 10-6",(Hispanic),'-,'-,'-,'-,MAEA,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,4:1338387
rs9648724-<b>?</b>,"1 x 10-6",(Hispanic),'-,'-,'-,'-,PRKAG2,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,7:151805216
rs9648724-<b>?</b>,"1 x 10-6",(Hispanic),'-,'-,'-,'-,PRKAG2,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,7:151805216
rs2398827-<b>?</b>,"2 x 10-6",(Hispanic),'-,'-,'-,'-,"NINJ1, WNK2","Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,9:93144825
rs2398827-<b>?</b>,"3 x 10-6",(Hispanic),'-,'-,'-,'-,"NINJ1, WNK2","Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,9:93144825
rs12879808-<b>?</b>,"4 x 10-6",(Hispanic),'-,'-,'-,'-,LINC02303,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,14:45770163
rs143370239-<b>?</b>,"6 x 10-6",(Hispanic),'-,'-,'-,'-,LINC02303,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,14:45753643
rs76170904-<b>?</b>,"7 x 10-6",(Hispanic),'-,'-,'-,'-,XYLT1,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,16:17289920
rs17562912-<b>?</b>,"6 x 10-6",(Hispanic),'-,'-,'-,'-,RPRD1A,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,18:36003353
rs12662869-<b>?</b>,"7 x 10-9",,'-,'-,'-,'-,SLC17A1,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,6:25784253
rs1408270-<b>?</b>,"6 x 10-7",,'-,'-,'-,'-,SLC17A3,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,6:25872956
rs359770-<b>?</b>,"4 x 10-6",,'-,'-,'-,'-,'-,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,18:76070681
rs75899098-<b>?</b>,"3 x 10-6",(African),'-,'-,'-,'-,ZNF589,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,3:48245424
rs138424282-<b>?</b>,"3 x 10-6",(African),'-,'-,'-,'-,ZNF589,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,3:48250588
chr3:48297176-<b>?</b>,"3 x 10-6",(African),'-,'-,'-,'-,'-,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,"Mapping not available"
rs6909587-<b>?</b>,"3 x 10-7",(African),'-,'-,'-,'-,MIR1202,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,6:155880114
rs3808044-<b>?</b>,"2 x 10-6",(African),'-,'-,'-,'-,RELN,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,7:103480601
rs10823406-<b>?</b>,"9 x 10-6",(African),'-,'-,'-,'-,"NEUROG3, TMEM256P1","Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,10:69552267
rs8040826-<b>?</b>,"4 x 10-6",(African),'-,'-,'-,'-,"CRABP1, WDR61","Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,15:78324744
rs2570249-<b>?</b>,"5 x 10-6",(African),'-,'-,'-,'-,TMOD3,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,15:51861156
rs2570218-<b>?</b>,"5 x 10-6",(African),'-,'-,'-,'-,TMOD3,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,15:51909434
rs2554341-<b>?</b>,"6 x 10-6",(African),'-,'-,'-,'-,"TMOD3, LEO1","Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,15:51938495
rs2554321-<b>?</b>,"6 x 10-6",(African),'-,'-,'-,'-,"LEO1, TMOD3","Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,15:51942335
rs4309482-<b>?</b>,"9 x 10-6",(African),'-,'-,'-,'-,LINC01929,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,18:55083238
rs74885319-<b>?</b>,"2 x 10-6",(EA),'-,'-,'-,'-,KIDINS220,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,2:8728387
rs61742863-<b>?</b>,"2 x 10-6",(EA),'-,'-,'-,'-,KIDINS220,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,2:8736912
rs72786317-<b>?</b>,"2 x 10-6",(EA),'-,'-,'-,'-,KIDINS220,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,2:8739425
rs10025419-<b>?</b>,"1 x 10-6",(EA),'-,'-,'-,'-,EMCN,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,4:100647799
rs2866233-<b>?</b>,"1 x 10-6",(EA),'-,'-,'-,'-,EMCN,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,4:100649444
rs2866220-<b>?</b>,"3 x 10-6",(EA),'-,'-,'-,'-,EMCN,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,4:100619148
rs12505444-<b>?</b>,"3 x 10-6",(EA),'-,'-,'-,'-,EMCN,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,4:100620445
rs4493542-<b>?</b>,"3 x 10-6",(EA),'-,'-,'-,'-,EMCN,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,4:100621270
rs4417977-<b>?</b>,"3 x 10-6",(EA),'-,'-,'-,'-,EMCN,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,4:100632743
rs4635820-<b>?</b>,"3 x 10-6",(EA),'-,'-,'-,'-,EMCN,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,4:100633888
rs6532889-<b>?</b>,"3 x 10-6",(EA),'-,'-,'-,'-,EMCN,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,4:100634019
rs4334765-<b>?</b>,"3 x 10-6",(EA),'-,'-,'-,'-,EMCN,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,4:100634613
rs2903216-<b>?</b>,"3 x 10-6",(EA),'-,'-,'-,'-,EMCN,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,4:100641700
chr4:101569837-<b>?</b>,"3 x 10-6",(EA),'-,'-,'-,'-,'-,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,"Mapping not available"
rs10013079-<b>?</b>,"4 x 10-6",(EA),'-,'-,'-,'-,UNC5C,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,4:95471966
rs4401457-<b>?</b>,"5 x 10-6",(EA),'-,'-,'-,'-,EMCN,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,4:100630158
rs10013079-<b>?</b>,"5 x 10-6",(EA),'-,'-,'-,'-,UNC5C,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,4:95471966
rs7154653-<b>?</b>,"2 x 10-7",(EA),'-,'-,'-,'-,RIN3,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,14:92577033
rs6575267-<b>?</b>,"2 x 10-7",(EA),'-,'-,'-,'-,RIN3,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,14:92580988
rs6575267-<b>?</b>,"4 x 10-7",(EA),'-,'-,'-,'-,RIN3,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,14:92580988
rs12587266-<b>?</b>,"4 x 10-7",(EA),'-,'-,'-,'-,RIN3,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,14:92580298
rs7160376-<b>?</b>,"2 x 10-6",(EA),'-,'-,'-,'-,RIN3,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,14:92578323
rs7160376-<b>?</b>,"4 x 10-6",(EA),'-,'-,'-,'-,RIN3,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,14:92578323
rs7159925-<b>?</b>,"4 x 10-6",(EA),'-,'-,'-,'-,RIN3,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,14:92578339
rs438697-<b>?</b>,"8 x 10-6",,'-,'-,'-,'-,'-,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,1:82787449
rs887829-<b>?</b>,"7 x 10-12",,NR,'-,'-,'-,"UGT1A10, UGT1A3, UGT1A5, UGT1A6, UGT1A8, UGT1A7, UGT1A9, UGT1A4","Bilirubin levels in tenofovir-treated HIV infection","bilirubin measurement, response to tenofovir, HIV infection",GCST006074,2:233759924
rs4148325-<b>?</b>,"1 x 10-11",,NR,'-,'-,'-,"UGT1A10, UGT1A5, UGT1A6, UGT1A7, UGT1A1, UGT1A9, UGT1A8, UGT1A3, UGT1A4","Bilirubin levels in tenofovir-treated HIV infection","bilirubin measurement, response to tenofovir, HIV infection",GCST006074,2:233764663
rs6742078-<b>?</b>,"4 x 10-11",,NR,'-,'-,'-,"UGT1A7, UGT1A1, UGT1A9, UGT1A5, UGT1A3, UGT1A4, UGT1A10, UGT1A6, UGT1A8","Bilirubin levels in tenofovir-treated HIV infection","bilirubin measurement, response to tenofovir, HIV infection",GCST006074,2:233763993
rs4148324-<b>?</b>,"9 x 10-11",,NR,'-,'-,'-,"UGT1A10, UGT1A8, UGT1A3, UGT1A9, UGT1A6, UGT1A4, UGT1A7, UGT1A1, UGT1A5","Bilirubin levels in tenofovir-treated HIV infection","bilirubin measurement, response to tenofovir, HIV infection",GCST006074,2:233764076
rs929596-<b>?</b>,"1 x 10-10",,NR,'-,'-,'-,"UGT1A4, UGT1A10, UGT1A7, UGT1A5, UGT1A9, UGT1A8, UGT1A6, UGT1A1, UGT1A3","Bilirubin levels in tenofovir-treated HIV infection","bilirubin measurement, response to tenofovir, HIV infection",GCST006074,2:233765830
rs3771341-<b>?</b>,"1 x 10-10",,NR,'-,'-,'-,"UGT1A3, UGT1A7, UGT1A10, UGT1A8, UGT1A6, UGT1A1, UGT1A4, UGT1A9, UGT1A5","Bilirubin levels in tenofovir-treated HIV infection","bilirubin measurement, response to tenofovir, HIV infection",GCST006074,2:233764593
rs34352510-<b>?</b>,"3 x 10-10",,NR,'-,'-,'-,"UGT1A8, UGT1A3, UGT1A10, UGT1A4, UGT1A6, UGT1A5, UGT1A7, UGT1A9","Bilirubin levels in tenofovir-treated HIV infection","bilirubin measurement, response to tenofovir, HIV infection",GCST006074,2:233741916
rs10179091-<b>?</b>,"1 x 10-9",,NR,'-,'-,'-,"UGT1A7, UGT1A6, UGT1A4, UGT1A3, UGT1A5, UGT1A9, UGT1A10, UGT1A8","Bilirubin levels in tenofovir-treated HIV infection","bilirubin measurement, response to tenofovir, HIV infection",GCST006074,2:233749337
rs10929302-<b>?</b>,"2 x 10-9",,NR,'-,'-,'-,"UGT1A3, UGT1A8, UGT1A10, UGT1A6, UGT1A7, UGT1A4, UGT1A9, UGT1A5","Bilirubin levels in tenofovir-treated HIV infection","bilirubin measurement, response to tenofovir, HIV infection",GCST006074,2:233757136
rs6747843-<b>?</b>,"2 x 10-9",,NR,'-,'-,'-,"UGT1A8, UGT1A7, UGT1A4, UGT1A3, UGT1A5, UGT1A9, UGT1A10, UGT1A6","Bilirubin levels in tenofovir-treated HIV infection","bilirubin measurement, response to tenofovir, HIV infection",GCST006074,2:233755708
rs6714634-<b>?</b>,"2 x 10-9",,NR,'-,'-,'-,"UGT1A10, UGT1A8, UGT1A3, UGT1A9, UGT1A5, UGT1A6, UGT1A4, UGT1A7","Bilirubin levels in tenofovir-treated HIV infection","bilirubin measurement, response to tenofovir, HIV infection",GCST006074,2:233756119
rs2885296-<b>?</b>,"2 x 10-9",,NR,'-,'-,'-,"UGT1A6, UGT1A7, UGT1A5, UGT1A4, UGT1A10, UGT1A8, UGT1A9, UGT1A3","Bilirubin levels in tenofovir-treated HIV infection","bilirubin measurement, response to tenofovir, HIV infection",GCST006074,2:233750415
rs11695484-<b>?</b>,"3 x 10-9",,NR,'-,'-,'-,"UGT1A4, UGT1A3, UGT1A8, UGT1A5, UGT1A10, UGT1A7, UGT1A6, UGT1A9","Bilirubin levels in tenofovir-treated HIV infection","bilirubin measurement, response to tenofovir, HIV infection",GCST006074,2:233745803
rs11673726-<b>?</b>,"4 x 10-9",,NR,'-,'-,'-,"UGT1A7, UGT1A4, UGT1A6, UGT1A10, UGT1A5, UGT1A9, UGT1A3, UGT1A8","Bilirubin levels in tenofovir-treated HIV infection","bilirubin measurement, response to tenofovir, HIV infection",GCST006074,2:233755414
rs17864701-<b>?</b>,"5 x 10-9",,NR,'-,'-,'-,"UGT1A5, UGT1A10, UGT1A8, UGT1A4, UGT1A6, UGT1A7, UGT1A9, UGT1A3","Bilirubin levels in tenofovir-treated HIV infection","bilirubin measurement, response to tenofovir, HIV infection",GCST006074,2:233744071
rs17862875-<b>?</b>,"6 x 10-9",,NR,'-,'-,'-,"UGT1A5, UGT1A9, UGT1A4, UGT1A10, UGT1A8, UGT1A6, UGT1A7, UGT1A3","Bilirubin levels in tenofovir-treated HIV infection","bilirubin measurement, response to tenofovir, HIV infection",GCST006074,2:233740656
rs11888459-<b>?</b>,"6 x 10-9",,NR,'-,'-,'-,"UGT1A5, UGT1A6, UGT1A8, UGT1A2P, UGT1A9, UGT1A4, UGT1A10, UGT1A7, UGT1A3","Bilirubin levels in tenofovir-treated HIV infection","bilirubin measurement, response to tenofovir, HIV infection",GCST006074,2:233747994
rs10178992-<b>?</b>,"6 x 10-9",,NR,'-,'-,'-,"UGT1A6, UGT1A9, UGT1A5, UGT1A3, UGT1A4, UGT1A10, UGT1A8, UGT1A7","Bilirubin levels in tenofovir-treated HIV infection","bilirubin measurement, response to tenofovir, HIV infection",GCST006074,2:233749231
rs7604115-<b>?</b>,"6 x 10-9",,NR,'-,'-,'-,"UGT1A7, UGT1A4, UGT1A6, UGT1A10, UGT1A3, UGT1A8, UGT1A9, UGT1A5","Bilirubin levels in tenofovir-treated HIV infection","bilirubin measurement, response to tenofovir, HIV infection",GCST006074,2:233749470
rs10929301-<b>?</b>,"7 x 10-9",,NR,'-,'-,'-,"UGT1A7, UGT1A5, UGT1A4, UGT1A10, UGT1A6, UGT1A9, UGT1A8, UGT1A3","Bilirubin levels in tenofovir-treated HIV infection","bilirubin measurement, response to tenofovir, HIV infection",GCST006074,2:233755003
rs1317816-<b>?</b>,"5 x 10-6",(EA),'-,'-,'-,'-,SLC17A4,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,6:25765162
rs4712976-<b>?</b>,"8 x 10-6",(EA),'-,'-,'-,'-,SLC17A3,"Tenofovir clearance in HIV infection","response to tenofovir, HIV infection",GCST006073,6:25841975
rs12035735-<b>?</b>,"7 x 10-7",,NR,5,'-,[2.7-9.6],LRRC8D,"Thiopurine-induced digestive symptoms in inflammatory bowel disease","digestive system disease, response to thiopurine, inflammatory bowel disease",GCST006210,1:89839786
rs2622849-<b>T</b>,"2 x 10-7",,0.051,'-,"1.071 z score decrease",'-,COL11A1,"Bone mineral density change response to combined chemotherapy in acute lymphoblastic leukemia","spine bone mineral density change measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST005214,1:102955788
rs11025915-<b>A</b>,"4 x 10-6",,0.025,'-,"1.306 z score decrease",'-,NELL1,"Bone mineral density change response to combined chemotherapy in acute lymphoblastic leukemia","spine bone mineral density change measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST005214,11:21100413
rs1986582-<b>G</b>,"7 x 10-6",,0.120,'-,"0.629 z score decrease",'-,'-,"Bone mineral density change response to combined chemotherapy in acute lymphoblastic leukemia","spine bone mineral density change measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST005214,7:9391401
rs17047225-<b>C</b>,"8 x 10-6",,0.050,'-,"0.815 z score decrease",'-,TLL1,"Bone mineral density change response to combined chemotherapy in acute lymphoblastic leukemia","spine bone mineral density change measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST005214,4:166075994
rs61745304-<b>A</b>,"5 x 10-6",(EA),'-,2.66,'-,[1.09-6.50],MYH13,"Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,17:10319145
rs10046301-<b>C</b>,"6 x 10-6",(EA),'-,1.42,'-,[1.03-1.95],PLEKHG1,"Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,6:150804007
rs3935695-<b>C</b>,"7 x 10-6",(EA),'-,1.27,'-,[1.02-1.59],"HDAC4, LINC01940","Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,2:239001819
rs77589546-<b>G</b>,"7 x 10-6",(EA),'-,2.34,'-,[1.07-5.11],"ABI2, RAPH1","Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,2:203434784
rs7607659-<b>T</b>,"7 x 10-6",(EA),'-,2.95,'-,[1.09-7.98],RPL23AP27,"Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,2:104651032
rs267585-<b>T</b>,"8 x 10-6",(EA),'-,1.39,'-,[1.03-1.88],"NPAP1P6, LINC01507","Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,9:79932131
rs145744152-<b>C</b>,"9 x 10-6",(EA),'-,2.75,'-,[1.08-6.97],CFHR4,"Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,1:196902587
rs12748152-<b>C</b>,"1 x 10-8",(AA),'-,6.25,'-,[1.47-25],"PIGV, RN7SL165P","Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,1:26811902
rs149940960-<b>T</b>,"2 x 10-8",(AA),'-,6.666666,'-,[1.49-25],GREB1,"Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,2:11641492
rs72772090-<b>G</b>,"4 x 10-7",(AA),'-,5.263158,'-,[1.3-20],CAST,"Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,5:96700607
rs637868-<b>C</b>,"4 x 10-7",(AA),'-,1.5384616,'-,[1.08-2.22],PHGDH,"Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,1:119714487
rs6550253-<b>A</b>,"9 x 10-7",(AA),'-,2.95,'-,[1.17-7.45],LINC01811,"Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,3:34149739
rs6684897-<b>G</b>,"9 x 10-7",(AA),'-,1.8867927,'-,[1.1-3.23],YWHAQP9,"Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,1:238128048
rs4896310-<b>A</b>,"1 x 10-6",(AA),'-,2.11,'-,[1.11-4.03],"PERP, RPSAP42","Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,6:138018697
rs143928882-<b>C</b>,"2 x 10-6",(AA),'-,7.692308,'-,[1.32-50],DDR2,"Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,1:162767290
rs144122212-<b>T</b>,"2 x 10-6",(AA),'-,7.692308,'-,[1.32-50],MCM2,"Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,3:127621197
rs142605642-<b>C</b>,"2 x 10-6",(AA),'-,7.692308,'-,[1.32-50],KCNB1,"Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,20:49374264
rs116783514-<b>C</b>,"2 x 10-6",(AA),'-,4.09,'-,[1.19-13.99],SFI1,"Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,22:31590150
rs75094162-<b>T</b>,"2 x 10-6",(AA),'-,2.9411764,'-,[1.15-7.14],ZFP14,"Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,19:36341148
rs146058206-<b>A</b>,"2 x 10-6",(AA),'-,9.02,'-,[1.31-62.00],"C2orf81, DCTN1-AS1","Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,2:74395262
rs114440645-<b>G</b>,"2 x 10-6",(AA),'-,9.02,'-,[1.31-62.00],'-,"Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,9:103849449
rs61610071-<b>G</b>,"2 x 10-6",(AA),'-,9.02,'-,[1.31-62.00],"BEND7, SEPHS1","Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,10:13373961
rs4759570-<b>A</b>,"2 x 10-6",(AA),'-,9.02,'-,[1.31-62.00],TMEM132D,"Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,12:129452215
rs139242087-<b>T</b>,"3 x 10-6",(AA),'-,8.55,'-,[1.30-56.03],MED18,"Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,1:28334563
rs41307935-<b>C</b>,"1 x 10-7",(AA),'-,4.5454545,'-,[1.33-16.67],ZDHHC18,"Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,1:26854576
rs738409-<b>G</b>,"3 x 10-8",,'-,1.29,'-,[1.04-1.58],PNPLA3,"Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,22:43928847
rs144104656-<b>G</b>,"2 x 10-7",,'-,8.04,'-,[1.36-47.52],'-,"Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,2:118661291
rs147481775-<b>A</b>,"6 x 10-7",,'-,4.66,'-,[1.22-17.88],DEPDC5,"Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,22:31829377
rs74709575-<b>C</b>,"1 x 10-6",,'-,4.52,'-,[1.19-17.19],LINC02334,"Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,13:38041119
rs17857135-<b>T</b>,"2 x 10-6",,'-,1.2820514,'-,[1.03-1.59],RNF213,"Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,17:80288362
rs112769843-<b>C</b>,"2 x 10-6",,'-,1.8518518,'-,[1.06-3.12],TAFA2,"Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,12:61914884
rs11696756-<b>A</b>,"3 x 10-6",,'-,1.39,'-,[1.03-1.86],SSTR4,"Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,20:23001450
rs12530134-<b>A</b>,"4 x 10-6",,'-,1.36,'-,[1.03-1.80],"PDCD2, OR4F7P","Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,6:170610382
rs117483095-<b>T</b>,"4 x 10-6",,'-,1.62,'-,[1.05-2.50],FNBP1,"Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,9:130022496
rs113941845-<b>A</b>,"4 x 10-6",,'-,1.24,'-,[1.02-1.51],LINC01937,"Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,2:238593191
rs145145722-<b>T</b>,"4 x 10-6",,'-,2.3809524,'-,[1.09-5.26],AHR,"Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,7:17203933
rs11020478-<b>G</b>,"4 x 10-6",,'-,1.21,'-,[1.02-1.43],CEP295,"Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,11:93676282
rs1348850-<b>A</b>,"4 x 10-6",,'-,1.22,'-,[1.02-1.46],AGPS,"Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,2:177553847
rs7024024-<b>A</b>,"4 x 10-6",,'-,1.2195122,'-,[1.02-1.47],"SEMA4D, GADD45G","Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,9:89595680
rs149940960-<b>T</b>,"4 x 10-6",,'-,6.25,'-,[1.18-33.33],GREB1,"Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,2:11641492
rs143969105-<b>G</b>,"4 x 10-6",,'-,8.68,'-,[1.21-62.08],"AVIL, TSFM","Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,12:57807682
rs75870332-<b>A</b>,"5 x 10-6",,'-,1.51,'-,[1.04-2.19],'-,"Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,14:27284333
rs58800477-<b>G</b>,"5 x 10-6",,'-,4.1,'-,[1.13-14.91],CDKAL1,"Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,6:20759346
rs149850605-<b>T</b>,"5 x 10-6",,'-,6.09,'-,[1.16-31.9],'-,"Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,9:26228660
rs738408-<b>T</b>,"2 x 10-7",(EA),'-,1.36,'-,[1.05-1.77],PNPLA3,"Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,22:43928850
rs34531324-<b>T</b>,"9 x 10-7",(EA),'-,1.29,'-,[1.03-1.61],LINC01411,"Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,5:174435441
rs73188336-<b>T</b>,"2 x 10-6",(EA),'-,4.23,'-,[1.16-15.4],SGO1-AS1,"Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,3:20984460
rs11696756-<b>A</b>,"2 x 10-6",(EA),'-,1.51,'-,[1.04-2.17],SSTR4,"Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,20:23001450
rs143969105-<b>G</b>,"4 x 10-6",(EA),'-,9.04,'-,[1.23-66.26],"AVIL, TSFM","Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,12:57807682
rs123509-<b>T</b>,"5 x 10-6",(EA),'-,1.3,'-,[1.02-1.65],KLHL40,"Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,3:42691976
rs9836270-<b>A</b>,"2 x 10-6",(Hispanic),'-,1.98,'-,[1.11-3.53],CPNE4,"Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,3:132198152
rs2139953-<b>A</b>,"5 x 10-6",(Hispanic),'-,2,'-,[1.1-3.7],Metazoa_SRP,"Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,15:96565598
rs11753479-<b>G</b>,"5 x 10-6",(Hispanic),'-,2.3255813,'-,[1.11-4.76],LINC02540,"Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,6:76693087
rs4653367-<b>G</b>,"7 x 10-6",(Hispanic),'-,2.0408163,'-,[1.09-3.85],CSMD2,"Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)","serum alanine aminotransferase measurement, response to combination chemotherapy, acute lymphoblastic leukemia",GCST004250,1:34012883
rs16935279-<b>C</b>,"5 x 10-10",,0.014,'-,"0.7918 unit decrease",[NR],LINC01592,"Pharmacokinetics of antiepileptic drugs in severe mental disorder (concentration drug ratio)","unipolar depression, schizophrenia, bipolar disorder, concentration dose ratio, response to anticonvulsant",GCST002887,8:68961217
rs11829119-<b>C</b>,"1 x 10-7",,0.063,'-,"0.4991 unit decrease",[NR],RPL7P6,"Pharmacokinetics of antiepileptic drugs in severe mental disorder (concentration drug ratio)","unipolar depression, schizophrenia, bipolar disorder, concentration dose ratio, response to anticonvulsant",GCST002887,12:19040597
rs17066873-<b>C</b>,"2 x 10-7",,0.039,'-,"0.9277 unit decrease",[NR],"KCTD12, BTF3P11","Pharmacokinetics of antiepileptic drugs in severe mental disorder (concentration drug ratio)","unipolar depression, schizophrenia, bipolar disorder, concentration dose ratio, response to anticonvulsant",GCST002887,13:76889874
rs17790731-<b>A</b>,"2 x 10-7",,0.034,'-,"0.531 unit decrease",[NR],RFESD,"Pharmacokinetics of antiepileptic drugs in severe mental disorder (concentration drug ratio)","unipolar depression, schizophrenia, bipolar disorder, concentration dose ratio, response to anticonvulsant",GCST002887,5:95647825
rs11861787-<b>C</b>,"3 x 10-6",,0.25,1.8868,'-,[NR],TMEM114,"Epilepsy (remission after treatment)","response to drug, epilepsy",GCST002141,16:8467743
rs12744221-<b>C</b>,"6 x 10-6",,0.65,1.66,'-,[NR],RNF115,"Epilepsy (remission after treatment)","response to drug, epilepsy",GCST002141,1:145789475
rs72698613-<b>A</b>,"4 x 10-6",,0.92,2.39,'-,[NR],'-,"Epilepsy (remission after treatment)","response to drug, epilepsy",GCST002141,4:175087067
rs61670327-<b>A</b>,"7 x 10-7",,0.52,1.7241,'-,[NR],"LINC01019, LINC01377","Epilepsy (remission after treatment)","response to drug, epilepsy",GCST002141,5:3276582
rs492146-<b>A</b>,"2 x 10-7",,0.52,1.7544,'-,[NR],"GSTA9P, GSTA4","Epilepsy (remission after treatment)","response to drug, epilepsy",GCST002141,6:52971097
rs72700966-<b>C</b>,"3 x 10-7",,0.92,2.7,'-,[NR],PTPRD,"Epilepsy (remission after treatment)","response to drug, epilepsy",GCST002141,9:10505224
rs143536437-<b>C</b>,"3 x 10-6",,0.72,1.73,'-,[NR],GOLGA8H,"Epilepsy (remission after treatment)","response to drug, epilepsy",GCST002141,15:30606129
rs12627019-<b>?</b>,"8 x 10-7",(EA),NR,'-,"0.0101 mmol/L increase",[0.0097-0.0105],MAPK6P2,"Triglyceride levels x loop diuretics use interaction","triglyceride measurement, response to diuretic",GCST009615,21:22517587
rs10733277-<b>?</b>,"7 x 10-7",(African),NR,'-,"0.2219 unit increase",[0.14-0.31],NFIB,"HDL cholesterol levels x thiazide or thiazide-like diuretics use interaction","response to diuretic, high density lipoprotein cholesterol measurement",GCST009616,9:14256214
rs10507678-<b>?</b>,"4 x 10-7",(African),NR,'-,"0.0719 unit increase",[0.043-0.1],LINC00448,"HDL cholesterol levels x thiazide or thiazide-like diuretics use interaction","response to diuretic, high density lipoprotein cholesterol measurement",GCST009616,13:62595133
rs1971692-<b>?</b>,"7 x 10-7",,NR,'-,"0.0339 unit decrease",[0.02-0.048],RABGAP1,"HDL cholesterol levels x thiazide or thiazide-like diuretics use interaction","response to diuretic, high density lipoprotein cholesterol measurement",GCST009616,9:123102213
rs10083510-<b>?</b>,"3 x 10-7",(African),NR,'-,"0.053 unit decrease",[0.033-0.073],TRIP11,"HDL cholesterol levels x thiazide or thiazide-like diuretics use interaction","response to diuretic, high density lipoprotein cholesterol measurement",GCST009616,14:91996153
rs6043629-<b>?</b>,"1 x 10-8",,NR,'-,"0.0874 unit increase",[0.057-0.118],MACROD2,"HDL cholesterol levels x thiazide or thiazide-like diuretics use interaction","response to diuretic, high density lipoprotein cholesterol measurement",GCST009616,20:15939653
rs9983495-<b>?</b>,"3 x 10-7",,NR,'-,"0.0409 unit decrease",[0.023-0.059],GRIK1,"HDL cholesterol levels x thiazide or thiazide-like diuretics use interaction","response to diuretic, high density lipoprotein cholesterol measurement",GCST009616,21:29824456
rs2359740-<b>?</b>,"1 x 10-7",(EA),NR,'-,"0.1363 unit increase",[0.074-0.199],"BATF, FLVCR2","LDL cholesterol levels x thiazide or thiazide-like diuretics use interaction","response to diuretic, low density lipoprotein cholesterol measurement",GCST009617,14:75557476
rs2304976-<b>?</b>,"1 x 10-7",,NR,'-,"0.1288 unit decrease",[0.08-0.177],KIAA0753,"LDL cholesterol levels x thiazide or thiazide-like diuretics use interaction","response to diuretic, low density lipoprotein cholesterol measurement",GCST009617,17:6622699
rs1926511-<b>?</b>,"1 x 10-7",(EA),NR,'-,"0.0107 unit increase",[0.011-0.011],MYO16,"Triglyceride levels x thiazide or thiazide-like diuretics use interaction","triglyceride measurement, response to diuretic",GCST009612,13:108703588
rs510438-<b>?</b>,"5 x 10-7",(EA),NR,'-,"0.0107 unit increase",[0.011-0.011],"GRP, RAX","Triglyceride levels x thiazide or thiazide-like diuretics use interaction","triglyceride measurement, response to diuretic",GCST009612,18:59265813
rs4653061-<b>?</b>,"6 x 10-7",(African),NR,'-,"0.0122 unit increase",[0.012-0.013],MIR552,"Triglyceride levels x thiazide or thiazide-like diuretics use interaction","triglyceride measurement, response to diuretic",GCST009612,1:34606697
rs2887973-<b>?</b>,"7 x 10-7",(African),NR,'-,"0.3856 unit increase",[0.24-0.53],LINC01320,"HDL cholesterol levels x loop diuretics use interaction","response to diuretic, high density lipoprotein cholesterol measurement",GCST009613,2:34462843
rs7141457-<b>?</b>,"4 x 10-8",(African),NR,'-,"0.2462 unit increase",[0.16-0.33],"TEX21P, LINC00648","HDL cholesterol levels x loop diuretics use interaction","response to diuretic, high density lipoprotein cholesterol measurement",GCST009613,14:47870315
rs2422862-<b>?</b>,"3 x 10-7",(African),NR,'-,"0.3199 unit increase",[0.21-0.43],ITPA,"HDL cholesterol levels x loop diuretics use interaction","response to diuretic, high density lipoprotein cholesterol measurement",GCST009613,20:3219057
rs7924536-<b>?</b>,"6 x 10-7",,NR,'-,"0.0952 unit increase",[0.059-0.132],TEAD1,"HDL cholesterol levels x loop diuretics use interaction","response to diuretic, high density lipoprotein cholesterol measurement",GCST009613,11:12896203
rs203202-<b>?</b>,"2 x 10-7",(EA),NR,'-,"0.1231 unit increase",[0.076-0.17],RNU6-551P,"LDL cholesterol levels x loop diuretics use interaction","response to diuretic, low density lipoprotein cholesterol measurement",GCST009614,4:107408461
rs12208017-<b>?</b>,"4 x 10-8",(African),NR,'-,"0.8105 unit increase",[0.52-1.1],'-,"LDL cholesterol levels x loop diuretics use interaction","response to diuretic, low density lipoprotein cholesterol measurement",GCST009614,"Mapping not available"
rs1312663-<b>?</b>,"4 x 10-7",(African),NR,'-,"0.691 unit decrease",[0.43-0.95],"RNU6-366P, CPSF2","LDL cholesterol levels x loop diuretics use interaction","response to diuretic, low density lipoprotein cholesterol measurement",GCST009614,14:92222336
rs1034637-<b>?</b>,"8 x 10-7",,NR,'-,"0.1166 unit increase",[0.072-0.161],"RNU6-551P, IDUA","LDL cholesterol levels x loop diuretics use interaction","response to diuretic, low density lipoprotein cholesterol measurement",GCST009614,4:107388616
rs11808336-<b>?</b>,"6 x 10-8",(EA),NR,'-,"0.0098 mmol/L increase",[0.0092-0.0104],FGGY,"Triglyceride levels x loop diuretics use interaction","triglyceride measurement, response to diuretic",GCST009615,1:59498642
rs17119531-<b>?</b>,"4 x 10-6",,NR,'-,"0.0126 mmol/L increase",[0.012-0.013],FGGY,"Triglyceride levels x loop diuretics use interaction","triglyceride measurement, response to diuretic",GCST009615,1:59501922
rs1463034-<b>?</b>,"2 x 10-9",(EA),NR,'-,"0.0126 mmol/L increase",[0.012-0.013],COL11A1,"Triglyceride levels x loop diuretics use interaction","triglyceride measurement, response to diuretic",GCST009615,1:102989661
rs1463034-<b>?</b>,"2 x 10-6",,NR,'-,"0.0121 mmol/L increase",[0.012-0.012],COL11A1,"Triglyceride levels x loop diuretics use interaction","triglyceride measurement, response to diuretic",GCST009615,1:102989661
rs7607797-<b>?</b>,"4 x 10-8",(EA),NR,'-,"0.0127 mmol/L increase",[0.012-0.013],SLC9A4,"Triglyceride levels x loop diuretics use interaction","triglyceride measurement, response to diuretic",GCST009615,2:117470626
rs4554091-<b>?</b>,"6 x 10-8",(African),NR,'-,"0.0137 mmol/L increase",[0.013-0.015],'-,"Triglyceride levels x loop diuretics use interaction","triglyceride measurement, response to diuretic",GCST009615,4:129379460
rs11100093-<b>?</b>,"2 x 10-6",,NR,'-,"0.0104 mmol/L increase",[0.01-0.011],"Y_RNA, GLRB","Triglyceride levels x loop diuretics use interaction","triglyceride measurement, response to diuretic",GCST009615,4:157072890
rs7841861-<b>?</b>,"4 x 10-6",,NR,'-,"0.0103 mmol/L increase",[0.0099-0.0107],BAALC-AS1,"Triglyceride levels x loop diuretics use interaction","triglyceride measurement, response to diuretic",GCST009615,8:103247598
rs7077598-<b>?</b>,"7 x 10-7",(EA),NR,'-,"0.0102 mmol/L increase",[0.0098-0.0106],KIAA1217,"Triglyceride levels x loop diuretics use interaction","triglyceride measurement, response to diuretic",GCST009615,10:24229251
rs10508671-<b>?</b>,"1 x 10-8",,NR,'-,"0.0102 mmol/L increase",[0.0098-0.0106],KIAA1217,"Triglyceride levels x loop diuretics use interaction","triglyceride measurement, response to diuretic",GCST009615,10:24245127
rs10762762-<b>?</b>,"1 x 10-7",(EA),NR,'-,"0.01 mmol/L increase",[0.0094-0.0106],LNCAROD,"Triglyceride levels x loop diuretics use interaction","triglyceride measurement, response to diuretic",GCST009615,10:52494056
rs11016373-<b>?</b>,"5 x 10-7",(EA),NR,'-,"0.0099 mmol/L increase",[0.0095-0.0103],'-,"Triglyceride levels x loop diuretics use interaction","triglyceride measurement, response to diuretic",GCST009615,10:128598438
rs16921999-<b>?</b>,"1 x 10-6",,NR,'-,"0.0099 mmol/L increase",[0.0093-0.0105],'-,"Triglyceride levels x loop diuretics use interaction","triglyceride measurement, response to diuretic",GCST009615,11:95499569
rs2790503-<b>?</b>,"3 x 10-7",(EA),NR,'-,"0.0126 mmol/L increase",[0.012-0.013],GNG2,"Triglyceride levels x loop diuretics use interaction","triglyceride measurement, response to diuretic",GCST009615,14:51842495
rs2790503-<b>?</b>,"6 x 10-6",,NR,'-,"0.0121 mmol/L increase",[0.012-0.012],GNG2,"Triglyceride levels x loop diuretics use interaction","triglyceride measurement, response to diuretic",GCST009615,14:51842495
rs2278458-<b>?</b>,"4 x 10-7",(EA),NR,'-,"0.0101 mmol/L increase",[0.0097-0.0105],CYFIP1,"Triglyceride levels x loop diuretics use interaction","triglyceride measurement, response to diuretic",GCST009615,15:22873211
rs2278458-<b>?</b>,"3 x 10-6",,NR,'-,"0.0104 mmol/L increase",[0.01-0.011],CYFIP1,"Triglyceride levels x loop diuretics use interaction","triglyceride measurement, response to diuretic",GCST009615,15:22873211
rs11863116-<b>?</b>,"3 x 10-7",(EA),NR,'-,"0.0124 mmol/L increase",[0.012-0.013],"GSE1, LINC00311","Triglyceride levels x loop diuretics use interaction","triglyceride measurement, response to diuretic",GCST009615,16:85284953
rs6054018-<b>?</b>,"2 x 10-10",(African),NR,'-,"0.0139 mmol/L increase",[0.013-0.015],TARDBPP1,"Triglyceride levels x loop diuretics use interaction","triglyceride measurement, response to diuretic",GCST009615,20:6246589
rs7508797-<b>?</b>,"3 x 10-7",(African),NR,'-,"0.0083 mmol/L increase",[0.0073-0.0093],RNU1-23P,"Triglyceride levels x loop diuretics use interaction","triglyceride measurement, response to diuretic",GCST009615,20:24238748
rs7262233-<b>?</b>,"9 x 10-6",(EA),NR,'-,"0.0101 mmol/L increase",[0.0097-0.0105],TSHZ2,"Triglyceride levels x loop diuretics use interaction","triglyceride measurement, response to diuretic",GCST009615,20:53484682
rs6728642-<b>A</b>,"5 x 10-8",,'-,'-,'-,'-,FAM178B,"Bipolar disorder lithium response (continuous) or schizophrenia","schizophrenia, bipolar disorder, response to lithium ion",GCST005081,2:96941334
rs62200793-<b>T</b>,"1 x 10-8",,'-,'-,'-,'-,ZNF804A,"Bipolar disorder lithium response (continuous) or schizophrenia","schizophrenia, bipolar disorder, response to lithium ion",GCST005081,2:184885915
rs7588746-<b>A</b>,"4 x 10-8",,'-,'-,'-,'-,'-,"Bipolar disorder lithium response (continuous) or schizophrenia","schizophrenia, bipolar disorder, response to lithium ion",GCST005081,2:200121622
rs3919583-<b>A</b>,"5 x 10-9",,'-,'-,'-,'-,LINC02488,"Bipolar disorder lithium response (continuous) or schizophrenia","schizophrenia, bipolar disorder, response to lithium ion",GCST005081,5:87651774
rs144373461-<b>A</b>,"1 x 10-17",,'-,'-,'-,'-,"HLA-V, IFITM4P","Bipolar disorder lithium response (continuous) or schizophrenia","schizophrenia, bipolar disorder, response to lithium ion",GCST005081,6:29783228
rs209474-<b>A</b>,"2 x 10-8",,'-,'-,'-,'-,HLA-DMA,"Bipolar disorder lithium response (continuous) or schizophrenia","schizophrenia, bipolar disorder, response to lithium ion",GCST005081,6:32956807
rs1521470-<b>A</b>,"3 x 10-8",,'-,'-,'-,'-,ADCY1,"Bipolar disorder lithium response (continuous) or schizophrenia","schizophrenia, bipolar disorder, response to lithium ion",GCST005081,7:45607253
rs79403677-<b>T</b>,"2 x 10-8",,'-,'-,'-,'-,FAM177A1,"Bipolar disorder lithium response (continuous) or schizophrenia","schizophrenia, bipolar disorder, response to lithium ion",GCST005081,14:35069925
rs324899-<b>A</b>,"2 x 10-8",,'-,'-,'-,'-,LINC00461,"Bipolar disorder lithium response (categorical) or schizophrenia","schizophrenia, bipolar disorder, response to lithium ion",GCST005082,5:88619764
rs6942227-<b>A</b>,"3 x 10-8",,'-,'-,'-,'-,CMAHP,"Bipolar disorder lithium response (categorical) or schizophrenia","schizophrenia, bipolar disorder, response to lithium ion",GCST005082,6:25177280
rs142425863-<b>T</b>,"5 x 10-11",,'-,'-,'-,'-,"HLA-V, IFITM4P","Bipolar disorder lithium response (categorical) or schizophrenia","schizophrenia, bipolar disorder, response to lithium ion",GCST005082,6:29783976
rs59724122-<b>T</b>,"5 x 10-9",,'-,'-,'-,'-,GULOP,"Bipolar disorder lithium response (categorical) or schizophrenia","schizophrenia, bipolar disorder, response to lithium ion",GCST005082,8:27567179
rs61123830-<b>A</b>,"5 x 10-8",,'-,'-,'-,'-,GRAMD1B,"Bipolar disorder lithium response (categorical) or schizophrenia","schizophrenia, bipolar disorder, response to lithium ion",GCST005082,11:123522138
rs7959663-<b>C</b>,"3 x 10-8",,'-,'-,'-,'-,MYO1H,"Bipolar disorder lithium response (categorical) or schizophrenia","schizophrenia, bipolar disorder, response to lithium ion",GCST005082,12:109446562
rs66486766-<b>A</b>,"1 x 10-11",,'-,'-,'-,'-,"EFL1P1, DNM1P41","Bipolar disorder lithium response (categorical) or schizophrenia","schizophrenia, bipolar disorder, response to lithium ion",GCST005082,15:84137308
rs7405404-<b>T</b>,"5 x 10-11",,'-,'-,'-,'-,'-,"Bipolar disorder lithium response (categorical) or schizophrenia","schizophrenia, bipolar disorder, response to lithium ion",GCST005082,16:13656002
rs2302045-<b>T</b>,"4 x 10-7",,0.067,'-,"0.4064 unit decrease",[NR],"SNED1, MTERF4","Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio)","unipolar depression, schizophrenia, bipolar disorder, concentration dose ratio, response to antipsychotic drug",GCST002888,2:241081801
rs6586354-<b>A</b>,"1 x 10-7",,0.226,'-,"0.2802 unit decrease",[NR],"RN7SL668P, RNY4P16","Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio)","unipolar depression, schizophrenia, bipolar disorder, concentration dose ratio, response to antipsychotic drug",GCST002888,1:234897489
rs17154917-<b>T</b>,"3 x 10-7",,0.022,'-,"0.6656 unit decrease",[NR],'-,"Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio)","unipolar depression, schizophrenia, bipolar disorder, concentration dose ratio, response to antipsychotic drug",GCST002888,7:81207393
rs4077408-<b>A</b>,"8 x 10-6",(EA),0.69,'-,"0.25 unit increase",[NR],HHAT,"Cardiovascular disease in hypertension (ACE inhibitor interaction)","hypertension, cardiovascular disease, response to angiotensin-converting enzyme inhibitor",GCST003186,1:210587100
rs7696430-<b>A</b>,"8 x 10-8",,0.157,'-,"0.014 unit increase",[0.0081-0.0199],LIMCH1,"Response to statins (LDL cholesterol change)","response to statin, low density lipoprotein cholesterol measurement",GCST002675,4:41488438
rs981844-<b>A</b>,"1 x 10-6",,0.747,'-,"0.009 unit increase",[0.0051-0.0129],RNF175,"Response to statins (LDL cholesterol change)","response to statin, low density lipoprotein cholesterol measurement",GCST002675,4:153730876
rs10455872-<b>G</b>,"7 x 10-44",,0.087,'-,"0.052 unit increase",[0.044-0.060],LPA,"Response to statins (LDL cholesterol change)","response to statin, low density lipoprotein cholesterol measurement",GCST002675,6:160589086
rs12428035-<b>T</b>,"8 x 10-7",,0.110,'-,"0.013 unit decrease",[0.0071-0.0189],"DNAJC3-DT, DZIP1","Response to statins (LDL cholesterol change)","response to statin, low density lipoprotein cholesterol measurement",GCST002675,13:95648618
rs11638450-<b>T</b>,"3 x 10-7",,0.376,'-,"0.012 unit decrease",[0.0081-0.0159],CEMIP,"Response to statins (LDL cholesterol change)","response to statin, low density lipoprotein cholesterol measurement",GCST002675,15:80898191
rs445925-<b>A</b>,"9 x 10-29",,0.157,'-,"0.051 unit decrease",[0.041-0.061],"APOC1, APOE","Response to statins (LDL cholesterol change)","response to statin, low density lipoprotein cholesterol measurement",GCST002675,19:44912383
rs2897639-<b>?</b>,"2 x 10-7",(African),'-,'-,'-,'-,DCC,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,18:77568791
rs73412846-<b>?</b>,"5 x 10-6",(African),'-,'-,'-,'-,'-,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,18:29446329
rs10468897-<b>?</b>,"5 x 10-6",(African),'-,'-,'-,'-,'-,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,18:29441032
rs10399860-<b>?</b>,"9 x 10-6",(EA),'-,'-,'-,'-,CHRM3,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,1:239901238
rs2129530-<b>?</b>,"9 x 10-6",(EA),'-,'-,'-,'-,GALNT18,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,11:11376738
chr12:9365073-<b>?</b>,"2 x 10-6",(African),'-,'-,'-,'-,'-,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,"Mapping not available"
rs17007660-<b>?</b>,"2 x 10-6",(EA),'-,'-,'-,'-,LIN7A,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,12:80917670
rs7974884-<b>?</b>,"3 x 10-6",(EA),'-,'-,'-,'-,LIN7A,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,12:80915504
rs34500073-<b>?</b>,"3 x 10-6",(EA),'-,'-,'-,'-,LIN7A,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,12:80917603
rs6539535-<b>?</b>,"3 x 10-6",(EA),'-,'-,'-,'-,LIN7A,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,12:80918934
rs7959128-<b>?</b>,"3 x 10-6",(EA),'-,'-,'-,'-,LIN7A,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,12:80919031
rs11114652-<b>?</b>,"3 x 10-6",(EA),'-,'-,'-,'-,LIN7A,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,12:80916873
rs17804080-<b>?</b>,"3 x 10-6",(EA),'-,'-,'-,'-,A2MP1,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,12:9235414
rs4962347-<b>?</b>,"3 x 10-6",(EA),'-,'-,'-,'-,C10orf90,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,10:126609535
rs2129532-<b>?</b>,"4 x 10-6",(EA),'-,'-,'-,'-,GALNT18,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,11:11376812
rs978471-<b>?</b>,"4 x 10-6",(EA),'-,'-,'-,'-,C10orf90,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,10:126614850
rs1436793-<b>?</b>,"4 x 10-6",(EA),'-,'-,'-,'-,C10orf90,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,10:126615939
rs2842161-<b>?</b>,"4 x 10-6",(EA),'-,'-,'-,'-,C10orf90,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,10:126616457
rs57961998-<b>?</b>,"6 x 10-6",(EA),'-,'-,'-,'-,"PZP, A2MP1","Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,12:9225633
rs73057767-<b>?</b>,"6 x 10-6",(EA),'-,'-,'-,'-,"PZP, A2MP1","Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,12:9227522
rs73057770-<b>?</b>,"6 x 10-6",(EA),'-,'-,'-,'-,"PZP, A2MP1","Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,12:9227541
rs67775007-<b>?</b>,"6 x 10-6",(EA),'-,'-,'-,'-,"A2MP1, PZP","Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,12:9228478
chr12:9383002-<b>?</b>,"6 x 10-6",(African),'-,'-,'-,'-,'-,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,"Mapping not available"
rs7710776-<b>?</b>,"3 x 10-6",(EA),'-,'-,'-,'-,LINC00461,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,5:88560042
rs10071077-<b>?</b>,"3 x 10-6",(EA),'-,'-,'-,'-,LINC00461,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,5:88560241
rs906956-<b>?</b>,"4 x 10-6",,'-,'-,'-,'-,"OR5AP1P, OR5AP2","6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,11:56639492
rs17150276-<b>?</b>,"5 x 10-6",,'-,'-,'-,'-,"OR5T1, OR8H1","6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,11:56286353
rs1945279-<b>?</b>,"5 x 10-6",,'-,'-,'-,'-,"OR5M10, OR5M11","6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,11:56566682
rs1355242-<b>?</b>,"4 x 10-6",,'-,'-,'-,'-,"OR5M12P, OR5AM1P","6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,11:56626174
rs2664570-<b>?</b>,"9 x 10-6",(EA),'-,'-,'-,'-,PREX1,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,20:48624820
rs731580-<b>?</b>,"2 x 10-6",(EA),'-,'-,'-,'-,FGD5,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,3:14815331
rs2480181-<b>?</b>,"5 x 10-6",(African),'-,'-,'-,'-,"MRAP2, LINC02857","6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,6:84030677
rs11106805-<b>?</b>,"7 x 10-6",(African),'-,'-,'-,'-,"LINC02413, Y_RNA","6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,12:93020495
rs2112424-<b>?</b>,"3 x 10-6",(EA),'-,'-,'-,'-,LINC00461,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,5:88598828
rs324898-<b>?</b>,"3 x 10-6",(EA),'-,'-,'-,'-,LINC00461,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,5:88618709
rs324884-<b>?</b>,"3 x 10-6",(EA),'-,'-,'-,'-,LINC00461,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,5:88565282
rs2438466-<b>?</b>,"4 x 10-6",(EA),'-,'-,'-,'-,LINC00461,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,5:88583650
rs73135714-<b>?</b>,"6 x 10-6",(EA),'-,'-,'-,'-,PREX1,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,20:48614297
rs12230258-<b>?</b>,"9 x 10-6",(African),'-,'-,'-,'-,"PLEKHA8P1, RNA5SP361","6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,12:45143962
rs141827060-<b>?</b>,"1 x 10-6",(African),'-,'-,'-,'-,IGSF11,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,3:119132020
rs11926663-<b>?</b>,"1 x 10-6",(African),'-,'-,'-,'-,IGSF11,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,3:119125638
rs11914494-<b>?</b>,"1 x 10-6",(African),'-,'-,'-,'-,IGSF11,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,3:119121264
rs652106-<b>?</b>,"6 x 10-6",(EA),'-,'-,'-,'-,"OR5M7P, OR5M6P","6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,11:56505171
rs610410-<b>?</b>,"6 x 10-6",(EA),'-,'-,'-,'-,"OR5M6P, OR5M7P","6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,11:56505351
chr7:140468067-<b>?</b>,"6 x 10-6",(EA),'-,'-,'-,'-,'-,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,"Mapping not available"
rs582939-<b>?</b>,"7 x 10-6",(EA),'-,'-,'-,'-,"OR5M2P, OR5M3","6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,11:56473714
rs603926-<b>?</b>,"7 x 10-6",(EA),'-,'-,'-,'-,OR5M2P,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,11:56477759
chr11:56250191-<b>?</b>,"7 x 10-6",(EA),'-,'-,'-,'-,'-,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,"Mapping not available"
rs594854-<b>?</b>,"7 x 10-6",(EA),'-,'-,'-,'-,OR5M2P,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,11:56483758
rs669501-<b>?</b>,"7 x 10-6",(EA),'-,'-,'-,'-,"OR5M7P, OR5M8","6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,11:56493213
rs11705830-<b>?</b>,"3 x 10-6",(African),'-,'-,'-,'-,ERC2,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,3:55916101
rs11923949-<b>?</b>,"3 x 10-6",(African),'-,'-,'-,'-,IGSF11,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,3:119140849
rs11106805-<b>?</b>,"5 x 10-6",(African),'-,'-,'-,'-,"LINC02413, Y_RNA","6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,12:93020495
rs2870682-<b>?</b>,"6 x 10-6",(African),'-,'-,'-,'-,GRID2,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,4:93155023
rs9453288-<b>?</b>,"7 x 10-6",(African),'-,'-,'-,'-,EYS,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,6:65378418
rs77197299-<b>?</b>,"7 x 10-6",(African),'-,'-,'-,'-,SIAH3,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,13:45777530
rs4859214-<b>?</b>,"8 x 10-6",(African),'-,'-,'-,'-,'-,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,3:182309318
rs12230258-<b>?</b>,"8 x 10-6",(African),'-,'-,'-,'-,"PLEKHA8P1, RNA5SP361","6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,12:45143962
rs731580-<b>?</b>,"1 x 10-6",(EA),'-,'-,'-,'-,FGD5,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,3:14815331
rs1733826-<b>?</b>,"4 x 10-6",(EA),'-,'-,'-,'-,BRAF,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,7:140795773
rs2112424-<b>?</b>,"4 x 10-6",(EA),'-,'-,'-,'-,LINC00461,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,5:88598828
rs2438466-<b>?</b>,"4 x 10-6",(EA),'-,'-,'-,'-,LINC00461,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,5:88583650
rs16993962-<b>?</b>,"8 x 10-6",(EA),'-,'-,'-,'-,PREX1,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,20:48611439
rs2511145-<b>?</b>,"7 x 10-6",(EA),'-,'-,'-,'-,"OR5M7P, OR5M8","6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,11:56493486
rs638436-<b>?</b>,"7 x 10-6",(EA),'-,'-,'-,'-,"OR5M7P, OR5M8","6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,11:56495636
rs638452-<b>?</b>,"7 x 10-6",(EA),'-,'-,'-,'-,"OR5M7P, OR5M8","6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,11:56495642
rs676794-<b>?</b>,"7 x 10-6",(EA),'-,'-,'-,'-,OR5M2P,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,11:56482648
rs6448638-<b>?</b>,"7 x 10-7",(Hispanic),'-,'-,'-,'-,LINC02472,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,4:29333941
rs4435343-<b>?</b>,"8 x 10-7",(Hispanic),'-,'-,'-,'-,SYT4,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,18:43322011
rs1966678-<b>?</b>,"1 x 10-6",(Hispanic),'-,'-,'-,'-,LINC02472,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,4:29322410
rs2226150-<b>?</b>,"1 x 10-6",(Hispanic),'-,'-,'-,'-,'-,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,6:77349634
rs16893073-<b>?</b>,"1 x 10-6",(Hispanic),'-,'-,'-,'-,C5orf17,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,5:24072508
rs13292946-<b>?</b>,"2 x 10-6",(Hispanic),'-,'-,'-,'-,OLFM1,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,9:135116709
rs16867887-<b>?</b>,"3 x 10-6",(Hispanic),'-,'-,'-,'-,LINC02472,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,4:29323274
rs11103684-<b>?</b>,"3 x 10-6",(Hispanic),'-,'-,'-,'-,OLFM1,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,9:135120224
rs11834-<b>?</b>,"3 x 10-6",(Hispanic),'-,'-,'-,'-,OLFM1,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,9:135120566
rs2604271-<b>?</b>,"3 x 10-6",(Hispanic),'-,'-,'-,'-,'-,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,9:74276496
rs1592216-<b>?</b>,"3 x 10-6",(Hispanic),'-,'-,'-,'-,HTR1B,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,6:77389978
rs1935737-<b>?</b>,"3 x 10-6",(Hispanic),'-,'-,'-,'-,HTR1B,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,6:77364760
rs7562658-<b>?</b>,"3 x 10-6",(Hispanic),'-,'-,'-,'-,HNRNPA1P57,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,2:41139011
rs1342634-<b>?</b>,"4 x 10-6",(Hispanic),'-,'-,'-,'-,HTR1B,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,6:77374254
rs625001-<b>?</b>,"4 x 10-6",(Hispanic),'-,'-,'-,'-,TXNL1,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,18:56601279
rs11103683-<b>?</b>,"4 x 10-6",(Hispanic),'-,'-,'-,'-,OLFM1,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,9:135117933
rs6902991-<b>?</b>,"4 x 10-6",(Hispanic),'-,'-,'-,'-,TSBP1-AS1,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,6:77351264
rs9361224-<b>?</b>,"5 x 10-6",(Hispanic),'-,'-,'-,'-,'-,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,6:77352894
rs904200-<b>?</b>,"7 x 10-6",(Hispanic),'-,'-,'-,'-,"LINC01082, LINC01081","6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,16:86220110
rs11981075-<b>?</b>,"7 x 10-6",(Hispanic),'-,'-,'-,'-,SEMA3A,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,7:83876076
rs7039098-<b>?</b>,"2 x 10-7",(Hispanic),'-,'-,'-,'-,OLFM1,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,9:135121473
rs7035473-<b>?</b>,"2 x 10-7",(Hispanic),'-,'-,'-,'-,OLFM1,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,9:135121519
rs7047901-<b>?</b>,"2 x 10-7",(Hispanic),'-,'-,'-,'-,OLFM1,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,9:135121569
rs10119043-<b>?</b>,"2 x 10-7",(Hispanic),'-,'-,'-,'-,OLFM1,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,9:135122706
rs6448638-<b>?</b>,"7 x 10-7",(Hispanic),'-,'-,'-,'-,LINC02472,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,4:29333941
rs79666748-<b>?</b>,"7 x 10-7",(Hispanic),'-,'-,'-,'-,SYT4,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,18:43280443
rs116965780-<b>?</b>,"7 x 10-7",(Hispanic),'-,'-,'-,'-,SYT4,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,18:43300829
rs4435343-<b>?</b>,"7 x 10-7",(Hispanic),'-,'-,'-,'-,SYT4,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,18:43322011
rs2226150-<b>?</b>,"7 x 10-7",(Hispanic),'-,'-,'-,'-,'-,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,6:77349634
rs1836778-<b>?</b>,"9 x 10-7",(Hispanic),'-,'-,'-,'-,LINC02472,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,4:29332870
rs1966678-<b>?</b>,"1 x 10-6",(Hispanic),'-,'-,'-,'-,LINC02472,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,4:29322410
rs55920741-<b>?</b>,"1 x 10-6",(Hispanic),'-,'-,'-,'-,LINC02472,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,4:29331415
rs9341664-<b>?</b>,"1 x 10-6",(Hispanic),'-,'-,'-,'-,HTR1B,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,6:77375469
rs73055009-<b>?</b>,"1 x 10-6",(Hispanic),'-,'-,'-,'-,C5orf17,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,5:24058406
rs10054178-<b>?</b>,"1 x 10-6",(Hispanic),'-,'-,'-,'-,C5orf17,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,5:24059742
rs113051092-<b>?</b>,"1 x 10-6",(Hispanic),'-,'-,'-,'-,C5orf17,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,5:24060490
rs73055087-<b>?</b>,"1 x 10-6",(Hispanic),'-,'-,'-,'-,C5orf17,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,5:24062454
rs79056512-<b>?</b>,"1 x 10-6",(Hispanic),'-,'-,'-,'-,C5orf17,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,5:24063287
rs10041590-<b>?</b>,"1 x 10-6",(Hispanic),'-,'-,'-,'-,C5orf17,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,5:24064827
rs10056373-<b>?</b>,"1 x 10-6",(Hispanic),'-,'-,'-,'-,C5orf17,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,5:24069684
rs906956-<b>?</b>,"4 x 10-6",,'-,'-,'-,'-,"OR5AP1P, OR5AP2","6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,11:56639492
rs121882-<b>?</b>,"6 x 10-6",,'-,'-,'-,'-,ARHGAP26,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,5:143153779
rs11227719-<b>?</b>,"6 x 10-6",,'-,'-,'-,'-,"OR5T3, OR5T1","6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,11:56269311
GA021270-<b>?</b>,"6 x 10-6",,'-,'-,'-,'-,'-,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,"Mapping not available"
rs1397050-<b>?</b>,"7 x 10-6",,'-,'-,'-,'-,"OR5M1, OR5M13P","6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,11:56604281
rs17150286-<b>?</b>,"9 x 10-6",,'-,'-,'-,'-,OR8H1,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,11:56289943
rs10827209-<b>?</b>,"7 x 10-7",,'-,'-,'-,'-,NRP1,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,10:33198261
rs11228672-<b>?</b>,"1 x 10-6",,'-,'-,'-,'-,OR5M13P,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,11:56597931
rs638436-<b>?</b>,"1 x 10-6",,'-,'-,'-,'-,"OR5M7P, OR5M8","6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,11:56495636
rs638452-<b>?</b>,"1 x 10-6",,'-,'-,'-,'-,"OR5M7P, OR5M8","6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,11:56495642
rs11228326-<b>?</b>,"2 x 10-6",,'-,'-,'-,'-,"OR8U3, OR5M4P","6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,11:56423917
rs652106-<b>?</b>,"2 x 10-6",,'-,'-,'-,'-,"OR5M7P, OR5M6P","6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,11:56505171
rs13076411-<b>?</b>,"3 x 10-6",,'-,'-,'-,'-,LRRC3B,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,3:26547929
rs10510578-<b>?</b>,"3 x 10-6",,'-,'-,'-,'-,LRRC3B,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,3:26526585
rs10896497-<b>?</b>,"3 x 10-6",,'-,'-,'-,'-,"OR5AM1P, OR5M12P","6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,11:56622809
rs13072945-<b>?</b>,"3 x 10-6",,'-,'-,'-,'-,LRRC3B,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,3:26535293
rs62249990-<b>?</b>,"3 x 10-6",,'-,'-,'-,'-,LRRC3B,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,3:26537687
chr3:26596160-<b>?</b>,"3 x 10-6",,'-,'-,'-,'-,'-,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,"Mapping not available"
rs35524753-<b>?</b>,"4 x 10-6",,'-,'-,'-,'-,LRRC3B,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,3:26524192
chr3:26593850-<b>?</b>,"4 x 10-6",,'-,'-,'-,'-,'-,"6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,"Mapping not available"
rs1080800-<b>?</b>,"4 x 10-6",,'-,'-,'-,'-,"OR5M11, OR5M10","6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,11:56543614
rs12787983-<b>?</b>,"4 x 10-6",,'-,'-,'-,'-,"OR5M11, OR5M10","6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006072,11:56548598
rs7109445-<b>?</b>,"3 x 10-7",(Hispanic),'-,'-,'-,'-,CLMP,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,11:123094779
rs67033239-<b>?</b>,"6 x 10-6",(EA),'-,'-,'-,'-,A2MP1,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,12:9231340
rs17062789-<b>?</b>,"3 x 10-7",(Hispanic),'-,'-,'-,'-,DLGAP2,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,8:1203198
rs4936767-<b>?</b>,"6 x 10-7",(Hispanic),'-,'-,'-,'-,"RPS26P43, RPL34P23","Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,11:123047451
rs7109445-<b>?</b>,"7 x 10-7",(Hispanic),'-,'-,'-,'-,CLMP,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,11:123094779
rs4936770-<b>?</b>,"9 x 10-7",(Hispanic),'-,'-,'-,'-,HSPA8,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,11:123058167
rs4802-<b>?</b>,"3 x 10-7",(Hispanic),'-,'-,'-,'-,HSPA8,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,11:123057914
rs4936770-<b>?</b>,"3 x 10-7",(Hispanic),'-,'-,'-,'-,HSPA8,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,11:123058167
rs6677658-<b>?</b>,"3 x 10-6",(Hispanic),'-,'-,'-,'-,RYR2,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,1:237396237
rs7688805-<b>?</b>,"4 x 10-6",(Hispanic),'-,'-,'-,'-,"KCNIP4, PACRGL","Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,4:20730711
rs505601-<b>?</b>,"5 x 10-6",(Hispanic),'-,'-,'-,'-,FHOD3,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,18:36700168
rs57580384-<b>?</b>,"5 x 10-7",(Hispanic),'-,'-,'-,'-,"EBF2, RNA5SP258","Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,8:26048063
chr11:122962586-<b>?</b>,"6 x 10-7",(Hispanic),'-,'-,'-,'-,'-,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,"Mapping not available"
rs10892961-<b>?</b>,"6 x 10-7",(Hispanic),'-,'-,'-,'-,CLMP,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,11:123093392
rs55980452-<b>?</b>,"1 x 10-6",(Hispanic),'-,'-,'-,'-,"RNA5SP258, EBF2","Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,8:26046363
rs72609945-<b>?</b>,"1 x 10-6",(Hispanic),'-,'-,'-,'-,"RNA5SP258, EBF2","Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,8:26048781
rs2226150-<b>?</b>,"1 x 10-6",(Hispanic),'-,'-,'-,'-,'-,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,6:77349634
rs59926619-<b>?</b>,"1 x 10-6",(Hispanic),'-,'-,'-,'-,"EBF2, RNA5SP258","Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,8:26050704
rs9341664-<b>?</b>,"1 x 10-6",(Hispanic),'-,'-,'-,'-,HTR1B,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,6:77375469
rs2682618-<b>?</b>,"5 x 10-6",,'-,'-,'-,'-,IRAG2,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,12:127505259
rs34574970-<b>?</b>,"9 x 10-6",,'-,'-,'-,'-,TRPM3,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,9:70524146
rs390296-<b>?</b>,"2 x 10-6",,'-,'-,'-,'-,RNPEP,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,1:82786827
rs2571468-<b>?</b>,"6 x 10-6",(African),'-,'-,'-,'-,'-,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,4:30214051
rs6863176-<b>?</b>,"3 x 10-6",(African),'-,'-,'-,'-,SNORD81,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,5:18238325
rs6863176-<b>?</b>,"4 x 10-6",(African),'-,'-,'-,'-,SNORD81,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,5:18238325
rs2459464-<b>?</b>,"5 x 10-6",(African),'-,'-,'-,'-,C7,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,5:40948388
rs75989043-<b>?</b>,"3 x 10-6",(African),'-,'-,'-,'-,RANP9,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,8:33138620
rs73251320-<b>?</b>,"6 x 10-6",(EA),'-,'-,'-,'-,A2MP1,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,12:9230942
rs7696218-<b>?</b>,"3 x 10-7",(Hispanic),'-,'-,'-,'-,PACRGL,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,4:20721189
rs17062791-<b>?</b>,"2 x 10-7",(Hispanic),'-,'-,'-,'-,DLGAP2,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,8:1203431
rs73670671-<b>?</b>,"3 x 10-7",(Hispanic),'-,'-,'-,'-,DLGAP2,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,8:1203645
rs1461494-<b>?</b>,"3 x 10-7",(Hispanic),'-,'-,'-,'-,"HSPA8, RPL31P47","Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,11:123055777
rs2226150-<b>?</b>,"2 x 10-6",(Hispanic),'-,'-,'-,'-,'-,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,6:77349634
rs1592216-<b>?</b>,"3 x 10-6",(Hispanic),'-,'-,'-,'-,HTR1B,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,6:77389978
rs2883821-<b>?</b>,"3 x 10-6",(Hispanic),'-,'-,'-,'-,IGSF21,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,1:18240357
rs11218976-<b>?</b>,"5 x 10-7",(Hispanic),'-,'-,'-,'-,CLMP,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,11:123090950
rs7121616-<b>?</b>,"5 x 10-7",(Hispanic),'-,'-,'-,'-,CLMP,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,11:123095918
rs1935737-<b>?</b>,"5 x 10-6",(Hispanic),'-,'-,'-,'-,HTR1B,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,6:77364760
rs1342634-<b>?</b>,"5 x 10-6",(Hispanic),'-,'-,'-,'-,HTR1B,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,6:77374254
rs7064462-<b>?</b>,"5 x 10-6",(Hispanic),'-,'-,'-,'-,LHFPL1,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,X:112671016
rs7562658-<b>?</b>,"6 x 10-6",(Hispanic),'-,'-,'-,'-,HNRNPA1P57,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,2:41139011
rs6902991-<b>?</b>,"6 x 10-6",(Hispanic),'-,'-,'-,'-,TSBP1-AS1,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,6:77351264
rs7923837-<b>?</b>,"7 x 10-6",(Hispanic),'-,'-,'-,'-,Y_RNA,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,10:92722160
rs4709724-<b>?</b>,"7 x 10-6",(Hispanic),'-,'-,'-,'-,QKI,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,6:163586391
rs7941144-<b>?</b>,"8 x 10-6",(Hispanic),'-,'-,'-,'-,CLMP,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,11:123079805
rs12592731-<b>?</b>,"8 x 10-6",(Hispanic),'-,'-,'-,'-,SNRPN,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,15:24925023
rs36111427-<b>?</b>,"9 x 10-6",(Hispanic),'-,'-,'-,'-,"DCBLD1, RAP1BP3","Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,6:117432671
rs34003842-<b>?</b>,"2 x 10-7",(Hispanic),'-,'-,'-,'-,DLGAP2,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,8:1206131
rs17062791-<b>?</b>,"2 x 10-7",(Hispanic),'-,'-,'-,'-,DLGAP2,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,8:1203431
rs4936767-<b>?</b>,"2 x 10-7",(Hispanic),'-,'-,'-,'-,"RPS26P43, RPL34P23","Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,11:123047451
rs10098430-<b>?</b>,"3 x 10-6",(African),'-,'-,'-,'-,'-,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,8:33141855
rs55983391-<b>?</b>,"3 x 10-6",(African),'-,'-,'-,'-,'-,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,8:33145354
chr8:33032156-<b>?</b>,"3 x 10-6",(African),'-,'-,'-,'-,'-,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,"Mapping not available"
rs72749479-<b>?</b>,"7 x 10-7",(African),'-,'-,'-,'-,'-,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,9:80667356
rs72749483-<b>?</b>,"7 x 10-7",(African),'-,'-,'-,'-,'-,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,9:80670259
rs11011237-<b>?</b>,"2 x 10-7",(African),'-,'-,'-,'-,TACC1P1,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,10:37531016
rs10827791-<b>?</b>,"2 x 10-6",(African),'-,'-,'-,'-,TACC1P1,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,10:37530781
rs73412830-<b>?</b>,"5 x 10-6",(African),'-,'-,'-,'-,'-,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,18:29443322
rs10521695-<b>?</b>,"8 x 10-6",(African),'-,'-,'-,'-,"TUBAP6, LUZP4","Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,X:115373069
rs11114652-<b>?</b>,"3 x 10-6",(EA),'-,'-,'-,'-,LIN7A,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,12:80916873
rs4962347-<b>?</b>,"4 x 10-6",(EA),'-,'-,'-,'-,C10orf90,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,10:126609535
rs17804080-<b>?</b>,"5 x 10-6",(EA),'-,'-,'-,'-,A2MP1,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,12:9235414
rs16918212-<b>?</b>,"7 x 10-6",(EA),'-,'-,'-,'-,A2MP1,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,12:9232362
rs7585799-<b>?</b>,"7 x 10-6",(EA),'-,'-,'-,'-,TRAPPC12,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,2:3461039
rs10827791-<b>?</b>,"2 x 10-6",(African),'-,'-,'-,'-,TACC1P1,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,10:37530781
rs7082049-<b>?</b>,"3 x 10-6",(African),'-,'-,'-,'-,TACC1P1,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,10:37530427
rs11191554-<b>?</b>,"3 x 10-6",(African),'-,'-,'-,'-,NT5C2,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,10:103095521
rs10786737-<b>?</b>,"4 x 10-6",(African),'-,'-,'-,'-,NT5C2,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,10:103097461
rs10786737-<b>?</b>,"4 x 10-6",(African),'-,'-,'-,'-,NT5C2,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,10:103097461
chr10:104857205-<b>?</b>,"5 x 10-6",(African),'-,'-,'-,'-,'-,"Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,"Mapping not available"
rs10827797-<b>?</b>,"7 x 10-6",(African),'-,'-,'-,'-,"MTND1P18, TACC1P1","Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,10:37548585
rs11106805-<b>?</b>,"3 x 10-6",(African),'-,'-,'-,'-,"LINC02413, Y_RNA","Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,12:93020495
rs11106805-<b>?</b>,"3 x 10-6",(African),'-,'-,'-,'-,"LINC02413, Y_RNA","Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,12:93020495
rs17067414-<b>?</b>,"4 x 10-6",(African),'-,'-,'-,'-,"SIAH3, ZC3H13","Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,13:45895072
rs7996510-<b>?</b>,"6 x 10-6",(African),'-,'-,'-,'-,"ZC3H13, SIAH3","Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)","response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,13:45896242
rs17158930-<b>G</b>,"3 x 10-7",,0.193,'-,"0.3082 unit decrease",[NR],DOCK4,"Pharmacokinetics of antidepressant drugs in severe mental disorder (concentration dose ratio)","unipolar depression, schizophrenia, bipolar disorder, concentration dose ratio, response to antidepressant",GCST002891,7:111871082
rs138922423-<b>?</b>,"3 x 10-6",,'-,16.02,'-,[4.99-51.46],RNU4ATAC8P,"Childhood ALL/LBL (acute lymphoblastic leukemia/lymphoblastic lymphoma) treatment-related venous thromboembolism","venous thromboembolism, acute lymphoblastic leukemia, lymphoblastic lymphoma, response to antineoplastic agent",GCST010463,1:73916690
rs4845725-<b>?</b>,"4 x 10-6",,'-,3.8,'-,[2.15-6.71],"S100A10, NBPF18P","Childhood ALL/LBL (acute lymphoblastic leukemia/lymphoblastic lymphoma) treatment-related venous thromboembolism","venous thromboembolism, acute lymphoblastic leukemia, lymphoblastic lymphoma, response to antineoplastic agent",GCST010463,1:152001324
rs115456075-<b>?</b>,"3 x 10-6",,'-,8.51,'-,[3.45-20.95],"CAMSAP2, DDX59-AS1","Childhood ALL/LBL (acute lymphoblastic leukemia/lymphoblastic lymphoma) treatment-related venous thromboembolism","venous thromboembolism, acute lymphoblastic leukemia, lymphoblastic lymphoma, response to antineoplastic agent",GCST010463,1:200705097
rs570684-<b>?</b>,"4 x 10-7",,'-,9.090909,'-,[3.85-20],KALRN,"Childhood ALL/LBL (acute lymphoblastic leukemia/lymphoblastic lymphoma) treatment-related venous thromboembolism","venous thromboembolism, acute lymphoblastic leukemia, lymphoblastic lymphoma, response to antineoplastic agent",GCST010463,3:124403999
rs4546143-<b>?</b>,"2 x 10-6",,'-,2.39,'-,[1.67-3.43],RYK,"Childhood ALL/LBL (acute lymphoblastic leukemia/lymphoblastic lymphoma) treatment-related venous thromboembolism","venous thromboembolism, acute lymphoblastic leukemia, lymphoblastic lymphoma, response to antineoplastic agent",GCST010463,3:134066333
rs60440889-<b>?</b>,"2 x 10-6",,'-,3.55,'-,[2.11-5.96],U6,"Childhood ALL/LBL (acute lymphoblastic leukemia/lymphoblastic lymphoma) treatment-related venous thromboembolism","venous thromboembolism, acute lymphoblastic leukemia, lymphoblastic lymphoma, response to antineoplastic agent",GCST010463,4:13138969
rs7682733-<b>?</b>,"3 x 10-7",,'-,3.2258062,'-,[2.08-5],ANTXR2,"Childhood ALL/LBL (acute lymphoblastic leukemia/lymphoblastic lymphoma) treatment-related venous thromboembolism","venous thromboembolism, acute lymphoblastic leukemia, lymphoblastic lymphoma, response to antineoplastic agent",GCST010463,4:80012071
rs7677291-<b>?</b>,"4 x 10-6",,'-,2.11,'-,[1.53-2.9],'-,"Childhood ALL/LBL (acute lymphoblastic leukemia/lymphoblastic lymphoma) treatment-related venous thromboembolism","venous thromboembolism, acute lymphoblastic leukemia, lymphoblastic lymphoma, response to antineoplastic agent",GCST010463,4:129240194
rs72951801-<b>?</b>,"1 x 10-6",,'-,33.333336,'-,[8.33-100],"IQCM, LINC02355","Childhood ALL/LBL (acute lymphoblastic leukemia/lymphoblastic lymphoma) treatment-related venous thromboembolism","venous thromboembolism, acute lymphoblastic leukemia, lymphoblastic lymphoma, response to antineoplastic agent",GCST010463,4:149285924
rs139018151-<b>?</b>,"2 x 10-6",,'-,20,'-,[5.56-50],LINC02208,"Childhood ALL/LBL (acute lymphoblastic leukemia/lymphoblastic lymphoma) treatment-related venous thromboembolism","venous thromboembolism, acute lymphoblastic leukemia, lymphoblastic lymphoma, response to antineoplastic agent",GCST010463,5:118430038
rs79055704-<b>?</b>,"2 x 10-6",,'-,25.8,'-,[6.86-97.11],"SRFBP1, FTMT","Childhood ALL/LBL (acute lymphoblastic leukemia/lymphoblastic lymphoma) treatment-related venous thromboembolism","venous thromboembolism, acute lymphoblastic leukemia, lymphoblastic lymphoma, response to antineoplastic agent",GCST010463,5:121927889
rs115072237-<b>?</b>,"3 x 10-6",,'-,5.882353,'-,[2.78-12.5],PKHD1,"Childhood ALL/LBL (acute lymphoblastic leukemia/lymphoblastic lymphoma) treatment-related venous thromboembolism","venous thromboembolism, acute lymphoblastic leukemia, lymphoblastic lymphoma, response to antineoplastic agent",GCST010463,6:51658941
rs72926690-<b>?</b>,"3 x 10-6",,'-,4.46,'-,[2.38-8.38],LINC02531,"Childhood ALL/LBL (acute lymphoblastic leukemia/lymphoblastic lymphoma) treatment-related venous thromboembolism","venous thromboembolism, acute lymphoblastic leukemia, lymphoblastic lymphoma, response to antineoplastic agent",GCST010463,6:92640153
rs73152871-<b>?</b>,"2 x 10-6",,'-,14.285714,'-,[4.76-50],CEP41,"Childhood ALL/LBL (acute lymphoblastic leukemia/lymphoblastic lymphoma) treatment-related venous thromboembolism","venous thromboembolism, acute lymphoblastic leukemia, lymphoblastic lymphoma, response to antineoplastic agent",GCST010463,7:130403724
rs16868899-<b>?</b>,"4 x 10-6",,'-,6.24,'-,[2.87-13.57],NCALD,"Childhood ALL/LBL (acute lymphoblastic leukemia/lymphoblastic lymphoma) treatment-related venous thromboembolism","venous thromboembolism, acute lymphoblastic leukemia, lymphoblastic lymphoma, response to antineoplastic agent",GCST010463,8:102029950
rs117233659-<b>?</b>,"4 x 10-6",,'-,9.090909,'-,[3.57-25],RIC1,"Childhood ALL/LBL (acute lymphoblastic leukemia/lymphoblastic lymphoma) treatment-related venous thromboembolism","venous thromboembolism, acute lymphoblastic leukemia, lymphoblastic lymphoma, response to antineoplastic agent",GCST010463,9:5731974
rs67134687-<b>?</b>,"4 x 10-6",,'-,7.142857,'-,[3.12-16.67],MTAP,"Childhood ALL/LBL (acute lymphoblastic leukemia/lymphoblastic lymphoma) treatment-related venous thromboembolism","venous thromboembolism, acute lymphoblastic leukemia, lymphoblastic lymphoma, response to antineoplastic agent",GCST010463,9:21845309
rs71372609-<b>?</b>,"4 x 10-6",,'-,14.285714,'-,[4.55-50],RNY4P18,"Childhood ALL/LBL (acute lymphoblastic leukemia/lymphoblastic lymphoma) treatment-related venous thromboembolism","venous thromboembolism, acute lymphoblastic leukemia, lymphoblastic lymphoma, response to antineoplastic agent",GCST010463,9:111139461
rs143580123-<b>?</b>,"5 x 10-6",,'-,16.666668,'-,[5.26-50],USP54,"Childhood ALL/LBL (acute lymphoblastic leukemia/lymphoblastic lymphoma) treatment-related venous thromboembolism","venous thromboembolism, acute lymphoblastic leukemia, lymphoblastic lymphoma, response to antineoplastic agent",GCST010463,10:73604776
rs142811167-<b>?</b>,"5 x 10-6",,'-,87.06,'-,[12.84-590.36],OVCH2,"Childhood ALL/LBL (acute lymphoblastic leukemia/lymphoblastic lymphoma) treatment-related venous thromboembolism","venous thromboembolism, acute lymphoblastic leukemia, lymphoblastic lymphoma, response to antineoplastic agent",GCST010463,11:7698038
chr11:28307404-<b>?</b>,"5 x 10-6",,'-,12.9,'-,[4.32-38.55],'-,"Childhood ALL/LBL (acute lymphoblastic leukemia/lymphoblastic lymphoma) treatment-related venous thromboembolism","venous thromboembolism, acute lymphoblastic leukemia, lymphoblastic lymphoma, response to antineoplastic agent",GCST010463,"Mapping not available"
rs17134658-<b>?</b>,"5 x 10-6",,'-,5.5555553,'-,[2.63-11.11],CNTN5,"Childhood ALL/LBL (acute lymphoblastic leukemia/lymphoblastic lymphoma) treatment-related venous thromboembolism","venous thromboembolism, acute lymphoblastic leukemia, lymphoblastic lymphoma, response to antineoplastic agent",GCST010463,11:99911908
rs140514603-<b>?</b>,"3 x 10-6",,'-,25,'-,[6.25-100],"RIN3, SLC24A4","Childhood ALL/LBL (acute lymphoblastic leukemia/lymphoblastic lymphoma) treatment-related venous thromboembolism","venous thromboembolism, acute lymphoblastic leukemia, lymphoblastic lymphoma, response to antineoplastic agent",GCST010463,14:92511954
rs61037031-<b>?</b>,"2 x 10-6",,'-,4.02,'-,[2.27-7.12],NR2F2-AS1,"Childhood ALL/LBL (acute lymphoblastic leukemia/lymphoblastic lymphoma) treatment-related venous thromboembolism","venous thromboembolism, acute lymphoblastic leukemia, lymphoblastic lymphoma, response to antineoplastic agent",GCST010463,15:96309570
rs1804772-<b>?</b>,"4 x 10-7",,'-,8.1,'-,[3.61-18.18],ALOX15B,"Childhood ALL/LBL (acute lymphoblastic leukemia/lymphoblastic lymphoma) treatment-related venous thromboembolism","venous thromboembolism, acute lymphoblastic leukemia, lymphoblastic lymphoma, response to antineoplastic agent",GCST010463,17:8048687
rs56929051-<b>?</b>,"3 x 10-6",,'-,15.21,'-,[4.87-47.46],MIR3976HG,"Childhood ALL/LBL (acute lymphoblastic leukemia/lymphoblastic lymphoma) treatment-related venous thromboembolism","venous thromboembolism, acute lymphoblastic leukemia, lymphoblastic lymphoma, response to antineoplastic agent",GCST010463,18:5856605
rs35229355-<b>T</b>,"5 x 10-6",,NR,7.24,'-,[2.46-21.30],RNU7-152P,"Response to treatment for acute lymphoblastic leukemia","acute lymphoblastic leukemia, response to antineoplastic agent",GCST000323,6:155608667
rs2901286-<b>A</b>,"4 x 10-6",,NR,4.66,'-,[1.58-13.7],"RPL19P16, LINC01153","Response to treatment for acute lymphoblastic leukemia","acute lymphoblastic leukemia, response to antineoplastic agent",GCST000323,10:121141109
rs6125048-<b>T</b>,"2 x 10-6",,NR,2.73,'-,[1.08-6.88],NCOA3,"Response to treatment for acute lymphoblastic leukemia","acute lymphoblastic leukemia, response to antineoplastic agent",GCST000323,20:47579861
rs17007695-<b>C</b>,"9 x 10-7",,NR,2.67,'-,[1.53-4.68],IL15,"Response to treatment for acute lymphoblastic leukemia","acute lymphoblastic leukemia, response to antineoplastic agent",GCST000323,4:141788570
rs1569175-<b>T</b>,"9 x 10-7",,NR,2.73,'-,[1.52-4.93],'-,"Response to treatment for acute lymphoblastic leukemia","acute lymphoblastic leukemia, response to antineoplastic agent",GCST000323,2:200157231
rs6971925-<b>T</b>,"3 x 10-6",,NR,13.91,'-,[2.72-70.92],DGKB,"Response to treatment for acute lymphoblastic leukemia","acute lymphoblastic leukemia, response to antineoplastic agent",GCST000323,7:14406292
rs4723619-<b>C</b>,"3 x 10-6",,NR,3.01,'-,[1.50-6.03],ELMO1,"Response to treatment for acute lymphoblastic leukemia","acute lymphoblastic leukemia, response to antineoplastic agent",GCST000323,7:37226747
rs10508343-<b>A</b>,"8 x 10-6",,NR,3.81,'-,[1.40-10.40],"GATA3, PRPF38AP1","Response to treatment for acute lymphoblastic leukemia","acute lymphoblastic leukemia, response to antineoplastic agent",GCST000323,10:8108750
rs267759-<b>A</b>,"7 x 10-6",,NR,3.23,'-,[1.52-6.87],LMBRD2,"Response to treatment for acute lymphoblastic leukemia","acute lymphoblastic leukemia, response to antineoplastic agent",GCST000323,5:36137518
rs7115578-<b>A</b>,"8 x 10-6",,NR,1.86,'-,[1.23-2.79],MAML2,"Response to treatment for acute lymphoblastic leukemia","acute lymphoblastic leukemia, response to antineoplastic agent",GCST000323,11:96266936
rs7128311-<b>C</b>,"5 x 10-6",,NR,13.9,'-,[2.72-71.1],"HMGB1P40, PRMT3","Response to treatment for acute lymphoblastic leukemia","acute lymphoblastic leukemia, response to antineoplastic agent",GCST000323,11:20540973
rs359312-<b>T</b>,"9 x 10-8",,NR,3.91,'-,[1.52-10.10],ST8SIA6,"Response to treatment for acute lymphoblastic leukemia","acute lymphoblastic leukemia, response to antineoplastic agent",GCST000323,10:17346144
rs2811511-<b>A</b>,"1 x 10-6",,0.161,'-,"0.059 unit increase",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128194145
rs2811528-<b>A</b>,"1 x 10-6",,0.16,'-,"0.059 unit increase",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128275593
rs2955096-<b>A</b>,"1 x 10-6",,0.16,'-,"0.059 unit increase",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128259023
rs2687730-<b>T</b>,"1 x 10-6",,0.151,'-,"0.059 unit increase",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128196614
rs2811381-<b>A</b>,"1 x 10-6",,0.16,'-,"0.059 unit increase",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128279069
rs35381637-<b>A</b>,"3 x 10-6",,0.16,'-,"0.059 unit increase",NR,DOCK8,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,9:306277
rs12959333-<b>T</b>,"5 x 10-6",,0.87,'-,"0.059 unit increase",NR,GALNT1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,18:35619952
rs12903285-<b>A</b>,"1 x 10-10",,0.465,'-,"0.06 unit increase",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78486611
rs1960493-<b>A</b>,"1 x 10-10",,0.342,'-,"0.06 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144504600
rs1512283-<b>T</b>,"1 x 10-10",,0.342,'-,"0.06 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144509941
rs72736802-<b>A</b>,"3 x 10-10",,0.597,'-,"0.06 unit increase",NR,"CRABP1, IREB2","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78427159
rs2456020-<b>T</b>,"2 x 10-9",,0.286,'-,"0.06 unit increase",NR,CHRNA5,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78576056
rs12499125-<b>A</b>,"4 x 10-9",,0.278,'-,"0.06 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144442422
rs149774458-<b>C</b>,"4 x 10-9",,0.278,'-,"0.06 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144436675
rs34490121-<b>A</b>,"5 x 10-9",,0.278,'-,"0.06 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144432849
rs6828795-<b>T</b>,"6 x 10-9",,0.281,'-,"0.06 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144453608
rs140908948-<b>A</b>,"7 x 10-9",,0.276,'-,"0.06 unit increase",NR,NDUFB4P12,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144437576
rs7673195-<b>A</b>,"2 x 10-8",,0.262,'-,"0.06 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144394135
rs626750-<b>A</b>,"6 x 10-8",,0.198,'-,"0.06 unit increase",NR,"MMP12, MMP3","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:102850214
rs60446182-<b>A</b>,"1 x 10-7",,0.548,'-,"0.06 unit increase",NR,"CYP2F2P, CYP2A6","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,19:40842093
rs2316205-<b>T</b>,"1 x 10-7",,0.545,'-,"0.06 unit increase",NR,"CYP2F2P, CYP2A6","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,19:40840863
rs2955098-<b>T</b>,"7 x 10-7",,0.162,'-,"0.06 unit increase",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128260658
rs6798749-<b>A</b>,"9 x 10-7",,0.326,'-,"0.06 unit increase",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128338054
rs13067650-<b>A</b>,"1 x 10-6",,0.151,'-,"0.06 unit increase",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128170699
rs10934850-<b>A</b>,"1 x 10-6",,0.678,'-,"0.06 unit increase",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128168114
rs569207-<b>T</b>,"1 x 10-9",,0.236,'-,"0.062 unit increase",NR,CHRNA5,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78580777
rs637137-<b>A</b>,"1 x 10-9",,0.239,'-,"0.062 unit increase",NR,CHRNA5,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78581634
rs576982-<b>T</b>,"2 x 10-9",,0.237,'-,"0.062 unit increase",NR,CHRNA5,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78578461
rs7174348-<b>A</b>,"8 x 10-8",,0.182,'-,"0.062 unit increase",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78500097
rs6783253-<b>A</b>,"4 x 10-7",,0.155,'-,"0.062 unit increase",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128132718
rs13071740-<b>T</b>,"4 x 10-7",,0.156,'-,"0.062 unit increase",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128162725
rs13077790-<b>T</b>,"4 x 10-7",,0.156,'-,"0.062 unit increase",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128163815
rs13077913-<b>A</b>,"4 x 10-7",,0.156,'-,"0.062 unit increase",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128163761
rs6800225-<b>T</b>,"4 x 10-7",,0.155,'-,"0.062 unit increase",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128143335
rs34817706-<b>A</b>,"4 x 10-7",,0.155,'-,"0.062 unit increase",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128142215
rs6797834-<b>T</b>,"5 x 10-7",,0.155,'-,"0.062 unit increase",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128137557
rs11714052-<b>A</b>,"5 x 10-7",,0.144,'-,"0.062 unit increase",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128095614
rs5019044-<b>A</b>,"5 x 10-7",,0.161,'-,"0.062 unit increase",NR,"IREB2, HYKK","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78503940
rs35515217-<b>T</b>,"5 x 10-7",,0.144,'-,"0.062 unit increase",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128094968
rs11724319-<b>A</b>,"2 x 10-6",,0.773,'-,"0.062 unit increase",NR,"KRT18P51, HHIP-AS1","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144589888
rs61204066-<b>A</b>,"3 x 10-9",,0.206,'-,"0.063 unit increase",NR,HYKK,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78522956
rs12593950-<b>C</b>,"4 x 10-9",,0.232,'-,"0.063 unit increase",NR,CHRNB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78628593
rs28437878-<b>T</b>,"5 x 10-9",,0.204,'-,"0.063 unit increase",NR,HYKK,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78515530
rs6495309-<b>T</b>,"5 x 10-9",,0.367,'-,"0.063 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,"Mapping not available"
rs66987356-<b>A</b>,"5 x 10-7",,0.144,'-,"0.063 unit increase",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128122255
rs35421223-<b>A</b>,"5 x 10-7",,0.144,'-,"0.063 unit increase",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128111036
rs9920506-<b>A</b>,"7 x 10-7",,0.186,'-,"0.063 unit increase",NR,CHRNB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78638715
rs80162468-<b>T</b>,"1 x 10-6",,0.689,'-,"0.063 unit increase",NR,"ADAMTS7, CHRNB4","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78733974
rs8040868-<b>T</b>,"1 x 10-13",,0.434,'-,"0.064 unit increase",NR,CHRNA3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78618839
rs6837671-<b>A</b>,"3 x 10-13",,0.537,'-,"0.064 unit increase",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88951941
rs56050323-<b>A</b>,"2 x 10-6",,0.161,'-,"0.058 unit increase",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128128455
rs34172752-<b>A</b>,"2 x 10-6",,0.153,'-,"0.058 unit increase",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128122901
rs35531186-<b>T</b>,"2 x 10-6",,0.153,'-,"0.058 unit increase",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128122217
rs34562493-<b>T</b>,"3 x 10-6",,0.153,'-,"0.058 unit increase",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128098179
rs11709377-<b>A</b>,"4 x 10-6",,0.157,'-,"0.058 unit increase",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128096827
rs1961266-<b>A</b>,"4 x 10-10",,0.347,'-,"0.059 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144483361
rs7666298-<b>A</b>,"4 x 10-10",,0.347,'-,"0.059 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144480798
rs75772244-<b>T</b>,"5 x 10-10",,0.343,'-,"0.059 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144486505
rs17019340-<b>A</b>,"7 x 10-9",,0.278,'-,"0.059 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144412631
rs4290852-<b>T</b>,"1 x 10-8",,0.283,'-,"0.059 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144415320
rs12438659-<b>A</b>,"2 x 10-8",,0.222,'-,"0.059 unit increase",NR,HYKK,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78532582
rs2938671-<b>A</b>,"1 x 10-7",,0.198,'-,"0.059 unit increase",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78440412
rs2656070-<b>A</b>,"5 x 10-7",,0.177,'-,"0.059 unit increase",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78437910
rs1317681-<b>A</b>,"6 x 10-7",,0.844,'-,"0.059 unit increase",NR,TGFB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:218401860
rs2955077-<b>A</b>,"1 x 10-6",,0.16,'-,"0.059 unit increase",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128240026
rs2955078-<b>A</b>,"1 x 10-6",,0.16,'-,"0.059 unit increase",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128240343
rs2955081-<b>A</b>,"1 x 10-6",,0.161,'-,"0.059 unit increase",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128241456
rs6765233-<b>T</b>,"1 x 10-6",,0.16,'-,"0.059 unit increase",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128284007
rs2955133-<b>T</b>,"1 x 10-6",,0.16,'-,"0.059 unit increase",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128226479
rs11710627-<b>C</b>,"1 x 10-6",,0.163,'-,"0.059 unit increase",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128328166
rs11710704-<b>A</b>,"1 x 10-6",,0.163,'-,"0.059 unit increase",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128328393
rs73197388-<b>T</b>,"1 x 10-6",,0.163,'-,"0.059 unit increase",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128325077
rs55925538-<b>A</b>,"1 x 10-6",,0.163,'-,"0.059 unit increase",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128324034
rs2955126-<b>A</b>,"1 x 10-6",,0.16,'-,"0.059 unit increase",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128207411
rs2955129-<b>T</b>,"1 x 10-6",,0.162,'-,"0.059 unit increase",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128210364
rs34709844-<b>A</b>,"3 x 10-6",,0.153,'-,"0.057 unit increase",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128100026
rs6787614-<b>A</b>,"3 x 10-6",,0.156,'-,"0.057 unit increase",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128098635
rs35437840-<b>T</b>,"3 x 10-6",,0.158,'-,"0.057 unit increase",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128106463
rs34545799-<b>T</b>,"3 x 10-6",,0.158,'-,"0.057 unit increase",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128118665
rs36069551-<b>A</b>,"3 x 10-6",,0.154,'-,"0.057 unit increase",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128095234
rs55684215-<b>A</b>,"3 x 10-6",,0.157,'-,"0.057 unit increase",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128093949
rs13091198-<b>T</b>,"3 x 10-6",,0.154,'-,"0.057 unit increase",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128093194
rs12903295-<b>A</b>,"8 x 10-11",,0.436,'-,"0.058 unit increase",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78486630
rs1813337-<b>A</b>,"6 x 10-10",,0.347,'-,"0.058 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144486570
rs34991888-<b>T</b>,"1 x 10-8",,0.276,'-,"0.058 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144350967
rs17709487-<b>T</b>,"1 x 10-8",,0.276,'-,"0.058 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144348912
rs4240361-<b>A</b>,"1 x 10-8",,0.275,'-,"0.058 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144365095
rs4240362-<b>C</b>,"1 x 10-8",,0.275,'-,"0.058 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144365211
rs13128377-<b>T</b>,"1 x 10-8",,0.277,'-,"0.058 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144399479
rs74877722-<b>T</b>,"1 x 10-8",,0.277,'-,"0.058 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144392734
rs2915695-<b>T</b>,"1 x 10-7",,0.189,'-,"0.058 unit increase",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78447129
rs16969894-<b>T</b>,"2 x 10-7",,0.19,'-,"0.058 unit increase",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78484114
rs958025-<b>T</b>,"2 x 10-7",,0.19,'-,"0.058 unit increase",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78467006
rs2656056-<b>T</b>,"2 x 10-7",,0.21,'-,"0.058 unit increase",NR,"CRABP1, IREB2","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78430177
rs2036533-<b>A</b>,"2 x 10-7",,0.189,'-,"0.058 unit increase",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78489345
rs2036529-<b>A</b>,"2 x 10-7",,0.197,'-,"0.058 unit increase",NR,"IREB2, CRABP1","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78433930
rs7100689-<b>A</b>,"4 x 10-7",,0.77,'-,"0.058 unit increase",NR,TSPAN14,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,10:80462422
rs2811549-<b>T</b>,"1 x 10-6",,0.16,'-,"0.058 unit increase",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128219865
rs2811536-<b>A</b>,"1 x 10-6",,0.16,'-,"0.058 unit increase",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128270076
rs11707462-<b>C</b>,"2 x 10-6",,0.161,'-,"0.058 unit increase",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128119787
rs62310476-<b>A</b>,"3 x 10-7",,0.3,'-,"0.049 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88911177
rs34563625-<b>C</b>,"6 x 10-7",,0.371,'-,"0.049 unit decrease",NR,"CHRNB4, ADAMTS7","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78727936
rs11639044-<b>T</b>,"8 x 10-7",,0.407,'-,"0.049 unit decrease",NR,ADAMTS7,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78791472
rs4693973-<b>A</b>,"1 x 10-6",,0.264,'-,"0.049 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88876516
rs7098414-<b>A</b>,"3 x 10-6",,0.25,'-,"0.049 unit decrease",NR,TSPAN14,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,10:80454830
rs3025388-<b>A</b>,"4 x 10-6",,0.248,'-,"0.049 unit decrease",NR,DBH,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,9:133638134
rs12905273-<b>A</b>,"4 x 10-6",,0.702,'-,"0.049 unit decrease",NR,CHRNB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78710413
rs13107186-<b>A</b>,"9 x 10-8",,0.401,'-,"0.048 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144522887
rs143379756-<b>A</b>,"1 x 10-7",,0.405,'-,"0.048 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144526014
rs1032296-<b>T</b>,"2 x 10-7",,0.585,'-,"0.048 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144513536
rs2202507-<b>T</b>,"4 x 10-7",,0.559,'-,"0.048 unit decrease",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144336529
rs113134286-<b>T</b>,"4 x 10-7",,0.382,'-,"0.048 unit decrease",NR,CHRNB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78720546
rs3829786-<b>A</b>,"4 x 10-7",,0.383,'-,"0.048 unit decrease",NR,CHRNB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78727204
rs11629637-<b>T</b>,"5 x 10-7",,0.58,'-,"0.048 unit decrease",NR,CHRNB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78726682
rs12648534-<b>T</b>,"5 x 10-7",,0.296,'-,"0.048 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88878055
rs10019681-<b>T</b>,"5 x 10-7",,0.724,'-,"0.048 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88911381
rs4693977-<b>A</b>,"6 x 10-7",,0.298,'-,"0.048 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88932928
rs11632102-<b>A</b>,"7 x 10-7",,0.407,'-,"0.048 unit decrease",NR,ADAMTS7,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78793715
rs62334702-<b>A</b>,"7 x 10-7",,0.724,'-,"0.048 unit decrease",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144385151
rs4887113-<b>T</b>,"1 x 10-6",,0.412,'-,"0.048 unit decrease",NR,ADAMTS7,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78802945
rs80229697-<b>A</b>,"1 x 10-6",,0.355,'-,"0.048 unit decrease",NR,"CHRNB4, ADAMTS7","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78730274
rs7169223-<b>A</b>,"2 x 10-6",,0.694,'-,"0.048 unit decrease",NR,CHRNB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78699774
rs7688932-<b>T</b>,"5 x 10-6",,0.256,'-,"0.048 unit decrease",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144358521
rs7692102-<b>A</b>,"3 x 10-7",,0.395,'-,"0.047 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144535989
rs7010805-<b>T</b>,"6 x 10-7",,0.47,'-,"0.047 unit decrease",NR,"PLEC, EPPK1","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,8:143902552
rs12512788-<b>A</b>,"6 x 10-7",,0.564,'-,"0.047 unit decrease",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144328123
rs11639375-<b>A</b>,"7 x 10-7",,0.375,'-,"0.047 unit decrease",NR,"CHRNB4, ADAMTS7","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78731872
rs11639382-<b>A</b>,"7 x 10-7",,0.375,'-,"0.047 unit decrease",NR,"CHRNB4, ADAMTS7","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78731926
rs1825082-<b>A</b>,"7 x 10-7",,0.375,'-,"0.047 unit decrease",NR,"ADAMTS7, CHRNB4","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78731091
rs11639347-<b>T</b>,"7 x 10-7",,0.375,'-,"0.047 unit decrease",NR,"ADAMTS7, CHRNB4","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78732008
rs1542726-<b>A</b>,"7 x 10-7",,0.376,'-,"0.047 unit decrease",NR,"HHIP-AS1, KRT18P51","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144594617
rs11639166-<b>C</b>,"8 x 10-7",,0.375,'-,"0.047 unit decrease",NR,"ADAMTS7, CHRNB4","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78731424
rs4846478-<b>C</b>,"8 x 10-7",,0.714,'-,"0.047 unit decrease",NR,TGFB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:218424986
rs4846480-<b>A</b>,"8 x 10-7",,0.714,'-,"0.047 unit decrease",NR,TGFB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:218425127
rs7671167-<b>T</b>,"9 x 10-8",,0.468,'-,"0.046 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88962828
rs6828982-<b>T</b>,"5 x 10-7",,0.391,'-,"0.046 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144549452
rs6537280-<b>T</b>,"7 x 10-7",,0.305,'-,"0.046 unit decrease",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144359226
rs13113445-<b>T</b>,"9 x 10-7",,0.406,'-,"0.046 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144551614
rs900-<b>A</b>,"1 x 10-6",,0.714,'-,"0.046 unit decrease",NR,TGFB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:218441563
rs3813565-<b>T</b>,"1 x 10-6",,0.623,'-,"0.046 unit decrease",NR,CHRNB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78727268
rs56077246-<b>T</b>,"2 x 10-6",,0.621,'-,"0.046 unit decrease",NR,"EPPK1, PLEC","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,8:143909325
rs13328032-<b>A</b>,"2 x 10-6",,0.31,'-,"0.046 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88888722
rs4693971-<b>T</b>,"5 x 10-6",,0.261,'-,"0.046 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88872408
rs1795739-<b>A</b>,"3 x 10-7",,0.463,'-,"0.045 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:89009162
rs1489764-<b>T</b>,"5 x 10-7",,0.392,'-,"0.045 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144533076
rs7682431-<b>C</b>,"6 x 10-7",,0.37,'-,"0.045 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88844510
rs7254192-<b>A</b>,"1 x 10-6",,0.461,'-,"0.045 unit decrease",NR,"SNRPA, MIA-RAB4B","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,19:40767794
rs2279011-<b>T</b>,"1 x 10-6",,0.554,'-,"0.045 unit decrease",NR,SNRPA,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,19:40763383
rs6812520-<b>A</b>,"1 x 10-6",,0.304,'-,"0.045 unit decrease",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144394507
rs12645910-<b>T</b>,"1 x 10-6",,0.305,'-,"0.045 unit decrease",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144386269
rs17726276-<b>A</b>,"2 x 10-6",,0.462,'-,"0.044 unit decrease",NR,"RAB4B, MIA-RAB4B, RAB4B-EGLN2","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,19:40785214
rs7655235-<b>A</b>,"2 x 10-6",,0.453,'-,"0.044 unit decrease",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144329238
rs1505771-<b>T</b>,"2 x 10-6",,0.347,'-,"0.044 unit decrease",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144317833
rs518425-<b>A</b>,"2 x 10-6",,0.654,'-,"0.044 unit decrease",NR,CHRNA5,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78591471
rs10000225-<b>A</b>,"3 x 10-6",,0.35,'-,"0.044 unit decrease",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144312789
rs6537285-<b>A</b>,"3 x 10-6",,0.296,'-,"0.044 unit decrease",NR,INPP4B,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144388995
rs7549303-<b>C</b>,"3 x 10-6",,0.71,'-,"0.044 unit decrease",NR,"TGFB2, LINC02869","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:218453979
rs4475093-<b>C</b>,"3 x 10-6",,0.304,'-,"0.044 unit decrease",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144371524
rs12973666-<b>C</b>,"2 x 10-6",,0.463,'-,"0.043 unit decrease",NR,"MIA-RAB4B, RAB4B-EGLN2, RAB4B","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,19:40783492
rs7155-<b>A</b>,"3 x 10-6",,0.509,'-,"0.043 unit decrease",NR,PLEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,8:143915294
rs7015048-<b>T</b>,"2 x 10-6",,0.537,'-,"0.042 unit decrease",NR,"EPPK1, PLEC","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,8:143910115
rs4077669-<b>A</b>,"3 x 10-6",,0.566,'-,"0.042 unit decrease",NR,"PLEC, EPPK1","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,8:143902404
rs13146548-<b>A</b>,"4 x 10-6",,0.606,'-,"0.042 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:89003574
rs13129885-<b>A</b>,"4 x 10-6",,0.607,'-,"0.042 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:89006461
rs1458562-<b>T</b>,"2 x 10-6",,0.427,'-,"0.041 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88932447
rs7690839-<b>A</b>,"2 x 10-6",,0.574,'-,"0.041 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88898173
rs4693980-<b>A</b>,"2 x 10-6",,0.576,'-,"0.041 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88964837
rs10008568-<b>A</b>,"3 x 10-6",,0.57,'-,"0.04 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88933041
rs13149750-<b>A</b>,"3 x 10-6",,0.571,'-,"0.04 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88933843
rs7671261-<b>A</b>,"4 x 10-6",,0.582,'-,"0.04 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88962667
rs3846287-<b>T</b>,"4 x 10-6",,0.581,'-,"0.04 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88961961
rs6824218-<b>T</b>,"4 x 10-6",,0.57,'-,"0.04 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88919919
rs1903003-<b>T</b>,"5 x 10-6",,0.426,'-,"0.04 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88965146
rs4505789-<b>A</b>,"5 x 10-6",,0.561,'-,"0.039 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88904464
rs4693978-<b>A</b>,"3 x 10-6",,0.427,'-,"0.04 unit increase",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88933016
rs7683975-<b>A</b>,"1 x 10-6",,0.301,'-,"0.045 unit decrease",NR,ARHGAP10,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144358549
rs6537287-<b>A</b>,"1 x 10-6",,0.305,'-,"0.045 unit decrease",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144390875
rs4383570-<b>T</b>,"1 x 10-6",,0.305,'-,"0.045 unit decrease",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144383452
rs6828489-<b>T</b>,"1 x 10-6",,0.362,'-,"0.045 unit decrease",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144313363
rs6821716-<b>A</b>,"1 x 10-6",,0.42,'-,"0.045 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144531551
rs6537284-<b>A</b>,"1 x 10-6",,0.305,'-,"0.045 unit decrease",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144382539
rs4469023-<b>A</b>,"1 x 10-6",,0.405,'-,"0.045 unit decrease",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144379282
rs4572828-<b>T</b>,"1 x 10-6",,0.304,'-,"0.045 unit decrease",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144399141
rs7670758-<b>A</b>,"1 x 10-6",,0.622,'-,"0.045 unit decrease",NR,"HHIP-AS1, KRT18P51","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144590723
rs7376541-<b>T</b>,"2 x 10-6",,0.302,'-,"0.045 unit decrease",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144378974
rs1473526-<b>T</b>,"2 x 10-6",,0.406,'-,"0.045 unit decrease",NR,"LINC02869, TGFB2","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:218447405
rs7461753-<b>A</b>,"2 x 10-6",,0.624,'-,"0.045 unit decrease",NR,"PLEC, EPPK1","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,8:143907330
rs10429950-<b>T</b>,"2 x 10-6",,0.586,'-,"0.045 unit decrease",NR,"LINC02869, TGFB2","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:218451191
rs56117011-<b>A</b>,"3 x 10-6",,0.624,'-,"0.045 unit decrease",NR,PLEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,8:143925474
rs35916068-<b>A</b>,"3 x 10-6",,0.624,'-,"0.045 unit decrease",NR,PLEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,8:143925516
rs11778026-<b>T</b>,"4 x 10-6",,0.623,'-,"0.045 unit decrease",NR,PLEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,8:143922240
rs2015850-<b>A</b>,"5 x 10-6",,0.718,'-,"0.045 unit decrease",NR,"TGFB2, LINC02869","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:218448759
rs1708667-<b>T</b>,"3 x 10-7",,0.467,'-,"0.044 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:89008459
rs6849143-<b>T</b>,"3 x 10-7",,0.589,'-,"0.044 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:89007338
rs10015415-<b>T</b>,"3 x 10-7",,0.467,'-,"0.044 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:89007052
rs6852288-<b>C</b>,"4 x 10-7",,0.468,'-,"0.044 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:89004659
rs1964516-<b>T</b>,"5 x 10-7",,0.468,'-,"0.044 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88954758
rs7937-<b>T</b>,"7 x 10-7",,0.392,'-,"0.044 unit decrease",NR,"RAB4B, MIA-RAB4B, RAB4B-EGLN2","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,19:40796801
rs12510044-<b>C</b>,"1 x 10-6",,0.388,'-,"0.044 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144563486
rs7377575-<b>T</b>,"1 x 10-6",,0.654,'-,"0.044 unit decrease",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144333533
rs11633178-<b>A</b>,"7 x 10-9",,0.619,'-,"0.055 unit increase",NR,CHRNB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78652196
rs186854840-<b>T</b>,"3 x 10-8",,0.349,'-,"0.055 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144396313
rs8042494-<b>T</b>,"7 x 10-8",,0.236,'-,"0.055 unit increase",NR,CHRNA3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78615668
rs9672608-<b>A</b>,"4 x 10-7",,0.202,'-,"0.055 unit increase",NR,"IREB2, HYKK","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78505121
rs1342586-<b>T</b>,"4 x 10-7",,0.81,'-,"0.056 unit increase",NR,TGFB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:218424517
rs4887084-<b>T</b>,"9 x 10-7",,0.631,'-,"0.056 unit increase",NR,"ADAMTS7, CHRNB4","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78733251
rs11711710-<b>T</b>,"3 x 10-6",,0.168,'-,"0.056 unit increase",NR,"RUVBL1, EEFSEC","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128153663
rs34749881-<b>T</b>,"3 x 10-6",,0.168,'-,"0.056 unit increase",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128151426
rs2811530-<b>A</b>,"4 x 10-6",,0.166,'-,"0.056 unit increase",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128274323
rs2869967-<b>T</b>,"1 x 10-10",,0.394,'-,"0.057 unit increase",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88948181
rs12461964-<b>A</b>,"2 x 10-7",,0.549,'-,"0.057 unit increase",NR,"CYP2F2P, CYP2A6","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,19:40835324
rs2568499-<b>T</b>,"2 x 10-7",,0.189,'-,"0.057 unit increase",NR,"CRABP1, IREB2","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78430017
rs2999077-<b>A</b>,"2 x 10-6",,0.162,'-,"0.057 unit increase",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128239571
rs60387553-<b>A</b>,"2 x 10-6",,0.166,'-,"0.057 unit increase",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128110125
rs11706455-<b>A</b>,"2 x 10-6",,0.164,'-,"0.057 unit increase",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128173148
rs11715661-<b>T</b>,"3 x 10-6",,0.153,'-,"0.057 unit increase",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128102003
rs8043009-<b>C</b>,"6 x 10-8",,0.236,'-,"0.055 unit increase",NR,CHRNA3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78615812
rs7181245-<b>T</b>,"2 x 10-7",,0.223,'-,"0.055 unit increase",NR,HYKK,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78522047
rs74925218-<b>T</b>,"4 x 10-7",,0.205,'-,"0.055 unit increase",NR,"HYKK, IREB2","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78504390
rs6586028-<b>T</b>,"4 x 10-6",,0.81,'-,"0.055 unit increase",NR,TSPAN14,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,10:80494228
rs17766168-<b>A</b>,"3 x 10-8",,0.275,'-,"0.056 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144351540
rs2869045-<b>T</b>,"3 x 10-7",,0.191,'-,"0.056 unit increase",NR,"IREB2, CRABP1","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78426557
rs12048582-<b>T</b>,"3 x 10-7",,0.194,'-,"0.056 unit increase",NR,TGFB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:218419695
rs4887053-<b>A</b>,"6 x 10-7",,0.819,'-,"0.056 unit increase",NR,"CRABP1, IREB2","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78420357
rs35474770-<b>A</b>,"3 x 10-6",,0.619,'-,"0.056 unit increase",NR,ADAMTS7,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78781658
rs7698984-<b>A</b>,"3 x 10-8",,0.601,'-,"0.05 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144515929
rs6829956-<b>T</b>,"3 x 10-8",,0.603,'-,"0.05 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144519136
rs13116999-<b>A</b>,"4 x 10-8",,0.603,'-,"0.05 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144521212
rs6835019-<b>A</b>,"4 x 10-7",,0.723,'-,"0.05 unit increase",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88926504
rs7164594-<b>T</b>,"1 x 10-6",,0.284,'-,"0.05 unit increase",NR,HYKK,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78510715
rs4886582-<b>A</b>,"1 x 10-6",,0.654,'-,"0.05 unit increase",NR,"ADAMTS7, CHRNB4","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78729099
rs6537298-<b>T</b>,"3 x 10-9",,0.572,'-,"0.051 unit increase",NR,"KRT18P51, HHIP-AS1","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144585719
rs1996371-<b>T</b>,"1 x 10-7",,0.568,'-,"0.051 unit increase",NR,CHRNB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78664464
rs11072792-<b>A</b>,"2 x 10-7",,0.6,'-,"0.051 unit increase",NR,CHRNB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78707569
rs7171869-<b>A</b>,"7 x 10-7",,0.302,'-,"0.051 unit increase",NR,CHRNA3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78608567
rs608194-<b>T</b>,"3 x 10-6",,0.228,'-,"0.051 unit increase",NR,MMP12,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:102873357
rs12050525-<b>T</b>,"3 x 10-6",,0.618,'-,"0.051 unit increase",NR,ADAMTS7,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78783404
rs13164077-<b>A</b>,"5 x 10-6",,0.756,'-,"0.051 unit increase",NR,RN7SL87P,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,5:144064468
rs916888-<b>T</b>,"5 x 10-6",,0.763,'-,"0.051 unit increase",NR,WNT3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,17:46785767
rs1512288-<b>A</b>,"2 x 10-9",,0.451,'-,"0.052 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144570129
rs720484-<b>A</b>,"3 x 10-9",,0.41,'-,"0.052 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144541212
rs12593229-<b>T</b>,"7 x 10-9",,0.451,'-,"0.052 unit increase",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78472948
rs12899351-<b>T</b>,"7 x 10-9",,0.45,'-,"0.052 unit increase",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78500056
rs8043227-<b>C</b>,"7 x 10-9",,0.451,'-,"0.052 unit increase",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78476529
rs6537291-<b>A</b>,"9 x 10-9",,0.427,'-,"0.052 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144542922
rs7660385-<b>T</b>,"6 x 10-8",,0.695,'-,"0.052 unit increase",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88939668
rs8192477-<b>C</b>,"2 x 10-7",,0.316,'-,"0.052 unit increase",NR,CHRNA3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78618121
rs57064725-<b>A</b>,"6 x 10-7",,0.273,'-,"0.052 unit increase",NR,PSMA4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78540694
rs7086627-<b>T</b>,"8 x 10-7",,0.759,'-,"0.052 unit increase",NR,TSPAN14,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,10:80460841
rs12438181-<b>A</b>,"1 x 10-6",,0.212,'-,"0.052 unit increase",NR,HYKK,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78519756
rs1565330-<b>T</b>,"2 x 10-13",,0.365,'-,"0.071 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144561395
rs1980056-<b>A</b>,"2 x 10-13",,0.365,'-,"0.071 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144563771
rs1828590-<b>A</b>,"2 x 10-13",,0.369,'-,"0.071 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144552044
rs28498264-<b>T</b>,"5 x 10-11",,0.212,'-,"0.071 unit increase",NR,PSMA4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78545331
rs58365910-<b>T</b>,"7 x 10-15",,0.652,'-,"0.072 unit increase",NR,"CHRNA5, PSMA4","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78556692
rs11852372-<b>A</b>,"3 x 10-13",,0.685,'-,"0.072 unit increase",NR,HYKK,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78509052
rs12461383-<b>C</b>,"1 x 10-7",,0.544,'-,"0.072 unit increase",NR,"CYP2A7, CYP2A6","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,19:40864433
rs62346060-<b>A</b>,"4 x 10-7",,0.205,'-,"0.072 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144548221
rs114176245-<b>T</b>,"1 x 10-6",,0.114,'-,"0.072 unit increase",NR,"MMP3, MMP12","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:102848803
rs2195728-<b>A</b>,"5 x 10-6",,0.128,'-,"0.072 unit increase",NR,TRDN,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,6:123289037
rs2089162-<b>A</b>,"1 x 10-12",,0.66,'-,"0.073 unit increase",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78447421
rs57837628-<b>A</b>,"4 x 10-8",,0.538,'-,"0.073 unit increase",NR,"CYP2A7, CYP2A6","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,19:40852005
rs72981680-<b>A</b>,"8 x 10-7",,0.115,'-,"0.073 unit increase",NR,"MMP12, MMP3","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:102851128
rs72981684-<b>T</b>,"9 x 10-7",,0.115,'-,"0.073 unit increase",NR,"MMP12, MMP3","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:102853480
rs72981698-<b>T</b>,"9 x 10-7",,0.115,'-,"0.073 unit increase",NR,"MMP12, MMP3","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:102855809
rs72983508-<b>A</b>,"9 x 10-7",,0.115,'-,"0.073 unit increase",NR,"MMP12, MMP3","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:102856678
rs17368659-<b>T</b>,"1 x 10-6",,0.362,'-,"0.073 unit increase",NR,MMP12,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:102872031
rs72981683-<b>A</b>,"1 x 10-6",,0.114,'-,"0.073 unit increase",NR,"MMP12, MMP3","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:102851883
rs8042849-<b>T</b>,"4 x 10-15",,0.56,'-,"0.074 unit increase",NR,HYKK,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78525587
rs13113591-<b>T</b>,"9 x 10-14",,0.351,'-,"0.074 unit increase",NR,"KRT18P51, ENPEP","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144567945
rs17484235-<b>C</b>,"2 x 10-13",,0.663,'-,"0.074 unit increase",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78469072
rs72738732-<b>C</b>,"2 x 10-13",,0.663,'-,"0.074 unit increase",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78459846
rs6833979-<b>A</b>,"1 x 10-12",,0.316,'-,"0.074 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144542369
rs72981675-<b>T</b>,"7 x 10-7",,0.115,'-,"0.074 unit increase",NR,"MMP3, MMP12","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:102850520
rs2811416-<b>T</b>,"1 x 10-6",,0.11,'-,"0.074 unit increase",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128273095
rs72738847-<b>T</b>,"4 x 10-7",,0.103,'-,"0.085 unit increase",NR,LINC02869,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:218503102
rs72738861-<b>T</b>,"1 x 10-6",,0.084,'-,"0.085 unit increase",NR,LINC02869,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:218520470
rs138544659-<b>T</b>,"3 x 10-16",,0.708,'-,"0.087 unit increase",NR,CHRNA3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78608359
rs72738855-<b>T</b>,"9 x 10-7",,0.082,'-,"0.087 unit increase",NR,LINC02869,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:218510342
rs72738838-<b>C</b>,"5 x 10-7",,0.082,'-,"0.088 unit increase",NR,LINC02869,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:218485034
rs72738837-<b>T</b>,"5 x 10-7",,0.082,'-,"0.088 unit increase",NR,LINC02869,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:218485016
rs35450021-<b>T</b>,"5 x 10-7",,0.082,'-,"0.088 unit increase",NR,LINC02869,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:218482944
rs72673821-<b>A</b>,"3 x 10-6",,0.074,'-,"0.088 unit increase",NR,"INTS12, GSTCD, GSTCD-AS1","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:105797096
rs76873050-<b>T</b>,"5 x 10-6",,0.073,'-,"0.088 unit increase",NR,"LINC00290, LINC02500","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:181194263
rs75621874-<b>A</b>,"3 x 10-6",,0.937,'-,"0.089 unit increase",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88797227
rs12409794-<b>A</b>,"7 x 10-8",,0.09,'-,"0.09 unit increase",NR,LINC02785,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:108041481
rs76419734-<b>T</b>,"5 x 10-6",,0.061,'-,"0.09 unit increase",NR,"INTS12, ARHGEF38","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:105703128
rs17036129-<b>T</b>,"4 x 10-6",,0.642,'-,"0.092 unit increase",NR,"ARHGEF38, INTS12","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:105703372
rs115962916-<b>T</b>,"4 x 10-6",,0.064,'-,"0.092 unit increase",NR,INTS12,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:105880558
rs17331332-<b>A</b>,"3 x 10-6",,0.064,'-,"0.093 unit increase",NR,INTS12,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:105886950
rs151317012-<b>T</b>,"3 x 10-6",,0.064,'-,"0.093 unit increase",NR,INTS12,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:105885037
rs12586420-<b>A</b>,"3 x 10-7",(AA),0.351,'-,"0.095 unit increase",NR,LINC02309,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,14:86302020
rs12586478-<b>G</b>,"3 x 10-7",(AA),0.352,'-,"0.095 unit increase",NR,LINC02309,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,14:86302021
rs73783837-<b>G</b>,"4 x 10-6",(AA),0.834,'-,"0.098 unit increase",NR,SYNE1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,6:152323860
rs73783839-<b>G</b>,"2 x 10-6",(AA),0.843,'-,"0.104 unit increase",NR,SYNE1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,6:152323999
rs73783833-<b>T</b>,"1 x 10-6",(AA),0.844,'-,"0.105 unit increase",NR,SYNE1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,6:152322700
rs17082463-<b>G</b>,"8 x 10-7",(AA),0.844,'-,"0.106 unit increase",NR,SYNE1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,6:152320256
rs59071593-<b>T</b>,"9 x 10-7",(AA),0.845,'-,"0.107 unit increase",NR,SYNE1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,6:152315899
rs75556600-<b>T</b>,"1 x 10-6",(AA),0.862,'-,"0.114 unit increase",NR,SYNE1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,6:152317347
rs67077197-<b>T</b>,"2 x 10-6",,0.042,'-,"0.121 unit increase",NR,GNAI1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,7:80183510
rs145287362-<b>G</b>,"3 x 10-6",(AA),0.995,'-,"0.632 unit increase",NR,"RNU6-788P, UBE2E1-AS1","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:23714179
rs149318287-<b>A</b>,"2 x 10-6",(AA),0.995,'-,"0.65 unit increase",NR,LARGE1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,22:33429482
rs147913210-<b>G</b>,"3 x 10-6",(AA),0.994,'-,"0.679 unit increase",NR,DOCK5,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,8:25272717
rs182387400-<b>T</b>,"2 x 10-6",(AA),0.994,'-,"0.68 unit increase",NR,DOCK5,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,8:25272192
rs148133787-<b>C</b>,"2 x 10-6",(AA),0.995,'-,"0.682 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,18:27647495
rs114946066-<b>C</b>,"1 x 10-6",(AA),0.993,'-,"0.683 unit increase",NR,TRA2B,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:185935309
rs182242981-<b>T</b>,"4 x 10-6",(AA),0.996,'-,"0.687 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:59431621
rs145669774-<b>A</b>,"2 x 10-6",(AA),0.996,'-,"0.689 unit increase",NR,"IGF2BP2, TRA2B","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:185827714
rs182544594-<b>G</b>,"4 x 10-6",(AA),0.996,'-,"0.694 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:59424442
rs147922770-<b>G</b>,"1 x 10-6",(AA),0.994,'-,"0.712 unit increase",NR,"TRA2B, IGF2BP2","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:185871153
rs115082929-<b>G</b>,"2 x 10-6",(AA),0.996,'-,"0.735 unit increase",NR,HMGN2P24,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:40757421
rs189845032-<b>A</b>,"4 x 10-6",(AA),0.997,'-,"0.76 unit increase",NR,MAST4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,5:67078056
rs114304737-<b>A</b>,"3 x 10-6",(AA),0.997,'-,"0.771 unit increase",NR,LINC02795,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:86265746
rs112448655-<b>A</b>,"1 x 10-6",(AA),0.997,'-,"0.777 unit increase",NR,CLSTN2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:140092787
rs183110392-<b>T</b>,"3 x 10-6",(AA),0.996,'-,"0.787 unit increase",NR,COL1A2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,7:94423978
rs188764199-<b>C</b>,"4 x 10-6",(AA),0.997,'-,"0.803 unit increase",NR,TXNRD3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:126585469
rs111899708-<b>A</b>,"5 x 10-6",(AA),0.994,'-,"0.807 unit increase",NR,"MTCO1P45, TCF7L1","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,2:155194623
rs182858794-<b>A</b>,"5 x 10-7",(AA),0.996,'-,"0.812 unit increase",NR,COL1A2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,7:94352240
rs189780858-<b>T</b>,"4 x 10-6",(AA),0.998,'-,"0.82 unit increase",NR,DLG2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:84206103
rs146799327-<b>T</b>,"1 x 10-6",(AA),0.996,'-,"0.822 unit increase",NR,TUT1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:62579559
rs188809019-<b>T</b>,"4 x 10-6",(AA),0.997,'-,"0.827 unit increase",NR,RN7SKP226,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,8:128273989
rs141521978-<b>T</b>,"2 x 10-6",(AA),0.996,'-,"0.831 unit increase",NR,SP100,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,2:230447662
rs184963741-<b>C</b>,"2 x 10-6",(AA),0.997,'-,"0.836 unit increase",NR,SP100,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,2:230468771
rs114302618-<b>A</b>,"8 x 10-7",(AA),0.997,'-,"0.845 unit increase",NR,COL1A2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,7:94337748
rs191347135-<b>A</b>,"2 x 10-6",(AA),0.998,'-,"0.852 unit increase",NR,NUP210P1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:126664490
rs148560653-<b>C</b>,"2 x 10-6",(AA),0.997,'-,"0.863 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,16:60905873
rs191000678-<b>T</b>,"1 x 10-6",(AA),0.998,'-,"0.884 unit increase",NR,CCDC91,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,12:28134057
rs9904045-<b>T</b>,"2 x 10-6",(AA),0.997,'-,"0.884 unit increase",NR,CEP112,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,17:66055608
rs182923613-<b>T</b>,"1 x 10-6",(AA),0.998,'-,"0.89 unit increase",NR,ABHD5,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:43791731
rs186679854-<b>A</b>,"3 x 10-6",(AA),0.998,'-,"0.903 unit increase",NR,"LINC01471, LINC02016","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:127423049
rs116129203-<b>A</b>,"3 x 10-6",(AA),0.996,'-,"0.938 unit increase",NR,"DEFA6, RPL23AP96","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,8:6921801
rs187206368-<b>A</b>,"4 x 10-6",(AA),0.997,'-,"0.943 unit increase",NR,RBMS3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:29039771
rs187478995-<b>T</b>,"2 x 10-6",(AA),0.998,'-,"0.948 unit increase",NR,"MIR8054, WIZP1","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:23413389
rs190321959-<b>T</b>,"3 x 10-7",(AA),0.997,'-,"0.965 unit increase",NR,UROC1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:126504646
rs191698899-<b>A</b>,"6 x 10-8",(AA),0.997,'-,"0.994 unit increase",NR,COL1A2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,7:94386418
rs191979398-<b>A</b>,"6 x 10-8",(AA),0.997,'-,"0.998 unit increase",NR,COL1A2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,7:94378695
rs189936349-<b>A</b>,"5 x 10-8",(AA),0.998,'-,"1.002 unit increase",NR,COL1A2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,7:94371162
rs116375068-<b>A</b>,"9 x 10-7",(AA),0.998,'-,"1.007 unit increase",NR,MIR3681HG,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,2:12072677
rs147831109-<b>T</b>,"4 x 10-6",(AA),0.998,'-,"1.013 unit increase",NR,WIZP1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:23360815
rs73200436-<b>A</b>,"4 x 10-6",(AA),0.997,'-,"1.016 unit increase",NR,"RN7SKP250, MVK","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,12:109624888
rs144276489-<b>A</b>,"4 x 10-6",(AA),0.997,'-,"1.032 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:194892491
rs115144339-<b>T</b>,"1 x 10-6",(AA),0.997,'-,"1.063 unit increase",NR,SLC35B3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,6:8383251
rs138064340-<b>C</b>,"6 x 10-8",(AA),0.997,'-,"1.07 unit increase",NR,LINC02304,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,14:97143565
rs78702938-<b>G</b>,"5 x 10-7",(AA),0.997,'-,"1.088 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:194915525
rs143522076-<b>G</b>,"8 x 10-7",(AA),0.998,'-,"1.091 unit increase",NR,GAN,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,16:81342247
rs28497028-<b>A</b>,"9 x 10-7",(AA),0.998,'-,"1.097 unit increase",NR,GAN,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,16:81338985
rs141026162-<b>C</b>,"3 x 10-6",(AA),0.998,'-,"1.115 unit increase",NR,"DDX18P4, CTBP2P4","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,5:98650925
rs147851892-<b>G</b>,"9 x 10-7",(AA),0.998,'-,"1.122 unit increase",NR,"ADAMDEC1, ADAM28","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,8:24376842
rs138325697-<b>T</b>,"4 x 10-7",(AA),0.997,'-,"1.132 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:194720384
rs55916418-<b>T</b>,"2 x 10-6",(AA),0.999,'-,"1.159 unit increase",NR,LINC02795,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:86287235
rs144324177-<b>T</b>,"7 x 10-7",(AA),0.998,'-,"1.171 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:194789928
rs142429672-<b>C</b>,"4 x 10-6",(AA),0.999,'-,"1.187 unit increase",NR,NCSTNP1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,21:27513372
rs137917644-<b>T</b>,"2 x 10-7",(AA),0.998,'-,"1.212 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:104934188
rs187464554-<b>T</b>,"2 x 10-7",(AA),0.998,'-,"1.212 unit increase",NR,IL12RB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:104934232
rs150884133-<b>A</b>,"3 x 10-7",(AA),0.998,'-,"1.221 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:104928578
rs184686040-<b>G</b>,"8 x 10-7",(AA),0.998,'-,"1.222 unit increase",NR,HULC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,6:8450770
rs79131758-<b>C</b>,"8 x 10-7",(AA),0.998,'-,"1.231 unit increase",NR,ESRRG,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:216796235
rs187226391-<b>C</b>,"2 x 10-7",(AA),0.998,'-,"1.235 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:104948564
rs141838403-<b>C</b>,"3 x 10-6",(AA),0.999,'-,"1.249 unit increase",NR,NCSTNP1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,21:27518107
rs145996888-<b>T</b>,"2 x 10-6",(AA),0.998,'-,"1.255 unit increase",NR,"RUSF1, AHSP","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,16:31514307
rs142313660-<b>T</b>,"1 x 10-6",(AA),0.998,'-,"1.264 unit increase",NR,GAN,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,16:81336535
rs184241568-<b>G</b>,"3 x 10-6",(AA),0.998,'-,"1.266 unit increase",NR,"LINC01312, TARID","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,6:133855490
rs183884080-<b>G</b>,"2 x 10-6",(AA),0.999,'-,"1.307 unit increase",NR,IFNG-AS1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,12:68228197
rs138250198-<b>T</b>,"2 x 10-6",(AA),0.998,'-,"1.315 unit increase",NR,"ITGAM, TRIM72","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,16:31250535
rs184737911-<b>G</b>,"9 x 10-7",(AA),0.999,'-,"1.323 unit increase",NR,LDB3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,10:86671535
rs79237515-<b>T</b>,"3 x 10-7",(AA),0.998,'-,"1.326 unit increase",NR,RNU6-983P,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:194579896
rs138897663-<b>A</b>,"7 x 10-7",(AA),0.999,'-,"1.327 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:104912880
rs139202427-<b>A</b>,"2 x 10-6",(AA),0.999,'-,"1.348 unit increase",NR,"LINC01673, NCSTNP1","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,21:27545615
rs191506206-<b>G</b>,"3 x 10-6",(AA),0.999,'-,"1.375 unit increase",NR,LINC02770,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:192021237
rs139875745-<b>G</b>,"7 x 10-8",(AA),0.998,'-,"1.381 unit increase",NR,"ITGAX, ITGAD","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,16:31385571
rs143404520-<b>T</b>,"9 x 10-7",(AA),0.999,'-,"1.382 unit increase",NR,SPOCK1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,5:137070147
rs188840013-<b>C</b>,"3 x 10-6",(AA),0.998,'-,"1.385 unit increase",NR,KIF2B,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,17:53914642
rs186112291-<b>T</b>,"1 x 10-6",(AA),0.999,'-,"1.388 unit increase",NR,PYCARD,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,16:31201860
rs142976294-<b>G</b>,"2 x 10-6",(AA),0.999,'-,"1.415 unit increase",NR,"NCSTNP1, LINC01673","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,21:27554802
rs76759221-<b>C</b>,"7 x 10-7",(AA),0.998,'-,"1.438 unit increase",NR,CHRM3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:239553545
rs144060362-<b>T</b>,"3 x 10-7",(AA),0.999,'-,"1.44 unit increase",NR,ACKR3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,2:236675079
rs139680557-<b>T</b>,"4 x 10-6",(AA),0.998,'-,"1.44 unit increase",NR,"PWP1, BTBD11","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,12:107667812
rs149808359-<b>G</b>,"1 x 10-7",(AA),0.998,'-,"1.447 unit increase",NR,ITGAX,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,16:31372806
rs146495511-<b>A</b>,"3 x 10-6",(AA),0.998,'-,"1.449 unit increase",NR,CIB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,2:26602830
rs144975701-<b>T</b>,"2 x 10-6",(AA),0.999,'-,"1.451 unit increase",NR,"CLEC4G, CD209","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,19:7735580
rs138157192-<b>A</b>,"2 x 10-6",(AA),0.999,'-,"1.452 unit increase",NR,"LINC02770, RGS18","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:192074327
rs142080098-<b>C</b>,"2 x 10-6",(AA),0.999,'-,"1.455 unit increase",NR,CLEC4G,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,19:7731664
rs146861169-<b>T</b>,"2 x 10-6",(AA),0.999,'-,"1.465 unit increase",NR,"FCER2, CLEC4G","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,19:7727357
rs191211294-<b>A</b>,"4 x 10-6",(AA),0.999,'-,"1.47 unit increase",NR,KCNT2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:196300631
rs187061080-<b>A</b>,"3 x 10-6",(AA),0.999,'-,"1.501 unit increase",NR,RGS21,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:192320904
rs189578969-<b>T</b>,"5 x 10-6",(AA),0.999,'-,"1.509 unit increase",NR,"COX7B2, RAC1P2","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:46730273
rs191097752-<b>C</b>,"5 x 10-6",(AA),0.999,'-,"1.539 unit increase",NR,TET2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:105181834
rs191279589-<b>T</b>,"3 x 10-6",(AA),0.999,'-,"1.544 unit increase",NR,CXXC4-AS1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:104684840
rs144394173-<b>T</b>,"4 x 10-6",(AA),0.998,'-,"1.569 unit increase",NR,RNU7-144P,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,20:48496708
rs185751587-<b>A</b>,"8 x 10-7",(AA),0.999,'-,"1.575 unit increase",NR,HULC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,6:8816262
rs145717157-<b>T</b>,"5 x 10-6",(AA),0.999,'-,"1.584 unit increase",NR,RNU6-408P,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,18:29133313
rs193022444-<b>C</b>,"4 x 10-6",(AA),0.999,'-,"1.592 unit increase",NR,COX7B2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:46767359
rs187229201-<b>G</b>,"1 x 10-6",(AA),0.999,'-,"1.614 unit increase",NR,"FCER2, CLEC4G","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,19:7708989
rs186640425-<b>G</b>,"2 x 10-6",(AA),0.999,'-,"1.619 unit increase",NR,FCER2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,19:7701931
rs186152940-<b>A</b>,"3 x 10-6",(AA),0.999,'-,"1.62 unit increase",NR,LINC00871,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,14:46007781
rs185275068-<b>A</b>,"1 x 10-6",(AA),0.999,'-,"1.622 unit increase",NR,CHRM3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:239443989
rs147990222-<b>C</b>,"3 x 10-6",(AA),0.999,'-,"1.632 unit increase",NR,"TARID, LINC01312","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,6:133872330
rs182482821-<b>C</b>,"1 x 10-6",(AA),0.999,'-,"1.637 unit increase",NR,HULC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,6:8536139
rs188245701-<b>T</b>,"2 x 10-7",(AA),0.998,'-,"1.685 unit increase",NR,CHN1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,2:174986861
rs116554435-<b>G</b>,"2 x 10-6",(AA),0.999,'-,"1.686 unit increase",NR,LINC01865,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,2:381284
rs644885-<b>A</b>,"2 x 10-6",,0.215,'-,"0.052 unit increase",NR,"MMP3, MMP12","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:102857881
rs6537294-<b>A</b>,"1 x 10-9",,0.384,'-,"0.053 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144558611
rs12501071-<b>T</b>,"2 x 10-9",,0.409,'-,"0.053 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144569207
rs1964678-<b>A</b>,"4 x 10-9",,0.453,'-,"0.053 unit increase",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78461658
rs8042260-<b>A</b>,"4 x 10-9",,0.451,'-,"0.053 unit increase",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78482032
rs12916801-<b>A</b>,"6 x 10-9",,0.452,'-,"0.053 unit increase",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78476788
rs12902602-<b>A</b>,"5 x 10-8",,0.608,'-,"0.053 unit increase",NR,CHRNB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78675059
rs11072766-<b>T</b>,"8 x 10-7",,0.2,'-,"0.053 unit increase",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78479204
rs7174190-<b>T</b>,"9 x 10-7",,0.199,'-,"0.053 unit increase",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78471275
rs12101809-<b>T</b>,"9 x 10-7",,0.2,'-,"0.053 unit increase",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78487459
rs28511883-<b>T</b>,"9 x 10-7",,0.2,'-,"0.053 unit increase",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78491341
rs660599-<b>A</b>,"1 x 10-6",,0.219,'-,"0.053 unit increase",NR,"MMP3, MMP12","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:102859026
rs2343306-<b>T</b>,"2 x 10-6",,0.775,'-,"0.053 unit increase",NR,TSPAN14,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,10:80470390
rs6828540-<b>A</b>,"7 x 10-10",,0.387,'-,"0.054 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144542079
rs1818444-<b>A</b>,"2 x 10-9",,0.369,'-,"0.054 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144551799
rs72743199-<b>A</b>,"2 x 10-8",,0.61,'-,"0.054 unit increase",NR,CHRNB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78683513
rs12899135-<b>A</b>,"4 x 10-8",,0.608,'-,"0.054 unit increase",NR,CHRNB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78662037
rs2938674-<b>A</b>,"5 x 10-7",,0.2,'-,"0.054 unit increase",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78465571
rs2656072-<b>A</b>,"6 x 10-7",,0.201,'-,"0.054 unit increase",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78451950
rs2656073-<b>T</b>,"6 x 10-7",,0.2,'-,"0.054 unit increase",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78449934
rs2656074-<b>T</b>,"7 x 10-7",,0.2,'-,"0.054 unit increase",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78449042
rs2568490-<b>T</b>,"7 x 10-7",,0.2,'-,"0.054 unit increase",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78446028
rs35031105-<b>T</b>,"7 x 10-7",,0.201,'-,"0.054 unit increase",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78480464
rs2869561-<b>T</b>,"1 x 10-6",,0.627,'-,"0.054 unit increase",NR,"ADAMTS7, CHRNB4","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78733174
rs7910643-<b>A</b>,"5 x 10-6",,0.812,'-,"0.054 unit increase",NR,TSPAN14,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,10:80492013
rs35822625-<b>C</b>,"4 x 10-6",(AA),0.987,'-,"0.372 unit increase",NR,"DCLK1, SOHLH2","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,13:36140232
rs188403275-<b>A</b>,"4 x 10-7",,0.006,'-,"0.407 unit increase",NR,CELF4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,18:37435185
rs146939578-<b>A</b>,"4 x 10-6",(AA),0.991,'-,"0.41 unit increase",NR,"Y_RNA, TMEM200A","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,6:130525260
rs143997509-<b>C</b>,"4 x 10-6",(AA),0.991,'-,"0.411 unit increase",NR,"Y_RNA, TMEM200A","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,6:130525597
rs115971165-<b>T</b>,"8 x 10-7",(AA),0.985,'-,"0.415 unit increase",NR,"RNU7-126P, SLC34A2","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:25638750
rs77295064-<b>T</b>,"2 x 10-6",(AA),0.988,'-,"0.439 unit increase",NR,"PHBP1, ULBP3","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,6:150047189
rs187203999-<b>T</b>,"2 x 10-6",(AA),0.982,'-,"0.455 unit increase",NR,LRP1B,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,2:140908346
rs148732433-<b>T</b>,"2 x 10-6",(AA),0.992,'-,"0.466 unit increase",NR,"LINC01794, SLC8A1","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,2:40664561
rs140979249-<b>G</b>,"4 x 10-6",(AA),0.989,'-,"0.472 unit increase",NR,DCLK1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,13:36029824
rs144339868-<b>A</b>,"2 x 10-6",,0.003,'-,"0.486 unit increase",NR,LINC02527,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,6:111918607
rs142859932-<b>G</b>,"3 x 10-6",(AA),0.991,'-,"0.487 unit increase",NR,"HCN4, REC114","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:73438342
rs116229052-<b>T</b>,"5 x 10-6",(AA),0.991,'-,"0.497 unit increase",NR,RGS7,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:240842483
rs190130937-<b>C</b>,"3 x 10-6",(AA),0.993,'-,"0.517 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,7:13071553
rs186885683-<b>A</b>,"3 x 10-6",,0.996,'-,"0.525 unit increase",NR,PIKFYVE,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,2:208333903
rs191299947-<b>A</b>,"1 x 10-6",(AA),0.994,'-,"0.556 unit increase",NR,ARNT2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:80585216
rs189211803-<b>C</b>,"3 x 10-6",(AA),0.995,'-,"0.557 unit increase",NR,Y_RNA,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,6:130559379
rs75311705-<b>A</b>,"3 x 10-7",(AA),0.991,'-,"0.56 unit increase",NR,TMEM132B,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,12:125230050
rs116884796-<b>G</b>,"9 x 10-7",(AA),0.992,'-,"0.564 unit increase",NR,RBMX2P4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,7:13014569
rs74731421-<b>A</b>,"1 x 10-6",(AA),0.993,'-,"0.568 unit increase",NR,TTC6,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,14:37741081
rs75455452-<b>T</b>,"4 x 10-6",(AA),0.994,'-,"0.578 unit increase",NR,MSC-AS1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,8:72079345
rs187636186-<b>T</b>,"4 x 10-6",(AA),0.994,'-,"0.578 unit increase",NR,MSC-AS1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,8:72090233
rs192074192-<b>G</b>,"4 x 10-6",(AA),0.994,'-,"0.579 unit increase",NR,MSC-AS1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,8:72113598
rs150663730-<b>A</b>,"2 x 10-6",(AA),0.995,'-,"0.607 unit increase",NR,LARGE1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,22:33431492
rs114396821-<b>G</b>,"3 x 10-6",(AA),0.995,'-,"0.623 unit increase",NR,DIRC3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,2:217344304
rs73200449-<b>T</b>,"2 x 10-6",(AA),0.994,'-,"0.629 unit increase",NR,"MVK, RN7SKP250","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,12:109641162
rs7181486-<b>T</b>,"3 x 10-12",,0.666,'-,"0.064 unit increase",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78449276
rs56219465-<b>A</b>,"3 x 10-12",,0.666,'-,"0.064 unit increase",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78450237
rs17483686-<b>A</b>,"3 x 10-12",,0.666,'-,"0.064 unit increase",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78441048
rs17483721-<b>T</b>,"4 x 10-12",,0.403,'-,"0.064 unit increase",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78441389
rs13142879-<b>T</b>,"2 x 10-11",,0.345,'-,"0.064 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144489325
rs7656246-<b>A</b>,"2 x 10-11",,0.345,'-,"0.064 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144491359
rs55988292-<b>A</b>,"2 x 10-11",,0.624,'-,"0.064 unit increase",NR,CHRNB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78643826
rs62334742-<b>A</b>,"4 x 10-11",,0.342,'-,"0.064 unit increase",NR,FREM3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144459481
rs67426328-<b>C</b>,"1 x 10-10",,0.617,'-,"0.064 unit increase",NR,CHRNB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78641976
rs7183604-<b>T</b>,"4 x 10-10",,0.237,'-,"0.064 unit increase",NR,CHRNA3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78606871
rs12510916-<b>T</b>,"8 x 10-10",,0.282,'-,"0.064 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144451096
rs35212593-<b>A</b>,"3 x 10-9",,0.203,'-,"0.064 unit increase",NR,"PSMA4, HYKK","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78539484
rs59133824-<b>A</b>,"3 x 10-9",,0.204,'-,"0.064 unit increase",NR,PSMA4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78541108
rs1711731-<b>A</b>,"3 x 10-8",,0.192,'-,"0.064 unit increase",NR,CHRNA5,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78569576
rs2130499-<b>T</b>,"3 x 10-11",,0.342,'-,"0.065 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144467682
rs55694701-<b>T</b>,"3 x 10-11",,0.342,'-,"0.065 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144461375
rs35755165-<b>A</b>,"2 x 10-8",,0.559,'-,"0.065 unit increase",NR,"CYP2F2P, CYP2A6","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,19:40840084
rs7678427-<b>A</b>,"5 x 10-12",,0.343,'-,"0.066 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144512423
rs13142776-<b>A</b>,"7 x 10-12",,0.343,'-,"0.066 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144512139
rs3825845-<b>T</b>,"5 x 10-10",,0.212,'-,"0.066 unit increase",NR,CHRNA3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78617916
rs9788682-<b>A</b>,"7 x 10-9",,0.186,'-,"0.066 unit increase",NR,HYKK,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78510244
rs28395178-<b>A</b>,"1 x 10-8",,0.191,'-,"0.066 unit increase",NR,"CHRNA5, PSMA4","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78558216
rs28669908-<b>A</b>,"5 x 10-8",,0.178,'-,"0.066 unit increase",NR,CHRNA3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78617925
rs995758-<b>T</b>,"1 x 10-12",,0.361,'-,"0.067 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144557049
rs10863398-<b>A</b>,"1 x 10-8",,0.202,'-,"0.067 unit increase",NR,TGFB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:218414937
rs56113850-<b>T</b>,"2 x 10-8",,0.458,'-,"0.067 unit increase",NR,CYP2A6,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,19:40847202
rs9788721-<b>T</b>,"2 x 10-14",,0.62,'-,"0.068 unit increase",NR,HYKK,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78510527
rs1489763-<b>T</b>,"5 x 10-13",,0.364,'-,"0.068 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144533080
rs7173514-<b>T</b>,"1 x 10-10",,0.233,'-,"0.068 unit increase",NR,"PSMA4, CHRNA5","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78557576
rs503464-<b>A</b>,"1 x 10-10",,0.236,'-,"0.068 unit increase",NR,CHRNA5,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78565554
rs189218934-<b>T</b>,"6 x 10-10",,0.389,'-,"0.068 unit increase",NR,CHRNA3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78611645
rs7170068-<b>A</b>,"9 x 10-10",,0.209,'-,"0.068 unit increase",NR,CHRNA3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78620601
rs6829184-<b>A</b>,"5 x 10-13",,0.36,'-,"0.069 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144549505
rs664172-<b>A</b>,"2 x 10-9",,0.199,'-,"0.069 unit increase",NR,CHRNA5,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78570420
rs2999089-<b>C</b>,"2 x 10-7",,0.119,'-,"0.069 unit increase",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128216316
rs1317286-<b>A</b>,"3 x 10-14",,0.656,'-,"0.07 unit increase",NR,CHRNA3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78603787
rs8034191-<b>T</b>,"1 x 10-13",,0.335,'-,"0.07 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,"Mapping not available"
rs1542725-<b>T</b>,"2 x 10-13",,0.365,'-,"0.07 unit increase",NR,"ENPP7P9, KRT18P51","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144567182
rs11940733-<b>A</b>,"2 x 10-13",,0.364,'-,"0.07 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144568176
rs12509311-<b>T</b>,"2 x 10-13",,0.365,'-,"0.07 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144557510
rs1489760-<b>A</b>,"3 x 10-13",,0.366,'-,"0.07 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144553145
rs113352275-<b>T</b>,"1 x 10-9",,0.185,'-,"0.07 unit increase",NR,PSMA4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78548225
rs55781567-<b>C</b>,"7 x 10-15",,0.649,'-,"0.071 unit increase",NR,CHRNA5,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78565644
rs2009746-<b>A</b>,"2 x 10-14",,0.668,'-,"0.071 unit increase",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78461760
rs7697189-<b>C</b>,"9 x 10-14",,0.361,'-,"0.071 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144515742
rs6537292-<b>T</b>,"1 x 10-13",,0.366,'-,"0.071 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144548816
rs1980057-<b>T</b>,"1 x 10-13",,0.58,'-,"0.071 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144564586
rs13129662-<b>T</b>,"1 x 10-13",,0.366,'-,"0.071 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144533222
rs7435469-<b>T</b>,"2 x 10-13",,0.367,'-,"0.071 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144534398
rs28626624-<b>T</b>,"2 x 10-13",,0.365,'-,"0.071 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144561091
rs17361668-<b>A</b>,"1 x 10-6",,0.113,'-,"0.074 unit increase",NR,"MMP12, MMP3","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:102849613
rs55853698-<b>T</b>,"7 x 10-14",,0.654,'-,"0.075 unit increase",NR,CHRNA5,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78565597
rs1504550-<b>A</b>,"1 x 10-13",,0.663,'-,"0.075 unit increase",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78473908
rs72743158-<b>T</b>,"3 x 10-13",,0.633,'-,"0.075 unit increase",NR,CHRNB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78634103
rs17484524-<b>A</b>,"1 x 10-13",,0.663,'-,"0.076 unit increase",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78480334
rs113029345-<b>T</b>,"8 x 10-8",,0.568,'-,"0.076 unit increase",NR,"CYP2A6, CYP2A7","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,19:40864271
rs6867276-<b>A</b>,"3 x 10-6",,0.888,'-,"0.076 unit increase",NR,RICTOR,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,5:38999043
rs13103766-<b>A</b>,"3 x 10-6",(AA),0.596,'-,"0.076 unit increase",NR,IL21,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:122596078
rs17486195-<b>A</b>,"2 x 10-15",,0.665,'-,"0.077 unit increase",NR,CHRNA5,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78572855
rs7180002-<b>A</b>,"1 x 10-15",,0.664,'-,"0.078 unit increase",NR,CHRNA5,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78581651
rs17486278-<b>A</b>,"3 x 10-18",,0.647,'-,"0.079 unit increase",NR,CHRNA5,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78575140
rs146009840-<b>A</b>,"2 x 10-15",,0.657,'-,"0.079 unit increase",NR,CHRNA3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78613835
rs4423038-<b>A</b>,"2 x 10-6",,0.914,'-,"0.079 unit increase",NR,LINC02785,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:108044836
rs9322369-<b>T</b>,"2 x 10-6",(AA),0.37,'-,"0.079 unit increase",NR,SYNE1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,6:152346796
rs55676755-<b>C</b>,"2 x 10-17",,0.667,'-,"0.08 unit increase",NR,CHRNA3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78606590
rs12499182-<b>C</b>,"2 x 10-14",,0.331,'-,"0.081 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144526904
rs6835650-<b>T</b>,"8 x 10-14",,0.318,'-,"0.081 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144542415
rs56117933-<b>T</b>,"3 x 10-10",,0.79,'-,"0.082 unit increase",NR,"HYKK, PSMA4","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78540007
rs3971860-<b>A</b>,"2 x 10-7",,0.76,'-,"0.082 unit increase",NR,"ADAMTS7, CHRNB4","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78733936
rs951985-<b>T</b>,"2 x 10-13",,0.698,'-,"0.083 unit increase",NR,"IREB2, CRABP1","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78428581
rs7547759-<b>T</b>,"5 x 10-8",,0.755,'-,"0.083 unit increase",NR,LINC02869,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:218466247
rs141518190-<b>A</b>,"5 x 10-16",,0.699,'-,"0.084 unit increase",NR,CHRNA3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78608305
rs41313742-<b>T</b>,"4 x 10-7",,0.107,'-,"0.084 unit increase",NR,LINC02869,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:218523561
rs28875200-<b>A</b>,"4 x 10-6",(AA),0.742,'-,"0.084 unit increase",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:89106777
rs72738850-<b>A</b>,"4 x 10-7",,0.103,'-,"0.085 unit increase",NR,LINC02869,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:218507703
rs117851058-<b>A</b>,"3 x 10-6",,0.019,'-,"0.161 unit increase",NR,"EGLN2, RAB4B-EGLN2","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,19:40803685
rs17356206-<b>C</b>,"2 x 10-6",(AA),0.939,'-,"0.162 unit increase",NR,PHLPP2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,16:71702456
rs12447672-<b>A</b>,"2 x 10-6",(AA),0.939,'-,"0.164 unit increase",NR,PHLPP2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,16:71681228
rs71386933-<b>T</b>,"1 x 10-6",(AA),0.937,'-,"0.164 unit increase",NR,AP1G1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,16:71787897
rs140878064-<b>T</b>,"3 x 10-6",,0.022,'-,"0.167 unit increase",NR,"CYP2F2P, CYP2T1P","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,19:40816049
rs150978828-<b>T</b>,"5 x 10-6",(AA),0.954,'-,"0.19 unit increase",NR,Metazoa_SRP,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:37207984
rs80328607-<b>T</b>,"1 x 10-6",(AA),0.954,'-,"0.198 unit increase",NR,NXPH1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,7:8412293
rs75890985-<b>C</b>,"1 x 10-6",(AA),0.954,'-,"0.199 unit increase",NR,NXPH1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,7:8411282
rs111751834-<b>G</b>,"1 x 10-6",(AA),0.954,'-,"0.199 unit increase",NR,NXPH1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,7:8412106
rs115028228-<b>T</b>,"5 x 10-6",(AA),0.962,'-,"0.199 unit increase",NR,MS4A6E,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:60366057
rs114615507-<b>G</b>,"4 x 10-6",(AA),0.962,'-,"0.2 unit increase",NR,MS4A6E,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:60358344
rs114894087-<b>G</b>,"5 x 10-6",(AA),0.962,'-,"0.2 unit increase",NR,MS4A6E,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:60359373
rs75092417-<b>G</b>,"5 x 10-6",(AA),0.963,'-,"0.201 unit increase",NR,MS4A6E,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:60347284
rs115301024-<b>A</b>,"4 x 10-6",(AA),0.962,'-,"0.201 unit increase",NR,MS4A6E,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:60354268
rs189504960-<b>T</b>,"3 x 10-6",(AA),0.946,'-,"0.204 unit increase",NR,RPL21P71,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:147229732
rs73134727-<b>T</b>,"4 x 10-6",,0.02,'-,"0.205 unit increase",NR,CADM2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:85366725
rs141697181-<b>T</b>,"3 x 10-6",,0.02,'-,"0.208 unit increase",NR,CADM2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:85170483
rs73138705-<b>T</b>,"4 x 10-6",,0.02,'-,"0.208 unit increase",NR,CADM2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:85421211
rs73134752-<b>A</b>,"4 x 10-6",,0.02,'-,"0.208 unit increase",NR,CADM2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:85388588
rs73140731-<b>A</b>,"4 x 10-6",,0.02,'-,"0.208 unit increase",NR,CADM2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:85456609
rs145968728-<b>A</b>,"9 x 10-7",,0.03,'-,"0.211 unit increase",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144530351
rs73137637-<b>T</b>,"2 x 10-6",,0.018,'-,"0.211 unit increase",NR,"CADM2, LINC02025","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:84957714
rs77771494-<b>T</b>,"3 x 10-6",(AA),0.963,'-,"0.211 unit increase",NR,MS4A6E,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:60340627
rs79010836-<b>C</b>,"2 x 10-6",(AA),0.963,'-,"0.212 unit increase",NR,MS4A6E,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:60343130
rs114021604-<b>G</b>,"2 x 10-6",(AA),0.963,'-,"0.212 unit increase",NR,MS4A6E,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:60343330
rs5757673-<b>T</b>,"1 x 10-6",(AA),0.878,'-,"0.126 unit increase",NR,"TAB1, MGAT3","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,22:39441915
rs7941140-<b>T</b>,"2 x 10-6",(AA),0.909,'-,"0.133 unit increase",NR,"SIK3, PAFAH1B2","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:117126045
rs7286917-<b>A</b>,"1 x 10-6",(AA),0.898,'-,"0.133 unit increase",NR,MGAT3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,22:39464863
rs140401531-<b>A</b>,"2 x 10-6",(AA),0.874,'-,"0.137 unit increase",NR,CAMTA1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:7594142
rs2008174-<b>C</b>,"3 x 10-6",(AA),0.925,'-,"0.142 unit increase",NR,MGAT3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,22:39464125
rs909674-<b>C</b>,"2 x 10-6",(AA),0.926,'-,"0.143 unit increase",NR,MGAT3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,22:39463164
rs67163887-<b>G</b>,"4 x 10-6",(AA),0.917,'-,"0.146 unit increase",NR,JPH3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,16:87660435
rs3959642-<b>A</b>,"1 x 10-7",(AA),0.912,'-,"0.149 unit increase",NR,MGAT3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,22:39464584
rs1009115-<b>C</b>,"3 x 10-6",(AA),0.932,'-,"0.15 unit increase",NR,NXPH1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,7:8395352
rs12935422-<b>A</b>,"3 x 10-6",(AA),0.935,'-,"0.151 unit increase",NR,MARVELD3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,16:71630322
rs34381861-<b>C</b>,"4 x 10-6",(AA),0.935,'-,"0.152 unit increase",NR,"TAT-AS1, MARVELD3","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,16:71606327
rs17355804-<b>G</b>,"2 x 10-6",(AA),0.929,'-,"0.152 unit increase",NR,PHLPP2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,16:71683311
rs71403859-<b>T</b>,"3 x 10-6",(AA),0.935,'-,"0.154 unit increase",NR,"MARVELD3, TAT-AS1","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,16:71606304
rs12923781-<b>A</b>,"3 x 10-6",(AA),0.936,'-,"0.154 unit increase",NR,"MARVELD3, TAT-AS1","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,16:71619561
rs12927768-<b>A</b>,"2 x 10-6",(AA),0.936,'-,"0.156 unit increase",NR,"TAT-AS1, MARVELD3","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,16:71611360
rs12149264-<b>G</b>,"3 x 10-6",(AA),0.936,'-,"0.156 unit increase",NR,PHLPP2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,16:71687018
rs12444156-<b>T</b>,"4 x 10-6",(AA),0.938,'-,"0.156 unit increase",NR,AP1G1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,16:71807354
rs112458284-<b>T</b>,"3 x 10-7",,0.965,'-,"0.158 unit increase",NR,PPP4R4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,14:94206394
rs35538253-<b>T</b>,"2 x 10-6",(AA),0.937,'-,"0.158 unit increase",NR,PHLPP2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,16:71644072
rs12924650-<b>T</b>,"2 x 10-6",(AA),0.937,'-,"0.158 unit increase",NR,PHLPP2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,16:71672005
rs12920890-<b>A</b>,"2 x 10-6",(AA),0.938,'-,"0.158 unit increase",NR,AP1G1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,16:71753685
rs12149533-<b>T</b>,"3 x 10-6",(AA),0.939,'-,"0.158 unit increase",NR,AP1G1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,16:71768043
rs117821847-<b>T</b>,"4 x 10-6",,0.019,'-,"0.159 unit increase",NR,"RAB4B-EGLN2, EGLN2","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,19:40804983
rs117391664-<b>A</b>,"5 x 10-6",,0.019,'-,"0.159 unit increase",NR,"EGLN2, RAB4B-EGLN2","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,19:40803245
rs144553930-<b>T</b>,"4 x 10-6",,0.019,'-,"0.16 unit increase",NR,"EGLN2, RAB4B-EGLN2","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,19:40807356
rs138753278-<b>A</b>,"4 x 10-6",(AA),0.966,'-,"0.216 unit increase",NR,"MS4A5, MS4A14","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:60427341
rs75368561-<b>G</b>,"5 x 10-6",(AA),0.969,'-,"0.221 unit increase",NR,MS4A14,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:60413302
rs77253690-<b>G</b>,"3 x 10-6",(AA),0.97,'-,"0.228 unit increase",NR,"MS4A5, MS4A14","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:60424840
rs114230339-<b>T</b>,"5 x 10-6",(AA),0.966,'-,"0.252 unit increase",NR,LNPK,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,2:175994795
rs149746592-<b>A</b>,"1 x 10-6",(AA),0.976,'-,"0.262 unit increase",NR,"AHNAK, EEF1G","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:62558235
rs111394397-<b>T</b>,"3 x 10-6",(AA),0.979,'-,"0.263 unit increase",NR,TUT1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:62584219
rs116766958-<b>T</b>,"2 x 10-6",(AA),0.978,'-,"0.266 unit increase",NR,TUT1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:62579038
rs187116366-<b>T</b>,"3 x 10-6",,0.991,'-,"0.268 unit increase",NR,TRPM3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,9:71300536
rs116335148-<b>T</b>,"4 x 10-6",(AA),0.973,'-,"0.273 unit increase",NR,SMYD3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:245917498
rs116647499-<b>A</b>,"4 x 10-6",(AA),0.973,'-,"0.274 unit increase",NR,SMYD3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:245919582
rs115107872-<b>G</b>,"4 x 10-6",(AA),0.973,'-,"0.275 unit increase",NR,SMYD3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:245913962
rs149960642-<b>T</b>,"5 x 10-7",,0.99,'-,"0.294 unit increase",NR,LINC00276,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,2:14063520
rs78507937-<b>T</b>,"6 x 10-7",(AA),0.982,'-,"0.298 unit increase",NR,"ASGR2, CLEC10A","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,17:7084522
rs147345944-<b>T</b>,"5 x 10-7",,0.992,'-,"0.3 unit increase",NR,PTPRD,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,9:9479463
rs183699028-<b>A</b>,"2 x 10-6",,0.989,'-,"0.303 unit increase",NR,LINC00276,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,2:14017130
rs35540212-<b>A</b>,"2 x 10-6",(AA),0.98,'-,"0.313 unit increase",NR,"CCDC169-SOHLH2, SOHLH2","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,13:36194545
rs151060619-<b>A</b>,"1 x 10-6",(AA),0.976,'-,"0.322 unit increase",NR,PRKD2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,19:46710054
rs116910038-<b>T</b>,"3 x 10-6",(AA),0.982,'-,"0.329 unit increase",NR,TSPAN19,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,12:85030315
rs75185364-<b>C</b>,"1 x 10-6",(AA),0.976,'-,"0.329 unit increase",NR,PRKD2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,19:46689684
rs114855972-<b>A</b>,"1 x 10-6",(AA),0.976,'-,"0.329 unit increase",NR,PRKD2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,19:46691629
rs147565295-<b>A</b>,"1 x 10-6",(AA),0.976,'-,"0.329 unit increase",NR,PRKD2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,19:46691998
rs139399000-<b>G</b>,"1 x 10-6",(AA),0.977,'-,"0.329 unit increase",NR,PRKD2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,19:46701184
rs115824942-<b>T</b>,"1 x 10-6",(AA),0.977,'-,"0.329 unit increase",NR,PRKD2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,19:46705125
rs138814219-<b>T</b>,"7 x 10-7",(AA),0.976,'-,"0.336 unit increase",NR,PRKD2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,19:46693389
rs188160653-<b>T</b>,"3 x 10-6",,0.992,'-,"0.345 unit increase",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88755629
rs150411716-<b>T</b>,"3 x 10-6",(AA),0.999,'-,"1.69 unit increase",NR,LINC01865,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,2:374709
rs188695430-<b>T</b>,"3 x 10-6",(AA),0.999,'-,"1.705 unit increase",NR,CYP24A1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,20:54169727
rs188686089-<b>A</b>,"1 x 10-6",(AA),0.999,'-,"1.758 unit increase",NR,CHRM3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:239529929
rs77830002-<b>T</b>,"1 x 10-6",(AA),0.999,'-,"1.776 unit increase",NR,CHRM3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:239536529
rs139175374-<b>C</b>,"4 x 10-6",(AA),0.999,'-,"1.8 unit increase",NR,USP33,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:77743731
rs185969863-<b>A</b>,"2 x 10-6",(AA),0.999,'-,"1.808 unit increase",NR,"HTR1F, RNU6-873P","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:87778047
rs187885921-<b>C</b>,"5 x 10-6",(AA),0.999,'-,"1.821 unit increase",NR,"TDGF1P4, FAM50B","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,6:3894081
rs181881613-<b>T</b>,"4 x 10-6",(AA),0.999,'-,"1.826 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,14:39836370
rs181124765-<b>G</b>,"2 x 10-6",(AA),0.999,'-,"1.829 unit increase",NR,"BCAS1, CYP24A1","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,20:54094901
rs181987887-<b>A</b>,"2 x 10-6",(AA),0.999,'-,"1.85 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,13:76672384
rs187076367-<b>A</b>,"1 x 10-6",(AA),0.999,'-,"1.863 unit increase",NR,CHRNA1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,2:174772186
rs181870845-<b>A</b>,"4 x 10-6",(AA),0.999,'-,"1.909 unit increase",NR,GIPC2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:78066881
rs183468661-<b>T</b>,"2 x 10-6",(AA),0.999,'-,"1.915 unit increase",NR,RLF,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:40169170
rs186739251-<b>C</b>,"2 x 10-8",(AA),0.999,'-,"1.943 unit increase",NR,COBL,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,7:50988350
rs183032784-<b>A</b>,"1 x 10-6",(AA),1.0,'-,"1.96 unit increase",NR,KSR2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,12:117819409
rs187013403-<b>C</b>,"4 x 10-6",(AA),1.0,'-,"1.966 unit increase",NR,"WDR4P2, PLEK","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,2:68399866
rs192994403-<b>C</b>,"3 x 10-6",(AA),0.999,'-,"1.985 unit increase",NR,CASC9,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,8:75299098
rs149843939-<b>C</b>,"9 x 10-8",(AA),0.999,'-,"1.986 unit increase",NR,P2RY1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:152894604
rs187803700-<b>T</b>,"3 x 10-6",(AA),1.0,'-,"1.988 unit increase",NR,"PLEK, WDR4P2","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,2:68403424
rs181794654-<b>G</b>,"3 x 10-6",(AA),1.0,'-,"2.022 unit increase",NR,"PLEK, WDR4P2","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,2:68411552
rs147031024-<b>T</b>,"3 x 10-6",(AA),1.0,'-,"2.023 unit increase",NR,"WDR4P2, PLEK","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,2:68411766
rs187068710-<b>T</b>,"2 x 10-6",(AA),1.0,'-,"2.034 unit increase",NR,"WDR4P2, PLEK","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,2:68412584
rs142609709-<b>T</b>,"2 x 10-6",(AA),1.0,'-,"2.066 unit increase",NR,"WDR4P2, PLEK","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,2:68415288
rs140910939-<b>T</b>,"2 x 10-7",(AA),1.0,'-,"2.096 unit increase",NR,P2RY1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:152886027
rs182728150-<b>T</b>,"3 x 10-6",(AA),1.0,'-,"2.099 unit increase",NR,HTR1F,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:87842065
rs146622168-<b>T</b>,"3 x 10-6",(AA),1.0,'-,"2.101 unit increase",NR,"NPSR1, DPY19L1","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,7:34897925
rs150450027-<b>T</b>,"3 x 10-7",(AA),1.0,'-,"2.105 unit increase",NR,LINC01085,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:14125119
rs4542491-<b>C</b>,"3 x 10-6",(AA),1.0,'-,"2.107 unit increase",NR,CCDC59,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,12:82143065
rs117876032-<b>A</b>,"2 x 10-6",(AA),0.999,'-,"2.11 unit increase",NR,TMEM132B,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,12:125251457
rs189505973-<b>G</b>,"2 x 10-6",(AA),1.0,'-,"2.127 unit increase",NR,"PLEK, WDR4P2","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,2:68419733
rs148200394-<b>T</b>,"2 x 10-8",(AA),0.999,'-,"2.133 unit increase",NR,P2RY1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:152858319
rs184852128-<b>T</b>,"1 x 10-6",(AA),1.0,'-,"2.156 unit increase",NR,LRRC4C,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:40624331
rs114239771-<b>A</b>,"3 x 10-8",(AA),0.999,'-,"2.157 unit increase",NR,"ATP5MGP5, P2RY1","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:152823207
rs190262953-<b>T</b>,"2 x 10-6",(AA),1.0,'-,"2.16 unit increase",NR,"LINC02823, SCARB1","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,12:91432197
rs74507156-<b>A</b>,"4 x 10-6",(AA),1.0,'-,"2.162 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:195774530
rs191739273-<b>G</b>,"2 x 10-7",(AA),1.0,'-,"2.177 unit increase",NR,LINC00871,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,14:45943510
rs181609621-<b>C</b>,"3 x 10-6",(AA),1.0,'-,"2.19 unit increase",NR,"DNM1L, FGD4","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,12:32657825
rs139236384-<b>G</b>,"1 x 10-6",(AA),1.0,'-,"2.192 unit increase",NR,CCDC59,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,12:82156246
rs189806577-<b>T</b>,"4 x 10-6",(AA),1.0,'-,"2.193 unit increase",NR,DPY19L1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,7:34937658
rs73098786-<b>T</b>,"5 x 10-6",(AA),0.999,'-,"2.194 unit increase",NR,DPY19L1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,7:34983359
rs183160876-<b>T</b>,"9 x 10-7",(AA),1.0,'-,"2.194 unit increase",NR,LINC02426,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,12:82069660
rs191755093-<b>T</b>,"2 x 10-7",(AA),1.0,'-,"2.206 unit increase",NR,LINC00871,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,14:46095452
rs190957092-<b>C</b>,"9 x 10-8",(AA),0.999,'-,"2.21 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:162004826
rs191151465-<b>C</b>,"5 x 10-6",(AA),0.999,'-,"2.215 unit increase",NR,LINC02131,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,16:77560555
rs145882615-<b>G</b>,"3 x 10-6",(AA),1.0,'-,"2.216 unit increase",NR,PPM1L,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:160998999
rs182554582-<b>A</b>,"5 x 10-7",(AA),0.999,'-,"2.216 unit increase",NR,"GRID1, WAPL","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,10:86435202
rs147174681-<b>G</b>,"3 x 10-6",(AA),0.999,'-,"2.216 unit increase",NR,SLC6A2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,16:55684185
rs191390172-<b>C</b>,"3 x 10-6",(AA),1.0,'-,"2.22 unit increase",NR,PPM1L,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:161047595
rs185832426-<b>G</b>,"5 x 10-8",(AA),0.999,'-,"2.231 unit increase",NR,ATP5MGP5,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:152791434
rs181840477-<b>T</b>,"5 x 10-8",(AA),0.999,'-,"2.235 unit increase",NR,ATP5MGP5,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:152775700
rs142900875-<b>T</b>,"9 x 10-8",(AA),0.999,'-,"2.257 unit increase",NR,ATP5MGP5,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:152767335
rs7815327-<b>T</b>,"3 x 10-6",(AA),0.999,'-,"2.281 unit increase",NR,PCM1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,8:134043260
rs182275499-<b>G</b>,"1 x 10-6",(AA),0.999,'-,"2.294 unit increase",NR,PPM1L,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:160872707
rs150391545-<b>G</b>,"2 x 10-6",(AA),1.0,'-,"2.295 unit increase",NR,PPM1L,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:160863649
rs187303806-<b>C</b>,"1 x 10-6",(AA),1.0,'-,"2.295 unit increase",NR,NMD3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:161163687
rs149794616-<b>C</b>,"6 x 10-7",(AA),0.999,'-,"2.324 unit increase",NR,PPM1L,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:160837076
rs187984862-<b>C</b>,"4 x 10-7",(AA),1.0,'-,"2.334 unit increase",NR,CHRM3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:239313891
rs188255132-<b>A</b>,"4 x 10-6",(AA),1.0,'-,"2.347 unit increase",NR,PPFIA2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,12:81329409
rs142560558-<b>G</b>,"9 x 10-7",(AA),1.0,'-,"2.349 unit increase",NR,"EEF1GP4, NMD3","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:161323419
rs140014224-<b>G</b>,"8 x 10-7",(AA),1.0,'-,"2.355 unit increase",NR,NMD3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:161238986
rs192376484-<b>A</b>,"5 x 10-7",(AA),1.0,'-,"2.355 unit increase",NR,"PSMC1P7, SPTSSB","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:161338027
rs146844429-<b>G</b>,"3 x 10-7",(AA),0.999,'-,"2.36 unit increase",NR,"PPM1L, SNORA72","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:160753967
rs183498415-<b>T</b>,"4 x 10-6",(AA),1.0,'-,"2.365 unit increase",NR,DPY19L2P1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,7:35113789
rs182750324-<b>A</b>,"8 x 10-7",(AA),1.0,'-,"2.373 unit increase",NR,PPM1L,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:160883870
rs138436123-<b>C</b>,"1 x 10-6",(AA),0.999,'-,"2.387 unit increase",NR,FLYWCH1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,16:2928067
rs192294496-<b>T</b>,"8 x 10-7",(AA),1.0,'-,"2.389 unit increase",NR,NMD3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:161113786
rs188531091-<b>G</b>,"7 x 10-7",(AA),1.0,'-,"2.397 unit increase",NR,PPM1L,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:160844528
rs186451686-<b>A</b>,"7 x 10-7",(AA),1.0,'-,"2.398 unit increase",NR,PPM1L,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:160835568
rs141644443-<b>G</b>,"3 x 10-6",(AA),1.0,'-,"2.399 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:147055572
rs187607716-<b>G</b>,"3 x 10-7",(AA),1.0,'-,"2.412 unit increase",NR,"KERA, LUM","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,12:91093740
rs190431552-<b>G</b>,"7 x 10-7",(AA),1.0,'-,"2.422 unit increase",NR,"SNORA72, PPM1L","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:160701558
rs114659987-<b>A</b>,"3 x 10-9",(AA),0.999,'-,"2.463 unit increase",NR,COBL,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,7:51027266
rs190343823-<b>C</b>,"3 x 10-6",(AA),0.999,'-,"2.482 unit increase",NR,MOCOS,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,18:36255373
rs186289784-<b>A</b>,"5 x 10-6",(AA),1.0,'-,"2.507 unit increase",NR,AMPH,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,7:38587791
rs116765889-<b>A</b>,"4 x 10-7",(AA),0.999,'-,"2.508 unit increase",NR,RPS20P10,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,2:71986427
rs181167431-<b>A</b>,"1 x 10-6",(AA),1.0,'-,"2.522 unit increase",NR,PSMD7-DT,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,16:74045127
rs192522312-<b>C</b>,"2 x 10-7",(AA),1.0,'-,"2.547 unit increase",NR,RPL10L,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,14:46613268
rs12807873-<b>T</b>,"5 x 10-6",(AA),0.999,'-,"2.582 unit increase",NR,GRIA4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:105755896
rs192514502-<b>T</b>,"4 x 10-7",(AA),0.999,'-,"2.597 unit increase",NR,MCTP1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,5:94898594
rs183726757-<b>T</b>,"5 x 10-6",(AA),1.0,'-,"2.616 unit increase",NR,GLIS3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,9:3795100
rs182429428-<b>C</b>,"3 x 10-6",(AA),0.999,'-,"2.627 unit increase",NR,BTBD3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,20:11927362
rs150347869-<b>A</b>,"4 x 10-7",(AA),1.0,'-,"2.647 unit increase",NR,EPS15P1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,7:46857957
rs191275341-<b>C</b>,"1 x 10-8",(AA),1.0,'-,"2.669 unit increase",NR,"DCT, GPC6","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,13:94414867
rs190509410-<b>A</b>,"2 x 10-6",(AA),1.0,'-,"2.674 unit increase",NR,"LINC02625, ARID5B","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,10:61866735
rs184757371-<b>A</b>,"3 x 10-6",(AA),0.999,'-,"2.679 unit increase",NR,BTBD3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,20:11938277
rs180692309-<b>T</b>,"2 x 10-6",(AA),0.999,'-,"2.682 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,2:49462295
rs181778161-<b>G</b>,"6 x 10-7",(AA),0.999,'-,"2.685 unit increase",NR,"LINC01375, LINC01374","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,10:89931743
rs189354479-<b>G</b>,"2 x 10-6",(AA),1.0,'-,"2.728 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:195841818
rs191953093-<b>A</b>,"2 x 10-6",(AA),1.0,'-,"2.752 unit increase",NR,MR1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:181037745
rs185449237-<b>A</b>,"3 x 10-7",(AA),1.0,'-,"2.782 unit increase",NR,RPL10L,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,14:46730130
rs192383543-<b>C</b>,"3 x 10-7",(AA),1.0,'-,"2.784 unit increase",NR,RPL10L,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,14:46731659
rs190183456-<b>C</b>,"2 x 10-6",(AA),1.0,'-,"2.826 unit increase",NR,KNOP1P3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,2:51455317
rs185746565-<b>C</b>,"3 x 10-6",(AA),1.0,'-,"2.84 unit increase",NR,NUP205,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,7:135575301
rs117767473-<b>A</b>,"2 x 10-8",(AA),0.999,'-,"2.856 unit increase",NR,SHANK2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:70480488
rs187133462-<b>A</b>,"1 x 10-7",(AA),1.0,'-,"3.055 unit increase",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,2:122730415
rs190230151-<b>G</b>,"6 x 10-7",(AA),1.0,'-,"3.075 unit increase",NR,KPNA4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:160528918
rs147846168-<b>A</b>,"1 x 10-8",(AA),1.0,'-,"3.109 unit increase",NR,"FOXF2-DT, LINC01394","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,6:1340507
rs144903619-<b>T</b>,"2 x 10-6",(AA),1.0,'-,"3.123 unit increase",NR,SHANK2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:70499504
rs143737902-<b>G</b>,"1 x 10-6",(AA),1.0,'-,"3.126 unit increase",NR,SHANK2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:70474318
rs180910263-<b>G</b>,"9 x 10-7",(AA),1.0,'-,"3.166 unit increase",NR,"SHANK2, CTTN","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:70464940
rs139052640-<b>C</b>,"2 x 10-6",(AA),1.0,'-,"3.397 unit increase",NR,LINC01740,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:212555028
rs188694422-<b>A</b>,"5 x 10-7",(AA),1.0,'-,"3.398 unit increase",NR,TRIM59,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:160458729
rs191765304-<b>T</b>,"5 x 10-7",(AA),1.0,'-,"3.4 unit increase",NR,TRIM59,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:160458581
rs185914258-<b>C</b>,"4 x 10-6",(AA),1.0,'-,"3.495 unit increase",NR,"LINC01394, FOXQ1","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,6:1315560
rs188669819-<b>T</b>,"3 x 10-6",(AA),1.0,'-,"3.495 unit increase",NR,MDGA2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,14:46881819
rs142210607-<b>T</b>,"2 x 10-6",(AA),1.0,'-,"3.918 unit increase",NR,"LINC02358, RPL38P3","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:54885528
rs74629737-<b>C</b>,"8 x 10-7",(AA),1.0,'-,"4.013 unit increase",NR,BMPER,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,7:34053842
rs185857144-<b>C</b>,"2 x 10-6",(AA),1.0,'-,"4.664 unit increase",NR,KRT18P33,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,2:65692385
rs181585632-<b>C</b>,"2 x 10-6",(AA),1.0,'-,"4.957 unit increase",NR,"RNU6-873P, PSMC1P6","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:87703285
rs182019417-<b>G</b>,"2 x 10-6",(AA),1.0,'-,"4.972 unit increase",NR,"RNU6-873P, PSMC1P6","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:87644709
rs183369465-<b>T</b>,"2 x 10-6",(AA),1.0,'-,"4.98 unit increase",NR,ROBO2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:76951749
rs189419463-<b>C</b>,"3 x 10-6",(AA),1.0,'-,"5.813 unit increase",NR,"BTBD11, SETP7","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,12:107307709
rs72743158-<b>T</b>,"8 x 10-14",,0.637,'-,"0.016 unit increase",'-,CHRNB4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78634103
rs12510916-<b>T</b>,"8 x 10-13",,0.28,'-,"0.016 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144451096
rs951985-<b>T</b>,"4 x 10-12",,0.7,'-,"0.016 unit increase",'-,"IREB2, CRABP1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78428581
rs494963-<b>A</b>,"8 x 10-8",,0.114,'-,"0.016 unit increase",'-,"MMP12, MMP3","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102845095
rs1940938-<b>A</b>,"1 x 10-7",,0.122,'-,"0.016 unit increase",'-,"MMP13, RNU7-159P","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102904114
rs470234-<b>T</b>,"2 x 10-7",,0.114,'-,"0.016 unit increase",'-,WTAPP1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102811075
rs470530-<b>A</b>,"2 x 10-7",,0.114,'-,"0.016 unit increase",'-,WTAPP1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102810218
rs476762-<b>A</b>,"2 x 10-7",,0.114,'-,"0.016 unit increase",'-,MMP3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102839976
rs475937-<b>A</b>,"2 x 10-7",,0.114,'-,"0.016 unit increase",'-,WTAPP1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102816969
rs520146-<b>T</b>,"2 x 10-7",,0.114,'-,"0.016 unit increase",'-,WTAPP1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102819400
rs569444-<b>A</b>,"2 x 10-7",,0.115,'-,"0.016 unit increase",'-,"WTAPP1, MMP3","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102836574
rs473238-<b>T</b>,"2 x 10-7",,0.115,'-,"0.016 unit increase",'-,WTAPP1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102829629
rs593698-<b>A</b>,"2 x 10-7",,0.115,'-,"0.016 unit increase",'-,WTAPP1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102833745
rs605949-<b>T</b>,"2 x 10-7",,0.115,'-,"0.016 unit increase",'-,WTAPP1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102835016
rs566125-<b>T</b>,"2 x 10-7",,0.366,'-,"0.016 unit increase",'-,MMP3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102839740
rs564018-<b>A</b>,"2 x 10-7",,0.114,'-,"0.016 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,"Mapping not available"
rs595128-<b>T</b>,"2 x 10-7",,0.114,'-,"0.016 unit increase",'-,WTAPP1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102822378
rs688258-<b>A</b>,"2 x 10-7",,0.114,'-,"0.016 unit increase",'-,WTAPP1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102821364
rs505987-<b>A</b>,"2 x 10-7",,0.115,'-,"0.016 unit increase",'-,WTAPP1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102815179
rs1374531-<b>A</b>,"2 x 10-6",,0.076,'-,"0.016 unit increase",'-,ARHGEF38,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:105602775
rs12409794-<b>A</b>,"4 x 10-6",,0.089,'-,"0.016 unit increase",'-,LINC02785,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:108041481
rs17486278-<b>A</b>,"4 x 10-20",,0.65,'-,"0.017 unit increase",'-,CHRNA5,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78575140
rs55676755-<b>C</b>,"2 x 10-19",,0.67,'-,"0.017 unit increase",'-,CHRNA3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78606590
rs6537292-<b>T</b>,"9 x 10-18",,0.364,'-,"0.017 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144548816
rs7697189-<b>C</b>,"1 x 10-17",,0.359,'-,"0.017 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144515742
rs188403275-<b>A</b>,"4 x 10-8",,0.006,'-,"0.091 unit increase",'-,CELF4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,18:37435185
rs279720-<b>A</b>,"4 x 10-6",,0.998,'-,"0.151 unit increase",'-,"ZNF334, ZNF840P","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,20:46495583
rs112905267-<b>A</b>,"1 x 10-9",(AA),0.998,'-,"0.3 unit increase",'-,MGMT,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,10:129430063
rs191729664-<b>T</b>,"3 x 10-9",(AA),0.999,'-,"0.671 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,7:126012545
rs192522312-<b>C</b>,"3 x 10-9",(AA),1.0,'-,"0.579 unit increase",'-,RPL10L,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:46613268
rs191755093-<b>T</b>,"3 x 10-9",(AA),1.0,'-,"0.5 unit increase",'-,LINC00871,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:46095452
rs191739273-<b>G</b>,"3 x 10-9",(AA),1.0,'-,"0.495 unit increase",'-,LINC00871,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:45943510
rs74910874-<b>T</b>,"4 x 10-9",(AA),0.999,'-,"0.393 unit increase",'-,GRIP1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:66693030
rs185449237-<b>A</b>,"4 x 10-9",(AA),1.0,'-,"0.632 unit increase",'-,RPL10L,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:46730130
rs192383543-<b>C</b>,"4 x 10-9",(AA),1.0,'-,"0.633 unit increase",'-,RPL10L,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:46731659
rs149083189-<b>G</b>,"4 x 10-9",(AA),0.998,'-,"0.292 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,18:27689117
rs185206099-<b>C</b>,"5 x 10-9",(AA),0.999,'-,"0.377 unit increase",'-,"MCPH1, MCPH1-AS1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,8:6619777
rs183032784-<b>A</b>,"6 x 10-9",(AA),1.0,'-,"0.471 unit increase",'-,KSR2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:117819409
rs73803919-<b>A</b>,"7 x 10-9",(AA),0.994,'-,"0.171 unit increase",'-,TENM2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,5:167648655
rs76752096-<b>A</b>,"8 x 10-9",(AA),0.999,'-,"0.431 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,18:27557095
rs73326661-<b>A</b>,"1 x 10-8",(AA),0.981,'-,"0.085 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,5:164340325
rs183464040-<b>G</b>,"2 x 10-8",(AA),0.999,'-,"0.622 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,7:125970659
rs112302542-<b>G</b>,"2 x 10-8",(AA),0.997,'-,"0.267 unit increase",'-,MGMT,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,10:129386747
rs145287362-<b>G</b>,"3 x 10-8",(AA),0.995,'-,"0.149 unit increase",'-,"RNU6-788P, UBE2E1-AS1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:23714179
rs182387400-<b>T</b>,"3 x 10-8",(AA),0.994,'-,"0.158 unit increase",'-,DOCK5,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,8:25272192
rs147913210-<b>G</b>,"3 x 10-8",(AA),0.994,'-,"0.158 unit increase",'-,DOCK5,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,8:25272717
rs141644443-<b>G</b>,"3 x 10-8",(AA),1.0,'-,"0.559 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:147055572
rs187327935-<b>T</b>,"4 x 10-8",(AA),0.998,'-,"0.306 unit increase",'-,RN7SKP279,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:127473986
rs148064379-<b>G</b>,"5 x 10-8",(AA),0.999,'-,"0.368 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:5679087
rs184940006-<b>G</b>,"5 x 10-8",(AA),1.0,'-,"0.577 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,13:104425807
rs141008343-<b>A</b>,"4 x 10-7",(AA),0.989,'-,"0.08 unit increase",'-,"BCRP9, LINC00345","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,13:67734913
rs74341662-<b>G</b>,"4 x 10-7",(AA),0.988,'-,"0.086 unit increase",'-,RNU6-351P,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:104958037
rs79843055-<b>C</b>,"4 x 10-7",(AA),1.0,'-,"0.425 unit increase",'-,"NTS, MGAT4C","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:85890681
rs115942227-<b>A</b>,"4 x 10-7",(AA),0.992,'-,"0.114 unit increase",'-,POLR2M,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:57812835
rs149074315-<b>C</b>,"4 x 10-7",(AA),0.996,'-,"0.14 unit increase",'-,POLR2M,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:57796691
rs73838651-<b>C</b>,"4 x 10-7",(AA),0.989,'-,"0.087 unit increase",'-,RNU6-351P,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:104946758
rs143410069-<b>C</b>,"4 x 10-7",(AA),0.999,'-,"0.342 unit increase",'-,KALRN,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:124554316
rs142255501-<b>A</b>,"4 x 10-7",(AA),0.997,'-,"0.164 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:182222359
rs151058966-<b>G</b>,"5 x 10-7",(AA),0.999,'-,"0.341 unit increase",'-,KALRN,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:124556840
rs183244340-<b>T</b>,"5 x 10-7",(AA),0.999,'-,"0.366 unit increase",'-,MGAT4C,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:86611799
rs147068743-<b>A</b>,"5 x 10-7",(AA),1.0,'-,"0.637 unit increase",'-,CRK,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,17:1460181
rs147508746-<b>C</b>,"5 x 10-7",(AA),0.997,'-,"0.165 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:182219289
rs149450639-<b>C</b>,"5 x 10-7",(AA),0.999,'-,"0.348 unit increase",'-,"FTLP4, RPS26P2","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:30907837
rs73780158-<b>G</b>,"5 x 10-7",(AA),0.98,'-,"0.062 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,5:101256390
rs180709182-<b>C</b>,"5 x 10-7",(AA),1.0,'-,"0.602 unit increase",'-,SEMA6D,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:47706433
rs182242981-<b>T</b>,"5 x 10-7",(AA),0.996,'-,"0.149 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:59431621
rs182234674-<b>T</b>,"5 x 10-7",(AA),0.998,'-,"0.273 unit increase",'-,PROX1-AS1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:213932400
rs56010636-<b>A</b>,"5 x 10-7",(AA),0.998,'-,"0.287 unit increase",'-,"C8orf37-AS1, SRSF3P2","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,8:95854121
rs192178588-<b>A</b>,"5 x 10-7",(AA),0.996,'-,"0.171 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,18:27643043
rs148246786-<b>C</b>,"5 x 10-7",(AA),0.974,'-,"0.059 unit increase",'-,POLR2M,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:57809785
rs80324951-<b>C</b>,"5 x 10-7",(AA),0.999,'-,"0.346 unit increase",'-,"RPS26P2, FTLP4","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:30910161
rs185692311-<b>C</b>,"5 x 10-7",(AA),0.999,'-,"0.535 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,6:40806656
rs113414285-<b>C</b>,"6 x 10-7",(AA),0.998,'-,"0.217 unit increase",'-,ADAM7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,8:24537750
rs182544594-<b>G</b>,"6 x 10-7",(AA),0.996,'-,"0.15 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:59424442
rs1025561-<b>A</b>,"6 x 10-7",(AA),0.696,'-,"0.019 unit increase",'-,LINC00856,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,10:78627927
rs6537294-<b>A</b>,"9 x 10-14",,0.384,'-,"0.013 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144558611
rs6837671-<b>A</b>,"5 x 10-13",,0.535,'-,"0.013 unit increase",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88951941
rs4416442-<b>T</b>,"1 x 10-12",,0.547,'-,"0.013 unit increase",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88945562
rs720484-<b>A</b>,"2 x 10-12",,0.41,'-,"0.013 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144541212
rs10519203-<b>A</b>,"2 x 10-12",,0.638,'-,"0.013 unit increase",'-,HYKK,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78521704
rs6537291-<b>A</b>,"6 x 10-12",,0.428,'-,"0.013 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144542922
rs13142879-<b>T</b>,"1 x 10-11",,0.344,'-,"0.013 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144489325
rs7656246-<b>A</b>,"1 x 10-11",,0.344,'-,"0.013 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144491359
rs2009746-<b>A</b>,"1 x 10-11",,0.672,'-,"0.013 unit increase",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78461760
rs2130499-<b>T</b>,"2 x 10-11",,0.339,'-,"0.013 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144467682
rs7666298-<b>A</b>,"2 x 10-11",,0.346,'-,"0.013 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144480798
rs1813337-<b>A</b>,"2 x 10-11",,0.345,'-,"0.013 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144486570
rs1961266-<b>A</b>,"2 x 10-11",,0.346,'-,"0.013 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144483361
rs55988292-<b>A</b>,"2 x 10-11",,0.628,'-,"0.013 unit increase",'-,CHRNB4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78643826
rs75772244-<b>T</b>,"6 x 10-11",,0.341,'-,"0.013 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144486505
rs3825845-<b>T</b>,"5 x 10-9",,0.213,'-,"0.013 unit increase",'-,CHRNA3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78617916
rs503464-<b>A</b>,"6 x 10-9",,0.236,'-,"0.013 unit increase",'-,CHRNA5,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78565554
rs7170068-<b>A</b>,"9 x 10-9",,0.21,'-,"0.013 unit increase",'-,CHRNA3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78620601
rs1342586-<b>T</b>,"9 x 10-9",,0.811,'-,"0.013 unit increase",'-,TGFB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218424517
rs664172-<b>A</b>,"5 x 10-8",,0.2,'-,"0.013 unit increase",'-,CHRNA5,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78570420
rs3875149-<b>A</b>,"6 x 10-8",,0.388,'-,"0.013 unit increase",'-,"CYP2A7, CYP2A6","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,19:40854091
rs7143806-<b>A</b>,"9 x 10-8",,0.165,'-,"0.013 unit increase",'-,RIN3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:92637384
rs17184313-<b>T</b>,"1 x 10-7",,0.648,'-,"0.013 unit increase",'-,RIN3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:92635906
rs72699866-<b>A</b>,"1 x 10-7",,0.162,'-,"0.013 unit increase",'-,RIN3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:92648442
rs11624512-<b>T</b>,"2 x 10-7",,0.166,'-,"0.013 unit increase",'-,RIN3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:92644775
rs188330159-<b>G</b>,"1 x 10-7",(AA),0.999,'-,"0.379 unit increase",'-,GNPATP,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,16:60660279
rs114607539-<b>A</b>,"1 x 10-7",(AA),0.999,'-,"0.379 unit increase",'-,GNPATP,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,16:60663682
rs146680296-<b>G</b>,"1 x 10-7",(AA),0.999,'-,"0.379 unit increase",'-,GNPATP,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,16:60676568
rs150896862-<b>T</b>,"1 x 10-7",(AA),0.999,'-,"0.381 unit increase",'-,GNPATP,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,16:60656528
rs139202427-<b>A</b>,"1 x 10-7",(AA),0.999,'-,"0.301 unit increase",'-,"LINC01673, NCSTNP1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,21:27545615
rs76770574-<b>T</b>,"1 x 10-7",(AA),0.998,'-,"0.237 unit increase",'-,MYL3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:46866428
rs184181234-<b>C</b>,"1 x 10-7",(AA),0.999,'-,"0.377 unit increase",'-,GNPATP,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,16:60692303
rs143132326-<b>G</b>,"1 x 10-7",(AA),0.999,'-,"0.377 unit increase",'-,GNPATP,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,16:60700763
rs74681184-<b>T</b>,"1 x 10-7",(AA),0.999,'-,"0.377 unit increase",'-,GNPATP,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,16:60710719
rs142976294-<b>G</b>,"1 x 10-7",(AA),0.999,'-,"0.314 unit increase",'-,"NCSTNP1, LINC01673","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,21:27554802
rs148560677-<b>C</b>,"1 x 10-7",(AA),0.998,'-,"0.289 unit increase",'-,ULK4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:41405099
rs149476743-<b>T</b>,"1 x 10-7",(AA),0.995,'-,"0.143 unit increase",'-,PKHD1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,6:51770381
rs181167431-<b>A</b>,"1 x 10-7",(AA),1.0,'-,"0.541 unit increase",'-,PSMD7-DT,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,16:74045127
rs148319405-<b>T</b>,"2 x 10-7",(AA),0.999,'-,"0.53 unit increase",'-,LINC02128,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,16:50874907
rs72657970-<b>A</b>,"2 x 10-7",(AA),0.999,'-,"0.288 unit increase",'-,MSC-AS1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,8:71895852
rs192994403-<b>C</b>,"2 x 10-7",(AA),0.999,'-,"0.441 unit increase",'-,CASC9,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,8:75299098
rs184118729-<b>A</b>,"2 x 10-7",(AA),0.993,'-,"0.118 unit increase",'-,"OR7E90P, RNU2-21P","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:158899025
rs150576801-<b>T</b>,"2 x 10-7",(AA),0.995,'-,"0.139 unit increase",'-,PKHD1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,6:51819190
rs148788110-<b>C</b>,"2 x 10-7",(AA),0.99,'-,"0.086 unit increase",'-,"NPM1P22, BCRP9","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,13:67792069
rs150450027-<b>T</b>,"2 x 10-7",(AA),1.0,'-,"0.424 unit increase",'-,LINC01085,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:14125119
rs116768843-<b>A</b>,"2 x 10-7",(AA),0.999,'-,"0.371 unit increase",'-,GNPATP,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,16:60698264
rs17189216-<b>G</b>,"2 x 10-7",(AA),0.968,'-,"0.063 unit increase",'-,CCN3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,8:119436692
rs147851892-<b>G</b>,"2 x 10-7",(AA),0.998,'-,"0.236 unit increase",'-,"ADAMDEC1, ADAM28","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,8:24376842
rs183770498-<b>T</b>,"2 x 10-7",(AA),0.967,'-,"0.052 unit decrease",'-,PARD3B,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:205036152
rs1585518-<b>G</b>,"2 x 10-7",(AA),0.964,'-,"0.061 unit increase",'-,"ENPP2, CCN3","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,8:119462998
rs114659987-<b>A</b>,"5 x 10-8",(AA),0.999,'-,"0.452 unit increase",'-,COBL,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,7:51027266
rs150829342-<b>G</b>,"5 x 10-8",(AA),0.998,'-,"0.2 unit increase",'-,DLG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:84107286
rs191110399-<b>G</b>,"5 x 10-8",(AA),0.998,'-,"0.3 unit increase",'-,RN7SKP279,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:127477916
rs118084537-<b>T</b>,"6 x 10-8",(AA),0.989,'-,"0.124 unit increase",'-,"PPFIA1, FADD","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:70244600
rs189780858-<b>T</b>,"6 x 10-8",(AA),0.998,'-,"0.192 unit increase",'-,DLG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:84206103
rs191732819-<b>A</b>,"6 x 10-8",(AA),1.0,'-,"1.028 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,16:13771370
rs146895361-<b>A</b>,"6 x 10-8",(AA),0.995,'-,"0.15 unit increase",'-,PKHD1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,6:51824798
rs11174267-<b>A</b>,"6 x 10-8",(AA),0.139,'-,"0.025 unit decrease",'-,TAFA2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:61992819
rs186108482-<b>G</b>,"6 x 10-8",(AA),1.0,'-,"0.811 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,16:13765334
rs114174633-<b>A</b>,"6 x 10-8",(AA),1.0,'-,"0.592 unit increase",'-,GALNTL5,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,7:152009104
rs189354479-<b>G</b>,"7 x 10-8",(AA),1.0,'-,"0.615 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:195841818
rs147463808-<b>T</b>,"7 x 10-8",(AA),0.998,'-,"0.305 unit increase",'-,EEF1AKMT4-ECE2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:5679297
rs188669819-<b>T</b>,"8 x 10-8",(AA),1.0,'-,"0.799 unit increase",'-,MDGA2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:46881819
rs144029093-<b>T</b>,"8 x 10-8",(AA),0.999,'-,"0.406 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:80199371
rs181238686-<b>A</b>,"8 x 10-8",(AA),0.998,'-,"0.325 unit increase",'-,R3HDM2P2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,6:103979780
rs12815303-<b>G</b>,"8 x 10-8",(AA),0.86,'-,"0.024 unit increase",'-,TAFA2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:61993402
rs190738582-<b>T</b>,"8 x 10-8",(AA),0.998,'-,"0.323 unit increase",'-,R3HDM2P2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,6:103974497
rs12817011-<b>C</b>,"8 x 10-8",(AA),0.86,'-,"0.024 unit increase",'-,TAFA2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:61993506
rs12817007-<b>C</b>,"8 x 10-8",(AA),0.86,'-,"0.024 unit increase",'-,TAFA2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:61993501
rs192772225-<b>A</b>,"9 x 10-8",(AA),1.0,'-,"0.47 unit increase",'-,DLG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:84337159
rs141838403-<b>C</b>,"9 x 10-8",(AA),0.999,'-,"0.282 unit increase",'-,NCSTNP1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,21:27518107
rs141497497-<b>T</b>,"9 x 10-8",(AA),0.998,'-,"0.269 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,10:129350991
rs188003336-<b>G</b>,"1 x 10-6",(AA),0.998,'-,"0.296 unit increase",'-,ULK4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:41396140
rs142429672-<b>C</b>,"1 x 10-6",(AA),0.999,'-,"0.274 unit increase",'-,NCSTNP1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,21:27513372
rs142001454-<b>C</b>,"1 x 10-7",(AA),0.99,'-,"0.107 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,5:164341532
rs148187869-<b>A</b>,"3 x 10-7",(AA),0.997,'-,"0.228 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,18:27681874
rs138746541-<b>A</b>,"3 x 10-7",(AA),0.999,'-,"0.365 unit increase",'-,"FTLP4, RPS26P2","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:30904473
rs146111930-<b>A</b>,"3 x 10-7",(AA),0.997,'-,"0.228 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,18:27682406
rs142181472-<b>C</b>,"3 x 10-7",(AA),0.998,'-,"0.238 unit increase",'-,"RPL10P1, NCSTNP1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,21:27487918
rs184897315-<b>G</b>,"4 x 10-7",(AA),1.0,'-,"0.855 unit increase",'-,LINC02240,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,5:125220077
rs139528199-<b>C</b>,"4 x 10-7",(AA),0.999,'-,"0.362 unit increase",'-,"RPS26P2, FTLP4","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:30905407
rs180692309-<b>T</b>,"4 x 10-7",(AA),0.999,'-,"0.568 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:49462295
rs138607199-<b>A</b>,"4 x 10-7",(AA),0.989,'-,"0.08 unit increase",'-,BCRP9,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,13:67693880
rs79030472-<b>A</b>,"4 x 10-7",(AA),0.99,'-,"0.109 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:23053133
rs148342344-<b>G</b>,"4 x 10-7",(AA),0.989,'-,"0.08 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,13:67689147
rs76225479-<b>G</b>,"4 x 10-7",(AA),0.997,'-,"0.224 unit increase",'-,"RN7SKP113, LDHAP1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:4903619
rs146844429-<b>G</b>,"4 x 10-7",(AA),0.999,'-,"0.468 unit increase",'-,"PPM1L, SNORA72","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:160753967
rs73838658-<b>T</b>,"4 x 10-7",(AA),0.988,'-,"0.086 unit increase",'-,"FAM13A, RNU6-351P","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:104966151
rs73838654-<b>C</b>,"4 x 10-7",(AA),0.989,'-,"0.088 unit increase",'-,RNU6-351P,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:104953387
rs73838655-<b>C</b>,"4 x 10-7",(AA),0.989,'-,"0.088 unit increase",'-,RNU6-351P,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:104953429
rs73838652-<b>A</b>,"4 x 10-7",(AA),0.989,'-,"0.088 unit increase",'-,RNU6-351P,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:104950293
rs56235007-<b>C</b>,"4 x 10-7",(AA),0.989,'-,"0.088 unit increase",'-,RNU6-351P,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:104952626
rs73838653-<b>A</b>,"4 x 10-7",(AA),0.989,'-,"0.088 unit increase",'-,RNU6-351P,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:104950568
rs79131758-<b>C</b>,"4 x 10-7",(AA),0.998,'-,"0.251 unit increase",'-,ESRRG,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:216796235
rs186046079-<b>T</b>,"4 x 10-7",(AA),0.999,'-,"0.332 unit increase",'-,MCPH1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,8:6611193
rs141318698-<b>G</b>,"4 x 10-7",(AA),0.989,'-,"0.08 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,13:67660827
rs76177788-<b>T</b>,"4 x 10-7",(AA),1.0,'-,"0.49 unit increase",'-,MGAT4C,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:86150461
rs187133462-<b>A</b>,"4 x 10-7",(AA),1.0,'-,"0.578 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:122730415
rs147410855-<b>C</b>,"4 x 10-7",(AA),0.995,'-,"0.153 unit increase",'-,FGGY-DT,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:59272220
rs192692653-<b>T</b>,"4 x 10-7",(AA),1.0,'-,"0.571 unit increase",'-,GNG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:51917768
rs144046596-<b>T</b>,"6 x 10-7",(AA),0.985,'-,"0.08 unit increase",'-,"RPS29P13, RFX6","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,6:117011437
rs111754512-<b>T</b>,"6 x 10-7",(AA),0.999,'-,"0.217 unit increase",'-,ADAM7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,8:24543135
rs147368481-<b>A</b>,"6 x 10-7",(AA),0.999,'-,"0.344 unit increase",'-,"FTLP4, RPS26P2","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:30912423
rs2593149-<b>T</b>,"6 x 10-7",(AA),0.694,'-,"0.018 unit increase",'-,LINC00856,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,10:78630510
rs76695314-<b>T</b>,"6 x 10-7",(AA),0.999,'-,"0.343 unit increase",'-,"FTLP4, RPS26P2","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:30912927
rs191531070-<b>T</b>,"6 x 10-7",(AA),0.998,'-,"0.225 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:25419356
rs187930576-<b>C</b>,"6 x 10-7",(AA),0.998,'-,"0.226 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:25426267
rs181672678-<b>G</b>,"6 x 10-7",(AA),0.998,'-,"0.225 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:25425075
rs183191361-<b>T</b>,"6 x 10-7",(AA),0.999,'-,"0.444 unit increase",'-,"LINC02886, CASC9","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,8:75171012
rs138094162-<b>G</b>,"6 x 10-7",(AA),0.999,'-,"0.287 unit increase",'-,"MCPH1, MCPH1-AS1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,8:6632047
rs114946066-<b>C</b>,"6 x 10-7",(AA),0.993,'-,"0.139 unit increase",'-,TRA2B,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:185935309
rs146977322-<b>A</b>,"6 x 10-7",(AA),0.998,'-,"0.216 unit increase",'-,PRKN,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,6:161699571
rs187039407-<b>T</b>,"6 x 10-7",(AA),0.999,'-,"0.296 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:86947997
rs77285130-<b>T</b>,"6 x 10-7",(AA),0.994,'-,"0.108 unit increase",'-,CXXC4-AS1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:104807863
rs184963741-<b>C</b>,"6 x 10-7",(AA),0.997,'-,"0.173 unit increase",'-,SP100,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:230468771
rs184991195-<b>T</b>,"6 x 10-7",(AA),0.988,'-,"0.08 unit increase",'-,DPP3P2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:73562263
rs73836173-<b>A</b>,"6 x 10-7",(AA),0.993,'-,"0.102 unit increase",'-,CXXC4-AS1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:104828376
rs144148493-<b>G</b>,"7 x 10-7",(AA),0.999,'-,"0.295 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:86966444
rs7164035-<b>A</b>,"7 x 10-7",(AA),0.973,'-,"0.058 unit increase",'-,POLR2M,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:57810043
rs187035304-<b>T</b>,"7 x 10-7",(AA),0.999,'-,"0.318 unit increase",'-,MGAT4C,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:86835965
rs139467600-<b>T</b>,"7 x 10-7",(AA),0.998,'-,"0.235 unit increase",'-,SLC35F3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:233939651
rs185216905-<b>T</b>,"7 x 10-7",(AA),0.999,'-,"0.447 unit increase",'-,NCOR2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:124602646
rs188585019-<b>A</b>,"7 x 10-7",(AA),0.999,'-,"0.49 unit increase",'-,MGAT4C,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:86171148
rs181927184-<b>A</b>,"7 x 10-7",(AA),0.998,'-,"0.304 unit increase",'-,"SYF2, IFITM3P7","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:25157453
rs188470542-<b>T</b>,"7 x 10-7",(AA),1.0,'-,"0.772 unit increase",'-,"TLE4, NPAP1P6","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:79789191
rs4290852-<b>T</b>,"2 x 10-11",,0.281,'-,"0.014 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144415320
rs149774458-<b>C</b>,"2 x 10-11",,0.275,'-,"0.014 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144436675
rs34490121-<b>A</b>,"2 x 10-11",,0.275,'-,"0.014 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144432849
rs140908948-<b>A</b>,"2 x 10-11",,0.274,'-,"0.014 unit increase",'-,NDUFB4P12,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144437576
rs17709487-<b>T</b>,"2 x 10-11",,0.273,'-,"0.014 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144348912
rs62334742-<b>A</b>,"2 x 10-11",,0.34,'-,"0.014 unit increase",'-,FREM3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144459481
rs67426328-<b>C</b>,"2 x 10-11",,0.621,'-,"0.014 unit increase",'-,CHRNB4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78641976
rs17019340-<b>A</b>,"3 x 10-11",,0.275,'-,"0.014 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144412631
rs13128377-<b>T</b>,"3 x 10-11",,0.275,'-,"0.014 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144399479
rs74877722-<b>T</b>,"3 x 10-11",,0.274,'-,"0.014 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144392734
rs4240361-<b>A</b>,"4 x 10-11",,0.272,'-,"0.014 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144365095
rs4240362-<b>C</b>,"4 x 10-11",,0.272,'-,"0.014 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144365211
rs17766168-<b>A</b>,"7 x 10-11",,0.273,'-,"0.014 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144351540
rs626750-<b>A</b>,"1 x 10-9",,0.2,'-,"0.014 unit increase",'-,"MMP12, MMP3","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102850214
rs56113850-<b>T</b>,"5 x 10-9",,0.462,'-,"0.014 unit increase",'-,CYP2A6,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,19:40847202
rs112370326-<b>C</b>,"9 x 10-8",,0.158,'-,"0.014 unit increase",'-,RIN3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:92611988
rs75662783-<b>A</b>,"1 x 10-7",,0.158,'-,"0.014 unit increase",'-,RIN3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:92605807
rs77503186-<b>A</b>,"1 x 10-7",,0.158,'-,"0.014 unit increase",'-,RIN3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:92605191
rs75070309-<b>A</b>,"1 x 10-7",,0.158,'-,"0.014 unit increase",'-,RIN3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:92606131
rs72697295-<b>C</b>,"1 x 10-7",,0.157,'-,"0.014 unit increase",'-,RIN3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:92603635
rs11621587-<b>C</b>,"1 x 10-7",,0.159,'-,"0.014 unit increase",'-,RIN3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:92631994
rs57837628-<b>A</b>,"7 x 10-7",,0.542,'-,"0.014 unit increase",'-,"CYP2A7, CYP2A6","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,19:40852005
rs2005108-<b>T</b>,"1 x 10-7",,0.118,'-,"0.014 unit increase",'-,"RNU7-159P, BOLA3P1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102899623
rs12907764-<b>A</b>,"2 x 10-6",,0.641,'-,"0.014 unit increase",'-,ADAMTS7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78778096
rs113029345-<b>T</b>,"2 x 10-6",,0.571,'-,"0.014 unit increase",'-,"CYP2A6, CYP2A7","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,19:40864271
rs112560164-<b>A</b>,"2 x 10-7",,0.163,'-,"0.013 unit increase",'-,RIN3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:92646579
rs72699855-<b>C</b>,"2 x 10-7",,0.162,'-,"0.013 unit increase",'-,RIN3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:92639608
rs10498635-<b>T</b>,"3 x 10-7",,0.352,'-,"0.013 unit increase",'-,RIN3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:92636964
rs72699846-<b>A</b>,"3 x 10-7",,0.156,'-,"0.013 unit increase",'-,RIN3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:92632272
rs7141996-<b>A</b>,"3 x 10-7",,0.156,'-,"0.013 unit increase",'-,RIN3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:92627953
rs6681129-<b>T</b>,"4 x 10-7",,0.154,'-,"0.013 unit increase",'-,"U3, LINC02869","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218527042
rs181700380-<b>T</b>,"6 x 10-7",,0.306,'-,"0.013 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144395373
rs72738863-<b>A</b>,"7 x 10-7",,0.158,'-,"0.013 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218525386
rs79596128-<b>T</b>,"8 x 10-7",,0.156,'-,"0.013 unit increase",'-,RIN3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:92608102
rs12023501-<b>A</b>,"8 x 10-7",,0.158,'-,"0.013 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218524640
rs2999089-<b>C</b>,"8 x 10-7",,0.119,'-,"0.013 unit increase",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128216316
rs80162468-<b>T</b>,"1 x 10-6",,0.692,'-,"0.013 unit increase",'-,"ADAMTS7, CHRNB4","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78733974
rs12461383-<b>C</b>,"3 x 10-6",,0.549,'-,"0.013 unit increase",'-,"CYP2A7, CYP2A6","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,19:40864433
rs9788721-<b>T</b>,"2 x 10-14",,0.621,'-,"0.014 unit increase",'-,HYKK,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78510527
rs1317286-<b>A</b>,"3 x 10-14",,0.658,'-,"0.014 unit increase",'-,CHRNA3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78603787
rs8034191-<b>T</b>,"6 x 10-14",,0.331,'-,"0.014 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,"Mapping not available"
rs6828540-<b>A</b>,"8 x 10-14",,0.387,'-,"0.014 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144542079
rs1818444-<b>A</b>,"3 x 10-13",,0.369,'-,"0.014 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144551799
rs7678427-<b>A</b>,"1 x 10-12",,0.341,'-,"0.014 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144512423
rs13142776-<b>A</b>,"2 x 10-12",,0.34,'-,"0.014 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144512139
rs6828795-<b>T</b>,"9 x 10-12",,0.279,'-,"0.014 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144453608
rs17019354-<b>T</b>,"9 x 10-12",,0.275,'-,"0.014 unit increase",'-,TET2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144445825
rs12499125-<b>A</b>,"1 x 10-11",,0.275,'-,"0.014 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144442422
rs55694701-<b>T</b>,"1 x 10-11",,0.339,'-,"0.014 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144461375
rs34991888-<b>T</b>,"2 x 10-11",,0.273,'-,"0.014 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144350967
rs140839642-<b>A</b>,"4 x 10-6",,0.128,'-,"0.014 unit increase",'-,"MMP3, MMP12","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102858081
rs58365910-<b>T</b>,"1 x 10-15",,0.655,'-,"0.015 unit increase",'-,"CHRNA5, PSMA4","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78556692
rs8042849-<b>T</b>,"3 x 10-15",,0.561,'-,"0.015 unit increase",'-,HYKK,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78525587
rs55781567-<b>C</b>,"6 x 10-15",,0.651,'-,"0.015 unit increase",'-,CHRNA5,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78565644
rs11852372-<b>A</b>,"1 x 10-13",,0.689,'-,"0.015 unit increase",'-,HYKK,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78509052
rs17484524-<b>A</b>,"5 x 10-13",,0.666,'-,"0.015 unit increase",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78480334
rs1504550-<b>A</b>,"8 x 10-13",,0.666,'-,"0.015 unit increase",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78473908
rs13105210-<b>T</b>,"1 x 10-12",,0.278,'-,"0.015 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144341775
rs17484235-<b>C</b>,"2 x 10-12",,0.666,'-,"0.015 unit increase",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78469072
rs72738732-<b>C</b>,"2 x 10-12",,0.666,'-,"0.015 unit increase",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78459846
rs2089162-<b>A</b>,"2 x 10-12",,0.662,'-,"0.015 unit increase",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78447421
rs7673195-<b>A</b>,"2 x 10-11",,0.26,'-,"0.015 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144394135
rs117068593-<b>T</b>,"2 x 10-8",,0.168,'-,"0.015 unit increase",'-,RIN3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:92651884
rs11724319-<b>A</b>,"2 x 10-8",,0.773,'-,"0.015 unit increase",'-,"KRT18P51, HHIP-AS1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144589888
rs646910-<b>A</b>,"3 x 10-7",,0.114,'-,"0.015 unit increase",'-,MMP3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102838791
rs655403-<b>T</b>,"3 x 10-7",,0.115,'-,"0.015 unit increase",'-,MMP3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102837776
rs499459-<b>A</b>,"4 x 10-7",,0.114,'-,"0.015 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,"Mapping not available"
rs2811416-<b>T</b>,"2 x 10-6",,0.11,'-,"0.015 unit increase",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128273095
rs1489763-<b>T</b>,"2 x 10-17",,0.361,'-,"0.016 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144533080
rs6829184-<b>A</b>,"1 x 10-16",,0.358,'-,"0.016 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144549505
rs7180002-<b>A</b>,"1 x 10-16",,0.667,'-,"0.016 unit increase",'-,CHRNA5,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78581651
rs17486195-<b>A</b>,"1 x 10-16",,0.668,'-,"0.016 unit increase",'-,CHRNA5,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78572855
rs995758-<b>T</b>,"4 x 10-16",,0.359,'-,"0.016 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144557049
rs6833979-<b>A</b>,"7 x 10-15",,0.314,'-,"0.016 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144542369
rs55853698-<b>T</b>,"1 x 10-14",,0.658,'-,"0.016 unit increase",'-,CHRNA5,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78565597
rs187162159-<b>C</b>,"2 x 10-7",(AA),0.995,'-,"0.166 unit increase",'-,DOCK5,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,8:25254090
rs115605431-<b>T</b>,"2 x 10-7",(AA),0.999,'-,"0.417 unit increase",'-,SDK1-AS1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,7:3182015
rs139916902-<b>G</b>,"2 x 10-7",(AA),0.999,'-,"0.263 unit increase",'-,"RPL10P1, NCSTNP1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,21:27469761
rs115249811-<b>C</b>,"2 x 10-7",(AA),1.0,'-,"0.834 unit increase",'-,NRXN1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:50699981
rs72657954-<b>A</b>,"2 x 10-7",(AA),0.999,'-,"0.288 unit increase",'-,MSC-AS1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,8:71858071
rs190343823-<b>C</b>,"2 x 10-7",(AA),0.999,'-,"0.549 unit increase",'-,MOCOS,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,18:36255373
rs191275341-<b>C</b>,"2 x 10-7",(AA),1.0,'-,"0.481 unit increase",'-,"DCT, GPC6","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,13:94414867
rs190957092-<b>C</b>,"2 x 10-7",(AA),0.999,'-,"0.425 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:162004826
rs144087410-<b>T</b>,"2 x 10-7",(AA),0.999,'-,"0.397 unit increase",'-,INSL6,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:5185581
rs116837984-<b>A</b>,"2 x 10-7",(AA),0.994,'-,"0.121 unit increase",'-,ULK4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:41353856
rs191185851-<b>T</b>,"3 x 10-7",(AA),0.998,'-,"0.252 unit increase",'-,LINC01804,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:15736293
rs76507695-<b>G</b>,"3 x 10-7",(AA),0.999,'-,"0.328 unit increase",'-,PIEZO1P2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,20:58780995
rs181954514-<b>A</b>,"3 x 10-7",(AA),1.0,'-,"0.598 unit increase",'-,MIGA1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:77787349
rs73075135-<b>T</b>,"3 x 10-7",(AA),1.0,'-,"0.671 unit increase",'-,ERC2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:55748913
rs117375698-<b>T</b>,"3 x 10-7",(AA),0.999,'-,"0.397 unit increase",'-,MTND4P3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,7:68250721
rs182344828-<b>G</b>,"3 x 10-7",(AA),1.0,'-,"0.645 unit increase",'-,"Y_RNA, MBL2","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,10:52833566
rs145583199-<b>C</b>,"3 x 10-7",(AA),0.999,'-,"0.41 unit increase",'-,CLDND1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:98518342
rs150343078-<b>T</b>,"3 x 10-7",(AA),0.999,'-,"0.44 unit increase",'-,CNTN4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:2831489
rs191663403-<b>C</b>,"3 x 10-7",(AA),0.999,'-,"0.425 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:59350530
rs190671939-<b>T</b>,"3 x 10-7",(AA),1.0,'-,"0.539 unit increase",'-,ADGRA1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,10:133096483
rs112448655-<b>A</b>,"3 x 10-7",(AA),0.997,'-,"0.163 unit increase",'-,CLSTN2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:140092787
rs74498795-<b>G</b>,"3 x 10-7",(AA),0.999,'-,"0.224 unit increase",'-,PRSS46P,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:46734762
rs189970609-<b>C</b>,"3 x 10-7",(AA),0.999,'-,"0.372 unit increase",'-,"FTLP4, RPS26P2","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:30898163
rs140594067-<b>A</b>,"3 x 10-7",(AA),0.998,'-,"0.219 unit increase",'-,PRKN,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,6:161689529
rs139088314-<b>T</b>,"3 x 10-7",(AA),0.999,'-,"0.366 unit increase",'-,"RPS26P2, FTLP4","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:30902952
rs1980057-<b>T</b>,"1 x 10-17",,0.581,'-,"0.017 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144564586
rs7435469-<b>T</b>,"1 x 10-17",,0.366,'-,"0.017 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144534398
rs28626624-<b>T</b>,"1 x 10-17",,0.362,'-,"0.017 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144561091
rs1980056-<b>A</b>,"1 x 10-17",,0.362,'-,"0.017 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144563771
rs13129662-<b>T</b>,"1 x 10-17",,0.364,'-,"0.017 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144533222
rs1565330-<b>T</b>,"1 x 10-17",,0.362,'-,"0.017 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144561395
rs1542725-<b>T</b>,"1 x 10-17",,0.362,'-,"0.017 unit increase",'-,"ENPP7P9, KRT18P51","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144567182
rs11940733-<b>A</b>,"1 x 10-17",,0.361,'-,"0.017 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144568176
rs1828590-<b>A</b>,"2 x 10-17",,0.366,'-,"0.017 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144552044
rs12509311-<b>T</b>,"2 x 10-17",,0.363,'-,"0.017 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144557510
rs1489760-<b>A</b>,"3 x 10-17",,0.363,'-,"0.017 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144553145
rs146009840-<b>A</b>,"2 x 10-16",,0.66,'-,"0.017 unit increase",'-,CHRNA3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78613835
rs7547759-<b>T</b>,"7 x 10-8",,0.756,'-,"0.017 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218466247
rs3971860-<b>A</b>,"3 x 10-7",,0.762,'-,"0.017 unit increase",'-,"ADAMTS7, CHRNB4","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78733936
rs13113591-<b>T</b>,"1 x 10-17",,0.349,'-,"0.018 unit increase",'-,"KRT18P51, ENPEP","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144567945
rs141518190-<b>A</b>,"6 x 10-17",,0.702,'-,"0.018 unit increase",'-,CHRNA3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78608305
rs138544659-<b>T</b>,"8 x 10-17",,0.712,'-,"0.018 unit increase",'-,CHRNA3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78608359
rs56117933-<b>T</b>,"5 x 10-11",,0.792,'-,"0.018 unit increase",'-,"HYKK, PSMA4","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78540007
rs62346060-<b>A</b>,"3 x 10-10",,0.204,'-,"0.018 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144548221
rs116187470-<b>A</b>,"2 x 10-8",,0.115,'-,"0.018 unit increase",'-,"MMP12, MMP3","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102846910
rs72738847-<b>T</b>,"5 x 10-8",,0.106,'-,"0.018 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218503102
rs72738850-<b>A</b>,"6 x 10-8",,0.106,'-,"0.018 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218507703
rs41313742-<b>T</b>,"1 x 10-7",,0.109,'-,"0.018 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218523561
rs400942-<b>T</b>,"1 x 10-6",,0.875,'-,"0.018 unit increase",'-,LILRB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,19:54277703
rs12499182-<b>C</b>,"3 x 10-18",,0.328,'-,"0.019 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144526904
rs6835650-<b>T</b>,"3 x 10-18",,0.317,'-,"0.019 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144542415
rs72981675-<b>T</b>,"4 x 10-10",,0.114,'-,"0.019 unit increase",'-,"MMP3, MMP12","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102850520
rs72981680-<b>A</b>,"4 x 10-10",,0.114,'-,"0.019 unit increase",'-,"MMP12, MMP3","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102851128
rs72981684-<b>T</b>,"4 x 10-10",,0.114,'-,"0.019 unit increase",'-,"MMP12, MMP3","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102853480
rs72981698-<b>T</b>,"4 x 10-10",,0.114,'-,"0.019 unit increase",'-,"MMP12, MMP3","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102855809
rs72983508-<b>A</b>,"4 x 10-10",,0.114,'-,"0.019 unit increase",'-,"MMP12, MMP3","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102856678
rs72981683-<b>A</b>,"6 x 10-10",,0.114,'-,"0.019 unit increase",'-,"MMP12, MMP3","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102851883
rs17368659-<b>T</b>,"6 x 10-10",,0.367,'-,"0.019 unit increase",'-,MMP12,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102872031
rs114176245-<b>T</b>,"7 x 10-10",,0.114,'-,"0.019 unit increase",'-,"MMP3, MMP12","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102848803
rs72738855-<b>T</b>,"1 x 10-7",,0.083,'-,"0.019 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218510342
rs72738861-<b>T</b>,"2 x 10-7",,0.085,'-,"0.019 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218520470
rs35450021-<b>T</b>,"2 x 10-7",,0.084,'-,"0.019 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218482944
rs72738837-<b>T</b>,"2 x 10-7",,0.084,'-,"0.019 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218485016
rs72738838-<b>C</b>,"2 x 10-7",,0.084,'-,"0.019 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218485034
rs17361668-<b>A</b>,"4 x 10-10",,0.112,'-,"0.02 unit increase",'-,"MMP12, MMP3","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102849613
rs61493282-<b>T</b>,"8 x 10-8",,0.073,'-,"0.02 unit increase",'-,"BOLA3P1, RNU7-159P","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102884138
rs142849437-<b>T</b>,"4 x 10-6",,0.025,'-,"0.033 unit increase",'-,"LINC00469, SDK2","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,17:73717900
rs112458284-<b>T</b>,"9 x 10-11",,0.965,'-,"0.041 unit increase",'-,PPP4R4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:94206394
rs141697181-<b>T</b>,"3 x 10-6",,0.02,'-,"0.042 unit increase",'-,CADM2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:85170483
rs145968728-<b>A</b>,"5 x 10-7",,0.03,'-,"0.044 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144530351
rs73137637-<b>T</b>,"1 x 10-6",,0.018,'-,"0.045 unit increase",'-,"CADM2, LINC02025","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:84957714
rs147345944-<b>T</b>,"2 x 10-7",,0.992,'-,"0.063 unit increase",'-,PTPRD,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:9479463
rs182934215-<b>C</b>,"1 x 10-6",,0.993,'-,"0.072 unit increase",'-,"RP1L1, PRSS55","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,8:10576632
rs188160653-<b>T</b>,"2 x 10-6",,0.992,'-,"0.072 unit increase",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88755629
rs144855337-<b>T</b>,"4 x 10-6",,0.994,'-,"0.076 unit increase",'-,HNRNPA1P57,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:41218539
rs145317423-<b>C</b>,"2 x 10-6",(AA),0.984,'-,"0.066 unit increase",'-,EDIL3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,5:84072226
rs185438855-<b>G</b>,"2 x 10-6",(AA),0.999,'-,"0.372 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:131140615
rs149819415-<b>G</b>,"2 x 10-6",(AA),1.0,'-,"0.881 unit increase",'-,RPL23AP22,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:193670497
rs113936974-<b>T</b>,"2 x 10-6",(AA),1.0,'-,"0.409 unit increase",'-,LINC00469,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,17:73890491
rs150335055-<b>T</b>,"2 x 10-6",(AA),0.999,'-,"0.214 unit increase",'-,RNU6-526P,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,8:9386754
rs188858915-<b>C</b>,"2 x 10-6",(AA),0.999,'-,"0.267 unit increase",'-,"MCPH1-AS1, MCPH1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,8:6637312
rs191947856-<b>A</b>,"2 x 10-6",(AA),0.996,'-,"0.162 unit increase",'-,CNTNAP5,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:124683675
rs187785117-<b>T</b>,"2 x 10-6",(AA),0.999,'-,"0.405 unit increase",'-,RB1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,13:48575735
rs6069919-<b>T</b>,"2 x 10-6",(AA),0.908,'-,"0.028 unit increase",'-,RNU6-929P,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,20:56880653
rs191299947-<b>A</b>,"2 x 10-6",(AA),0.994,'-,"0.107 unit increase",'-,ARNT2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:80585216
rs114791918-<b>A</b>,"2 x 10-6",(AA),0.999,'-,"0.284 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:28128821
rs190569495-<b>T</b>,"2 x 10-6",(AA),0.999,'-,"0.296 unit increase",'-,STX18-AS1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:4655815
rs77213524-<b>T</b>,"2 x 10-6",(AA),0.999,'-,"0.314 unit increase",'-,"HSPA8P17, FTLP4","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:30975834
rs193251247-<b>A</b>,"2 x 10-6",(AA),0.999,'-,"0.4 unit increase",'-,RB1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,13:48589044
rs187769864-<b>A</b>,"2 x 10-6",(AA),1.0,'-,"0.613 unit increase",'-,"SPARC, FAT2","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,5:151632752
rs192525030-<b>T</b>,"2 x 10-6",(AA),1.0,'-,"0.625 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:208497362
rs72890852-<b>T</b>,"2 x 10-6",(AA),0.565,'-,"0.016 unit decrease",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97621479
rs148861184-<b>A</b>,"2 x 10-6",(AA),0.999,'-,"0.314 unit increase",'-,"HSPA8P17, FTLP4","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:30975639
rs62531470-<b>T</b>,"2 x 10-6",(AA),0.999,'-,"0.356 unit increase",'-,KANK1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:540319
rs186451686-<b>A</b>,"2 x 10-6",(AA),1.0,'-,"0.454 unit increase",'-,PPM1L,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:160835568
rs145505122-<b>C</b>,"2 x 10-6",(AA),0.999,'-,"0.314 unit increase",'-,"FTLP4, HSPA8P17","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:30975568
rs188531091-<b>G</b>,"2 x 10-6",(AA),1.0,'-,"0.454 unit increase",'-,PPM1L,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:160844528
rs189909051-<b>T</b>,"2 x 10-6",(AA),0.999,'-,"0.41 unit increase",'-,GALNT11,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,7:152034718
rs185636671-<b>A</b>,"2 x 10-6",(AA),0.999,'-,"0.453 unit increase",'-,"FUOM, ECHS1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,10:133359290
rs17026855-<b>A</b>,"2 x 10-6",(AA),0.618,'-,"0.016 unit decrease",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97670238
rs192180133-<b>C</b>,"2 x 10-6",(AA),0.999,'-,"0.519 unit increase",'-,GNG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:51865528
rs181295069-<b>T</b>,"2 x 10-6",(AA),0.999,'-,"0.308 unit increase",'-,"YBX1P9, PARP1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:226324765
rs144060362-<b>T</b>,"2 x 10-6",(AA),0.999,'-,"0.265 unit increase",'-,ACKR3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:236675079
rs147515761-<b>C</b>,"2 x 10-6",(AA),0.987,'-,"0.074 unit increase",'-,RNU6-351P,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:104922762
rs183816717-<b>A</b>,"2 x 10-6",(AA),0.999,'-,"0.465 unit increase",'-,RB1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,13:48445893
rs186788172-<b>C</b>,"2 x 10-6",(AA),0.999,'-,"0.321 unit increase",'-,"TRARG1, YWHAE","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,17:1335895
rs77905828-<b>A</b>,"2 x 10-6",(AA),0.978,'-,"0.054 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,5:101180165
rs144473309-<b>A</b>,"2 x 10-6",(AA),0.982,'-,"0.069 unit increase",'-,ZNF503-AS1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,10:75369403
rs150425940-<b>A</b>,"2 x 10-6",(AA),0.988,'-,"0.078 unit increase",'-,"GP9, RAB43","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:129083346
rs145803288-<b>T</b>,"2 x 10-6",(AA),1.0,'-,"0.348 unit increase",'-,"UBASH3B, GLULP3","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:122619951
rs187899339-<b>G</b>,"2 x 10-6",(AA),0.999,'-,"0.361 unit increase",'-,RPSAP48,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,8:110106221
rs139632137-<b>A</b>,"2 x 10-6",(AA),0.999,'-,"0.283 unit increase",'-,BTBD9,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,6:38286043
rs115034739-<b>G</b>,"2 x 10-6",(AA),0.999,'-,"0.285 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:28117642
rs74492808-<b>G</b>,"2 x 10-6",(AA),0.999,'-,"0.285 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:28122677
rs117814736-<b>C</b>,"2 x 10-6",(AA),0.998,'-,"0.268 unit increase",'-,TMEM106B,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,7:12141131
rs183820509-<b>A</b>,"2 x 10-6",(AA),0.998,'-,"0.268 unit increase",'-,TMEM106B,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,7:12141195
rs150765348-<b>C</b>,"2 x 10-6",(AA),1.0,'-,"0.426 unit increase",'-,ZNF385D,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:22363816
rs61095879-<b>G</b>,"2 x 10-6",(AA),0.992,'-,"0.09 unit increase",'-,CXXC4-AS1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:104657944
rs141958207-<b>T</b>,"2 x 10-6",(AA),0.998,'-,"0.268 unit increase",'-,TMEM106B,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,7:12141874
rs114639778-<b>G</b>,"2 x 10-6",(AA),0.998,'-,"0.257 unit increase",'-,OTOG,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:17597184
rs146646693-<b>T</b>,"2 x 10-6",(AA),0.999,'-,"0.303 unit increase",'-,"TAFA4, PSMC1P1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:68663397
rs182272664-<b>A</b>,"2 x 10-6",(AA),0.999,'-,"0.383 unit increase",'-,ST8SIA1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:22312006
rs114496665-<b>C</b>,"2 x 10-6",(AA),0.999,'-,"0.246 unit increase",'-,NBEAL2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:47007485
rs147962389-<b>A</b>,"2 x 10-6",(AA),0.999,'-,"0.413 unit increase",'-,GALNT11,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,7:152033806
rs141332792-<b>G</b>,"2 x 10-6",(AA),1.0,'-,"0.631 unit increase",'-,IQCJ-SCHIP1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:159294501
rs116590076-<b>C</b>,"3 x 10-6",(AA),0.999,'-,"0.285 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:28069785
rs183433534-<b>A</b>,"3 x 10-6",(AA),0.996,'-,"0.214 unit increase",'-,SLC25A27,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,6:46656242
rs189178057-<b>C</b>,"3 x 10-6",(AA),0.999,'-,"0.331 unit increase",'-,SEM1P1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,5:45972251
rs73838634-<b>G</b>,"3 x 10-6",(AA),0.987,'-,"0.072 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:104872888
rs181660893-<b>A</b>,"3 x 10-6",(AA),0.997,'-,"0.17 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:81799810
rs181310918-<b>C</b>,"3 x 10-6",(AA),0.99,'-,"0.082 unit increase",'-,CXXC4-AS1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:104806235
rs184737911-<b>G</b>,"3 x 10-6",(AA),0.999,'-,"0.249 unit increase",'-,LDB3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,10:86671535
rs150369165-<b>G</b>,"3 x 10-6",(AA),0.995,'-,"0.187 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,13:82395345
rs186915809-<b>A</b>,"3 x 10-6",(AA),1.0,'-,"1.227 unit increase",'-,PALM2AKAP2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:109705718
rs73276024-<b>A</b>,"3 x 10-6",(AA),0.825,'-,"0.02 unit decrease",'-,LINC00520,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:55890203
rs184665953-<b>G</b>,"3 x 10-6",(AA),0.999,'-,"0.281 unit increase",'-,GABRA2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:46442317
rs192739715-<b>C</b>,"3 x 10-6",(AA),0.998,'-,"0.181 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,7:52098061
rs146346907-<b>G</b>,"3 x 10-6",(AA),1.0,'-,"0.75 unit increase",'-,"HCFC2P1, TNFSF13B","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,13:108380923
rs143988467-<b>G</b>,"3 x 10-6",(AA),0.977,'-,"0.049 unit increase",'-,"FFAR4, CEP55","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,10:93557637
rs79105493-<b>C</b>,"3 x 10-6",(AA),0.998,'-,"0.254 unit increase",'-,"LGI1, FRA10AC1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,10:93715597
rs4888873-<b>C</b>,"3 x 10-6",(AA),0.957,'-,"0.04 unit increase",'-,WWOX,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,16:78903241
rs150267141-<b>T</b>,"3 x 10-6",(AA),0.992,'-,"0.134 unit increase",'-,"PPFIA1, FADD","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:70242193
rs181284109-<b>G</b>,"3 x 10-6",(AA),0.999,'-,"0.356 unit increase",'-,USP37,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:218480989
rs1532993-<b>C</b>,"3 x 10-6",(AA),0.668,'-,"0.016 unit increase",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97587250
rs142973438-<b>A</b>,"3 x 10-6",(AA),0.977,'-,"0.049 unit increase",'-,"CEP55, FFAR4","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,10:93556242
rs150281976-<b>T</b>,"3 x 10-6",(AA),0.995,'-,"0.139 unit increase",'-,DOCK5,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,8:25273943
rs185508190-<b>A</b>,"3 x 10-6",(AA),1.0,'-,"0.729 unit increase",'-,NRXN1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:50958832
rs188867939-<b>G</b>,"3 x 10-6",(AA),0.995,'-,"0.159 unit increase",'-,LINC01495,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:22482668
rs142560558-<b>G</b>,"3 x 10-6",(AA),1.0,'-,"0.44 unit increase",'-,"EEF1GP4, NMD3","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:161323419
rs148444376-<b>C</b>,"4 x 10-6",(AA),0.989,'-,"0.076 unit increase",'-,DAPL1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:158832953
rs192514502-<b>T</b>,"3 x 10-6",(AA),0.999,'-,"0.476 unit increase",'-,MCTP1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,5:94898594
rs139222478-<b>G</b>,"3 x 10-6",(AA),0.999,'-,"0.366 unit increase",'-,"NPEPL1, STX16-NPEPL1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,20:58709873
rs142772618-<b>C</b>,"3 x 10-6",(AA),0.992,'-,"0.102 unit increase",'-,ROBO2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:77576298
rs192030704-<b>C</b>,"3 x 10-6",(AA),0.998,'-,"0.258 unit increase",'-,"LINC02294, LINC02588","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:26777641
rs143335239-<b>A</b>,"3 x 10-6",(AA),0.999,'-,"0.271 unit increase",'-,"MCPH1, MCPH1-AS1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,8:6643288
rs113752012-<b>A</b>,"3 x 10-6",(AA),0.999,'-,"0.448 unit increase",'-,CT70,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:104978546
rs56392554-<b>G</b>,"3 x 10-6",(AA),0.989,'-,"0.08 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,6:120176040
rs72890876-<b>C</b>,"3 x 10-6",(AA),0.624,'-,"0.016 unit decrease",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97644428
rs185569610-<b>C</b>,"3 x 10-6",(AA),0.999,'-,"0.359 unit increase",'-,ADTRP,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,6:11785127
rs1012333-<b>C</b>,"3 x 10-6",(AA),0.624,'-,"0.016 unit decrease",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97641006
rs878361-<b>C</b>,"3 x 10-6",(AA),0.84,'-,"0.02 unit increase",'-,KIAA0087,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,7:26518249
rs181902743-<b>G</b>,"3 x 10-6",(AA),1.0,'-,"0.503 unit increase",'-,CEP128,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:80663845
rs60217712-<b>T</b>,"3 x 10-6",(AA),0.563,'-,"0.015 unit decrease",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97632665
rs140798517-<b>C</b>,"3 x 10-6",(AA),0.996,'-,"0.188 unit increase",'-,RAB6B,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:133878284
rs149619169-<b>C</b>,"3 x 10-6",(AA),0.999,'-,"0.398 unit increase",'-,GALNT11,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,7:152041967
rs148376973-<b>T</b>,"3 x 10-6",(AA),0.999,'-,"0.397 unit increase",'-,GALNT11,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,7:152042185
rs55901496-<b>G</b>,"3 x 10-6",(AA),0.563,'-,"0.015 unit decrease",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97628841
rs2078362-<b>C</b>,"3 x 10-6",(AA),0.563,'-,"0.015 unit decrease",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97631608
rs151074357-<b>C</b>,"3 x 10-6",(AA),0.999,'-,"0.24 unit increase",'-,SETD2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:47034978
rs143838614-<b>T</b>,"3 x 10-6",(AA),0.987,'-,"0.071 unit increase",'-,DPP3P2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:73436451
rs143915539-<b>T</b>,"3 x 10-6",(AA),0.986,'-,"0.075 unit increase",'-,"FANCD2, FANCD2OS","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:10086675
rs138897663-<b>A</b>,"3 x 10-6",(AA),0.999,'-,"0.248 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:104912880
rs183544847-<b>G</b>,"3 x 10-6",(AA),0.999,'-,"0.384 unit increase",'-,FAM227A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,22:38595548
rs56404102-<b>C</b>,"3 x 10-6",(AA),0.987,'-,"0.072 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:104874359
rs141455065-<b>T</b>,"3 x 10-6",(AA),0.992,'-,"0.087 unit increase",'-,BCRP9,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,13:67711360
rs7243817-<b>C</b>,"4 x 10-6",(AA),0.134,'-,"0.021 unit increase",'-,LINC01915,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,18:24552530
rs147910279-<b>T</b>,"4 x 10-6",(AA),0.997,'-,"0.151 unit increase",'-,"GULP1, LINC01090","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:188379871
rs148340644-<b>T</b>,"4 x 10-6",(AA),1.0,'-,"0.543 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:29299831
rs187306222-<b>T</b>,"4 x 10-6",(AA),0.999,'-,"0.346 unit increase",'-,C2orf16,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:27579638
rs138048027-<b>A</b>,"4 x 10-6",(AA),0.999,'-,"0.472 unit increase",'-,LINC02305,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:84007953
rs75598744-<b>C</b>,"4 x 10-6",(AA),0.997,'-,"0.168 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:81789339
rs59775286-<b>T</b>,"4 x 10-6",(AA),0.945,'-,"0.034 unit increase",'-,DPP3P2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:73513806
rs76839023-<b>G</b>,"4 x 10-6",(AA),0.975,'-,"0.057 unit increase",'-,MTCO1P40,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,17:53198213
rs190801949-<b>G</b>,"4 x 10-6",(AA),0.998,'-,"0.286 unit increase",'-,"OFCC1, RNU6ATAC21P","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,6:10213427
rs187979858-<b>A</b>,"4 x 10-6",(AA),0.998,'-,"0.2 unit increase",'-,SARDH,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:133734976
rs149406381-<b>A</b>,"4 x 10-6",(AA),0.998,'-,"0.278 unit increase",'-,"FTLP4, RPS26P2","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:30915161
rs188724679-<b>C</b>,"4 x 10-6",(AA),0.999,'-,"0.43 unit increase",'-,MTG1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,10:133411351
rs114004118-<b>A</b>,"4 x 10-6",(AA),0.999,'-,"0.392 unit increase",'-,GALNT11,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,7:152045017
rs183470003-<b>T</b>,"4 x 10-6",(AA),0.999,'-,"0.231 unit increase",'-,MARCHF1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:164374247
rs181043431-<b>T</b>,"4 x 10-6",(AA),0.999,'-,"0.439 unit increase",'-,"KCNK3, RPL37P11","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:26686308
rs186074592-<b>T</b>,"4 x 10-6",(AA),1.0,'-,"0.784 unit increase",'-,ST13P7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,7:133170513
rs117911949-<b>A</b>,"4 x 10-6",(AA),0.999,'-,"0.42 unit increase",'-,SIPA1L1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:71550072
rs192419686-<b>T</b>,"4 x 10-6",(AA),0.999,'-,"0.321 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,5:45888273
rs73838632-<b>G</b>,"4 x 10-6",(AA),0.988,'-,"0.073 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:104862232
rs186609563-<b>G</b>,"4 x 10-6",(AA),0.994,'-,"0.138 unit increase",'-,CNTNAP5,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:124811228
rs140785266-<b>G</b>,"4 x 10-6",(AA),1.0,'-,"0.412 unit increase",'-,RASSF9,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:85802145
rs191414751-<b>C</b>,"4 x 10-6",(AA),0.999,'-,"0.32 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,5:45858866
rs9935937-<b>C</b>,"4 x 10-6",(AA),0.911,'-,"0.027 unit decrease",'-,WDR59,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,16:74952587
rs17607-<b>A</b>,"4 x 10-6",(AA),0.993,'-,"0.11 unit increase",'-,CD68,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,17:7581464
rs138258488-<b>G</b>,"4 x 10-6",(AA),0.998,'-,"0.169 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:81779894
rs114258913-<b>G</b>,"3 x 10-6",(AA),0.982,'-,"0.074 unit decrease",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,8:92513175
rs28766878-<b>C</b>,"3 x 10-6",(AA),0.688,'-,"0.017 unit increase",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97584198
rs146978549-<b>G</b>,"3 x 10-6",(AA),0.999,'-,"0.423 unit increase",'-,SKP1P2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:16896978
rs192294496-<b>T</b>,"3 x 10-6",(AA),1.0,'-,"0.449 unit increase",'-,NMD3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:161113786
rs147153117-<b>T</b>,"3 x 10-6",(AA),0.999,'-,"0.342 unit increase",'-,LINC02127,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,16:51027617
rs185580150-<b>G</b>,"3 x 10-6",(AA),0.999,'-,"0.347 unit increase",'-,GCKR,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:27507500
rs149157446-<b>G</b>,"3 x 10-6",(AA),0.999,'-,"0.502 unit increase",'-,"PNPLA5, PNPLA3","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,22:43909694
rs148138116-<b>T</b>,"3 x 10-6",(AA),0.997,'-,"0.175 unit increase",'-,TCF4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,18:55534249
rs117767473-<b>A</b>,"3 x 10-6",(AA),0.999,'-,"0.474 unit increase",'-,SHANK2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:70480488
rs137877371-<b>T</b>,"3 x 10-6",(AA),0.96,'-,"0.044 unit increase",'-,"MS4A1, MS4A12","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:60473547
rs117802898-<b>C</b>,"3 x 10-6",(AA),0.998,'-,"0.181 unit increase",'-,GRID2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:93085618
rs79765414-<b>A</b>,"3 x 10-6",(AA),0.999,'-,"0.418 unit increase",'-,"MYL12B, LINC01895","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,18:3325611
rs59810062-<b>A</b>,"3 x 10-6",(AA),0.563,'-,"0.015 unit decrease",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97642695
rs77653389-<b>C</b>,"3 x 10-6",(AA),0.972,'-,"0.062 unit increase",'-,GRIK3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:36847104
rs146750542-<b>A</b>,"3 x 10-6",(AA),0.998,'-,"0.214 unit increase",'-,"LINC02313, ARHGAP5-AS1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:32030965
rs188954228-<b>C</b>,"3 x 10-6",(AA),0.998,'-,"0.263 unit increase",'-,ATG2A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:64915453
rs2391285-<b>A</b>,"3 x 10-6",(AA),0.162,'-,"0.02 unit decrease",'-,"LINC02860, KIAA0087","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,7:26542177
rs144250695-<b>G</b>,"3 x 10-6",(AA),0.567,'-,"0.015 unit decrease",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97637323
rs11934983-<b>C</b>,"3 x 10-6",(AA),0.692,'-,"0.016 unit increase",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97538779
rs138006855-<b>A</b>,"3 x 10-6",(AA),0.999,'-,"0.308 unit increase",'-,"LRRC7, LINC01758","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:69484016
rs17486278-<b>C</b>,"3 x 10-6",(AA),0.709,'-,"0.016 unit increase",'-,CHRNA5,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78575140
rs73836179-<b>G</b>,"3 x 10-6",(AA),0.988,'-,"0.074 unit increase",'-,CXXC4-AS1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:104833383
rs192691827-<b>G</b>,"3 x 10-6",(AA),0.992,'-,"0.09 unit increase",'-,"FTH1P21, CTSO","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:155958547
rs141395649-<b>C</b>,"3 x 10-6",(AA),0.999,'-,"0.27 unit increase",'-,"MCPH1, MCPH1-AS1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,8:6641169
rs190045766-<b>T</b>,"3 x 10-6",(AA),0.999,'-,"0.429 unit increase",'-,"RPL17P36, LDHAP5","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,10:118884374
rs182823009-<b>C</b>,"3 x 10-6",(AA),0.999,'-,"0.332 unit increase",'-,"MORF4L2P1, CHIC2","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:54073775
rs115082929-<b>G</b>,"3 x 10-6",(AA),0.996,'-,"0.143 unit increase",'-,HMGN2P24,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:40757421
rs55760002-<b>G</b>,"3 x 10-6",(AA),0.955,'-,"0.04 unit increase",'-,WWOX,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,16:78904746
rs116335274-<b>G</b>,"3 x 10-6",(AA),0.999,'-,"0.286 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:28145182
rs181391108-<b>C</b>,"3 x 10-6",(AA),1.0,'-,"0.425 unit increase",'-,HMGB1P5,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:22389331
rs181741409-<b>A</b>,"3 x 10-6",(AA),0.999,'-,"0.462 unit increase",'-,SUPT3H,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,6:45190049
rs184680785-<b>C</b>,"3 x 10-6",(AA),0.997,'-,"0.17 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:25410146
rs115371810-<b>G</b>,"3 x 10-6",(AA),1.0,'-,"0.484 unit increase",'-,GAP43,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:115615117
rs181697701-<b>C</b>,"3 x 10-6",(AA),1.0,'-,"0.765 unit increase",'-,SETP7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:107217272
rs9599394-<b>T</b>,"3 x 10-6",(AA),0.951,'-,"0.034 unit increase",'-,"SNRPFP3, ZDHHC20P4","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,13:69085628
rs190971703-<b>T</b>,"3 x 10-6",(AA),0.999,'-,"0.285 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:28074270
rs138465513-<b>G</b>,"3 x 10-6",(AA),1.0,'-,"0.914 unit increase",'-,"IQCJ, IQCJ-SCHIP1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:159017006
rs184061709-<b>G</b>,"3 x 10-6",(AA),1.0,'-,"0.38 unit increase",'-,ST8SIA1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:22309344
rs182426545-<b>T</b>,"3 x 10-6",(AA),0.999,'-,"0.24 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,13:63519212
rs181293434-<b>T</b>,"3 x 10-6",(AA),0.999,'-,"0.282 unit increase",'-,"PRKCH, LINC01303","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:61551126
rs1567287-<b>T</b>,"3 x 10-6",(AA),0.67,'-,"0.016 unit increase",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97587979
rs182750324-<b>A</b>,"3 x 10-6",(AA),1.0,'-,"0.448 unit increase",'-,PPM1L,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:160883870
rs190821608-<b>C</b>,"3 x 10-6",(AA),1.0,'-,"0.488 unit increase",'-,KIF16B,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,20:16299665
rs76264265-<b>T</b>,"3 x 10-6",(AA),0.972,'-,"0.062 unit increase",'-,GRIK3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:36843789
rs76142193-<b>A</b>,"3 x 10-6",(AA),0.564,'-,"0.016 unit decrease",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97621608
rs181328644-<b>C</b>,"3 x 10-6",(AA),0.999,'-,"0.348 unit increase",'-,"NPSR1-AS1, NPSR1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,7:34859802
rs150347869-<b>A</b>,"3 x 10-6",(AA),1.0,'-,"0.483 unit increase",'-,EPS15P1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,7:46857957
rs190650493-<b>G</b>,"3 x 10-6",(AA),0.999,'-,"0.362 unit increase",'-,CCDC178,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,18:33045045
rs149774937-<b>C</b>,"3 x 10-6",(AA),0.999,'-,"0.401 unit increase",'-,GALNT11,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,7:152039935
rs190230151-<b>G</b>,"3 x 10-6",(AA),1.0,'-,"0.571 unit increase",'-,KPNA4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:160528918
rs185205268-<b>G</b>,"4 x 10-6",(AA),0.998,'-,"0.236 unit increase",'-,ARHGEF5,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,7:144378024
rs184699315-<b>T</b>,"4 x 10-6",(AA),0.999,'-,"0.478 unit increase",'-,TSPAN8,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:71256999
rs116126197-<b>A</b>,"4 x 10-6",(AA),0.997,'-,"0.246 unit increase",'-,"HDAC11-AS1, NUP210","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:13439534
rs187797607-<b>A</b>,"4 x 10-6",(AA),0.999,'-,"0.368 unit increase",'-,MGMT,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,10:129403597
rs77988765-<b>G</b>,"4 x 10-6",(AA),0.973,'-,"0.047 unit increase",'-,"FADD, PPFIA1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:70211479
rs118061259-<b>G</b>,"4 x 10-6",(AA),0.997,'-,"0.157 unit increase",'-,ABRA,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,8:106815850
rs191390172-<b>C</b>,"4 x 10-6",(AA),1.0,'-,"0.435 unit increase",'-,PPM1L,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:161047595
rs115081025-<b>A</b>,"4 x 10-6",(AA),0.945,'-,"0.033 unit increase",'-,DPP3P2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:73524131
rs58710288-<b>C</b>,"4 x 10-6",(AA),0.945,'-,"0.034 unit increase",'-,DPP3P2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:73513840
rs184606651-<b>G</b>,"4 x 10-6",(AA),0.999,'-,"0.32 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,5:45868075
rs17026828-<b>A</b>,"4 x 10-6",(AA),0.562,'-,"0.016 unit decrease",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97588360
rs58111058-<b>G</b>,"4 x 10-6",(AA),0.622,'-,"0.015 unit decrease",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97676392
rs114785263-<b>T</b>,"4 x 10-6",(AA),0.945,'-,"0.034 unit increase",'-,DPP3P2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:73512614
rs115038670-<b>T</b>,"4 x 10-6",(AA),0.992,'-,"0.118 unit increase",'-,KCNH7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:162753662
rs190027738-<b>A</b>,"4 x 10-6",(AA),0.997,'-,"0.216 unit increase",'-,ZFAND3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,6:38150966
rs192784693-<b>T</b>,"4 x 10-6",(AA),1.0,'-,"0.542 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:82574790
rs11956923-<b>C</b>,"4 x 10-6",(AA),0.723,'-,"0.016 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,5:101240577
rs116107739-<b>A</b>,"4 x 10-6",(AA),0.945,'-,"0.034 unit increase",'-,DPP3P2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:73512602
rs140011970-<b>G</b>,"4 x 10-6",(AA),0.993,'-,"0.117 unit increase",'-,SLCO3A1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:92107050
rs145882615-<b>G</b>,"4 x 10-6",(AA),1.0,'-,"0.435 unit increase",'-,PPM1L,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:160998999
rs182791062-<b>G</b>,"4 x 10-6",(AA),1.0,'-,"0.506 unit increase",'-,"LINC01933, GLRA1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,5:151939561
rs143655133-<b>A</b>,"4 x 10-6",(AA),1.0,'-,"0.667 unit increase",'-,PACRG,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,6:162772357
rs143566192-<b>G</b>,"4 x 10-6",(AA),0.999,'-,"0.242 unit increase",'-,LINC02454,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:65599978
rs143087368-<b>G</b>,"4 x 10-6",(AA),0.996,'-,"0.187 unit increase",'-,"RAB6B, C3orf36","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:133910095
rs150256815-<b>G</b>,"4 x 10-6",(AA),0.999,'-,"0.39 unit increase",'-,GALNT11,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,7:152046708
rs737693-<b>A</b>,"4 x 10-10",,0.886,'-,"0.019 unit decrease",'-,"MMP12, MMP3","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102855411
rs72983513-<b>T</b>,"5 x 10-10",,0.886,'-,"0.019 unit decrease",'-,"MMP12, MMP3","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102858254
rs28381684-<b>A</b>,"5 x 10-10",,0.886,'-,"0.019 unit decrease",'-,MMP12,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102866461
rs2276109-<b>T</b>,"7 x 10-10",,0.887,'-,"0.019 unit decrease",'-,"MMP12, BOLA3P1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102875061
rs17368582-<b>T</b>,"8 x 10-10",,0.886,'-,"0.019 unit decrease",'-,MMP12,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102867344
rs6656288-<b>A</b>,"1 x 10-7",,0.917,'-,"0.019 unit decrease",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218493087
rs78242330-<b>T</b>,"3 x 10-6",,0.918,'-,"0.019 unit decrease",'-,RIN3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:92645370
rs13141641-<b>T</b>,"1 x 10-19",,0.632,'-,"0.018 unit decrease",'-,"HHIP-AS1, KRT18P51","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144585304
rs56077333-<b>A</b>,"1 x 10-19",,0.314,'-,"0.018 unit decrease",'-,CHRNA3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78606661
rs147144681-<b>T</b>,"3 x 10-18",,0.309,'-,"0.018 unit decrease",'-,CHRNA3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78608566
rs13140176-<b>A</b>,"1 x 10-17",,0.652,'-,"0.018 unit decrease",'-,"KRT18P51, THEGL","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144567946
rs147499554-<b>T</b>,"6 x 10-17",,0.298,'-,"0.018 unit decrease",'-,CHRNA3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78608308
rs17368814-<b>A</b>,"2 x 10-9",,0.366,'-,"0.018 unit decrease",'-,"MMP12, BOLA3P1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102877965
rs147089648-<b>T</b>,"9 x 10-7",,0.082,'-,"0.018 unit decrease",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88953220
rs6057884-<b>A</b>,"1 x 10-6",,0.164,'-,"0.018 unit decrease",'-,PXMP4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,20:33708875
rs451000-<b>T</b>,"1 x 10-6",,0.124,'-,"0.018 unit decrease",'-,LILRB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,19:54277700
rs450937-<b>T</b>,"1 x 10-6",,0.125,'-,"0.018 unit decrease",'-,LILRB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,19:54277687
rs114205691-<b>T</b>,"6 x 10-19",,0.33,'-,"0.017 unit decrease",'-,CHRNA3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78608771
rs12504628-<b>T</b>,"9 x 10-18",,0.641,'-,"0.017 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144515172
rs11938745-<b>T</b>,"1 x 10-17",,0.636,'-,"0.017 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144544616
rs13147758-<b>A</b>,"1 x 10-17",,0.636,'-,"0.017 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144539078
rs11936476-<b>T</b>,"1 x 10-17",,0.636,'-,"0.017 unit decrease",'-,"KRT18P51, MIR5091","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144537332
rs720485-<b>A</b>,"1 x 10-17",,0.579,'-,"0.017 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144541436
rs1512281-<b>A</b>,"2 x 10-17",,0.631,'-,"0.017 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144513749
rs140330585-<b>A</b>,"5 x 10-17",,0.335,'-,"0.017 unit decrease",'-,CHRNA5,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78574103
rs7172118-<b>A</b>,"6 x 10-17",,0.333,'-,"0.017 unit decrease",'-,CHRNA5,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78570111
rs6817238-<b>T</b>,"6 x 10-16",,0.689,'-,"0.017 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144542381
rs16969968-<b>A</b>,"1 x 10-15",,0.578,'-,"0.017 unit decrease",'-,CHRNA5,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78590583
rs4887067-<b>A</b>,"3 x 10-15",,0.342,'-,"0.017 unit decrease",'-,"CHRNA3, CHRNA5","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78594605
rs8192482-<b>T</b>,"3 x 10-15",,0.342,'-,"0.017 unit decrease",'-,"CHRNA5, CHRNA3","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78593856
rs34684276-<b>A</b>,"8 x 10-13",,0.291,'-,"0.017 unit decrease",'-,HYKK,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78520813
rs7526672-<b>T</b>,"6 x 10-8",,0.754,'-,"0.017 unit decrease",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218472531
rs3971859-<b>T</b>,"2 x 10-7",,0.238,'-,"0.017 unit decrease",'-,"ADAMTS7, CHRNB4","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78733935
rs12743469-<b>A</b>,"4 x 10-7",,0.894,'-,"0.017 unit decrease",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218477441
rs12914385-<b>T</b>,"6 x 10-18",,0.63,'-,"0.016 unit decrease",'-,CHRNA3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78606381
rs1489762-<b>T</b>,"4 x 10-17",,0.638,'-,"0.016 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144533812
rs6817273-<b>T</b>,"5 x 10-17",,0.584,'-,"0.016 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144570851
rs12511230-<b>A</b>,"8 x 10-17",,0.64,'-,"0.016 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144550093
rs36023701-<b>C</b>,"9 x 10-17",,0.639,'-,"0.016 unit decrease",'-,"KRT18P51, EGF","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144544309
rs1051730-<b>A</b>,"1 x 10-16",,0.67,'-,"0.016 unit decrease",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,"Mapping not available"
rs951266-<b>A</b>,"2 x 10-16",,0.596,'-,"0.016 unit decrease",'-,CHRNA5,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78586199
rs1032297-<b>A</b>,"2 x 10-16",,0.408,'-,"0.016 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144513592
rs13118928-<b>A</b>,"3 x 10-16",,0.587,'-,"0.016 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144565237
rs13148031-<b>A</b>,"4 x 10-16",,0.642,'-,"0.016 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144539186
rs1813903-<b>C</b>,"4 x 10-16",,0.641,'-,"0.016 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144556897
rs6842889-<b>T</b>,"4 x 10-16",,0.646,'-,"0.016 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144558728
rs72740964-<b>A</b>,"7 x 10-16",,0.342,'-,"0.016 unit decrease",'-,CHRNA5,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78576294
rs56390833-<b>A</b>,"7 x 10-16",,0.329,'-,"0.016 unit decrease",'-,CHRNA5,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78585039
rs72740955-<b>T</b>,"7 x 10-16",,0.335,'-,"0.016 unit decrease",'-,"PSMA4, CHRNA5","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78557437
rs183813555-<b>T</b>,"2 x 10-6",,0.002,'-,"0.142 unit decrease",'-,FBLN7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:112167619
rs181563674-<b>T</b>,"2 x 10-6",(AA),0.997,'-,"0.165 unit increase",'-,"TOMM20P1, GDPD4","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:77301788
rs150923551-<b>A</b>,"2 x 10-6",(AA),0.997,'-,"0.165 unit increase",'-,GDPD4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:77294895
rs191623547-<b>C</b>,"2 x 10-6",(AA),0.997,'-,"0.199 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:25360086
rs193113980-<b>T</b>,"2 x 10-6",(AA),0.998,'-,"0.297 unit increase",'-,CHIC2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:54023216
rs193058367-<b>A</b>,"2 x 10-6",(AA),0.998,'-,"0.199 unit increase",'-,"LINC02017, CACNA2D3","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:55091110
rs185837131-<b>T</b>,"2 x 10-6",(AA),0.999,'-,"0.453 unit increase",'-,RB1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,13:48455468
rs185011186-<b>A</b>,"2 x 10-6",(AA),0.999,'-,"0.302 unit increase",'-,"HSDL2, C9orf147","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:112400052
rs117660864-<b>G</b>,"2 x 10-6",(AA),0.997,'-,"0.199 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:25337613
rs188061594-<b>T</b>,"2 x 10-6",(AA),0.999,'-,"0.418 unit increase",'-,GALNT11,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,7:152032132
rs191413231-<b>A</b>,"2 x 10-6",(AA),0.999,'-,"0.299 unit increase",'-,GRIN2B,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:13477668
rs144137862-<b>G</b>,"2 x 10-6",(AA),0.998,'-,"0.255 unit increase",'-,HINT1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,5:131105953
rs185095244-<b>A</b>,"2 x 10-6",(AA),1.0,'-,"0.389 unit increase",'-,PTPRD,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:8766114
rs189985091-<b>G</b>,"2 x 10-6",(AA),0.996,'-,"0.137 unit increase",'-,LINC01807,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:228488673
rs192376484-<b>A</b>,"2 x 10-6",(AA),1.0,'-,"0.445 unit increase",'-,"PSMC1P7, SPTSSB","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:161338027
rs142944815-<b>G</b>,"2 x 10-6",(AA),1.0,'-,"0.39 unit increase",'-,PTPRD,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:8773566
rs140682412-<b>C</b>,"2 x 10-6",(AA),1.0,'-,"0.436 unit increase",'-,"MINPP1, RPS26P38","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,10:87572949
rs182302106-<b>G</b>,"2 x 10-6",(AA),0.999,'-,"0.45 unit increase",'-,DLGAP2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,8:1507009
rs188838161-<b>T</b>,"2 x 10-6",(AA),0.999,'-,"0.527 unit increase",'-,"GNG2, OR7E159P","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:51821390
rs187943782-<b>T</b>,"2 x 10-6",(AA),0.994,'-,"0.116 unit increase",'-,MAPRE3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:26982518
rs78589086-<b>C</b>,"2 x 10-6",(AA),0.999,'-,"0.355 unit increase",'-,"RPS26P2, FTLP4","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:30889009
rs186856805-<b>C</b>,"2 x 10-6",(AA),1.0,'-,"0.679 unit increase",'-,UBTD1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,10:97512247
rs2402444-<b>G</b>,"2 x 10-6",(AA),0.907,'-,"0.028 unit increase",'-,"SERPINA10, SERPINA6","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:94299335
rs183456655-<b>G</b>,"2 x 10-6",(AA),0.997,'-,"0.199 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:25341335
rs138641425-<b>A</b>,"2 x 10-6",(AA),0.999,'-,"0.389 unit increase",'-,"FGF12-AS1, FGF12","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:192261578
rs115148171-<b>C</b>,"2 x 10-6",(AA),0.999,'-,"0.359 unit increase",'-,"TSKU, GUCY2EP","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:76730556
rs144190017-<b>T</b>,"2 x 10-7",,0.004,'-,"0.127 unit decrease",'-,OR7K1P,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:25423826
rs144587541-<b>A</b>,"4 x 10-6",,0.004,'-,"0.1 unit decrease",'-,"ARNT2, RNU6-380P","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:80627367
rs138615762-<b>T</b>,"3 x 10-6",,0.01,'-,"0.076 unit decrease",'-,"UBE2G1, SPNS3","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,17:4425017
rs77640143-<b>T</b>,"4 x 10-6",,0.993,'-,"0.057 unit decrease",'-,COL3A1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:188922101
rs111974986-<b>T</b>,"3 x 10-6",,0.012,'-,"0.051 unit decrease",'-,DDX24,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:94067389
rs182700414-<b>T</b>,"4 x 10-6",,0.017,'-,"0.047 unit decrease",'-,BRINP1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:119209492
rs75588466-<b>A</b>,"2 x 10-8",,0.96,'-,"0.046 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144489641
rs112635299-<b>T</b>,"2 x 10-9",,0.02,'-,"0.045 unit decrease",'-,"SERPINA1, SERPINA2","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:94371805
rs17791975-<b>A</b>,"9 x 10-7",,0.981,'-,"0.045 unit decrease",'-,CADM2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:85068884
rs73125111-<b>C</b>,"9 x 10-7",,0.981,'-,"0.045 unit decrease",'-,CADM2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:85061820
rs116155186-<b>T</b>,"3 x 10-6",,0.981,'-,"0.045 unit decrease",'-,CADM2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:85319669
rs17733561-<b>A</b>,"2 x 10-6",,0.981,'-,"0.043 unit decrease",'-,CADM2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:84964010
rs73130739-<b>T</b>,"3 x 10-6",,0.98,'-,"0.043 unit decrease",'-,CADM2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:85238146
rs117172443-<b>T</b>,"2 x 10-6",,0.981,'-,"0.041 unit decrease",'-,"SDK2, LINC00469","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,17:73716977
rs45505795-<b>C</b>,"1 x 10-10",,0.036,'-,"0.039 unit decrease",'-,SERPINA10,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:94290606
rs28929474-<b>T</b>,"1 x 10-8",,0.022,'-,"0.039 unit decrease",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,"Mapping not available"
rs76565382-<b>C</b>,"3 x 10-6",,0.028,'-,"0.034 unit decrease",'-,"GPRIN3, RNU6-907P","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:89183662
rs140607031-<b>A</b>,"2 x 10-6",,0.033,'-,"0.032 unit decrease",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88979901
rs7664805-<b>C</b>,"3 x 10-6",,0.084,'-,"0.028 unit decrease",'-,NPNT,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:105922801
rs17368890-<b>T</b>,"9 x 10-9",,0.934,'-,"0.024 unit decrease",'-,"BOLA3P1, RNU7-159P","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102881870
rs9992239-<b>C</b>,"2 x 10-6",,0.044,'-,"0.023 unit decrease",'-,HERC3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88691722
rs72983521-<b>T</b>,"6 x 10-8",,0.934,'-,"0.022 unit decrease",'-,"MMP12, MMP3","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102859302
rs72985562-<b>T</b>,"1 x 10-6",,0.931,'-,"0.021 unit decrease",'-,"RNU7-159P, MMP13","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102929549
rs190065944-<b>A</b>,"1 x 10-14",,0.268,'-,"0.02 unit decrease",'-,CHRNA5,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78567268
rs192253363-<b>G</b>,"2 x 10-6",(AA),0.998,'-,"0.161 unit increase",'-,"LINC00911, FLRT2","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:85507056
rs138641402-<b>A</b>,"2 x 10-18",,0.67,'-,"0.019 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144524627
rs116540944-<b>G</b>,"2 x 10-6",(AA),0.973,'-,"0.064 unit increase",'-,GRIK3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:36840193
rs185671464-<b>C</b>,"2 x 10-6",(AA),0.999,'-,"0.326 unit increase",'-,LNCAROD,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,10:52727160
rs185836767-<b>C</b>,"2 x 10-6",(AA),0.998,'-,"0.226 unit increase",'-,"SLC37A4, HYOU1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:119042344
rs17026850-<b>C</b>,"2 x 10-6",(AA),0.568,'-,"0.016 unit decrease",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97629722
rs182491339-<b>G</b>,"2 x 10-6",(AA),1.0,'-,"0.581 unit increase",'-,FUT8,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:65583211
rs960450-<b>T</b>,"2 x 10-6",(AA),0.318,'-,"0.016 unit decrease",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97545408
rs78242550-<b>A</b>,"2 x 10-6",(AA),0.999,'-,"0.284 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:28136480
rs71420856-<b>T</b>,"2 x 10-6",(AA),0.999,'-,"0.326 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:128805127
rs186822321-<b>A</b>,"2 x 10-6",(AA),0.999,'-,"0.424 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:129479620
rs186485497-<b>A</b>,"2 x 10-6",(AA),0.999,'-,"0.278 unit increase",'-,GNAS,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,20:58882287
rs730954-<b>A</b>,"2 x 10-6",(AA),0.832,'-,"0.02 unit increase",'-,KIAA0087,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,7:26535047
rs142535958-<b>A</b>,"2 x 10-6",(AA),0.999,'-,"0.43 unit increase",'-,"CEP126, CFAP300","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102005612
rs17438732-<b>G</b>,"2 x 10-6",(AA),0.682,'-,"0.016 unit increase",'-,PRKN,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,6:162414738
rs150432113-<b>G</b>,"3 x 10-6",(AA),0.999,'-,"0.355 unit increase",'-,MCPH1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,8:6606264
rs192264222-<b>T</b>,"3 x 10-6",(AA),0.988,'-,"0.073 unit increase",'-,RNU6-351P,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:104904293
rs192256335-<b>G</b>,"3 x 10-6",(AA),1.0,'-,"0.604 unit increase",'-,RALGPS1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:126963541
rs73838643-<b>T</b>,"3 x 10-6",(AA),0.988,'-,"0.073 unit increase",'-,RNU6-351P,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:104901402
rs73838644-<b>A</b>,"3 x 10-6",(AA),0.988,'-,"0.073 unit increase",'-,RNU6-351P,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:104903977
rs190262953-<b>T</b>,"3 x 10-6",(AA),1.0,'-,"0.427 unit increase",'-,"LINC02823, SCARB1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:91432197
rs190431552-<b>G</b>,"3 x 10-6",(AA),1.0,'-,"0.457 unit increase",'-,"SNORA72, PPM1L","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:160701558
rs188193075-<b>G</b>,"3 x 10-6",(AA),0.998,'-,"0.228 unit increase",'-,"HYOU1, SLC37A4","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:119031413
rs150556575-<b>G</b>,"3 x 10-6",(AA),0.998,'-,"0.228 unit increase",'-,"SLC37A4, HYOU1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:119031528
rs73838646-<b>C</b>,"3 x 10-6",(AA),0.988,'-,"0.073 unit increase",'-,RNU6-351P,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:104913341
rs186821245-<b>C</b>,"3 x 10-6",(AA),0.997,'-,"0.204 unit increase",'-,"VAV2, SARDH","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:133740913
rs191335472-<b>A</b>,"3 x 10-6",(AA),0.999,'-,"0.482 unit increase",'-,"RPL7P2, PDYN-AS1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,20:2061706
rs145368269-<b>C</b>,"3 x 10-6",(AA),0.993,'-,"0.092 unit increase",'-,"FTH1P21, CTSO","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:155966037
rs9599403-<b>A</b>,"3 x 10-6",(AA),0.934,'-,"0.03 unit increase",'-,SNRPFP3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,13:69102202
rs143324395-<b>G</b>,"3 x 10-6",(AA),0.997,'-,"0.18 unit increase",'-,GRID2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:93092840
rs186116546-<b>T</b>,"3 x 10-6",(AA),1.0,'-,"0.559 unit increase",'-,FUT8,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:65519458
rs144152585-<b>A</b>,"3 x 10-6",(AA),1.0,'-,"0.616 unit increase",'-,"IQCJ-SCHIP1, IQCJ","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:159195041
rs73838636-<b>A</b>,"3 x 10-6",(AA),0.988,'-,"0.073 unit increase",'-,RNU6-351P,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:104884939
rs149727148-<b>C</b>,"3 x 10-6",(AA),0.984,'-,"0.075 unit increase",'-,DPP3P2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:73571138
rs143902882-<b>T</b>,"3 x 10-6",(AA),0.993,'-,"0.106 unit increase",'-,ROBO2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:77561056
rs182332476-<b>G</b>,"3 x 10-6",(AA),0.999,'-,"0.283 unit increase",'-,"RPA3P2, RN7SKP256","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,6:53405757
rs74275091-<b>T</b>,"3 x 10-6",(AA),1.0,'-,"0.675 unit increase",'-,"EYA2, RN7SKP33","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,20:46889794
rs1541692-<b>C</b>,"3 x 10-6",(AA),0.327,'-,"0.016 unit decrease",'-,MAF,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,16:79574795
rs59626546-<b>G</b>,"3 x 10-6",(AA),0.954,'-,"0.04 unit increase",'-,WWOX,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,16:78904692
rs116518699-<b>T</b>,"3 x 10-6",(AA),0.988,'-,"0.072 unit increase",'-,"PKP4-AS1, DAPL1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:158785159
rs78736651-<b>A</b>,"3 x 10-6",(AA),0.988,'-,"0.079 unit increase",'-,CXXC4-AS1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:104815102
rs188694422-<b>A</b>,"3 x 10-6",(AA),1.0,'-,"0.633 unit increase",'-,TRIM59,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:160458729
rs191935895-<b>A</b>,"3 x 10-6",(AA),0.999,'-,"0.334 unit increase",'-,RPL23AP54,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,8:5409789
rs191765304-<b>T</b>,"3 x 10-6",(AA),1.0,'-,"0.634 unit increase",'-,TRIM59,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:160458581
rs181309176-<b>T</b>,"3 x 10-6",(AA),0.999,'-,"0.282 unit increase",'-,"ART2P, ART2BP","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:72507928
rs78170588-<b>A</b>,"3 x 10-6",(AA),0.993,'-,"0.096 unit increase",'-,MGAT5,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:134450700
rs139606157-<b>A</b>,"3 x 10-6",(AA),0.992,'-,"0.1 unit increase",'-,ULK4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:41545601
rs73838071-<b>A</b>,"3 x 10-6",(AA),0.997,'-,"0.154 unit increase",'-,TET2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:105275820
rs144872818-<b>T</b>,"3 x 10-6",(AA),0.996,'-,"0.186 unit increase",'-,"VWC2, ZPBP","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,7:49854599
rs145481885-<b>G</b>,"3 x 10-6",(AA),0.991,'-,"0.081 unit increase",'-,"Y_RNA, TMEM200A","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,6:130534326
rs866743-<b>T</b>,"3 x 10-6",(AA),0.383,'-,"0.015 unit decrease",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,6:169028357
rs187260613-<b>A</b>,"3 x 10-6",(AA),0.996,'-,"0.172 unit increase",'-,LINC02345,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:38051807
rs113870173-<b>A</b>,"4 x 10-6",(AA),0.994,'-,"0.119 unit increase",'-,POLR2M,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:57812601
rs182755327-<b>T</b>,"4 x 10-6",(AA),0.999,'-,"0.236 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,13:63550470
rs142206003-<b>A</b>,"4 x 10-6",(AA),0.996,'-,"0.152 unit increase",'-,"LINC01090, GULP1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:188379824
rs116554817-<b>A</b>,"4 x 10-6",(AA),0.998,'-,"0.246 unit increase",'-,"HDAC11-AS1, NUP210","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:13430001
rs2136082-<b>T</b>,"4 x 10-6",(AA),0.625,'-,"0.016 unit decrease",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97630842
rs189158807-<b>T</b>,"4 x 10-6",(AA),0.998,'-,"0.246 unit increase",'-,"NUP210, HDAC11-AS1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:13431318
rs147576484-<b>T</b>,"4 x 10-6",(AA),0.625,'-,"0.016 unit decrease",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97639419
rs146109676-<b>C</b>,"4 x 10-6",(AA),1.0,'-,"0.425 unit increase",'-,PAMR1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:35431829
rs146071159-<b>C</b>,"4 x 10-6",(AA),0.994,'-,"0.12 unit increase",'-,POLR2M,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:57812035
rs187885921-<b>C</b>,"4 x 10-6",(AA),0.999,'-,"0.366 unit increase",'-,"TDGF1P4, FAM50B","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,6:3894081
rs183747217-<b>C</b>,"4 x 10-6",(AA),0.999,'-,"0.394 unit increase",'-,GALNT11,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,7:152043726
rs142936968-<b>T</b>,"4 x 10-6",(AA),0.993,'-,"0.111 unit increase",'-,OCA2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:27979785
rs147130662-<b>C</b>,"4 x 10-6",(AA),0.998,'-,"0.227 unit increase",'-,"RPL10P1, NCSTNP1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,21:27457936
rs115854050-<b>A</b>,"4 x 10-6",(AA),0.996,'-,"0.119 unit increase",'-,CD74,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,5:150404756
rs187460213-<b>G</b>,"4 x 10-6",(AA),0.998,'-,"0.237 unit increase",'-,"DCTN4, SMIM3","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,5:150770273
rs145710351-<b>A</b>,"4 x 10-6",(AA),0.99,'-,"0.076 unit increase",'-,DAPL1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:158820733
rs117932668-<b>A</b>,"4 x 10-6",(AA),0.997,'-,"0.177 unit increase",'-,GRID2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:93094538
rs58724568-<b>A</b>,"4 x 10-6",(AA),0.618,'-,"0.015 unit decrease",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97707609
rs144572046-<b>T</b>,"4 x 10-6",(AA),0.978,'-,"0.054 unit increase",'-,"PRDM11, LINC02685","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:45037580
rs180976407-<b>G</b>,"4 x 10-6",(AA),0.999,'-,"0.319 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,5:45831388
rs182751789-<b>C</b>,"4 x 10-6",(AA),0.997,'-,"0.181 unit increase",'-,MIR217HG,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:55990538
rs184522131-<b>G</b>,"4 x 10-6",(AA),1.0,'-,"0.513 unit increase",'-,DAPK1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:87562606
rs77556290-<b>A</b>,"4 x 10-6",(AA),0.986,'-,"0.074 unit increase",'-,RNU6-351P,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:104959593
rs184759447-<b>T</b>,"4 x 10-6",(AA),0.999,'-,"0.324 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,5:45904254
rs183832949-<b>A</b>,"4 x 10-6",(AA),0.999,'-,"0.49 unit increase",'-,MYL10,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,7:101620046
rs145068833-<b>T</b>,"4 x 10-6",(AA),0.989,'-,"0.076 unit increase",'-,PTPRD,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:9450039
rs13191310-<b>T</b>,"4 x 10-6",(AA),0.304,'-,"0.016 unit decrease",'-,PRKN,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,6:162415264
rs2289936-<b>G</b>,"4 x 10-6",(AA),0.97,'-,"0.047 unit increase",'-,WIF1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:65077687
rs193182884-<b>A</b>,"4 x 10-6",(AA),0.999,'-,"0.541 unit increase",'-,CYSLTR2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,13:48658683
rs73777486-<b>G</b>,"4 x 10-6",(AA),0.976,'-,"0.052 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,5:101065730
rs151274007-<b>C</b>,"4 x 10-6",(AA),1.0,'-,"0.671 unit increase",'-,PACRG,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,6:162757714
rs115855507-<b>A</b>,"4 x 10-6",(AA),0.945,'-,"0.033 unit increase",'-,DPP3P2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:73498902
rs59901031-<b>G</b>,"4 x 10-6",(AA),0.566,'-,"0.015 unit decrease",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97640640
rs72892812-<b>C</b>,"4 x 10-6",(AA),0.618,'-,"0.015 unit decrease",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97659585
rs73777909-<b>C</b>,"4 x 10-6",(AA),0.976,'-,"0.051 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,5:101173291
rs58423913-<b>C</b>,"4 x 10-6",(AA),0.957,'-,"0.038 unit increase",'-,WWOX,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,16:78896840
rs138394018-<b>G</b>,"4 x 10-6",(AA),0.997,'-,"0.162 unit increase",'-,MYO7A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:77209072
rs72890889-<b>A</b>,"4 x 10-6",(AA),0.562,'-,"0.015 unit decrease",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97650378
rs143404520-<b>T</b>,"4 x 10-6",(AA),0.999,'-,"0.258 unit increase",'-,SPOCK1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,5:137070147
rs140065777-<b>T</b>,"4 x 10-6",(AA),0.999,'-,"0.312 unit increase",'-,HCN1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,5:45770380
rs192665745-<b>G</b>,"4 x 10-6",(AA),1.0,'-,"0.672 unit increase",'-,"GAD2, APBB1IP","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,10:26338452
rs181995593-<b>C</b>,"4 x 10-6",(AA),0.998,'-,"0.224 unit increase",'-,KCNIP4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:21881462
rs61012000-<b>T</b>,"4 x 10-6",(AA),0.622,'-,"0.015 unit decrease",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97704089
rs191199264-<b>A</b>,"4 x 10-6",(AA),1.0,'-,"0.492 unit increase",'-,LINC01933,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,5:152021139
rs140014224-<b>G</b>,"4 x 10-6",(AA),1.0,'-,"0.436 unit increase",'-,NMD3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:161238986
rs191540052-<b>A</b>,"4 x 10-6",(AA),0.999,'-,"0.271 unit increase",'-,"MSX1, LDHAP1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:4885387
rs59602504-<b>G</b>,"4 x 10-6",(AA),0.562,'-,"0.015 unit decrease",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97642556
rs190548655-<b>T</b>,"4 x 10-6",(AA),0.999,'-,"0.239 unit increase",'-,"U3, LARS2","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:45346659
rs190057637-<b>T</b>,"4 x 10-6",(AA),0.999,'-,"0.426 unit increase",'-,Y_RNA,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:59472550
rs56945629-<b>T</b>,"4 x 10-6",(AA),0.562,'-,"0.015 unit decrease",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97646488
rs137917644-<b>T</b>,"1 x 10-6",(AA),0.998,'-,"0.225 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:104934188
rs187464554-<b>T</b>,"1 x 10-6",(AA),0.998,'-,"0.225 unit increase",'-,IL12RB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:104934232
rs74838144-<b>A</b>,"1 x 10-6",(AA),0.999,'-,"0.32 unit increase",'-,"FTLP4, HSPA8P17","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:30971371
rs192748541-<b>A</b>,"1 x 10-6",(AA),1.0,'-,"0.434 unit increase",'-,PLAGL1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,6:144052556
rs73839333-<b>A</b>,"2 x 10-6",(AA),0.991,'-,"0.09 unit increase",'-,CXXC4-AS1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:104726945
rs141034416-<b>T</b>,"2 x 10-6",(AA),0.998,'-,"0.181 unit increase",'-,DIRC3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:217352604
rs117000167-<b>G</b>,"2 x 10-6",(AA),1.0,'-,"0.568 unit increase",'-,"TTLL11, TTLL11-IT1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:121916542
rs145613323-<b>A</b>,"5 x 10-6",(AA),0.999,'-,"0.396 unit increase",'-,"CTD-3080P12.3, SLC6A19","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,5:1189559
rs60804385-<b>C</b>,"5 x 10-6",(AA),0.614,'-,"0.015 unit decrease",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97665399
rs189265675-<b>T</b>,"5 x 10-6",(AA),1.0,'-,"0.597 unit increase",'-,VMAC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,19:5907412
rs187730847-<b>G</b>,"5 x 10-6",(AA),0.994,'-,"0.122 unit increase",'-,LYST,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:235862573
rs61734084-<b>G</b>,"5 x 10-6",(AA),0.998,'-,"0.224 unit increase",'-,NBEAL2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:46988740
rs185746565-<b>C</b>,"5 x 10-6",(AA),1.0,'-,"0.554 unit increase",'-,NUP205,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,7:135575301
rs138355804-<b>T</b>,"5 x 10-6",(AA),0.998,'-,"0.291 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:30400627
rs190312121-<b>A</b>,"5 x 10-6",(AA),1.0,'-,"0.764 unit increase",'-,SMPD4P2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,13:19157404
rs59172540-<b>G</b>,"5 x 10-6",(AA),0.614,'-,"0.015 unit decrease",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97660479
rs185609610-<b>G</b>,"5 x 10-6",(AA),0.999,'-,"0.331 unit increase",'-,RNA5SP172,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:177528406
rs182057829-<b>G</b>,"5 x 10-6",(AA),1.0,'-,"0.557 unit increase",'-,Y_RNA,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:97018549
rs143359137-<b>T</b>,"5 x 10-6",(AA),0.999,'-,"0.464 unit increase",'-,STON1-GTF2A1L,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:48615693
rs187497509-<b>G</b>,"5 x 10-6",(AA),1.0,'-,"0.404 unit increase",'-,R3HDML,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,20:44350931
rs144908958-<b>A</b>,"5 x 10-6",(AA),1.0,'-,"0.616 unit increase",'-,ASIC2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,17:33205396
rs7573615-<b>T</b>,"5 x 10-6",(AA),0.542,'-,"0.014 unit decrease",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:52999557
rs76933135-<b>T</b>,"5 x 10-6",(AA),0.975,'-,"0.05 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,5:101121240
rs151181520-<b>T</b>,"5 x 10-6",(AA),0.998,'-,"0.199 unit increase",'-,THEMIS,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,6:127903022
rs191899678-<b>T</b>,"5 x 10-6",(AA),0.987,'-,"0.069 unit increase",'-,LINC01826,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:123166233
rs34664138-<b>T</b>,"4 x 10-9",,0.792,'-,"0.063 unit decrease",NR,"PSMA4, HYKK","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78539282
rs59683676-<b>T</b>,"4 x 10-9",,0.792,'-,"0.063 unit decrease",NR,PSMA4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78541111
rs13329271-<b>A</b>,"4 x 10-9",,0.78,'-,"0.063 unit decrease",NR,"CHRNB4, CHRNA3","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78621888
rs7169584-<b>A</b>,"4 x 10-9",,0.794,'-,"0.063 unit decrease",NR,HYKK,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78530318
rs951984-<b>A</b>,"4 x 10-8",,0.27,'-,"0.063 unit decrease",NR,"IREB2, CRABP1","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78428573
rs8192733-<b>C</b>,"3 x 10-7",,0.431,'-,"0.063 unit decrease",NR,CYP2A6,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,19:40843645
rs4886585-<b>A</b>,"1 x 10-6",,0.31,'-,"0.063 unit decrease",NR,"ADAMTS7, CHRNB4","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78733973
rs1812329-<b>A</b>,"1 x 10-12",,0.466,'-,"0.062 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88948767
rs2869966-<b>T</b>,"1 x 10-12",,0.55,'-,"0.062 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88947927
rs2656065-<b>A</b>,"1 x 10-12",,0.54,'-,"0.062 unit decrease",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78458207
rs2568494-<b>A</b>,"2 x 10-12",,0.545,'-,"0.062 unit decrease",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78448622
rs8039449-<b>T</b>,"2 x 10-11",,0.364,'-,"0.062 unit decrease",NR,"CHRNB4, CHRNA3","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78622192
rs148428208-<b>G</b>,"3 x 10-6",(AA),0.998,'-,"1.173 unit decrease",NR,LINC01350,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:185597419
rs144575900-<b>G</b>,"3 x 10-6",(AA),0.991,'-,"0.469 unit decrease",NR,SRIP1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:58006746
rs139873132-<b>T</b>,"1 x 10-6",(AA),0.984,'-,"0.337 unit decrease",NR,RN7SKP46,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:157831833
rs151121608-<b>G</b>,"8 x 10-7",(AA),0.982,'-,"0.335 unit decrease",NR,ISCA1P1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,5:62840167
rs190817748-<b>A</b>,"3 x 10-6",(AA),0.984,'-,"0.312 unit decrease",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,7:52071882
rs4908799-<b>A</b>,"4 x 10-6",,0.008,'-,"0.293 unit decrease",NR,CA6,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:8970994
rs111588657-<b>A</b>,"4 x 10-6",(AA),0.983,'-,"0.29 unit decrease",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,7:52066107
rs149411586-<b>A</b>,"5 x 10-6",,0.987,'-,"0.25 unit decrease",NR,YWHAH,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,22:31955305
rs140993796-<b>A</b>,"3 x 10-6",,0.01,'-,"0.247 unit decrease",NR,RPL36AP35,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,9:108774076
rs116155186-<b>T</b>,"1 x 10-6",,0.981,'-,"0.225 unit decrease",NR,CADM2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:85319669
rs73125111-<b>C</b>,"1 x 10-6",,0.98,'-,"0.216 unit decrease",NR,CADM2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:85061820
rs17791975-<b>A</b>,"1 x 10-6",,0.98,'-,"0.216 unit decrease",NR,CADM2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:85068884
rs73130739-<b>T</b>,"3 x 10-6",,0.98,'-,"0.208 unit decrease",NR,CADM2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:85238146
rs17733561-<b>A</b>,"3 x 10-6",,0.981,'-,"0.205 unit decrease",NR,CADM2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:84964010
rs75588466-<b>A</b>,"1 x 10-6",,0.96,'-,"0.196 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144489641
rs112635299-<b>T</b>,"3 x 10-7",,0.02,'-,"0.186 unit decrease",NR,"SERPINA1, SERPINA2","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,14:94371805
rs4803370-<b>A</b>,"3 x 10-6",,0.978,'-,"0.166 unit decrease",NR,CYP2T1P,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,19:40812029
rs76565382-<b>C</b>,"4 x 10-6",,0.028,'-,"0.166 unit decrease",NR,"GPRIN3, RNU6-907P","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:89183662
rs147893869-<b>C</b>,"1 x 10-6",,0.978,'-,"0.165 unit decrease",NR,"CYP2T1P, CYP2F2P","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,19:40815169
rs28929474-<b>T</b>,"1 x 10-6",,0.023,'-,"0.162 unit decrease",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,"Mapping not available"
rs149812270-<b>A</b>,"4 x 10-6",,0.981,'-,"0.16 unit decrease",NR,CYP2T1P,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,19:40809421
rs117139969-<b>T</b>,"4 x 10-6",,0.981,'-,"0.159 unit decrease",NR,"RAB4B-EGLN2, EGLN2","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,19:40806017
rs45505795-<b>C</b>,"1 x 10-7",,0.036,'-,"0.155 unit decrease",NR,SERPINA10,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,14:94290606
rs7664805-<b>C</b>,"1 x 10-6",,0.085,'-,"0.141 unit decrease",NR,NPNT,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:105922801
rs17717876-<b>T</b>,"1 x 10-6",,0.043,'-,"0.138 unit decrease",NR,EBF1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,5:159046359
rs113228472-<b>A</b>,"4 x 10-6",,0.04,'-,"0.126 unit decrease",NR,"RN7SKP244, HERC3","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88591861
rs12928939-<b>G</b>,"4 x 10-6",(AA),0.107,'-,"0.118 unit decrease",NR,AP1G1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,16:71766142
rs893239-<b>C</b>,"1 x 10-6",(AA),0.523,'-,"0.117 unit decrease",NR,LFNG,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,7:2525634
rs7741183-<b>C</b>,"4 x 10-7",(AA),0.162,'-,"0.108 unit decrease",NR,SYNE1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,6:152320521
rs4865309-<b>G</b>,"4 x 10-6",(AA),0.76,'-,"0.1 unit decrease",NR,SRIP1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:58178629
rs17368890-<b>T</b>,"2 x 10-6",,0.934,'-,"0.096 unit decrease",NR,"BOLA3P1, RNU7-159P","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:102881870
rs72673889-<b>A</b>,"3 x 10-6",,0.936,'-,"0.094 unit decrease",NR,INTS12,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:105889390
rs72673891-<b>A</b>,"3 x 10-6",,0.936,'-,"0.094 unit decrease",NR,INTS12,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:105893145
rs4076943-<b>T</b>,"2 x 10-7",(AA),0.725,'-,"0.094 unit decrease",NR,MTND5P21,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:11239853
rs72673888-<b>T</b>,"3 x 10-6",,0.936,'-,"0.093 unit decrease",NR,INTS12,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:105887024
rs187455071-<b>A</b>,"3 x 10-6",,0.936,'-,"0.093 unit decrease",NR,INTS12,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:105884727
rs11727735-<b>A</b>,"4 x 10-6",,0.062,'-,"0.092 unit decrease",NR,"GSTCD, INTS12","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:105710713
rs11730660-<b>A</b>,"4 x 10-6",,0.936,'-,"0.092 unit decrease",NR,INTS12,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:105879222
rs12439240-<b>T</b>,"9 x 10-9",,0.778,'-,"0.061 unit decrease",NR,HYKK,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78536749
rs3813570-<b>T</b>,"1 x 10-8",,0.78,'-,"0.061 unit decrease",NR,PSMA4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78540490
rs586701-<b>T</b>,"7 x 10-8",,0.806,'-,"0.061 unit decrease",NR,"MMP12, MMP3","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:102853999
rs1700006-<b>A</b>,"9 x 10-8",,0.812,'-,"0.061 unit decrease",NR,CHRNA5,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78583281
rs67575175-<b>T</b>,"5 x 10-7",,0.843,'-,"0.061 unit decrease",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128161383
rs2687723-<b>C</b>,"5 x 10-7",,0.844,'-,"0.061 unit decrease",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128146716
rs11716941-<b>A</b>,"6 x 10-7",,0.843,'-,"0.061 unit decrease",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128156531
rs6439116-<b>A</b>,"7 x 10-7",,0.844,'-,"0.061 unit decrease",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128130224
rs56328893-<b>A</b>,"7 x 10-7",,0.844,'-,"0.061 unit decrease",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128322987
rs73201462-<b>A</b>,"7 x 10-7",,0.845,'-,"0.061 unit decrease",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128340450
rs11706304-<b>A</b>,"8 x 10-7",,0.845,'-,"0.061 unit decrease",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128331771
rs57735707-<b>T</b>,"8 x 10-7",,0.844,'-,"0.061 unit decrease",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128346972
rs35937742-<b>A</b>,"1 x 10-10",,0.658,'-,"0.06 unit decrease",NR,"TECRL, KRT18P51","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144504697
rs13114851-<b>T</b>,"4 x 10-9",,0.722,'-,"0.06 unit decrease",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144440786
rs57007317-<b>A</b>,"4 x 10-9",,0.722,'-,"0.06 unit decrease",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144433913
rs57901555-<b>T</b>,"5 x 10-9",,0.722,'-,"0.06 unit decrease",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144433760
rs1490151-<b>T</b>,"5 x 10-9",,0.722,'-,"0.06 unit decrease",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144433371
rs12499685-<b>T</b>,"5 x 10-9",,0.725,'-,"0.06 unit decrease",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144445348
rs4337751-<b>T</b>,"9 x 10-8",,0.572,'-,"0.06 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144524173
rs13062252-<b>T</b>,"8 x 10-7",,0.832,'-,"0.06 unit decrease",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128109788
rs2811387-<b>T</b>,"9 x 10-7",,0.84,'-,"0.06 unit decrease",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128296335
rs112321636-<b>T</b>,"2 x 10-6",,0.375,'-,"0.06 unit decrease",NR,ADAMTS7,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78779758
rs2004038-<b>A</b>,"2 x 10-6",,0.377,'-,"0.06 unit decrease",NR,ADAMTS7,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78779064
rs56304346-<b>A</b>,"4 x 10-10",,0.653,'-,"0.059 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144476714
rs12441088-<b>T</b>,"3 x 10-9",,0.369,'-,"0.059 unit decrease",NR,CHRNB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78635922
rs143677104-<b>A</b>,"5 x 10-6",(AA),1.0,'-,"0.562 unit increase",'-,LINC01734,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,20:39164371
rs58864230-<b>T</b>,"5 x 10-6",(AA),0.614,'-,"0.015 unit decrease",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97660843
rs1911792-<b>G</b>,"5 x 10-6",(AA),0.678,'-,"0.016 unit increase",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97585312
rs7662978-<b>C</b>,"5 x 10-6",(AA),0.558,'-,"0.015 unit decrease",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97600266
rs187303806-<b>C</b>,"5 x 10-6",(AA),1.0,'-,"0.432 unit increase",'-,NMD3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:161163687
rs144910173-<b>C</b>,"5 x 10-6",(AA),0.7,'-,"0.017 unit increase",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97539380
rs145688504-<b>T</b>,"5 x 10-6",(AA),0.999,'-,"0.412 unit increase",'-,GRID2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:92783539
rs72889102-<b>G</b>,"5 x 10-6",(AA),0.559,'-,"0.015 unit decrease",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97586061
rs111668083-<b>G</b>,"5 x 10-6",(AA),0.937,'-,"0.036 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:27806558
rs192316701-<b>C</b>,"5 x 10-6",(AA),0.997,'-,"0.163 unit increase",'-,DLGAP2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,8:1507902
rs139509979-<b>G</b>,"5 x 10-6",(AA),0.999,'-,"0.41 unit increase",'-,LARGE1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,22:33189162
rs72889099-<b>G</b>,"5 x 10-6",(AA),0.559,'-,"0.015 unit decrease",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97584287
rs1508459-<b>G</b>,"5 x 10-6",(AA),0.559,'-,"0.015 unit decrease",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97587829
rs139557951-<b>C</b>,"5 x 10-6",(AA),0.999,'-,"0.384 unit increase",'-,GALNT11,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,7:152051389
rs186953828-<b>A</b>,"5 x 10-6",(AA),0.729,'-,"0.018 unit decrease",'-,LINC02196,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,5:7196327
rs61456001-<b>G</b>,"5 x 10-6",(AA),0.559,'-,"0.015 unit decrease",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97588825
rs141955301-<b>T</b>,"5 x 10-6",(AA),1.0,'-,"0.631 unit increase",'-,CACNA1C,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:2249572
rs138071473-<b>T</b>,"5 x 10-6",(AA),1.0,'-,"0.698 unit increase",'-,"PRPF18, FRMD4A","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,10:13631528
rs111563375-<b>T</b>,"5 x 10-6",(AA),1.0,'-,"0.591 unit increase",'-,VMAC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,19:5908751
rs180765220-<b>T</b>,"5 x 10-6",(AA),0.996,'-,"0.168 unit increase",'-,"EFEMP1, RN7SKP208","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:55929425
rs138411828-<b>C</b>,"5 x 10-6",(AA),1.0,'-,"0.684 unit increase",'-,LINC01492,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:103124098
rs146799327-<b>T</b>,"5 x 10-6",(AA),0.996,'-,"0.155 unit increase",'-,TUT1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:62579559
rs146868790-<b>C</b>,"5 x 10-6",(AA),0.999,'-,"0.34 unit increase",'-,"NRL, PCK2","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:24105707
rs1541424-<b>G</b>,"5 x 10-6",(AA),0.161,'-,"0.02 unit decrease",'-,KIAA0087,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,7:26517802
rs147415896-<b>C</b>,"5 x 10-6",(AA),0.994,'-,"0.137 unit increase",'-,SLCO3A1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:92083285
rs188360948-<b>T</b>,"2 x 10-6",(AA),0.949,'-,"0.043 unit decrease",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,13:54740790
rs188657011-<b>A</b>,"2 x 10-6",(AA),0.999,'-,"0.367 unit increase",'-,SUPT3H,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,6:45048787
rs144903619-<b>T</b>,"2 x 10-6",(AA),1.0,'-,"0.621 unit increase",'-,SHANK2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:70499504
rs80328607-<b>T</b>,"2 x 10-6",(AA),0.954,'-,"0.039 unit increase",'-,NXPH1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,7:8412293
rs148738653-<b>T</b>,"2 x 10-6",(AA),0.996,'-,"0.135 unit increase",'-,C2orf16,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:27545546
rs150884133-<b>A</b>,"2 x 10-6",(AA),0.998,'-,"0.226 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:104928578
rs192109529-<b>C</b>,"2 x 10-6",(AA),0.999,'-,"0.371 unit increase",'-,"Metazoa_SRP, NUCKS1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:205710266
rs189693121-<b>A</b>,"2 x 10-6",(AA),0.999,'-,"0.441 unit increase",'-,BUD13,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:116753379
rs143661751-<b>G</b>,"2 x 10-6",(AA),1.0,'-,"0.464 unit increase",'-,ZFHX3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,16:73688392
rs183468661-<b>T</b>,"2 x 10-6",(AA),0.999,'-,"0.388 unit increase",'-,RLF,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:40169170
rs181290688-<b>A</b>,"2 x 10-6",(AA),0.999,'-,"0.441 unit increase",'-,BUD13,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:116753380
rs188526878-<b>T</b>,"2 x 10-6",(AA),1.0,'-,"0.69 unit increase",'-,"F2R, F2RL1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,5:76748557
rs143737902-<b>G</b>,"2 x 10-6",(AA),1.0,'-,"0.617 unit increase",'-,SHANK2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:70474318
rs191378958-<b>G</b>,"2 x 10-6",(AA),0.999,'-,"0.402 unit increase",'-,"HSPA8P17, FTLP4","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:30976708
rs66820110-<b>C</b>,"2 x 10-6",(AA),0.974,'-,"0.05 unit increase",'-,CNTNAP5,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:124684911
rs1454137-<b>A</b>,"2 x 10-6",(AA),0.974,'-,"0.05 unit increase",'-,CNTNAP5,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:124685052
rs142026888-<b>C</b>,"2 x 10-6",(AA),0.598,'-,"0.016 unit decrease",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97635458
rs17011859-<b>G</b>,"2 x 10-6",(AA),0.974,'-,"0.05 unit increase",'-,CNTNAP5,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:124684116
rs17011865-<b>A</b>,"2 x 10-6",(AA),0.974,'-,"0.05 unit increase",'-,CNTNAP5,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:124684636
rs1454139-<b>G</b>,"2 x 10-6",(AA),0.974,'-,"0.049 unit increase",'-,CNTNAP5,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:124682918
rs17011851-<b>A</b>,"2 x 10-6",(AA),0.974,'-,"0.049 unit increase",'-,CNTNAP5,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:124682779
rs115559601-<b>T</b>,"2 x 10-6",(AA),0.993,'-,"0.102 unit increase",'-,CD180,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,5:67223330
rs150029151-<b>A</b>,"2 x 10-6",(AA),1.0,'-,"0.432 unit increase",'-,PLAGL1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,6:144025056
rs72674100-<b>A</b>,"2 x 10-6",(AA),0.943,'-,"0.035 unit increase",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97164138
rs144424757-<b>G</b>,"2 x 10-6",(AA),0.998,'-,"0.234 unit increase",'-,"DLC1, RNU6-842P","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,8:13072284
rs55958997-<b>A</b>,"6 x 10-13",,0.368,'-,"0.066 unit decrease",NR,"CHRNA3, CHRNB4","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78623530
rs6817273-<b>T</b>,"2 x 10-12",,0.583,'-,"0.066 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144570851
rs4887087-<b>T</b>,"2 x 10-8",,0.38,'-,"0.066 unit decrease",NR,"CHRNB4, ADAMTS7","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78734199
rs2869566-<b>T</b>,"2 x 10-8",,0.38,'-,"0.066 unit decrease",NR,"ADAMTS7, CHRNB4","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78734154
rs4886590-<b>A</b>,"2 x 10-7",,0.371,'-,"0.066 unit decrease",NR,ADAMTS7,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78782164
rs11185951-<b>C</b>,"1 x 10-6",,0.146,'-,"0.066 unit decrease",NR,SH2D4B,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,10:80541780
rs973796-<b>A</b>,"8 x 10-12",,0.657,'-,"0.065 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144502816
rs35440220-<b>A</b>,"2 x 10-11",,0.653,'-,"0.065 unit decrease",NR,"HMGB1P44, KRT18P51","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144478680
rs56268708-<b>C</b>,"3 x 10-11",,0.659,'-,"0.065 unit decrease",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144461380
rs1505770-<b>T</b>,"3 x 10-11",,0.658,'-,"0.065 unit decrease",NR,UGT2B7,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144459650
rs17047804-<b>T</b>,"2 x 10-7",,0.845,'-,"0.065 unit decrease",NR,TGFB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:218409436
rs72738736-<b>T</b>,"3 x 10-12",,0.335,'-,"0.064 unit decrease",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78472780
rs17483929-<b>A</b>,"3 x 10-12",,0.596,'-,"0.064 unit decrease",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78450034
rs55983731-<b>T</b>,"3 x 10-12",,0.334,'-,"0.064 unit decrease",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78442927
rs72738718-<b>C</b>,"3 x 10-12",,0.333,'-,"0.064 unit decrease",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78443096
rs11637630-<b>A</b>,"4 x 10-10",,0.762,'-,"0.064 unit decrease",NR,CHRNA3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78607377
rs938682-<b>A</b>,"5 x 10-10",,0.63,'-,"0.064 unit decrease",NR,CHRNA3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78604205
rs28534575-<b>T</b>,"5 x 10-9",,0.779,'-,"0.064 unit decrease",NR,CHRNB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78631503
rs684513-<b>C</b>,"2 x 10-8",,0.806,'-,"0.064 unit decrease",NR,CHRNA5,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78566058
rs36061084-<b>A</b>,"1 x 10-6",,0.402,'-,"0.064 unit decrease",NR,ADAMTS7,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78781911
rs10851907-<b>A</b>,"3 x 10-13",,0.446,'-,"0.063 unit decrease",NR,"CHRNA3, CHRNB4","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78623522
rs1032295-<b>T</b>,"3 x 10-10",,0.581,'-,"0.063 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144513432
rs7163730-<b>A</b>,"3 x 10-9",,0.35,'-,"0.063 unit decrease",NR,HYKK,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78522339
rs12441426-<b>T</b>,"3 x 10-9",,0.793,'-,"0.063 unit decrease",NR,HYKK,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78519987
rs34138960-<b>A</b>,"4 x 10-9",,0.792,'-,"0.063 unit decrease",NR,"PSMA4, HYKK","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78539326
rs2276109-<b>T</b>,"1 x 10-6",,0.887,'-,"0.072 unit decrease",NR,"MMP12, BOLA3P1","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:102875061
rs17368582-<b>T</b>,"1 x 10-6",,0.886,'-,"0.072 unit decrease",NR,MMP12,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:102867344
rs2036527-<b>A</b>,"9 x 10-15",,0.6,'-,"0.071 unit decrease",NR,"PSMA4, CHRNA5","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78559273
rs12504628-<b>T</b>,"9 x 10-14",,0.639,'-,"0.071 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144515172
rs13147758-<b>A</b>,"1 x 10-13",,0.634,'-,"0.071 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144539078
rs11936476-<b>T</b>,"1 x 10-13",,0.634,'-,"0.071 unit decrease",NR,"KRT18P51, MIR5091","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144537332
rs11938745-<b>T</b>,"1 x 10-13",,0.634,'-,"0.071 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144544616
rs720485-<b>A</b>,"1 x 10-13",,0.578,'-,"0.071 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144541436
rs4243084-<b>C</b>,"8 x 10-14",,0.338,'-,"0.07 unit decrease",NR,CHRNA3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78619330
rs2955083-<b>A</b>,"2 x 10-7",,0.882,'-,"0.07 unit decrease",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128242335
rs17368814-<b>A</b>,"3 x 10-6",,0.362,'-,"0.07 unit decrease",NR,"MMP12, BOLA3P1","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:102877965
rs12511230-<b>A</b>,"2 x 10-13",,0.637,'-,"0.069 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144550093
rs36023701-<b>C</b>,"3 x 10-13",,0.637,'-,"0.069 unit decrease",NR,"KRT18P51, EGF","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144544309
rs905739-<b>A</b>,"7 x 10-11",,0.781,'-,"0.069 unit decrease",NR,"CHRNA5, PSMA4","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78552768
rs12440014-<b>C</b>,"3 x 10-10",,0.782,'-,"0.069 unit decrease",NR,CHRNB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78634384
rs11715394-<b>A</b>,"2 x 10-7",,0.882,'-,"0.069 unit decrease",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128174721
rs13148031-<b>A</b>,"5 x 10-13",,0.639,'-,"0.068 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144539186
rs1032297-<b>A</b>,"6 x 10-13",,0.411,'-,"0.068 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144513592
rs6842889-<b>T</b>,"9 x 10-13",,0.643,'-,"0.068 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144558728
rs1489762-<b>T</b>,"9 x 10-13",,0.636,'-,"0.067 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144533812
rs13118928-<b>A</b>,"1 x 10-12",,0.586,'-,"0.067 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144565237
rs1813903-<b>C</b>,"1 x 10-12",,0.639,'-,"0.067 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144556897
rs34265962-<b>A</b>,"3 x 10-12",,0.655,'-,"0.067 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144504784
rs4887109-<b>T</b>,"2 x 10-7",,0.37,'-,"0.067 unit decrease",NR,ADAMTS7,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78781952
rs2999090-<b>A</b>,"4 x 10-7",,0.317,'-,"0.067 unit decrease",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128212497
rs185538822-<b>A</b>,"4 x 10-6",,0.936,'-,"0.092 unit decrease",NR,INTS12,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:105882525
rs75581102-<b>A</b>,"3 x 10-6",,0.064,'-,"0.091 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88804354
rs8079658-<b>A</b>,"5 x 10-6",(AA),0.793,'-,"0.091 unit decrease",NR,CEP112,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,17:65795365
rs77140172-<b>A</b>,"3 x 10-6",,0.064,'-,"0.09 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88796147
rs74811486-<b>T</b>,"3 x 10-6",,0.064,'-,"0.09 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88801349
rs72671826-<b>T</b>,"5 x 10-6",,0.939,'-,"0.09 unit decrease",NR,"ARHGEF38, INTS12","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:105703345
rs190065944-<b>A</b>,"4 x 10-12",,0.27,'-,"0.089 unit decrease",NR,CHRNA5,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78567268
rs112542013-<b>T</b>,"3 x 10-6",,0.063,'-,"0.089 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88797162
rs6847567-<b>T</b>,"3 x 10-6",,0.063,'-,"0.089 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88785771
rs6656288-<b>A</b>,"6 x 10-7",,0.918,'-,"0.088 unit decrease",NR,LINC02869,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:218493087
rs147089648-<b>T</b>,"6 x 10-7",,0.083,'-,"0.087 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88953220
rs72671852-<b>A</b>,"5 x 10-6",,0.939,'-,"0.085 unit decrease",NR,"INTS12, GSTCD","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:105725192
rs56077333-<b>A</b>,"5 x 10-18",,0.318,'-,"0.084 unit decrease",NR,CHRNA3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78606661
rs147144681-<b>T</b>,"6 x 10-17",,0.312,'-,"0.084 unit decrease",NR,CHRNA3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78608566
rs147499554-<b>T</b>,"5 x 10-16",,0.301,'-,"0.084 unit decrease",NR,CHRNA3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78608308
rs138641402-<b>A</b>,"9 x 10-15",,0.668,'-,"0.083 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144524627
rs7526672-<b>T</b>,"6 x 10-8",,0.754,'-,"0.083 unit decrease",NR,LINC02869,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:218472531
rs3971859-<b>T</b>,"3 x 10-7",,0.24,'-,"0.082 unit decrease",NR,"ADAMTS7, CHRNB4","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78733935
rs114205691-<b>T</b>,"1 x 10-17",,0.334,'-,"0.08 unit decrease",NR,CHRNA3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78608771
rs4887067-<b>A</b>,"5 x 10-15",,0.346,'-,"0.079 unit decrease",NR,"CHRNA3, CHRNA5","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78594605
rs12914385-<b>T</b>,"1 x 10-17",,0.626,'-,"0.078 unit decrease",NR,CHRNA3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78606381
rs140330585-<b>A</b>,"1 x 10-15",,0.337,'-,"0.078 unit decrease",NR,CHRNA5,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78574103
rs951266-<b>A</b>,"1 x 10-15",,0.596,'-,"0.078 unit decrease",NR,CHRNA5,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78586199
rs7172118-<b>A</b>,"2 x 10-15",,0.336,'-,"0.078 unit decrease",NR,CHRNA5,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78570111
rs56390833-<b>A</b>,"2 x 10-15",,0.333,'-,"0.078 unit decrease",NR,CHRNA5,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78585039
rs8192482-<b>T</b>,"6 x 10-15",,0.346,'-,"0.078 unit decrease",NR,"CHRNA5, CHRNA3","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78593856
rs16969968-<b>A</b>,"6 x 10-15",,0.578,'-,"0.078 unit decrease",NR,CHRNA5,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78590583
rs72740964-<b>A</b>,"8 x 10-15",,0.344,'-,"0.078 unit decrease",NR,CHRNA5,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78576294
rs12743469-<b>A</b>,"2 x 10-6",,0.896,'-,"0.078 unit decrease",NR,LINC02869,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:218477441
rs78366141-<b>A</b>,"5 x 10-6",,0.096,'-,"0.078 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88882544
rs1051730-<b>A</b>,"2 x 10-15",,0.666,'-,"0.077 unit decrease",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,"Mapping not available"
rs11633958-<b>T</b>,"3 x 10-14",,0.343,'-,"0.077 unit decrease",NR,CHRNA5,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78569722
rs34684276-<b>A</b>,"2 x 10-11",,0.295,'-,"0.077 unit decrease",NR,HYKK,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78520813
rs17487223-<b>T</b>,"2 x 10-14",,0.353,'-,"0.076 unit decrease",NR,CHRNB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78631645
rs667282-<b>T</b>,"9 x 10-10",,0.368,'-,"0.062 unit decrease",NR,CHRNA5,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78571130
rs2036534-<b>T</b>,"6 x 10-9",,0.646,'-,"0.062 unit decrease",NR,HYKK,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78534606
rs4887072-<b>A</b>,"2 x 10-8",,0.779,'-,"0.062 unit decrease",NR,CHRNB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78633093
rs184277845-<b>A</b>,"4 x 10-8",,0.65,'-,"0.062 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144397227
rs8102900-<b>A</b>,"3 x 10-7",,0.619,'-,"0.062 unit decrease",NR,"CYP2A6, CYP2A7","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,19:40861023
rs35804055-<b>A</b>,"4 x 10-7",,0.848,'-,"0.062 unit decrease",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128107736
rs11709725-<b>A</b>,"5 x 10-7",,0.845,'-,"0.062 unit decrease",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128139090
rs34689870-<b>A</b>,"8 x 10-7",,0.848,'-,"0.062 unit decrease",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128141636
rs11709611-<b>T</b>,"9 x 10-7",,0.851,'-,"0.062 unit decrease",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128348432
rs61823428-<b>A</b>,"1 x 10-6",,0.865,'-,"0.062 unit decrease",NR,TGFB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:218398415
rs7674369-<b>A</b>,"2 x 10-12",,0.468,'-,"0.061 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88951025
rs7682317-<b>T</b>,"2 x 10-12",,0.449,'-,"0.061 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88939679
rs1512282-<b>A</b>,"4 x 10-11",,0.34,'-,"0.061 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144510345
rs13142439-<b>A</b>,"4 x 10-9",,0.721,'-,"0.061 unit decrease",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144450284
rs6855812-<b>A</b>,"4 x 10-9",,0.721,'-,"0.061 unit decrease",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144448594
rs4835177-<b>A</b>,"4 x 10-9",,0.581,'-,"0.061 unit decrease",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144352776
rs190169131-<b>G</b>,"1 x 10-6",(AA),0.998,'-,"0.315 unit increase",'-,"RN7SKP121, LINC02712","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:127398707
rs190972371-<b>C</b>,"1 x 10-6",(AA),0.998,'-,"0.22 unit increase",'-,SPINK2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:56814244
rs139704751-<b>T</b>,"1 x 10-6",(AA),1.0,'-,"0.59 unit increase",'-,"TMEM86B, PTPRH","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,19:55224110
rs112458284-<b>C</b>,"1 x 10-6",(AA),0.993,'-,"0.109 unit increase",'-,PPP4R4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:94206394
rs139479025-<b>C</b>,"1 x 10-6",(AA),0.999,'-,"0.374 unit increase",'-,AIFM2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,10:70120545
rs141088253-<b>G</b>,"1 x 10-6",(AA),0.999,'-,"0.384 unit increase",'-,RPL23AP54,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,8:5426774
rs145330511-<b>T</b>,"1 x 10-6",(AA),0.995,'-,"0.127 unit increase",'-,POLR2M,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:57808394
rs77928651-<b>A</b>,"1 x 10-6",(AA),0.999,'-,"0.254 unit increase",'-,BTBD9,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,6:38283599
rs187226391-<b>C</b>,"1 x 10-6",(AA),0.998,'-,"0.228 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:104948564
rs140949321-<b>A</b>,"1 x 10-6",(AA),0.994,'-,"0.127 unit increase",'-,POLR2M,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:57809666
rs141521978-<b>T</b>,"1 x 10-6",(AA),0.996,'-,"0.168 unit increase",'-,SP100,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:230447662
rs186586221-<b>C</b>,"1 x 10-6",(AA),0.999,'-,"0.332 unit increase",'-,KCNC2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:75180543
rs187607716-<b>G</b>,"1 x 10-6",(AA),1.0,'-,"0.451 unit increase",'-,"KERA, LUM","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:91093740
rs139367725-<b>C</b>,"1 x 10-6",(AA),0.69,'-,"0.017 unit increase",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97565435
rs183397371-<b>C</b>,"1 x 10-6",(AA),0.998,'-,"0.231 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:25458903
rs184167040-<b>A</b>,"1 x 10-6",(AA),1.0,'-,"0.544 unit increase",'-,KC6,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,18:41458077
rs148460633-<b>G</b>,"1 x 10-6",(AA),0.63,'-,"0.017 unit decrease",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97635631
rs138869894-<b>A</b>,"1 x 10-6",(AA),1.0,'-,"0.576 unit increase",'-,"IQCJ-SCHIP1, IQCJ","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:159127152
rs111926416-<b>A</b>,"1 x 10-6",(AA),0.999,'-,"0.33 unit increase",'-,LINC02074,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,17:73947436
rs75890985-<b>C</b>,"1 x 10-6",(AA),0.954,'-,"0.039 unit increase",'-,NXPH1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,7:8411282
rs141510725-<b>G</b>,"1 x 10-6",(AA),0.999,'-,"0.32 unit increase",'-,"HSPA8P17, FTLP4","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:30973109
rs138792676-<b>A</b>,"1 x 10-6",(AA),0.999,'-,"0.32 unit increase",'-,"HSPA8P17, FTLP4","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:30973700
rs78797065-<b>C</b>,"1 x 10-6",(AA),0.997,'-,"0.176 unit increase",'-,RN7SL201P,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:81893393
rs184676284-<b>A</b>,"1 x 10-6",(AA),0.999,'-,"0.32 unit increase",'-,"FTLP4, HSPA8P17","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:30972357
rs142487520-<b>C</b>,"1 x 10-6",(AA),0.998,'-,"0.204 unit increase",'-,RNU6-526P,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,8:9416866
rs140444490-<b>C</b>,"1 x 10-6",(AA),0.999,'-,"0.431 unit increase",'-,MGAT4C,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:86467199
rs138833221-<b>A</b>,"1 x 10-6",(AA),0.998,'-,"0.217 unit increase",'-,KIAA0825,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,5:94360594
rs74507156-<b>A</b>,"1 x 10-6",(AA),1.0,'-,"0.454 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:195774530
rs117094540-<b>T</b>,"1 x 10-6",(AA),0.999,'-,"0.35 unit increase",'-,"NPEPL1, STX16-NPEPL1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,20:58695608
rs188500549-<b>A</b>,"1 x 10-6",(AA),1.0,'-,"0.573 unit increase",'-,MAGI1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:65521486
rs184852128-<b>T</b>,"1 x 10-6",(AA),1.0,'-,"0.432 unit increase",'-,LRRC4C,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:40624331
rs184091137-<b>T</b>,"1 x 10-6",(AA),1.0,'-,"0.705 unit increase",'-,LINC01625,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,6:139456693
rs62038064-<b>G</b>,"1 x 10-6",(AA),0.956,'-,"0.042 unit increase",'-,WWOX,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,16:78903855
rs188024766-<b>G</b>,"1 x 10-6",(AA),1.0,'-,"0.377 unit increase",'-,ANO4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:100959756
rs147616082-<b>A</b>,"1 x 10-6",(AA),1.0,'-,"0.764 unit increase",'-,GRIP1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:66788009
rs189340018-<b>C</b>,"1 x 10-6",(AA),1.0,'-,"0.804 unit increase",'-,SETP7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:107234902
rs138402956-<b>C</b>,"1 x 10-6",(AA),0.996,'-,"0.168 unit increase",'-,MIR217HG,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:55970665
rs141892389-<b>A</b>,"1 x 10-6",(AA),0.999,'-,"0.495 unit increase",'-,GALNTL5,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,7:152019626
rs180910263-<b>G</b>,"1 x 10-6",(AA),1.0,'-,"0.625 unit increase",'-,"SHANK2, CTTN","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:70464940
rs192229215-<b>A</b>,"1 x 10-6",(AA),1.0,'-,"0.634 unit increase",'-,SEMA6D,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:47756369
rs182382461-<b>G</b>,"1 x 10-6",(AA),0.999,'-,"0.509 unit increase",'-,PRAMENP,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,22:22004543
rs182328274-<b>T</b>,"1 x 10-6",(AA),1.0,'-,"0.801 unit increase",'-,"SETP7, BTBD11","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:107274025
rs114831632-<b>A</b>,"1 x 10-6",(AA),0.995,'-,"0.122 unit increase",'-,POLR2M,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:57793174
rs192256367-<b>T</b>,"1 x 10-6",(AA),1.0,'-,"0.801 unit increase",'-,SETP7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:107254627
rs184252378-<b>G</b>,"1 x 10-6",(AA),1.0,'-,"1.006 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,16:8072670
rs182115318-<b>T</b>,"1 x 10-6",(AA),0.995,'-,"0.149 unit increase",'-,DOCK5,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,8:25271207
rs149794616-<b>C</b>,"1 x 10-6",(AA),0.999,'-,"0.45 unit increase",'-,PPM1L,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:160837076
rs187206368-<b>A</b>,"1 x 10-6",(AA),0.997,'-,"0.199 unit increase",'-,RBMS3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:29039771
rs192046469-<b>T</b>,"1 x 10-6",(AA),0.999,'-,"0.336 unit increase",'-,"MORF4L2P1, CHIC2","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:54078576
rs140526800-<b>T</b>,"1 x 10-6",(AA),0.995,'-,"0.121 unit increase",'-,POLR2M,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:57797137
rs147410223-<b>G</b>,"7 x 10-7",(AA),0.783,'-,"0.021 unit increase",'-,"NKX3-1, SINHCAFP3","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,8:23649866
rs183755958-<b>T</b>,"7 x 10-7",(AA),1.0,'-,"0.551 unit increase",'-,GNG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:51840760
rs187003284-<b>T</b>,"7 x 10-7",(AA),1.0,'-,"0.545 unit increase",'-,MGAT4C,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:86205087
rs185677526-<b>T</b>,"7 x 10-7",(AA),0.998,'-,"0.183 unit increase",'-,"FLRT2, LINC00911","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:85475717
rs183029213-<b>C</b>,"8 x 10-7",(AA),0.997,'-,"0.209 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:25395087
rs56804048-<b>C</b>,"8 x 10-7",(AA),0.99,'-,"0.089 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,6:120154438
rs141475580-<b>A</b>,"8 x 10-7",(AA),0.999,'-,"0.416 unit increase",'-,"TMEM200C, L3MBTL4","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,18:5936482
rs191356286-<b>C</b>,"8 x 10-7",(AA),0.997,'-,"0.174 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:82098692
rs141318925-<b>C</b>,"8 x 10-7",(AA),1.0,'-,"0.459 unit increase",'-,RN7SL282P,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,18:6623041
rs185898158-<b>A</b>,"8 x 10-7",(AA),1.0,'-,"0.5 unit increase",'-,"KRT8P31, ELOVL7","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,5:60746670
rs186947746-<b>A</b>,"8 x 10-7",(AA),1.0,'-,"0.498 unit increase",'-,"KRT8P31, DEPDC1B","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,5:60736451
rs189326995-<b>C</b>,"8 x 10-7",(AA),0.999,'-,"0.443 unit increase",'-,FGF12,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:192657709
rs17785414-<b>A</b>,"8 x 10-7",(AA),0.999,'-,"0.337 unit increase",'-,"RPS26P2, FTLP4","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:30916632
rs188593748-<b>A</b>,"8 x 10-7",(AA),0.999,'-,"0.451 unit increase",'-,PNPLA8,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,7:108516778
rs72877580-<b>G</b>,"8 x 10-7",(AA),0.653,'-,"0.017 unit decrease",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97708348
rs182554582-<b>A</b>,"8 x 10-7",(AA),0.999,'-,"0.433 unit increase",'-,"GRID1, WAPL","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,10:86435202
rs142991058-<b>G</b>,"8 x 10-7",(AA),0.996,'-,"0.15 unit increase",'-,KCTD2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,17:75050075
rs147510300-<b>G</b>,"8 x 10-7",(AA),1.0,'-,"0.498 unit increase",'-,"NTS, MGAT4C","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:85924770
rs142916547-<b>G</b>,"8 x 10-7",(AA),0.999,'-,"0.422 unit increase",'-,CYCSP39,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,16:25489121
rs150696478-<b>A</b>,"8 x 10-7",(AA),1.0,'-,"0.498 unit increase",'-,"MGAT4C, NTS","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:85927609
rs186361153-<b>G</b>,"9 x 10-7",(AA),1.0,'-,"0.489 unit increase",'-,RIPOR2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,6:24992134
rs118152513-<b>C</b>,"9 x 10-7",(AA),0.999,'-,"0.349 unit increase",'-,ANO4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:100790474
rs186147679-<b>A</b>,"9 x 10-7",(AA),0.998,'-,"0.221 unit increase",'-,KIAA0825,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,5:94373417
rs186819721-<b>A</b>,"9 x 10-7",(AA),0.996,'-,"0.186 unit increase",'-,MIR217HG,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:55970017
rs183825572-<b>A</b>,"9 x 10-7",(AA),1.0,'-,"0.379 unit increase",'-,ANO4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:100871067
rs183974900-<b>G</b>,"1 x 10-6",(AA),0.999,'-,"0.398 unit increase",'-,MIR100HG,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:122398906
rs186699656-<b>T</b>,"1 x 10-6",(AA),0.999,'-,"0.239 unit increase",'-,LINC01095,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:146119791
rs143976741-<b>G</b>,"1 x 10-6",(AA),0.999,'-,"0.32 unit increase",'-,"FTLP4, HSPA8P17","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:30966397
rs73838638-<b>G</b>,"1 x 10-6",(AA),0.994,'-,"0.104 unit increase",'-,RNU6-351P,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:104890543
rs189431351-<b>T</b>,"1 x 10-6",(AA),0.999,'-,"0.359 unit increase",'-,OFCC1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,6:10195190
rs142965926-<b>G</b>,"1 x 10-6",(AA),0.996,'-,"0.189 unit increase",'-,"VAV2, SARDH","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:133753006
rs1585775-<b>T</b>,"1 x 10-6",(AA),0.022,'-,"0.052 unit decrease",'-,ZPLD1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:102280281
rs77902874-<b>A</b>,"1 x 10-6",(AA),0.957,'-,"0.043 unit increase",'-,"MS4A1, MS4A12","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:60483872
rs138833465-<b>G</b>,"1 x 10-6",(AA),0.992,'-,"0.12 unit increase",'-,"PRELID3BP1, XRCC6P3","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:220411530
rs191926782-<b>A</b>,"1 x 10-6",(AA),0.998,'-,"0.166 unit increase",'-,"FLRT2, LINC00911","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:85489827
rs190486114-<b>A</b>,"1 x 10-6",(AA),0.996,'-,"0.184 unit increase",'-,"MIR217HG, RN7SKP208","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:55955794
rs77628219-<b>G</b>,"1 x 10-6",(AA),0.999,'-,"0.277 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:87010353
rs72890850-<b>G</b>,"1 x 10-6",(AA),0.57,'-,"0.017 unit decrease",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97615952
rs147134271-<b>G</b>,"1 x 10-6",(AA),0.998,'-,"0.231 unit increase",'-,HYOU1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:119053427
rs192210795-<b>T</b>,"1 x 10-6",(AA),1.0,'-,"0.542 unit increase",'-,KALRN,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:124201267
rs114304737-<b>A</b>,"1 x 10-6",(AA),0.997,'-,"0.159 unit increase",'-,LINC02795,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:86265746
rs142422697-<b>C</b>,"1 x 10-6",(AA),0.996,'-,"0.189 unit increase",'-,ZPBP,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,7:49925695
rs146002062-<b>G</b>,"1 x 10-6",(AA),0.991,'-,"0.12 unit increase",'-,MAST4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,5:66990321
rs146255527-<b>T</b>,"1 x 10-6",(AA),0.997,'-,"0.233 unit increase",'-,PPM1E,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,17:58873207
rs182408739-<b>C</b>,"1 x 10-6",(AA),0.999,'-,"0.299 unit increase",'-,MSRB3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:65332869
rs139530741-<b>G</b>,"1 x 10-6",(AA),0.993,'-,"0.111 unit increase",'-,CLNS1A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:77555551
rs138387343-<b>C</b>,"1 x 10-6",(AA),0.997,'-,"0.232 unit increase",'-,"PPM1E, TRIM37","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,17:58983272
rs186171056-<b>T</b>,"1 x 10-6",(AA),1.0,'-,"0.349 unit increase",'-,"TBX4, NACA2","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,17:61528728
rs12642926-<b>A</b>,"1 x 10-6",(AA),0.69,'-,"0.017 unit increase",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97568217
rs893239-<b>C</b>,"1 x 10-6",(AA),0.523,'-,"0.023 unit decrease",'-,LFNG,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,7:2525634
rs7941140-<b>T</b>,"9 x 10-7",(AA),0.909,'-,"0.027 unit increase",'-,"SIK3, PAFAH1B2","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:117126045
rs188240612-<b>A</b>,"9 x 10-7",(AA),0.999,'-,"0.487 unit increase",'-,CFAP300,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102073763
rs142119409-<b>C</b>,"9 x 10-7",(AA),0.999,'-,"0.308 unit increase",'-,"CYP4F9P, LINC00661","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,19:16005621
rs1434432-<b>C</b>,"9 x 10-7",(AA),0.628,'-,"0.017 unit increase",'-,LINC00856,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,10:78637093
rs143639284-<b>A</b>,"9 x 10-7",(AA),0.999,'-,"0.468 unit increase",'-,INSL6,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:5140958
rs17785420-<b>G</b>,"9 x 10-7",(AA),0.999,'-,"0.334 unit increase",'-,"FTLP4, RPS26P2","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:30920640
rs2391283-<b>A</b>,"9 x 10-7",(AA),0.156,'-,"0.021 unit decrease",'-,KIAA0087,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,7:26530640
rs139048350-<b>A</b>,"9 x 10-7",(AA),0.999,'-,"0.331 unit increase",'-,"FTLP4, RPS26P2","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:30926855
rs192568883-<b>T</b>,"9 x 10-7",(AA),1.0,'-,"0.809 unit increase",'-,SETP7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:107212348
rs117041046-<b>C</b>,"9 x 10-7",(AA),0.999,'-,"0.309 unit increase",'-,GNAS,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,20:58907185
rs76187983-<b>G</b>,"9 x 10-7",(AA),0.987,'-,"0.079 unit increase",'-,RNU6-351P,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:104931965
rs188006861-<b>A</b>,"9 x 10-7",(AA),0.991,'-,"0.096 unit increase",'-,AFAP1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:7849116
rs61068760-<b>G</b>,"9 x 10-7",(AA),0.987,'-,"0.079 unit increase",'-,RNU6-351P,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:104930719
rs138549889-<b>T</b>,"9 x 10-7",(AA),0.999,'-,"0.331 unit increase",'-,"RPS26P2, FTLP4","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:30928041
rs145444918-<b>A</b>,"1 x 10-6",(AA),0.999,'-,"0.328 unit increase",'-,FTLP4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:30934831
rs184557780-<b>T</b>,"1 x 10-6",(AA),0.999,'-,"0.32 unit increase",'-,"HSPA8P17, FTLP4","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:30953078
rs2047925-<b>C</b>,"1 x 10-6",(AA),0.958,'-,"0.042 unit increase",'-,WWOX,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,16:78902011
rs188120168-<b>C</b>,"1 x 10-6",(AA),0.998,'-,"0.23 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:25442020
rs75214736-<b>C</b>,"1 x 10-6",(AA),0.999,'-,"0.32 unit increase",'-,"HSPA8P17, FTLP4","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:30953853
rs142054194-<b>T</b>,"1 x 10-6",(AA),0.999,'-,"0.43 unit increase",'-,MGAT4C,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:86470463
rs151101851-<b>G</b>,"1 x 10-6",(AA),0.999,'-,"0.32 unit increase",'-,"FTLP4, HSPA8P17","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:30955026
rs181710595-<b>G</b>,"1 x 10-6",(AA),0.999,'-,"0.433 unit increase",'-,CDH13,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,16:83433739
rs151321188-<b>G</b>,"1 x 10-6",(AA),0.999,'-,"0.32 unit increase",'-,"HSPA8P17, FTLP4","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:30957907
rs146103351-<b>A</b>,"1 x 10-6",(AA),0.996,'-,"0.167 unit increase",'-,PAK1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:77322906
rs143053231-<b>G</b>,"1 x 10-6",(AA),1.0,'-,"0.415 unit increase",'-,ITGA7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:55697248
rs7715474-<b>T</b>,"3 x 10-6",,0.477,'-,"0.008 unit decrease",'-,RNU4-69P,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,5:120809073
rs13149750-<b>A</b>,"3 x 10-6",,0.57,'-,"0.008 unit decrease",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88933843
rs34375054-<b>A</b>,"4 x 10-6",,0.626,'-,"0.008 unit decrease",'-,"TMEM132B, AACS","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:125181350
rs1619599-<b>A</b>,"4 x 10-6",,0.601,'-,"0.008 unit decrease",'-,"TSEN2, PPARG","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:12462791
rs1699346-<b>A</b>,"4 x 10-6",,0.601,'-,"0.008 unit decrease",'-,"TSEN2, PPARG","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:12462796
rs10008568-<b>A</b>,"5 x 10-6",,0.57,'-,"0.008 unit decrease",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88933041
rs7690839-<b>A</b>,"5 x 10-6",,0.573,'-,"0.008 unit decrease",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88898173
rs2427345-<b>T</b>,"3 x 10-6",,0.593,'-,"0.008 unit increase",'-,"GATA5, RBBP8NL","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,20:62440555
rs4693974-<b>A</b>,"4 x 10-6",,0.428,'-,"0.008 unit increase",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88889244
rs11857532-<b>T</b>,"5 x 10-6",,0.519,'-,"0.008 unit increase",'-,CHRNB4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78675926
rs4693978-<b>A</b>,"5 x 10-6",,0.428,'-,"0.008 unit increase",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88933016
rs3009947-<b>T</b>,"9 x 10-8",,0.478,'-,"0.009 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218515813
rs4887057-<b>A</b>,"4 x 10-7",,0.425,'-,"0.009 unit increase",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78468576
rs1795720-<b>T</b>,"4 x 10-7",,0.531,'-,"0.009 unit increase",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:89008103
rs6852928-<b>T</b>,"4 x 10-7",,0.531,'-,"0.009 unit increase",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:89005042
rs2178586-<b>T</b>,"5 x 10-7",,0.532,'-,"0.009 unit increase",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:89004169
rs6823536-<b>T</b>,"5 x 10-7",,0.531,'-,"0.009 unit increase",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:89007381
rs6666381-<b>A</b>,"8 x 10-7",,0.377,'-,"0.009 unit increase",'-,"LINC02869, TGFB2","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218454682
rs6495314-<b>A</b>,"1 x 10-6",,0.39,'-,"0.009 unit increase",'-,CHRNB4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78668187
rs1473527-<b>A</b>,"2 x 10-6",,0.508,'-,"0.009 unit increase",'-,"LINC02869, TGFB2","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218448977
rs7661046-<b>T</b>,"4 x 10-6",,0.662,'-,"0.009 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144339343
rs11466399-<b>A</b>,"5 x 10-6",,0.337,'-,"0.009 unit increase",'-,TGFB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218418281
rs6845536-<b>T</b>,"7 x 10-9",,0.405,'-,"0.01 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144531631
rs3857043-<b>T</b>,"8 x 10-9",,0.414,'-,"0.01 unit increase",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88961439
rs1489761-<b>A</b>,"1 x 10-8",,0.602,'-,"0.01 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144534339
rs28455964-<b>T</b>,"2 x 10-8",,0.619,'-,"0.01 unit increase",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88849758
rs4886580-<b>T</b>,"2 x 10-8",,0.598,'-,"0.01 unit increase",'-,CHRNB4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78677043
rs1964678-<b>A</b>,"4 x 10-8",,0.458,'-,"0.01 unit increase",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78461658
rs7674469-<b>A</b>,"4 x 10-8",,0.608,'-,"0.01 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144536849
rs6537297-<b>T</b>,"6 x 10-8",,0.62,'-,"0.01 unit increase",'-,"HHIP-AS1, KRT18P51","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144580877
rs6657698-<b>A</b>,"6 x 10-8",,0.412,'-,"0.01 unit increase",'-,"LINC02869, TGFB2","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218449933
rs8043227-<b>C</b>,"6 x 10-8",,0.456,'-,"0.01 unit increase",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78476529
rs1797070-<b>A</b>,"7 x 10-8",,0.293,'-,"0.01 unit increase",'-,"LINC02869, TGFB2","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218456859
rs12593229-<b>T</b>,"7 x 10-8",,0.456,'-,"0.01 unit increase",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78472948
rs72736802-<b>A</b>,"8 x 10-8",,0.595,'-,"0.01 unit increase",'-,"CRABP1, IREB2","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78427159
rs13106167-<b>T</b>,"8 x 10-8",,0.432,'-,"0.01 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144308558
rs6830970-<b>A</b>,"8 x 10-8",,0.378,'-,"0.01 unit increase",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88855930
rs8042260-<b>A</b>,"9 x 10-8",,0.456,'-,"0.01 unit increase",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78482032
rs4693976-<b>T</b>,"9 x 10-8",,0.425,'-,"0.01 unit increase",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88918689
rs6666438-<b>T</b>,"1 x 10-7",,0.531,'-,"0.01 unit increase",'-,U3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218564761
rs12899351-<b>T</b>,"1 x 10-7",,0.457,'-,"0.01 unit increase",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78500056
rs12916801-<b>A</b>,"1 x 10-7",,0.459,'-,"0.01 unit increase",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78476788
rs28529050-<b>A</b>,"1 x 10-7",,0.697,'-,"0.01 unit increase",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88899639
rs7668636-<b>T</b>,"1 x 10-7",,0.696,'-,"0.01 unit increase",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88898156
rs4846483-<b>A</b>,"1 x 10-7",,0.59,'-,"0.01 unit increase",'-,"LINC02869, TGFB2","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218459026
rs62308746-<b>T</b>,"1 x 10-7",,0.7,'-,"0.01 unit increase",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88884818
rs6843820-<b>C</b>,"2 x 10-7",,0.582,'-,"0.01 unit increase",'-,"KRT18P51, MANBA","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144531552
rs622912-<b>T</b>,"2 x 10-7",,0.547,'-,"0.01 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218497015
rs6835019-<b>A</b>,"2 x 10-7",,0.721,'-,"0.01 unit increase",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88926504
rs7177699-<b>T</b>,"2 x 10-7",,0.409,'-,"0.01 unit increase",'-,ADAMTS7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78797392
rs2999090-<b>A</b>,"3 x 10-6",,0.318,'-,"0.013 unit decrease",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128212497
rs7674369-<b>A</b>,"2 x 10-12",,0.472,'-,"0.012 unit decrease",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88951025
rs10851907-<b>A</b>,"2 x 10-12",,0.445,'-,"0.012 unit decrease",'-,"CHRNA3, CHRNB4","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78623522
rs2869966-<b>T</b>,"2 x 10-12",,0.55,'-,"0.012 unit decrease",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88947927
rs7682317-<b>T</b>,"2 x 10-12",,0.451,'-,"0.012 unit decrease",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88939679
rs1812329-<b>A</b>,"2 x 10-12",,0.468,'-,"0.012 unit decrease",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88948767
rs6831503-<b>A</b>,"2 x 10-12",,0.578,'-,"0.012 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144550793
rs11100860-<b>A</b>,"3 x 10-12",,0.579,'-,"0.012 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144557987
rs1828591-<b>A</b>,"3 x 10-12",,0.534,'-,"0.012 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144559628
rs6830832-<b>T</b>,"3 x 10-12",,0.576,'-,"0.012 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144544339
rs2045517-<b>T</b>,"6 x 10-12",,0.485,'-,"0.012 unit decrease",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88949813
rs1512282-<b>A</b>,"7 x 10-11",,0.338,'-,"0.012 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144510345
rs35937742-<b>A</b>,"1 x 10-10",,0.66,'-,"0.012 unit decrease",'-,"TECRL, KRT18P51","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144504697
rs17483929-<b>A</b>,"2 x 10-10",,0.597,'-,"0.012 unit decrease",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78450034
rs7677035-<b>A</b>,"2 x 10-10",,0.572,'-,"0.012 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144516167
rs72738736-<b>T</b>,"3 x 10-10",,0.332,'-,"0.012 unit decrease",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78472780
rs55983731-<b>T</b>,"3 x 10-10",,0.33,'-,"0.012 unit decrease",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78442927
rs72738718-<b>C</b>,"3 x 10-10",,0.329,'-,"0.012 unit decrease",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78443096
rs62334702-<b>A</b>,"2 x 10-9",,0.727,'-,"0.012 unit decrease",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144385151
rs1542726-<b>A</b>,"3 x 10-9",,0.372,'-,"0.012 unit decrease",'-,"HHIP-AS1, KRT18P51","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144594617
rs2170311-<b>A</b>,"3 x 10-9",,0.376,'-,"0.012 unit decrease",'-,CHRNB4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78655269
rs4887077-<b>T</b>,"6 x 10-9",,0.428,'-,"0.012 unit decrease",'-,CHRNB4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78686022
rs938682-<b>A</b>,"2 x 10-8",,0.629,'-,"0.012 unit decrease",'-,CHRNA3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78604205
rs11637630-<b>A</b>,"2 x 10-8",,0.76,'-,"0.012 unit decrease",'-,CHRNA3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78607377
rs905739-<b>A</b>,"3 x 10-8",,0.781,'-,"0.012 unit decrease",'-,"CHRNA5, PSMA4","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78552768
rs11709725-<b>A</b>,"1 x 10-6",,0.843,'-,"0.012 unit decrease",'-,RUVBL1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128139090
rs12047243-<b>A</b>,"2 x 10-6",,0.836,'-,"0.012 unit decrease",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218511498
rs12045026-<b>T</b>,"2 x 10-6",,0.827,'-,"0.012 unit decrease",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218512653
rs12025970-<b>A</b>,"2 x 10-6",,0.83,'-,"0.012 unit decrease",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218518160
rs67575175-<b>T</b>,"2 x 10-6",,0.84,'-,"0.012 unit decrease",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128161383
rs2811392-<b>A</b>,"2 x 10-6",,0.834,'-,"0.012 unit decrease",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128305133
rs2687723-<b>C</b>,"2 x 10-6",,0.843,'-,"0.012 unit decrease",'-,RUVBL1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128146716
rs11716941-<b>A</b>,"2 x 10-6",,0.841,'-,"0.012 unit decrease",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128156531
rs12022110-<b>A</b>,"2 x 10-6",,0.83,'-,"0.012 unit decrease",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218514453
rs4357586-<b>T</b>,"2 x 10-6",,0.83,'-,"0.012 unit decrease",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218516032
rs6604623-<b>A</b>,"2 x 10-6",,0.83,'-,"0.012 unit decrease",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218515494
rs72738857-<b>T</b>,"2 x 10-6",,0.83,'-,"0.012 unit decrease",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218512377
rs4886586-<b>A</b>,"2 x 10-6",,0.352,'-,"0.012 unit decrease",'-,"ADAMTS7, CHRNB4","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78734332
rs17014483-<b>T</b>,"2 x 10-6",,0.674,'-,"0.012 unit decrease",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88746440
rs34689870-<b>A</b>,"2 x 10-6",,0.846,'-,"0.012 unit decrease",'-,RUVBL1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128141636
rs72738843-<b>T</b>,"2 x 10-6",,0.832,'-,"0.012 unit decrease",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218500894
rs12048013-<b>A</b>,"2 x 10-6",,0.828,'-,"0.012 unit decrease",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218511789
rs6439116-<b>A</b>,"2 x 10-6",,0.843,'-,"0.012 unit decrease",'-,RUVBL1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128130224
rs72987546-<b>T</b>,"2 x 10-6",,0.831,'-,"0.012 unit decrease",'-,"MMP13, DCUN1D5","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102965751
rs7532546-<b>A</b>,"3 x 10-6",,0.834,'-,"0.012 unit decrease",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218510186
rs72987535-<b>T</b>,"3 x 10-6",,0.824,'-,"0.012 unit decrease",'-,"DCUN1D5, MMP13","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102964311
rs8192733-<b>C</b>,"3 x 10-6",,0.428,'-,"0.012 unit decrease",'-,CYP2A6,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,19:40843645
rs12044802-<b>T</b>,"4 x 10-6",,0.84,'-,"0.012 unit decrease",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218512033
rs2013701-<b>T</b>,"1 x 10-10",,0.514,'-,"0.011 unit decrease",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88963935
rs7671167-<b>T</b>,"2 x 10-10",,0.467,'-,"0.011 unit decrease",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88962828
rs1032295-<b>T</b>,"3 x 10-12",,0.582,'-,"0.014 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144513432
rs6855812-<b>A</b>,"1 x 10-11",,0.724,'-,"0.014 unit decrease",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144448594
rs13142439-<b>A</b>,"1 x 10-11",,0.723,'-,"0.014 unit decrease",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144450284
rs13114851-<b>T</b>,"1 x 10-11",,0.725,'-,"0.014 unit decrease",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144440786
rs6834183-<b>T</b>,"2 x 10-11",,0.727,'-,"0.014 unit decrease",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144349803
rs56268708-<b>C</b>,"2 x 10-11",,0.662,'-,"0.014 unit decrease",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144461380
rs1490151-<b>T</b>,"2 x 10-11",,0.724,'-,"0.014 unit decrease",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144433371
rs57007317-<b>A</b>,"2 x 10-11",,0.725,'-,"0.014 unit decrease",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144433913
rs57901555-<b>T</b>,"2 x 10-11",,0.725,'-,"0.014 unit decrease",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144433760
rs12499685-<b>T</b>,"2 x 10-11",,0.727,'-,"0.014 unit decrease",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144445348
rs17766287-<b>T</b>,"2 x 10-11",,0.273,'-,"0.014 unit decrease",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144357685
rs12500355-<b>T</b>,"9 x 10-11",,0.725,'-,"0.014 unit decrease",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144400670
rs586701-<b>T</b>,"1 x 10-9",,0.805,'-,"0.014 unit decrease",'-,"MMP12, MMP3","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102853999
rs754388-<b>C</b>,"6 x 10-9",,0.829,'-,"0.014 unit decrease",'-,RIN3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:92649065
rs2869566-<b>T</b>,"2 x 10-8",,0.379,'-,"0.014 unit decrease",'-,"ADAMTS7, CHRNB4","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78734154
rs8102900-<b>A</b>,"3 x 10-8",,0.617,'-,"0.014 unit decrease",'-,"CYP2A6, CYP2A7","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,19:40861023
rs4887087-<b>T</b>,"3 x 10-8",,0.376,'-,"0.014 unit decrease",'-,"CHRNB4, ADAMTS7","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78734199
rs17047804-<b>T</b>,"3 x 10-8",,0.842,'-,"0.014 unit decrease",'-,TGFB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218409436
rs4886590-<b>A</b>,"7 x 10-8",,0.369,'-,"0.014 unit decrease",'-,ADAMTS7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78782164
rs4887109-<b>T</b>,"9 x 10-8",,0.367,'-,"0.014 unit decrease",'-,ADAMTS7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78781952
rs72699804-<b>A</b>,"1 x 10-7",,0.842,'-,"0.014 unit decrease",'-,RIN3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:92605461
rs35629566-<b>C</b>,"1 x 10-7",,0.842,'-,"0.014 unit decrease",'-,RIN3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:92605972
rs72697297-<b>T</b>,"1 x 10-7",,0.843,'-,"0.014 unit decrease",'-,RIN3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:92603644
rs8010344-<b>A</b>,"2 x 10-7",,0.844,'-,"0.014 unit decrease",'-,RIN3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:92620573
rs36061084-<b>A</b>,"2 x 10-7",,0.398,'-,"0.014 unit decrease",'-,ADAMTS7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78781911
rs2656065-<b>A</b>,"4 x 10-10",,0.538,'-,"0.011 unit decrease",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78458207
rs7681384-<b>T</b>,"6 x 10-10",,0.411,'-,"0.011 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144515862
rs2568494-<b>A</b>,"1 x 10-9",,0.542,'-,"0.011 unit decrease",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78448622
rs13107186-<b>A</b>,"1 x 10-9",,0.4,'-,"0.011 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144522887
rs1512285-<b>A</b>,"2 x 10-9",,0.425,'-,"0.011 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144529807
rs4835637-<b>A</b>,"2 x 10-9",,0.394,'-,"0.011 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144517875
rs12904234-<b>T</b>,"4 x 10-9",,0.562,'-,"0.011 unit decrease",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78487042
rs143379756-<b>A</b>,"5 x 10-9",,0.402,'-,"0.011 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144526014
rs6821114-<b>A</b>,"6 x 10-9",,0.392,'-,"0.011 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144531237
rs7670758-<b>A</b>,"6 x 10-9",,0.626,'-,"0.011 unit decrease",'-,"HHIP-AS1, KRT18P51","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144590723
rs11639372-<b>T</b>,"9 x 10-9",,0.381,'-,"0.011 unit decrease",'-,CHRNB4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78674313
rs11072791-<b>A</b>,"1 x 10-8",,0.389,'-,"0.011 unit decrease",'-,CHRNB4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78704734
rs12592111-<b>A</b>,"1 x 10-8",,0.529,'-,"0.011 unit decrease",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78475004
rs1021071-<b>C</b>,"1 x 10-8",,0.389,'-,"0.011 unit decrease",'-,CHRNB4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78675837
rs12901913-<b>T</b>,"1 x 10-8",,0.39,'-,"0.011 unit decrease",'-,CHRNB4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78689006
rs922692-<b>A</b>,"1 x 10-8",,0.389,'-,"0.011 unit decrease",'-,CHRNB4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78691872
rs11072790-<b>T</b>,"2 x 10-8",,0.385,'-,"0.011 unit decrease",'-,CHRNB4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78699683
rs12910627-<b>C</b>,"2 x 10-8",,0.385,'-,"0.011 unit decrease",'-,CHRNB4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78702591
rs1032296-<b>T</b>,"2 x 10-8",,0.586,'-,"0.011 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144513536
rs11638372-<b>T</b>,"2 x 10-8",,0.423,'-,"0.011 unit decrease",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,"Mapping not available"
rs11638830-<b>C</b>,"2 x 10-8",,0.387,'-,"0.011 unit decrease",'-,CHRNB4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78655977
rs4846480-<b>A</b>,"2 x 10-8",,0.713,'-,"0.011 unit decrease",'-,TGFB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218425127
rs11072785-<b>T</b>,"3 x 10-8",,0.386,'-,"0.011 unit decrease",'-,CHRNB4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78675887
rs4886579-<b>T</b>,"3 x 10-8",,0.386,'-,"0.011 unit decrease",'-,CHRNB4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78676914
rs4846478-<b>C</b>,"3 x 10-8",,0.713,'-,"0.011 unit decrease",'-,TGFB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218424986
rs637137-<b>A</b>,"6 x 10-8",,0.241,'-,"0.011 unit increase",'-,CHRNA5,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78581634
rs11631955-<b>A</b>,"7 x 10-8",,0.596,'-,"0.011 unit increase",'-,ADAMTS7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78793573
rs8192477-<b>C</b>,"1 x 10-7",,0.32,'-,"0.011 unit increase",'-,CHRNA3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78618121
rs11072792-<b>A</b>,"1 x 10-7",,0.602,'-,"0.011 unit increase",'-,CHRNB4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78707569
rs576982-<b>T</b>,"1 x 10-7",,0.239,'-,"0.011 unit increase",'-,CHRNA5,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78578461
rs35212593-<b>A</b>,"3 x 10-7",,0.203,'-,"0.011 unit increase",'-,"PSMA4, HYKK","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78539484
rs59133824-<b>A</b>,"3 x 10-7",,0.204,'-,"0.011 unit increase",'-,PSMA4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78541108
rs61204066-<b>A</b>,"5 x 10-7",,0.206,'-,"0.011 unit increase",'-,HYKK,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78522956
rs28437878-<b>T</b>,"5 x 10-7",,0.204,'-,"0.011 unit increase",'-,HYKK,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78515530
rs12461964-<b>A</b>,"5 x 10-7",,0.551,'-,"0.011 unit increase",'-,"CYP2F2P, CYP2A6","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,19:40835324
rs608194-<b>T</b>,"8 x 10-7",,0.229,'-,"0.011 unit increase",'-,MMP12,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102873357
rs11072804-<b>T</b>,"9 x 10-7",,0.629,'-,"0.011 unit increase",'-,ADAMTS7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78786144
rs1825087-<b>A</b>,"1 x 10-6",,0.621,'-,"0.011 unit increase",'-,ADAMTS7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78784772
rs60446182-<b>A</b>,"1 x 10-6",,0.55,'-,"0.011 unit increase",'-,"CYP2F2P, CYP2A6","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,19:40842093
rs2869561-<b>T</b>,"1 x 10-6",,0.629,'-,"0.011 unit increase",'-,"ADAMTS7, CHRNB4","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78733174
rs28681284-<b>T</b>,"1 x 10-6",,0.184,'-,"0.011 unit increase",'-,CHRNA3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78616223
rs9788682-<b>A</b>,"2 x 10-6",,0.185,'-,"0.011 unit increase",'-,HYKK,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78510244
rs1711731-<b>A</b>,"2 x 10-6",,0.192,'-,"0.011 unit increase",'-,CHRNA5,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78569576
rs958025-<b>T</b>,"2 x 10-6",,0.189,'-,"0.011 unit increase",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78467006
rs4699934-<b>T</b>,"2 x 10-6",,0.766,'-,"0.011 unit increase",'-,PDE4D,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,5:59037944
rs13069054-<b>A</b>,"2 x 10-6",,0.183,'-,"0.011 unit increase",'-,RUVBL1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128137139
rs7174348-<b>A</b>,"2 x 10-6",,0.181,'-,"0.011 unit increase",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78500097
rs2656056-<b>T</b>,"3 x 10-6",,0.209,'-,"0.011 unit increase",'-,"CRABP1, IREB2","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78430177
rs2568499-<b>T</b>,"3 x 10-6",,0.188,'-,"0.011 unit increase",'-,"CRABP1, IREB2","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78430017
rs2915695-<b>T</b>,"3 x 10-6",,0.188,'-,"0.011 unit increase",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78447129
rs2656074-<b>T</b>,"5 x 10-6",,0.2,'-,"0.01 unit increase",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78449042
rs4887053-<b>A</b>,"5 x 10-6",,0.82,'-,"0.01 unit increase",'-,"CRABP1, IREB2","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78420357
rs6537298-<b>T</b>,"2 x 10-10",,0.572,'-,"0.011 unit increase",'-,"KRT18P51, HHIP-AS1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144585719
rs2904259-<b>T</b>,"2 x 10-10",,0.464,'-,"0.011 unit increase",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88964563
rs2656052-<b>A</b>,"7 x 10-10",,0.607,'-,"0.011 unit increase",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78448590
rs2938670-<b>T</b>,"7 x 10-10",,0.607,'-,"0.011 unit increase",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78448346
rs7698984-<b>A</b>,"2 x 10-9",,0.602,'-,"0.011 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144515929
rs7658614-<b>A</b>,"2 x 10-9",,0.597,'-,"0.011 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144524542
rs6829956-<b>T</b>,"2 x 10-9",,0.606,'-,"0.011 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144519136
rs13116999-<b>A</b>,"3 x 10-9",,0.606,'-,"0.011 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144521212
rs4835639-<b>T</b>,"3 x 10-9",,0.606,'-,"0.011 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144530761
rs12903295-<b>A</b>,"4 x 10-9",,0.441,'-,"0.011 unit increase",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78486630
rs12903285-<b>A</b>,"6 x 10-9",,0.47,'-,"0.011 unit increase",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78486611
rs2456020-<b>T</b>,"1 x 10-8",,0.29,'-,"0.011 unit increase",'-,CHRNA5,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78576056
rs1489765-<b>T</b>,"2 x 10-8",,0.614,'-,"0.011 unit increase",'-,"HHIP-AS1, KRT18P51","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144595226
rs12902602-<b>A</b>,"2 x 10-8",,0.612,'-,"0.011 unit increase",'-,CHRNB4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78675059
rs7660385-<b>T</b>,"2 x 10-8",,0.692,'-,"0.011 unit increase",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88939668
rs7663740-<b>T</b>,"2 x 10-8",,0.607,'-,"0.011 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144547693
rs6658473-<b>T</b>,"2 x 10-8",,0.287,'-,"0.011 unit increase",'-,TGFB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218427077
rs10482792-<b>A</b>,"3 x 10-8",,0.287,'-,"0.011 unit increase",'-,TGFB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218432119
rs1890995-<b>A</b>,"3 x 10-8",,0.287,'-,"0.011 unit increase",'-,TGFB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218431336
rs4846479-<b>T</b>,"3 x 10-8",,0.713,'-,"0.011 unit increase",'-,TGFB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218425068
rs1996371-<b>T</b>,"4 x 10-8",,0.57,'-,"0.011 unit increase",'-,CHRNB4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78664464
rs7515360-<b>A</b>,"4 x 10-8",,0.291,'-,"0.011 unit increase",'-,"TGFB2, LINC02869","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218453278
rs569207-<b>T</b>,"5 x 10-8",,0.237,'-,"0.011 unit increase",'-,CHRNA5,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78580777
rs6797834-<b>T</b>,"1 x 10-6",,0.157,'-,"0.012 unit increase",'-,RUVBL1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128137557
rs28669908-<b>A</b>,"2 x 10-6",,0.177,'-,"0.012 unit increase",'-,CHRNA3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78617925
rs12033060-<b>T</b>,"2 x 10-6",,0.307,'-,"0.012 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218517972
rs4012266-<b>A</b>,"2 x 10-6",,0.166,'-,"0.012 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218491466
rs6783253-<b>A</b>,"2 x 10-6",,0.157,'-,"0.012 unit increase",'-,RUVBL1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128132718
rs13071740-<b>T</b>,"2 x 10-6",,0.158,'-,"0.012 unit increase",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128162725
rs13077790-<b>T</b>,"2 x 10-6",,0.158,'-,"0.012 unit increase",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128163815
rs13077913-<b>A</b>,"2 x 10-6",,0.158,'-,"0.012 unit increase",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128163761
rs12026169-<b>A</b>,"2 x 10-6",,0.164,'-,"0.012 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218511508
rs12022585-<b>A</b>,"2 x 10-6",,0.17,'-,"0.012 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218517790
rs12032263-<b>T</b>,"2 x 10-6",,0.17,'-,"0.012 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218517510
rs6798749-<b>A</b>,"2 x 10-6",,0.33,'-,"0.012 unit increase",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128338054
rs11721213-<b>T</b>,"2 x 10-6",,0.203,'-,"0.012 unit increase",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128348598
rs1015275-<b>C</b>,"2 x 10-6",,0.165,'-,"0.012 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218496799
rs72738842-<b>A</b>,"2 x 10-6",,0.165,'-,"0.012 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218499465
rs73192978-<b>A</b>,"2 x 10-6",,0.157,'-,"0.012 unit increase",'-,RUVBL1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128149432
rs34174370-<b>T</b>,"2 x 10-6",,0.168,'-,"0.012 unit increase",'-,RUVBL1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128130901
rs11709066-<b>A</b>,"2 x 10-6",,0.159,'-,"0.012 unit increase",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128156069
rs12568141-<b>A</b>,"2 x 10-6",,0.17,'-,"0.012 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218516117
rs7516501-<b>A</b>,"2 x 10-6",,0.17,'-,"0.012 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218515944
rs6604620-<b>C</b>,"2 x 10-6",,0.179,'-,"0.012 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218513401
rs6690726-<b>A</b>,"2 x 10-6",,0.17,'-,"0.012 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218505359
rs12040654-<b>A</b>,"2 x 10-6",,0.165,'-,"0.012 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218486935
rs2955129-<b>T</b>,"2 x 10-6",,0.163,'-,"0.012 unit increase",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128210364
rs6604621-<b>A</b>,"2 x 10-6",,0.175,'-,"0.012 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218513613
rs11634351-<b>A</b>,"3 x 10-8",,0.387,'-,"0.011 unit decrease",'-,CHRNB4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78652376
rs10429950-<b>T</b>,"3 x 10-8",,0.583,'-,"0.011 unit decrease",'-,"LINC02869, TGFB2","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218451191
rs900-<b>A</b>,"3 x 10-8",,0.713,'-,"0.011 unit decrease",'-,TGFB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218441563
rs7549303-<b>C</b>,"4 x 10-8",,0.709,'-,"0.011 unit decrease",'-,"TGFB2, LINC02869","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218453979
rs1473526-<b>T</b>,"4 x 10-8",,0.408,'-,"0.011 unit decrease",'-,"LINC02869, TGFB2","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218447405
rs4420500-<b>T</b>,"5 x 10-8",,0.371,'-,"0.011 unit decrease",'-,CHRNB4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78670622
rs10028589-<b>T</b>,"6 x 10-8",,0.297,'-,"0.011 unit decrease",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88919909
rs4887113-<b>T</b>,"6 x 10-8",,0.408,'-,"0.011 unit decrease",'-,ADAMTS7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78802945
rs11632102-<b>A</b>,"7 x 10-8",,0.404,'-,"0.011 unit decrease",'-,ADAMTS7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78793715
rs11639044-<b>T</b>,"1 x 10-7",,0.404,'-,"0.011 unit decrease",'-,ADAMTS7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78791472
rs8192478-<b>A</b>,"1 x 10-7",,0.68,'-,"0.011 unit decrease",'-,CHRNA3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78618120
rs6697759-<b>T</b>,"2 x 10-7",,0.406,'-,"0.011 unit decrease",'-,"TGFB2, LINC02869","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218449752
rs1690790-<b>A</b>,"4 x 10-7",,0.407,'-,"0.011 unit decrease",'-,"U3, LINC02869","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218528059
rs7163730-<b>A</b>,"4 x 10-7",,0.351,'-,"0.011 unit decrease",'-,HYKK,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78522339
rs12441426-<b>T</b>,"5 x 10-7",,0.793,'-,"0.011 unit decrease",'-,HYKK,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78519987
rs34138960-<b>A</b>,"5 x 10-7",,0.792,'-,"0.011 unit decrease",'-,"PSMA4, HYKK","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78539326
rs34664138-<b>T</b>,"5 x 10-7",,0.792,'-,"0.011 unit decrease",'-,"PSMA4, HYKK","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78539282
rs59683676-<b>T</b>,"5 x 10-7",,0.792,'-,"0.011 unit decrease",'-,PSMA4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78541111
rs7169584-<b>A</b>,"6 x 10-7",,0.794,'-,"0.011 unit decrease",'-,HYKK,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78530318
rs2036534-<b>T</b>,"7 x 10-7",,0.646,'-,"0.011 unit decrease",'-,HYKK,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78534606
rs11858210-<b>A</b>,"9 x 10-7",,0.372,'-,"0.011 unit decrease",'-,ADAMTS7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78786016
rs11072803-<b>A</b>,"1 x 10-6",,0.373,'-,"0.011 unit decrease",'-,ADAMTS7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78785536
rs2904220-<b>T</b>,"1 x 10-6",,0.378,'-,"0.011 unit decrease",'-,ADAMTS7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78784362
rs4887083-<b>T</b>,"1 x 10-6",,0.371,'-,"0.011 unit decrease",'-,"ADAMTS7, CHRNB4","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78733235
rs684513-<b>C</b>,"1 x 10-6",,0.806,'-,"0.011 unit decrease",'-,CHRNA5,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78566058
rs4700319-<b>T</b>,"2 x 10-6",,0.228,'-,"0.011 unit decrease",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,"Mapping not available"
rs4887086-<b>T</b>,"2 x 10-6",,0.372,'-,"0.011 unit decrease",'-,"CHRNB4, ADAMTS7","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78734187
rs7146689-<b>T</b>,"2 x 10-6",,0.823,'-,"0.011 unit decrease",'-,RIN3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:92633679
rs2656071-<b>A</b>,"2 x 10-6",,0.812,'-,"0.011 unit decrease",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78453001
rs4886587-<b>A</b>,"2 x 10-6",,0.374,'-,"0.011 unit decrease",'-,"ADAMTS7, CHRNB4","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78734480
rs1498605-<b>A</b>,"3 x 10-6",,0.224,'-,"0.011 unit decrease",'-,PDE4D,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,5:59037489
rs2568488-<b>A</b>,"3 x 10-6",,0.812,'-,"0.011 unit decrease",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78444251
rs2955097-<b>C</b>,"3 x 10-6",,0.808,'-,"0.011 unit decrease",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128259662
rs2568497-<b>T</b>,"3 x 10-6",,0.812,'-,"0.011 unit decrease",'-,"IREB2, CRABP1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78429055
rs3813567-<b>A</b>,"3 x 10-6",,0.808,'-,"0.011 unit decrease",'-,CHRNB4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78642209
rs2869032-<b>T</b>,"3 x 10-6",,0.82,'-,"0.011 unit decrease",'-,"IREB2, CRABP1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78422219
rs951984-<b>A</b>,"3 x 10-6",,0.267,'-,"0.011 unit decrease",'-,"IREB2, CRABP1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78428573
rs2568485-<b>T</b>,"4 x 10-6",,0.812,'-,"0.011 unit decrease",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78459772
rs6537279-<b>A</b>,"4 x 10-6",,0.797,'-,"0.011 unit decrease",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144353887
rs4693980-<b>A</b>,"4 x 10-9",,0.578,'-,"0.01 unit decrease",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88964837
rs1964516-<b>T</b>,"6 x 10-9",,0.466,'-,"0.01 unit decrease",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88954758
rs3846287-<b>T</b>,"1 x 10-8",,0.584,'-,"0.01 unit decrease",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88961961
rs7671261-<b>A</b>,"1 x 10-8",,0.584,'-,"0.01 unit decrease",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88962667
rs1903003-<b>T</b>,"2 x 10-8",,0.425,'-,"0.01 unit decrease",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88965146
rs7692102-<b>A</b>,"2 x 10-8",,0.393,'-,"0.01 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144535989
rs2202507-<b>T</b>,"5 x 10-8",,0.562,'-,"0.01 unit decrease",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144336529
rs1489764-<b>T</b>,"5 x 10-8",,0.389,'-,"0.01 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144533076
rs11637656-<b>T</b>,"5 x 10-8",,0.546,'-,"0.01 unit decrease",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78459619
rs12512788-<b>A</b>,"6 x 10-8",,0.566,'-,"0.01 unit decrease",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144328123
rs4299116-<b>A</b>,"6 x 10-8",,0.546,'-,"0.01 unit decrease",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78473852
rs6828982-<b>T</b>,"6 x 10-8",,0.388,'-,"0.01 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144549452
rs12910910-<b>T</b>,"6 x 10-8",,0.545,'-,"0.01 unit decrease",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78475508
rs1504549-<b>T</b>,"7 x 10-8",,0.544,'-,"0.01 unit decrease",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78474287
rs1062980-<b>T</b>,"7 x 10-8",,0.365,'-,"0.01 unit decrease",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78500185
rs36146269-<b>A</b>,"7 x 10-8",,0.542,'-,"0.01 unit decrease",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78487168
rs1690789-<b>T</b>,"8 x 10-8",,0.455,'-,"0.01 unit decrease",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218524685
rs8042238-<b>T</b>,"8 x 10-8",,0.544,'-,"0.01 unit decrease",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78481929
rs4887059-<b>T</b>,"9 x 10-8",,0.538,'-,"0.01 unit decrease",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78489753
rs550238-<b>A</b>,"9 x 10-8",,0.455,'-,"0.01 unit decrease",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218517606
rs58281712-<b>C</b>,"1 x 10-7",,0.302,'-,"0.01 unit decrease",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88889805
rs11638490-<b>T</b>,"1 x 10-7",,0.378,'-,"0.01 unit decrease",'-,CHRNB4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78715608
rs62310476-<b>A</b>,"1 x 10-7",,0.303,'-,"0.01 unit decrease",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88911177
rs7695732-<b>C</b>,"1 x 10-7",,0.303,'-,"0.01 unit decrease",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88911640
rs13113445-<b>T</b>,"1 x 10-7",,0.403,'-,"0.01 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144551614
rs11634543-<b>T</b>,"1 x 10-7",,0.378,'-,"0.01 unit decrease",'-,CHRNB4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78713162
rs4693975-<b>T</b>,"1 x 10-7",,0.303,'-,"0.01 unit decrease",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88900733
rs7687539-<b>A</b>,"1 x 10-7",,0.3,'-,"0.01 unit decrease",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88885633
rs965604-<b>A</b>,"1 x 10-7",,0.535,'-,"0.01 unit decrease",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78496881
rs4362358-<b>T</b>,"1 x 10-7",,0.543,'-,"0.01 unit decrease",'-,"IREB2, HYKK","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78503762
rs13107665-<b>A</b>,"1 x 10-7",,0.42,'-,"0.01 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144551492
rs13180-<b>T</b>,"2 x 10-7",,0.458,'-,"0.01 unit decrease",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78497146
rs2015850-<b>A</b>,"2 x 10-7",,0.716,'-,"0.01 unit decrease",'-,"TGFB2, LINC02869","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218448759
rs7682431-<b>C</b>,"2 x 10-7",,0.372,'-,"0.01 unit decrease",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88844510
rs12594711-<b>T</b>,"2 x 10-7",,0.539,'-,"0.01 unit decrease",'-,"HYKK, IREB2","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78501579
rs10019681-<b>T</b>,"2 x 10-7",,0.722,'-,"0.01 unit decrease",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88911381
rs4693977-<b>A</b>,"2 x 10-7",,0.301,'-,"0.01 unit decrease",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88932928
rs2964991-<b>T</b>,"3 x 10-7",,0.448,'-,"0.01 unit decrease",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218511890
rs12510044-<b>C</b>,"3 x 10-7",,0.385,'-,"0.01 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144563486
rs796395-<b>A</b>,"3 x 10-7",,0.449,'-,"0.01 unit decrease",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218508629
rs7173267-<b>C</b>,"3 x 10-7",,0.397,'-,"0.01 unit decrease",'-,ADAMTS7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78800408
rs12648534-<b>T</b>,"3 x 10-7",,0.298,'-,"0.01 unit decrease",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88878055
rs28610385-<b>A</b>,"3 x 10-7",,0.396,'-,"0.01 unit decrease",'-,ADAMTS7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78798264
rs2641530-<b>T</b>,"3 x 10-7",,0.308,'-,"0.01 unit decrease",'-,ACVR1B,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:51991027
rs1797069-<b>A</b>,"3 x 10-7",,0.732,'-,"0.01 unit decrease",'-,"LINC02869, TGFB2","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218455991
rs12592721-<b>C</b>,"4 x 10-7",,0.397,'-,"0.01 unit decrease",'-,ADAMTS7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78806803
rs6821716-<b>A</b>,"4 x 10-7",,0.418,'-,"0.01 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144531551
rs1690791-<b>A</b>,"4 x 10-7",,0.468,'-,"0.01 unit decrease",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218471980
rs34563625-<b>C</b>,"5 x 10-7",,0.37,'-,"0.01 unit decrease",'-,"CHRNB4, ADAMTS7","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78727936
rs11629637-<b>T</b>,"5 x 10-7",,0.581,'-,"0.01 unit decrease",'-,CHRNB4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78726682
rs113134286-<b>T</b>,"6 x 10-7",,0.379,'-,"0.01 unit decrease",'-,CHRNB4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78720546
rs3829786-<b>A</b>,"6 x 10-7",,0.38,'-,"0.01 unit decrease",'-,CHRNB4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78727204
rs12441088-<b>T</b>,"7 x 10-7",,0.37,'-,"0.01 unit decrease",'-,CHRNB4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78635922
rs1108581-<b>A</b>,"7 x 10-7",,0.297,'-,"0.01 unit decrease",'-,DBH,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:133640119
rs34275594-<b>A</b>,"8 x 10-7",,0.704,'-,"0.01 unit decrease",'-,CHRNB4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78688940
rs13328032-<b>A</b>,"8 x 10-7",,0.311,'-,"0.01 unit decrease",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88888722
rs6604615-<b>T</b>,"8 x 10-7",,0.681,'-,"0.01 unit decrease",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218461020
rs11639166-<b>C</b>,"9 x 10-7",,0.372,'-,"0.01 unit decrease",'-,"ADAMTS7, CHRNB4","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78731424
rs4619908-<b>A</b>,"1 x 10-6",,0.456,'-,"0.01 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144523965
rs2277546-<b>A</b>,"1 x 10-6",,0.395,'-,"0.01 unit decrease",'-,ADAMTS7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78791034
rs7177514-<b>C</b>,"1 x 10-6",,0.759,'-,"0.01 unit decrease",'-,CHRNA3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78615064
rs8042059-<b>A</b>,"1 x 10-6",,0.759,'-,"0.01 unit decrease",'-,CHRNA3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78615517
rs3025388-<b>A</b>,"1 x 10-6",,0.252,'-,"0.01 unit decrease",'-,DBH,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:133638134
rs8042374-<b>A</b>,"1 x 10-6",,0.627,'-,"0.01 unit decrease",'-,CHRNA3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78615690
rs11639347-<b>T</b>,"1 x 10-6",,0.372,'-,"0.01 unit decrease",'-,"ADAMTS7, CHRNB4","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78732008
rs11639375-<b>A</b>,"1 x 10-6",,0.372,'-,"0.01 unit decrease",'-,"CHRNB4, ADAMTS7","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78731872
rs11639382-<b>A</b>,"1 x 10-6",,0.372,'-,"0.01 unit decrease",'-,"CHRNB4, ADAMTS7","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78731926
rs1825082-<b>A</b>,"1 x 10-6",,0.372,'-,"0.01 unit decrease",'-,"ADAMTS7, CHRNB4","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78731091
rs6495308-<b>T</b>,"1 x 10-6",,0.375,'-,"0.01 unit decrease",'-,CHRNA3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78615314
rs11072806-<b>A</b>,"1 x 10-6",,0.39,'-,"0.01 unit decrease",'-,ADAMTS7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78786732
rs1764705-<b>T</b>,"1 x 10-6",,0.443,'-,"0.01 unit decrease",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218475214
rs28602288-<b>T</b>,"1 x 10-6",,0.625,'-,"0.01 unit decrease",'-,"CYP2A7, CYP2G1P","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,19:40882835
rs4887069-<b>A</b>,"2 x 10-6",,0.756,'-,"0.01 unit decrease",'-,CHRNA3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78616728
rs2003347-<b>T</b>,"2 x 10-6",,0.559,'-,"0.01 unit decrease",'-,LHX1-DT,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,17:36916062
rs2644899-<b>T</b>,"2 x 10-6",,0.744,'-,"0.01 unit decrease",'-,RAB4B-EGLN2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,19:40797044
rs80229697-<b>A</b>,"2 x 10-6",,0.353,'-,"0.01 unit decrease",'-,"CHRNB4, ADAMTS7","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78730274
rs12439240-<b>T</b>,"2 x 10-6",,0.777,'-,"0.01 unit decrease",'-,HYKK,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78536749
rs1994016-<b>T</b>,"2 x 10-6",,0.367,'-,"0.01 unit decrease",'-,ADAMTS7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78787892
rs3813570-<b>T</b>,"2 x 10-6",,0.779,'-,"0.01 unit decrease",'-,PSMA4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78540490
rs4886584-<b>A</b>,"2 x 10-6",,0.343,'-,"0.01 unit decrease",'-,"ADAMTS7, CHRNB4","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78729122
rs4886583-<b>A</b>,"2 x 10-6",,0.34,'-,"0.01 unit decrease",'-,"CHRNB4, ADAMTS7","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78729103
rs3025387-<b>A</b>,"2 x 10-6",,0.742,'-,"0.01 unit decrease",'-,DBH,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:133637865
rs4693973-<b>A</b>,"3 x 10-6",,0.267,'-,"0.01 unit decrease",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88876516
rs12185265-<b>C</b>,"3 x 10-6",,0.556,'-,"0.01 unit decrease",'-,LHX1-DT,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,17:36916999
rs1394371-<b>T</b>,"3 x 10-6",,0.723,'-,"0.01 unit decrease",'-,"IREB2, CRABP1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78432127
rs3025386-<b>T</b>,"3 x 10-6",,0.741,'-,"0.01 unit decrease",'-,DBH,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:133637642
rs7169223-<b>A</b>,"3 x 10-6",,0.696,'-,"0.01 unit decrease",'-,CHRNB4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78699774
rs924840-<b>A</b>,"4 x 10-6",,0.812,'-,"0.01 unit decrease",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78439466
rs10851906-<b>A</b>,"4 x 10-6",,0.812,'-,"0.01 unit decrease",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78482334
rs3025383-<b>T</b>,"4 x 10-6",,0.715,'-,"0.01 unit decrease",'-,DBH,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:133637247
rs2656055-<b>A</b>,"4 x 10-6",,0.803,'-,"0.01 unit decrease",'-,"CRABP1, IREB2","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78427852
rs7688932-<b>T</b>,"4 x 10-6",,0.255,'-,"0.01 unit decrease",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144358521
rs2958719-<b>A</b>,"5 x 10-6",,0.8,'-,"0.01 unit decrease",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78450687
rs13284520-<b>A</b>,"5 x 10-6",,0.735,'-,"0.01 unit decrease",'-,DBH,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:133637450
rs1795739-<b>A</b>,"4 x 10-7",,0.465,'-,"0.009 unit decrease",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:89009162
rs1708667-<b>T</b>,"4 x 10-7",,0.469,'-,"0.009 unit decrease",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:89008459
rs10015415-<b>T</b>,"5 x 10-7",,0.469,'-,"0.009 unit decrease",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:89007052
rs6849143-<b>T</b>,"5 x 10-7",,0.589,'-,"0.009 unit decrease",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:89007338
rs6852288-<b>C</b>,"6 x 10-7",,0.47,'-,"0.009 unit decrease",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:89004659
rs1318580-<b>T</b>,"8 x 10-7",,0.622,'-,"0.009 unit decrease",'-,"TGFB2, LINC02869","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218455687
rs771998-<b>T</b>,"1 x 10-6",,0.599,'-,"0.009 unit decrease",'-,ACVR1B,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:51964411
rs2798631-<b>A</b>,"1 x 10-6",,0.551,'-,"0.009 unit decrease",'-,TGFB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218438536
rs13118083-<b>A</b>,"2 x 10-6",,0.438,'-,"0.009 unit decrease",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144306448
rs6604614-<b>C</b>,"2 x 10-6",,0.628,'-,"0.009 unit decrease",'-,"LINC02869, TGFB2","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218458110
rs3813565-<b>T</b>,"2 x 10-6",,0.626,'-,"0.009 unit decrease",'-,CHRNB4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78727268
rs1108548-<b>A</b>,"2 x 10-6",,0.629,'-,"0.009 unit decrease",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218461445
rs6822064-<b>T</b>,"4 x 10-6",,0.32,'-,"0.009 unit decrease",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144342604
rs7359276-<b>T</b>,"4 x 10-6",,0.686,'-,"0.009 unit decrease",'-,CHRNA3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78600319
rs7937-<b>T</b>,"2 x 10-6",,0.39,'-,"0.008 unit decrease",'-,"RAB4B, MIA-RAB4B, RAB4B-EGLN2","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,19:40796801
rs1458562-<b>T</b>,"2 x 10-6",,0.428,'-,"0.008 unit decrease",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88932447
rs4505789-<b>A</b>,"3 x 10-6",,0.559,'-,"0.008 unit decrease",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88904464
rs2811536-<b>A</b>,"9 x 10-7",,0.162,'-,"0.012 unit increase",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128270076
rs2955078-<b>A</b>,"1 x 10-6",,0.162,'-,"0.012 unit increase",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128240343
rs2811549-<b>T</b>,"1 x 10-6",,0.162,'-,"0.012 unit increase",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128219865
rs12030863-<b>T</b>,"1 x 10-6",,0.171,'-,"0.012 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218521283
rs73197383-<b>T</b>,"1 x 10-6",,0.157,'-,"0.012 unit increase",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128311631
rs2955133-<b>T</b>,"1 x 10-6",,0.162,'-,"0.012 unit increase",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128226479
rs56287882-<b>A</b>,"1 x 10-6",,0.158,'-,"0.012 unit increase",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128311500
rs6604617-<b>C</b>,"1 x 10-6",,0.169,'-,"0.012 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218502176
rs6656475-<b>A</b>,"1 x 10-6",,0.169,'-,"0.012 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218502063
rs7537063-<b>T</b>,"1 x 10-6",,0.169,'-,"0.012 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218502891
rs12565438-<b>T</b>,"1 x 10-6",,0.171,'-,"0.012 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218520110
rs10429952-<b>T</b>,"1 x 10-6",,0.169,'-,"0.012 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218507756
rs112756090-<b>T</b>,"1 x 10-6",,0.169,'-,"0.012 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218508033
rs7553124-<b>A</b>,"1 x 10-6",,0.171,'-,"0.012 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218508160
rs11118114-<b>A</b>,"1 x 10-6",,0.169,'-,"0.012 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218506344
rs12563082-<b>T</b>,"1 x 10-6",,0.169,'-,"0.012 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218506388
rs2955126-<b>A</b>,"1 x 10-6",,0.162,'-,"0.012 unit increase",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128207411
rs7545447-<b>A</b>,"1 x 10-6",,0.169,'-,"0.012 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218510675
rs11118112-<b>T</b>,"1 x 10-6",,0.165,'-,"0.012 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218499915
rs12025796-<b>A</b>,"1 x 10-6",,0.165,'-,"0.012 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218500660
rs12039922-<b>A</b>,"1 x 10-6",,0.165,'-,"0.012 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218500473
rs34817706-<b>A</b>,"1 x 10-6",,0.156,'-,"0.012 unit increase",'-,RUVBL1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128142215
rs6800225-<b>T</b>,"1 x 10-6",,0.156,'-,"0.012 unit increase",'-,RUVBL1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128143335
rs2811511-<b>A</b>,"1 x 10-6",,0.162,'-,"0.012 unit increase",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128194145
rs73192979-<b>T</b>,"1 x 10-6",,0.158,'-,"0.012 unit increase",'-,RUVBL1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128149478
rs59606962-<b>T</b>,"4 x 10-6",(AA),0.562,'-,"0.015 unit decrease",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97646811
rs76550486-<b>A</b>,"4 x 10-6",(AA),0.998,'-,"0.31 unit increase",'-,HCN1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,5:45479793
rs181225015-<b>T</b>,"4 x 10-6",(AA),0.999,'-,"0.347 unit increase",'-,DNAAF1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,16:84170772
rs138043549-<b>G</b>,"4 x 10-6",(AA),0.976,'-,"0.051 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,5:101057657
rs149746592-<b>A</b>,"4 x 10-6",(AA),0.976,'-,"0.05 unit increase",'-,"AHNAK, EEF1G","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:62558235
rs192166173-<b>A</b>,"4 x 10-6",(AA),0.999,'-,"0.342 unit increase",'-,"ROR1, PGM1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:63696337
rs184381023-<b>G</b>,"4 x 10-6",(AA),0.992,'-,"0.104 unit decrease",'-,"DMAC2, Metazoa_SRP","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,19:41441320
rs183323229-<b>G</b>,"4 x 10-6",(AA),0.996,'-,"0.177 unit increase",'-,CCDC7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,10:32879287
rs181881613-<b>T</b>,"4 x 10-6",(AA),0.999,'-,"0.363 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:39836370
rs138037897-<b>A</b>,"5 x 10-6",(AA),0.999,'-,"0.298 unit increase",'-,TMTC1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:29832565
rs149504921-<b>C</b>,"5 x 10-6",(AA),0.992,'-,"0.097 unit increase",'-,DISC1FP1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:90852917
rs78681061-<b>A</b>,"5 x 10-6",(AA),0.624,'-,"0.016 unit decrease",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97624475
rs79534246-<b>A</b>,"5 x 10-6",(AA),0.996,'-,"0.17 unit increase",'-,FERMT2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:52919724
rs139337462-<b>G</b>,"5 x 10-6",(AA),0.999,'-,"0.296 unit increase",'-,TMTC1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:29831367
rs57750317-<b>G</b>,"5 x 10-6",(AA),0.614,'-,"0.015 unit decrease",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97665825
rs147620864-<b>G</b>,"5 x 10-6",(AA),0.998,'-,"0.315 unit increase",'-,MSH2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:47459393
rs17026847-<b>T</b>,"5 x 10-6",(AA),0.562,'-,"0.015 unit decrease",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97629047
rs17487223-<b>T</b>,"3 x 10-15",,0.349,'-,"0.016 unit decrease",'-,CHRNB4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78631645
rs11633958-<b>T</b>,"1 x 10-14",,0.34,'-,"0.016 unit decrease",'-,CHRNA5,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78569722
rs2869548-<b>A</b>,"6 x 10-14",,0.364,'-,"0.016 unit decrease",'-,CHRNB4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78630296
rs150986675-<b>T</b>,"6 x 10-8",,0.879,'-,"0.016 unit decrease",'-,"MMP13, RNU7-159P","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102906573
rs680753-<b>C</b>,"2 x 10-7",,0.886,'-,"0.016 unit decrease",'-,MMP3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102840850
rs470292-<b>A</b>,"2 x 10-7",,0.886,'-,"0.016 unit decrease",'-,WTAPP1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102814664
rs470928-<b>A</b>,"2 x 10-7",,0.886,'-,"0.016 unit decrease",'-,WTAPP1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102814649
rs563096-<b>A</b>,"2 x 10-7",,0.885,'-,"0.016 unit decrease",'-,"MMP3, WTAPP1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102836635
rs525119-<b>T</b>,"2 x 10-7",,0.885,'-,"0.016 unit decrease",'-,WTAPP1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102831415
rs553542-<b>T</b>,"2 x 10-7",,0.885,'-,"0.016 unit decrease",'-,WTAPP1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102830645
rs646760-<b>A</b>,"2 x 10-7",,0.885,'-,"0.016 unit decrease",'-,WTAPP1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102832547
rs611705-<b>T</b>,"2 x 10-7",,0.886,'-,"0.016 unit decrease",'-,WTAPP1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102823737
rs78366141-<b>A</b>,"5 x 10-6",,0.096,'-,"0.016 unit decrease",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88882544
rs2036527-<b>A</b>,"7 x 10-16",,0.601,'-,"0.015 unit decrease",'-,"PSMA4, CHRNA5","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78559273
rs8031948-<b>T</b>,"3 x 10-15",,0.333,'-,"0.015 unit decrease",'-,HYKK,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78523715
rs72738786-<b>T</b>,"4 x 10-14",,0.334,'-,"0.015 unit decrease",'-,HYKK,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78535744
rs11858836-<b>A</b>,"1 x 10-12",,0.333,'-,"0.015 unit decrease",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78490935
rs17405217-<b>T</b>,"2 x 10-12",,0.333,'-,"0.015 unit decrease",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78438807
rs72738704-<b>C</b>,"2 x 10-12",,0.336,'-,"0.015 unit decrease",'-,"IREB2, CRABP1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78427490
rs17483548-<b>A</b>,"3 x 10-12",,0.332,'-,"0.015 unit decrease",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78437971
rs4835177-<b>A</b>,"3 x 10-12",,0.581,'-,"0.015 unit decrease",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144352776
rs184277845-<b>A</b>,"2 x 10-10",,0.653,'-,"0.015 unit decrease",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144397227
rs12913260-<b>A</b>,"5 x 10-8",,0.371,'-,"0.015 unit decrease",'-,ADAMTS7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78778753
rs72699818-<b>T</b>,"7 x 10-8",,0.844,'-,"0.015 unit decrease",'-,RIN3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:92611266
rs7531382-<b>T</b>,"4 x 10-7",,0.881,'-,"0.015 unit decrease",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218508773
rs142026888-<b>T</b>,"4 x 10-6",,0.641,'-,"0.015 unit decrease",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97635458
rs443874-<b>T</b>,"5 x 10-6",,0.149,'-,"0.015 unit decrease",'-,LILRB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,19:54275535
rs6537296-<b>A</b>,"2 x 10-15",,0.63,'-,"0.014 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144566782
rs4243084-<b>C</b>,"2 x 10-14",,0.335,'-,"0.014 unit decrease",'-,CHRNA3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78619330
rs12506874-<b>A</b>,"7 x 10-14",,0.613,'-,"0.014 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144546060
rs55958997-<b>A</b>,"1 x 10-13",,0.365,'-,"0.014 unit decrease",'-,"CHRNA3, CHRNB4","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78623530
rs34265962-<b>A</b>,"1 x 10-12",,0.656,'-,"0.014 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144504784
rs973796-<b>A</b>,"3 x 10-12",,0.66,'-,"0.014 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144502816
rs2955083-<b>A</b>,"6 x 10-7",,0.882,'-,"0.014 unit decrease",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128242335
rs7655625-<b>T</b>,"6 x 10-14",,0.43,'-,"0.013 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144564763
rs6537293-<b>A</b>,"7 x 10-14",,0.619,'-,"0.013 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144558609
rs1489759-<b>A</b>,"7 x 10-13",,0.467,'-,"0.013 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144553321
rs8039449-<b>T</b>,"2 x 10-12",,0.361,'-,"0.013 unit decrease",'-,"CHRNB4, CHRNA3","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78622192
rs2130339-<b>A</b>,"2 x 10-12",,0.58,'-,"0.013 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144543733
rs35440220-<b>A</b>,"2 x 10-11",,0.656,'-,"0.013 unit decrease",'-,"HMGB1P44, KRT18P51","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144478680
rs1505770-<b>T</b>,"2 x 10-11",,0.661,'-,"0.013 unit decrease",'-,UGT2B7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144459650
rs56304346-<b>A</b>,"6 x 10-11",,0.656,'-,"0.013 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144476714
rs148200221-<b>A</b>,"2 x 10-9",,0.663,'-,"0.013 unit decrease",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144397211
rs72738834-<b>A</b>,"7 x 10-9",,0.81,'-,"0.013 unit decrease",'-,"TGFB2, LINC02869","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218450546
rs10482796-<b>T</b>,"1 x 10-8",,0.809,'-,"0.013 unit decrease",'-,TGFB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218432293
rs12023953-<b>T</b>,"1 x 10-8",,0.811,'-,"0.013 unit decrease",'-,"LINC02869, TGFB2","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218449297
rs12440014-<b>C</b>,"2 x 10-8",,0.782,'-,"0.013 unit decrease",'-,CHRNB4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78634384
rs654600-<b>A</b>,"2 x 10-8",,0.792,'-,"0.013 unit decrease",'-,"MMP3, MMP12","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102858443
rs1075472-<b>A</b>,"9 x 10-8",,0.839,'-,"0.013 unit decrease",'-,RIN3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:92641786
rs11623779-<b>T</b>,"2 x 10-7",,0.363,'-,"0.013 unit decrease",'-,RIN3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:92630046
rs112321636-<b>T</b>,"4 x 10-7",,0.372,'-,"0.013 unit decrease",'-,ADAMTS7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78779758
rs2004038-<b>A</b>,"4 x 10-7",,0.375,'-,"0.013 unit decrease",'-,ADAMTS7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78779064
rs11709611-<b>T</b>,"4 x 10-7",,0.85,'-,"0.013 unit decrease",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128348432
rs60831762-<b>A</b>,"6 x 10-7",,0.843,'-,"0.013 unit decrease",'-,"U3, LINC02869","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218528109
rs7524827-<b>A</b>,"6 x 10-7",,0.842,'-,"0.013 unit decrease",'-,"LINC02869, U3","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218527186
rs11715394-<b>A</b>,"9 x 10-7",,0.882,'-,"0.013 unit decrease",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128174721
rs72738844-<b>T</b>,"1 x 10-6",,0.835,'-,"0.013 unit decrease",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218501255
rs4886585-<b>A</b>,"1 x 10-6",,0.307,'-,"0.013 unit decrease",'-,"ADAMTS7, CHRNB4","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78733973
rs667282-<b>T</b>,"3 x 10-8",,0.37,'-,"0.012 unit decrease",'-,CHRNA5,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78571130
rs4337751-<b>T</b>,"5 x 10-8",,0.568,'-,"0.012 unit decrease",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144524173
rs13329271-<b>A</b>,"6 x 10-8",,0.779,'-,"0.012 unit decrease",'-,"CHRNB4, CHRNA3","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78621888
rs674546-<b>A</b>,"6 x 10-8",,0.777,'-,"0.012 unit decrease",'-,"MMP12, MMP3","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102859908
rs28534575-<b>T</b>,"9 x 10-8",,0.778,'-,"0.012 unit decrease",'-,CHRNB4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78631503
rs662558-<b>T</b>,"1 x 10-7",,0.776,'-,"0.012 unit decrease",'-,"MMP3, MMP12","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102847964
rs10028679-<b>T</b>,"2 x 10-7",,0.264,'-,"0.012 unit decrease",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88920019
rs10746379-<b>A</b>,"2 x 10-7",,0.822,'-,"0.012 unit decrease",'-,TGFB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218402545
rs4887072-<b>A</b>,"2 x 10-7",,0.778,'-,"0.012 unit decrease",'-,CHRNB4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78633093
rs3894347-<b>A</b>,"3 x 10-7",,0.361,'-,"0.012 unit decrease",'-,"CHRNB4, ADAMTS7","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78733659
rs9308385-<b>T</b>,"5 x 10-7",,0.819,'-,"0.012 unit decrease",'-,TGFB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218432614
rs2811387-<b>T</b>,"5 x 10-7",,0.838,'-,"0.012 unit decrease",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128296335
rs138914938-<b>C</b>,"5 x 10-7",,0.379,'-,"0.012 unit decrease",'-,ADAMTS7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78781112
rs12908207-<b>T</b>,"7 x 10-7",,0.37,'-,"0.012 unit decrease",'-,"ADAMTS7, CHRNB4","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78733621
rs57735707-<b>T</b>,"8 x 10-7",,0.843,'-,"0.012 unit decrease",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128346972
rs12023777-<b>A</b>,"9 x 10-7",,0.83,'-,"0.012 unit decrease",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218521649
rs2955088-<b>T</b>,"9 x 10-7",,0.838,'-,"0.012 unit decrease",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128244867
rs10163145-<b>A</b>,"9 x 10-7",,0.371,'-,"0.012 unit decrease",'-,ADAMTS7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78782993
rs2999083-<b>T</b>,"9 x 10-7",,0.838,'-,"0.012 unit decrease",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128235591
rs2811400-<b>A</b>,"9 x 10-7",,0.838,'-,"0.012 unit decrease",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128269024
rs2811414-<b>C</b>,"9 x 10-7",,0.838,'-,"0.012 unit decrease",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128272334
rs12023695-<b>A</b>,"1 x 10-6",,0.829,'-,"0.012 unit decrease",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218521302
rs2999080-<b>A</b>,"1 x 10-6",,0.838,'-,"0.012 unit decrease",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128237865
rs2955085-<b>A</b>,"1 x 10-6",,0.838,'-,"0.012 unit decrease",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128243914
rs2999072-<b>C</b>,"1 x 10-6",,0.838,'-,"0.012 unit decrease",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128244033
rs12048052-<b>A</b>,"1 x 10-6",,0.828,'-,"0.012 unit decrease",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218511946
rs4886591-<b>A</b>,"1 x 10-6",,0.386,'-,"0.012 unit decrease",'-,ADAMTS7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78782176
rs73201462-<b>A</b>,"1 x 10-6",,0.843,'-,"0.012 unit decrease",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128340450
rs34409786-<b>A</b>,"1 x 10-6",,0.838,'-,"0.012 unit decrease",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128169332
rs12041344-<b>T</b>,"1 x 10-6",,0.831,'-,"0.012 unit decrease",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218503717
rs6666152-<b>A</b>,"1 x 10-6",,0.831,'-,"0.012 unit decrease",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218501533
rs6668599-<b>A</b>,"1 x 10-6",,0.831,'-,"0.012 unit decrease",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218501588
rs882251-<b>C</b>,"1 x 10-6",,0.831,'-,"0.012 unit decrease",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218503341
rs882252-<b>A</b>,"1 x 10-6",,0.831,'-,"0.012 unit decrease",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218503622
rs56398881-<b>T</b>,"1 x 10-6",,0.831,'-,"0.012 unit decrease",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218505281
rs150751768-<b>A</b>,"1 x 10-6",,0.831,'-,"0.012 unit decrease",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218504461
rs11118118-<b>T</b>,"1 x 10-6",,0.829,'-,"0.012 unit decrease",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218520349
rs10429951-<b>A</b>,"1 x 10-6",,0.831,'-,"0.012 unit decrease",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218507634
rs72738851-<b>T</b>,"1 x 10-6",,0.831,'-,"0.012 unit decrease",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218507967
rs72738854-<b>A</b>,"1 x 10-6",,0.831,'-,"0.012 unit decrease",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218508919
rs7528401-<b>C</b>,"1 x 10-6",,0.831,'-,"0.012 unit decrease",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218507396
rs7532551-<b>A</b>,"1 x 10-6",,0.831,'-,"0.012 unit decrease",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218510194
rs2955130-<b>A</b>,"1 x 10-6",,0.838,'-,"0.012 unit decrease",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128218971
rs7536603-<b>A</b>,"1 x 10-6",,0.831,'-,"0.012 unit decrease",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218506048
rs2811486-<b>A</b>,"1 x 10-6",,0.838,'-,"0.012 unit decrease",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128201232
rs11706304-<b>A</b>,"1 x 10-6",,0.843,'-,"0.012 unit decrease",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128331771
rs12046780-<b>A</b>,"1 x 10-6",,0.832,'-,"0.012 unit decrease",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218500251
rs12026168-<b>C</b>,"1 x 10-6",,0.837,'-,"0.012 unit decrease",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218511504
rs56328893-<b>A</b>,"1 x 10-6",,0.842,'-,"0.012 unit decrease",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128322987
rs6675293-<b>A</b>,"1 x 10-6",,0.834,'-,"0.012 unit decrease",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218509485
rs11639181-<b>A</b>,"1 x 10-6",,0.406,'-,"0.01 unit increase",'-,"CHRNB4, ADAMTS7","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78731674
rs11639049-<b>A</b>,"1 x 10-6",,0.628,'-,"0.01 unit increase",'-,"ADAMTS7, CHRNB4","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78731388
rs1825083-<b>T</b>,"1 x 10-6",,0.628,'-,"0.01 unit increase",'-,"ADAMTS7, CHRNB4","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78731125
rs2869554-<b>T</b>,"1 x 10-6",,0.636,'-,"0.01 unit increase",'-,"CHRNB4, ADAMTS7","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78728695
rs11072805-<b>T</b>,"1 x 10-6",,0.629,'-,"0.01 unit increase",'-,ADAMTS7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78786176
rs10033824-<b>T</b>,"2 x 10-6",,0.744,'-,"0.01 unit increase",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88887588
rs8027972-<b>T</b>,"2 x 10-6",,0.647,'-,"0.01 unit increase",'-,"ADAMTS7, CHRNB4","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78730273
rs4886592-<b>T</b>,"2 x 10-6",,0.606,'-,"0.01 unit increase",'-,ADAMTS7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78790205
rs12508709-<b>T</b>,"2 x 10-6",,0.404,'-,"0.01 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144398392
rs12441354-<b>A</b>,"2 x 10-6",,0.22,'-,"0.01 unit increase",'-,HYKK,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78528674
rs4886582-<b>A</b>,"2 x 10-6",,0.658,'-,"0.01 unit increase",'-,"ADAMTS7, CHRNB4","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78729099
rs7164594-<b>T</b>,"2 x 10-6",,0.287,'-,"0.01 unit increase",'-,HYKK,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78510715
rs74925218-<b>T</b>,"3 x 10-6",,0.205,'-,"0.01 unit increase",'-,"HYKK, IREB2","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78504390
rs55955238-<b>T</b>,"3 x 10-6",,0.441,'-,"0.01 unit increase",'-,LHX1-DT,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,17:36913639
rs3025385-<b>T</b>,"3 x 10-6",,0.259,'-,"0.01 unit increase",'-,DBH,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,9:133637617
rs12438659-<b>A</b>,"3 x 10-6",,0.223,'-,"0.01 unit increase",'-,HYKK,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78532582
rs9672608-<b>A</b>,"3 x 10-6",,0.202,'-,"0.01 unit increase",'-,"IREB2, HYKK","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78505121
rs2036533-<b>A</b>,"4 x 10-6",,0.188,'-,"0.01 unit increase",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78489345
rs2036529-<b>A</b>,"4 x 10-6",,0.196,'-,"0.01 unit increase",'-,"IREB2, CRABP1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78433930
rs2938671-<b>A</b>,"4 x 10-6",,0.197,'-,"0.01 unit increase",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78440412
rs1286664-<b>T</b>,"4 x 10-6",,0.649,'-,"0.01 unit increase",'-,RARB,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:25487789
rs2869045-<b>T</b>,"4 x 10-6",,0.191,'-,"0.01 unit increase",'-,"IREB2, CRABP1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78426557
rs2938674-<b>A</b>,"5 x 10-6",,0.2,'-,"0.01 unit increase",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78465571
rs2568490-<b>T</b>,"5 x 10-6",,0.2,'-,"0.01 unit increase",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78446028
rs2656073-<b>T</b>,"5 x 10-6",,0.2,'-,"0.01 unit increase",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78449934
rs10021465-<b>A</b>,"2 x 10-7",,0.552,'-,"0.01 unit increase",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88829210
rs11638321-<b>T</b>,"3 x 10-7",,0.605,'-,"0.01 unit increase",'-,ADAMTS7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78799841
rs10047116-<b>A</b>,"3 x 10-7",,0.532,'-,"0.01 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218464949
rs11856536-<b>A</b>,"3 x 10-7",,0.603,'-,"0.01 unit increase",'-,ADAMTS7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78801983
rs8043009-<b>C</b>,"3 x 10-7",,0.237,'-,"0.01 unit increase",'-,CHRNA3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78615812
rs7663578-<b>A</b>,"3 x 10-7",,0.589,'-,"0.01 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144547639
rs11634450-<b>A</b>,"3 x 10-7",,0.603,'-,"0.01 unit increase",'-,ADAMTS7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78800859
rs10029430-<b>A</b>,"3 x 10-7",,0.616,'-,"0.01 unit increase",'-,"KRT18P51, HHIP-AS1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144577260
rs4834988-<b>A</b>,"4 x 10-7",,0.615,'-,"0.01 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144557625
rs62308745-<b>T</b>,"4 x 10-7",,0.698,'-,"0.01 unit increase",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88880152
rs3825807-<b>A</b>,"4 x 10-7",,0.604,'-,"0.01 unit increase",'-,ADAMTS7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78796769
rs575544-<b>A</b>,"4 x 10-7",,0.532,'-,"0.01 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218469799
rs623356-<b>T</b>,"4 x 10-7",,0.551,'-,"0.01 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218474044
rs6704255-<b>A</b>,"5 x 10-7",,0.311,'-,"0.01 unit increase",'-,TGFB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218444201
rs8038543-<b>A</b>,"5 x 10-7",,0.622,'-,"0.01 unit increase",'-,CHRNB4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78725343
rs7512679-<b>T</b>,"5 x 10-7",,0.323,'-,"0.01 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218461737
rs1342590-<b>T</b>,"6 x 10-7",,0.425,'-,"0.01 unit increase",'-,"LINC02869, TGFB2","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218446304
rs6683598-<b>T</b>,"6 x 10-7",,0.574,'-,"0.01 unit increase",'-,TGFB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218444558
rs12899147-<b>A</b>,"6 x 10-7",,0.605,'-,"0.01 unit increase",'-,ADAMTS7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78787170
rs76919723-<b>T</b>,"6 x 10-7",,0.625,'-,"0.01 unit increase",'-,CHRNB4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78724939
rs35583595-<b>C</b>,"7 x 10-7",,0.623,'-,"0.01 unit increase",'-,"ADAMTS7, CHRNB4","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78727810
rs12903203-<b>T</b>,"8 x 10-7",,0.605,'-,"0.01 unit increase",'-,ADAMTS7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78792591
rs8042494-<b>T</b>,"8 x 10-7",,0.237,'-,"0.01 unit increase",'-,CHRNA3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78615668
rs34225855-<b>C</b>,"9 x 10-7",,0.628,'-,"0.01 unit increase",'-,"ADAMTS7, CHRNB4","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78729794
rs2277545-<b>T</b>,"1 x 10-6",,0.605,'-,"0.01 unit increase",'-,ADAMTS7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78791249
rs615098-<b>T</b>,"6 x 10-8",,0.769,'-,"0.012 unit increase",'-,"MMP3, MMP12","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102849947
rs660599-<b>A</b>,"7 x 10-8",,0.222,'-,"0.012 unit increase",'-,"MMP3, MMP12","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102859026
rs189218934-<b>T</b>,"1 x 10-7",,0.392,'-,"0.012 unit increase",'-,CHRNA3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78611645
rs12593950-<b>C</b>,"1 x 10-7",,0.234,'-,"0.012 unit increase",'-,CHRNB4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78628593
rs644885-<b>A</b>,"2 x 10-7",,0.217,'-,"0.012 unit increase",'-,"MMP3, MMP12","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102857881
rs10863398-<b>A</b>,"2 x 10-7",,0.207,'-,"0.012 unit increase",'-,TGFB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218414937
rs113352275-<b>T</b>,"3 x 10-7",,0.185,'-,"0.012 unit increase",'-,PSMA4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78548225
rs2316205-<b>T</b>,"4 x 10-7",,0.549,'-,"0.012 unit increase",'-,"CYP2F2P, CYP2A6","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,19:40840863
rs35474770-<b>A</b>,"4 x 10-7",,0.622,'-,"0.012 unit increase",'-,ADAMTS7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78781658
rs12050525-<b>T</b>,"5 x 10-7",,0.622,'-,"0.012 unit increase",'-,ADAMTS7,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78783404
rs4887084-<b>T</b>,"5 x 10-7",,0.633,'-,"0.012 unit increase",'-,"ADAMTS7, CHRNB4","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78733251
rs2955098-<b>T</b>,"6 x 10-7",,0.164,'-,"0.012 unit increase",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128260658
rs1890994-<b>T</b>,"6 x 10-7",,0.615,'-,"0.012 unit increase",'-,TGFB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218431367
rs72738830-<b>A</b>,"7 x 10-7",,0.183,'-,"0.012 unit increase",'-,TGFB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218424290
rs4572101-<b>T</b>,"7 x 10-7",,0.198,'-,"0.012 unit increase",'-,"MMP13, DCUN1D5","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,11:102966830
rs2955081-<b>A</b>,"7 x 10-7",,0.163,'-,"0.012 unit increase",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128241456
rs6765233-<b>T</b>,"7 x 10-7",,0.162,'-,"0.012 unit increase",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128284007
rs2811381-<b>A</b>,"8 x 10-7",,0.162,'-,"0.012 unit increase",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128279069
rs35755165-<b>A</b>,"8 x 10-7",,0.562,'-,"0.012 unit increase",'-,"CYP2F2P, CYP2A6","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,19:40840084
rs2811528-<b>A</b>,"9 x 10-7",,0.162,'-,"0.012 unit increase",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128275593
rs12045035-<b>A</b>,"9 x 10-7",,0.17,'-,"0.012 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218521705
rs61044849-<b>T</b>,"9 x 10-7",,0.157,'-,"0.012 unit increase",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128346623
rs2955096-<b>A</b>,"9 x 10-7",,0.162,'-,"0.012 unit increase",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128259023
rs28395178-<b>A</b>,"9 x 10-7",,0.191,'-,"0.012 unit increase",'-,"CHRNA5, PSMA4","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78558216
rs2955077-<b>A</b>,"9 x 10-7",,0.162,'-,"0.012 unit increase",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128240026
rs16969894-<b>T</b>,"3 x 10-6",,0.189,'-,"0.011 unit increase",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78484114
rs11627441-<b>A</b>,"4 x 10-6",,0.162,'-,"0.011 unit increase",'-,RIN3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:92632889
rs2687730-<b>T</b>,"4 x 10-6",,0.153,'-,"0.011 unit increase",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128196614
rs1498604-<b>A</b>,"4 x 10-6",,0.768,'-,"0.011 unit increase",'-,PDE4D,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,5:59037333
rs2869967-<b>T</b>,"7 x 10-12",,0.393,'-,"0.012 unit increase",'-,FAM13A,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:88948181
rs8040868-<b>T</b>,"9 x 10-12",,0.433,'-,"0.012 unit increase",'-,CHRNA3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78618839
rs931794-<b>A</b>,"4 x 10-11",,0.407,'-,"0.012 unit increase",'-,HYKK,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78533838
rs1960493-<b>A</b>,"1 x 10-10",,0.34,'-,"0.012 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144504600
rs1512283-<b>T</b>,"1 x 10-10",,0.34,'-,"0.012 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144509941
rs17483721-<b>T</b>,"2 x 10-10",,0.403,'-,"0.012 unit increase",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78441389
rs56219465-<b>A</b>,"2 x 10-10",,0.669,'-,"0.012 unit increase",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78450237
rs7181486-<b>T</b>,"2 x 10-10",,0.669,'-,"0.012 unit increase",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78449276
rs17483686-<b>A</b>,"3 x 10-10",,0.67,'-,"0.012 unit increase",'-,IREB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78441048
rs12499537-<b>T</b>,"4 x 10-10",,0.298,'-,"0.012 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144426946
rs186854840-<b>T</b>,"1 x 10-9",,0.348,'-,"0.012 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144396313
rs1394998-<b>T</b>,"2 x 10-9",,0.727,'-,"0.012 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144381003
rs1505766-<b>T</b>,"2 x 10-9",,0.274,'-,"0.012 unit increase",'-,STX18,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144387147
rs11633178-<b>A</b>,"2 x 10-9",,0.622,'-,"0.012 unit increase",'-,CHRNB4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78652196
rs72743199-<b>A</b>,"8 x 10-9",,0.613,'-,"0.012 unit increase",'-,CHRNB4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78683513
rs12899135-<b>A</b>,"1 x 10-8",,0.612,'-,"0.012 unit increase",'-,CHRNB4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78662037
rs7173514-<b>T</b>,"1 x 10-8",,0.234,'-,"0.012 unit increase",'-,"PSMA4, CHRNA5","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78557576
rs12048582-<b>T</b>,"2 x 10-8",,0.193,'-,"0.012 unit increase",'-,TGFB2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218419695
rs7183604-<b>T</b>,"2 x 10-8",,0.239,'-,"0.012 unit increase",'-,CHRNA3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78606871
rs28498264-<b>T</b>,"3 x 10-8",,0.213,'-,"0.012 unit increase",'-,PSMA4,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78545331
rs6495309-<b>T</b>,"5 x 10-8",,0.367,'-,"0.012 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,"Mapping not available"
rs2811530-<b>A</b>,"2 x 10-6",,0.168,'-,"0.012 unit increase",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128274323
rs11710627-<b>C</b>,"2 x 10-6",,0.165,'-,"0.012 unit increase",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128328166
rs11710704-<b>A</b>,"2 x 10-6",,0.165,'-,"0.012 unit increase",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128328393
rs55925538-<b>A</b>,"2 x 10-6",,0.165,'-,"0.012 unit increase",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128324034
rs73197388-<b>T</b>,"2 x 10-6",,0.165,'-,"0.012 unit increase",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128325077
rs12039493-<b>A</b>,"2 x 10-6",,0.175,'-,"0.012 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218504957
rs35347185-<b>T</b>,"2 x 10-6",,0.158,'-,"0.012 unit increase",'-,RUVBL1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128135684
rs6665024-<b>A</b>,"2 x 10-6",,0.693,'-,"0.012 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218517235
rs11706455-<b>A</b>,"2 x 10-6",,0.167,'-,"0.012 unit increase",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128173148
rs11714619-<b>A</b>,"2 x 10-6",,0.158,'-,"0.012 unit increase",'-,RUVBL1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128131233
rs2999077-<b>A</b>,"2 x 10-6",,0.164,'-,"0.012 unit increase",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128239571
rs6693039-<b>C</b>,"2 x 10-6",,0.165,'-,"0.012 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218481165
rs13059975-<b>T</b>,"2 x 10-6",,0.158,'-,"0.012 unit increase",'-,RUVBL1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128130841
rs12040383-<b>A</b>,"2 x 10-6",,0.169,'-,"0.012 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218511718
rs13095660-<b>T</b>,"3 x 10-6",,0.158,'-,"0.012 unit increase",'-,RUVBL1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128129313
rs6788497-<b>T</b>,"3 x 10-6",,0.158,'-,"0.012 unit increase",'-,RUVBL1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128129545
rs7553145-<b>T</b>,"3 x 10-6",,0.171,'-,"0.012 unit increase",'-,LINC02869,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:218508210
rs10934850-<b>A</b>,"4 x 10-6",,0.676,'-,"0.012 unit increase",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128168114
rs13067650-<b>A</b>,"4 x 10-6",,0.153,'-,"0.012 unit increase",'-,EEFSEC,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128170699
rs66987356-<b>A</b>,"4 x 10-6",,0.145,'-,"0.012 unit increase",'-,RUVBL1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128122255
rs35421223-<b>A</b>,"4 x 10-6",,0.145,'-,"0.012 unit increase",'-,RUVBL1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128111036
rs11714052-<b>A</b>,"5 x 10-6",,0.145,'-,"0.012 unit increase",'-,RUVBL1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128095614
rs35515217-<b>T</b>,"5 x 10-6",,0.145,'-,"0.012 unit increase",'-,RUVBL1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:128094968
rs12501071-<b>T</b>,"7 x 10-14",,0.409,'-,"0.013 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144569207
rs1512288-<b>A</b>,"8 x 10-14",,0.451,'-,"0.013 unit increase",'-,KRT18P51,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:144570129
rs6784159-<b>T</b>,"2 x 10-6",,0.839,'-,"0.058 unit decrease",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128124535
rs33998546-<b>T</b>,"2 x 10-6",,0.839,'-,"0.058 unit decrease",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128112195
rs35145572-<b>C</b>,"2 x 10-6",,0.836,'-,"0.058 unit decrease",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128128575
rs55777628-<b>T</b>,"2 x 10-6",,0.84,'-,"0.058 unit decrease",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128103178
rs34955225-<b>A</b>,"3 x 10-6",,0.847,'-,"0.058 unit decrease",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128106235
rs11719079-<b>C</b>,"3 x 10-6",,0.847,'-,"0.058 unit decrease",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128105206
rs12261331-<b>T</b>,"4 x 10-6",,0.149,'-,"0.058 unit decrease",NR,TSPAN14,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,10:80527771
rs2045517-<b>T</b>,"1 x 10-10",,0.481,'-,"0.057 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88949813
rs6537296-<b>A</b>,"2 x 10-10",,0.628,'-,"0.057 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144566782
rs12592111-<b>A</b>,"8 x 10-10",,0.535,'-,"0.057 unit decrease",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78475004
rs12500355-<b>T</b>,"2 x 10-8",,0.723,'-,"0.057 unit decrease",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144400670
rs2568497-<b>T</b>,"2 x 10-7",,0.811,'-,"0.057 unit decrease",NR,"IREB2, CRABP1","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78429055
rs4886586-<b>A</b>,"1 x 10-6",,0.355,'-,"0.057 unit decrease",NR,"ADAMTS7, CHRNB4","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78734332
rs60464856-<b>A</b>,"2 x 10-6",,0.836,'-,"0.057 unit decrease",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128123377
rs34228187-<b>T</b>,"2 x 10-6",,0.836,'-,"0.057 unit decrease",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128097590
rs13082038-<b>C</b>,"3 x 10-6",,0.844,'-,"0.057 unit decrease",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128109613
rs112434347-<b>C</b>,"3 x 10-6",,0.846,'-,"0.057 unit decrease",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128121604
rs138573550-<b>A</b>,"3 x 10-6",,0.842,'-,"0.057 unit decrease",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128121182
rs35947214-<b>C</b>,"3 x 10-6",,0.842,'-,"0.057 unit decrease",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128114388
rs67940364-<b>T</b>,"3 x 10-6",,0.842,'-,"0.057 unit decrease",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128114510
rs6785535-<b>A</b>,"3 x 10-6",,0.842,'-,"0.057 unit decrease",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128115852
rs11720239-<b>A</b>,"3 x 10-6",,0.673,'-,"0.057 unit decrease",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128099112
rs36059338-<b>C</b>,"3 x 10-6",,0.846,'-,"0.057 unit decrease",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128097084
rs34403909-<b>A</b>,"3 x 10-6",,0.843,'-,"0.057 unit decrease",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128091602
rs35724792-<b>A</b>,"3 x 10-6",,0.846,'-,"0.057 unit decrease",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128090773
rs6537293-<b>A</b>,"9 x 10-10",,0.618,'-,"0.054 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144558609
rs1062980-<b>T</b>,"1 x 10-9",,0.365,'-,"0.054 unit decrease",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78500185
rs922692-<b>A</b>,"2 x 10-8",,0.392,'-,"0.054 unit decrease",NR,CHRNB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78691872
rs12910627-<b>C</b>,"3 x 10-8",,0.388,'-,"0.054 unit decrease",NR,CHRNB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78702591
rs4886579-<b>T</b>,"3 x 10-8",,0.389,'-,"0.054 unit decrease",NR,CHRNB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78676914
rs12910984-<b>A</b>,"9 x 10-8",,0.613,'-,"0.054 unit decrease",NR,CHRNA3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78599285
rs8042374-<b>A</b>,"1 x 10-7",,0.627,'-,"0.054 unit decrease",NR,CHRNA3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78615690
rs8042059-<b>A</b>,"1 x 10-7",,0.76,'-,"0.054 unit decrease",NR,CHRNA3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78615517
rs7177514-<b>C</b>,"1 x 10-7",,0.76,'-,"0.054 unit decrease",NR,CHRNA3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78615064
rs6495308-<b>T</b>,"1 x 10-7",,0.373,'-,"0.054 unit decrease",NR,CHRNA3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78615314
rs2958719-<b>A</b>,"6 x 10-7",,0.8,'-,"0.054 unit decrease",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78450687
rs148200221-<b>A</b>,"7 x 10-7",,0.661,'-,"0.054 unit decrease",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144397211
rs2656069-<b>T</b>,"7 x 10-7",,0.648,'-,"0.054 unit decrease",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78453365
rs674546-<b>A</b>,"1 x 10-6",,0.78,'-,"0.054 unit decrease",NR,"MMP12, MMP3","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:102859908
rs4887083-<b>T</b>,"1 x 10-6",,0.373,'-,"0.054 unit decrease",NR,"ADAMTS7, CHRNB4","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78733235
rs662558-<b>T</b>,"2 x 10-6",,0.778,'-,"0.054 unit decrease",NR,"MMP3, MMP12","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:102847964
rs7655625-<b>T</b>,"1 x 10-9",,0.43,'-,"0.053 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144564763
rs8042238-<b>T</b>,"4 x 10-9",,0.549,'-,"0.053 unit decrease",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78481929
rs36146269-<b>A</b>,"5 x 10-9",,0.548,'-,"0.053 unit decrease",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78487168
rs4887059-<b>T</b>,"5 x 10-9",,0.546,'-,"0.053 unit decrease",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78489753
rs4299116-<b>A</b>,"6 x 10-9",,0.548,'-,"0.053 unit decrease",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78473852
rs4362358-<b>T</b>,"6 x 10-9",,0.548,'-,"0.053 unit decrease",NR,"IREB2, HYKK","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78503762
rs11637656-<b>T</b>,"6 x 10-9",,0.55,'-,"0.053 unit decrease",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78459619
rs11072790-<b>T</b>,"3 x 10-8",,0.388,'-,"0.053 unit decrease",NR,CHRNB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78699683
rs11072785-<b>T</b>,"3 x 10-8",,0.389,'-,"0.053 unit decrease",NR,CHRNB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78675887
rs11634543-<b>T</b>,"8 x 10-8",,0.382,'-,"0.051 unit decrease",NR,CHRNB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78713162
rs28602288-<b>T</b>,"3 x 10-7",,0.626,'-,"0.051 unit decrease",NR,"CYP2A7, CYP2G1P","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,19:40882835
rs3025383-<b>T</b>,"9 x 10-7",,0.718,'-,"0.051 unit decrease",NR,DBH,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,9:133637247
rs4886583-<b>A</b>,"1 x 10-6",,0.344,'-,"0.051 unit decrease",NR,"CHRNB4, ADAMTS7","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78729103
rs2013701-<b>T</b>,"7 x 10-9",,0.514,'-,"0.05 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88963935
rs7681384-<b>T</b>,"1 x 10-8",,0.412,'-,"0.05 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144515862
rs4835637-<b>A</b>,"4 x 10-8",,0.397,'-,"0.05 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144517875
rs1512285-<b>A</b>,"5 x 10-8",,0.428,'-,"0.05 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144529807
rs11638490-<b>T</b>,"1 x 10-7",,0.381,'-,"0.05 unit decrease",NR,CHRNB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78715608
rs58281712-<b>C</b>,"2 x 10-7",,0.299,'-,"0.05 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88889805
rs7359276-<b>T</b>,"4 x 10-7",,0.688,'-,"0.05 unit decrease",NR,CHRNA3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78600319
rs34275594-<b>A</b>,"4 x 10-7",,0.703,'-,"0.05 unit decrease",NR,CHRNB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78688940
rs1394371-<b>T</b>,"5 x 10-7",,0.721,'-,"0.05 unit decrease",NR,"IREB2, CRABP1","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78432127
rs72480748-<b>A</b>,"6 x 10-7",,0.285,'-,"0.05 unit decrease",NR,"CYP2G1P, CYP2A7P2","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,19:40908576
rs4886584-<b>A</b>,"1 x 10-6",,0.347,'-,"0.05 unit decrease",NR,"ADAMTS7, CHRNB4","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78729122
rs6821114-<b>A</b>,"9 x 10-8",,0.395,'-,"0.049 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144531237
rs6822064-<b>T</b>,"1 x 10-7",,0.318,'-,"0.049 unit decrease",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144342604
rs4266245-<b>A</b>,"1 x 10-7",,0.315,'-,"0.049 unit decrease",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144346628
rs4493485-<b>T</b>,"1 x 10-7",,0.315,'-,"0.049 unit decrease",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144346482
rs4340757-<b>C</b>,"1 x 10-7",,0.315,'-,"0.049 unit decrease",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144349919
rs10028589-<b>T</b>,"3 x 10-7",,0.296,'-,"0.049 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88919909
rs7687539-<b>A</b>,"3 x 10-7",,0.298,'-,"0.049 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88885633
rs13107665-<b>A</b>,"3 x 10-7",,0.424,'-,"0.049 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144551492
rs4693975-<b>T</b>,"3 x 10-7",,0.3,'-,"0.049 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88900733
rs7695732-<b>C</b>,"3 x 10-7",,0.3,'-,"0.049 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88911640
rs3813567-<b>A</b>,"1 x 10-7",,0.808,'-,"0.059 unit decrease",NR,CHRNB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78642209
rs2656071-<b>A</b>,"2 x 10-7",,0.811,'-,"0.059 unit decrease",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78453001
rs3894347-<b>A</b>,"4 x 10-7",,0.362,'-,"0.059 unit decrease",NR,"CHRNB4, ADAMTS7","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78733659
rs34409786-<b>A</b>,"9 x 10-7",,0.839,'-,"0.059 unit decrease",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128169332
rs2811392-<b>A</b>,"1 x 10-6",,0.836,'-,"0.059 unit decrease",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128305133
rs2955085-<b>A</b>,"1 x 10-6",,0.84,'-,"0.059 unit decrease",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128243914
rs2999072-<b>C</b>,"1 x 10-6",,0.84,'-,"0.059 unit decrease",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128244033
rs2955088-<b>T</b>,"1 x 10-6",,0.84,'-,"0.059 unit decrease",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128244867
rs2955130-<b>A</b>,"1 x 10-6",,0.84,'-,"0.059 unit decrease",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128218971
rs2999080-<b>A</b>,"1 x 10-6",,0.84,'-,"0.059 unit decrease",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128237865
rs2999083-<b>T</b>,"1 x 10-6",,0.84,'-,"0.059 unit decrease",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128235591
rs2811486-<b>A</b>,"1 x 10-6",,0.839,'-,"0.059 unit decrease",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128201232
rs62533402-<b>T</b>,"3 x 10-6",,0.84,'-,"0.059 unit decrease",NR,DOCK8,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,9:306734
rs12904234-<b>T</b>,"9 x 10-11",,0.566,'-,"0.058 unit decrease",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78487042
rs1108581-<b>A</b>,"9 x 10-9",,0.292,'-,"0.058 unit decrease",NR,DBH,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,9:133640119
rs6834183-<b>T</b>,"1 x 10-8",,0.724,'-,"0.058 unit decrease",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144349803
rs17766287-<b>T</b>,"1 x 10-8",,0.275,'-,"0.058 unit decrease",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144357685
rs2568488-<b>A</b>,"2 x 10-7",,0.811,'-,"0.058 unit decrease",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78444251
rs2568485-<b>T</b>,"2 x 10-7",,0.811,'-,"0.058 unit decrease",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78459772
rs654600-<b>A</b>,"2 x 10-7",,0.793,'-,"0.058 unit decrease",NR,"MMP3, MMP12","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:102858443
rs10851906-<b>A</b>,"2 x 10-7",,0.811,'-,"0.058 unit decrease",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78482334
rs924840-<b>A</b>,"2 x 10-7",,0.811,'-,"0.058 unit decrease",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78439466
rs2869032-<b>T</b>,"3 x 10-7",,0.819,'-,"0.058 unit decrease",NR,"IREB2, CRABP1","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78422219
rs2811400-<b>A</b>,"1 x 10-6",,0.84,'-,"0.058 unit decrease",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128269024
rs2811414-<b>C</b>,"1 x 10-6",,0.84,'-,"0.058 unit decrease",NR,EEFSEC,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128272334
rs13060453-<b>T</b>,"3 x 10-6",,0.846,'-,"0.057 unit decrease",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128091895
rs12901913-<b>T</b>,"2 x 10-8",,0.392,'-,"0.056 unit decrease",NR,CHRNB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78689006
rs28602670-<b>C</b>,"5 x 10-7",,0.81,'-,"0.056 unit decrease",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78475825
rs77438389-<b>C</b>,"6 x 10-7",,0.798,'-,"0.056 unit decrease",NR,"CRABP1, IREB2","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78433929
rs4886587-<b>A</b>,"9 x 10-7",,0.377,'-,"0.056 unit decrease",NR,"ADAMTS7, CHRNB4","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78734480
rs9633740-<b>A</b>,"2 x 10-6",,0.187,'-,"0.056 unit decrease",NR,TSPAN14,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,10:80505515
rs11719546-<b>A</b>,"3 x 10-6",,0.834,'-,"0.056 unit decrease",NR,"RUVBL1, EEFSEC","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128153759
rs138914938-<b>C</b>,"3 x 10-6",,0.382,'-,"0.056 unit decrease",NR,ADAMTS7,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78781112
rs67674204-<b>A</b>,"4 x 10-6",,0.841,'-,"0.056 unit decrease",NR,RUVBL1,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:128105935
rs11639372-<b>T</b>,"5 x 10-9",,0.384,'-,"0.055 unit decrease",NR,CHRNB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78674313
rs2170311-<b>A</b>,"8 x 10-9",,0.379,'-,"0.055 unit decrease",NR,CHRNB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78655269
rs4887077-<b>T</b>,"2 x 10-8",,0.43,'-,"0.055 unit decrease",NR,CHRNB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78686022
rs11072791-<b>A</b>,"2 x 10-8",,0.391,'-,"0.055 unit decrease",NR,CHRNB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78704734
rs7181447-<b>A</b>,"1 x 10-7",,0.776,'-,"0.055 unit decrease",NR,HYKK,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78522225
rs4461039-<b>A</b>,"2 x 10-7",,0.777,'-,"0.055 unit decrease",NR,HYKK,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78525105
rs28480606-<b>A</b>,"4 x 10-7",,0.8,'-,"0.055 unit decrease",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78469971
rs10482796-<b>T</b>,"5 x 10-7",,0.809,'-,"0.055 unit decrease",NR,TGFB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:218432293
rs72738834-<b>A</b>,"5 x 10-7",,0.809,'-,"0.055 unit decrease",NR,"TGFB2, LINC02869","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:218450546
rs2656055-<b>A</b>,"5 x 10-7",,0.802,'-,"0.055 unit decrease",NR,"CRABP1, IREB2","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78427852
rs1993484-<b>T</b>,"6 x 10-7",,0.228,'-,"0.055 unit decrease",NR,TSPAN14,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,10:80462942
rs12023953-<b>T</b>,"6 x 10-7",,0.81,'-,"0.055 unit decrease",NR,"LINC02869, TGFB2","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:218449297
rs4887086-<b>T</b>,"1 x 10-6",,0.376,'-,"0.055 unit decrease",NR,"CHRNB4, ADAMTS7","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78734187
rs12908207-<b>T</b>,"1 x 10-6",,0.372,'-,"0.055 unit decrease",NR,"ADAMTS7, CHRNB4","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78733621
rs10746379-<b>A</b>,"3 x 10-6",,0.824,'-,"0.055 unit decrease",NR,TGFB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:218402545
rs12506874-<b>A</b>,"7 x 10-10",,0.613,'-,"0.054 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144546060
rs1021071-<b>C</b>,"5 x 10-8",,0.391,'-,"0.053 unit decrease",NR,CHRNB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78675837
rs11634351-<b>A</b>,"6 x 10-8",,0.39,'-,"0.053 unit decrease",NR,CHRNB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78652376
rs11638372-<b>T</b>,"8 x 10-8",,0.424,'-,"0.053 unit decrease",NR,'-,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,"Mapping not available"
rs4420500-<b>T</b>,"1 x 10-7",,0.375,'-,"0.053 unit decrease",NR,CHRNB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78670622
rs4887069-<b>A</b>,"2 x 10-7",,0.758,'-,"0.053 unit decrease",NR,CHRNA3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78616728
rs67175876-<b>A</b>,"2 x 10-7",,0.676,'-,"0.053 unit decrease",NR,CHRNB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78636057
rs2568493-<b>A</b>,"8 x 10-7",,0.8,'-,"0.053 unit decrease",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78447891
rs2568483-<b>A</b>,"9 x 10-7",,0.799,'-,"0.053 unit decrease",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78460001
rs10028679-<b>T</b>,"2 x 10-6",,0.259,'-,"0.053 unit decrease",NR,FAM13A,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:88920019
rs1489759-<b>A</b>,"1 x 10-9",,0.466,'-,"0.052 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144553321
rs2130339-<b>A</b>,"3 x 10-9",,0.581,'-,"0.052 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144543733
rs6830832-<b>T</b>,"3 x 10-9",,0.577,'-,"0.052 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144544339
rs6831503-<b>A</b>,"3 x 10-9",,0.58,'-,"0.052 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144550793
rs7677035-<b>A</b>,"6 x 10-9",,0.57,'-,"0.052 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144516167
rs1504549-<b>T</b>,"7 x 10-9",,0.549,'-,"0.052 unit decrease",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78474287
rs13180-<b>T</b>,"8 x 10-9",,0.452,'-,"0.052 unit decrease",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78497146
rs965604-<b>A</b>,"9 x 10-9",,0.53,'-,"0.052 unit decrease",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78496881
rs12910910-<b>T</b>,"1 x 10-8",,0.55,'-,"0.052 unit decrease",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78475508
rs12594711-<b>T</b>,"1 x 10-8",,0.543,'-,"0.052 unit decrease",NR,"HYKK, IREB2","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78501579
rs11638830-<b>C</b>,"7 x 10-8",,0.39,'-,"0.052 unit decrease",NR,CHRNB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78655977
rs8192478-<b>A</b>,"2 x 10-7",,0.684,'-,"0.052 unit decrease",NR,CHRNA3,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78618120
rs7084416-<b>A</b>,"3 x 10-6",,0.193,'-,"0.052 unit decrease",NR,SH2D4B,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,10:80544541
rs7097610-<b>T</b>,"5 x 10-6",,0.181,'-,"0.052 unit decrease",NR,SH2D4B,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,10:80544406
rs1828591-<b>A</b>,"4 x 10-9",,0.535,'-,"0.051 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144559628
rs11100860-<b>A</b>,"4 x 10-9",,0.58,'-,"0.051 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144557987
rs150174091-<b>G</b>,"5 x 10-6",(AA),0.999,'-,"0.262 unit increase",'-,HEATR1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,1:236584261
rs185603859-<b>G</b>,"5 x 10-6",(AA),0.999,'-,"0.229 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,13:63474356
rs11175944-<b>C</b>,"5 x 10-6",(AA),0.312,'-,"0.016 unit decrease",'-,"HMGA2, HMGA2-AS1","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,12:65862615
rs56681491-<b>G</b>,"5 x 10-6",(AA),0.695,'-,"0.016 unit increase",'-,PRKN,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,6:162415192
rs180919520-<b>C</b>,"5 x 10-6",(AA),0.997,'-,"0.218 unit increase",'-,"FAM193A, TNIP2","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:2737648
rs60338266-<b>A</b>,"5 x 10-6",(AA),0.695,'-,"0.016 unit increase",'-,PRKN,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,6:162415180
rs7658560-<b>T</b>,"5 x 10-6",(AA),0.626,'-,"0.015 unit decrease",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97714221
rs7658798-<b>G</b>,"5 x 10-6",(AA),0.626,'-,"0.015 unit decrease",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97714434
rs7676966-<b>C</b>,"5 x 10-6",(AA),0.562,'-,"0.015 unit decrease",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97625522
rs2859815-<b>C</b>,"5 x 10-6",(AA),0.826,'-,"0.021 unit increase",'-,LINC01179,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:165751684
rs149069622-<b>G</b>,"5 x 10-6",(AA),0.999,'-,"0.383 unit increase",'-,GALNT11,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,7:152052174
rs182033693-<b>C</b>,"5 x 10-6",(AA),1.0,'-,"0.54 unit increase",'-,GALNT17,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,7:71157441
rs61154600-<b>T</b>,"5 x 10-6",(AA),0.56,'-,"0.015 unit decrease",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97590469
rs58276078-<b>C</b>,"5 x 10-6",(AA),0.56,'-,"0.015 unit decrease",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97590475
rs56880249-<b>C</b>,"5 x 10-6",(AA),0.56,'-,"0.015 unit decrease",'-,STPG2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:97589677
rs183529902-<b>C</b>,"5 x 10-6",(AA),0.998,'-,"0.26 unit increase",'-,'-,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,8:36022514
rs56077333-<b>A</b>,"6 x 10-6",(AA),0.82,'-,"0.02 unit increase",'-,CHRNA3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,15:78606661
rs192087058-<b>A</b>,"2 x 10-6",(AA),0.998,'-,"0.211 unit increase",'-,THEMIS,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,6:127890661
rs140660435-<b>C</b>,"2 x 10-6",(AA),1.0,'-,"0.51 unit increase",'-,"LINC02305, RNU6ATAC28P","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,14:83825919
rs190951784-<b>A</b>,"2 x 10-6",(AA),0.995,'-,"0.145 unit increase",'-,DOCK5,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,8:25274007
rs150612539-<b>C</b>,"2 x 10-6",(AA),1.0,'-,"0.441 unit increase",'-,PLAGL1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,6:143952786
rs73839334-<b>A</b>,"2 x 10-6",(AA),0.991,'-,"0.09 unit increase",'-,CXXC4-AS1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,4:104730381
rs149667740-<b>G</b>,"2 x 10-6",(AA),0.999,'-,"0.362 unit increase",'-,FGF12,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:192299812
rs111751834-<b>G</b>,"2 x 10-6",(AA),0.954,'-,"0.039 unit increase",'-,NXPH1,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,7:8412106
rs144261207-<b>A</b>,"2 x 10-6",(AA),0.997,'-,"0.179 unit increase",'-,MYL3,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:46869103
rs144222594-<b>A</b>,"2 x 10-6",(AA),0.998,'-,"0.234 unit increase",'-,"DLC1, RNU6-842P","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,8:13073995
rs78274021-<b>T</b>,"2 x 10-6",(AA),0.998,'-,"0.27 unit increase",'-,GAP43,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,3:115616672
rs185237819-<b>G</b>,"2 x 10-6",(AA),1.0,'-,"0.631 unit increase",'-,LHFPL2,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,5:78749087
rs12700745-<b>G</b>,"2 x 10-6",(AA),0.805,'-,"0.019 unit increase",'-,KIAA0087,"Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,7:26530916
rs148169454-<b>A</b>,"2 x 10-6",(AA),0.989,'-,"0.087 unit increase",'-,"OR7E28P, OR7E90P","Post bronchodilator FEV1/FVC ratio","response to bronchodilator, FEV/FEC ratio",GCST003264,2:158872545
rs6817238-<b>T</b>,"3 x 10-13",,0.687,'-,"0.076 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144542381
rs8031948-<b>T</b>,"3 x 10-15",,0.336,'-,"0.075 unit decrease",NR,HYKK,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78523715
rs72740955-<b>T</b>,"1 x 10-14",,0.338,'-,"0.075 unit decrease",NR,"PSMA4, CHRNA5","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78557437
rs72738704-<b>C</b>,"2 x 10-13",,0.34,'-,"0.075 unit decrease",NR,"IREB2, CRABP1","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78427490
rs17282209-<b>T</b>,"1 x 10-6",,0.883,'-,"0.075 unit decrease",NR,MGLL,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,3:127996353
rs13140176-<b>A</b>,"1 x 10-13",,0.65,'-,"0.074 unit decrease",NR,"KRT18P51, THEGL","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144567946
rs17405217-<b>T</b>,"2 x 10-13",,0.336,'-,"0.074 unit decrease",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78438807
rs17483548-<b>A</b>,"3 x 10-13",,0.336,'-,"0.074 unit decrease",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78437971
rs11858836-<b>A</b>,"3 x 10-13",,0.336,'-,"0.074 unit decrease",NR,IREB2,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78490935
rs2869548-<b>A</b>,"4 x 10-13",,0.367,'-,"0.074 unit decrease",NR,CHRNB4,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78630296
rs737693-<b>A</b>,"9 x 10-7",,0.885,'-,"0.073 unit decrease",NR,"MMP12, MMP3","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:102855411
rs72983513-<b>T</b>,"9 x 10-7",,0.886,'-,"0.073 unit decrease",NR,"MMP12, MMP3","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:102858254
rs28381684-<b>A</b>,"1 x 10-6",,0.886,'-,"0.073 unit decrease",NR,MMP12,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,11:102866461
rs140237746-<b>A</b>,"5 x 10-6",,0.145,'-,"0.073 unit decrease",NR,"RNU6-907P, GPRIN3","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:89150413
rs12121801-<b>T</b>,"5 x 10-6",,0.905,'-,"0.073 unit decrease",NR,LINC02785,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,1:108058660
rs1512973-<b>G</b>,"5 x 10-6",(AA),0.4,'-,"0.073 unit decrease",NR,IL21,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:122584901
rs13141641-<b>T</b>,"4 x 10-14",,0.63,'-,"0.072 unit decrease",NR,"HHIP-AS1, KRT18P51","Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144585304
rs1512281-<b>A</b>,"6 x 10-14",,0.628,'-,"0.072 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,4:144513749
rs72738786-<b>T</b>,"8 x 10-14",,0.336,'-,"0.072 unit decrease",NR,HYKK,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78535744
rs12913260-<b>A</b>,"7 x 10-8",,0.374,'-,"0.072 unit decrease",NR,ADAMTS7,"Post bronchodilator FEV1","forced expiratory volume, response to bronchodilator",GCST003262,15:78778753
chr8:83741379-<b>?</b>,"2 x 10-6",,NR,'-,"5.0755 unit decrease",[2.98-7.17],'-,"Post-bronchodilator lung function in asthma (FVC)","response to bronchodilator, asthma, vital capacity",GCST011800,"Mapping not available"
chr8:119895298-<b>?</b>,"4 x 10-7",,NR,'-,"11.6893 unit increase",[7.16-16.22],'-,"Post-bronchodilator lung function in asthma (FVC)","response to bronchodilator, asthma, vital capacity",GCST011800,"Mapping not available"
chr11:118932913-<b>?</b>,"9 x 10-9",,NR,'-,"18.9094 unit increase",[12.46-25.36],'-,"Post-bronchodilator lung function in asthma (FVC)","response to bronchodilator, asthma, vital capacity",GCST011800,"Mapping not available"
chr12:107662094-<b>?</b>,"7 x 10-7",,NR,'-,"5.1924 unit decrease",[3.13-7.25],'-,"Post-bronchodilator lung function in asthma (FVC)","response to bronchodilator, asthma, vital capacity",GCST011800,"Mapping not available"
chr12:115797499-<b>?</b>,"6 x 10-7",,NR,'-,"6.6259 unit increase",[4.02-9.23],'-,"Post-bronchodilator lung function in asthma (FVC)","response to bronchodilator, asthma, vital capacity",GCST011800,"Mapping not available"
chr17:74377172-<b>?</b>,"5 x 10-7",,NR,'-,"4.8181 unit increase",[2.95-6.69],'-,"Post-bronchodilator lung function in asthma (FVC)","response to bronchodilator, asthma, vital capacity",GCST011800,"Mapping not available"
chr18:67404973-<b>?</b>,"1 x 10-6",,NR,'-,"16.484 unit increase",[9.82-23.15],'-,"Post-bronchodilator lung function in asthma (FVC)","response to bronchodilator, asthma, vital capacity",GCST011800,"Mapping not available"
chr19:4291817-<b>?</b>,"5 x 10-8",,NR,'-,"5.2674 unit increase",[3.38-7.15],'-,"Post-bronchodilator lung function in asthma (FVC)","response to bronchodilator, asthma, vital capacity",GCST011800,"Mapping not available"
chr19:36372775-<b>?</b>,"1 x 10-6",,NR,'-,"4.2774 unit decrease",[2.53-6.02],'-,"Post-bronchodilator lung function in asthma (FVC)","response to bronchodilator, asthma, vital capacity",GCST011800,"Mapping not available"
chr21:18234328-<b>?</b>,"1 x 10-6",,NR,'-,"12.7085 unit increase",[7.57-17.84],'-,"Post-bronchodilator lung function in asthma (FVC)","response to bronchodilator, asthma, vital capacity",GCST011800,"Mapping not available"
chr21:43755177-<b>?</b>,"1 x 10-6",,NR,'-,"5.5767 unit increase",[3.32-7.83],'-,"Post-bronchodilator lung function in asthma (FVC)","response to bronchodilator, asthma, vital capacity",GCST011800,"Mapping not available"
chr1:117580100-<b>?</b>,"1 x 10-6",,NR,'-,"7.0892 unit decrease",[4.25-9.93],'-,"Post-bronchodilator lung function in asthma (FEV1/FVC)","response to bronchodilator, asthma, FEV/FEC ratio",GCST011801,"Mapping not available"
chr1:180886944-<b>?</b>,"2 x 10-7",,NR,'-,"7.0382 unit decrease",[4.39-9.68],'-,"Post-bronchodilator lung function in asthma (FEV1/FVC)","response to bronchodilator, asthma, FEV/FEC ratio",GCST011801,"Mapping not available"
chr1:185527158-<b>?</b>,"4 x 10-7",,NR,'-,"9.4499 unit decrease",[5.8-13.1],'-,"Post-bronchodilator lung function in asthma (FEV1/FVC)","response to bronchodilator, asthma, FEV/FEC ratio",GCST011801,"Mapping not available"
chr2:26392354-<b>?</b>,"2 x 10-6",,NR,'-,"2.422 unit decrease",[1.43-3.41],'-,"Post-bronchodilator lung function in asthma (FEV1/FVC)","response to bronchodilator, asthma, FEV/FEC ratio",GCST011801,"Mapping not available"
chr2:171008016-<b>?</b>,"5 x 10-7",,NR,'-,"6.9043 unit decrease",[4.22-9.59],'-,"Post-bronchodilator lung function in asthma (FEV1/FVC)","response to bronchodilator, asthma, FEV/FEC ratio",GCST011801,"Mapping not available"
chr3:22321021-<b>?</b>,"2 x 10-7",,NR,'-,"7.8568 unit decrease",[4.88-10.84],'-,"Post-bronchodilator lung function in asthma (FEV1/FVC)","response to bronchodilator, asthma, FEV/FEC ratio",GCST011801,"Mapping not available"
chr3:49908748-<b>?</b>,"5 x 10-7",,NR,'-,"8.5469 unit decrease",[5.21-11.88],'-,"Post-bronchodilator lung function in asthma (FEV1/FVC)","response to bronchodilator, asthma, FEV/FEC ratio",GCST011801,"Mapping not available"
chr4:55555416-<b>?</b>,"2 x 10-6",,NR,'-,"4.4167 unit decrease",[2.61-6.23],'-,"Post-bronchodilator lung function in asthma (FEV1/FVC)","response to bronchodilator, asthma, FEV/FEC ratio",GCST011801,"Mapping not available"
chr4:70338226-<b>?</b>,"3 x 10-7",,NR,'-,"8.7913 unit decrease",[5.44-12.14],'-,"Post-bronchodilator lung function in asthma (FEV1/FVC)","response to bronchodilator, asthma, FEV/FEC ratio",GCST011801,"Mapping not available"
chr5:89139642-<b>?</b>,"5 x 10-7",,NR,'-,"8.3271 unit decrease",[5.09-11.56],'-,"Post-bronchodilator lung function in asthma (FEV1/FVC)","response to bronchodilator, asthma, FEV/FEC ratio",GCST011801,"Mapping not available"
chr8:4110597-<b>?</b>,"2 x 10-6",,NR,'-,"3.3772 unit decrease",[2-4.76],'-,"Post-bronchodilator lung function in asthma (FEV1/FVC)","response to bronchodilator, asthma, FEV/FEC ratio",GCST011801,"Mapping not available"
chr10:69583770-<b>?</b>,"2 x 10-6",,NR,'-,"4.7114 unit decrease",[2.79-6.64],'-,"Post-bronchodilator lung function in asthma (FEV1/FVC)","response to bronchodilator, asthma, FEV/FEC ratio",GCST011801,"Mapping not available"
chr11:35570480-<b>?</b>,"1 x 10-6",,NR,'-,"6.1461 unit decrease",[3.66-8.64],'-,"Post-bronchodilator lung function in asthma (FEV1/FVC)","response to bronchodilator, asthma, FEV/FEC ratio",GCST011801,"Mapping not available"
chr12:4773488-<b>?</b>,"2 x 10-7",,NR,'-,"7.0233 unit decrease",[4.38-9.67],'-,"Post-bronchodilator lung function in asthma (FEV1/FVC)","response to bronchodilator, asthma, FEV/FEC ratio",GCST011801,"Mapping not available"
chr14:38963901-<b>?</b>,"8 x 10-7",,NR,'-,"3.332 unit decrease",[2.01-4.65],'-,"Post-bronchodilator lung function in asthma (FEV1/FVC)","response to bronchodilator, asthma, FEV/FEC ratio",GCST011801,"Mapping not available"
chr15:76057493-<b>?</b>,"3 x 10-7",,NR,'-,"1.8888 unit decrease",[1.17-2.61],'-,"Post-bronchodilator lung function in asthma (FEV1/FVC)","response to bronchodilator, asthma, FEV/FEC ratio",GCST011801,"Mapping not available"
chr15:85798401-<b>?</b>,"9 x 10-8",,NR,'-,"6.7846 unit decrease",[4.3-9.27],'-,"Post-bronchodilator lung function in asthma (FEV1/FVC)","response to bronchodilator, asthma, FEV/FEC ratio",GCST011801,"Mapping not available"
chr15:88957199-<b>?</b>,"2 x 10-6",,NR,'-,"2.8154 unit decrease",[1.66-3.97],'-,"Post-bronchodilator lung function in asthma (FEV1/FVC)","response to bronchodilator, asthma, FEV/FEC ratio",GCST011801,"Mapping not available"
chr15:93817218-<b>?</b>,"2 x 10-7",,NR,'-,"5.0171 unit decrease",[3.12-6.91],'-,"Post-bronchodilator lung function in asthma (FEV1/FVC)","response to bronchodilator, asthma, FEV/FEC ratio",GCST011801,"Mapping not available"
chr17:57263393-<b>?</b>,"1 x 10-6",,NR,'-,"1.838 unit decrease",[1.09-2.58],'-,"Post-bronchodilator lung function in asthma (FEV1/FVC)","response to bronchodilator, asthma, FEV/FEC ratio",GCST011801,"Mapping not available"
chr17:78917207-<b>?</b>,"7 x 10-7",,NR,'-,"7.8302 unit decrease",[4.73-10.93],'-,"Post-bronchodilator lung function in asthma (FEV1/FVC)","response to bronchodilator, asthma, FEV/FEC ratio",GCST011801,"Mapping not available"
chr8:25026871-<b>?</b>,"1 x 10-6",,NR,'-,"11.5466 unit increase",[6.9-16.19],'-,"Post-bronchodilator lung function in asthma (FEV1)","forced expiratory volume, response to bronchodilator, asthma",GCST011799,"Mapping not available"
chr9:86916173-<b>?</b>,"2 x 10-7",,NR,'-,"4.5789 unit decrease",[2.85-6.31],'-,"Post-bronchodilator lung function in asthma (FEV1)","forced expiratory volume, response to bronchodilator, asthma",GCST011799,"Mapping not available"
chr10:85216527-<b>?</b>,"2 x 10-6",,NR,'-,"6.4536 unit increase",[3.81-9.1],'-,"Post-bronchodilator lung function in asthma (FEV1)","forced expiratory volume, response to bronchodilator, asthma",GCST011799,"Mapping not available"
chr22:45424732-<b>?</b>,"2 x 10-7",,NR,'-,"9.6769 unit increase",[6.05-13.3],'-,"Post-bronchodilator lung function in asthma (FEV1)","forced expiratory volume, response to bronchodilator, asthma",GCST011799,"Mapping not available"
chr1:195778940-<b>?</b>,"5 x 10-7",,NR,'-,"3.6116 unit decrease",[2.2-5.02],'-,"Post-bronchodilator lung function in asthma (FVC)","response to bronchodilator, asthma, vital capacity",GCST011800,"Mapping not available"
chr2:115978242-<b>?</b>,"1 x 10-6",,NR,'-,"6.1979 unit increase",[3.71-8.69],'-,"Post-bronchodilator lung function in asthma (FVC)","response to bronchodilator, asthma, vital capacity",GCST011800,"Mapping not available"
chr5:16893255-<b>?</b>,"3 x 10-7",,NR,'-,"9.3027 unit decrease",[5.76-12.85],'-,"Post-bronchodilator lung function in asthma (FEV1)","forced expiratory volume, response to bronchodilator, asthma",GCST011799,"Mapping not available"
chr12:107662094-<b>?</b>,"1 x 10-7",,NR,'-,"5.3677 unit decrease",[3.37-7.37],'-,"Post-bronchodilator lung function in asthma (FEV1)","forced expiratory volume, response to bronchodilator, asthma",GCST011799,"Mapping not available"
chr18:9409089-<b>?</b>,"2 x 10-6",,NR,'-,"8.288 unit decrease",[4.9-11.68],'-,"Post-bronchodilator lung function in asthma (FEV1)","forced expiratory volume, response to bronchodilator, asthma",GCST011799,"Mapping not available"
chr19:45782594-<b>?</b>,"1 x 10-6",,NR,'-,"5.3018 unit decrease",[3.17-7.44],'-,"Post-bronchodilator lung function in asthma (FEV1)","forced expiratory volume, response to bronchodilator, asthma",GCST011799,"Mapping not available"
chr6:162713288-<b>?</b>,"1 x 10-7",,NR,'-,"14.0917 unit increase",[8.84-19.34],'-,"Post-bronchodilator lung function in asthma (FVC)","response to bronchodilator, asthma, vital capacity",GCST011800,"Mapping not available"
rs11252394-<b>A</b>,"2 x 10-7","(Additive Model)",0.08,'-,'-,'-,LINC00702,"Asthma (bronchodilator response)","response to bronchodilator, asthma",GCST001911,10:4198678
rs6988229-<b>T</b>,"9 x 10-6","(Recessive Model)",0.20,'-,'-,'-,COL22A1,"Asthma (bronchodilator response)","response to bronchodilator, asthma",GCST001911,8:138872266
rs350729-<b>?</b>,"2 x 10-10",,NR,'-,"2.26 unit decrease",[NR],MIR4431,"Bronchodilator response in asthma","response to bronchodilator, asthma",GCST002796,2:52756635
rs115067260-<b>A</b>,"5 x 10-9","(BDRABS, AA)",0.97,'-,"0.17 unit increase",[0.11-0.23],CDH13,"Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,16:83788697
rs140948272-<b>C</b>,"5 x 10-9","(BDRABS, AA)",0.99,'-,"0.33 unit increase",[0.21-0.45],PITPNA,"Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,17:1557602
rs78060357-<b>A</b>,"5 x 10-7","(BDRPRED, AA)",0.9,'-,"2.88 unit increase",[1.76-4],PLXNA4,"Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,7:132371489
rs78060357-<b>A</b>,"8 x 10-8","(BDRABS, AA)",0.9,'-,"0.08 unit increase",[0.041-0.119],PLXNA4,"Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,7:132371489
rs145442019-<b>A</b>,"9 x 10-8","(BDRABS, AA)",0.99,'-,"0.203 unit increase",[0.13-0.28],HSBP1,"Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,16:83811073
rs13345720-<b>C</b>,"1 x 10-7","(BDRABS, AA)",0.34,'-,"0.05 unit decrease",[0.03-0.07],"RNASEH2A, HOOK2, THSD8","Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,19:12806872
rs114871691-<b>A</b>,"1 x 10-7","(BDRABS, AA)",0.95,'-,"0.114 unit increase",[0.075-0.153],BTBD11,"Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,12:107412042
rs139218005-<b>A</b>,"1 x 10-6","(BDRPRED, AA)",0.97,'-,"4.935 unit increase",[3.19-6.68],MAPK6P1,"Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,8:53535172
rs2295599-<b>A</b>,"5 x 10-7","(BDRABS, AA)",0.1,'-,"0.07 unit increase",[0.043-0.097],SYCP2L,"Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,6:10961221
rs149447163-<b>G</b>,"6 x 10-7","(BDRABS, AA)",0.98,'-,"0.191 unit increase",[0.12-0.27],UBR3,"Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,2:169966664
rs145986148-<b>A</b>,"7 x 10-7","(BDRABS, AA)",0.98,'-,"0.169 unit increase",[0.1-0.24],KCNG4,"Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,16:84238246
rs12529809-<b>G</b>,"8 x 10-7","(BDRABS, AA)",0.88,'-,"0.07 unit decrease",[0.05-0.09],"SYCP2L, ELOVL2","Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,6:10980406
rs387092-<b>A</b>,"1 x 10-6","(BDRABS, AA)",0.99,'-,"0.2 unit increase",[0.12-0.28],"MLYCD, HSBP1","Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,16:83858182
rs4742936-<b>C</b>,"1 x 10-6","(BDRABS, AA)",0.94,'-,"0.088 unit increase",[0.053-0.123],"CT70, RN7SKP191","Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,9:105008735
rs61824320-<b>A</b>,"2 x 10-7",(BDRABS),NR,'-,"0.0142 unit decrease",[0.0089-0.0195],KCNK1,"Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,1:233659564
rs9898686-<b>T</b>,"2 x 10-7",(BDRABS),NR,'-,"0.0138 unit increase",[0.0085-0.0191],CASC17,"Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,17:71077051
rs12956045-<b>A</b>,"8 x 10-7",(BDRABS),NR,'-,"0.013 unit decrease",[0.0079-0.0181],"MC2R, MC5R","Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,18:13843247
rs114132812-<b>A</b>,"1 x 10-8","(BDRPRED, AA)",0.98,'-,"7.63 unit increase",[5.04-10.22],CDH13,"Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,16:83784283
rs76677753-<b>A</b>,"2 x 10-8","(BDRPRED, AA)",0.99,'-,"9.49 unit increase",[6.22-12.76],"GOLGA8B, LINC02252","Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,15:34605865
rs13345720-<b>C</b>,"2 x 10-7","(BDRPRED, AA)",0.34,'-,"1.83 unit decrease",[1.14-2.52],"RNASEH2A, HOOK2, THSD8","Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,19:12806872
rs114871691-<b>A</b>,"2 x 10-7","(BDRPRED, AA)",0.95,'-,"4.116 unit increase",[2.57-5.66],BTBD11,"Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,12:107412042
rs76999017-<b>G</b>,"1 x 10-6","(BDRBASE, AA)",0.95,'-,"8.263 unit decrease",[4.99-11.54],INPP5D,"Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,2:233067548
rs12956045-<b>A</b>,"5 x 10-7",(BDRBASE),NR,'-,"0.45 unit decrease",[0.27-0.63],"MC2R, MC5R","Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,18:13843247
rs11245387-<b>T</b>,"3 x 10-7","(BDRPRED, AA)",0.4,'-,"1.76 unit decrease",[1.09-2.43],"NPM1P31, ABRAXAS2","Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,10:124849256
rs28650403-<b>G</b>,"1 x 10-6",(BDRBASE),NR,'-,"1.26 unit decrease",[0.75-1.77],NWD1,"Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,19:16733921
rs143859190-<b>T</b>,"4 x 10-7","(BDRPRED, AA)",0.99,'-,"8.1 unit increase",[5-11.2],GALNT13,"Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,2:154320444
rs188637550-<b>T</b>,"5 x 10-7","(BDRPRED, AA)",0.98,'-,"6.89 unit increase",[4.31-9.65],"FGL1, MTUS1","Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,8:17825558
rs76677753-<b>A</b>,"8 x 10-8","(BDRABS, AA)",0.99,'-,"0.25 unit increase",[0.15-0.35],"GOLGA8B, LINC02252","Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,15:34605865
rs12529809-<b>G</b>,"5 x 10-7","(BDRPRED, AA)",0.88,'-,"2.64 unit decrease",[1.62-3.66],"SYCP2L, ELOVL2","Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,6:10980406
rs188524320-<b>C</b>,"6 x 10-7","(BDRPRED, AA)",0.99,'-,"7.01 unit increase",[4.27-9.75],"PCM1, ASAH1","Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,8:18028933
rs4742936-<b>C</b>,"7 x 10-7","(BDRPRED, AA)",0.94,'-,"3.28 unit increase",[1.99-4.57],"CT70, RN7SKP191","Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,9:105008735
rs17116498-<b>C</b>,"7 x 10-7","(BDRPRED, AA)",0.99,'-,"7.07 unit increase",[4.29-9.85],FGL1,"Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,8:17892390
rs60085550-<b>G</b>,"2 x 10-7","(BDRABS, AA)",0.97,'-,"0.157 unit increase",[0.098-0.216],OR6F1,"Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,1:247713666
rs68193035-<b>A</b>,"2 x 10-7",(BDRPRED),NR,'-,"1.26 unit increase",[0.79-1.73],CASC17,"Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,17:71077529
rs10056066-<b>A</b>,"5 x 10-8","(BDRBASE, AA)",0.07,'-,"7.12 unit increase",[4.59-9.65],SGCD,"Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,5:156434616
rs143376495-<b>G</b>,"1 x 10-7","(BDRBASE, AA)",0.99,'-,"19.47 unit decrease",[12.36-26.58],"RPS17P5, FTH1P5","Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,6:50885046
rs2295599-<b>A</b>,"1 x 10-7","(BDRBASE, AA)",0.1,'-,"6 unit increase",[3.79-8.21],SYCP2L,"Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,6:10961221
rs11651753-<b>T</b>,"3 x 10-7","(BDRBASE, AA)",0.22,'-,"4.22 unit increase",[2.62-5.82],"PNPO, PRR15L","Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,17:47951723
rs75762663-<b>A</b>,"5 x 10-7","(BDRBASE, AA)",0.99,'-,"19.22 unit decrease",[11.77-26.67],RN7SKP6,"Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,13:56806283
rs77347308-<b>A</b>,"5 x 10-7","(BDRBASE, AA)",0.99,'-,"17.14 unit decrease",[10.5-23.78],CDH13,"Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,16:82761814
rs77094751-<b>G</b>,"6 x 10-7","(BDRBASE, AA)",0.96,'-,"10.23 unit decrease",[6.25-14.21],Y_RNA,"Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,18:78469272
rs62385074-<b>G</b>,"6 x 10-7","(BDRBASE, AA)",0.96,'-,"10.17 unit decrease",[6.19-14.15],"LCP2, LINC01366","Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,5:170304613
rs141697850-<b>C</b>,"7 x 10-7","(BDRBASE, AA)",0.99,'-,"15.05 unit decrease",[9.15-20.95],RNU6-119P,"Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,4:116884973
rs12529809-<b>G</b>,"8 x 10-7","(BDRBASE, AA)",0.88,'-,"5.674 unit decrease",[3.44-7.91],"SYCP2L, ELOVL2","Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,6:10980406
rs2575515-<b>T</b>,"8 x 10-7","(BDRBASE, AA)",0.47,'-,"3.525 unit increase",[2.13-4.92],RN7SKP82,"Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,4:42798439
rs7848679-<b>G</b>,"9 x 10-7","(BDRBASE, AA)",0.93,'-,"6.96 unit increase",[4.2-9.72],CT70,"Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,9:104992270
rs72653721-<b>C</b>,"3 x 10-7","(BDRPRED, AA)",0.88,'-,"2.746 unit decrease",[1.71-3.78],SYCP2L,"Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,6:10971653
rs147388556-<b>T</b>,"3 x 10-7","(BDRPRED, AA)",0.96,'-,"4.17 unit increase",[2.58-5.76],'-,"Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,1:82605935
rs2278843-<b>G</b>,"7 x 10-7",(BDRBASE),NR,'-,"0.42 unit increase",[0.26-0.58],PKD2L1,"Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,10:100296751
rs145442019-<b>A</b>,"4 x 10-7","(BDRPRED, AA)",0.99,'-,"7.1 unit increase",[4.38-9.82],HSBP1,"Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,16:83811073
rs68120025-<b>C</b>,"3 x 10-7","(BDRABS, EA)",NR,'-,"0.014 unit increase",[0.0081-0.0199],CASC17,"Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,17:71077504
rs77119843-<b>C</b>,"5 x 10-7","(BDRBASE, EA)",NR,'-,"6.23 unit increase",[3.8-8.66],"DIRC3, DIRC3-AS1","Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,2:217300520
rs68193035-<b>A</b>,"6 x 10-7","(BDRBASE, EA)",NR,'-,"1.27 unit increase",[0.78-1.76],CASC17,"Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,17:71077529
rs10279301-<b>C</b>,"9 x 10-7","(BDRPRED, EA)",NR,'-,"0.61 unit decrease",[0.37-0.85],LINC01006,"Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,7:156468621
rs77119843-<b>C</b>,"1 x 10-6","(BDRPRED, EA)",NR,'-,"2.23 unit increase",[1.33-3.13],"DIRC3, DIRC3-AS1","Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,2:217300520
rs7079679-<b>A</b>,"2 x 10-9","(BDRPRED, EA)",NR,'-,"0.41 unit increase",[0.23-0.59],PKD2L1,"Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,10:100295789
rs79311676-<b>G</b>,"2 x 10-6","(BDRPRED, EA)",NR,'-,"0.76 unit increase",[0.45-1.07],MAD1L1,"Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)","FEV change measurement, response to bronchodilator, chronic obstructive pulmonary disease",GCST003830,7:1870814
rs141238427-<b>A</b>,"3 x 10-6",(AA),0.955,'-,"0.067 unit increase",NR,"NNT-AS1, PAIP1","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43567490
rs115426610-<b>T</b>,"3 x 10-6",(AA),0.955,'-,"0.067 unit increase",NR,"PAIP1, NNT-AS1","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43568015
rs78646877-<b>G</b>,"3 x 10-6",(AA),0.955,'-,"0.067 unit increase",NR,"PAIP1, NNT-AS1","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43569800
rs180834883-<b>G</b>,"2 x 10-6",(AA),0.956,'-,"0.068 unit increase",NR,TMEM267,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43465041
rs115252650-<b>T</b>,"2 x 10-6",(AA),0.956,'-,"0.068 unit increase",NR,TMEM267,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43470558
rs76677587-<b>C</b>,"2 x 10-6",(AA),0.956,'-,"0.068 unit increase",NR,TMEM267,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43483182
rs76881288-<b>G</b>,"2 x 10-6",(AA),0.956,'-,"0.068 unit increase",NR,C5orf34,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43488334
rs146735629-<b>T</b>,"2 x 10-6",(AA),0.956,'-,"0.068 unit increase",NR,C5orf34,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43491837
rs76396004-<b>T</b>,"2 x 10-6",(AA),0.956,'-,"0.068 unit increase",NR,"PAIP1, C5orf34-AS1","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43524457
rs13382275-<b>G</b>,"4 x 10-6",(AA),0.95,'-,"0.069 unit increase",NR,SNTG2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,2:969893
rs10439273-<b>A</b>,"9 x 10-7",(AA),0.04,'-,"0.069 unit increase",NR,SPAG16,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,2:214283391
rs147861254-<b>T</b>,"2 x 10-6",(AA),0.951,'-,"0.07 unit increase",NR,ARSB,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43814221
rs73251207-<b>G</b>,"1 x 10-6",(AA),0.951,'-,"0.07 unit increase",NR,"JPH3, ZCCHC14","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,16:87582215
rs76640434-<b>A</b>,"1 x 10-6",(AA),0.956,'-,"0.071 unit increase",NR,"CCL28, TMEM267","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43435641
rs183575223-<b>T</b>,"3 x 10-6",(AA),0.963,'-,"0.074 unit increase",NR,"TMEM267, CCL28","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43417980
rs115681743-<b>G</b>,"3 x 10-6",(AA),0.963,'-,"0.074 unit increase",NR,"TMEM267, CCL28","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43420040
rs78044334-<b>T</b>,"3 x 10-6",(AA),0.963,'-,"0.074 unit increase",NR,"TMEM267, CCL28","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43420159
rs75386498-<b>A</b>,"2 x 10-6",(AA),0.963,'-,"0.074 unit increase",NR,"TMEM267, CCL28","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43426316
rs192225282-<b>A</b>,"2 x 10-6",(AA),0.961,'-,"0.074 unit increase",NR,NNT,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43672861
rs189522918-<b>T</b>,"2 x 10-6",(AA),0.964,'-,"0.075 unit increase",NR,"CCL28, TMEM267","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43439818
rs77194569-<b>T</b>,"2 x 10-6",(AA),0.964,'-,"0.075 unit increase",NR,TMEM267,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43448147
rs116000348-<b>G</b>,"2 x 10-6",(AA),0.964,'-,"0.075 unit increase",NR,TMEM267,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43454458
rs78321138-<b>A</b>,"2 x 10-6",(AA),0.964,'-,"0.075 unit increase",NR,TMEM267,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43456374
rs79923522-<b>A</b>,"2 x 10-6",(AA),0.964,'-,"0.075 unit increase",NR,"C5orf34, TMEM267","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43485870
rs7712914-<b>G</b>,"2 x 10-6",(AA),0.963,'-,"0.075 unit increase",NR,C5orf34,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43494112
rs9687653-<b>T</b>,"3 x 10-6",,0.39,'-,"0.011 unit decrease",NR,DNAH5,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:13746951
rs34476088-<b>A</b>,"3 x 10-6",,0.387,'-,"0.011 unit decrease",NR,DNAH5,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:13747718
rs11936476-<b>T</b>,"3 x 10-6",,0.614,'-,"0.011 unit decrease",NR,"KRT18P51, MIR5091","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144537332
rs1489762-<b>T</b>,"3 x 10-6",,0.614,'-,"0.011 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144533812
rs6537296-<b>A</b>,"3 x 10-6",,0.613,'-,"0.011 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144566782
rs209348-<b>T</b>,"3 x 10-6",,0.502,'-,"0.011 unit decrease",NR,GABRG2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:162081722
rs7655625-<b>T</b>,"3 x 10-6",,0.497,'-,"0.011 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144564763
rs720485-<b>A</b>,"4 x 10-6",,0.502,'-,"0.011 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144541436
rs11938745-<b>T</b>,"4 x 10-6",,0.614,'-,"0.011 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144544616
rs12506874-<b>A</b>,"4 x 10-6",,0.614,'-,"0.011 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144546060
rs13147758-<b>A</b>,"4 x 10-6",,0.614,'-,"0.011 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144539078
rs13148031-<b>A</b>,"4 x 10-6",,0.614,'-,"0.011 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144539186
rs36023701-<b>C</b>,"4 x 10-6",,0.614,'-,"0.011 unit decrease",NR,"KRT18P51, EGF","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144544309
rs11118888-<b>C</b>,"4 x 10-6",,0.454,'-,"0.011 unit decrease",NR,LINC02257,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:221902383
rs11118889-<b>A</b>,"4 x 10-6",,0.454,'-,"0.011 unit decrease",NR,LINC02257,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:221902460
rs2130339-<b>A</b>,"4 x 10-6",,0.616,'-,"0.011 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144543733
rs6604685-<b>T</b>,"4 x 10-6",,0.454,'-,"0.011 unit decrease",NR,LINC02257,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:221903075
rs6897741-<b>T</b>,"4 x 10-6",,0.51,'-,"0.011 unit decrease",NR,DNAH5,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:13749128
rs12511230-<b>A</b>,"4 x 10-6",,0.613,'-,"0.011 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144550093
rs6831503-<b>A</b>,"4 x 10-6",,0.613,'-,"0.011 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144550793
rs1828591-<b>A</b>,"4 x 10-6",,0.502,'-,"0.011 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144559628
rs6537293-<b>A</b>,"4 x 10-6",,0.616,'-,"0.011 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144558609
rs1813903-<b>C</b>,"4 x 10-6",,0.613,'-,"0.011 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144556897
rs1489759-<b>A</b>,"4 x 10-6",,0.497,'-,"0.011 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144553321
rs6830832-<b>T</b>,"4 x 10-6",,0.613,'-,"0.011 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144544339
rs140263876-<b>A</b>,"5 x 10-7",(AA),0.965,'-,"0.081 unit increase",NR,NNT,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43746442
rs151142406-<b>T</b>,"5 x 10-7",(AA),0.965,'-,"0.081 unit increase",NR,NNT,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43751664
rs114693035-<b>A</b>,"6 x 10-7",(AA),0.965,'-,"0.081 unit increase",NR,NNT,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43753616
rs146358354-<b>A</b>,"6 x 10-7",(AA),0.965,'-,"0.081 unit increase",NR,NNT,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43754000
rs9928486-<b>C</b>,"1 x 10-6",(AA),0.96,'-,"0.082 unit increase",NR,PRKCB,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,16:24076855
rs35526040-<b>T</b>,"9 x 10-7",(AA),0.959,'-,"0.084 unit increase",NR,PRKCB,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,16:24082016
rs12929627-<b>T</b>,"7 x 10-7",(AA),0.96,'-,"0.088 unit increase",NR,PRKCB,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,16:24083656
rs34289708-<b>C</b>,"6 x 10-7",(AA),0.96,'-,"0.088 unit increase",NR,PRKCB,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,16:24084053
rs60451608-<b>G</b>,"1 x 10-6",(AA),0.972,'-,"0.09 unit increase",NR,KLHL32,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,6:97108568
rs73758115-<b>T</b>,"1 x 10-6",(AA),0.972,'-,"0.091 unit increase",NR,KLHL32,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,6:97123820
rs73758117-<b>T</b>,"1 x 10-6",(AA),0.972,'-,"0.091 unit increase",NR,KLHL32,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,6:97125724
rs73758118-<b>A</b>,"1 x 10-6",(AA),0.972,'-,"0.091 unit increase",NR,KLHL32,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,6:97131188
rs55884448-<b>A</b>,"1 x 10-6",(AA),0.972,'-,"0.092 unit increase",NR,MMS22L,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,6:97153651
rs60610103-<b>G</b>,"2 x 10-6",(AA),0.973,'-,"0.092 unit increase",NR,MMS22L,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,6:97176861
rs189239081-<b>C</b>,"2 x 10-6",(AA),0.973,'-,"0.093 unit increase",NR,MMS22L,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,6:97194003
rs13009756-<b>G</b>,"4 x 10-6",(AA),0.932,'-,"0.094 unit increase",NR,"KCNF1, TDRD15","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,2:10966787
rs73760105-<b>T</b>,"2 x 10-6",(AA),0.974,'-,"0.094 unit increase",NR,MMS22L,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,6:97214366
rs79077948-<b>T</b>,"2 x 10-6",(AA),0.974,'-,"0.094 unit increase",NR,MMS22L,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,6:97219046
rs59581213-<b>G</b>,"2 x 10-6",(AA),0.974,'-,"0.094 unit increase",NR,MMS22L,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,6:97220137
rs73760117-<b>C</b>,"2 x 10-6",(AA),0.974,'-,"0.095 unit increase",NR,MMS22L,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,6:97267700
rs73760151-<b>C</b>,"2 x 10-6",(AA),0.975,'-,"0.095 unit increase",NR,MMS22L,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,6:97289332
rs800823-<b>C</b>,"4 x 10-6",(AA),0.976,'-,"0.113 unit increase",NR,SP100,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,2:192355686
rs113203253-<b>A</b>,"4 x 10-6",(AA),0.984,'-,"0.115 unit increase",NR,MPO,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,17:58270707
rs150758818-<b>G</b>,"2 x 10-6",(AA),0.986,'-,"0.12 unit increase",NR,LPO,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,17:58247407
rs140543894-<b>G</b>,"1 x 10-6",(AA),0.985,'-,"0.121 unit increase",NR,MKS1,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,17:58211748
rs72946119-<b>T</b>,"8 x 10-7",(AA),0.955,'-,"0.074 unit decrease",NR,SPAG16,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,2:214293542
rs72952025-<b>C</b>,"1 x 10-6",(AA),0.951,'-,"0.068 unit decrease",NR,SPAG16,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,2:214313545
rs17492699-<b>C</b>,"3 x 10-7",(AA),0.924,'-,"0.063 unit decrease",NR,CDH2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,18:27900550
rs111756326-<b>A</b>,"3 x 10-6",,0.96,'-,"0.05 unit decrease",NR,PRDM16,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:3286711
rs144892944-<b>A</b>,"4 x 10-6",,0.015,'-,"0.047 unit decrease",NR,'-,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:238903198
rs113177748-<b>A</b>,"4 x 10-6",,0.015,'-,"0.046 unit decrease",NR,'-,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:238928998
rs112425727-<b>A</b>,"4 x 10-6",,0.015,'-,"0.046 unit decrease",NR,RN7SL165P,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:238925589
rs6669578-<b>T</b>,"4 x 10-6",,0.015,'-,"0.046 unit decrease",NR,'-,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:238920407
rs6676535-<b>A</b>,"5 x 10-6",,0.015,'-,"0.046 unit decrease",NR,'-,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:238916009
rs9970786-<b>A</b>,"4 x 10-6",,0.017,'-,"0.045 unit decrease",NR,'-,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:238927214
rs12579846-<b>G</b>,"2 x 10-6",(AA),0.132,'-,"0.038 unit decrease",NR,TAFA2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,12:62115547
rs143863913-<b>T</b>,"5 x 10-6",,0.036,'-,"0.035 unit decrease",NR,"SYN3, LINC01640","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,22:33093125
rs7695246-<b>C</b>,"5 x 10-6",(AA),0.69,'-,"0.033 unit decrease",NR,CFI,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:109767656
rs562188-<b>G</b>,"1 x 10-7",(AA),0.594,'-,"0.033 unit decrease",NR,"NANOS1, LDHAP5","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,10:118985443
rs9325081-<b>G</b>,"5 x 10-6",(AA),0.267,'-,"0.03 unit decrease",NR,SPINK14,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:148171783
rs6017235-<b>A</b>,"6 x 10-7",(AA),0.474,'-,"0.03 unit decrease",NR,TOX2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,20:43991952
rs56292044-<b>T</b>,"3 x 10-6",(AA),0.557,'-,"0.027 unit decrease",NR,PSD3,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,8:137764304
rs72768842-<b>T</b>,"2 x 10-6",,0.083,'-,"0.02 unit decrease",NR,TENT2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:79678643
rs12657392-<b>A</b>,"2 x 10-6",,0.463,'-,"0.02 unit decrease",NR,TENT2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:79667500
rs72768824-<b>T</b>,"2 x 10-6",,0.083,'-,"0.02 unit decrease",NR,TENT2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:79659016
rs60449834-<b>A</b>,"3 x 10-6",,0.085,'-,"0.02 unit decrease",NR,TENT2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:79662163
rs72768817-<b>C</b>,"3 x 10-6",,0.085,'-,"0.02 unit decrease",NR,TENT2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:79648548
rs72768807-<b>A</b>,"3 x 10-6",,0.084,'-,"0.02 unit decrease",NR,TENT2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:79637821
rs114878198-<b>A</b>,"3 x 10-6",,0.085,'-,"0.02 unit decrease",NR,TENT2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:79644084
rs680753-<b>C</b>,"7 x 10-7",,0.884,'-,"0.018 unit decrease",NR,MMP3,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,11:102840850
rs75401687-<b>T</b>,"2 x 10-6",(AA),0.964,'-,"0.075 unit increase",NR,"C5orf34, C5orf34-AS1","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43515071
rs79942555-<b>T</b>,"2 x 10-6",(AA),0.964,'-,"0.075 unit increase",NR,C5orf34-AS1,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43520422
rs141017100-<b>T</b>,"2 x 10-6",(AA),0.963,'-,"0.075 unit increase",NR,PAIP1,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43531587
rs115378923-<b>T</b>,"2 x 10-6",(AA),0.963,'-,"0.075 unit increase",NR,PAIP1,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43548586
rs116695782-<b>A</b>,"2 x 10-6",(AA),0.963,'-,"0.075 unit increase",NR,PAIP1,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43551732
rs79481971-<b>C</b>,"2 x 10-6",(AA),0.963,'-,"0.075 unit increase",NR,PAIP1,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43554017
rs77683199-<b>A</b>,"2 x 10-6",(AA),0.963,'-,"0.075 unit increase",NR,"NNT-AS1, PAIP1","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43558350
rs114512566-<b>C</b>,"1 x 10-6",(AA),0.963,'-,"0.075 unit increase",NR,"NNT-AS1, PAIP1","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43563335
rs116448453-<b>T</b>,"1 x 10-6",(AA),0.963,'-,"0.075 unit increase",NR,NNT-AS1,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43573032
rs115648704-<b>G</b>,"1 x 10-6",(AA),0.963,'-,"0.075 unit increase",NR,"NNT-AS1, AMD1P3","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43587726
rs114955764-<b>A</b>,"1 x 10-6",(AA),0.963,'-,"0.075 unit increase",NR,NNT-AS1,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43588739
rs76517075-<b>T</b>,"1 x 10-6",(AA),0.963,'-,"0.075 unit increase",NR,NNT-AS1,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43590406
rs79482941-<b>T</b>,"1 x 10-6",(AA),0.963,'-,"0.075 unit increase",NR,NNT-AS1,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43594489
rs79548306-<b>A</b>,"1 x 10-6",(AA),0.963,'-,"0.075 unit increase",NR,NNT-AS1,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43596243
rs77333560-<b>T</b>,"1 x 10-6",(AA),0.963,'-,"0.075 unit increase",NR,NNT-AS1,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43596244
rs114176814-<b>T</b>,"1 x 10-6",(AA),0.963,'-,"0.075 unit increase",NR,NNT-AS1,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43600874
rs115760645-<b>G</b>,"1 x 10-6",(AA),0.963,'-,"0.075 unit increase",NR,NNT,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43643123
rs74863720-<b>A</b>,"1 x 10-6",(AA),0.963,'-,"0.075 unit increase",NR,NNT,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43649503
rs75999006-<b>A</b>,"1 x 10-6",(AA),0.963,'-,"0.075 unit increase",NR,NNT,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43677651
rs7709284-<b>G</b>,"1 x 10-6",(AA),0.963,'-,"0.075 unit increase",NR,NNT,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43688821
rs114770284-<b>G</b>,"4 x 10-6",(AA),0.965,'-,"0.076 unit increase",NR,'-,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43867704
rs75650673-<b>G</b>,"4 x 10-6",(AA),0.965,'-,"0.076 unit increase",NR,'-,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43879888
rs115007675-<b>A</b>,"4 x 10-6",(AA),0.965,'-,"0.076 unit increase",NR,'-,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43888181
rs78883564-<b>C</b>,"4 x 10-6",(AA),0.965,'-,"0.076 unit increase",NR,'-,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43888634
rs75617866-<b>A</b>,"4 x 10-6",(AA),0.965,'-,"0.077 unit increase",NR,'-,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43858572
rs1985875-<b>A</b>,"2 x 10-6",(AA),0.859,'-,"0.038 unit increase",NR,TAFA2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,12:62114243
rs9739546-<b>G</b>,"2 x 10-6",(AA),0.859,'-,"0.038 unit increase",NR,TAFA2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,12:62114656
rs9738294-<b>A</b>,"3 x 10-6",(AA),0.859,'-,"0.038 unit increase",NR,TAFA2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,12:62114708
rs1009168-<b>G</b>,"2 x 10-6",(AA),0.859,'-,"0.038 unit increase",NR,TAFA2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,12:62116714
rs9706154-<b>T</b>,"2 x 10-6",(AA),0.859,'-,"0.038 unit increase",NR,TAFA2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,12:62119801
rs9739682-<b>T</b>,"2 x 10-6",(AA),0.859,'-,"0.038 unit increase",NR,TAFA2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,12:62122868
rs8036358-<b>G</b>,"1 x 10-6",(AA),0.842,'-,"0.038 unit increase",NR,LINC01584,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:86008512
rs12185079-<b>T</b>,"4 x 10-6",(AA),0.828,'-,"0.038 unit increase",NR,LYSMD4,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:99731048
rs1444250-<b>T</b>,"2 x 10-6",(AA),0.859,'-,"0.039 unit increase",NR,TAFA2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,12:62107393
rs11174324-<b>T</b>,"2 x 10-6",(AA),0.86,'-,"0.039 unit increase",NR,TAFA2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,12:62108469
rs10784281-<b>A</b>,"2 x 10-6",(AA),0.86,'-,"0.039 unit increase",NR,TAFA2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,12:62109198
rs9738122-<b>G</b>,"2 x 10-6",(AA),0.859,'-,"0.039 unit increase",NR,TAFA2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,12:62120892
rs1975494-<b>G</b>,"1 x 10-6",(AA),0.862,'-,"0.04 unit increase",NR,TAFA2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,12:62114416
rs2073183-<b>G</b>,"2 x 10-6",(AA),0.114,'-,"0.041 unit increase",NR,"EFHC1, TRAM2","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,6:52501964
rs78472555-<b>C</b>,"2 x 10-6",(AA),0.86,'-,"0.042 unit increase",NR,LYSMD4,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:99727117
rs77928077-<b>G</b>,"5 x 10-6",(AA),0.896,'-,"0.043 unit increase",NR,MPZL1,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:167762224
rs9975325-<b>A</b>,"4 x 10-6",,0.023,'-,"0.049 unit increase",NR,LINC01695,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,21:28318903
rs138755414-<b>T</b>,"4 x 10-6",,0.018,'-,"0.052 unit increase",NR,LINC01695,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,21:28304351
rs9874264-<b>C</b>,"5 x 10-6",(AA),0.893,'-,"0.052 unit increase",NR,"ETV5, NMRAL2P","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,3:185991711
rs144560641-<b>A</b>,"2 x 10-6",,0.012,'-,"0.055 unit increase",NR,LINC02328,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,14:85870160
rs11247124-<b>A</b>,"2 x 10-6",(AA),0.93,'-,"0.058 unit increase",NR,LYSMD4,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:99725520
rs140006825-<b>C</b>,"4 x 10-6",,0.016,'-,"0.059 unit increase",NR,"PPP4R2, RNU6-557P","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,3:73088330
rs2123926-<b>C</b>,"1 x 10-6",(AA),0.93,'-,"0.059 unit increase",NR,LYSMD4,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:99724313
rs6497718-<b>A</b>,"3 x 10-6",(AA),0.929,'-,"0.06 unit increase",NR,PRKCB,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,16:24080517
rs7205511-<b>T</b>,"2 x 10-6",(AA),0.931,'-,"0.064 unit increase",NR,PRKCB,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,16:24083382
rs10932534-<b>C</b>,"5 x 10-6",(AA),0.282,'-,"0.03 unit increase",NR,SPAG16,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,2:214335263
rs1912191-<b>A</b>,"4 x 10-6",(AA),0.28,'-,"0.03 unit increase",NR,SPAG16,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,2:214352818
rs12332430-<b>T</b>,"5 x 10-6",(AA),0.738,'-,"0.03 unit increase",NR,SPINK14,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:148170734
rs10886358-<b>G</b>,"3 x 10-6",(AA),0.547,'-,"0.03 unit increase",NR,"NANOS1, LDHAP5","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,10:118984783
rs11198709-<b>C</b>,"4 x 10-6",(AA),0.554,'-,"0.03 unit increase",NR,"LDHAP5, NANOS1","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,10:118985429
rs1912188-<b>A</b>,"1 x 10-6",(AA),0.285,'-,"0.033 unit increase",NR,SPAG16,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,2:214354143
rs10476890-<b>A</b>,"9 x 10-7",(AA),0.748,'-,"0.033 unit increase",NR,"SPINK14, SPINK5","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:148168700
rs13017349-<b>A</b>,"1 x 10-6",(AA),0.236,'-,"0.035 unit increase",NR,SPAG16,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,2:214354463
rs147410223-<b>G</b>,"2 x 10-6",(AA),0.766,'-,"0.036 unit increase",NR,"NKX3-1, SINHCAFP3","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,8:23649866
rs1444249-<b>C</b>,"4 x 10-6",(AA),0.861,'-,"0.038 unit increase",NR,TAFA2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,12:62107415
rs116828138-<b>G</b>,"3 x 10-6",(AA),0.86,'-,"0.038 unit increase",NR,TAFA2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,12:62109650
rs117128498-<b>G</b>,"3 x 10-6",(AA),0.86,'-,"0.038 unit increase",NR,TAFA2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,12:62109736
rs10877792-<b>A</b>,"3 x 10-6",(AA),0.86,'-,"0.038 unit increase",NR,TAFA2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,12:62109840
rs11174325-<b>T</b>,"5 x 10-6",(AA),0.862,'-,"0.038 unit increase",NR,TAFA2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,12:62109992
rs9668676-<b>A</b>,"3 x 10-6",(AA),0.86,'-,"0.038 unit increase",NR,TAFA2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,12:62110418
rs117854849-<b>G</b>,"3 x 10-6",(AA),0.86,'-,"0.038 unit increase",NR,TAFA2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,12:62111035
rs114085878-<b>C</b>,"3 x 10-6",(AA),0.86,'-,"0.038 unit increase",NR,TAFA2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,12:62111453
rs145861664-<b>C</b>,"4 x 10-6",(AA),0.86,'-,"0.038 unit increase",NR,TAFA2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,12:62111677
rs140296914-<b>C</b>,"3 x 10-6",(AA),0.86,'-,"0.038 unit increase",NR,TAFA2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,12:62111988
rs9668015-<b>T</b>,"3 x 10-6",(AA),0.86,'-,"0.038 unit increase",NR,TAFA2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,12:62112714
rs9668369-<b>C</b>,"3 x 10-6",(AA),0.86,'-,"0.038 unit increase",NR,TAFA2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,12:62113061
rs12425896-<b>C</b>,"3 x 10-6",(AA),0.859,'-,"0.038 unit increase",NR,TAFA2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,12:62113121
rs35194524-<b>G</b>,"3 x 10-6",(AA),0.859,'-,"0.038 unit increase",NR,TAFA2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,12:62113419
rs12829595-<b>G</b>,"3 x 10-6",(AA),0.859,'-,"0.038 unit increase",NR,TAFA2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,12:62113737
rs9668865-<b>C</b>,"3 x 10-6",(AA),0.859,'-,"0.038 unit increase",NR,TAFA2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,12:62113808
rs116165861-<b>G</b>,"2 x 10-6",(AA),0.998,'-,"0.385 unit increase",NR,'-,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,2:122244902
rs140381154-<b>G</b>,"1 x 10-6",(AA),0.998,'-,"0.387 unit increase",NR,'-,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,2:122330705
rs142412198-<b>A</b>,"1 x 10-6",(AA),0.998,'-,"0.388 unit increase",NR,'-,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,2:122343972
rs148581520-<b>C</b>,"1 x 10-6",(AA),0.998,'-,"0.388 unit increase",NR,'-,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,2:122366459
rs142846286-<b>A</b>,"3 x 10-6",(AA),0.998,'-,"0.398 unit increase",NR,LINC01258,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:38503116
rs138158254-<b>A</b>,"5 x 10-7",(AA),0.998,'-,"0.4 unit increase",NR,'-,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,2:122448415
rs114979721-<b>A</b>,"5 x 10-7",(AA),0.998,'-,"0.403 unit increase",NR,'-,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,2:122416258
rs142793646-<b>A</b>,"4 x 10-7",(AA),0.998,'-,"0.404 unit increase",NR,'-,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,2:122410236
rs191663403-<b>C</b>,"5 x 10-6",(AA),0.998,'-,"0.43 unit increase",NR,'-,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,3:59350530
rs188074355-<b>A</b>,"4 x 10-6",(AA),0.999,'-,"0.558 unit increase",NR,'-,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,2:122268572
rs180791571-<b>A</b>,"7 x 10-7",(AA),0.999,'-,"0.982 unit increase",NR,NIFK-AS1,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,2:121706919
rs143980687-<b>G</b>,"5 x 10-6",(AA),0.999,'-,"1.017 unit increase",NR,WNT5B,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,12:1552442
rs190845920-<b>C</b>,"3 x 10-6",(AA),1.0,'-,"4.466 unit increase",NR,DNAJA1P2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,2:153665233
rs185158884-<b>G</b>,"6 x 10-7",(AA),1.0,'-,"12.238 unit increase",NR,LINC01162,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,7:20975374
rs186879571-<b>T</b>,"2 x 10-7",,0.003,'-,"0.532 unit decrease",NR,"TMEM132C, LINC02368","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,12:128168286
rs140385970-<b>T</b>,"9 x 10-7",,0.002,'-,"0.306 unit decrease",NR,TBX4,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,17:61482988
rs62522179-<b>C</b>,"4 x 10-6",,0.011,'-,"0.236 unit decrease",NR,DENND3,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,8:141144597
rs188564008-<b>A</b>,"4 x 10-6",,0.002,'-,"0.219 unit decrease",NR,ADGRL3,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:61313578
rs147776718-<b>A</b>,"1 x 10-6",,0.003,'-,"0.156 unit decrease",NR,FBXL7,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:15826358
rs193141495-<b>A</b>,"4 x 10-6",,0.003,'-,"0.155 unit decrease",NR,FBXL7,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:15802129
rs186968760-<b>A</b>,"4 x 10-6",,0.003,'-,"0.14 unit decrease",NR,FBXL7,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:15922585
rs150081574-<b>A</b>,"5 x 10-7",(AA),0.984,'-,"0.13 unit decrease",NR,LINC02625,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,10:61805594
rs4549165-<b>C</b>,"4 x 10-6",(AA),0.022,'-,"0.098 unit decrease",NR,SULF2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,20:47707282
rs191631123-<b>A</b>,"2 x 10-6",,0.007,'-,"0.093 unit decrease",NR,NRG1,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,8:32586186
rs142075585-<b>A</b>,"3 x 10-6",,0.012,'-,"0.074 unit decrease",NR,GDI2P1,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,7:48855664
rs6688272-<b>T</b>,"9 x 10-7",,0.4,'-,"0.012 unit increase",NR,CFH,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:196715262
rs72743158-<b>T</b>,"9 x 10-7",,0.579,'-,"0.012 unit increase",NR,CHRNB4,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78634103
rs3766405-<b>T</b>,"9 x 10-7",,0.4,'-,"0.012 unit increase",NR,CFH,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:196726031
rs1512288-<b>A</b>,"1 x 10-6",,0.498,'-,"0.012 unit increase",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144570129
rs2089162-<b>A</b>,"1 x 10-6",,0.61,'-,"0.012 unit increase",NR,IREB2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78447421
rs3924223-<b>A</b>,"1 x 10-6",,0.543,'-,"0.012 unit increase",NR,LINC02257,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:221905852
rs7697189-<b>C</b>,"1 x 10-6",,0.386,'-,"0.012 unit increase",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144515742
rs12501071-<b>T</b>,"1 x 10-6",,0.394,'-,"0.012 unit increase",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144569207
rs17484524-<b>A</b>,"1 x 10-6",,0.613,'-,"0.012 unit increase",NR,IREB2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78480334
rs56219465-<b>A</b>,"2 x 10-6",,0.61,'-,"0.012 unit increase",NR,IREB2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78450237
rs7181486-<b>T</b>,"2 x 10-6",,0.61,'-,"0.012 unit increase",NR,IREB2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78449276
rs2009746-<b>A</b>,"2 x 10-6",,0.609,'-,"0.012 unit increase",NR,IREB2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78461760
rs1504550-<b>A</b>,"2 x 10-6",,0.613,'-,"0.012 unit increase",NR,IREB2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78473908
rs17484235-<b>C</b>,"2 x 10-6",,0.614,'-,"0.012 unit increase",NR,IREB2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78469072
rs2656052-<b>A</b>,"2 x 10-6",,0.609,'-,"0.012 unit increase",NR,IREB2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78448590
rs2938670-<b>T</b>,"2 x 10-6",,0.609,'-,"0.012 unit increase",NR,IREB2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78448346
rs72738732-<b>C</b>,"2 x 10-6",,0.614,'-,"0.012 unit increase",NR,IREB2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78459846
rs17483721-<b>T</b>,"2 x 10-6",,0.503,'-,"0.012 unit increase",NR,IREB2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78441389
rs17483686-<b>A</b>,"2 x 10-6",,0.61,'-,"0.012 unit increase",NR,IREB2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78441048
rs7435469-<b>T</b>,"2 x 10-6",,0.388,'-,"0.012 unit increase",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144534398
rs1502045-<b>A</b>,"3 x 10-6",,0.422,'-,"0.012 unit increase",NR,DNAH5,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:13745610
rs6889428-<b>T</b>,"3 x 10-6",,0.625,'-,"0.012 unit increase",NR,DNAH5,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:13750866
rs13113591-<b>T</b>,"4 x 10-6",,0.37,'-,"0.012 unit increase",NR,"KRT18P51, ENPEP","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144567945
rs6537291-<b>A</b>,"4 x 10-6",,0.402,'-,"0.012 unit increase",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144542922
rs55676755-<b>C</b>,"2 x 10-7",,0.6,'-,"0.013 unit increase",NR,CHRNA3,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78606590
rs566125-<b>T</b>,"1 x 10-6",,0.521,'-,"0.018 unit increase",NR,MMP3,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,11:102839740
rs475937-<b>A</b>,"1 x 10-6",,0.115,'-,"0.018 unit increase",NR,WTAPP1,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,11:102816969
rs505987-<b>A</b>,"1 x 10-6",,0.116,'-,"0.018 unit increase",NR,WTAPP1,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,11:102815179
rs520146-<b>T</b>,"1 x 10-6",,0.115,'-,"0.018 unit increase",NR,WTAPP1,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,11:102819400
rs470234-<b>T</b>,"1 x 10-6",,0.115,'-,"0.018 unit increase",NR,WTAPP1,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,11:102811075
rs470530-<b>A</b>,"2 x 10-6",,0.115,'-,"0.018 unit increase",NR,WTAPP1,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,11:102810218
rs116187470-<b>A</b>,"2 x 10-6",,0.115,'-,"0.018 unit increase",NR,"MMP12, MMP3","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,11:102846910
rs17361668-<b>A</b>,"3 x 10-6",,0.108,'-,"0.018 unit increase",NR,"MMP12, MMP3","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,11:102849613
rs114176245-<b>T</b>,"3 x 10-6",,0.11,'-,"0.018 unit increase",NR,"MMP3, MMP12","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,11:102848803
rs72981680-<b>A</b>,"4 x 10-6",,0.11,'-,"0.018 unit increase",NR,"MMP12, MMP3","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,11:102851128
rs111786708-<b>C</b>,"1 x 10-6",(AA),0.985,'-,"0.121 unit increase",NR,MKS1,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,17:58211816
rs146873050-<b>C</b>,"1 x 10-6",(AA),0.985,'-,"0.121 unit increase",NR,MKS1,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,17:58213965
rs141829479-<b>A</b>,"1 x 10-6",(AA),0.985,'-,"0.122 unit increase",NR,LPO,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,17:58227703
rs116372990-<b>A</b>,"1 x 10-6",(AA),0.985,'-,"0.122 unit increase",NR,LPO,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,17:58232901
rs116284889-<b>A</b>,"2 x 10-6",(AA),0.985,'-,"0.122 unit increase",NR,LPO,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,17:58239361
rs150713181-<b>G</b>,"4 x 10-7",(AA),0.984,'-,"0.124 unit increase",NR,BTBD9,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,6:38371756
rs149065551-<b>G</b>,"2 x 10-6",(AA),0.979,'-,"0.124 unit increase",NR,MPPE1P1,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,14:89076277
rs17236697-<b>G</b>,"3 x 10-6",(AA),0.985,'-,"0.125 unit increase",NR,PPM1L,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,3:160896432
rs114407411-<b>A</b>,"2 x 10-7",(AA),0.984,'-,"0.128 unit increase",NR,BTBD9,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,6:38383336
rs192452148-<b>T</b>,"2 x 10-7",(AA),0.984,'-,"0.129 unit increase",NR,BTBD9,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,6:38387529
rs189669683-<b>C</b>,"1 x 10-7",(AA),0.984,'-,"0.129 unit increase",NR,BNC2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,9:16810447
rs9491524-<b>C</b>,"2 x 10-6",(AA),0.987,'-,"0.135 unit increase",NR,'-,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,6:98413127
rs79764963-<b>T</b>,"4 x 10-6",(AA),0.989,'-,"0.159 unit increase",NR,"RNU7-190P, MTCO1P43","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,2:117065840
rs6969354-<b>G</b>,"4 x 10-6",(AA),0.985,'-,"0.163 unit increase",NR,GRB10,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,7:50821551
rs113142635-<b>C</b>,"5 x 10-6",(AA),0.991,'-,"0.165 unit increase",NR,LINC01934,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,2:181406316
rs187858337-<b>T</b>,"5 x 10-6",(AA),0.991,'-,"0.165 unit increase",NR,"OR9G3P, OR9G1","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,11:56713568
rs115455308-<b>C</b>,"4 x 10-6",(AA),0.992,'-,"0.167 unit increase",NR,CLEC4F,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,2:70815286
rs77173971-<b>T</b>,"1 x 10-6",,0.99,'-,"0.168 unit increase",NR,"HNRNPA1P20, LINC02032","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,3:148161644
rs144177292-<b>T</b>,"1 x 10-6",(AA),0.99,'-,"0.178 unit increase",NR,RNPEP,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:201994931
rs78737652-<b>A</b>,"3 x 10-6",(AA),0.993,'-,"0.18 unit increase",NR,PCDH15,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,10:54137311
rs186132788-<b>A</b>,"2 x 10-6",(AA),0.994,'-,"0.183 unit increase",NR,GCNT1,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,9:76467796
rs112377817-<b>G</b>,"2 x 10-6",(AA),0.992,'-,"0.184 unit increase",NR,"LINC01934, ITGA4","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,2:181420378
rs190588926-<b>T</b>,"2 x 10-6",(AA),0.99,'-,"0.185 unit increase",NR,"LINC02710, LINC02489","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,11:46221989
rs141680974-<b>A</b>,"3 x 10-6",(AA),0.992,'-,"0.188 unit increase",NR,"LINC02710, FBLIM1P2","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,11:46211266
rs138263114-<b>G</b>,"5 x 10-6",(AA),0.995,'-,"0.191 unit increase",NR,ITGA4,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,2:181477669
rs1828590-<b>A</b>,"4 x 10-6",,0.387,'-,"0.011 unit increase",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144552044
rs995758-<b>T</b>,"4 x 10-6",,0.387,'-,"0.011 unit increase",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144557049
rs6673137-<b>A</b>,"4 x 10-6",,0.541,'-,"0.011 unit increase",NR,LINC02257,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:221901288
rs11118886-<b>C</b>,"5 x 10-6",,0.546,'-,"0.011 unit increase",NR,LINC02257,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:221902320
rs36040446-<b>T</b>,"5 x 10-6",,0.546,'-,"0.011 unit increase",NR,LINC02257,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:221901875
rs1942108-<b>A</b>,"5 x 10-6",,0.491,'-,"0.011 unit increase",NR,'-,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,11:100521130
rs1317286-<b>A</b>,"4 x 10-7",,0.598,'-,"0.012 unit increase",NR,CHRNA3,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78603787
rs10519203-<b>A</b>,"5 x 10-7",,0.595,'-,"0.012 unit increase",NR,HYKK,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78521704
rs7180002-<b>A</b>,"6 x 10-7",,0.601,'-,"0.012 unit increase",NR,CHRNA5,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78581651
rs17486195-<b>A</b>,"6 x 10-7",,0.601,'-,"0.012 unit increase",NR,CHRNA5,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78572855
rs2274700-<b>A</b>,"6 x 10-7",,0.4,'-,"0.012 unit increase",NR,CFH,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:196713817
rs7535263-<b>A</b>,"6 x 10-7",,0.4,'-,"0.012 unit increase",NR,CFH,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:196713216
rs17486278-<b>A</b>,"7 x 10-7",,0.601,'-,"0.012 unit increase",NR,CHRNA5,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78575140
rs931794-<b>A</b>,"7 x 10-7",,0.497,'-,"0.012 unit increase",NR,HYKK,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78533838
rs1329427-<b>T</b>,"7 x 10-7",,0.397,'-,"0.012 unit increase",NR,CFH,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:196735429
rs9788721-<b>T</b>,"7 x 10-7",,0.595,'-,"0.012 unit increase",NR,HYKK,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78510527
rs55781567-<b>C</b>,"8 x 10-7",,0.597,'-,"0.012 unit increase",NR,CHRNA5,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78565644
rs58365910-<b>T</b>,"8 x 10-7",,0.595,'-,"0.012 unit increase",NR,"CHRNA5, PSMA4","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78556692
rs55853698-<b>T</b>,"8 x 10-7",,0.597,'-,"0.012 unit increase",NR,CHRNA5,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78565597
rs1329428-<b>T</b>,"8 x 10-7",,0.601,'-,"0.012 unit increase",NR,CFH,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:196733680
rs7540032-<b>T</b>,"8 x 10-7",,0.49,'-,"0.012 unit increase",NR,CFH,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:196732154
rs1410996-<b>A</b>,"9 x 10-7",,0.49,'-,"0.012 unit increase",NR,CFH,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:196727803
rs10801559-<b>A</b>,"9 x 10-7",,0.399,'-,"0.012 unit increase",NR,CFH,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:196735074
rs10922109-<b>A</b>,"9 x 10-7",,0.399,'-,"0.012 unit increase",NR,CFH,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:196735502
rs7514261-<b>A</b>,"9 x 10-7",,0.399,'-,"0.012 unit increase",NR,CFH,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:196731784
rs4243084-<b>C</b>,"3 x 10-7",,0.403,'-,"0.012 unit decrease",NR,CHRNA3,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78619330
rs13141641-<b>T</b>,"3 x 10-7",,0.608,'-,"0.012 unit decrease",NR,"HHIP-AS1, KRT18P51","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144585304
rs951266-<b>A</b>,"4 x 10-7",,0.502,'-,"0.012 unit decrease",NR,CHRNA5,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78586199
rs17487223-<b>T</b>,"4 x 10-7",,0.416,'-,"0.012 unit decrease",NR,CHRNB4,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78631645
rs16969968-<b>A</b>,"4 x 10-7",,0.503,'-,"0.012 unit decrease",NR,CHRNA5,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78590583
rs4887067-<b>A</b>,"4 x 10-7",,0.399,'-,"0.012 unit decrease",NR,"CHRNA3, CHRNA5","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78594605
rs8192482-<b>T</b>,"5 x 10-7",,0.399,'-,"0.012 unit decrease",NR,"CHRNA5, CHRNA3","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78593856
rs8031948-<b>T</b>,"5 x 10-7",,0.403,'-,"0.012 unit decrease",NR,HYKK,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78523715
rs72738786-<b>T</b>,"5 x 10-7",,0.402,'-,"0.012 unit decrease",NR,HYKK,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78535744
rs11118892-<b>C</b>,"5 x 10-7",,0.443,'-,"0.012 unit decrease",NR,LINC02257,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:221910253
rs56390833-<b>A</b>,"5 x 10-7",,0.396,'-,"0.012 unit decrease",NR,CHRNA5,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78585039
rs72740964-<b>A</b>,"6 x 10-7",,0.399,'-,"0.012 unit decrease",NR,CHRNA5,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78576294
rs7172118-<b>A</b>,"6 x 10-7",,0.399,'-,"0.012 unit decrease",NR,CHRNA5,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78570111
rs10737680-<b>A</b>,"6 x 10-7",,0.6,'-,"0.012 unit decrease",NR,CFH,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:196710325
rs140330585-<b>A</b>,"7 x 10-7",,0.4,'-,"0.012 unit decrease",NR,CHRNA5,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78574103
rs2036527-<b>A</b>,"7 x 10-7",,0.504,'-,"0.012 unit decrease",NR,"PSMA4, CHRNA5","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78559273
rs55958997-<b>A</b>,"7 x 10-7",,0.425,'-,"0.012 unit decrease",NR,"CHRNA3, CHRNB4","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78623530
rs72740955-<b>T</b>,"7 x 10-7",,0.402,'-,"0.012 unit decrease",NR,"PSMA4, CHRNA5","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78557437
rs11633958-<b>T</b>,"7 x 10-7",,0.396,'-,"0.012 unit decrease",NR,CHRNA5,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78569722
rs12914385-<b>T</b>,"8 x 10-7",,0.551,'-,"0.012 unit decrease",NR,CHRNA3,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78606381
rs10801558-<b>T</b>,"9 x 10-7",,0.601,'-,"0.012 unit decrease",NR,CFH,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:196729914
rs10922108-<b>A</b>,"9 x 10-7",,0.602,'-,"0.012 unit decrease",NR,CFH,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:196732343
rs4457591-<b>T</b>,"9 x 10-7",,0.498,'-,"0.012 unit decrease",NR,LINC02257,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:221905258
rs10922106-<b>A</b>,"9 x 10-7",,0.6,'-,"0.012 unit decrease",NR,CFH,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:196722334
rs8039449-<b>T</b>,"1 x 10-6",,0.429,'-,"0.012 unit decrease",NR,"CHRNB4, CHRNA3","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78622192
rs78958340-<b>T</b>,"1 x 10-6",(AA),0.964,'-,"0.078 unit increase",NR,CCL28,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43411501
rs79600599-<b>A</b>,"1 x 10-6",(AA),0.966,'-,"0.079 unit increase",NR,NNT,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43779081
rs9938585-<b>T</b>,"3 x 10-6",(AA),0.961,'-,"0.079 unit increase",NR,PRKCB,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,16:24073880
rs12921419-<b>G</b>,"1 x 10-6",(AA),0.958,'-,"0.079 unit increase",NR,PRKCB,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,16:24078450
rs150379724-<b>T</b>,"7 x 10-7",(AA),0.965,'-,"0.08 unit increase",NR,NNT,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43722453
rs76434282-<b>A</b>,"7 x 10-7",(AA),0.964,'-,"0.08 unit increase",NR,NNT,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43732804
rs149945008-<b>T</b>,"8 x 10-7",(AA),0.966,'-,"0.08 unit increase",NR,NNT,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43756357
rs144969515-<b>A</b>,"9 x 10-7",(AA),0.966,'-,"0.08 unit increase",NR,NNT,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43756828
rs114493850-<b>T</b>,"9 x 10-7",(AA),0.966,'-,"0.08 unit increase",NR,NNT,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43757677
rs182876247-<b>A</b>,"1 x 10-6",(AA),0.965,'-,"0.08 unit increase",NR,NNT,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43758860
rs7706711-<b>T</b>,"9 x 10-7",(AA),0.966,'-,"0.08 unit increase",NR,NNT,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43760615
rs80059051-<b>A</b>,"9 x 10-7",(AA),0.966,'-,"0.08 unit increase",NR,NNT,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43761610
rs116599402-<b>T</b>,"1 x 10-6",(AA),0.966,'-,"0.08 unit increase",NR,NNT,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43765573
rs79580180-<b>T</b>,"1 x 10-6",(AA),0.966,'-,"0.08 unit increase",NR,NNT,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43767333
rs115955109-<b>A</b>,"1 x 10-6",(AA),0.966,'-,"0.08 unit increase",NR,NNT,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43774010
rs192558570-<b>G</b>,"1 x 10-6",(AA),0.966,'-,"0.08 unit increase",NR,NNT,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43792425
rs114091587-<b>C</b>,"1 x 10-6",(AA),0.966,'-,"0.08 unit increase",NR,NNT,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43799826
rs75618061-<b>G</b>,"1 x 10-6",(AA),0.966,'-,"0.08 unit increase",NR,NNT,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43800729
rs78796889-<b>A</b>,"1 x 10-6",(AA),0.966,'-,"0.08 unit increase",NR,"GRAMD2B, NNT","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43802247
rs138936180-<b>T</b>,"2 x 10-6",(AA),0.967,'-,"0.08 unit increase",NR,'-,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43818694
rs76279502-<b>A</b>,"2 x 10-6",(AA),0.967,'-,"0.08 unit increase",NR,'-,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43826303
rs186211928-<b>C</b>,"5 x 10-7",(AA),0.965,'-,"0.081 unit increase",NR,NNT,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43741451
rs144585579-<b>G</b>,"5 x 10-7",(AA),0.965,'-,"0.081 unit increase",NR,NNT,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43744043
rs191814357-<b>A</b>,"5 x 10-7",(AA),0.965,'-,"0.081 unit increase",NR,NNT,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43745320
rs185720825-<b>T</b>,"5 x 10-7",(AA),0.965,'-,"0.081 unit increase",NR,NNT,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:43745660
rs72981684-<b>T</b>,"4 x 10-6",,0.11,'-,"0.018 unit increase",NR,"MMP12, MMP3","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,11:102853480
rs72981675-<b>T</b>,"4 x 10-6",,0.109,'-,"0.018 unit increase",NR,"MMP3, MMP12","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,11:102850520
rs72981698-<b>T</b>,"4 x 10-6",,0.11,'-,"0.018 unit increase",NR,"MMP12, MMP3","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,11:102855809
rs72983508-<b>A</b>,"4 x 10-6",,0.11,'-,"0.018 unit increase",NR,"MMP12, MMP3","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,11:102856678
rs72981683-<b>A</b>,"4 x 10-6",,0.109,'-,"0.018 unit increase",NR,"MMP12, MMP3","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,11:102851883
rs655403-<b>T</b>,"6 x 10-7",,0.117,'-,"0.019 unit increase",NR,MMP3,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,11:102837776
rs72768835-<b>T</b>,"2 x 10-6",,0.916,'-,"0.02 unit increase",NR,TENT2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:79672784
rs61212610-<b>A</b>,"2 x 10-6",,0.917,'-,"0.02 unit increase",NR,TENT2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:79666069
rs72768826-<b>A</b>,"2 x 10-6",,0.917,'-,"0.02 unit increase",NR,TENT2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:79660249
rs113902152-<b>A</b>,"2 x 10-6",,0.917,'-,"0.02 unit increase",NR,TENT2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:79681418
rs56064438-<b>T</b>,"2 x 10-6",,0.917,'-,"0.02 unit increase",NR,TENT2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:79679085
rs55687040-<b>C</b>,"3 x 10-6",,0.915,'-,"0.02 unit increase",NR,TENT2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:79650392
rs11198708-<b>A</b>,"5 x 10-6",(AA),0.555,'-,"0.029 unit increase",NR,"LDHAP5, NANOS1","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,10:118985398
rs6817273-<b>T</b>,"1 x 10-6",,0.503,'-,"0.012 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144570851
rs6677089-<b>A</b>,"1 x 10-6",,0.6,'-,"0.012 unit decrease",NR,CFH,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:196715183
rs10922105-<b>A</b>,"1 x 10-6",,0.6,'-,"0.012 unit decrease",NR,CFH,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:196721120
rs10922104-<b>A</b>,"1 x 10-6",,0.6,'-,"0.012 unit decrease",NR,CFH,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:196718600
rs3753395-<b>A</b>,"1 x 10-6",,0.6,'-,"0.012 unit decrease",NR,CFH,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:196717522
rs10465586-<b>A</b>,"1 x 10-6",,0.602,'-,"0.012 unit decrease",NR,CFH,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:196718199
rs12504628-<b>T</b>,"1 x 10-6",,0.614,'-,"0.012 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144515172
rs11858836-<b>A</b>,"2 x 10-6",,0.387,'-,"0.012 unit decrease",NR,IREB2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78490935
rs17483929-<b>A</b>,"2 x 10-6",,0.497,'-,"0.012 unit decrease",NR,IREB2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78450034
rs72738736-<b>T</b>,"2 x 10-6",,0.391,'-,"0.012 unit decrease",NR,IREB2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78472780
rs55983731-<b>T</b>,"2 x 10-6",,0.39,'-,"0.012 unit decrease",NR,IREB2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78442927
rs2568494-<b>A</b>,"2 x 10-6",,0.496,'-,"0.012 unit decrease",NR,IREB2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78448622
rs72738718-<b>C</b>,"2 x 10-6",,0.388,'-,"0.012 unit decrease",NR,IREB2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78443096
rs17405217-<b>T</b>,"2 x 10-6",,0.386,'-,"0.012 unit decrease",NR,IREB2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78438807
rs2656065-<b>A</b>,"3 x 10-6",,0.496,'-,"0.012 unit decrease",NR,IREB2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78458207
rs17483548-<b>A</b>,"3 x 10-6",,0.386,'-,"0.012 unit decrease",NR,IREB2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78437971
rs2134257-<b>A</b>,"3 x 10-6",,0.374,'-,"0.012 unit decrease",NR,DNAH5,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:13756020
rs2134259-<b>T</b>,"3 x 10-6",,0.374,'-,"0.012 unit decrease",NR,DNAH5,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:13755842
rs13140176-<b>A</b>,"3 x 10-6",,0.631,'-,"0.012 unit decrease",NR,"KRT18P51, THEGL","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144567946
rs72738704-<b>C</b>,"4 x 10-6",,0.39,'-,"0.012 unit decrease",NR,"IREB2, CRABP1","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78427490
rs6881967-<b>A</b>,"4 x 10-6",,0.702,'-,"0.012 unit decrease",NR,DNAH5,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:13741054
rs6842889-<b>T</b>,"3 x 10-6",,0.617,'-,"0.011 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144558728
rs13118928-<b>A</b>,"3 x 10-6",,0.502,'-,"0.011 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144565237
rs1604476-<b>T</b>,"3 x 10-6",,0.386,'-,"0.011 unit decrease",NR,DNAH5,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:13743975
rs10851907-<b>A</b>,"3 x 10-6",,0.476,'-,"0.011 unit decrease",NR,"CHRNA3, CHRNB4","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78623522
rs8034191-<b>T</b>,"3 x 10-7",,0.403,'-,"0.013 unit increase",NR,'-,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,"Mapping not available"
rs11852372-<b>A</b>,"3 x 10-7",,0.62,'-,"0.013 unit increase",NR,HYKK,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78509052
rs146009840-<b>A</b>,"3 x 10-7",,0.6,'-,"0.013 unit increase",NR,CHRNA3,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78613835
rs8042849-<b>T</b>,"5 x 10-7",,0.534,'-,"0.013 unit increase",NR,HYKK,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78525587
rs72736802-<b>A</b>,"8 x 10-7",,0.614,'-,"0.013 unit increase",NR,"CRABP1, IREB2","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78427159
rs12499182-<b>C</b>,"1 x 10-6",,0.351,'-,"0.013 unit increase",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144526904
rs7823498-<b>T</b>,"3 x 10-6",,0.784,'-,"0.013 unit increase",NR,NRG1,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,8:32546055
rs6835650-<b>T</b>,"4 x 10-6",,0.334,'-,"0.013 unit increase",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144542415
rs951985-<b>T</b>,"4 x 10-6",,0.649,'-,"0.013 unit increase",NR,"IREB2, CRABP1","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78428581
rs4236709-<b>A</b>,"4 x 10-6",,0.784,'-,"0.013 unit increase",NR,NRG1,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,8:32552592
rs141518190-<b>A</b>,"4 x 10-7",,0.64,'-,"0.014 unit increase",NR,CHRNA3,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78608305
rs138544659-<b>T</b>,"5 x 10-7",,0.65,'-,"0.014 unit increase",NR,CHRNA3,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78608359
rs9765543-<b>A</b>,"2 x 10-6",,0.705,'-,"0.014 unit increase",NR,DNAH5,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:13748060
rs56117933-<b>T</b>,"1 x 10-6",,0.762,'-,"0.015 unit increase",NR,"HYKK, PSMA4","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78540007
rs494963-<b>A</b>,"6 x 10-7",,0.116,'-,"0.018 unit increase",NR,"MMP12, MMP3","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,11:102845095
rs646910-<b>A</b>,"6 x 10-7",,0.117,'-,"0.018 unit increase",NR,MMP3,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,11:102838791
rs569444-<b>A</b>,"7 x 10-7",,0.116,'-,"0.018 unit increase",NR,"WTAPP1, MMP3","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,11:102836574
rs593698-<b>A</b>,"7 x 10-7",,0.116,'-,"0.018 unit increase",NR,WTAPP1,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,11:102833745
rs605949-<b>T</b>,"7 x 10-7",,0.116,'-,"0.018 unit increase",NR,WTAPP1,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,11:102835016
rs476762-<b>A</b>,"7 x 10-7",,0.116,'-,"0.018 unit increase",NR,MMP3,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,11:102839976
rs473238-<b>T</b>,"7 x 10-7",,0.116,'-,"0.018 unit increase",NR,WTAPP1,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,11:102829629
rs595128-<b>T</b>,"9 x 10-7",,0.116,'-,"0.018 unit increase",NR,WTAPP1,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,11:102822378
rs499459-<b>A</b>,"9 x 10-7",,0.116,'-,"0.018 unit increase",NR,'-,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,"Mapping not available"
rs564018-<b>A</b>,"1 x 10-6",,0.116,'-,"0.018 unit increase",NR,'-,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,"Mapping not available"
rs688258-<b>A</b>,"1 x 10-6",,0.116,'-,"0.018 unit increase",NR,WTAPP1,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,11:102821364
rs141053791-<b>A</b>,"2 x 10-6",(AA),0.991,'-,"0.191 unit increase",NR,LINC02710,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,11:46219359
rs8178393-<b>T</b>,"1 x 10-6",(AA),0.992,'-,"0.194 unit increase",NR,LPO,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,17:58263090
rs191962835-<b>T</b>,"3 x 10-6",(AA),0.992,'-,"0.197 unit increase",NR,"LINC02489, LINC02710","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,11:46231662
rs181783266-<b>T</b>,"9 x 10-7",(AA),0.988,'-,"0.207 unit increase",NR,MBOAT1,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,6:20030374
rs148133787-<b>C</b>,"6 x 10-7",(AA),0.992,'-,"0.208 unit increase",NR,'-,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,18:27647495
rs116039626-<b>T</b>,"2 x 10-6",(AA),0.99,'-,"0.218 unit increase",NR,AGAP1,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,2:235445091
rs139070430-<b>A</b>,"5 x 10-6",,0.998,'-,"0.219 unit increase",NR,ADGRL3,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:61316056
rs45593035-<b>A</b>,"3 x 10-6",(AA),0.99,'-,"0.242 unit increase",NR,GAD1,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,2:170814980
rs116135467-<b>G</b>,"7 x 10-7",(AA),0.993,'-,"0.242 unit increase",NR,"WNT10A, WNT6","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,2:218877731
rs148411008-<b>T</b>,"3 x 10-6",(AA),0.991,'-,"0.243 unit increase",NR,ERICH2,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,2:170797762
rs139817151-<b>G</b>,"5 x 10-6",(AA),0.997,'-,"0.249 unit increase",NR,C7,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,5:40967607
rs76742446-<b>T</b>,"1 x 10-6",(AA),0.993,'-,"0.249 unit increase",NR,"INSIG1-DT, RN7SKP280","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,7:155280909
rs149083189-<b>G</b>,"4 x 10-6",(AA),0.996,'-,"0.249 unit increase",NR,'-,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,18:27689117
rs142015091-<b>C</b>,"5 x 10-6",(AA),0.996,'-,"0.288 unit increase",NR,PTPRD,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,9:10530738
rs139872551-<b>C</b>,"3 x 10-6",(AA),0.997,'-,"0.297 unit increase",NR,"RPL31P33, RPA3P2","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,6:53373738
rs147558739-<b>T</b>,"4 x 10-6",(AA),0.998,'-,"0.314 unit increase",NR,"RN7SKP256, RPA3P2","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,6:53391282
rs150978385-<b>T</b>,"3 x 10-6",(AA),0.997,'-,"0.317 unit increase",NR,"RPA3P2, RPL31P33","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,6:53376037
rs139078029-<b>T</b>,"3 x 10-6",(AA),0.997,'-,"0.317 unit increase",NR,"RPL31P33, RPA3P2","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,6:53376818
rs141925252-<b>G</b>,"3 x 10-6",(AA),0.997,'-,"0.317 unit increase",NR,"RPA3P2, RPL31P33","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,6:53377679
rs185126447-<b>A</b>,"2 x 10-6",(AA),0.997,'-,"0.318 unit increase",NR,"RPA3P2, RN7SKP256","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,6:53381392
rs190310258-<b>A</b>,"2 x 10-6",(AA),0.998,'-,"0.321 unit increase",NR,"RPA3P2, RPL31P33","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,6:53373568
rs148575805-<b>A</b>,"2 x 10-6",(AA),0.998,'-,"0.322 unit increase",NR,"RPL31P28, RPL31P33","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,6:53367028
rs138711232-<b>A</b>,"2 x 10-6",(AA),0.998,'-,"0.323 unit increase",NR,"RPL31P28, RPL31P33","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,6:53366216
rs143262451-<b>A</b>,"7 x 10-7",(AA),0.996,'-,"0.353 unit increase",NR,"FNBP1L, Y_RNA","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:93407898
rs140671052-<b>G</b>,"5 x 10-6",(AA),0.996,'-,"0.383 unit increase",NR,PMPCAP1,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:92179937
rs11118885-<b>T</b>,"5 x 10-6",,0.501,'-,"0.011 unit decrease",NR,LINC02257,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:221902117
rs1032297-<b>A</b>,"5 x 10-6",,0.49,'-,"0.011 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144513592
rs1512281-<b>A</b>,"5 x 10-6",,0.602,'-,"0.011 unit decrease",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144513749
rs6829184-<b>A</b>,"3 x 10-6",,0.385,'-,"0.011 unit increase",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144549505
rs11940733-<b>A</b>,"3 x 10-6",,0.386,'-,"0.011 unit increase",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144568176
rs8040868-<b>T</b>,"3 x 10-6",,0.498,'-,"0.011 unit increase",NR,CHRNA3,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,15:78618839
rs13129662-<b>T</b>,"3 x 10-6",,0.386,'-,"0.011 unit increase",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144533222
rs1489763-<b>T</b>,"3 x 10-6",,0.386,'-,"0.011 unit increase",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144533080
rs7534469-<b>A</b>,"3 x 10-6",,0.546,'-,"0.011 unit increase",NR,LINC02257,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:221903607
rs1542725-<b>T</b>,"3 x 10-6",,0.387,'-,"0.011 unit increase",NR,"ENPP7P9, KRT18P51","Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144567182
rs6657194-<b>C</b>,"3 x 10-6",,0.544,'-,"0.011 unit increase",NR,LINC02257,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:221901166
rs2378491-<b>A</b>,"4 x 10-6",,0.546,'-,"0.011 unit increase",NR,LINC02257,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:221903172
rs2378492-<b>T</b>,"4 x 10-6",,0.546,'-,"0.011 unit increase",NR,LINC02257,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:221903405
rs1565330-<b>T</b>,"4 x 10-6",,0.387,'-,"0.011 unit increase",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144561395
rs1980056-<b>A</b>,"4 x 10-6",,0.386,'-,"0.011 unit increase",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144563771
rs28626624-<b>T</b>,"4 x 10-6",,0.387,'-,"0.011 unit increase",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144561091
rs6537292-<b>T</b>,"4 x 10-6",,0.387,'-,"0.011 unit increase",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144548816
rs6828540-<b>A</b>,"4 x 10-6",,0.386,'-,"0.011 unit increase",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144542079
rs720484-<b>A</b>,"4 x 10-6",,0.386,'-,"0.011 unit increase",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144541212
rs1980057-<b>T</b>,"4 x 10-6",,0.503,'-,"0.011 unit increase",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144564586
rs4460649-<b>C</b>,"4 x 10-6",,0.546,'-,"0.011 unit increase",NR,LINC02257,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:221903741
rs6537294-<b>A</b>,"4 x 10-6",,0.387,'-,"0.011 unit increase",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144558611
rs11118887-<b>T</b>,"4 x 10-6",,0.546,'-,"0.011 unit increase",NR,LINC02257,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,1:221902355
rs12509311-<b>T</b>,"4 x 10-6",,0.387,'-,"0.011 unit increase",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144557510
rs1489760-<b>A</b>,"4 x 10-6",,0.387,'-,"0.011 unit increase",NR,KRT18P51,"Post bronchodilator FEV1/FVC ratio in COPD","response to bronchodilator, chronic obstructive pulmonary disease, FEV/FEC ratio",GCST003265,4:144553145
rs60451608-<b>G</b>,"2 x 10-6",(AA),0.972,'-,"0.369 unit increase",NR,KLHL32,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,6:97108568
rs60610103-<b>G</b>,"4 x 10-6",(AA),0.973,'-,"0.371 unit increase",NR,MMS22L,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,6:97176861
rs73758115-<b>T</b>,"2 x 10-6",(AA),0.972,'-,"0.372 unit increase",NR,KLHL32,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,6:97123820
rs73758117-<b>T</b>,"2 x 10-6",(AA),0.972,'-,"0.372 unit increase",NR,KLHL32,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,6:97125724
rs73758118-<b>A</b>,"1 x 10-6",(AA),0.972,'-,"0.373 unit increase",NR,KLHL32,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,6:97131188
rs55884448-<b>A</b>,"2 x 10-6",(AA),0.972,'-,"0.378 unit increase",NR,MMS22L,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,6:97153651
rs189239081-<b>C</b>,"4 x 10-6",(AA),0.973,'-,"0.378 unit increase",NR,MMS22L,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,6:97194003
rs73760105-<b>T</b>,"4 x 10-6",(AA),0.974,'-,"0.378 unit increase",NR,MMS22L,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,6:97214366
rs79077948-<b>T</b>,"4 x 10-6",(AA),0.974,'-,"0.378 unit increase",NR,MMS22L,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,6:97219046
rs59581213-<b>G</b>,"4 x 10-6",(AA),0.974,'-,"0.378 unit increase",NR,MMS22L,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,6:97220137
rs79969755-<b>A</b>,"3 x 10-6",(AA),0.968,'-,"0.4 unit increase",NR,"RNU5F-8P, Y_RNA","Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,1:240687991
rs189297294-<b>C</b>,"4 x 10-6",(AA),0.976,'-,"0.464 unit increase",NR,"AQP8, RN7SL557P","Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,16:25210495
rs7249887-<b>T</b>,"2 x 10-6",(AA),0.81,'-,"0.145 unit increase",NR,TSHZ3-AS1,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,19:31358462
rs9990514-<b>C</b>,"8 x 10-8",(AA),0.719,'-,"0.15 unit increase",NR,ZFP42,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,4:187920994
rs111786708-<b>C</b>,"4 x 10-6",(AA),0.985,'-,"0.482 unit increase",NR,MKS1,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,17:58211816
rs141829479-<b>A</b>,"4 x 10-6",(AA),0.985,'-,"0.487 unit increase",NR,LPO,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,17:58227703
rs116284889-<b>A</b>,"4 x 10-6",(AA),0.985,'-,"0.49 unit increase",NR,LPO,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,17:58239361
rs116372990-<b>A</b>,"3 x 10-6",(AA),0.985,'-,"0.491 unit increase",NR,LPO,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,17:58232901
rs145284077-<b>A</b>,"3 x 10-6",(AA),0.989,'-,"0.596 unit increase",NR,"CD207, CLEC4F","Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,2:70825868
rs141721054-<b>G</b>,"4 x 10-6",(AA),0.991,'-,"0.63 unit increase",NR,ASAP1,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,8:130189367
rs6765707-<b>T</b>,"4 x 10-6",(AA),0.832,'-,"0.162 unit increase",NR,RBMS3,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,3:29783668
rs11051170-<b>T</b>,"2 x 10-6",(AA),0.878,'-,"0.188 unit increase",NR,TSPAN11,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,12:30932465
rs118009632-<b>T</b>,"2 x 10-6",,0.015,'-,"0.212 unit increase",NR,PDE1B,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,12:54565888
rs79414853-<b>T</b>,"4 x 10-6",(AA),0.924,'-,"0.223 unit increase",NR,ADGRV1,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,5:90781734
rs73177427-<b>T</b>,"4 x 10-6",(AA),0.925,'-,"0.224 unit increase",NR,ADGRV1,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,5:90766279
rs28493987-<b>C</b>,"6 x 10-7",,0.982,'-,"0.234 unit increase",NR,GDAP1,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,8:74428862
rs79238367-<b>C</b>,"5 x 10-6",(AA),0.928,'-,"0.249 unit increase",NR,MEIS2,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,15:37055464
rs142698760-<b>A</b>,"4 x 10-6",,0.006,'-,"0.285 unit increase",NR,C1orf185,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,1:51138594
rs187620787-<b>T</b>,"5 x 10-6",,0.006,'-,"0.288 unit increase",NR,C1orf185,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,1:51129334
rs149335852-<b>T</b>,"4 x 10-6",(AA),0.959,'-,"0.302 unit increase",NR,"VDAC2P5, SNORA74","Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,2:65196540
rs8031948-<b>T</b>,"2 x 10-6",,0.384,'-,"0.046 unit decrease",NR,HYKK,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,15:78523715
rs181020201-<b>A</b>,"7 x 10-7",,0.997,'-,"0.476 unit decrease",NR,C1orf185,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,1:51134390
rs186991869-<b>C</b>,"2 x 10-6",,0.994,'-,"0.408 unit decrease",NR,PTPRD,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,9:10098043
rs117770885-<b>T</b>,"4 x 10-6",,0.992,'-,"0.382 unit decrease",NR,PTPRD,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,9:10114755
rs184109064-<b>A</b>,"2 x 10-6",,0.993,'-,"0.3 unit decrease",NR,C1orf185,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,1:51138695
rs148657146-<b>T</b>,"5 x 10-6",,0.994,'-,"0.289 unit decrease",NR,C1orf185,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,1:51126728
rs180746259-<b>A</b>,"5 x 10-6",,0.994,'-,"0.286 unit decrease",NR,"CFL1P2, C1orf185","Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,1:51151838
rs12352894-<b>C</b>,"3 x 10-6",(AA),0.043,'-,"0.284 unit decrease",NR,U8,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,9:38197387
rs118189482-<b>T</b>,"4 x 10-7",,0.014,'-,"0.247 unit decrease",NR,DPP6,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,7:154668950
rs117276938-<b>C</b>,"1 x 10-6",,0.975,'-,"0.182 unit decrease",NR,"KCNA7, RN7SL708P","Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,19:49073545
rs181169315-<b>A</b>,"1 x 10-6",,0.059,'-,"0.179 unit decrease",NR,U3,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,5:35402086
rs1965221-<b>T</b>,"2 x 10-6",(AA),0.816,'-,"0.178 unit decrease",NR,PGAM1P5,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,12:95581262
rs10777709-<b>A</b>,"3 x 10-6",(AA),0.817,'-,"0.176 unit decrease",NR,PGAM1P5,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,12:95582210
rs650466-<b>T</b>,"5 x 10-6",,0.028,'-,"0.166 unit decrease",NR,TAOK3,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,12:118208856
rs61943529-<b>A</b>,"2 x 10-6",,0.032,'-,"0.164 unit decrease",NR,TAOK3,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,12:118164051
rs55781567-<b>C</b>,"3 x 10-6",,0.61,'-,"0.045 unit increase",NR,CHRNA5,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,15:78565644
rs2009746-<b>A</b>,"1 x 10-6",,0.627,'-,"0.046 unit increase",NR,IREB2,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,15:78461760
rs7864133-<b>A</b>,"4 x 10-6",(AA),0.753,'-,"0.132 unit decrease",NR,RPS20P25,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,9:81438771
rs10817688-<b>A</b>,"9 x 10-7",,0.818,'-,"0.076 unit increase",NR,DELEC1,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,9:114943689
rs182094574-<b>T</b>,"4 x 10-6",,0.884,'-,"0.102 unit increase",NR,NRXN2,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,11:64713670
rs150841795-<b>A</b>,"3 x 10-6",,0.05,'-,"0.112 unit increase",NR,'-,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,13:53563614
rs6841948-<b>C</b>,"1 x 10-6",(AA),0.478,'-,"0.114 unit increase",NR,ABLIM2,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,4:7986075
rs28478891-<b>T</b>,"4 x 10-6",,0.926,'-,"0.118 unit increase",NR,PIEZO2,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,18:10886343
rs12370990-<b>G</b>,"3 x 10-6",(AA),0.764,'-,"0.128 unit increase",NR,SCAF11,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,12:46036870
rs11183298-<b>C</b>,"2 x 10-6",(AA),0.771,'-,"0.132 unit increase",NR,"SCAF11, ATP5MC2","Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,12:46038807
rs6825162-<b>C</b>,"6 x 10-7",(AA),0.712,'-,"0.136 unit increase",NR,ZFP42,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,4:187926273
rs11878732-<b>A</b>,"2 x 10-7",(AA),0.645,'-,"0.136 unit increase",NR,TSHZ3,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,19:31337942
rs139134142-<b>A</b>,"5 x 10-6",(AA),0.985,'-,"0.49 unit decrease",NR,CATSPERB,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,14:91603145
rs2568494-<b>A</b>,"2 x 10-6",,0.504,'-,"0.044 unit decrease",NR,IREB2,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,15:78448622
rs72738718-<b>C</b>,"4 x 10-6",,0.372,'-,"0.044 unit decrease",NR,IREB2,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,15:78443096
rs17483929-<b>A</b>,"5 x 10-6",,0.527,'-,"0.044 unit decrease",NR,IREB2,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,15:78450034
rs4243084-<b>C</b>,"5 x 10-6",,0.384,'-,"0.044 unit decrease",NR,CHRNA3,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,15:78619330
rs7875024-<b>A</b>,"5 x 10-6",,0.663,'-,"0.044 unit decrease",NR,C9orf92,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,9:16288426
rs17486278-<b>A</b>,"2 x 10-6",,0.61,'-,"0.044 unit increase",NR,CHRNA5,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,15:78575140
rs6475025-<b>T</b>,"4 x 10-6",,0.664,'-,"0.044 unit increase",NR,C9orf92,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,9:16289430
rs56219465-<b>A</b>,"4 x 10-6",,0.626,'-,"0.044 unit increase",NR,IREB2,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,15:78450237
rs7181486-<b>T</b>,"4 x 10-6",,0.627,'-,"0.044 unit increase",NR,IREB2,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,15:78449276
rs55676755-<b>C</b>,"5 x 10-6",,0.62,'-,"0.044 unit increase",NR,CHRNA3,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,15:78606590
rs2656052-<b>A</b>,"2 x 10-6",,0.599,'-,"0.045 unit increase",NR,IREB2,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,15:78448590
rs2938670-<b>T</b>,"2 x 10-6",,0.599,'-,"0.045 unit increase",NR,IREB2,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,15:78448346
rs143863913-<b>T</b>,"4 x 10-6",,0.036,'-,"0.145 unit decrease",NR,"SYN3, LINC01640","Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,22:33093125
rs116317518-<b>T</b>,"2 x 10-6",,0.959,'-,"0.14 unit decrease",NR,ZNF385D,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,3:22154829
rs72736802-<b>A</b>,"2 x 10-6",,0.598,'-,"0.048 unit increase",NR,"CRABP1, IREB2","Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,15:78427159
rs9536463-<b>A</b>,"2 x 10-6",,0.95,'-,"0.112 unit decrease",NR,'-,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,13:53558112
rs148490655-<b>C</b>,"2 x 10-6",,0.11,'-,"0.102 unit decrease",NR,LINC00624,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,1:147427099
rs61906588-<b>T</b>,"4 x 10-6",,0.323,'-,"0.05 unit decrease",NR,LINC02151,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,11:116491937
rs551517-<b>T</b>,"2 x 10-6",,0.279,'-,"0.049 unit decrease",NR,LPAR1,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,9:110874513
rs6881967-<b>A</b>,"1 x 10-6",,0.69,'-,"0.048 unit decrease",NR,DNAH5,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,5:13741054
rs10853191-<b>A</b>,"5 x 10-6",,0.257,'-,"0.048 unit decrease",NR,PIEZO2,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,18:10889680
rs2656065-<b>A</b>,"7 x 10-7",,0.504,'-,"0.046 unit decrease",NR,IREB2,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,15:78458207
rs11183296-<b>T</b>,"5 x 10-6",(AA),0.792,'-,"0.141 unit increase",NR,SCAF11,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,12:46032954
rs11183289-<b>T</b>,"2 x 10-6",(AA),0.792,'-,"0.142 unit increase",NR,SCAF11,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,12:46027966
rs152784-<b>A</b>,"2 x 10-6",,0.041,'-,"0.144 unit increase",NR,FSTL4,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,5:133436739
rs146873050-<b>C</b>,"4 x 10-6",(AA),0.985,'-,"0.481 unit increase",NR,MKS1,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,17:58213965
rs73527062-<b>T</b>,"4 x 10-6",(AA),0.984,'-,"0.482 unit increase",NR,RNU6-214P,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,6:120442845
rs140543894-<b>G</b>,"4 x 10-6",(AA),0.985,'-,"0.482 unit increase",NR,MKS1,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,17:58211748
rs1353531-<b>T</b>,"1 x 10-6",(AA),0.817,'-,"0.151 unit increase",NR,TSHZ3-AS1,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,19:31356001
rs9765602-<b>C</b>,"4 x 10-6",(AA),0.842,'-,"0.154 unit increase",NR,U3,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,5:35426529
rs79643899-<b>C</b>,"4 x 10-6",(AA),0.842,'-,"0.154 unit increase",NR,U3,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,5:35429347
rs2371824-<b>T</b>,"4 x 10-6",(AA),0.832,'-,"0.162 unit increase",NR,RBMS3,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,3:29781107
rs6762867-<b>C</b>,"4 x 10-6",(AA),0.832,'-,"0.162 unit increase",NR,RBMS3,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,3:29783274
rs148684605-<b>C</b>,"6 x 10-7",(AA),0.989,'-,"0.644 unit increase",NR,RPS23P3,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,4:66475907
rs114120854-<b>A</b>,"6 x 10-7",(AA),0.989,'-,"0.656 unit increase",NR,RPS23P3,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,4:66494949
rs114681481-<b>T</b>,"3 x 10-6",(AA),0.991,'-,"0.664 unit increase",NR,RPS23P3,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,4:66464543
rs186974661-<b>A</b>,"3 x 10-6",(AA),0.991,'-,"0.675 unit increase",NR,RPS23P3,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,4:66470702
rs138896312-<b>C</b>,"1 x 10-6",(AA),0.99,'-,"0.683 unit increase",NR,"HAUS6P3, LINC01446","Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,7:53832430
rs144063842-<b>T</b>,"3 x 10-6",(AA),0.991,'-,"0.685 unit increase",NR,'-,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,4:66534537
rs115455308-<b>C</b>,"4 x 10-6",(AA),0.992,'-,"0.697 unit increase",NR,CLEC4F,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,2:70815286
rs144177292-<b>T</b>,"2 x 10-6",(AA),0.99,'-,"0.721 unit increase",NR,RNPEP,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,1:201994931
rs114771314-<b>T</b>,"4 x 10-6",(AA),0.995,'-,"0.86 unit increase",NR,"LURAP1L, LURAP1L-AS1","Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,9:12805031
rs114241027-<b>C</b>,"4 x 10-6",(AA),0.995,'-,"0.87 unit increase",NR,"LURAP1L-AS1, LURAP1L","Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,9:12802824
rs151046267-<b>T</b>,"4 x 10-6",(AA),0.996,'-,"0.888 unit increase",NR,"PNRC2P1, VDAC2P3","Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,1:117732097
rs140913792-<b>G</b>,"4 x 10-6",(AA),0.996,'-,"0.894 unit increase",NR,"VDAC2P3, PNRC2P1","Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,1:117699399
rs7542813-<b>A</b>,"2 x 10-6",(AA),0.993,'-,"0.971 unit increase",NR,EFCAB2,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,1:244970237
rs143037915-<b>A</b>,"1 x 10-6",(AA),0.996,'-,"0.983 unit increase",NR,MIR4527HG,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,18:47446850
rs145460587-<b>G</b>,"4 x 10-6",(AA),0.996,'-,"1.014 unit increase",NR,RNU1-14P,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,7:53373876
rs151156903-<b>C</b>,"4 x 10-6",(AA),0.994,'-,"1.143 unit increase",NR,PSMC1P3,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,7:136681608
rs73157010-<b>C</b>,"5 x 10-6",(AA),0.995,'-,"1.171 unit increase",NR,PSMC1P3,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,7:136712114
rs73157036-<b>A</b>,"3 x 10-6",(AA),0.994,'-,"1.173 unit increase",NR,PSMC1P3,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,7:136747093
rs73157032-<b>A</b>,"4 x 10-6",(AA),0.994,'-,"1.182 unit increase",NR,PSMC1P3,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,7:136743934
rs184886314-<b>T</b>,"2 x 10-6",(AA),0.996,'-,"1.185 unit increase",NR,NCSTN,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,1:160348147
rs187535555-<b>C</b>,"3 x 10-6",(AA),0.995,'-,"1.226 unit increase",NR,"AP5S1, MAVS","Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,20:3840516
rs17333649-<b>G</b>,"2 x 10-6",(AA),0.996,'-,"1.395 unit increase",NR,'-,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,2:5239054
rs74557801-<b>G</b>,"5 x 10-6",(AA),0.997,'-,"1.59 unit increase",NR,SPAG17,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,1:117978648
rs138325416-<b>C</b>,"6 x 10-7",(AA),0.998,'-,"4.31 unit increase",NR,HNRNPA1P58,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,6:24006333
rs149232124-<b>A</b>,"4 x 10-6",(AA),0.999,'-,"9.105 unit increase",NR,OXR1,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,8:106323167
rs184378308-<b>A</b>,"2 x 10-6",(AA),1.0,'-,"96.412 unit increase",NR,PSD2-AS1,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,5:139742662
rs184394765-<b>A</b>,"4 x 10-6",(AA),1.0,'-,"142.9 unit increase",NR,RPL37P6,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,8:56645824
rs189757960-<b>C</b>,"2 x 10-6",(AA),1.0,'-,"158.252 unit increase",NR,ABI3BP,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,3:100871511
rs7736304-<b>C</b>,"3 x 10-6",(AA),0.955,'-,"0.306 unit increase",NR,GRIA1,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,5:153669328
rs13382275-<b>G</b>,"2 x 10-7",(AA),0.95,'-,"0.321 unit increase",NR,SNTG2,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,2:969893
rs74888189-<b>T</b>,"1 x 10-6",(AA),0.959,'-,"0.331 unit increase",NR,GRIK4,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,11:120630009
rs79229131-<b>G</b>,"1 x 10-6",(AA),0.959,'-,"0.332 unit increase",NR,GRIK4,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,11:120632507
rs56144287-<b>A</b>,"1 x 10-6",(AA),0.959,'-,"0.333 unit increase",NR,GRIK4,"Post bronchodilator FEV1 in COPD","forced expiratory volume, response to bronchodilator, chronic obstructive pulmonary disease",GCST003263,11:120633858
rs295137-<b>T</b>,"1 x 10-6",,0.41,'-,'-,'-,SPATS2L,"Asthma (bronchodilator response)","response to bronchodilator, asthma",GCST001597,2:200285317
